<?xml version="1.0" encoding="UTF-8"?>
<rows>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938026</term_id>
  <id>940035</id>
  <title>Cervical Cancer  Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on cervical cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>940035</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940199</term_id>
  <id>940204</id>
  <title>Gallbladder Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Gallbladder Cancer </field_short_title>
  <field_page_description>Cancer that arises in the gallbladder is uncommon. Almost all gallbladder cancers are adenocarcinomas. The most common symptoms caused by gallbladder cancer are jaundice, pain, and fever. Find evidence-based information on gallbladder cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about gallbladder cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940204</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>940315</term_id>
  <id>940323</id>
  <title>Head and Neck Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on head and neck cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940323</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940375</term_id>
  <id>940382</id>
  <title>Kidney (Renal Cell) Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Kidney Cancer </field_short_title>
  <field_page_description>Kidney cancer has three main types. Renal cell cancer, or renal cell adenocarcinoma, forms in the tubules of the kidney. Transitional cell carcinoma forms in the renal pelvis and ureter. Wilms tumors are common in children. Find evidence-based information on kidney cancer treatment, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Kidney Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940382</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>963159</id>
  <title>Adjuvant Chemotherapy Modestly Improves Survival in Some Men with Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Adjuvant Chemotherapy Improves Prostate Cancer Survival</field_short_title>
  <field_page_description>Giving some men with prostate cancer chemotherapy after standard treatment with radiation and hormone therapy modestly improves how long they live, according to results from a new NCI-funded clinical trial.</field_page_description>
  <field_feature_card_description>Adjuvant chemotherapy improved survival in some men with prostate cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-08</field_date_posted>
  <field_date_reviewed>2015-06-05</field_date_reviewed>
  <field_pretty_url>adjuvant-chemo-prostate</field_pretty_url>
  <para_id>963159</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969910</term_id>
  <id>969912</id>
  <title>Funding for Research Areas</title>
  <langcode>en</langcode>
  <field_short_title>Research Funding</field_short_title>
  <field_page_description>See how appropriated funds are spent for frequently requested areas of cancer research.</field_page_description>
  <field_feature_card_description>See funding amounts for frequently requested areas of cancer research. </field_feature_card_description>
  <field_list_description>See dollar amounts for various disease areas ranging from AIDS to Uterine Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969912</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>971521</id>
  <title>In Mice, New Drug Conjugate Suggests Promise for Hard-to-Treat Pediatric Cancers</title>
  <langcode>en</langcode>
  <field_short_title>New Drug Conjugate Suggests Promise against Sarcoma</field_short_title>
  <field_page_description>Findings from a study in mice suggests that a new type of drug conjugate may have potential as a treatment for two cancers that are often diagnosed in children.</field_page_description>
  <field_feature_card_description>In mice, a new type of drug conjugate shows potential against cancers often diagnosed in children.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-30</field_date_posted>
  <field_date_reviewed>2015-06-30</field_date_reviewed>
  <field_pretty_url>hsp90-conjugate-sarcoma</field_pretty_url>
  <para_id>971521</para_id>
  <related_resource_id>6573026</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>971636</id>
  <title>NCI Launches Competition to Spur Research on Breast Cancer Genomics, Disease Risk</title>
  <langcode>en</langcode>
  <field_short_title>Competition Spurs Research on Breast Cancer Genomics and Risk</field_short_title>
  <field_page_description>Last month, NCI launched a competition to spur research in an area of great public health interest: the genomic basis of breast cancer and breast cancer risk.</field_page_description>
  <field_feature_card_description>Participants can earn up to $50,000 in prizes for their research findings.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-02</field_date_posted>
  <field_date_reviewed>2015-07-01</field_date_reviewed>
  <field_pretty_url>u4c-challenge</field_pretty_url>
  <para_id>971636</para_id>
  <related_resource_id>6572532</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>974312</id>
  <title>Cancer Currents Now Available in Spanish</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Currents Now Available in Spanish</field_short_title>
  <field_page_description>As part of our effort to more effectively reach patients, health care providers, and researchers with timely, authoritative, and scientifically accurate cancer information, we are now offering selected Cancer Currents blog posts in Spanish.</field_page_description>
  <field_feature_card_description>Translated selections from the Cancer Currents blog about cancer research news, NCI programs, and more. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-08</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <field_pretty_url>spanish-blog</field_pretty_url>
  <para_id>974312</para_id>
  <related_resource_id>6613681</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>84135</id>
  <title>Denosumab Effective for Multiple Myeloma and Solid Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Denosumab Effective for Multiple Myeloma and Solid Tumors</field_short_title>
  <field_page_description>Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).</field_page_description>
  <field_feature_card_description>Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-08</field_date_posted>
  <field_date_reviewed>2011-06-08</field_date_reviewed>
  <field_pretty_url>denosumab-prevent-bone-problems</field_pretty_url>
  <para_id>84135</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>89698</id>
  <title>Drugs Approved for Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Neuroblastoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for neuroblastoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-26</field_date_posted>
  <field_date_reviewed>2011-07-14</field_date_reviewed>
  <field_pretty_url>neuroblastoma</field_pretty_url>
  <para_id>89698</para_id>
  <related_resource_ids>6994579</related_resource_ids>
  <related_resource_ids>6994583</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1092140</term_id>
  <id>281222</id>
  <title>History of the NCI Cancer Centers Program</title>
  <langcode>en</langcode>
  <field_short_title>History of the NCI Cancer Centers Program</field_short_title>
  <field_page_description>A timeline of the development of NCI’s cancer centers program over the last 100 years.</field_page_description>
  <field_feature_card_description>A timeline of the development of NCI’s cancer centers program over the last 100 years.</field_feature_card_description>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-13</field_date_posted>
  <field_date_reviewed>2012-04-20</field_date_reviewed>
  <para_id>281222</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>907253</id>
  <title>e-ASIA Joint Research Program</title>
  <langcode>en</langcode>
  <field_short_title>e-ASIA Joint Research Program</field_short_title>
  <field_page_description>e-ASIA Joint Research Program</field_page_description>
  <field_feature_card_description>e-ASIA Joint Research Program</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-12</field_date_posted>
  <field_date_reviewed>2015-02-12</field_date_reviewed>
  <field_pretty_url>e-asia-jrp</field_pretty_url>
  <para_id>907253</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915538</term_id>
  <id>915540</id>
  <title>Stem Cell Transplants in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Stem Cell Transplant </field_short_title>
  <field_page_description>Stem cell transplants are procedures that restore blood-forming stem cells in cancer patients who have had theirs destroyed by very high doses of chemotherapy or radiation therapy. Learn about the types of transplants and side effects that may occur.</field_page_description>
  <field_feature_card_description>Stem cell transplants are procedures that restore blood-forming stem cells in cancer patients who have had theirs destroyed by very high doses of chemotherapy or radiation therapy. Learn about the types of transplants and side effects that may occur.</field_feature_card_description>
  <field_list_description>Stem cell transplants are procedures that restore blood-forming stem cells in cancer patients who have had theirs destroyed by very high doses of chemotherapy or radiation therapy. Learn about the types of transplants, side effects that may occur, and how stem cell transplants are used in cancer treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915540</para_id>
  <related_resource_ids>7090550</related_resource_ids>
  <related_resource_ids>7090554</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915609</term_id>
  <id>915644</id>
  <title>Cancer Health Disparities Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Health Disparities Research</field_short_title>
  <field_page_description>NCI is addressing cancer health disparities through its efforts in basic research, community-level programs, and more. </field_page_description>
  <field_feature_card_description>NCI is working to understand and address cancer health disparities, such as the higher cancer death rates, less frequent use of proven screening tests, and higher rates of advanced cancer diagnoses among certain populations as compared with others.</field_feature_card_description>
  <field_list_description>NCI is working to understand and address cancer health disparities, such as the higher cancer death rates, less frequent use of proven screening tests, and higher rates of advanced cancer diagnoses among certain populations as compared with others.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-12</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915644</para_id>
  <related_resource_ids>7190571</related_resource_ids>
  <related_resource_ids>7190577</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915611</term_id>
  <id>915651</id>
  <title>Cancer Genomics Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genomics Research</field_short_title>
  <field_page_description>Investigating the genetic foundations of cancer has improved our understanding of cancer biology and led to better prevention, diagnosis and treatment methods.</field_page_description>
  <field_feature_card_description>Understanding the genetic foundations of cancer leads to new methods of diagnosing and treating the disease.</field_feature_card_description>
  <field_list_description>Investigating the genetic foundations of cancer has improved our understanding of cancer biology and led to new methods of diagnosing and treating the disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-13</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915651</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915615</term_id>
  <id>915654</id>
  <title>Global Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Global Cancer Research</field_short_title>
  <field_page_description>NCI is confronting the global burden of cancer through many programs and international partnerships.</field_page_description>
  <field_feature_card_description>NCI is committed to supporting international programs and partnerships that drive progress against cancer worldwide.</field_feature_card_description>
  <field_list_description>NCI is confronting the global burden of cancer by creating sustainable international partnerships, supporting programs that address global gaps in research and scientific training, and disseminating information and best practices that drive improvements in cancer research and cancer control.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-12</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915654</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>916697</term_id>
  <id>916695</id>
  <title>Spotlight on Scientists</title>
  <langcode>en</langcode>
  <field_short_title>Spotlight on Scientists</field_short_title>
  <field_page_description>Written profiles highlighting the work of NCI and NCI-funded researchers, clinicians, and others who contribute to cancer research.</field_page_description>
  <field_feature_card_description>Written profiles highlighting the work of NCI and NCI-funded researchers, clinicians, and others who contribute to cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916695</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916793</term_id>
  <id>916804</id>
  <title>Funding Strategy</title>
  <langcode>en</langcode>
  <field_short_title>Funding Strategy</field_short_title>
  <field_page_description>NCI formulates funding guidelines based on expected allocations, program requirements, and funding history. Learn how NCI funding decisions are made.</field_page_description>
  <field_feature_card_description>The NCI funding strategy aims to fund the most promising scientific opportunities. </field_feature_card_description>
  <field_list_description>To fund the most promising scientific opportunities, NCI formulates guidelines based on expected allocations of funds, program requirements, and prior history.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-17</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916804</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>916848</term_id>
  <id>916849</id>
  <title>Contracts and Small Business</title>
  <langcode>en</langcode>
  <field_short_title>Contracts and Small Business</field_short_title>
  <field_page_description>Information about the types of contract mechanisms used by NCI to procure cancer research products and services.</field_page_description>
  <field_feature_card_description>Information about the types of contract mechanisms used by NCI to procure cancer research products and services.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916849</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939885</term_id>
  <id>939892</id>
  <title>Bone Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Bone Cancer</field_short_title>
  <field_page_description>There are several types of bone cancer. Osteosarcoma usually starts in osteoblasts, a type of bone cell that becomes new bone tissue. Ewing sarcoma arises from a primordial bone marrow–derived mesenchymal stem cell. Find evidence-based information on bone cancer including treatment, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about bone cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939892</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939958</term_id>
  <id>939963</id>
  <title>Breast Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer</field_short_title>
  <field_page_description>The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of a lobule and in other tissues of the breast. Find evidence-based information on breast cancer treatment, causes and prevention, genetics, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939963</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940109</term_id>
  <id>940116</id>
  <title>Esophageal Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Esophageal Cancer</field_short_title>
  <field_page_description>The incidence of esophageal cancer has risen in recent decades, coinciding with a shift in histologic type and primary tumor location. Find evidence-based information on esophageal cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about esophageal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940116</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940470</term_id>
  <id>940477</id>
  <title>Liver and Bile Duct Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Liver and Bile Duct Cancer</field_short_title>
  <field_page_description>Liver cancer includes two major types: hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer, also known as cholangiocarcinoma. Find evidence-based information on liver and bile duct cancer treatment, causes and prevention, screening, research, genomics and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about liver and bile duct cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940477</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>940508</id>
  <title>Lung Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on lung cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940508</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938229</term_id>
  <id>940618</id>
  <title>Plasma Cell Neoplasms (Including Multiple Myeloma) Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on plasma cell neoplasms (including multiple myeloma), which may include news stories, clinical trials, blog posts, and descriptions of active studies. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940618</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940704</term_id>
  <id>940711</id>
  <title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</field_short_title>
  <field_page_description>Ovarian epithelial, fallopian tube, and peritoneal cancers are diseases in which malignant cells form in the tissue covering the ovary, lining the fallopian tube, or peritoneum. Find evidence-based information on ovarian cancer treatment, causes and prevention, screening, research, genetics and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940711</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940261</term_id>
  <id>940266</id>
  <title>Gastrointestinal Carcinoid Tumors—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Gastrointestinal Carcinoid Tumors</field_short_title>
  <field_page_description>Gastrointestinal carcinoid tumors are rare, slow-growing tumors that originate in the neuroendocrine cells in the GI tract. Find evidence-based information on gastrointestinal carcinoid tumors treatment and research. </field_page_description>
  <field_list_description>NCI's gateway for information about Gastrointestinal Carcinoid.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940266</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>940829</term_id>
  <id>940837</id>
  <title>Pheochromocytoma and Paraganglioma Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on pheochromocytoma and paraganglioma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940837</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940858</term_id>
  <id>940863</id>
  <title>Pituitary Tumors—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Pituitary Tumors</field_short_title>
  <field_page_description>Pituitary tumors represent from 10% to 25% of all intracranial neoplasms. Pituitary tumors can be classified into three groups: benign adenoma, invasive adenoma, and carcinoma. Find evidence-based information on pituitary tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Pituitary Tumor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940863</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952678</term_id>
  <id>15332</id>
  <title>PDQ&amp;reg; Supportive and Palliative Care Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Supportive &amp;amp; Palliative Care Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of pain and palliative care, psychology, medical oncology, and pediatric oncology.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-05-01</field_date_posted>
  <field_date_reviewed>2005-04-12</field_date_reviewed>
  <para_id>15332</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>15397</id>
  <title>How To Handle Withdrawal Symptoms and Triggers When You Decide To Quit Smoking</title>
  <langcode>en</langcode>
  <field_short_title>Handling Withdrawal Symptoms &amp; Triggers When You Decide to Quit</field_short_title>
  <field_page_description>This fact sheet provides helpful tips related to smoking cessation.</field_page_description>
  <field_list_description>A fact sheet that provides helpful tips related to smoking cessation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-10-29</field_date_posted>
  <field_date_reviewed>2010-10-29</field_date_reviewed>
  <field_pretty_url>withdrawal-fact-sheet</field_pretty_url>
  <para_id>15397</para_id>
  <related_resource_ids>6152677</related_resource_ids>
  <related_resource_ids>6152678</related_resource_ids>
  <related_resource_ids>6152679</related_resource_ids>
  <related_resource_ids>6152680</related_resource_ids>
  <related_resource_ids>6152681</related_resource_ids>
  <related_resource_ids>6152682</related_resource_ids>
  <related_resource_ids>6152683</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911172</term_id>
  <id>15614</id>
  <title>Helicobacter pylori and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Helicobacter pylori and Cancer</field_short_title>
  <field_page_description>A fact sheet about the relationship between H. pylori infection and gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and other cancers.</field_page_description>
  <field_feature_card_description>A fact sheet about the relationship between H. pylori infection and gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and other cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-09-25</field_date_posted>
  <field_date_reviewed>2013-09-05</field_date_reviewed>
  <field_pretty_url>h-pylori-fact-sheet</field_pretty_url>
  <para_id>15614</para_id>
  <related_resource_ids>6934174</related_resource_ids>
  <related_resource_ids>6934175</related_resource_ids>
  <related_resource_ids>6934213</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11946</term_id>
  <id>15830</id>
  <title>Parathyroid Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Parathyroid Cancer</field_short_title>
  <field_page_description>Parathyroid tumors are usually benign (not cancer) and are called adenomas. Parathyroid cancer is very rare. Having certain inherited disorders can increase the risk of parathyroid cancer. Start here to find information on parathyroid cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Parathyroid Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2007-03-09</field_date_reviewed>
  <para_id>15830</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>929499</term_id>
  <id>16226</id>
  <title>Cancer Training at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Training at NCI</field_short_title>
  <field_page_description>Training, fellowships, and other professional education opportunities for students and scientists on the NIH/NCI campus in Maryland (intramural).</field_page_description>
  <field_feature_card_description>Find training, fellowships, and other professional education opportunities for students and scientists on the NIH and NCI campuses in Maryland.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2008-11-14</field_date_reviewed>
  <para_id>16226</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917289</term_id>
  <id>922315</id>
  <title>Resources for Health Professionals</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Health Professionals</field_short_title>
  <field_page_description>Get the latest information about cancer with our PDQ® Cancer Information Summaries and find NCI-supported clinical trials. We also offer training information and tools as well as resources for public health program planners and cancer registrars.</field_page_description>
  <field_feature_card_description>Find evidence-based information about cancer as well as risk assessment tools, training tools, and other resources.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-31</field_date_posted>
  <field_date_reviewed>2015-03-31</field_date_reviewed>
  <para_id>922315</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>923421</id>
  <title>Selenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Selenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers</field_short_title>
  <field_page_description>Learn the results of the Selenium and Vitamin E Cancer Prevention Trial. SELECT was a clinical trial to see if one or both of these substances could help prevent prostate cancer when taken as dietary supplements. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2008-10-31</field_date_posted>
  <field_date_reviewed>2015-04-03</field_date_reviewed>
  <field_pretty_url>select-trial-results-qa</field_pretty_url>
  <para_id>923421</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>930720</id>
  <title>Common Myths about Cancer and Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Common Myths about Cancer and Cancer Health Disparities</field_short_title>
  <field_page_description>To better understand cancer and cancer health disparities, CRCHD addresses five common misconceptions about cancer. </field_page_description>
  <field_feature_card_description>CRCHD addresses five common misconceptions about cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-09</field_date_posted>
  <field_date_reviewed>2015-04-09</field_date_reviewed>
  <field_pretty_url>chdmyths-spotlight</field_pretty_url>
  <para_id>930720</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936430</id>
  <title>Grantee Spotlight: Manuel L. Penichet, M.D., Ph.D. - Reprogramming the Immune System to Kill Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Manuel L. Penichet, M.D., Ph.D. - Reprogramming the Immune System to Kill Cancer </field_short_title>
  <field_page_description>Dr. Manuel L. Penichet, former CURE K01 trainee and NCI R01 grantee, aims to genetically engineer antibodies that can be used to directly target and eliminate cancer cells and also stimulate the body’s immune system to fight and destroy cancer.</field_page_description>
  <field_feature_card_description>Dr. Penichet aims to genetically engineer antibodies to fight cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-20</field_date_posted>
  <field_date_reviewed>2014-06-20</field_date_reviewed>
  <field_pretty_url>penichet-spotlight-blog</field_pretty_url>
  <para_id>936430</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>938033</id>
  <title>Grantee Spotlight: Marcia Cruz-Correa, M.D., Ph.D., Finds Link between Human Papillomavirus and Colorectal Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Marcia Cruz-Correa, M.D., Ph.D.</field_short_title>
  <field_page_description>Dr. Marcia Cruz-Correa, a CRCHD grantee, and her team of researchers from the University of Puerto Rico discovered a link between human papillomavirus and colorectal cancer in tissue samples from a large cohort of colorectal cancer patients.</field_page_description>
  <field_feature_card_description>Dr. Cruz-Correa find link between human papillomavirus and colorectal cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-14</field_date_posted>
  <field_date_reviewed>2014-03-14</field_date_reviewed>
  <field_pretty_url>cruz-correa-spotlight</field_pretty_url>
  <para_id>938033</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>938034</id>
  <title>Grantee Spotlight: Community Health Educator Antoinette Ayers, Helps VA Residents Become More Proactive about Managing Their Health</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Antoinette Ayers</field_short_title>
  <field_page_description>Ms. Antoinette Ayers, NCI/CRCHD National Outreach Network community health educator, is making health services more accessible to the people of Petersburg, VA by bringing a health resource center to the city's historic public library.</field_page_description>
  <field_feature_card_description>Ms. Ayers, NON CHE, brings health resource center to local public library.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-10</field_date_posted>
  <field_date_reviewed>2014-01-10</field_date_reviewed>
  <field_pretty_url>ayers-spotlight</field_pretty_url>
  <para_id>938034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939549</id>
  <title>CGH Celebrates Take Your Child To Work Day 2015</title>
  <langcode>en</langcode>
  <field_short_title>CGH Celebrates Take Your Child To Work Day 2015</field_short_title>
  <field_page_description>Shady Grove celebrated Take Your Child To Work Day this year with a variety of activities and sessions aimed at inspiring school-aged children to explore career paths in science and public service.  CGH hosted its inaugural Take Your Child To Work Day session: An Introduction to Global Health.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-28</field_date_posted>
  <field_date_reviewed>2015-04-28</field_date_reviewed>
  <field_pretty_url>tyctwd</field_pretty_url>
  <para_id>939549</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939581</id>
  <title>Hands-on Workshops Aim to Strengthen Tobacco Control Efforts in Indonesia</title>
  <langcode>en</langcode>
  <field_short_title>Hands-on Workshops Aim to Strengthen Tobacco Control Efforts in Indonesia</field_short_title>
  <field_page_description>The Global Adult Tobacco Survey (GATS), conducted in 2011 by the Indonesian National Institute of Health Research and Development and the U.S. Center for Disease Control and Prevention, showed that more than 67% of men and almost 40% of boys aged 13-15 use tobacco.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-29</field_date_reviewed>
  <field_pretty_url>indonesia-workshop2015</field_pretty_url>
  <para_id>939581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938137</term_id>
  <id>545408</id>
  <title>Electrocautery Superior to Topical Treatments for Precancerous Anal Lesions</title>
  <langcode>en</langcode>
  <field_short_title>Electrocautery for Precancerous Anal Lesions</field_short_title>
  <field_page_description>Results from a randomized clinical trial conducted in Amsterdam suggest that electrocautery is better than topical imiquimod or fluorouracil at treating potentially precancerous anal lesions in HIV-positive men who have sex with men.</field_page_description>
  <field_feature_card_description>Results from a randomized clinical trial conducted in Amsterdam suggest that electrocautery is better than topical imiquimod or fluorouracil at treating potentially precancerous anal lesions in HIV-positive men who have sex with men.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-04-04</field_date_posted>
  <field_date_reviewed>2013-04-02</field_date_reviewed>
  <field_pretty_url>electrocautery</field_pretty_url>
  <para_id>545408</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940546</term_id>
  <id>940553</id>
  <title>Lymphoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Lymphoma </field_short_title>
  <field_page_description>Lymphoma refers to cancers that form in the lymphatic system, including Hodgkin lymphoma, non-Hodgkin lymphoma, AIDS-related lymphoma, and primary CNS lymphoma. Find evidence-based information on lymphoma treatment, research, genomics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940553</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938103</term_id>
  <id>940554</id>
  <title>Lymphoma Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on lymphoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940554</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911286</term_id>
  <id>15469</id>
  <title>Cryosurgery in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Cryosurgery in Cancer Treatment</field_short_title>
  <field_page_description>A fact sheet that describes cryosurgery, the technique of using extreme cold to treat tumors. Lists the indications, risks, benefits, and side effects of cryotherapy.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-09-09</field_date_posted>
  <field_date_reviewed>2003-09-10</field_date_reviewed>
  <field_pretty_url>cryosurgery-fact-sheet</field_pretty_url>
  <para_id>15469</para_id>
  <related_resource_id>6934068</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>882493</term_id>
  <id>15541</id>
  <title>Formaldehyde and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Formaldehyde and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that discusses formaldehyde and its possible association with cancer. Includes resources for more information.</field_page_description>
  <field_feature_card_description>A fact sheet that discusses formaldehyde and its possible association with cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-10</field_date_posted>
  <field_date_reviewed>2011-06-10</field_date_reviewed>
  <field_pretty_url>formaldehyde-fact-sheet</field_pretty_url>
  <para_id>15541</para_id>
  <related_resource_id>6934336</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>11738</term_id>
  <id>16393</id>
  <title>NCI Cancer Genetics Services Directory: Search Results</title>
  <langcode>en</langcode>
  <field_short_title>NCI Cancer Genetics Services Directory: Search Results</field_short_title>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <field_pretty_url>results</field_pretty_url>
  <para_id>16393</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>63846</term_id>
  <id>63856</id>
  <title>Paying for Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Paying for Clinical Trials</field_short_title>
  <field_page_description>Learn about the different types of costs related to taking part in a clinical trial, who is expected to pay for which costs, and tips for working with insurance companies.</field_page_description>
  <field_feature_card_description>Learn about the different types of costs related to taking part in a clinical trial, who is expected to pay for which costs, and tips for working with insurance companies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-24</field_date_posted>
  <field_date_reviewed>2011-02-24</field_date_reviewed>
  <para_id>63856</para_id>
  <related_resource_ids>7090668</related_resource_ids>
  <related_resource_ids>7090669</related_resource_ids>
  <related_resource_ids>7090670</related_resource_ids>
  <related_resource_ids>7090672</related_resource_ids>
  <related_resource_ids>7090673</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>505751</id>
  <title>Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer</field_short_title>
  <field_page_description>In this trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomized to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy.</field_page_description>
  <field_feature_card_description>In this trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomized to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy.</field_feature_card_description>
  <field_list_description>In this phase III trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomly assigned either to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy without chemotherapy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2013-02-05</field_date_reviewed>
  <field_pretty_url>post-surgical-therapy</field_pretty_url>
  <para_id>505751</para_id>
  <related_resource_ids>6494185</related_resource_ids>
  <related_resource_ids>6494186</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505623</term_id>
  <id>505757</id>
  <title>Comment Policy</title>
  <langcode>en</langcode>
  <field_short_title>Comment Policy</field_short_title>
  <field_page_description>Learn the policy about how comments are managed on National Cancer Institute websites.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <para_id>505757</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>917518</id>
  <title>FDA Approves Panobinostat for Some Patients with Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Panobinostat for Some Patients with Multiple Myeloma</field_short_title>
  <field_page_description>The FDA granted accelerated approval of panobinostat for the treatment of multiple myeloma that has progressed after at least two prior standard therapies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-19</field_date_posted>
  <field_date_reviewed>2015-03-19</field_date_reviewed>
  <field_pretty_url>fda-approves-panobinostat</field_pretty_url>
  <para_id>917518</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917273</term_id>
  <id>917734</id>
  <title>National Clinical Trials Network (NCTN) Steering Committees</title>
  <langcode>en</langcode>
  <field_short_title>NCTN Steering Committees</field_short_title>
  <field_page_description>The National Clinical Trials Network (NCTN) Steering Committees review concepts, or proposals, for large phase 2 or phase 3 treatment or imaging trials conducted in the NCTN.</field_page_description>
  <field_feature_card_description>The NCTN Steering Committees review concepts for large phase 2 or phase 3 treatment or imaging trials conducted in the NCTN. </field_feature_card_description>
  <field_list_description>The National Clinical Trials Network (NCTN) Steering Committees review concepts for large phase 2 or phase 3 treatment or imaging trials conducted in the NCTN. A concept is a proposal describing the key design elements of the study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2015-03-20</field_date_reviewed>
  <para_id>917734</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1120550</id>
  <title>FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Checkpoint Inhibitor Use Changed for Bladder Cancer</field_short_title>
  <field_page_description>FDA has altered the approved uses of pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker.</field_page_description>
  <field_feature_card_description>For some patients, tumors must have specific biomarker.</field_feature_card_description>
  <field_list_description>FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-26</field_date_posted>
  <field_date_reviewed>2018-07-24</field_date_reviewed>
  <field_pretty_url>bladder-cancer-checkpoint-inhibitor-change</field_pretty_url>
  <para_id>1120550</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1120605</id>
  <title>Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and Helen Chen</title>
  <langcode>en</langcode>
  <field_short_title>Developing Biomarkers for Immunotherapy</field_short_title>
  <field_page_description>Identifying biomarkers for cancer immunotherapy is the goal of a new NCI-supported research network. Such markers can help to identify patients most likely to benefit from immune-based treatments. </field_page_description>
  <field_feature_card_description>New NCI network is focused on identifying who will benefit from immune-based treatments.</field_feature_card_description>
  <field_list_description>NCI is supporting a new research network to develop biomarkers for cancer immunotherapy. In this interview, NCI’s Dr. Helen Chen and Magdalena Thurin explain the networks’ structure and its goals.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-27</field_date_posted>
  <field_date_reviewed>2018-07-25</field_date_reviewed>
  <field_pretty_url>immunotherapy-biomarkers-research-network</field_pretty_url>
  <para_id>1120605</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121222</term_id>
  <id>1121223</id>
  <title>Develop Ways to Overcome Cancer’s Resistance to Therapy</title>
  <langcode>en</langcode>
  <field_short_title>Overcoming Drug Resistance</field_short_title>
  <field_page_description>Cancer cells can develop resistance to drugs that were previously effective. This Cancer Moonshot initiative aims to increase understanding of how this resistance develops, and to use biomarkers to predict who will develop it, and ways to counteract it to improve patient care and survival.</field_page_description>
  <field_feature_card_description>This Cancer Moonshot initiative aims to improve our understanding of drug resistance in cancer and how to overcome it.</field_feature_card_description>
  <field_list_description>Identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-01</field_date_reviewed>
  <para_id>1121223</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>315415</id>
  <title>More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails</title>
  <langcode>en</langcode>
  <field_short_title>More Chemotherapy May Help after Initial Treatment for Childhood Leukemia Fails</field_short_title>
  <field_page_description>A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.</field_page_description>
  <field_feature_card_description>A study suggests that at least some children diagnosed with acute lymphoblastic leukemia who respond poorly to initial chemotherapy may do better if they receive additional chemotherapy rather than a stem cell transplant.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-07</field_date_posted>
  <field_date_reviewed>2012-06-07</field_date_reviewed>
  <field_pretty_url>more-chemo-helps-all</field_pretty_url>
  <para_id>315415</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>417539</term_id>
  <id>321609</id>
  <title>About CCCT</title>
  <langcode>en</langcode>
  <field_short_title>About CCCT</field_short_title>
  <field_page_description>An overview of how the Coordinating Center for Clinical Trials supports NCI's clinical trials and translational research enterprises. Includes CCCT contact information.</field_page_description>
  <field_feature_card_description>Learn more about how CCCT supports NCI's clinical trials and translational research enterprises and how to contact us.</field_feature_card_description>
  <field_list_description>Learn more about how CCCT supports NCI's clinical trials and translational research enterprises and how to contact us.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-06-21</field_date_posted>
  <field_date_reviewed>2012-06-21</field_date_reviewed>
  <para_id>321609</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396055</term_id>
  <id>396077</id>
  <title>Use of Placebos</title>
  <langcode>en</langcode>
  <field_short_title>Use of Placebos</field_short_title>
  <field_page_description>Information about placebos and their role in cancer clinical trials.</field_page_description>
  <field_feature_card_description>Information about placebos and their role in cancer clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>396077</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>921705</id>
  <title>CGH and OCC Announce a New, Two-Year Funding Opportunity for NCI-designated Cancer Centers </title>
  <langcode>en</langcode>
  <field_short_title>CGH and OCC Announce a New, Two-Year Funding Opportunity for NCI-designated Cancer Centers </field_short_title>
  <field_page_description>CGH and OCC announce a new funding opportunity available from CGH for cancer prevention and control (CPC) researchers at NCI-designated cancer centers: Administrative Supplements to Promote Cancer Prevention and Control Research in Low and Middle Income Countries.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-30</field_date_reviewed>
  <field_pretty_url>funding-opportunity-cancercenters</field_pretty_url>
  <para_id>921705</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>922332</term_id>
  <id>922330</id>
  <title>Metastatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Metastatic Cancer</field_short_title>
  <field_page_description>Metastatic cancer is cancer that spreads from its site of origin to another part of the body. Learn how cancer spreads, possible symptoms, common sites where cancer spreads, and how to find out about treatment options.</field_page_description>
  <field_feature_card_description>Understand how and where cancer spreads, possible symptoms, and how to find information about treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-12</field_date_posted>
  <field_date_reviewed>2015-03-31</field_date_reviewed>
  <para_id>922330</para_id>
  <related_resource_ids>7126469</related_resource_ids>
  <related_resource_ids>7126476</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>922404</id>
  <title>Prostate Cancer Screening Results from the Prostate, Lung, Colorectal, and Ovarian Cancer Randomized Screening Trial: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Prostate Cancer Screening Results from PLCO</field_short_title>
  <field_page_description>Learn the results of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a large-scale clinical trial to determine whether certain cancer screening tests can help reduce deaths from prostate, lung, colorectal, and ovarian cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2009-03-19</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>plco-screening-results-qa</field_pretty_url>
  <para_id>922404</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938042</term_id>
  <id>940712</id>
  <title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on ovarian, fallopian tube, and primary peritoneal cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940712</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940801</term_id>
  <id>940806</id>
  <title>Penile Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Penile Cancer </field_short_title>
  <field_page_description>Penile cancer is most commonly squamous cell carcinoma. When diagnosed early, penile cancer is highly curable. Some studies suggest an association between human papillomavirus (HPV) infection and penile cancer. Find evidence-based information on penile cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Penile Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940806</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11972</term_id>
  <id>15562</id>
  <title>Thyroid Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Thyroid Cancer</field_short_title>
  <field_page_description>Thyroid cancer can be of four main types. Anaplastic thyroid cancer is hard to cure with current treatments, whereas papillary (the most common), follicular, and medullary thyroid cancer can usually be cured. Start here to find information on thyroid cancer treatment, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about thyroid cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15562</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952660</term_id>
  <id>15611</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Prevention</field_short_title>
  <field_page_description>Risk factors and methods to increase chances of preventing specific types of cancer.</field_page_description>
  <field_feature_card_description>Can you lower your risk of getting cancer? Learn more from our evidence-based information summaries.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15611</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>1052958</term_id>
  <id>16380</id>
  <title>Find NCI-Supported Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Find NCI-Supported Clinical Trials</field_short_title>
  <field_feature_card_description>Find an NCI-supported clinical trial—and learn how to locate other research studies—that may be right for you or a loved one.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16380</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127294</term_id>
  <id>57472</id>
  <title>FDA Terminology</title>
  <langcode>en</langcode>
  <field_short_title>FDA Terminology</field_short_title>
  <field_page_description>FDA works with NCI EVS to develop regulatory and other controlled terminology standards.</field_page_description>
  <field_feature_card_description>FDA works with NCI EVS to develop regulatory and other controlled terminology in several areas. Some 15,000 terms are stored in NCIt.</field_feature_card_description>
  <field_list_description>U.S. Food and Drug Administration (FDA) works with NCI EVS to develop regulatory and other controlled terminology in several areas. Some 15,000 terms are stored in NCI Thesaurus (NCIt).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-07</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>57472</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770435</term_id>
  <id>770436</id>
  <title>Genitourinary Cancers Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Genitourinary Cancers Steering Committee</field_short_title>
  <field_page_description>The Genitourinary Cancers Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials in genitourinary cancers.</field_page_description>
  <field_feature_card_description>The Genitourinary Cancers Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.  </field_feature_card_description>
  <field_list_description>The Genitourinary Cancers Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770436</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1137212</id>
  <title>After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought</title>
  <langcode>en</langcode>
  <field_short_title>Risks of Follow-Up Procedures after Lung Cancer Screening</field_short_title>
  <field_page_description>After lung cancer screening, complication rates from diagnostic procedures may be higher than indicated by results of the NLST trial, a new study suggests.</field_page_description>
  <field_feature_card_description>Complication rates in everyday care may be higher than thought, study suggests.</field_feature_card_description>
  <field_list_description>In everyday medical care, there may be more complications from invasive diagnostic procedures performed after lung cancer screening than has been reported in large studies.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-08</field_date_posted>
  <field_date_reviewed>2019-02-08</field_date_reviewed>
  <field_pretty_url>lung-cancer-screening-complications-diagnostic-follow-up</field_pretty_url>
  <para_id>1137212</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1137529</term_id>
  <id>1137530</id>
  <title>NCI Awardee Skills Development Consortium: Research Education Short Courses (UE5)</title>
  <langcode>en</langcode>
  <field_short_title>NCI UE5 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2011-03-18</field_date_reviewed>
  <para_id>1137530</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137868</id>
  <title>TCGA's Study of Thymoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Thymoma</field_short_title>
  <field_page_description>A summary of TCGA's study of thymic epithelial cancer (thymoma), including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Thymoma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>thymoma</field_pretty_url>
  <para_id>1137868</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137885</id>
  <title>TCGA's Study of Uterine Carcinosarcoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Uterine Carcinosarcoma</field_short_title>
  <field_page_description>TCGA's Study of Uterine Carcinosarcoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Uterine Carcinosarcoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of uterine carcinosarcoma endometrial cancer, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>uterine-carcinosarcoma</field_pretty_url>
  <para_id>1137885</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1138011</term_id>
  <id>1137918</id>
  <title>NCI/NIH Meeting Room  </title>
  <langcode>en</langcode>
  <field_short_title>NCI/NIH Meeting Room  </field_short_title>
  <field_page_description>Researchers can arrange a meeting with their Program Directors ahead of AACR to discuss individual grants and learn about new research initiatives at NCI. See the NCI Resource Room hours.</field_page_description>
  <field_feature_card_description>Researchers interested in meeting with their Program Directors should contact them ahead of AACR to arrange a time to meet at the NCI Resource Room. This space will be used for one-on-one consultations with NCI staff as well as small group meetings facili</field_feature_card_description>
  <field_list_description>Researchers interested in meeting with their Program Directors should contact them ahead of AACR to arrange a time to meet at the NCI/NIH Meeting Room.  This space will be used for one-on-one consultations with NCI staff as well as small group meetings facilitated by the NCI.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-08</field_date_posted>
  <field_date_reviewed>2018-03-26</field_date_reviewed>
  <para_id>1137918</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1140158</id>
  <title>Making Cancer Clinical Trials Available to More Patients</title>
  <langcode>en</langcode>
  <field_short_title>Making Cancer Clinical Trials Available to More Patients</field_short_title>
  <field_page_description>NCI is expanding eligibility criteria for cancer clinical trials in the hope that more patients will join trials, leading to more rapid advances in cancer care.</field_page_description>
  <field_feature_card_description>By expanding eligibility criteria, NCI hopes to speed advances in cancer care.</field_feature_card_description>
  <field_list_description>NCI is expanding eligibility criteria for its cancer clinical trials in the hope that more patients will join, leading to more rapid advances. The goal is to maximize the number of patients who are eligible to enroll while maintaining their safety.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-07</field_date_posted>
  <field_date_reviewed>2019-03-05</field_date_reviewed>
  <field_pretty_url>expanding-clinical-trial-eligibility-criteria</field_pretty_url>
  <para_id>1140158</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1115344</term_id>
  <id>1140726</id>
  <title>Blog Posts by the NCI Director Dr. Norman Sharpless</title>
  <langcode>en</langcode>
  <field_short_title>Blog Posts by the NCI Director</field_short_title>
  <field_page_description>NCI Director Dr. Norman Sharpless writes posts regularly for NCI's Cancer Currents Blog that highlight his vision for NCI, meetings with and partnerships in the cancer community, and strategic and scientific initiatives to advance cancer research and care.</field_page_description>
  <field_feature_card_description>NCI Director Dr. Sharpless writes posts for NCI's Cancer Currents Blog.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless writes posts for NCI's Cancer Currents Blog that highlight his vision for NCI, meetings with and partnerships in the cancer community, and strategic and scientific initiatives to advance cancer research and care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-07</field_date_posted>
  <field_date_reviewed>2019-03-07</field_date_reviewed>
  <para_id>1140726</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>915278</term_id>
  <id>915368</id>
  <title>Grant Resources</title>
  <langcode>en</langcode>
  <field_short_title>Grant Resources</field_short_title>
  <field_page_description>Resources to help with the NCI and NIH grants and funding process.</field_page_description>
  <field_feature_card_description>Resources to help with the NCI and NIH grants and funding process.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915368</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>914486</term_id>
  <id>915591</id>
  <title>Research Areas</title>
  <langcode>en</langcode>
  <field_short_title>Research Areas</field_short_title>
  <field_page_description>Making sustained progress against cancer requires advances across the research continuum. Learn about the breadth of NCI's work and the programs the institute supports to advance cancer research.</field_page_description>
  <field_feature_card_description>Learn about the breadth of NCI's work and the programs the institute supports to advance cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-13</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915591</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915603</term_id>
  <id>915637</id>
  <title>Cancer Biology Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Biology Research</field_short_title>
  <field_page_description>The broad base of knowledge created by studying the differences between normal cells and cancer cells has been critical to progress against the disease.</field_page_description>
  <field_feature_card_description>Studying the differences between normal cells and cancer cells is critical to progress against the disease.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-07</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915637</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915607</term_id>
  <id>915643</id>
  <title>Cancer Diagnosis Research </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Diagnosis Research </field_short_title>
  <field_page_description>Accurate information derived from diagnostic tools is critical for making decisions at all stages of cancer care. NCI supports research on the development of tests and imaging technologies that can provide specific information about an individual’s cancer.</field_page_description>
  <field_feature_card_description>NCI supports research on the development of tests and imaging technologies vital to progress against cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-13</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915643</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915605</term_id>
  <id>915676</id>
  <title>Cancer Screening and Early Detection Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Screening and Early Detection Research</field_short_title>
  <field_page_description>Information about cancer screening and early detection research, including a summary of NCI programs dedicated to advancing screening and early detection.</field_page_description>
  <field_feature_card_description>NCI supports and directs research on screening and the early detection of cancer, including studies to develop and validate biological markers.</field_feature_card_description>
  <field_list_description>NCI supports and directs research on screening and the early detection of cancer, including studies to develop and validate biological markers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-07</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915676</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911160</term_id>
  <id>916009</id>
  <title>Choices for Care When Treatment May Not Be an Option</title>
  <langcode>en</langcode>
  <field_short_title>Choices for Care</field_short_title>
  <field_page_description>Know your choices for cancer care when coping with advanced cancer. Learn about palliative care, hospice care, and trying a clinical trial. </field_page_description>
  <field_feature_card_description>When cancer treatment is no longer working, you still have choices for your care. Learn about palliative care, hospice care, and clinical trials for advanced cancer.</field_feature_card_description>
  <field_list_description>When standard cancer treatment is no longer working, you still have choices for your care. Learn about palliative care, hospice care, and clinical trials for advanced cancer.  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916009</para_id>
  <related_resource_ids>7183320</related_resource_ids>
  <related_resource_ids>7183321</related_resource_ids>
  <related_resource_ids>7183322</related_resource_ids>
  <related_resource_ids>7183327</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915803</term_id>
  <id>916020</id>
  <title>Coping with Your Feelings During Advanced Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Coping with Your Feelings During Advanced Cancer</field_short_title>
  <field_page_description>There are many difficult feelings that you can have when going through cancer. Having an advanced or metastatic cancer diagnosis can cause them to be more intense than ever. Know that you're not alone. Learn tips on how to cope with your feelings with an advanced cancer diagnosis.</field_page_description>
  <field_feature_card_description>There are many intense feelings that you can have when going through cancer. Know that you're not alone. Learn tips on coping with your emotions during advanced cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916020</para_id>
  <related_resource_ids>6920651</related_resource_ids>
  <related_resource_ids>6920652</related_resource_ids>
  <related_resource_ids>6920653</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911152</term_id>
  <id>916035</id>
  <title>Alcohol</title>
  <langcode>en</langcode>
  <field_short_title>Alcohol</field_short_title>
  <field_page_description>Brief information about cancer risk due to drinking alcohol.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916035</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915816</term_id>
  <id>916037</id>
  <title>Questions to Ask Your Doctor about Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask about Advanced Cancer</field_short_title>
  <field_page_description>Suggested questions to ask your doctor, if you find out you have advanced cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916037</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916689</term_id>
  <id>916690</id>
  <title>Frederick National Laboratory for Cancer Research </title>
  <langcode>en</langcode>
  <field_short_title>Frederick National Laboratory for Cancer Research </field_short_title>
  <field_page_description>The FNLCR combines private sector business practices with government infrastructure to conduct research and development in cancer and AIDS.</field_page_description>
  <field_feature_card_description>The FNLCR provides cancer researchers a bridge between basic research and clinical practice.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916690</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1125001</id>
  <title>Stimulating the Immune System Shrinks Some Slow-Growing Lymphomas</title>
  <langcode>en</langcode>
  <field_short_title>Stimulating Immune System Shrinks Some Lymphomas</field_short_title>
  <field_page_description>Injecting SD-101 into a single tumor, plus radiation, in patients with indolent B-cell lymphoma shrank tumors elsewhere in the body, trial results show.</field_page_description>
  <field_feature_card_description>Low-dose radiation and SD-101 shrank slow-growing B-cell lymphomas in small trial.</field_feature_card_description>
  <field_list_description>In a small trial involving patients with slow-growing B-cell lymphoma, injecting the compound SD-101 directly into tumors (in situ vaccination) and giving low-dose radiation shrank the injected tumors and, frequently, tumors elsewhere in the body.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-26</field_date_posted>
  <field_date_reviewed>2018-09-26</field_date_reviewed>
  <field_pretty_url>lymphoma-sd-101-in-situ-vaccine</field_pretty_url>
  <para_id>1125001</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1126138</id>
  <title>Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations</title>
  <langcode>en</langcode>
  <field_short_title>Using Artificial Intelligence to Classify Lung Cancer Types</field_short_title>
  <field_page_description>Using artificial intelligence, cancer researchers have trained a computer program to read slides of tissue samples and accurately identify the two most common forms of lung cancer.</field_page_description>
  <field_feature_card_description>The computer program can differentiate the two most common forms of lung cancer.</field_feature_card_description>
  <field_list_description>Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-10</field_date_posted>
  <field_date_reviewed>2018-10-09</field_date_reviewed>
  <field_pretty_url>artificial-intelligence-lung-cancer-classification</field_pretty_url>
  <para_id>1126138</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1126329</id>
  <title>Trial Results Highlight Changing Lung Cancer Treatment Landscape</title>
  <langcode>en</langcode>
  <field_short_title>Trials Highlight Changing Lung Cancer Treatment Landscape</field_short_title>
  <field_page_description>The ALK inhibitor brigatinib (Alunbrig) and checkpoint inhibitor durvalumab (Imfinzi) can improve outcomes in patients with advanced non-small cell lung cancer, results from two large clinical trials have affirmed.</field_page_description>
  <field_feature_card_description>Results affirm benefit of targeted agent and immunotherapy drug.</field_feature_card_description>
  <field_list_description>Results from two large clinical trials should cement the value of the drugs brigatinib (Alunbrig) and durvalumab (Imfinzi) in treating non-small cell lung cancer (NSCLC). The trial results, several experts said, confirm that the drugs can improve the outcomes of patients with advanced NSCLC.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-15</field_date_posted>
  <field_date_reviewed>2018-10-12</field_date_reviewed>
  <field_pretty_url>durvalumab-brigatinib-lung-cancer-trials</field_pretty_url>
  <para_id>1126329</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1126791</id>
  <title>Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Cemiplimab Approved for Advanced Squamous Cell Skin Cancer</field_short_title>
  <field_page_description>The immunotherapy drug cemiplimab (Libtayo) has been approved by FDA for advanced cutaneous squamous cell carcinoma, a common type of skin cancer. </field_page_description>
  <field_feature_card_description>The immunotherapy is the first agent to be approved by FDA for advanced SCC. </field_feature_card_description>
  <field_list_description>The Food and Drug Administration approved the immunotherapy drug cemiplimab (Libtayo) for an advanced form of cutaneous squamous cell carcinoma (SCC), a common type of skin cancer. It is the first agent to be approved specifically for advanced SCC.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-19</field_date_posted>
  <field_date_reviewed>2018-10-19</field_date_reviewed>
  <field_pretty_url>cemiplimab-fda-squamous-cell-carcinoma</field_pretty_url>
  <para_id>1126791</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1107074</term_id>
  <id>1127224</id>
  <title>Making the Case for Biomarkers in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Making the Case for Biomarkers in Cancer Treatment-T.J. Sharpe</field_short_title>
  <field_page_description>Read how melanoma survivor T.J. Sharpe’s experience on two clinical trials highlights the need for biomarkers to predict benefit from immunotherapy.</field_page_description>
  <field_feature_card_description>T.J. Sharpe’s melanoma tumors shrank within weeks of starting treatment with a PD-1 checkpoint inhibitor.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-24</field_date_reviewed>
  <field_pretty_url>tj-sharpe-biomarkers-immunotherapy-melanoma</field_pretty_url>
  <para_id>1127224</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1127271</id>
  <title>ATAC-seq on TCGA: Insights Into the Noncoding Region in Primary Cancers</title>
  <langcode>en</langcode>
  <field_short_title>ATAC-seq on TCGA</field_short_title>
  <field_page_description>Using a chromatin accessibility assay to examine the noncoding genome in TCGA.</field_page_description>
  <field_feature_card_description>The ATAC-seq chromatin accessibility assay provides insights into the puzzle of DNA regulatory elements and cancer.</field_feature_card_description>
  <field_list_description>Researchers used ATAC-seq to profile the chromatin accessibility of 410 TCGA samples representing 23 primary cancers. The study uncovered a vast number of novel DNA regulatory elements and their potential roles in cancer development, prognosis, and response to therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-25</field_date_posted>
  <field_date_reviewed>2018-10-25</field_date_reviewed>
  <field_pretty_url>atac-seq</field_pretty_url>
  <para_id>1127271</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>915259</id>
  <title>Special Spotlight: 2014 AACR Conference: The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: 2014 AACR Conference</field_short_title>
  <field_page_description>A focus of the 7thAACR annual conference was community engagement and how to attract and retain racial and ethnic populations. Three community health educators from CRCHD’s National Outreach Network program delivered presentations in this area.</field_page_description>
  <field_feature_card_description>CHEs from CRCHD’s NON program presented at the 7th AACR annual conference.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-01</field_date_posted>
  <field_date_reviewed>2014-12-01</field_date_reviewed>
  <field_pretty_url>2014aacr-spotlight-blog</field_pretty_url>
  <para_id>915259</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915528</term_id>
  <id>915530</id>
  <title>Immunotherapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy</field_short_title>
  <field_page_description>Immunotherapy is treatment that helps your immune system fight cancer. Get information about the different types of immunotherapy and what you can expect during treatment.</field_page_description>
  <field_feature_card_description>Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. </field_feature_card_description>
  <field_list_description>Immunotherapy is a type of treatment that helps your immune system fight cancer. Get information about the types of immunotherapy and what you can expect during treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-05-04</field_date_reviewed>
  <para_id>915530</para_id>
  <related_resource_ids>7170496</related_resource_ids>
  <related_resource_ids>7170497</related_resource_ids>
  <related_resource_ids>7170501</related_resource_ids>
  <related_resource_ids>7170503</related_resource_ids>
  <related_resource_ids>7170510</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915632</term_id>
  <id>915642</id>
  <title>Research on Causes of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Research on Causes of Cancer</field_short_title>
  <field_page_description>Understanding the exposures and risk factors that cause cancer, as well as the genetic abnormalities associated with the disease, has helped us to reduce certain exposures and to ameliorate their harmful effects.</field_page_description>
  <field_feature_card_description>Resesarch to understand the risk factors and mutations associated with cancer is vital to reducing cancer's harmful effects.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-12</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915642</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916029</term_id>
  <id>916030</id>
  <title>Planning for Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Planning for Advanced Cancer</field_short_title>
  <field_page_description>Find out what issues need to be addressed when dealing with an advanced or metastatic cancer diagnosis. Completing advance directives, looking at health insurance, organizing records and documents, and looking at the meanings in your life are some of the things to think about. </field_page_description>
  <field_feature_card_description>Learn what issues to plan for with an advanced cancer diagnosis</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916030</para_id>
  <related_resource_id>6995006</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>916482</id>
  <title>Smoking’s Disease Burden: Worse than Previously Thought?</title>
  <langcode>en</langcode>
  <field_short_title>Smoking’s Disease Burden: Worse than Previously Thought?</field_short_title>
  <field_page_description>According to a new study, smoking may be responsible for far more deaths each year than previously thought.</field_page_description>
  <field_feature_card_description>According to a new study, smoking may be responsible for far more deaths each year than previously thought.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <field_pretty_url>smoking-burden</field_pretty_url>
  <para_id>916482</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916837</term_id>
  <id>916787</id>
  <title>Annual Report to the Nation on the Status of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Annual Report to the Nation</field_short_title>
  <field_page_description>The Annual Report to the Nation on the Status of Cancer is an update of rates for new cases, deaths, and trends for the most common cancers in the United States. </field_page_description>
  <field_feature_card_description>Report provides an annual update of cancer incidence and mortality rates and trends in the United States.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-30</field_date_reviewed>
  <para_id>916787</para_id>
  <related_resource_ids>7066819</related_resource_ids>
  <related_resource_ids>7066820</related_resource_ids>
  <related_resource_ids>7066823</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917229</term_id>
  <id>917230</id>
  <title>Resources</title>
  <langcode>en</langcode>
  <field_short_title>Resources</field_short_title>
  <field_page_description>Find standardized case reporting forms (CRFs) and standard terms of agreement for research trial (START) clauses.</field_page_description>
  <field_feature_card_description>Find standardized case reporting forms (CRFs) and standard terms of agreement for research trial (START) clauses.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917230</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917279</term_id>
  <id>917306</id>
  <title>Cancer Care Delivery Research Steering Committee </title>
  <langcode>en</langcode>
  <field_short_title>CCDR Steering Committee</field_short_title>
  <field_page_description>The Cancer Care Delivery Research (CCDR) Steering Committee evaluates and prioritizes cancer care delivery research study concepts for trials conducted through NCORP.</field_page_description>
  <field_feature_card_description>The CCDR Steering Committee evaluates cancer care delivery concepts for trials conducted through NCORP.</field_feature_card_description>
  <field_list_description>The Cancer Care Delivery Research (CCDR) Steering Committee evaluates cancer care delivery research study concepts for trials conducted through NCORP.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917306</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916828</term_id>
  <id>916829</id>
  <title>Grants Management Contacts</title>
  <langcode>en</langcode>
  <field_short_title>Grants Management Contacts</field_short_title>
  <field_page_description>Contact a grants management specialist assigned to your institution. </field_page_description>
  <field_feature_card_description>FY2019 INSTITUTION ASSIGNMENTS</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-01</field_date_posted>
  <field_date_reviewed>2019-02-01</field_date_reviewed>
  <para_id>916829</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917216</term_id>
  <id>917217</id>
  <title>Childhood Cancers Research</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancers Research</field_short_title>
  <field_page_description>Learn about NCI-supported research efforts to address pediatric cancers, from basic science to clinical research on new treatments.</field_page_description>
  <field_feature_card_description>Learn about the range of research that NCI supports to address pediatric cancers, from basic science to clinical research.</field_feature_card_description>
  <field_list_description>Learn about the range of research that NCI supports to address pediatric cancers, from basic science to clinical research on new treatments, all aimed at providing the best care for childhood cancer patients and survivors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917217</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>917415</id>
  <title>Grantee Spotlight: Joseph Kofi Agyin, PhD, MBA - Exploring Bone-Targeted Proteasome Inhibitors to Cure Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Joseph Kofi Agyin, PhD, MBA </field_short_title>
  <field_page_description>Dr. Joseph Kofi Agyin, a CRCHD R21 Grantee, is studying the design and synthesis of bone-targeted proteasome inhibitors for treating multiple myeloma.</field_page_description>
  <field_feature_card_description>Dr. Agyin studies bone-targeted proteasome inhibitors to treating multiple myeloma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-14</field_date_posted>
  <field_date_reviewed>2014-07-14</field_date_reviewed>
  <field_pretty_url>agyin-spotlight-blog</field_pretty_url>
  <para_id>917415</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>917486</id>
  <title>Grantee Spotlight: Dana-Lynn Koomoa-Lange, Ph.D.- Exploring Chemical Pathways to Hinder Development of Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Dana-Lynn Koomoa-Lange, Ph.D.</field_short_title>
  <field_page_description>Dr. Dana-Lynn Koomoa-Lange, a CRCHD K01 grantee, is exploring signaling pathways in the progression of neuroblastoma, a nervous system cancer, in an effort to develop new drugs to thwart the disease.</field_page_description>
  <field_feature_card_description>Dr. Koomoa-Lange researches signaling pathways of neuroblastoma progression.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-23</field_date_posted>
  <field_date_reviewed>2014-09-23</field_date_reviewed>
  <para_id>917486</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917277</term_id>
  <id>917733</id>
  <title>NCI Community Oncology Research Program (NCORP) - Cancer Control Steering Committees</title>
  <langcode>en</langcode>
  <field_short_title>NCORP - Cancer Control Steering Committees</field_short_title>
  <field_page_description>Information about Cancer Care Delivery Research (CCDR) and Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committees, including membership, clinical trial planning meetings, publications and approved trials conducted through NCORP.</field_page_description>
  <field_feature_card_description>The NCORP Steering Committees review concepts for clinical trials to control cancer symptoms and cancer treatment side effects, concepts for studies of cancer care delivery, and cancer prevention, screening, and surveillance concepts.</field_feature_card_description>
  <field_list_description>The NCORP Steering Committees review concepts for clinical trials to control cancer symptoms and cancer treatment side effects, concepts for studies of cancer care delivery, and cancer prevention, screening, and surveillance concepts.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2015-03-20</field_date_reviewed>
  <para_id>917733</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916951</term_id>
  <id>918912</id>
  <title>NCI Advisory Boards, Committees, and Review Groups</title>
  <langcode>en</langcode>
  <field_short_title>Advisory Boards </field_short_title>
  <field_page_description>NCI relies on advisory committees to provide objective and expert advice on coordination of the National Cancer Program, NCI scientific priorities, and more.</field_page_description>
  <field_feature_card_description>NCI relies on advisory committees to provide advice on the National Cancer Program, NCI scientific priorities, and more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-23</field_date_posted>
  <field_date_reviewed>2015-03-23</field_date_reviewed>
  <para_id>918912</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129049</term_id>
  <id>1119757</id>
  <title>TCGA Research Network Publications</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Publications</field_short_title>
  <field_page_description>An up-to-date list of publications by The Cancer Genome Atlas, including analyses performed after the original cancer type-specific studies were completed.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-30</field_date_posted>
  <field_date_reviewed>2018-07-12</field_date_reviewed>
  <para_id>1119757</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1120535</id>
  <title>From Ignoring Features to Machine Learning Features: Computational Biology Then and Now</title>
  <langcode>en</langcode>
  <field_short_title>Computational Biology Then and Now</field_short_title>
  <field_page_description>How various aspects of the computational biology field has changed over the years</field_page_description>
  <field_feature_card_description>Computational Biology Then &amp; Now</field_feature_card_description>
  <field_list_description>Dr. John Weinstein discusses progress in computational biology over the 12-year span of TCGA. The field has expanded greatly, with researchers taking on more complex problems and trying different approaches.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-07-30</field_date_posted>
  <field_date_reviewed>2018-07-23</field_date_reviewed>
  <field_pretty_url>compbio-then-now</field_pretty_url>
  <para_id>1120535</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120625</id>
  <title>TCGA's Study of Breast Ductal Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Breast Ductal Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Breast Ductal Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Breast Ductal Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of breast ductal carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-26</field_date_posted>
  <field_date_reviewed>2018-07-26</field_date_reviewed>
  <field_pretty_url>breast-ductal</field_pretty_url>
  <para_id>1120625</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914810</term_id>
  <id>914834</id>
  <title>Step 1: Application Development &amp; Submission</title>
  <langcode>en</langcode>
  <field_short_title>Step 1: Application Development &amp; Submission</field_short_title>
  <field_page_description>There are nine research grant application types, each with specific procedures. Learn more about developing, submitting, and tracking a cancer research grant application.</field_page_description>
  <field_feature_card_description>Learn about specific procedures and required documentation for grant applications. </field_feature_card_description>
  <field_list_description>There are nine research grant application types, each with specific procedures and required documentation. Learn more about developing, submitting, and tracking a grant application.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-11</field_date_reviewed>
  <para_id>914834</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914812</term_id>
  <id>914835</id>
  <title>Step 2: Application Receipt &amp; Assignment</title>
  <langcode>en</langcode>
  <field_short_title>Step 2: Application Receipt &amp; Assignment</field_short_title>
  <field_page_description>Information on the assignment numbers the Center for Scientific Review (CSR) creates once an application is submitted and other submission policies.</field_page_description>
  <field_feature_card_description>After you develop and submit your application, the Center for Scientific Review (CSR) will assign your application to an Institute or Center (IC) at NIH based on the focus and mission of the IC.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-11</field_date_reviewed>
  <para_id>914835</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914943</term_id>
  <id>914948</id>
  <title>Fatigue and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Fatigue</field_short_title>
  <field_page_description>Fatigue is a common side effect of many cancer treatments such as chemotherapy, radiation therapy, immunotherapy, and surgery. Anemia and pain can also cause fatigue. Learn about symptoms and way to manage fatigue.</field_page_description>
  <field_list_description>Information about what causes cancer-related fatigue, a side effect of some cancer treatments. Symptoms and ways to manage fatigue during cancer treatment is also covered.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <para_id>914948</para_id>
  <related_resource_id>7120939</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>915079</term_id>
  <id>915081</id>
  <title>Center for Cancer Genomics Videos</title>
  <langcode>en</langcode>
  <field_short_title>CCG Videos</field_short_title>
  <field_page_description>Find video presentations, meeting addresses, and discussions about work by the NCI Center for Cancer Genomics (CCG).</field_page_description>
  <field_list_description>Find video presentations, meeting addresses, and discussions about work by the NCI Center for Cancer Genomics (CCG). Watch scientific experts and Mr. Joe Biden speak about the importance of genomics. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915081</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogSeries</CONTENTTYPENAME>
  <term_id>919423</term_id>
  <id>915110</id>
  <title>Insights &amp;amp; Innovations Blog</title>
  <langcode>en</langcode>
  <field_short_title>Insights &amp;amp; Innovations Blog</field_short_title>
  <field_page_description>Read interviews with investigators, updates from CCG's Director and others, CCG's latest news and announcements, and overviews of new influential papers in cancer genomics.</field_page_description>
  <field_feature_card_description>Read interviews with investigators, updates from CCG's Director and others, CCG's latest news and announcements, and overviews of new influential papers in cancer genomics.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-12</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915362</term_id>
  <id>915363</id>
  <title>Sunlight</title>
  <langcode>en</langcode>
  <field_short_title>Sunlight</field_short_title>
  <field_page_description>Exposure to UV radiation from the sun, sunlamps, and tanning booths causes early aging and skin damage that can lead to skin cancer. Find information, including tips, on how to protect your skin.</field_page_description>
  <field_feature_card_description>Exposure to UV radiation from the sun, sunlamps, and tanning booths causes  damage that can lead to skin cancer.</field_feature_card_description>
  <field_list_description>Exposure to UV radiation from the sun, sunlamps, and tanning booths causes  damage that can lead to skin cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915363</para_id>
  <related_resource_ids>6624699</related_resource_ids>
  <related_resource_ids>6624701</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>915365</id>
  <title>Tobacco </title>
  <langcode>en</langcode>
  <field_short_title>Tobacco </field_short_title>
  <field_page_description>Tobacco use is a leading cause of cancer and of death from cancer. Find resources on the harms of tobacco use and how to get help quitting.</field_page_description>
  <field_feature_card_description>Tobacco use is a leading cause of cancer and of death from cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915365</para_id>
  <related_resource_ids>7132803</related_resource_ids>
  <related_resource_ids>7132812</related_resource_ids>
  <related_resource_ids>7132813</related_resource_ids>
  <related_resource_ids>7132814</related_resource_ids>
  <related_resource_ids>7132816</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>916765</term_id>
  <id>916766</id>
  <title>Research Grants</title>
  <langcode>en</langcode>
  <field_short_title>Research Grants</field_short_title>
  <field_page_description>NCI funds a range of cancer research activities through various mechanisms and pay lines. Find cancer research funding opportunities.  </field_page_description>
  <field_feature_card_description>Funding opportunities, contact information, and funding patterns.</field_feature_card_description>
  <field_list_description>Find information about funding opportunities, strategy behind decisions on competing and non-competing applications, contact information for program directors, and funding patterns for previous years.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916766</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>906471</id>
  <title>FDA Grants Palbociclib Accelerated Approval for Advanced Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Grants Palbociclib Accelerated Approval for Advanced Breast Cancer</field_short_title>
  <field_page_description>Palbociclib (Ibrance) is approved to be used in combination with letrozole (Femara) to treat postmenopausal women with metastatic breast cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-11</field_date_posted>
  <field_date_reviewed>2015-02-11</field_date_reviewed>
  <field_pretty_url>palbociclib-breast-cancer</field_pretty_url>
  <para_id>906471</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>910207</id>
  <title>New from NCI: Resources, Tools, and News</title>
  <langcode>en</langcode>
  <field_short_title>New from NCI: Resources, Tools, and News</field_short_title>
  <field_page_description>NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-20</field_date_posted>
  <field_date_reviewed>2015-02-20</field_date_reviewed>
  <field_pretty_url>resources</field_pretty_url>
  <para_id>910207</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>911695</id>
  <title>Global Health Diplomacy Begins at Home</title>
  <langcode>en</langcode>
  <field_short_title>Global Health Diplomacy Begins at Home</field_short_title>
  <field_page_description>Global Health Diplomacy Begins at Home</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-27</field_date_posted>
  <field_date_reviewed>2015-02-27</field_date_reviewed>
  <field_pretty_url>globalhealthdiplomacy</field_pretty_url>
  <para_id>911695</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>914799</term_id>
  <id>914801</id>
  <title>Apply for a Grant</title>
  <langcode>en</langcode>
  <field_short_title>Apply for a Grant</field_short_title>
  <field_page_description>The NCI Grants Process provides an overview of the end-to-end lifecycle of grant funding. Learn about the types of funding available and the basics for application, review, award, and on-going administration within the NCI.</field_page_description>
  <field_feature_card_description>Understand the submission and review process and find resources to prepare your application. </field_feature_card_description>
  <field_list_description>The NCI Grants Process provides an overview of the end-to-end lifecycle of grant funding. Learn about the types of funding available and the basics for application, review, award, and on-going administration.

</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-11</field_date_posted>
  <field_date_reviewed>2015-03-11</field_date_reviewed>
  <para_id>914801</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938137</term_id>
  <id>915039</id>
  <title>Treating High-grade Lesions to Prevent Anal Cancer in HIV-infected People</title>
  <langcode>en</langcode>
  <field_short_title>Treating High-grade Lesions to Prevent Anal Cancer in HIV-infected People</field_short_title>
  <field_page_description>This study, called the ANCHOR trial, will investigate whether screening and prevention methods similar to those used to prevent cervical cancer can help prevent anal cancer in HIV-infected men and women. </field_page_description>
  <field_feature_card_description>This study will investigate whether certain screening and prevention methods can help prevent anal cancer in HIV-infected men and women. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-11</field_date_posted>
  <field_date_reviewed>2015-03-11</field_date_reviewed>
  <field_pretty_url>anchor-trial</field_pretty_url>
  <para_id>915039</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>915248</id>
  <title>Treatment Helps Preserve Fertility for Some Women with Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Treatment Helps Preserve Fertility for Some Women with Breast Cancer</field_short_title>
  <field_page_description>In a large clinical trial, giving a hormone-suppressing drug helped some younger women with breast cancer get pregnant after completing cancer treatment.</field_page_description>
  <field_feature_card_description>In a large clinical trial, giving a hormone-suppressing drug helped some younger women with breast cancer get pregnant after completing cancer treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-12</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <field_pretty_url>fertility-breast-cancer</field_pretty_url>
  <para_id>915248</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>914832</term_id>
  <id>915264</id>
  <title>Grant Closeout</title>
  <langcode>en</langcode>
  <field_short_title>Grant Closeout</field_short_title>
  <field_page_description>Requirements and reports to comply with grant closeout, including Final Federal Financial Report (FFR, SF425); Final Research Performance Progress Report (FRPPR); Interim Research Performance Progress Report (IRPPR); Final Invention Statement (FIS, HHS</field_page_description>
  <field_feature_card_description>Learn about the administrative actions and requirements to comply with grants closeout.</field_feature_card_description>
  <field_list_description>Find requirements and reports to comply with grant closeout, including Final Federal Financial Report (FFR, SF425); Final Research Performance Progress Report (FRPPR); Interim Research Performance Progress Report (IRPPR); Final Invention Statement (FIS, HHS 568); and Termination Notice (PHS, 416-7).
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915264</para_id>
  <related_resource_ids>6816694</related_resource_ids>
  <related_resource_ids>6816695</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>915360</id>
  <title>Radiation</title>
  <langcode>en</langcode>
  <field_short_title>Radiation </field_short_title>
  <field_page_description>Radiation of certain wavelengths, called ionizing radiation, has enough energy to damage DNA and cause cancer. Ionizing radiation includes radon, x-rays, gamma rays, and other forms of high-energy radiation. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915360</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>93439</id>
  <title>Drugs Approved for Skin Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Skin Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for skin cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-25</field_date_posted>
  <field_date_reviewed>2011-07-19</field_date_reviewed>
  <field_pretty_url>skin</field_pretty_url>
  <para_id>93439</para_id>
  <related_resource_ids>7192811</related_resource_ids>
  <related_resource_ids>7192825</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>623825</id>
  <title>Finasteride Reduces the Risk of Low-Grade Prostate Cancer in Men 55 and Older</title>
  <langcode>en</langcode>
  <field_short_title>Finasteride for Prostate Cancer Prevention</field_short_title>
  <field_page_description>A summary of results from a phase III trial that tested whether the drug finasteride could help prevent prostate cancer in men age 55 and older.</field_page_description>
  <field_feature_card_description>Long-term follow-up results from a phase III trial show that regular use of finasteride (Proscar®) for up to 7 years decreased the risk of low-grade prostate cancer in men age 55 and older compared with that in men who received a placebo. Although high-gr</field_feature_card_description>
  <field_list_description>Long-term follow-up results from a phase III trial show that regular use of finasteride (Proscar®) for up to 7 years decreased the risk of low-grade prostate cancer in men age 55 and older compared with that in men who received a placebo. Although high-grade cancers were more common in the finasteride group, the finasteride and placebo groups had similar 15-year overall survival rates.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-08-28</field_date_posted>
  <field_date_reviewed>2013-08-28</field_date_reviewed>
  <field_pretty_url>finasteride-reduces-low-grade</field_pretty_url>
  <para_id>623825</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917284</term_id>
  <id>917286</id>
  <title>Resources for You</title>
  <langcode>en</langcode>
  <field_short_title>Resources for You</field_short_title>
  <field_page_description>Let us help you find information and resources that fit your needs as a patient, health professional, researcher, or other visitor.</field_page_description>
  <field_feature_card_description>Let us help you find information and resources that fit your needs as a patient, health professional, researcher, or other visitor.</field_feature_card_description>
  <field_list_description>Find information and resources that fit your needs as a patient, caregiver, health professional, researcher, or other visitor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917286</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917297</term_id>
  <id>917517</id>
  <title>Resources for Advocates and Policymakers</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Advocates &amp; Policymakers</field_short_title>
  <field_page_description>Information for advocates and policy makers about NCI's priorities and the progress that has been made against cancer, how the institute conducts research and manages its budget, how investing in cancer research benefits the nation, and the Congressional activities relevant to cancer research.</field_page_description>
  <field_feature_card_description>Understand NCI priorities and funding and find resources to help you work with NCI to advance cancer research and improve patient outcomes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-19</field_date_posted>
  <field_date_reviewed>2015-03-19</field_date_reviewed>
  <para_id>917517</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1119768</id>
  <title>The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr. Judith Paice</title>
  <langcode>en</langcode>
  <field_short_title>The Opioid Epidemic and Cancer Pain Management</field_short_title>
  <field_page_description>The opioid epidemic is having a significant impact on cancer patients, says Dr. Judith Paice of Northwestern University. In this Cancer Currents post, she explains how oncologists can address concerns about opioid misuse when managing cancer pain.</field_page_description>
  <field_feature_card_description>Dr. Judith Paice discusses the epidemic’s impact on cancer patients.</field_feature_card_description>
  <field_list_description>Dr. Judith Paice, of the Cancer Pain Program at Northwestern University’s Feinberg School of Medicine, discusses the impacts of the opioid epidemic on cancer patients and how providers can address concerns about opioid misuse when managing cancer pain.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-16</field_date_posted>
  <field_date_reviewed>2018-07-13</field_date_reviewed>
  <field_pretty_url>opioid-crisis-cancer-pain-paice</field_pretty_url>
  <para_id>1119768</para_id>
  <related_resource_id>7071768</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1119945</term_id>
  <id>1119946</id>
  <title>Intensify Research on the Major Drivers of Childhood Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Drivers of Childhood Cancers</field_short_title>
  <field_page_description>Fusion oncoproteins can lead to the development of childhood cancers. This Cancer Moonshot initiative aims to improve our understanding of these proteins and develop inhibitors that target them.</field_page_description>
  <field_feature_card_description>Fusion oncoproteins are a major driver of childhood cancers. This research effort will help to improve understanding of these proteins and develop targeted treatments.</field_feature_card_description>
  <field_list_description>Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-07-13</field_date_reviewed>
  <para_id>1119946</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1119948</term_id>
  <id>1119949</id>
  <title>Analyze Patient Data and Biospecimens from Past Clinical Trials to Predict Future Patient Outcomes</title>
  <langcode>en</langcode>
  <field_short_title>Mine Past Patient Data to Predict Future Patient Outcomes</field_short_title>
  <field_page_description>Tumor samples and other biospecimens can be analyzed retrospectively to develop hypotheses about which tumor features can help predict clinical benefit. Ideally, this information can be used to improve treatment and outcomes for cancer patients. </field_page_description>
  <field_feature_card_description>A Cancer Moonshot initiative created to retrospectively analyze patient tumor samples to improve patient outcomes.</field_feature_card_description>
  <field_list_description>Predict response to standard treatments through retrospective analysis of patient specimens.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-07-13</field_date_reviewed>
  <para_id>1119949</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1120185</id>
  <title>Message from the Center for Global Health's Interim Director</title>
  <langcode>en</langcode>
  <field_short_title>Message from the Center for Global Health's Interim Director</field_short_title>
  <field_page_description>Center for Global Health Interim Director, Dr. Robert Croyle, discusses CGH accomplishments and plans for the new leadership.</field_page_description>
  <field_feature_card_description>CGH Interim Director, Dr. Croyle, discusses CGH accomplishments and plans for the new leadership.</field_feature_card_description>
  <field_list_description>Center for Global Interim Director, Dr. Robert Croyle, discusses CGH accomplishments and plans for the new leadership.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-07-23</field_date_posted>
  <field_date_reviewed>2018-07-20</field_date_reviewed>
  <field_pretty_url>interim-director-message</field_pretty_url>
  <para_id>1120185</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120685</id>
  <title>TCGA's Study of Cervical Cancer</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Cervical Cancer</field_short_title>
  <field_page_description>TCGA's Study of Cervical Cancer</field_page_description>
  <field_feature_card_description>TCGA's Study of Cervical Cancer</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of cervical cancer, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-26</field_date_posted>
  <field_date_reviewed>2018-07-26</field_date_reviewed>
  <field_pretty_url>cervical</field_pretty_url>
  <para_id>1120685</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121497</term_id>
  <id>1121498</id>
  <title>Develop New Cancer Technologies</title>
  <langcode>en</langcode>
  <field_short_title>Develop New Cancer Technologies</field_short_title>
  <field_page_description>The development of cancer technologies to characterize tumors and test therapies can transform cancer research and clinical care.</field_page_description>
  <field_feature_card_description>Advancing the development of technologies to characterize tumors and test therapies can increase the options available for clinical care patients.</field_feature_card_description>
  <field_list_description>Develop new enabling cancer technologies to characterize tumors and test therapies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-06</field_date_reviewed>
  <para_id>1121498</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121657</term_id>
  <id>1121658</id>
  <title>Expand Use of Proven Cancer Prevention and Early Detection Strategies</title>
  <langcode>en</langcode>
  <field_short_title>Expand Use of Prevention and Early Detection Strategies</field_short_title>
  <field_page_description>This initiative aims to develop, test, and adopt proven cancer prevention and early detection approaches to reduce cancer risk and cancer health disparities in all populations. </field_page_description>
  <field_feature_card_description>Development, implementation, and broad adoption of proven cancer prevention and detection approaches can reduce cancer risk in all populations.</field_feature_card_description>
  <field_list_description>Reduce cancer risk and cancer health disparities through the development, implementation, and broad adoption of proven cancer prevention and detection approaches. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <para_id>1121658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1122219</id>
  <title>Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later</title>
  <langcode>en</langcode>
  <field_short_title>Liquid Biopsy May Help Predict Breast Cancer Relapse</field_short_title>
  <field_page_description>The presence of circulating tumor cells found with a liquid biopsy may identify women treated for breast cancer who may be at higher risk of their disease returning years later. The findings may have implications for treatment, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Test results could help determine which patients need additional treatment.</field_feature_card_description>
  <field_list_description>Using a liquid biopsy to test for tumor cells circulating in blood, researchers found that, in women with breast cancer, the presence of these cells could identify women at risk of their cancer returning years later. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-15</field_date_posted>
  <field_date_reviewed>2018-08-15</field_date_reviewed>
  <field_pretty_url>liquid-biopsy-breast-cancer-late-recurrence</field_pretty_url>
  <para_id>1122219</para_id>
  <related_resource_id>7095170</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1122694</id>
  <title>Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Ribociclib Approval Expanded for Breast Cancer</field_short_title>
  <field_page_description>FDA has expanded the approval of ribociclib (Kisqali) for advanced breast cancer, including new uses in pre- and postmenopausal women. As this Cancer Currents post explains, it’s the first approval under a new FDA program to speed cancer drug reviews.</field_page_description>
  <field_feature_card_description>Approval is the first under a new FDA program to speed drug reviews.</field_feature_card_description>
  <field_list_description>FDA has expanded the approved uses of ribociclib (Kisqali) for women with advanced breast cancer, including new uses in pre- and postmenopausal women. It’s the first approval under a new FDA program to speed the review of cancer drugs.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-20</field_date_posted>
  <field_date_reviewed>2018-08-17</field_date_reviewed>
  <field_pretty_url>ribociclib-fda-expanded-approval-breast-cancer</field_pretty_url>
  <para_id>1122694</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1123840</id>
  <title>Finding Pediatric Cancer Genomic Data through PGDI</title>
  <langcode>en</langcode>
  <field_short_title>The Pediatric Genomic Data Inventory</field_short_title>
  <field_page_description>The Pediatric Genomic Data Inventory (PGDI) connects researchers with valuable pediatric cancer data.</field_page_description>
  <field_feature_card_description>Finding Pediatric Data with PGDI</field_feature_card_description>
  <field_list_description>The Pediatric Genomic Data Inventory (PGDI), developed by the Office of Cancer Genomics (OCG), is a new public resource informing researchers how and where to access globally generated pediatric cancer genomic datasets. Connecting researchers with data and fostering collaborations is key to furthering our understanding of childhood cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-08-31</field_date_reviewed>
  <field_pretty_url>PGDI</field_pretty_url>
  <para_id>1123840</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1123940</id>
  <title>TCGA's Study of Ovarian Serous Adenocarcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Ovarian Serous Adenocarcinoma</field_short_title>
  <field_page_description>TCGA's Study of Ovarian Serous Adenocarcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Ovarian Serous Adenocarcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of ovarian serous adenocarcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-09-05</field_date_reviewed>
  <field_pretty_url>ovarian</field_pretty_url>
  <para_id>1123940</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1016887</id>
  <title>Study Identifies New Opportunities for Targeted Immunotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Study Identifies New Opportunities for Targeted Immunotherapy</field_short_title>
  <field_page_description>A team of NCI researchers has reported that several types of gastrointestinal cancer have tumor-specific mutations that can be recognized by the immune system, thereby offering a new therapeutic opportunity for patients with these tumors.</field_page_description>
  <field_feature_card_description>NCI researchers have shown that several gastrointestinal cancers have tumor-specific genetic mutations that can be recognized by the immune system.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-29</field_date_posted>
  <field_date_reviewed>2015-10-29</field_date_reviewed>
  <field_pretty_url>tumor-specific-mutations-immunotherapy</field_pretty_url>
  <para_id>1016887</para_id>
  <related_resource_id>6572503</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1023566</term_id>
  <id>1023569</id>
  <title>Precision Medicine in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Precision Medicine</field_short_title>
  <field_page_description>Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment.</field_page_description>
  <field_feature_card_description>Precision medicine helps doctors select cancer treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the promise of precision medicine and the role it plays in cancer treatment.</field_feature_card_description>
  <field_list_description>Precision medicine helps doctors select treatments that are most likely to help patients based on a genetic understanding of their disease. Learn about the role precision medicine plays in cancer treatment, including how genetic changes in a person's cancer are identified and used to select treatments.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-16</field_date_posted>
  <field_date_reviewed>2015-11-06</field_date_reviewed>
  <para_id>1023569</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1026757</id>
  <title>Low Income Is a Barrier to Clinical Trial Enrollment, Study Suggests </title>
  <langcode>en</langcode>
  <field_short_title>Low Income Is a Barrier to Clinical Trial Enrollment, Study Suggests</field_short_title>
  <field_page_description>A new study has found that patients with annual household incomes below $50,000 were less likely to participate in a cancer clinical trial than those with higher incomes.</field_page_description>
  <field_feature_card_description>A new study has found that patients with lowest incomes are least likely to enroll.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <field_pretty_url>income-trials</field_pretty_url>
  <para_id>1026757</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026053</term_id>
  <id>1026805</id>
  <title>Current Congress </title>
  <langcode>en</langcode>
  <field_short_title>Current Congress </field_short_title>
  <field_page_description>Find legislation introduced in the 116th Congress that is relevant to the NCI.</field_page_description>
  <field_feature_card_description>Find legislation introduced in the 116th Congress that is relevant to the NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <para_id>1026805</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026804</term_id>
  <id>1026837</id>
  <title>Recent Public Laws</title>
  <langcode>en</langcode>
  <field_short_title>Recent Public Laws</field_short_title>
  <field_page_description>Read about legislation related to the mission of NCI that has been signed into law in recent years.</field_page_description>
  <field_feature_card_description>Read about legislation related to the mission of NCI that has been signed into law in recent years.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-11</field_date_posted>
  <field_date_reviewed>2015-11-17</field_date_reviewed>
  <para_id>1026837</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026857</term_id>
  <id>1026859</id>
  <title>OGCR Staff</title>
  <langcode>en</langcode>
  <field_short_title>OGCR Staff</field_short_title>
  <field_page_description>Find OGCR staff contact information for questions on current or past legislative activities that relate to the mission of NCI. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-01</field_date_posted>
  <field_date_reviewed>2015-11-18</field_date_reviewed>
  <para_id>1026859</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1027924</id>
  <title>Lung Cancer Precision Medicine Trials: Adapting to Progress</title>
  <langcode>en</langcode>
  <field_short_title>Lung Cancer Precision Medicine Trials</field_short_title>
  <field_page_description>Patients with lung cancer are benefiting from the boom in targeted and immune-based therapies. With a series of precision medicine trials, NCI is keeping pace with the rapidly changing treatment landscape for lung cancer.</field_page_description>
  <field_feature_card_description>Patients with lung cancer are benefiting from the boom in our understanding of the molecular drivers of tumors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-30</field_date_posted>
  <field_date_reviewed>2015-11-30</field_date_reviewed>
  <field_pretty_url>lung-cancer-landscape</field_pretty_url>
  <para_id>1027924</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65324</id>
  <title>Drugs Approved for Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Thyroid Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for thyroid cancer. The list includes generic names and brand names. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-11</field_date_reviewed>
  <field_pretty_url>thyroid</field_pretty_url>
  <para_id>65324</para_id>
  <related_resource_ids>6977364</related_resource_ids>
  <related_resource_ids>6977370</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11596</term_id>
  <id>65861</id>
  <title>Education and Training for Health Professionals </title>
  <langcode>en</langcode>
  <field_short_title>Education and Training for Health Professionals </field_short_title>
  <field_page_description>A collection of cancer education and training tools from NCI and NIH for health care providers, public health program planners, and cancer registrars. Courses are available in a variety of formats.</field_page_description>
  <field_list_description>The Cancer Classroom Series is a collection of webinars that highlights topics that provide the educational content, tools, and resources necessary for health professionals, especially those working in public health, to address cancer as a public health problem.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-15</field_date_posted>
  <field_date_reviewed>2011-03-15</field_date_reviewed>
  <para_id>65861</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>828700</id>
  <title>Grantee Spotlight: Harold "Bo" Netwon Lovvorn, III, M.D. - Molecular Analysis of Ethnic Variations in Wilms tumor</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Dr. Harold "Bow" Netwon Lovvorn</field_short_title>
  <field_page_description>Lovvorn's research focuses particularly on Wilms Tumor (WT), also known as nephroblastoma, which forms in the kidneys and often metastasizes to the lung, and sometimes to the liver. </field_page_description>
  <field_feature_card_description>Lovvorn's research focuses particularly on Wilms Tumor (WT), also known as nephroblastoma, which forms in the kidneys and often metastasizes to the lung, and sometimes to the liver. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-18</field_date_posted>
  <field_date_reviewed>2014-09-18</field_date_reviewed>
  <field_pretty_url>lovvorn-spotlight</field_pretty_url>
  <para_id>828700</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833177</term_id>
  <id>833185</id>
  <title>Community Networks Program Centers (CNPC)</title>
  <langcode>en</langcode>
  <field_short_title>Community Networks Program Centers (CNPC)</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833185</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938103</term_id>
  <id>836262</id>
  <title>Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma </title>
  <langcode>en</langcode>
  <field_short_title>Rituximab Retreatment for Low-Tumor Burden Follicular Lymphoma</field_short_title>
  <field_page_description>A summary of results from a randomized clinical trial of patients with low–tumor burden follicular lymphoma that compared maintenance therapy with rituximab versus retreatment with rituximab only when there was evidence of disease progression.</field_page_description>
  <field_feature_card_description>In a randomized clinical trial, patients with low–tumor burden follicular lymphoma who responded to initial treatment with rituximab experienced similar disease control whether they received rituximab maintenance therapy or were retreated with rituximab.</field_feature_card_description>
  <field_list_description>In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardless of whether they subsequently received maintenance therapy with rituximab or were retreated with rituximab only when there was evidence of disease progression.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-10-02</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>rituximab-retreatment-follicular</field_pretty_url>
  <para_id>836262</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836324</id>
  <title>Caring for the Caregiver</title>
  <langcode>en</langcode>
  <field_short_title>Caring for the Caregiver</field_short_title>
  <field_page_description>A condensed version of “When Someone You Love Is Being Treated for Cancer,” it covers practical, coping, and communication tips for friends and family members caring for loved ones with cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>caring-for-the-caregiver</field_pretty_url>
  <para_id>836324</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>848686</id>
  <title>The Mexican President, NCI’s Dr. Varmus, and Cancer Control in Mexico</title>
  <langcode>en</langcode>
  <field_short_title>The Mexican President, NCI’s Dr. Varmus, and Cancer Control in Mexico</field_short_title>
  <field_page_description>The Mexican President, NCI’s Dr. Varmus, and Cancer Control in Mexico</field_page_description>
  <field_feature_card_description>The Mexican President, NCI’s Dr. Varmus, and Cancer Control in Mexico</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-29</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <field_pretty_url>mexican-president</field_pretty_url>
  <para_id>848686</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133184</term_id>
  <id>1134555</id>
  <title>What are rare vascular tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Vascular Tumors</field_short_title>
  <field_page_description>Rare vascular tumors form in cells that make blood or lymph vessels, and can occur anywhere in the body, such as the skin, in the tissues below the skin, or in an organ. There are specific tumors that affect children, teens, and young adults.</field_page_description>
  <field_list_description>Rare vascular tumors form in cells that make blood or lymph vessels. They can occur anywhere in the body, such as the skin, in the tissues below the skin, or in an organ.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134555</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1136950</id>
  <title>Curbing Production of Immune Checkpoint Protein Slows Liver Cancer in Mice</title>
  <langcode>en</langcode>
  <field_short_title>Blocking Cancer’s Production of an Immune Checkpoint Protein</field_short_title>
  <field_page_description>Production of PD-L1, an immune checkpoint protein, can be blocked in mice with liver cancer by an investigational drug called eFT508, a new study shows.</field_page_description>
  <field_feature_card_description>An experimental drug disrupts production of an immune checkpoint protein.</field_feature_card_description>
  <field_list_description>Researchers have found an unconventional way to unleash the immune system against liver cancer in mice. The researchers used an investigational drug to curb the production of a checkpoint inhibitor protein that shields tumors from the immune system.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-06</field_date_posted>
  <field_date_reviewed>2019-02-05</field_date_reviewed>
  <field_pretty_url>translation-inhibitor-immune-checkpoint-protein</field_pretty_url>
  <para_id>1136950</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1137047</term_id>
  <id>1137048</id>
  <title>FNLCR Acquisitions FedBizOpps Notices</title>
  <langcode>en</langcode>
  <field_short_title>FedBizOpps Notices</field_short_title>
  <field_page_description>Browse the list of FedBizOpps Notices regarding the FNLCR prime contractor competitive acquisition process.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-07</field_date_posted>
  <field_date_reviewed>2019-02-07</field_date_reviewed>
  <para_id>1137048</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137767</id>
  <title>TCGA's Study of Prostate Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Prostate Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Prostate Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Prostate Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of prostate carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-14</field_date_posted>
  <field_date_reviewed>2019-02-14</field_date_reviewed>
  <field_pretty_url>prostate</field_pretty_url>
  <para_id>1137767</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137840</id>
  <title>TCGA's Study of Adult Soft Tissue Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Sarcoma</field_short_title>
  <field_page_description>A summary of TCGA's study of adult soft tissue sarcoma, including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Adult Soft Tissue Sarcoma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>sarcoma</field_pretty_url>
  <para_id>1137840</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137874</id>
  <title>TCGA'S Study of Papillary Thyroid Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA'S Study of Papillary Thyroid Carcinoma</field_short_title>
  <field_page_description>TCGA'S Study of Papillary Thyroid Carcinoma</field_page_description>
  <field_feature_card_description>TCGA'S Study of Papillary Thyroid Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of papillary thyroid carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>thyroid</field_pretty_url>
  <para_id>1137874</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>1133172</term_id>
  <id>1138903</id>
  <title>MyPART Search Results</title>
  <langcode>en</langcode>
  <field_short_title>MyPART Search Results</field_short_title>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <field_pretty_url>mypart-search-results</field_pretty_url>
  <para_id>1138903</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918922</term_id>
  <id>102551</id>
  <title>Drugs Approved for Different Types of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Different Types of Cancer</field_short_title>
  <field_page_description>Find drugs approved by the FDA for specific types of cancer.</field_page_description>
  <field_list_description>This page lists and links to NCI's pages of drugs approved for specific types of cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-11-02</field_date_posted>
  <field_date_reviewed>2011-08-04</field_date_reviewed>
  <para_id>102551</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>105034</id>
  <title>Drugs Approved for Penile Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Penile Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for penile cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-04</field_date_posted>
  <field_date_reviewed>2011-08-16</field_date_reviewed>
  <field_pretty_url>penile</field_pretty_url>
  <para_id>105034</para_id>
  <related_resource_ids>6994696</related_resource_ids>
  <related_resource_ids>6994697</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>979426</id>
  <title>Palbociclib Improves Survival in Women with Hormone Receptor-Positive Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Palbociclib for Advanced Breast Cancer</field_short_title>
  <field_page_description>An interim analysis of the PALOMA3 trial shows that women with hormone receptor-positive metastatic breast cancer who received palbociclib plus fulvestrant had longer progression-free survival rates than women who received a placebo plus fulvestrant.</field_page_description>
  <field_feature_card_description>Palbociclib plus fulvestrant extends the progression-free survival of some women with hormone receptor-positive metastatic breast cancer.</field_feature_card_description>
  <field_list_description>An interim analysis of the PALOMA3 trial shows that palbociclib plus fulvestrant extends the progression-free survival of some women with hormone receptor-positive metastatic breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-24</field_date_posted>
  <field_date_reviewed>2015-07-23</field_date_reviewed>
  <field_pretty_url>palbociclib-hormone-receptor-positive</field_pretty_url>
  <para_id>979426</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>988329</id>
  <title>Cancer Risk in Childhood Cancer Survivors Continues for Decades</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Risk for Childhood Cancer Survivors </field_short_title>
  <field_page_description>Survivors of childhood cancer have an elevated risk of developing second, distinct cancers into their forties and beyond, according to a new study.</field_page_description>
  <field_feature_card_description>Survivors of childhood cancer face decades of elevated risk for second cancers. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-31</field_date_posted>
  <field_date_reviewed>2015-08-31</field_date_reviewed>
  <field_pretty_url>childhood-longterm</field_pretty_url>
  <para_id>988329</para_id>
  <related_resource_id>6572591</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>988768</id>
  <title>Overdiagnosis of Cancer: Bringing an Important Problem into Focus </title>
  <langcode>en</langcode>
  <field_short_title>Overdiagnosis of Cancer Conference</field_short_title>
  <field_page_description>Experts are convening for a conference on the dilemmas posed by overdiagnosis in many types of diseases. Overdiagnosis is generally defined as the diagnosis of a disease or condition that is unlikely to ever cause harm.</field_page_description>
  <field_feature_card_description>Experts convene to discuss dilemma posed by the overdiagnosis of different diseases.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-28</field_date_posted>
  <field_date_reviewed>2015-08-28</field_date_reviewed>
  <field_pretty_url>overdiagnosis-meeting</field_pretty_url>
  <para_id>988768</para_id>
  <related_resource_ids>6572983</related_resource_ids>
  <related_resource_ids>6572985</related_resource_ids>
  <related_resource_ids>6572986</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>989418</id>
  <title>How You Can Help Medical Research: Donating Your Blood, Tissue, and Other Samples</title>
  <langcode>en</langcode>
  <field_short_title>How You Can Help Medical Research</field_short_title>
  <field_page_description>Learn more about how you or a loved one can advance cancer research by donating blood and tissue samples. </field_page_description>
  <field_feature_card_description>Learn more about how you or a loved one can advance cancer research by donating blood and tissue samples. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-01</field_date_posted>
  <field_date_reviewed>2015-09-01</field_date_reviewed>
  <field_pretty_url>help-research-donate-tissue</field_pretty_url>
  <para_id>989418</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1002751</id>
  <title>CPTAC, the Complementary Sibling of TCGA: An Interview with Dr. Henry Rodriguez about NCI’s Proteomics Program </title>
  <langcode>en</langcode>
  <field_short_title>Shedding New Light on Cancer Biology</field_short_title>
  <field_page_description>Dr. Henry Rodriguez explains the goals and future directions of CPTAC, a collaborative consortium of institutions and investigators who study cancer proteomics.</field_page_description>
  <field_feature_card_description>A Q&amp;A with Dr. Henry Rodriguez about NCI's Clinical Proteomic Tumor Analysis Consortium.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-18</field_date_posted>
  <field_date_reviewed>2015-09-17</field_date_reviewed>
  <field_pretty_url>cptac</field_pretty_url>
  <para_id>1002751</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1004321</term_id>
  <id>1004322</id>
  <title>Data Submission Under the Genomic Data Sharing (GDS) Policy</title>
  <langcode>en</langcode>
  <field_short_title>Data Submission</field_short_title>
  <field_page_description>Information for intramural, extramural, and non-NIH funded investigators looking to submit study data under the Genomic Data Sharing (GDS) Policy. </field_page_description>
  <field_list_description>Information about submitting data under the Genomic Data Sharing (GDS) Policy for intramural, extramural, and non-NIH funded investigators. Includes data sharing best practices, data sharing plans, and institutional certification.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-22</field_date_posted>
  <field_date_reviewed>2015-09-21</field_date_reviewed>
  <para_id>1004322</para_id>
  <related_resource_id>6895836</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1005118</id>
  <title>Thinking Out of the Box to Expand Research in LMICs </title>
  <langcode>en</langcode>
  <field_short_title>Thinking Out of the Box to Expand Research in LMICs </field_short_title>
  <field_page_description>Dr. Mahendra Naidoo, Fulbright Scholar with Johns Hopkins University, brings to CGH new approaches for public health – a cornerstone for research in NCDs.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-25</field_date_posted>
  <field_date_reviewed>2015-09-25</field_date_reviewed>
  <field_pretty_url>naidoo</field_pretty_url>
  <para_id>1005118</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1007484</term_id>
  <id>1007485</id>
  <title>Genomic Data Sharing (GDS) Policy Contact Information</title>
  <langcode>en</langcode>
  <field_short_title>Contact</field_short_title>
  <field_page_description>Genomic Data Sharing Policy contact information, including NCI-Designated GPAs by division or center. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-10-22</field_date_posted>
  <field_date_reviewed>2015-09-30</field_date_reviewed>
  <para_id>1007485</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1011547</id>
  <title>NCI’s Steven Rosenberg Wins Service to America Medal</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s Steven Rosenberg Wins Service to America Medal</field_short_title>
  <field_page_description>The Partnership for Public Service has awarded Steven A. Rosenberg, M.D., of NCI's Center for Cancer Research, with its highest 2015 Samuel J. Heyman Service to America Medal, or Sammie.</field_page_description>
  <field_feature_card_description>Dr. Rosenberg is named 2015 Federal Employee of the Year for pioneering immunotherapy work.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-07</field_date_posted>
  <field_date_reviewed>2015-10-06</field_date_reviewed>
  <field_pretty_url>rosenberg-sammie</field_pretty_url>
  <para_id>1011547</para_id>
  <related_resource_ids>6890210</related_resource_ids>
  <related_resource_ids>6890213</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1014272</id>
  <title>FDA Approves Combination Drug for Patients with Advanced Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Combination Drug to Treat Patients with Advanced Colorectal Cancer</field_short_title>
  <field_page_description>The FDA has approved a single drug that combines trifluridine and tipiracil to treat patients with metastatic colorectal cancer whose disease progressed after standard treatment.  </field_page_description>
  <field_feature_card_description>The FDA has approved a combination drug in tablet form to treat patients with advanced colorectal cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-14</field_date_posted>
  <field_date_reviewed>2015-10-13</field_date_reviewed>
  <field_pretty_url>lonsurf-colorectal</field_pretty_url>
  <para_id>1014272</para_id>
  <related_resource_id>6572701</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>101531</id>
  <title>Breast Cancers Arising Between Mammograms Have Aggressive Features</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancers Between Mammograms Have Aggressive Features</field_short_title>
  <field_page_description>Breast cancers that are discovered in the period between regular screening mammograms—known as interval cancers—are more likely to have features associated with aggressive behavior and a poor prognosis than cancers found via screening mammograms. </field_page_description>
  <field_list_description>Breast cancers that are discovered in the period between regular screening mammograms—known as interval cancers—are more likely to have features associated with aggressive behavior and a poor prognosis than cancers found via screening mammograms, according to research in the May 3, 2011, issue of the Journal of the National Cancer Institute.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-16</field_date_posted>
  <field_date_reviewed>2011-08-02</field_date_reviewed>
  <field_pretty_url>interval-breast-cancer</field_pretty_url>
  <para_id>101531</para_id>
  <related_resource_id>5817104</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>105038</id>
  <title>Drugs Approved for Vaginal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Vaginal Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) to prevent vaginal cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-25</field_date_posted>
  <field_date_reviewed>2011-08-16</field_date_reviewed>
  <field_pretty_url>vaginal</field_pretty_url>
  <para_id>105038</para_id>
  <related_resource_ids>6424471</related_resource_ids>
  <related_resource_ids>6424473</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>679331</id>
  <title>Relieving Mouth Sores from Cancer Treatment: The Discovery of Palifermin</title>
  <langcode>en</langcode>
  <field_short_title>Relieving Mouth Sores of Cancer Treatment</field_short_title>
  <field_page_description>Painful mouth and throat sores can be a side effect of intensive cancer treatments for many patients. Learn how NCI scientists developed the drug, Palifermin, which vastly improves the quality of life for cancer patients.</field_page_description>
  <field_feature_card_description>NCI research and collaboration led to the development of a drug for oral mucositis.</field_feature_card_description>
  <field_list_description>Intensive cancer treatments can lead to the inflammation of the mouth and throat in cancer patients. Learn how NCI scientists developed the drug, Palifermin, which vastly improves the quality of life for cancer patients by relieving mouth sores. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-23</field_date_posted>
  <field_date_reviewed>2013-12-12</field_date_reviewed>
  <field_pretty_url>oral-mucositis</field_pretty_url>
  <para_id>679331</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11954</term_id>
  <id>682307</id>
  <title>Hormone Therapy for Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Hormone Therapy for Prostate Cancer</field_short_title>
  <field_page_description>A fact sheet that describes hormone therapy and its role in treating prostate cancer. Includes information about the types of hormone therapy, how they are used, and possible side effects.</field_page_description>
  <field_feature_card_description>A fact sheet that describes hormone therapy and its role in treating prostate cancer. </field_feature_card_description>
  <field_list_description>A fact sheet that describes hormone therapy and its role in treating prostate cancer. Includes information about the different types of hormone therapy, how they are used, and possible side effects.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-01-17</field_date_posted>
  <field_date_reviewed>2014-06-23</field_date_reviewed>
  <field_pretty_url>prostate-hormone-therapy-fact-sheet</field_pretty_url>
  <para_id>682307</para_id>
  <related_resource_id>6934072</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>684837</id>
  <title>Enhancing Breast and Ovarian Cancer Care: The Discovery of BRCA1 and BRCA2</title>
  <langcode>en</langcode>
  <field_short_title>Enhancing Breast and Ovarian Cancer Care: BRCA1 and BRCA2</field_short_title>
  <field_page_description>NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer. From this research, a screening test was also developed to help patients make informed decisions about their health.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-07</field_date_posted>
  <field_date_reviewed>2013-12-23</field_date_reviewed>
  <field_pretty_url>brca</field_pretty_url>
  <para_id>684837</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911184</term_id>
  <id>695232</id>
  <title>Common Cancer Myths and Misconceptions</title>
  <langcode>en</langcode>
  <field_short_title>Common Cancer Myths and Misconceptions</field_short_title>
  <field_page_description>The latest science-based information concerning some common misconceptions about cancer. Learn the facts to worry less and make good health decisions.</field_page_description>
  <field_feature_card_description>Wrong ideas about cancer can lead to needless worry and even hinder good prevention and treatment decisions.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-02-03</field_date_posted>
  <field_date_reviewed>2014-01-23</field_date_reviewed>
  <para_id>695232</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>981175</id>
  <title>New Research: Using Lung Cancer Screening As An Opportunity to Help Smokers Quit</title>
  <langcode>en</langcode>
  <field_short_title>New Research: Using Lung Cancer Screening As An Opportunity to Help Smokers Quit</field_short_title>
  <field_page_description>NCI has released a new funding announcement to stimulate research on optimal smoking cessation approaches delivered in conjunction with lung cancer screening.</field_page_description>
  <field_feature_card_description>With more lung cancer screening expected, research will meet an important clinical need.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-29</field_date_posted>
  <field_date_reviewed>2015-07-29</field_date_reviewed>
  <field_pretty_url>cessation-rfa</field_pretty_url>
  <para_id>981175</para_id>
  <related_resource_id>6572538</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>982345</term_id>
  <id>982944</id>
  <title>Vulvar Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on vulvar cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-08-03</field_date_posted>
  <field_date_reviewed>2015-08-03</field_date_reviewed>
  <para_id>982944</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>985598</id>
  <title>Too Few Patients with Cancer Communicate Preferences for End-of-Life Care</title>
  <langcode>en</langcode>
  <field_short_title>Study Shows Need for End-of-Life Care Preferences</field_short_title>
  <field_page_description>Many patients with cancer and their physicians are not communicating about the patients’ preferences for end-of-life medical care, a new study suggests.</field_page_description>
  <field_feature_card_description>More patients are getting intensive treatment, perhaps unwanted, in the last days or weeks of life.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-10</field_date_posted>
  <field_date_reviewed>2015-08-10</field_date_reviewed>
  <field_pretty_url>end-of-life-communication</field_pretty_url>
  <para_id>985598</para_id>
  <related_resource_id>6797363</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>988770</id>
  <title>Study Identifies Biomarker that Detects Early Pancreatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Biomarker Detects Pancreatic Cancer</field_short_title>
  <field_page_description>Exosome Biomarker Detects Pancreatic Cancer</field_page_description>
  <field_feature_card_description>Biomarker on Exosomes Detects Pancreatic Cancer</field_feature_card_description>
  <field_list_description>Researchers from the University of Texas MD Anderson Cancer Center have identified a protein marker that is found at much higher levels in exosomes that derive from cancer cells compared to healthy cells, a discovery that may improve the detection and treatment of pancreatic cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-15</field_date_posted>
  <field_date_reviewed>2015-08-28</field_date_reviewed>
  <field_pretty_url>pancreatic-biomarker</field_pretty_url>
  <para_id>988770</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1001474</id>
  <title>FDA Approves Rolapitant to Prevent Nausea and Vomiting from Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Preventing Nausea and Vomiting from Chemotherapy</field_short_title>
  <field_page_description>The FDA has approved rolapitant to prevent chemotherapy-induced nausea and vomiting.</field_page_description>
  <field_feature_card_description>The FDA has approved rolapitant, a drug that blocks the activation of brain receptors involved in nausea and vomiting.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-11</field_date_posted>
  <field_date_reviewed>2015-09-10</field_date_reviewed>
  <field_pretty_url>rolapitant-approved</field_pretty_url>
  <para_id>1001474</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1004553</term_id>
  <id>1004557</id>
  <title>DCB Funding Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>DCB Funding Opportunities</field_short_title>
  <field_page_description>Find current funding opportunities in basic cancer biology from the Division of Cancer Biology (DCB).</field_page_description>
  <field_feature_card_description>Find current funding opportunities from DCB.</field_feature_card_description>
  <field_list_description>Find current funding opportunities, arranged by funding mechanisms, from the Division of Cancer Biology (DCB).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-09-22</field_date_reviewed>
  <para_id>1004557</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1012388</id>
  <title>Progress against Cancer: The Role of Basic Science</title>
  <langcode>en</langcode>
  <field_short_title>Progress against Cancer: The Role of Basic Science</field_short_title>
  <field_page_description>Acting NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.</field_page_description>
  <field_feature_card_description>Progress is only possible because of our efforts to understand the biological mechanisms underpinning cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-08</field_date_posted>
  <field_date_reviewed>2015-10-08</field_date_reviewed>
  <field_pretty_url>bypass-basic-science</field_pretty_url>
  <para_id>1012388</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1014294</term_id>
  <id>1014309</id>
  <title>NCI Outstanding Investigator Award Recipients</title>
  <langcode>en</langcode>
  <field_short_title>NCI Outstanding Investigator Award Recipients</field_short_title>
  <field_page_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_page_description>
  <field_feature_card_description>Learn how these grantees aim to break new ground in basic, translational, and behavioral cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-14</field_date_posted>
  <field_date_reviewed>2015-10-14</field_date_reviewed>
  <para_id>1014309</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1015446</id>
  <title>Long-Term Study Finds No Increased Risk of Miscarriage after HPV Vaccination</title>
  <langcode>en</langcode>
  <field_short_title>Long-Term Study Finds No Increased Risk of Miscarriage after HPV Vaccination</field_short_title>
  <field_page_description>Women in a clinical trial who became pregnant after vaccination with a bivalent human papillomavirus (HPV) vaccine did not have an increased risk of miscarriage.</field_page_description>
  <field_feature_card_description>A long-term study shows that women who became pregnant after HPV vaccination were not at greater risk of miscarriage.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-20</field_date_posted>
  <field_date_reviewed>2015-10-20</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-risk-miscarriage</field_pretty_url>
  <para_id>1015446</para_id>
  <related_resource_id>6572888</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>849032</term_id>
  <id>849033</id>
  <title>Basic and Translational Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Basic and Translational Cancer Research</field_short_title>
  <field_page_description>CRCHD supports basic and translational research funding opportunities to increase our scientific knowledge and ultimately reduce cancer health disparities. </field_page_description>
  <field_feature_card_description>Find basic and translational cancer health disparities research funding opportunities.</field_feature_card_description>
  <field_list_description>CRCHD supports basic and translational research funding opportunities to increase our scientific knowledge and ultimately reduce cancer health disparities. 
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-10-30</field_date_reviewed>
  <para_id>849033</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>12362</term_id>
  <id>857613</id>
  <title>Help Finding NCI-Supported Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Help Finding NCI-Supported Clinical Trials</field_short_title>
  <field_feature_card_description>Information explaining how to use the clinical trials search form to find NCI-supported clinical trials and review the results of your searches. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-13</field_date_posted>
  <field_date_reviewed>2014-11-13</field_date_reviewed>
  <para_id>857613</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1065398</id>
  <title>New on NCI Websites for October 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for October 2016</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-19</field_date_posted>
  <field_date_reviewed>2016-10-19</field_date_reviewed>
  <field_pretty_url>new-online-october-2016</field_pretty_url>
  <para_id>1065398</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066189</id>
  <title>Scientists Identify Potential Marker of Resistance to PARP Inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Study Identifies Potential Marker of PARP Inhibitor Resistance</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a new study from NCI researchers that could help predict whether a tumor will respond to a new class of promising cancer drugs.</field_page_description>
  <field_feature_card_description>Finding could help predict whether a tumor will respond to a certain class of promising cancer drugs.</field_feature_card_description>
  <field_list_description>Findings from a new study from NCI researchers could help predict whether a tumor will respond to a new class of promising cancer drugs, and identifies a potential way to overcome that resistance.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-31</field_date_posted>
  <field_date_reviewed>2016-10-31</field_date_reviewed>
  <field_pretty_url>parp-inhibitor-resistance</field_pretty_url>
  <para_id>1066189</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066246</id>
  <title>Olaratumab Approved to Treat Advanced Soft Tissue Sarcoma </title>
  <langcode>en</langcode>
  <field_short_title>New Treatment Approved for Soft Tissue Sarcoma </field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about the FDA’s granting accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma. </field_page_description>
  <field_feature_card_description>First new treatment for soft tissue sarcoma in 40 years.</field_feature_card_description>
  <field_list_description>The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-02</field_date_posted>
  <field_date_reviewed>2016-11-02</field_date_reviewed>
  <field_pretty_url>fda-olaratumab-sarcoma</field_pretty_url>
  <para_id>1066246</para_id>
  <related_resource_id>7250929</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1067855</id>
  <title>Diagnosed With Ovarian Cancer, a Researcher Mined TCGA Data to Study Her Own Disease</title>
  <langcode>en</langcode>
  <field_short_title>Researcher Studies Own Cancer</field_short_title>
  <field_page_description>Shirley Pepke, Ph.D., used her computational biology background to study her own ovarian cancer data in comparison to The Cancer Genome Atlas. </field_page_description>
  <field_feature_card_description>How a researcher used a personalized approach to her cancer treatment</field_feature_card_description>
  <field_list_description>Faced the bleak prognosis associated with stage IIIC ovarian cancer, Shirley Pepke, Ph.D., used her computational biology background to study her own cancer in comparison to TCGA data. Pepke has now been in remission for a year. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-12-06</field_date_posted>
  <field_date_reviewed>2016-12-02</field_date_reviewed>
  <field_pretty_url>personalized-cancer-treatment-TCGA-data</field_pretty_url>
  <para_id>1067855</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1069583</term_id>
  <id>1069584</id>
  <title>Track 2: Oncology Product Research and Review for Board Certified Oncologists</title>
  <langcode>en</langcode>
  <field_short_title>IOTF: Oncology Product Review for BC Oncologists</field_short_title>
  <field_page_description>NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.</field_page_description>
  <field_feature_card_description>Training for physicians in aspects of medical product development and standards.</field_feature_card_description>
  <field_list_description>This interagency program trains physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety and efficacy to facilitate movement from basic bench science to commercialization.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-21</field_date_posted>
  <field_date_reviewed>2016-12-21</field_date_reviewed>
  <para_id>1069584</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938135</term_id>
  <id>661405</id>
  <title>Combination of Nab-Paclitaxel and Gemcitabine Improves Survival in Patients with Metastatic Pancreatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer</field_short_title>
  <field_page_description>A summary of results from a phase III trial that compared the combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) versus gemcitabine alone in patients with metastatic pancreatic cancer. </field_page_description>
  <field_feature_card_description>In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated w</field_feature_card_description>
  <field_list_description>In an international randomized phase III trial, patients with metastatic pancreatic cancer who were treated with a combination of albumin-bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived longer than patients who were treated with gemcitabine alone. Patients who received both drugs also lived longer without their disease getting worse (progression-free survival).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-11-15</field_date_posted>
  <field_date_reviewed>2013-11-15</field_date_reviewed>
  <field_pretty_url>nab-paclitaxel-gemcitabine</field_pretty_url>
  <para_id>661405</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>898585</term_id>
  <id>675557</id>
  <title>NCI Portfolio Analyses</title>
  <langcode>en</langcode>
  <field_short_title>NCI Portfolio Analyses</field_short_title>
  <field_page_description>Reports that broadly describe the research funding and topic categories for specific portions of the NCI reserach portfolio.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-12-04</field_date_posted>
  <field_date_reviewed>2013-12-04</field_date_reviewed>
  <field_pretty_url>portfolio-analyses</field_pretty_url>
  <para_id>675557</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974631</term_id>
  <id>974632</id>
  <title>Comparison of Dollars, Positions, and Space</title>
  <langcode>en</langcode>
  <field_short_title>Comparison of Dollars, Positions &amp; Space</field_short_title>
  <field_page_description>Find information about obligations against the annual NCI appropriation for full-time equivalent (FTE) positions and occupied space since 2009.</field_page_description>
  <field_feature_card_description>Find information about obligations against the annual NCI appropriation for full-time equivalent (FTE) positions and occupied since 2009.</field_feature_card_description>
  <field_list_description>See obligations against the annual NCI appropriation, the total number full-time equivalent (FTE) positions (work years for NCI employees), and facility space in thousands of square feet.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-08</field_date_reviewed>
  <para_id>974632</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>978804</id>
  <title>Pembrolizumab Improves Progression-Free Survival in Patients with Ipilimumab-Resistant Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab for Ipilimumab-Resistant Melanoma</field_short_title>
  <field_page_description>KEYNOTE-002 was designed to test the safety and efficacy of two doses of pembrolizumab compared with chemotherapy in patients with ipilimumab-resistant melanoma; interim results show that pembrolizumab improves progression-free survival for these patients</field_page_description>
  <field_feature_card_description>Pembrolizumab improves progression-free survival in patients with ipilimumab-resistant melanoma</field_feature_card_description>
  <field_list_description>Results from the KEYNOTE-002 clinical trial show that pembrolizumab improves progression-free survival in patients with ipilimumab-resistant melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-20</field_date_posted>
  <field_date_reviewed>2015-07-20</field_date_reviewed>
  <field_pretty_url>pembrolizumab-ipilimumab-resistance</field_pretty_url>
  <para_id>978804</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>988377</term_id>
  <id>988378</id>
  <title>Division of Cancer Biology</title>
  <langcode>en</langcode>
  <field_short_title>Division of Cancer Biology</field_short_title>
  <field_page_description>DCB supports a broad range of investigator-initiated research in its mission to facilitate existing and emerging research areas in basic cancer biology.</field_page_description>
  <field_feature_card_description>Provides funding for basic research in cancer biology, which leads to better ways to study, prevent, and treat the disease. </field_feature_card_description>
  <field_list_description>The Division of Cancer Biology (DCB) supports basic research in all areas of cancer biology at academic institutions and research foundations across the United States. As part of NCI, DCB provides funding for research that investigates the basic biology behind cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-08-26</field_date_reviewed>
  <para_id>988378</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>989277</id>
  <title>Adding Chemotherapy to Hormone Therapy Extends Overall Survival in Metastatic Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Hormone Therapy Plus Chemotherapy for Metastatic Prostate Cancer</field_short_title>
  <field_page_description>A trial of androgen deprivation therapy (ADT) plus six cycles of docetaxel versus ADT alone found that after a median follow-up of nearly 29 months, median overall survival was 13.6 months longer with the combination therapy than with ADT alone.</field_page_description>
  <field_feature_card_description>Hormone therapy plus chemotherapy extends overall survival compared with hormone therapy alone in men with metastatic prostate cancer.</field_feature_card_description>
  <field_list_description>Adding the chemotherapy drug docetaxel to hormone therapy extended median overall survival by 13.6 months compared with hormone therapy alone in men with metastatic prostate cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-31</field_date_posted>
  <field_date_reviewed>2015-08-31</field_date_reviewed>
  <field_pretty_url>chemohormonal-treatment-extends-survival</field_pretty_url>
  <para_id>989277</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>993432</id>
  <title>NCI Initiative to Speed Development of Childhood Cancer Therapies </title>
  <langcode>en</langcode>
  <field_short_title>NCI Pediatric Preclinical Testing Consortium</field_short_title>
  <field_page_description>NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium, which is intended to help to prioritize which agents to pursue in pediatric clinical trials. </field_page_description>
  <field_feature_card_description>Five research teams have been selected to conduct preclinical testing of potential treatments for specific childhood cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-08</field_date_posted>
  <field_date_reviewed>2015-09-03</field_date_reviewed>
  <field_pretty_url>PPTC-awards</field_pretty_url>
  <para_id>993432</para_id>
  <related_resource_id>6572552</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>1001033</id>
  <title>Children with Cancer: A Guide for Parents</title>
  <langcode>en</langcode>
  <field_short_title>Children with Cancer: A Guide for Parents</field_short_title>
  <field_page_description>Information and advice for parents who have a child with cancer, including treatment, coping and support, health issues, integrative medicine, advanced cancer, and survivorship.</field_page_description>
  <field_feature_card_description>Practical information about childhood cancer, treatment, coping, and more for parents and health care providers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-09</field_date_posted>
  <field_date_reviewed>2015-09-09</field_date_reviewed>
  <field_pretty_url>guide-for-parents</field_pretty_url>
  <para_id>1001033</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>1001053</id>
  <title>Meta-Analysis Finds Benefits of Adjuvant Bisphosphonates for Postmenopausal Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Meta-Analysis Finds Benefits of Adjuvant Bisphosphonates for Postmenopausal Breast Cancer</field_short_title>
  <field_page_description>A summary of a meta-analysis of randomized trials of bisphosphonates as adjuvant therapy for women with early-stage breast cancer that shows the drugs can reduce the rate of disease recurrence in bone.</field_page_description>
  <field_feature_card_description>Bisphosphonates can reduce the rate of breast cancer recurrence in bone, according to a meta-analysis of randomized trials of bisphosphonates as adjuvant therapy for women with early-stage breast cancer.</field_feature_card_description>
  <field_list_description>Bisphosphonates can reduce the rate of breast cancer recurrence in bone, according to a meta-analysis of randomized trials of bisphosphonates as adjuvant therapy for women with early-stage breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-09</field_date_posted>
  <field_date_reviewed>2015-09-09</field_date_reviewed>
  <field_pretty_url>adjuvant-bisphosphonates-meta-analysis</field_pretty_url>
  <para_id>1001053</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>1025815</id>
  <title>No Magic Bullet for RAS</title>
  <langcode>en</langcode>
  <field_short_title>No Magic Bullet for RAS</field_short_title>
  <field_page_description>Kevin Haigis discusses the complicated natural histories of the different RAS genes mutated at different positions in different organs that result in human cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-13</field_date_posted>
  <field_date_reviewed>2015-11-09</field_date_reviewed>
  <field_pretty_url>ras-no-magic-bullet</field_pretty_url>
  <para_id>1025815</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026798</term_id>
  <id>1026806</id>
  <title>Biomedical Research Legislation</title>
  <langcode>en</langcode>
  <field_short_title>Biomedical Research Legislation</field_short_title>
  <field_page_description>Legislation from the current Congress dealing with biomedical research related to NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <para_id>1026806</para_id>
  <related_resource_id>7196094</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1026828</id>
  <title>NIH-IEEE 2015 Strategic Conference on Healthcare Innovations and Point-of-Care Technologies for Precision Medicine</title>
  <langcode>en</langcode>
  <field_short_title>NIH-IEEE 2015 Strategic Conference on Healthcare Innovations and Point-of-Care Technologies for Prec</field_short_title>
  <field_page_description>NIH and the Institute for Electrical and Electronics Engineering, Engineering in Medicine and Biology Society (IEEE/EMBS) hosted the third iteration of the Healthcare Innovations and Point-of-Care Technologies Conference last week.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-11-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <field_pretty_url>precision</field_pretty_url>
  <para_id>1026828</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1027009</term_id>
  <id>1027010</id>
  <title>Glossary of Legislative Terms</title>
  <langcode>en</langcode>
  <field_short_title>Glossary of Legislative Terms</field_short_title>
  <field_page_description>The Glossary of Legislative Terms provides brief explanations of terms and procedures used within the United States Congress.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1027010</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026794</term_id>
  <id>1027677</id>
  <title>Legislative Updates</title>
  <langcode>en</langcode>
  <field_short_title>Legislative Updates</field_short_title>
  <field_page_description>Recent developments on legislation involving cancer research, appropriations, congressional testimony and other related topics. </field_page_description>
  <field_feature_card_description>Recent developments on legislative activities and NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-24</field_date_reviewed>
  <para_id>1027677</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882432</term_id>
  <id>882433</id>
  <title>Radon</title>
  <langcode>en</langcode>
  <field_short_title>Radon</field_short_title>
  <field_page_description>Learn about radon, which can raise your risk of lung cancer. Radon gas usually exists at very low levels outdoors, but the gas can accumulate in areas without adequate ventilation, such as underground mines or residential basements.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-20</field_date_reviewed>
  <para_id>882433</para_id>
  <related_resource_id>7264546</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916480</term_id>
  <id>882436</id>
  <title>Nickel Compounds</title>
  <langcode>en</langcode>
  <field_short_title>Nickel Compounds</field_short_title>
  <field_page_description>Learn about nickel compounds, which can raise your risk of lung cancer and nasal cancer. Workers in mining, smelting, welding, and other industrial occupations are most commonly exposed to nickel.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <para_id>882436</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916476</term_id>
  <id>882439</id>
  <title>Indoor Emissions from the Household Combustion of Coal</title>
  <langcode>en</langcode>
  <field_short_title>Indoor Emissions from the Household Combustion of Coal</field_short_title>
  <field_page_description>Learn about the lung cancer risk associated with burning coal inside your home. Indoor emissions from the household combustion of coal contain harmful chemicals such as benzene, carbon monoxide, and formaldehyde. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <para_id>882439</para_id>
  <related_resource_id>7254846</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882600</term_id>
  <id>882601</id>
  <title>Arsenic</title>
  <langcode>en</langcode>
  <field_short_title>Arsenic</field_short_title>
  <field_page_description>Arsenic is a naturally occurring substance that can be found in air, water, and soil and is known to cause cancer. Inorganic arsenic is naturally present at high levels in the groundwater of certain countries, including the United States.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2018-12-31</field_date_reviewed>
  <para_id>882601</para_id>
  <related_resource_ids>7268125</related_resource_ids>
  <related_resource_ids>7268127</related_resource_ids>
  <related_resource_ids>7268688</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882633</term_id>
  <id>882634</id>
  <title>Cadmium</title>
  <langcode>en</langcode>
  <field_short_title>Cadmium</field_short_title>
  <field_page_description>Learn about cadmium, which may raise your risk of lung cancer. Cadmium is a natural element: all soils and rocks contain some cadmium. Exposure occurs mostly where cadmium products (such as batteries, pigments, metal coatings, and plastics) are made or recycled. Tobacco smoke also contains cadmium.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-01</field_date_reviewed>
  <para_id>882634</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>861456</term_id>
  <id>883849</id>
  <title>Causes and Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Causes and Prevention</field_short_title>
  <field_page_description>Covers known cancer risk factors, how certain cancers can be prevented, and ongoing research into causes and prevention.</field_page_description>
  <field_list_description>Covers known cancer risk factors, how certain cancers can be prevented, myths about causes and prevention, and ongoing research in this area.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-17</field_date_posted>
  <field_date_reviewed>2014-12-17</field_date_reviewed>
  <para_id>883849</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>860262</term_id>
  <id>883852</id>
  <title>Which Patients Will Benefit from Immunotherapy for Cancer? Some Hints Emerge</title>
  <langcode>en</langcode>
  <field_short_title>Who Will Benefit from Cancer Immunotherapy?</field_short_title>
  <field_page_description>Researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. The results could be the basis for a test that identifies likely responders.</field_page_description>
  <field_feature_card_description>Researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. The results could be the basis for a test that identifies likely responders.</field_feature_card_description>
  <field_list_description>Researchers have identified a “genetic signature” in the tumors of patients with advanced melanoma who responded to a form of immunotherapy called checkpoint blockade. The results could be the basis for a test that identifies likely responders to this treatment as well as for developing new treatments.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-17</field_date_posted>
  <field_date_reviewed>2014-12-17</field_date_reviewed>
  <field_pretty_url>who-responds-immunotherapy</field_pretty_url>
  <para_id>883852</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066696</id>
  <title>Connected Health: An Important Tool for Making Progress against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Connected Health and Progress against Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a new report from President’s Cancer Panel outlining how connective technologies can promote cancer prevention, enhance patients’ treatment experience, and accelerate progress in cancer research.</field_page_description>
  <field_feature_card_description>President’s Cancer Panel report addresses role of connective technologies in cancer.</field_feature_card_description>
  <field_list_description>A new report from the President’s Cancer Panel outlines how connective technologies can promote cancer prevention, enhance patients’ treatment experience, and accelerate progress in cancer research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-16</field_date_posted>
  <field_date_reviewed>2016-11-15</field_date_reviewed>
  <field_pretty_url>pcp-connected-health</field_pretty_url>
  <para_id>1066696</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1067313</id>
  <title>Cancer Metabolism: A Conversation with Jason Locasale</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Metabolism: A Conversation with Jason Locasale</field_short_title>
  <field_page_description>Cancers driven by oncogenes such as RAS have altered metabolic pathways. Scientists hope such differences make cancers vulnerable to new drugs.</field_page_description>
  <field_feature_card_description>In a new RAS Dialogue, Jason Locasale discusses how oncogenes such as mutant RAS change the ways cells convert nutrients to energy and growth and proliferation.</field_feature_card_description>
  <field_list_description>Cancers driven by oncogenes such as RAS have metabolic pathways that are significantly altered compared to normal cells. Jason Locasale studies how such differences can be used as vulnerabilities for improved treatments.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-28</field_date_posted>
  <field_date_reviewed>2016-11-28</field_date_reviewed>
  <field_pretty_url>cancer-metabolism-locasale</field_pretty_url>
  <para_id>1067313</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1067400</id>
  <title>Prescription Subsidies Reduce Breast Cancer Treatment Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Prescription Subsidies Reduce Breast Cancer Treatment Disparities</field_short_title>
  <field_page_description> An NCI Cancer Currents blog about a new study showing that subsidies for prescription drugs can help to reduce racial/ethnic disparities in the use of a proven breast cancer treatment.</field_page_description>
  <field_feature_card_description> Subsidies increased hormone therapy use in black, Hispanic women with breast cancer.</field_feature_card_description>
  <field_list_description>A new study has found that subsidies for prescription drugs can improve the use of adjuvant therapy in women with early-stage breast cancer and help reduce disparities in the use of these proven treatments among black and Hispanic women.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-30</field_date_posted>
  <field_date_reviewed>2016-11-30</field_date_reviewed>
  <field_pretty_url>subsidies-breast-disparities</field_pretty_url>
  <para_id>1067400</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1067637</id>
  <title>FDA Approves Nivolumab for Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Nivolumab for Head and Neck Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about the FDA approval of nivolumab for recurrent or progressive squamous cell carcinoma of the head and neck.</field_page_description>
  <field_feature_card_description>Second immunotherapy drug approved for this cancer type.</field_feature_card_description>
  <field_list_description>The FDA has approved nivolumab for squamous cell carcinoma of the head and neck that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-01</field_date_posted>
  <field_date_reviewed>2016-12-01</field_date_reviewed>
  <field_pretty_url>fda-nivolumab-scchn</field_pretty_url>
  <para_id>1067637</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068131</term_id>
  <id>1068213</id>
  <title>Track 1: Oncology Product Research and Review for M.D. Oncology Fellows</title>
  <langcode>en</langcode>
  <field_short_title>IOTF: Oncology Product Review for Oncology Fellows</field_short_title>
  <field_page_description>NCI and FDA collaborate to train physicians in clinical trials methodology and medical product development. Learn more about this cancer training program.</field_page_description>
  <field_feature_card_description>Training for physicians in clinical aspects of medical product development.</field_feature_card_description>
  <field_list_description>This interagency program trains physicians in aspects of clinical trials methodology and analysis, epidemiology, clinical aspects of medical product development to facilitate the movement of products from basic bench science to commercialization.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-08</field_date_posted>
  <field_date_reviewed>2016-12-08</field_date_reviewed>
  <para_id>1068213</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1123971</id>
  <title>Exosomes May Help Tumors Evade Immune System</title>
  <langcode>en</langcode>
  <field_short_title>Exosomes May Help Tumors Evade Immune System</field_short_title>
  <field_page_description>Exosomes studded with the PD-L1 protein may help cancers evade the immune system, findings from a new study suggest. The presence of exosomes bearing the immune checkpoint protein could be a treatment biomarker, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Melanomas may secrete exosomes with immune checkpoint proteins.</field_feature_card_description>
  <field_list_description>A new study has identified what may be an important and previously unknown route by which tumors evade the immune system: They secrete small membrane-encased sacs, called exosomes, studded with a protein that dials down the immune response.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-07</field_date_posted>
  <field_date_reviewed>2018-09-06</field_date_reviewed>
  <field_pretty_url>exosomes-tumors-evade-immune-system</field_pretty_url>
  <para_id>1123971</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1124104</term_id>
  <id>1124105</id>
  <title>Prevention and Early Detection of Hereditary Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Hereditary Cancer Prevention &amp; Detection </field_short_title>
  <field_page_description>This Moonshot initiative aims to develop effective cancer prevention and early detection approaches for those at high risk for inherited cancer syndromes and implement appropriate clinical management.</field_page_description>
  <field_feature_card_description>The goal of this research is to develop effective cancer prevention and early detection approaches for individuals at high risk for inherited cancer syndromes.</field_feature_card_description>
  <field_list_description>Improve current methods and develop new strategies for the prevention and early detection of cancer in individuals at high risk for cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <para_id>1124105</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124207</id>
  <title>NCI and FDA Address Common Concerns: A Win–Win for Making Progress against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>NCI and FDA Collaborating on Common Concerns</field_short_title>
  <field_page_description>NCI Director Dr. Norman Sharpless discusses efforts between NCI and FDA to advance progress against cancer, including initiatives to improve labeling of patient tumor and tissue samples and address challenges presented by new tobacco products.</field_page_description>
  <field_feature_card_description>Agencies collaborating to improve cancer research, tobacco control.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless discusses efforts between NCI and FDA to advance progress against cancer, including initiatives to improve labeling of patient tumor and tissue samples and to address challenges presented by new tobacco products.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-17</field_date_posted>
  <field_date_reviewed>2018-09-13</field_date_reviewed>
  <field_pretty_url>sharpless-nci-fda-collaboration</field_pretty_url>
  <para_id>1124207</para_id>
  <related_resource_ids>7122140</related_resource_ids>
  <related_resource_ids>7122141</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1124536</term_id>
  <id>1124541</id>
  <title>Strategic Planning at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Strategic Planning at NCI</field_short_title>
  <field_page_description>NCI’s strategic goals and priorities aim to direct progress against cancer to meet the needs of all people. Learn how priorities are set and how funding decisions are made at NCI.</field_page_description>
  <field_feature_card_description>Learn how priorities are set and how funding decisions are made at NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-15</field_date_posted>
  <field_date_reviewed>2018-09-19</field_date_reviewed>
  <para_id>1124541</para_id>
  <related_resource_id>7207391</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124643</id>
  <title>Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments</title>
  <langcode>en</langcode>
  <field_short_title>Investigating the Cardiac Side Effects of Cancer Treatments</field_short_title>
  <field_page_description>Certain cancer treatments can damage the heart and the cardiovascular system, a problem known as cardiotoxicity. Cardiologists and oncologists met recently to discuss strategies and future research directions for addressing these side effects. </field_page_description>
  <field_feature_card_description>Cardiologists, oncologists working to better address cardiotoxicity.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-21</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <field_pretty_url>cancer-treatment-heart-side-effects</field_pretty_url>
  <para_id>1124643</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1126546</term_id>
  <id>1126547</id>
  <title>2017 Outstanding Investigator Award Recipients</title>
  <langcode>en</langcode>
  <field_short_title>2017 NCI OIA Recipients</field_short_title>
  <field_page_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_page_description>
  <field_feature_card_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-15</field_date_posted>
  <field_date_reviewed>2015-10-14</field_date_reviewed>
  <para_id>1126547</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1077979</id>
  <title>Targeted Cancer Drug May Also Help Protect Fertility, Study Suggests</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Cancer Drug May Also Help Protect Fertility</field_short_title>
  <field_page_description>A Cancer Currents blog on a new study in mice suggesting that a class of targeted cancer drugs may help some women undergoing cancer treatments preserve their fertility.</field_page_description>
  <field_feature_card_description>Mouse study suggests mTOR inhibitors protect ovaries from chemotherapy.</field_feature_card_description>
  <field_list_description>Findings from a new study in mice suggest that a class of targeted cancer drugs may have another use in some younger women being treated for cancer: preserving their fertility. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-27</field_date_posted>
  <field_date_reviewed>2017-03-24</field_date_reviewed>
  <field_pretty_url>mtor-cancer-fertility-preservation</field_pretty_url>
  <para_id>1077979</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1081005</id>
  <title>Studies Identify Potential Treatment Strategies for Pediatric DIPG Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Studies Identify Potential Treatments for DIPG Brain Tumors</field_short_title>
  <field_page_description>A Cancer Currents blog on research from two studies which found that drugs known as PRC2 and BET inhibitors shrank tumors in mouse models of the childhood brain cancer DIPG. </field_page_description>
  <field_feature_card_description>Drugs already in clinical trials potential option for children with aggressive brain cancer.</field_feature_card_description>
  <field_list_description>Two studies have identified proteins that drive growth of diffuse intrinsic pontine glioma (DIPG) tumor cells. Blocking these targets with investigational drugs slowed tumor growth in animal models.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-13</field_date_posted>
  <field_date_reviewed>2017-04-13</field_date_reviewed>
  <field_pretty_url>dipg-treatment-strategies</field_pretty_url>
  <para_id>1081005</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1084389</id>
  <title>Mentor Spotlight: Elisa V. Bandera, MD, PhD</title>
  <langcode>en</langcode>
  <field_short_title>Mentor Spotlight: Elisa V. Bandera, MD, PhD</field_short_title>
  <field_page_description>Dr. Brian D. Gonzalez, a K01 awardee, shares how his mentor, Dr. Elisa V. Bandera, has supported his career development.</field_page_description>
  <field_feature_card_description>Dr. Brian D. Gonzalez shares how his mentor, Dr. Elisa V. Bandera, has positively influenced his career development.</field_feature_card_description>
  <field_list_description>Dr. Brian D. Gonzalez, a K01 awardee, shares how his mentor, Dr. Elisa V. Bandera, has supported his career development.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-11</field_date_posted>
  <field_date_reviewed>2017-05-11</field_date_reviewed>
  <field_pretty_url>mentor-spotlight-bandera</field_pretty_url>
  <para_id>1084389</para_id>
  <related_resource_id>6568895</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084764</id>
  <title>Global Health - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Global Health</field_short_title>
  <field_page_description>Blog posts on global cancer research—including factors that influence global cancer incidence and mortality and new research initiatives—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Global cancer research-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>global-health</field_pretty_url>
  <para_id>1084764</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084781</id>
  <title>Technology - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Technology</field_short_title>
  <field_page_description>Blog posts on technologies that affect cancer research and care—including new technologies for detecting cancer, testing treatments, storing/analyzing data, and improving patient care—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer research technology-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>technology</field_pretty_url>
  <para_id>1084781</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1085505</id>
  <title>Intensive Pre-Stem Cell Transplant Regimen May be Best for Younger Patients with AML, MDS</title>
  <langcode>en</langcode>
  <field_short_title>Pre-Stem Cell Transplant Treatment Regimen for AML, MDS</field_short_title>
  <field_page_description>A Cancer Currents blog on a study suggesting that an intensive preparatory regimen should be used for younger patients with AML undergoing a stem cell transplant.</field_page_description>
  <field_feature_card_description>For younger patients with AML, intensive regimen may be best.</field_feature_card_description>
  <field_list_description>Results from a large phase III clinical trial suggest that a highly intensive preparatory regimen should be used for younger patients with acute myeloid leukemia or myelodysplastic syndromes preparing to undergo an allogeneic stem cell transplant.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-26</field_date_posted>
  <field_date_reviewed>2017-05-18</field_date_reviewed>
  <field_pretty_url>aml-stem-cell-transplant</field_pretty_url>
  <para_id>1085505</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1085520</id>
  <title>FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Brigatinib Approved by FDA for Lung Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on the FDA’s approval of brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) that has alterations in the ALK gene.</field_page_description>
  <field_feature_card_description>Drug joins three others that target same genetic mutation.</field_feature_card_description>
  <field_list_description>On April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-19</field_date_posted>
  <field_date_reviewed>2017-05-19</field_date_reviewed>
  <field_pretty_url>brigatinib-fda-lung-cancer</field_pretty_url>
  <para_id>1085520</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068124</term_id>
  <id>1068994</id>
  <title>Current and Alumni Fellows</title>
  <langcode>en</langcode>
  <field_short_title>IOTF Current Fellows</field_short_title>
  <field_page_description>NCI and FDA collaborate to train scientists in research and research-related regulatory review. Meet the current IOTF fellows. </field_page_description>
  <field_feature_card_description>Learn how IOTF is helping current fellows achieve their professional goals.</field_feature_card_description>
  <field_list_description>This fellowship trains scientists in research and research-related regulatory review, policies, and regulations. Meet the current fellows and learn how IOTF is helping them achieve their professional goals.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-12</field_date_posted>
  <field_date_reviewed>2016-12-12</field_date_reviewed>
  <field_pretty_url>iotf-current-fellows</field_pretty_url>
  <para_id>1068994</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1069230</id>
  <title>Brain Cancer’s Cholesterol Addiction May Offer New Treatment Strategy</title>
  <langcode>en</langcode>
  <field_short_title>Targeting Cholesterol in Brain Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog post on a study showing that treating mice with brain tumors with a cholesterol-depleting drug slowed tumor growth and improved survival.</field_page_description>
  <field_feature_card_description>In a new study in mice, a cholesterol-depleting drug slowed tumor growth and improved survival.</field_feature_card_description>
  <field_list_description>Brain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-16</field_date_posted>
  <field_date_reviewed>2016-12-16</field_date_reviewed>
  <field_pretty_url>brain-cancer-cholesterol</field_pretty_url>
  <para_id>1069230</para_id>
  <related_resource_id>6586966</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1069455</id>
  <title>New Mouse Model Closely Mimics Most Common Leukemia in Infants</title>
  <langcode>en</langcode>
  <field_short_title>Improved Research Model for Childhood Leukemia</field_short_title>
  <field_page_description>A Cancer Currents blog post on a study describing the development of a long-sought-after mouse model for an aggressive form of acute lymphoblastic leukemia that occurs commonly in infants.</field_page_description>
  <field_feature_card_description>Model may accelerate development of new therapies for common cancer in infants.</field_feature_card_description>
  <field_list_description>Researchers have created a long-sought-after mouse model for an aggressive form of acute lymphoblastic leukemia that occurs commonly in infants and that the researchers believe can accelerate the development of new therapies for the disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-30</field_date_posted>
  <field_date_reviewed>2016-12-20</field_date_reviewed>
  <field_pretty_url>leukemia-infant-research-model</field_pretty_url>
  <para_id>1069455</para_id>
  <related_resource_id>6598343</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068124</term_id>
  <id>1069568</id>
  <title>IOTF Mentors: Track 3 and Track 4</title>
  <langcode>en</langcode>
  <field_short_title>IOTF Mentors: Tracks 3 and 4</field_short_title>
  <field_page_description>While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 3 and 4. </field_page_description>
  <field_feature_card_description>Senior FDA staff mentors for IOTF fellows in tracks 3 and 4. </field_feature_card_description>
  <field_list_description>While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 3 and 4.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-21</field_date_posted>
  <field_date_reviewed>2016-12-21</field_date_reviewed>
  <field_pretty_url>mentors-tracks-3-4</field_pretty_url>
  <para_id>1069568</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1069576</id>
  <title>New Targeted Therapies Show Promise for Treating Advanced GIST</title>
  <langcode>en</langcode>
  <field_short_title>Therapies Target Treatment-Resistant GIST</field_short_title>
  <field_page_description>A &lt;i&gt;Cancer Currents&lt;/i&gt; blog post on early-stage clinical trials of two new therapies that target genetic mutations in gastrointestinal stromal tumors that fuel resistance to standard therapies.</field_page_description>
  <field_feature_card_description>Two drugs target the genetic mutations that fuel resistance to other treatments.</field_feature_card_description>
  <field_list_description>Two new targeted therapies have shown promise in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to standard therapies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-21</field_date_posted>
  <field_date_reviewed>2016-12-21</field_date_reviewed>
  <field_pretty_url>targeting-gist-resistance</field_pretty_url>
  <para_id>1069576</para_id>
  <related_resource_id>6612007</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1070068</term_id>
  <id>1070069</id>
  <title>2017 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2017 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2017.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-12-30</field_date_posted>
  <field_date_reviewed>2016-12-30</field_date_reviewed>
  <para_id>1070069</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1072619</id>
  <title>NCTN/NCORP Data Archive: Expanding Access to Clinical Trial Data</title>
  <langcode>en</langcode>
  <field_short_title>NCTN/NCORP Data Archive: Expanding Access to Clinical Trial Data</field_short_title>
  <field_page_description>NCI is launching the NCTN/NCORP Data Archive, a centralized repository of patient-level data from phase III clinical trials conducted by NCI’s NCTN and NCORP trials programs and the National Cancer Institute of Canada-Clinical Trials Group.</field_page_description>
  <field_feature_card_description>Centralized repository of patient-level data will expand the value of NCI’s clinical trials portfolio. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-06</field_date_posted>
  <field_date_reviewed>2017-02-06</field_date_reviewed>
  <field_pretty_url>nctn-ncorp-data-archive</field_pretty_url>
  <para_id>1072619</para_id>
  <related_resource_id>6612721</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1072867</id>
  <title>Three-Drug Combination Extends Survival for Patients with Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Three-Drug Combination for Multiple Myeloma</field_short_title>
  <field_page_description>A Cancer Currents blog on a clinical trial showing that the combination of bortezomib, lenalidomide, and dexamethasone improves survival in multiple myeloma.</field_page_description>
  <field_feature_card_description>Combination should be adopted as standard of care for some patients, experts say.</field_feature_card_description>
  <field_list_description>A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-10</field_date_posted>
  <field_date_reviewed>2017-02-10</field_date_reviewed>
  <field_pretty_url>three-drug-combination-myeloma</field_pretty_url>
  <para_id>1072867</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11828</term_id>
  <id>884327</id>
  <title>Understanding Prostate Changes: A Health Guide for Men</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Prostate Changes</field_short_title>
  <field_page_description>Prostate changes and symptoms that are not cancer. Learn about symptoms, risk factors, and treatment for prostatitis, enlarged prostate (BPH), prostate cancer. Talk with doctor about prostate cancer screening tests (DRE, PSA), biopsy, and Gleason score.</field_page_description>
  <field_feature_card_description>Learn about symptoms, risk factors, and treatment for prostatitis, enlarged prostate (BPH), and prostate cancer.</field_feature_card_description>
  <field_list_description>Learn about symptoms, risk factors, and treatment for prostatitis, enlarged prostate (BPH), and prostate cancer. Talk with doctor about prostate cancer screening tests, getting a biopsy, and what your Gleason score means.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-18</field_date_posted>
  <field_date_reviewed>2014-12-18</field_date_reviewed>
  <para_id>884327</para_id>
  <related_resource_ids>6934031</related_resource_ids>
  <related_resource_ids>6934035</related_resource_ids>
  <related_resource_ids>6934036</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>890966</id>
  <title>New on Cancer.gov: Resources on Melanoma Therapies</title>
  <langcode>en</langcode>
  <field_short_title>New Resources on Melanoma Therapies</field_short_title>
  <field_page_description>A blog post about several new Cancer.gov resources that provide details about the changing treatment landscape for advanced melanoma.</field_page_description>
  <field_feature_card_description>Several new Cancer.gov resources that provide details about the changing treatment landscape for advanced melanoma.</field_feature_card_description>
  <field_list_description>Several new resources that provide more details about the changing treatment landscape for advanced melanoma have recently been added to Cancer.gov.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-06</field_date_posted>
  <field_date_reviewed>2015-01-06</field_date_reviewed>
  <field_pretty_url>melanoma-resources</field_pretty_url>
  <para_id>890966</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>915875</term_id>
  <id>894866</id>
  <title>Environmental Carcinogens and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Environmental Carcinogens and Cancer Risk</field_short_title>
  <field_page_description>Factors are discussed that may influence whether a person exposed to a cancer-causing substance (carcinogen) will develop cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2017-12-12</field_date_reviewed>
  <field_pretty_url>carcinogens</field_pretty_url>
  <para_id>894866</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>895701</id>
  <title>Program Spotlight: PACHE Partners Discuss Better Ways to Advance Cancer Health Equity</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: PACHE Partners Discuss Better Ways to Advance Cancer Health Equity</field_short_title>
  <field_page_description>Program Spotlight: PACHE Partners Meet to Discuss Future of Program and Better Ways to Advance Cancer Health Equity</field_page_description>
  <field_feature_card_description>Program Spotlight: PACHE Partners Meet to Discuss Future of Program and Better Ways to Advance Cancer Health Equity</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-23</field_date_posted>
  <field_date_reviewed>2014-10-23</field_date_reviewed>
  <field_pretty_url>pache-spotlight</field_pretty_url>
  <para_id>895701</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>898730</id>
  <title>November Spotlight: Native American Heritage Month and Cancer Awareness Highlights</title>
  <langcode>en</langcode>
  <field_short_title>November Spotlight: Native American Heritage Month and Cancer Awareness Highlights</field_short_title>
  <field_page_description>CRCHD recognizes Lung Cancer Awareness Month and celebrates Native American Heritage Month by highlighting disparities and CRCHD-funded research to reduce disparities. </field_page_description>
  <field_feature_card_description>CRCHD recognizes Lung Cancer Awareness and celebrates Native American Heritage Months.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-01</field_date_posted>
  <field_date_reviewed>2014-11-18</field_date_reviewed>
  <field_pretty_url>november-spotlight</field_pretty_url>
  <para_id>898730</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>898735</id>
  <title>Special Spotlight: Hispanic Heritage Month</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: Hispanic Heritage Month</field_short_title>
  <field_page_description>CRCHD celebrates Hispanic Heritage Month by highlighting CRCHD-funded research that aims to reduce cancer health disparities in Hispanics and Latinos.</field_page_description>
  <field_feature_card_description>CRCHD celebrates Hispanic Heritage Month.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-19</field_date_posted>
  <field_date_reviewed>2014-09-15</field_date_reviewed>
  <field_pretty_url>2014hispanicmonth-spotlight-blog</field_pretty_url>
  <para_id>898735</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899253</id>
  <title>Grantee Spotlight: Isabel Scarinci, Ph.D., M.P.H. - Ensuring Latina Immigrants Have Equal Breast and Cervical Cancer Care</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Isabel Scarinci, Ph.D., M.P.H. - Ensuring Latina Immigrants Have Equal Breast and</field_short_title>
  <field_page_description>Dr. Isabel C. Scarinci, a CRCHD U54 grantee, is ensuring that Latinos living in Alabama have access to cancer prevention and treatment.</field_page_description>
  <field_feature_card_description>Dr. Scarinci ensures Latinos in Alabama have access to cancer prevention and treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-29</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <field_pretty_url>scarinci-spotlight</field_pretty_url>
  <para_id>899253</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899272</id>
  <title>Grantee Spotlight: Marvella Ford, Ph.D. - Reducing Barriers to Surgical Cancer Care among African Americans with Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Marvella Ford, Ph.D. - Reducing Barriers to Surgical Cancer Care among African Am</field_short_title>
  <field_page_description>Drs. Marvella E. Ford and Nestor F. Esnaola were awarded a five-year NIH/NIMHD R01 grant to evaluate a patient navigation intervention to reduce barriers to surgical cancer care and improving surgical resection rates in African Americans with lung cancer. </field_page_description>
  <field_feature_card_description>Drs. Marvella E. Ford and Nestor F. Esnaola awarded five-year NIH/NIMHD R01 grant.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-10</field_date_posted>
  <field_date_reviewed>2014-01-10</field_date_reviewed>
  <field_pretty_url>ford-spotlight</field_pretty_url>
  <para_id>899272</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1088949</term_id>
  <id>1088954</id>
  <title>3D Models of Immunotherapy</title>
  <langcode>en</langcode>
  <field_short_title>3D Immunotherapy Models</field_short_title>
  <field_page_description>This collaborative grant is developing 3D models of both mouse and human biology to investigate aspects of therapeutic vaccination in order to answer key questions relevant to human cancer immunotherapy.</field_page_description>
  <field_feature_card_description>NCI-Funded grant investigating 3D Models of Immunotherapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2017-07-03</field_date_reviewed>
  <para_id>1088954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089222</id>
  <title>NCI's CURE Program—21 Years of Increasing Diversity in the Biomedical Workforce</title>
  <langcode>en</langcode>
  <field_short_title>Increasing Diversity in the Biomedical Workforce</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from Dr. Sanya Springfield on NCI’s CURE program, which helps to improve the diversity of people involved in cancer research and care.</field_page_description>
  <field_feature_card_description>NCI program celebrates 21 years of helping to improve the diversity of cancer researchers, clinicians.</field_feature_card_description>
  <field_list_description>NCI’s CURE program recently celebrated its 21st anniversary of providing training and other support to improve the diversity of people involved in cancer research and care. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-07-10</field_date_reviewed>
  <field_pretty_url>cure-workforce-diversity</field_pretty_url>
  <para_id>1089222</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1090424</id>
  <title>FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Blinatumomab Gets Full FDA Approval for ALL</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about the FDA changing its accelerated approval of blinatumomab (Blincyto) for some patients with acute lymphoblastic leukemia to a full approval.</field_page_description>
  <field_feature_card_description>Approval change also includes expanded indication for drug’s use.</field_feature_card_description>
  <field_list_description>FDA changed its accelerated approval of blinatumomab (Blincyto) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-25</field_date_posted>
  <field_date_reviewed>2017-07-25</field_date_reviewed>
  <field_pretty_url>blinatumomab-all-fda-full-approval</field_pretty_url>
  <para_id>1090424</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1092415</id>
  <title>Ras–dependent Paracrine Cascades</title>
  <langcode>en</langcode>
  <field_short_title>Ras–dependent Paracrine Cascades</field_short_title>
  <field_page_description>Interrupting paracrine cascades in the tumor microenvironment of pancreatic cancers may improve treatment.</field_page_description>
  <field_feature_card_description>The laboratory of Dr. Kenneth Olive studies how the dense fibrotic stroma of pancreatic cancers arises from and influences oncogenic RAS signaling.</field_feature_card_description>
  <field_list_description>Most pancreatic cancers are driven by mutant K-Ras genes, and comprise a minority of cancer cells in a densely fibrotic and highly secretory tumor microenvironment. Interrupting the paracrine cascades in pancreatic cancers may improve treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <field_pretty_url>paracrine-cascades</field_pretty_url>
  <para_id>1092415</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1093264</term_id>
  <id>1093265</id>
  <title>Fertility Issues in Girls and Women with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Female Fertility Issues</field_short_title>
  <field_page_description>Fertility issues are common in women getting cancer treatment. Fertility preservation options include egg freezing, embryo freezing, ovarian tissue freezing, ovarian shielding and ovarian transposition. Resources, support, and clinical trials are listed.</field_page_description>
  <field_feature_card_description>Fertility issues are common in girls and women being treated for cancer.</field_feature_card_description>
  <field_list_description>Fertility issues are common in girls and women receiving cancer treatment. Information about fertility preservation options, support, and clinical trials is listed.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-22</field_date_posted>
  <field_date_reviewed>2017-08-23</field_date_reviewed>
  <para_id>1093265</para_id>
  <related_resource_ids>7107111</related_resource_ids>
  <related_resource_ids>7107119</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1093276</term_id>
  <id>1093277</id>
  <title>Fertility Issues in Boys and Men with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Male Fertility Issues</field_short_title>
  <field_page_description>Fertility issues are common in boys and men getting cancer treatment. Fertility preservation options include sperm banking, testicular shielding, testicular sperm extraction (TESE), and testicular tissue freezing. Support and clinical trials are listed.</field_page_description>
  <field_feature_card_description>Fertility issues are common in boys and men being treated for cancer.</field_feature_card_description>
  <field_list_description>Fertility issues are common in boys and men receiving cancer treatment. Information about fertility preservation options, support, and clinical trials is listed.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-22</field_date_posted>
  <field_date_reviewed>2017-08-23</field_date_reviewed>
  <para_id>1093277</para_id>
  <related_resource_id>7107102</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068135</term_id>
  <id>1068977</id>
  <title>Track 3: Oncology Product Research and Review for Postdoctoral Research Fellows</title>
  <langcode>en</langcode>
  <field_short_title>IOTF: Oncology Product Review for Postdoc Fellows</field_short_title>
  <field_page_description>NCI and FDA collaborate to train physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety. Learn more about this cancer training program.</field_page_description>
  <field_feature_card_description>Training for postdocs to facilitate oncology product development. Applications due May 31.</field_feature_card_description>
  <field_list_description>This interagency program trains physicians in aspects of drug, biologic, or device development and standards for assessing medical product safety and efficacy to facilitate movement from basic bench science to commercialization.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-12</field_date_posted>
  <field_date_reviewed>2016-12-12</field_date_reviewed>
  <para_id>1068977</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1068985</id>
  <title>Single Tumor Cells Reveal Clues to Biology of Multiple Myeloma </title>
  <langcode>en</langcode>
  <field_short_title>Myeloma Cells in Blood Provide Disease Insights</field_short_title>
  <field_page_description>A Cancer Currents blog post about research showing that individual tumor cells in patients with multiple myeloma may provide important clues about the genetic drivers of their disease.   </field_page_description>
  <field_feature_card_description>Single cell analysis identifies genetic changes fueling the cancer.</field_feature_card_description>
  <field_list_description>A study suggests that individual tumor cells circulating in the blood of patients with multiple myeloma may be a new source of information about the genetic changes driving the disease. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-13</field_date_posted>
  <field_date_reviewed>2016-12-12</field_date_reviewed>
  <field_pretty_url>myeloma-ctcs-genomic</field_pretty_url>
  <para_id>1068985</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1070682</id>
  <title>TCGA to Complete its Final Analysis: the PanCanAtlas</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's PanCanAtlas</field_short_title>
  <field_page_description>The PanCanAtlas, TCGA’s final project, will analyze the whole TCGA dataset.</field_page_description>
  <field_list_description>TCGA’s data on all 33 cancer types will be integrated into its final analysis, called PanCanAtlas. PanCanAtlas will focus on the themes of cell-of-origin, oncogenic processes, and pathways. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-01-09</field_date_posted>
  <field_date_reviewed>2017-01-05</field_date_reviewed>
  <field_pretty_url>tcga-pancan-atlas</field_pretty_url>
  <para_id>1070682</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1070725</id>
  <title>Ibrutinib Relieves Chronic Graft-Versus-Host Disease Symptoms</title>
  <langcode>en</langcode>
  <field_short_title>Ibrutinib Effective against Graft-Versus-Host Disease</field_short_title>
  <field_page_description>A Cancer Currents blog post on results from a small clinical trial showing that ibrutinib can effectively treat graft-versus-host-disease, a common and serious complication of allogeneic stem cell transplants.</field_page_description>
  <field_feature_card_description>Targeted cancer drug helped alleviate symptoms of this serious stem cell transplant side effect. </field_feature_card_description>
  <field_list_description>The targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-11</field_date_posted>
  <field_date_reviewed>2017-01-06</field_date_reviewed>
  <field_pretty_url>ibrutinib-stem-cell-transplant-gvhd</field_pretty_url>
  <para_id>1070725</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1072254</id>
  <title>Functional Genomics Study Finds Druggable Target in &lt;em&gt;KRAS&lt;/em&gt;-mutant Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>New Lung Cancer Target</field_short_title>
  <field_page_description>A genomics study, published in &lt;em&gt;Nature&lt;/em&gt;, identified a vulnerability specific to &lt;em&gt;KRAS&lt;/em&gt;-mutant lung cancers that can be treated with available drugs.</field_page_description>
  <field_feature_card_description>Drug Target Found in KRAS Lung Cancer</field_feature_card_description>
  <field_list_description>A new study by the Cancer Target Discovery and Development Network identified XPO1 as a vulnerability specific to &lt;em&gt;KRAS&lt;/em&gt;-mutant lung cancers that responds to available drugs. Paired with genomics-based patient selection, this finding could improve lung cancer care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-02</field_date_posted>
  <field_date_reviewed>2017-02-02</field_date_reviewed>
  <field_pretty_url>xpo1-kras-lung-target</field_pretty_url>
  <para_id>1072254</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1073715</id>
  <title>RAS Pathway v3.0?</title>
  <langcode>en</langcode>
  <field_short_title>RAS Pathway v3.0?</field_short_title>
  <field_page_description>Defining the most important elements of RAS signaling is an important objective of the NCI RAS Initiative.  Advisor Frank McCormick invites community input on version 3 of the RAS Pathway.</field_page_description>
  <field_feature_card_description>Frank McCormick invites community input on version 3 of the RAS Pathway.</field_feature_card_description>
  <field_list_description>Defining the most important elements of RAS signaling is an important objective of the NCI RAS Initiative.  In a new RAS Dialogue post, advisor Frank McCormick invites community input on version 3.0 of the RAS Pathway.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-28</field_date_posted>
  <field_date_reviewed>2017-02-22</field_date_reviewed>
  <field_pretty_url>mccormick-ras-pathway-v3</field_pretty_url>
  <para_id>1073715</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074839</term_id>
  <id>1075487</id>
  <title>Computational Genomics Research</title>
  <langcode>en</langcode>
  <field_short_title>Computational Genomics Research</field_short_title>
  <field_page_description>NCI’s Center for Cancer Genomics uses computational cancer genomics to derive insight about cancer genes and pathways using big data.</field_page_description>
  <field_feature_card_description>Computational genomics uses statistical and computational approaches to derive insight from big data on cancer. </field_feature_card_description>
  <field_list_description>Computational genomics uses statistical and computational approaches to derive insight from big data on cancer. CCG’s Genomic Data Commons, a data-sharing platform for cancer research, makes diverse datasets compatible and accessible for the research community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-03-14</field_date_reviewed>
  <para_id>1075487</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1071552</id>
  <title>Kras and Cancer Metabolism: A Conversation with Carla Martins</title>
  <langcode>en</langcode>
  <field_short_title>Kras and Cancer Metabolism: A Conversation with Carla Martins</field_short_title>
  <field_page_description>Cancers in which both KRAS genes are mutated are more agressive and have different metabolism compared to cells with one mutated KRAS gene.</field_page_description>
  <field_feature_card_description>Cancers with two mutated KRAS genes are more agressive than those with one.</field_feature_card_description>
  <field_list_description>Our cells ordinarily have two copies of each gene, one maternal and one paternal. Cancers in which both KRAS genes are mutated are more aggressive and have different metabolic pathways compared to cancers which have only one mutated KRAS gene.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-01-23</field_date_posted>
  <field_date_reviewed>2017-01-23</field_date_reviewed>
  <field_pretty_url>mutant-kras-copy-number-martins</field_pretty_url>
  <para_id>1071552</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1071600</id>
  <title>Genome Study Points to New Subtypes of Esophageal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Study Points to Genetic Subtypes of Esophageal Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog post about a study by The Cancer Genome Atlas Research Network that identified distinct genetic and molecular changes in esophageal cancers that could improve their classification and identify potential new treatments.</field_page_description>
  <field_feature_card_description>Study finds key differences between tumors, providing framework for exploring new treatments.</field_feature_card_description>
  <field_list_description>A new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-25</field_date_posted>
  <field_date_reviewed>2017-01-25</field_date_reviewed>
  <field_pretty_url>esophageal-genomic-subtypes</field_pretty_url>
  <para_id>1071600</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1071837</id>
  <title>Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications</title>
  <langcode>en</langcode>
  <field_short_title>Less-Frequent Zoledronic Acid in Patients with Bone Metastases</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on a clinical trial showing that less frequent zoledronic acid treatment is effective in patients with cancer-related bone metastases.</field_page_description>
  <field_feature_card_description>Cancer patients with bone metastases can receive less-frequent zoledronic acid treatment to prevent bone complications.</field_feature_card_description>
  <field_list_description>In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-30</field_date_posted>
  <field_date_reviewed>2017-01-27</field_date_reviewed>
  <field_pretty_url>zoledronic-acid-bone-metastasis</field_pretty_url>
  <para_id>1071837</para_id>
  <related_resource_id>6624937</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1072223</id>
  <title>New Therapy Benefits Patients with Neuroendocrine Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Therapy Benefits Patients with Neuroendocrine Tumors</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on clinical trial results that suggest the new drug &lt;sup&gt;177&lt;/sup&gt;Lu-Dotatate may soon be a treatment option for advanced neuroendocrine tumors.</field_page_description>
  <field_feature_card_description>New treatment improves outcomes for patients with 'midgut' tumors.</field_feature_card_description>
  <field_list_description>Results from a clinical trial suggest that &lt;sup&gt;177&lt;/sup&gt;Lu-Dotatate may soon be a new treatment option for some patients with advanced neuroendocrine tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-02</field_date_posted>
  <field_date_reviewed>2017-02-01</field_date_reviewed>
  <field_pretty_url>new-treatment-neuroendocrine-tumors</field_pretty_url>
  <para_id>1072223</para_id>
  <related_resource_id>6612127</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1073678</term_id>
  <id>1073679</id>
  <title>Connect with Screen to Save</title>
  <langcode>en</langcode>
  <field_short_title>Connect with Screen to Save</field_short_title>
  <field_page_description>Join NCI community health educators and partners in helping to increase colorectal cancer screenings among men and women age 50–75 from racially and ethnically diverse communities and in rural areas.</field_page_description>
  <field_feature_card_description>Join NCI community health educators and partners in helping to increase colorectal cancer screening rates in communities that need it most. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-21</field_date_posted>
  <field_date_reviewed>2017-02-21</field_date_reviewed>
  <para_id>1073679</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073806</id>
  <title>Lung Cancer Screening Pilot Reveals Challenges, Growing Pains</title>
  <langcode>en</langcode>
  <field_short_title>U.S. Lung Cancer Screening Experience</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post the complexities and challenges associated with the expansion of lung cancer screening in the United States.</field_page_description>
  <field_feature_card_description>Project highlights complexities associated with the expansion of lung cancer screening. </field_feature_card_description>
  <field_list_description>A demonstration project by the Veterans Health Administration is highlighting some of the complexities and challenges associated with the expansion of lung cancer screening in the United States.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-27</field_date_posted>
  <field_date_reviewed>2017-02-24</field_date_reviewed>
  <field_pretty_url>lung-cancer-screening-challenges</field_pretty_url>
  <para_id>1073806</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1085525</id>
  <title>Mentor Spotlight: Monica L. Baskin, PhD</title>
  <langcode>en</langcode>
  <field_short_title>Mentor Spotlight: Monica L. Baskin, PhD</field_short_title>
  <field_page_description>Dr. Tiffany Carson, a K01 awardee, recognizes her mentor Dr. Monica Baskin for the guidance and encouragement that she has provided throughout her career.</field_page_description>
  <field_feature_card_description>Dr. Tiffany Carson recognizes her mentor Dr. Monica Baskin for the guidance and encouragement that she provided.  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-19</field_date_posted>
  <field_date_reviewed>2017-05-19</field_date_reviewed>
  <field_pretty_url>mentor-spotlight-baskin</field_pretty_url>
  <para_id>1085525</para_id>
  <related_resource_id>6582630</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>1085893</id>
  <title>ALCHEMIST &lt;span style="font-weight:normal"&gt;&lt;i&gt;(The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)&lt;/i&gt;&lt;/span&gt;:  Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials</field_short_title>
  <field_page_description>ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol</field_page_description>
  <field_list_description>ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those molecular changes can lead to improved survival</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-08-18</field_date_posted>
  <field_date_reviewed>2014-08-18</field_date_reviewed>
  <field_pretty_url>alechmist-launch-qa</field_pretty_url>
  <para_id>1085893</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1086595</id>
  <title>May 31st is World No Tobacco Day</title>
  <langcode>en</langcode>
  <field_short_title>May 31st is World No Tobacco Day</field_short_title>
  <field_page_description>We invite you to explore some of the other work that NCI is doing in the area of tobacco research, tobacco use prevention, and tobacco cessation. </field_page_description>
  <field_feature_card_description>Every year on May 31, people unite worldwide to raise awareness about tobacco and its global burden.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-31</field_date_posted>
  <field_date_reviewed>2017-05-31</field_date_reviewed>
  <field_pretty_url>wntd2017</field_pretty_url>
  <para_id>1086595</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>1086824</id>
  <title>Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer</field_short_title>
  <field_page_description>Combining Targeted Therapies for Newly Diagnosed Metastatic Lung Cancer</field_page_description>
  <field_feature_card_description>In this clinical trial, patients with newly diagnosed metastatic EGFR mutation-positive lung cancer will be randomly assigned to receive either the EGFR inhibitor afatinib alone or afatinib together with another EGFR inhibitor, cetuximab.</field_feature_card_description>
  <field_list_description>In this clinical trial, patients with newly diagnosed metastatic EGFR mutation-positive lung cancer will be randomly assigned to receive either the EGFR inhibitor afatinib alone or afatinib together with another EGFR inhibitor, cetuximab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-06</field_date_posted>
  <field_date_reviewed>2017-06-05</field_date_reviewed>
  <field_pretty_url>combined-targeted-therapies-nsclc</field_pretty_url>
  <para_id>1086824</para_id>
  <related_resource_ids>6599463</related_resource_ids>
  <related_resource_ids>6599465</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074837</term_id>
  <id>1086929</id>
  <title>Early Onset Malignancies Initiative</title>
  <langcode>en</langcode>
  <field_short_title>Early Onset Malignancies Initiative</field_short_title>
  <field_page_description>The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations.</field_page_description>
  <field_feature_card_description>EOMI studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations.</field_feature_card_description>
  <field_list_description>The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations. By characterizing cancers from minority/underserved sites of the NCI Community Oncology Research Program, the initiative aims to investigate the biology of these disparities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-06-07</field_date_reviewed>
  <field_pretty_url>early-onset-disparities</field_pretty_url>
  <para_id>1086929</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1087419</term_id>
  <id>1087420</id>
  <title>Cancer Tissue Engineering Collaborative </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Tissue Engineering Collaborative</field_short_title>
  <field_page_description>The NCI's Cancer Tissue Engineering Collaborative (TEC) supports the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.</field_page_description>
  <field_feature_card_description>NCI's Tissue Enginnering Consortium, supporting biomimetic tissue-engineered technologies for cancer research</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-31</field_date_posted>
  <field_date_reviewed>2017-06-14</field_date_reviewed>
  <para_id>1087420</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087503</id>
  <title>Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Abiraterone Improves Survival for Men with Hormone-Sensitive Prostate Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on results from two clinical trials that showed adding abiraterone to androgen-deprivation therapy improved survival for men with metastatic hormone-sensitive prostate cancer.</field_page_description>
  <field_feature_card_description>Adding the drug to standard hormone therapy helped men with metastatic disease live longer.</field_feature_card_description>
  <field_list_description>In two large clinical trials, adding the hormone-blocking drug abiraterone to androgen-deprivation therapy (ADT) allowed men with metastatic hormone-sensitive prostate cancer to live longer than men who were treated with ADT alone.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-19</field_date_posted>
  <field_date_reviewed>2017-06-16</field_date_reviewed>
  <field_pretty_url>abiraterone-hormone-sensitive-prostate</field_pretty_url>
  <para_id>1087503</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073211</id>
  <title>Combination Therapy Improves Survival for Some Men with Recurrent Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Androgen Deprivation Therapy for Recurrent Prostate Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on clinical trial results showing that adding androgen deprivation therapy to radiation therapy can improve survival for some men with recurrent prostate cancer.</field_page_description>
  <field_feature_card_description>Adding androgen deprivation therapy to radiation also lowered metastasis rates, study finds.</field_feature_card_description>
  <field_list_description>Long-term results from an NCI-sponsored clinical trial suggest that adding androgen deprivation therapy to radiation therapy can improve survival for some men with recurrent prostate cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-13</field_date_posted>
  <field_date_reviewed>2017-02-13</field_date_reviewed>
  <field_pretty_url>androgen-deprivation-therapy-prostate</field_pretty_url>
  <para_id>1073211</para_id>
  <related_resource_id>6612141</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073379</id>
  <title>Potential New Cancer Therapy Could Target Tumors Two Ways</title>
  <langcode>en</langcode>
  <field_short_title>Therapy Could Target Tumors Two Ways</field_short_title>
  <field_page_description>An &lt;i&gt;NCI Cancer Currents&lt;/i&gt; blog post on a potential new therapy that may work by both killing cancer cells and immune cells that can suppress the anti-cancer immune response.</field_page_description>
  <field_feature_card_description>Approach may kill cancer cells and enhance anti-cancer immune response.</field_feature_card_description>
  <field_list_description>A team of researchers has developed a potential new therapy that may work in two distinct ways to attack tumors, by directly killing cancer cells and immune cells that can suppress the anti-cancer immune response.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-15</field_date_posted>
  <field_date_reviewed>2017-02-15</field_date_reviewed>
  <field_pretty_url>tnfr2-target-tumors</field_pretty_url>
  <para_id>1073379</para_id>
  <related_resource_ids>6890366</related_resource_ids>
  <related_resource_ids>6890367</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1099300</term_id>
  <id>1073408</id>
  <title>Selected Presentations by Dr. Doug Lowy</title>
  <langcode>en</langcode>
  <field_short_title>Selected Presentations by Doug Lowy</field_short_title>
  <field_page_description>In these selected presentations, Douglas R. Lowy, M.D., Deputy Director of the National Cancer Institute (NCI), discusses strategic and scientific initiatives that are advancing  cancer research. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-28</field_date_posted>
  <field_date_reviewed>2017-02-15</field_date_reviewed>
  <para_id>1073408</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1119343</id>
  <title>Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents</title>
  <langcode>en</langcode>
  <field_short_title>HPV Vaccination and Parents: What Message Works Best?</field_short_title>
  <field_page_description>When it comes to the HPV vaccine, doctors should emphasize cancer prevention while discussing vaccination with the parents of preteens, results from a new study show. As this Cancer Currents post explains, parents thought this was the best message by far.</field_page_description>
  <field_feature_card_description>Emphasizing cancer prevention is the best choice, study finds. </field_feature_card_description>
  <field_list_description>Health care providers should emphasize cancer prevention when discussing HPV vaccination with the parents of preteens who are due to receive the vaccine, results from a new study show.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-10</field_date_posted>
  <field_date_reviewed>2018-07-05</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-parents-prevention-best-message</field_pretty_url>
  <para_id>1119343</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogSeries</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>860259</id>
  <title>Cancer Currents: An NCI Cancer Research Blog</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Currents Blog</field_short_title>
  <field_page_description>Cancer Currents blog providing news and research updates from the National Cancer Institute</field_page_description>
  <field_feature_card_description>Stay current with cancer research news, updates on NCI programs, and more. Selected posts also in Spanish.</field_feature_card_description>
  <field_list_description>News and research updates from the National Cancer Institute</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-20</field_date_posted>
  <field_date_reviewed>2014-11-20</field_date_reviewed>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>860833</id>
  <title>Get the Facts about Exposure to I-131 Radiation</title>
  <langcode>en</langcode>
  <field_short_title>I-131 Radiation Exposure from Fallout</field_short_title>
  <field_page_description>Discusses radioactive fallout from the nuclear weapons testing that occurred from the mid-1940s through the early 1960s and possible health risks, particularly thyroid cancer.</field_page_description>
  <field_feature_card_description>Discusses radioactive fallout from the nuclear weapons testing that occurred from the mid-1940s through the early 1960s and possible health risks, particularly thyroid cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-05</field_date_posted>
  <field_date_reviewed>2014-11-24</field_date_reviewed>
  <field_pretty_url>i-131</field_pretty_url>
  <para_id>860833</para_id>
  <related_resource_ids>6494490</related_resource_ids>
  <related_resource_ids>6494491</related_resource_ids>
  <related_resource_ids>6494492</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>866278</term_id>
  <id>866280</id>
  <title>Center for Cancer Genomics (CCG)</title>
  <langcode>en</langcode>
  <field_short_title>Center for Cancer Genomics (CCG)</field_short_title>
  <field_page_description>CCG programs and collaborations generate cancer genomic and clinical data, and make these data available for widespread use by the research community.</field_page_description>
  <field_feature_card_description>Generates cancer genomic and clinical data to improve patient outcomes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-04-13</field_date_reviewed>
  <para_id>866280</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882603</term_id>
  <id>882604</id>
  <title>Asbestos</title>
  <langcode>en</langcode>
  <field_short_title>Asbestos</field_short_title>
  <field_page_description>Asbestos are a group of naturally occurring fibrous minerals used in fire-resistant and insulating material. Breathing high levels of asbestos can cause several diseases, including lung cancer and malignant mesothelioma. The use of asbestos is now highly regulated in the United States.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-13</field_date_reviewed>
  <para_id>882604</para_id>
  <related_resource_id>7251711</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>890792</id>
  <title>Nivolumab Improves Overall Survival in Patients with Metastatic Melanoma without a BRAF Mutation</title>
  <langcode>en</langcode>
  <field_short_title>Nivolumab for Metastatic Melanoma without a BRAF Mutation</field_short_title>
  <field_page_description>A summary of results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.</field_page_description>
  <field_feature_card_description>Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.</field_feature_card_description>
  <field_list_description>Results from an international phase III trial show that nivolumab (Opdivo®) improves overall survival compared with the chemotherapy drug dacarbazine in patients with metastatic melanoma whose tumors do not have a mutation in the BRAF gene.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-06</field_date_posted>
  <field_date_reviewed>2015-01-06</field_date_reviewed>
  <field_pretty_url>nivolumab</field_pretty_url>
  <para_id>890792</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100206</id>
  <title>Many Ovarian Cancers May Start in Fallopian Tubes, Study Finds</title>
  <langcode>en</langcode>
  <field_short_title>Many Ovarian Cancers May Start in Fallopian Tubes</field_short_title>
  <field_page_description>The most common form of ovarian cancer may originate in the fallopian tubes, a study finding that has implications for prevention and detection of the disease.</field_page_description>
  <field_feature_card_description>Study adds to earlier evidence, may have implications for prevention and treatment.</field_feature_card_description>
  <field_list_description>A new study provides more evidence that the most common form of ovarian cancer may originate in the fallopian tubes, and that there is a window of nearly 7 years between development of fallopian tube lesions and the start of ovarian cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-15</field_date_posted>
  <field_date_reviewed>2017-11-14</field_date_reviewed>
  <field_pretty_url>ovarian-cancer-fallopian-tube-origins</field_pretty_url>
  <para_id>1100206</para_id>
  <related_resource_id>6786422</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1101546</id>
  <title>New Lancet Oncology publication - Defining a research and policy agenda for betel quid and areca nut</title>
  <langcode>en</langcode>
  <field_short_title>New Lancet Oncology publication - Defining a research and policy agenda for betel quid and areca nut</field_short_title>
  <field_page_description>Betel quid and areca nut, typically made up of a mixture of areca nut and slaked lime wrapped in a betel leaf with added flavorings, is a known risk factor for many oral and other associated cancers. There are more than 600 million betel quid or areca nut users worldwide (or 10% of the world’s population), making it a </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-08</field_date_posted>
  <field_date_reviewed>2017-12-07</field_date_reviewed>
  <field_pretty_url>betel-quid</field_pretty_url>
  <para_id>1101546</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1102079</term_id>
  <id>1102107</id>
  <title>Selected Presentations by the NCI Director</title>
  <langcode>en</langcode>
  <field_short_title>Selected Presentations by the NCI Director</field_short_title>
  <field_page_description>This page lists some of the presentations given by Dr. Norman "Ned" Sharpless during his time as NCI director.</field_page_description>
  <field_feature_card_description>The National Cancer Institute director is frequently asked to speak about a variety of topics of interest to the cancer community.</field_feature_card_description>
  <field_list_description>The National Cancer Institute director is frequently asked to speak about a variety of topics of interest to the cancer community. This page lists some of the presentations given by Dr. Norman Sharpless during his time in office.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-15</field_date_posted>
  <field_date_reviewed>2017-12-14</field_date_reviewed>
  <para_id>1102107</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102112</id>
  <title>Brentuximab Vedotin Approved for Two Rare Lymphomas</title>
  <langcode>en</langcode>
  <field_short_title>Brentuximab Approved for Two Rare Lymphomas</field_short_title>
  <field_page_description>Brentuximab vedotin (Adcetris®) has been approved for the treatment of adults who have been treated previously for either primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.</field_page_description>
  <field_feature_card_description>The antibody–drug conjugate treats two types of cutaneous T-cell lymphoma.</field_feature_card_description>
  <field_list_description>FDA has approved brentuximab vedotin (Adcetris®) for the treatment of adults who have been treated previously for either primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides, two rare lymphomas that start as rashes on the skin.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-18</field_date_posted>
  <field_date_reviewed>2017-12-15</field_date_reviewed>
  <field_pretty_url>brentuximab-fda-rare-lymphomas</field_pretty_url>
  <para_id>1102112</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1102804</id>
  <title>Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Decreasing Early Deaths in Patients with Rare Leukemia</field_short_title>
  <field_page_description>Acute promyelocytic leukemia (APL) is a highly curable cancer. A new NCI-funded clinical trial is aimed at preventing early deaths in patients with APL.</field_page_description>
  <field_feature_card_description>Unique clinical trial tackling serious issue in highly curable cancer.</field_feature_card_description>
  <field_list_description>In a unique clinical trial, a group of oncologists with experience treating acute promyelocytic leukemia are making themselves available around the clock to help clinicians at hospitals across the country treat their APL patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-03</field_date_posted>
  <field_date_reviewed>2018-01-02</field_date_reviewed>
  <field_pretty_url>apl-trial-preventing-early-death</field_pretty_url>
  <para_id>1102804</para_id>
  <related_resource_ids>7191758</related_resource_ids>
  <related_resource_ids>7191759</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1102848</id>
  <title>Acupuncture May Reduce Treatment-Related Joint Pain for Breast Cancer Patients</title>
  <langcode>en</langcode>
  <field_short_title>Acupuncture May Reduce Joint Pain Caused by Breast Cancer Therapy</field_short_title>
  <field_page_description>Acupuncture may reduce joint pain caused by aromatase inhibitors in postmenopausal women with breast cancer, according to results of a rigorous clinical trial.</field_page_description>
  <field_feature_card_description>Reducing joint pain caused by aromatase inhibitors may improve adherence to breast cancer therapy.</field_feature_card_description>
  <field_list_description>Joint pain caused by aromatase inhibitors in postmenopausal women with breast cancer can cause some women to stop taking the drugs. Reducing their symptoms may translate into better adherence to therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-08</field_date_posted>
  <field_date_reviewed>2018-01-04</field_date_reviewed>
  <field_pretty_url>acupuncture-aromatase-inhibitor-joint-pain</field_pretty_url>
  <para_id>1102848</para_id>
  <related_resource_ids>6812796</related_resource_ids>
  <related_resource_ids>6812797</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1104030</id>
  <title>Incidence of Cancers of the Lower Stomach Increasing among Younger Americans</title>
  <langcode>en</langcode>
  <field_short_title>Incidence of Lower Stomach Cancer in US Changing</field_short_title>
  <field_page_description>The incidence of cancer that occurs in the lower stomach has been increasing among Americans under age 50, particularly in non-Hispanic white women.</field_page_description>
  <field_feature_card_description>In the United States, the number of diagnoses is increasing in people under 50.</field_feature_card_description>
  <field_list_description>A type of cancer that occurs in the lower stomach has been increasing among some Americans under the age of 50, even though in the general population the incidence of all stomach cancers has been declining for decades, according to a new study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-18</field_date_posted>
  <field_date_reviewed>2018-01-16</field_date_reviewed>
  <field_pretty_url>lower-stomach-cancer-incidence-changing</field_pretty_url>
  <para_id>1104030</para_id>
  <related_resource_id>6816782</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904487</term_id>
  <id>882415</id>
  <title>Secondhand Tobacco Smoke (Environmental Tobacco Smoke) </title>
  <langcode>en</langcode>
  <field_short_title>Secondhand Tobacco Smoke (Environmental Tobacco Smoke) </field_short_title>
  <field_page_description>Learn about secondhand tobacco smoke, which can raise your risk of lung cancer. Secondhand tobacco smoke is the combination of the smoke given off by a burning tobacco product and the smoke exhaled by a smoker. Also called environmental tobacco smoke, involuntary smoke, and passive smoke.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-21</field_date_reviewed>
  <para_id>882415</para_id>
  <related_resource_ids>7261595</related_resource_ids>
  <related_resource_ids>7261596</related_resource_ids>
  <related_resource_ids>7261607</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882543</term_id>
  <id>882591</id>
  <title>Erionite</title>
  <langcode>en</langcode>
  <field_short_title>Erionite</field_short_title>
  <field_page_description>Learn about erionite, which can raise your risk of lung cancer and mesothelioma. Erionite is a a naturally occurring fibrous mineral. Erionite-related disease has been reported most often among road construction and maintenance workers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-13</field_date_reviewed>
  <para_id>882591</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904458</term_id>
  <id>882610</id>
  <title>Benzidine</title>
  <langcode>en</langcode>
  <field_short_title>Benzidine</field_short_title>
  <field_page_description>Learn about benzidine, exposure to which raises your risk of bladder cancer. Benzidine is a manufactured chemical. In the past, benzidine was used to produce dyes or products used in clinical laboratories. However, benzidine has not been sold in the United States since the mid-1970s.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-01-31</field_date_reviewed>
  <para_id>882610</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>892292</id>
  <title>Report Offers Comprehensive Look at Global Smokeless Tobacco Use</title>
  <langcode>en</langcode>
  <field_short_title>Comprehensive Look at Global Smokeless Tobacco Use Report</field_short_title>
  <field_page_description>The first report of its kind finds that more than 300 million people worldwide use smokeless tobacco products and that they are linked to a number of cancers.</field_page_description>
  <field_feature_card_description>Report discussing a comprehensive look at global smokeless tobacco use. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-07</field_date_posted>
  <field_date_reviewed>2015-01-07</field_date_reviewed>
  <field_pretty_url>smokeless-tobacco-report</field_pretty_url>
  <para_id>892292</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938229</term_id>
  <id>892451</id>
  <title>Three-Drug Combination Benefits Some Patients with Relapsed Multiple Myeloma </title>
  <langcode>en</langcode>
  <field_short_title>Three-Drug Combination for Relapsed Multiple Myeloma</field_short_title>
  <field_page_description>A summary of Interim results from an international, randomized phase III trial that suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed.</field_page_description>
  <field_feature_card_description>Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed.</field_feature_card_description>
  <field_list_description>Interim results from an international, randomized phase III trial suggest that adding carfilzomib (Kyprolis®) to a standard treatment improves outcomes for patients with multiple myeloma whose cancer has relapsed. Participants in the study who received carfilzomib plus lenalidomide (Revlimid®) and dexamethasone lived a median of 8.7 months longer without the disease getting worse than patients who received lenalidomide and dexamethasone alone.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-09</field_date_posted>
  <field_date_reviewed>2015-01-09</field_date_reviewed>
  <field_pretty_url>carfilzomib-lenalidomide-dexamethasone</field_pretty_url>
  <para_id>892451</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>894092</id>
  <title>Implementation Research Workshop in Argentina: Moving Research into Practice</title>
  <langcode>en</langcode>
  <field_short_title>Implementation Research Workshop in Argentina: Moving Research into Practice</field_short_title>
  <field_page_description>Research on implementation science addresses the level to which health interventions can fit within real-world public health and clinical service systems. The overall goal of the Introduction to Cancer Program Planning and Implementation Research Workshop was to train a critical mass of researchers, program managers, p</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-12</field_date_posted>
  <field_date_reviewed>2015-01-12</field_date_reviewed>
  <field_pretty_url>implementation-research-workshop</field_pretty_url>
  <para_id>894092</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899477</id>
  <title>Program Spotlight: University of Puerto Rico and MD Anderson Partnership Welcomes Its First Graduates, Dedicated to Researching Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: UPR and MD Anderson Partnership Welcomes Its First Graduates</field_short_title>
  <field_page_description>CRCHD joins the PIs and Diversity Training co-leaders of the Univ. of Puerto Rico and the Univ. of Texas MD Anderson Cancer Center U54 Partnership for Excellence in Cancer Research in congratulating its first graduates.</field_page_description>
  <field_feature_card_description>CRCHD congratulates the U54 Partnership for Excellence in Cancer Research’s first graduates.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-01</field_date_posted>
  <field_date_reviewed>2014-10-01</field_date_reviewed>
  <field_pretty_url>uprmda-spotlight</field_pretty_url>
  <para_id>899477</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882441</term_id>
  <id>882442</id>
  <title>Mineral Oils: Untreated and Mildly Treated</title>
  <langcode>en</langcode>
  <field_short_title>Mineral Oils: Untreated and Mildly Treated</field_short_title>
  <field_page_description>Learn about mineral oils, which can raise the risk of nonmelanoma skin cancer, particularly of the scrotum. Workers in a variety of manufacturing industries are most commonly exposed to mineral oils, as are workers in engine repair, copper mining, and commercial printing.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <para_id>882442</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882519</term_id>
  <id>882520</id>
  <title>Ethylene Oxide</title>
  <langcode>en</langcode>
  <field_short_title>Ethylene Oxide</field_short_title>
  <field_page_description>Learn about ethylene oxide, which can raise your risk of lymphoma and leukemia. Exposure may occur through industrial emissions, tobacco smoke, and the use of products sterilized with ethylene oxide, such as certain medical products or cosmetics. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2014-12-28</field_date_reviewed>
  <para_id>882520</para_id>
  <related_resource_id>7238398</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>890810</id>
  <title>RAS Pathway v2.0</title>
  <langcode>en</langcode>
  <field_short_title>RAS Pathway v2.0</field_short_title>
  <field_page_description>Frank McCormick, scientific lead of the RAS Initiative, incorporates over 30 suggestions from the RAS community to formulate an updated version of the RAS pathway, v2.0</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-13</field_date_posted>
  <field_date_reviewed>2015-01-06</field_date_reviewed>
  <field_pretty_url>ras-pathway-v2</field_pretty_url>
  <para_id>890810</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>898733</id>
  <title>October Spotlight: Breast Cancer Disparity Highlights</title>
  <langcode>en</langcode>
  <field_short_title>October Spotlight: Breast Cancer Disparity Highlights</field_short_title>
  <field_page_description>CRCHD recognizes Breast Cancer Awareness Month by highlighting breast cancer-related disparities and CRCHD grantees.</field_page_description>
  <field_feature_card_description>CRCHD recognizes Breast Cancer Awareness Month.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-01</field_date_posted>
  <field_date_reviewed>2014-10-01</field_date_reviewed>
  <field_pretty_url>october-spotlight</field_pretty_url>
  <para_id>898733</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>898807</id>
  <title>How Imatinib Transformed Leukemia Treatment and Cancer Research </title>
  <langcode>en</langcode>
  <field_short_title>How Gleevec Transformed Leukemia Treatment</field_short_title>
  <field_page_description>This story outlines the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginnings of precision medicine.</field_page_description>
  <field_feature_card_description>NCI-supported research led to the discovery of this landmark drug.</field_feature_card_description>
  <field_list_description>A modern-day miracle: A series of discoveries leads to a landmark cancer drug that transforms treatment and saves the lives of patients with CML. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-02</field_date_posted>
  <field_date_reviewed>2015-01-21</field_date_reviewed>
  <field_pretty_url>gleevec</field_pretty_url>
  <para_id>898807</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899532</id>
  <title>Grantee Spotlight: Kimberly Payne, Ph.D. - Investigating Leukemia Health Disparities in Hispanic and Native American Children</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Kimberly Payne, Ph.D. - Investigating Leukemia Health Disparities in Children</field_short_title>
  <field_page_description>Dr. Kimberly Payne, an NCI-CRCHD R21 grantee, investigates genetic causes related to higher death rates from B-cell Acute Lymphoblastic Leukemia in Hispanic and Native American children.</field_page_description>
  <field_feature_card_description>Dr. Payne investigates B-cell Acute Lymphoblastic Leukemia disparities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-19</field_date_posted>
  <field_date_reviewed>2014-09-19</field_date_reviewed>
  <field_pretty_url>payne-spotlight</field_pretty_url>
  <para_id>899532</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919023</term_id>
  <id>900519</id>
  <title>Media Contacts</title>
  <langcode>en</langcode>
  <field_short_title>Media Contacts</field_short_title>
  <field_page_description>How to contact the NCI Media Relations Branch.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-27</field_date_posted>
  <field_date_reviewed>2015-01-27</field_date_reviewed>
  <para_id>900519</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903590</term_id>
  <id>903603</id>
  <title>Advance Directives</title>
  <langcode>en</langcode>
  <field_short_title>Advance Directives</field_short_title>
  <field_page_description>Advance directives are legal documents that allow you to decide ahead of time what kind of medical care you want or who you want to make decisions for you if you're too ill to speak for yourself.</field_page_description>
  <field_feature_card_description>Advance directives are legal documents that allow you to decide ahead of time how you want to be treated.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-10</field_date_posted>
  <field_date_reviewed>2015-02-02</field_date_reviewed>
  <para_id>903603</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1098967</id>
  <title>With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Second CAR T-Cell Therapy</field_short_title>
  <field_page_description>FDA has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta™) for patients with advanced non-Hodgkin lymphoma, as this Cancer Currents article explains.</field_page_description>
  <field_feature_card_description>Approval of immunotherapy treatment is for patients with non-Hodgkin lymphoma.</field_feature_card_description>
  <field_list_description>One month after approving the first CAR T-cell therapy for cancer, FDA has approved a second such therapy. The treatment, axicabtagene ciloleucel (Yescarta™), was approved for some patients with advanced non-Hodgkin lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-25</field_date_posted>
  <field_date_reviewed>2017-10-24</field_date_reviewed>
  <field_pretty_url>yescarta-fda-lymphoma</field_pretty_url>
  <para_id>1098967</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100833</id>
  <title>Dasatinib Approved by FDA for Some Children with Chronic Myelogenous Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Dasatinib Approved for Some Children with Chronic Myelogenous Leukemia</field_short_title>
  <field_page_description>FDA has approved dasatinib (Sprycel®) for children with chronic myelogenous leukemia (CML) that expresses the Philadelphia chromosome and whose disease is in the chronic phase.</field_page_description>
  <field_feature_card_description>FDA approval covers treatment of CML that expresses Philadelphia chromosome.</field_feature_card_description>
  <field_list_description>On November 9, the FDA approved dasatinib (Sprycel®) for the treatment of children with chronic myelogenous leukemia (CML) whose cancer cells express the Philadelphia chromosome and whose disease is in a relatively early stage, known as the chronic phase. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-30</field_date_posted>
  <field_date_reviewed>2017-11-29</field_date_reviewed>
  <field_pretty_url>dasatinib-fda-cml-children</field_pretty_url>
  <para_id>1100833</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1102387</id>
  <title>How to Navigate the CTD&lt;sup&gt;2&lt;/sup&gt; Dashboard: Access to Translational Data</title>
  <langcode>en</langcode>
  <field_short_title>Navigating the CTD&lt;sup&gt;2&lt;/sup&gt; Dashboard</field_short_title>
  <field_page_description>How the NCI’s CTD&lt;sup&gt;2&lt;/sup&gt;Dashboard makes it easy to access and utilize genomic research data for developing cancer treatments.</field_page_description>
  <field_feature_card_description>Using the CTD&lt;sup&gt;2&lt;/sup&gt; Dashboard to access translational data</field_feature_card_description>
  <field_list_description>The Cancer Target Discovery and Development (CTD&lt;sup&gt;2&lt;/sup&gt;) Dashboard aims to provide easy exploration of data to non-computational scientists. Through an open-access web interface, users can view validated data and results assembled from multiple projects or CTD&lt;sup&gt;2&lt;/sup&gt; Centers. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-18</field_date_posted>
  <field_date_reviewed>2017-12-18</field_date_reviewed>
  <field_pretty_url>ctd2-dashboard</field_pretty_url>
  <para_id>1102387</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1102842</id>
  <title>Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>New Drug Combination Shows Promise for CLL</field_short_title>
  <field_page_description>Venetoclax (Venclexta) and rituximab (Rituxan) substantially improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with chemotherapy, MURANO trial shows.</field_page_description>
  <field_feature_card_description>Treatment with venetoclax plus rituximab may better prevent cancer progression.</field_feature_card_description>
  <field_list_description>Interim results from an ongoing clinical trial show that patients with relapsed or refractory chronic lymphocytic leukemia treated with rituximab plus venetoclax have longer progression-free survival compared with patients treated with chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-04</field_date_reviewed>
  <field_pretty_url>venetoclax-rituximab-cll</field_pretty_url>
  <para_id>1102842</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1104882</id>
  <title>The Challenging Landscape of Cancer and Aging: Charting a Way Forward</title>
  <langcode>en</langcode>
  <field_short_title>The Challenging Landscape of Cancer and Aging</field_short_title>
  <field_page_description>NCI Director Dr. Norman Sharpless discusses research to bettter understand the biology of aging and its relationship to cancer, as well as participation in cancer clinical trials by older patients.</field_page_description>
  <field_feature_card_description>NCI Director Dr. Norman Sharpless discusses research on the intersection of aging and cancer.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless discusses research on aging and cancer, including understanding the biology of aging and its relationship to cancer, the treatment of older patients, and ensuring older patients participate in cancer clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-24</field_date_posted>
  <field_date_reviewed>2018-01-24</field_date_reviewed>
  <field_pretty_url>sharpless-aging-cancer-research</field_pretty_url>
  <para_id>1104882</para_id>
  <related_resource_id>6894698</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107103</id>
  <title>Clinical Trials to Treat Childhood Embryonal Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Childhood Embryonal Tumors</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>childhood-embryonal-tumors</field_pretty_url>
  <para_id>1107103</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938135</term_id>
  <id>1110729</id>
  <title>TEST - What's New in Pancreatic Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>TEST - What's New in Pancreatic Cancer Research</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-21</field_date_posted>
  <field_date_reviewed>2018-03-21</field_date_reviewed>
  <field_pretty_url>draft</field_pretty_url>
  <para_id>1110729</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1111029</id>
  <title>Don't Miss the Connection: The Role of RAF1 and ROKα in RAS-Driven Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Caused by Mutant KRAS Requires RAF1 and ROKα</field_short_title>
  <field_page_description>Cancer caused by a mutant KRAS gene is dependent on the presence RAF1. Kinase-independent interaction of RAF1 with ROKα accounts for this dependence.</field_page_description>
  <field_feature_card_description>A new RAS Dialogue describes the essential role of RAF1 and ROKα in some cancers driven by mutant KRAS.</field_feature_card_description>
  <field_list_description>Cancer caused by a mutant KRAS gene is dependent on the presence of one of its downstream effectors, RAF1 (aka CRAF), but not on ARAF or BRAF. Kinase-independent interaction of RAF1 with ROKα accounts for at least some of this dependence.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-03-26</field_date_posted>
  <field_date_reviewed>2018-03-26</field_date_reviewed>
  <field_pretty_url>baccarini-rok</field_pretty_url>
  <para_id>1111029</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>912559</term_id>
  <id>895058</id>
  <title>CCG News and Events </title>
  <langcode>en</langcode>
  <field_short_title>CCG News &amp; Events </field_short_title>
  <field_page_description>NCI's Center for Cancer Genomics (CCG) has been widely recognized for its research efforts to facilitiate advances in cancer genomic research and improve patient outcomes. Find the latest news about and events featuring CCG.</field_page_description>
  <field_list_description>The Center for Cancer Genomics (CCG) has been widely recognized for its research efforts to facilitiate advances in cancer genomic research and improve patient outcomes. Find the latest news about and events featuring CCG.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-01-14</field_date_reviewed>
  <para_id>895058</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>898466</term_id>
  <id>898468</id>
  <title>Anemia and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Anemia</field_short_title>
  <field_page_description>Anemia is a side effect of cancer treatments, including chemotherapy and radiation therapy. It can make women and men feel fatigued, dizzy, and short of breath. Learn how to manage fatigue caused by anemia during cancer treatment.</field_page_description>
  <field_list_description>Information about what causes anemia, a side effect of some cancer treatments, and ways to prevent, treat, or lessen it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-02-13</field_date_reviewed>
  <para_id>898468</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>899180</id>
  <title>Grantee Spotlight: Bill Nelson, M.D., Ph.D. - Steering a Partnership to Improve Cancer Outcomes for African Americans in Maryland and DC</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Bill Nelson, M.D., Ph.D.</field_short_title>
  <field_page_description>Dr. William (Bill) Nelson is playing an integral role in advancing our understanding of cancer health disparities and helping to foster the interests of young students from underrepresented backgrounds in cancer/cancer health disparities research.</field_page_description>
  <field_feature_card_description>Dr. Nelson is advancing cancer health disparities research and supporting students.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-19</field_date_posted>
  <field_date_reviewed>2015-01-20</field_date_reviewed>
  <field_pretty_url>nelson-spotlight</field_pretty_url>
  <para_id>899180</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899353</id>
  <title>Program Spotlight: Arizona's Partnership for Native American Cancer Prevention - Fostering the Next Generation of Native American Cancer Researchers</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: Arizona's Partnership for Native American Cancer Prevention</field_short_title>
  <field_page_description>Monica Yellowhair is a promising young Navajo cancer researcher with the Partnership for Native American Cancer Prevention Training Program funded through the CRCHD’s PACHE program.</field_page_description>
  <field_feature_card_description>Monica Yellowhair is a Navajo cancer researcher with the NACP Training Program.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-11</field_date_posted>
  <field_date_reviewed>2014-12-11</field_date_reviewed>
  <field_pretty_url>nacp-spotlight</field_pretty_url>
  <para_id>899353</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899429</id>
  <title>Grantee Spotlight: Daniel Petereit, M.D. - A "Frontier" Oncologist Studying Smoking Cessation in American Indians </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Daniel Petereit, M.D. - A "Frontier" Oncologist Studying Smoking Cessation </field_short_title>
  <field_page_description>Dr. Daniel G. Petereit, is a frontier doctor who often travels as far as 200 miles to care for cancer patients and work with American Indian tribal leaders on a smoking cessation study.</field_page_description>
  <field_feature_card_description>Dr. Petereit works with American Indian tribal leaders on a smoking cessation study.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-05</field_date_posted>
  <field_date_reviewed>2014-05-05</field_date_reviewed>
  <field_pretty_url>petereit-spotlight</field_pretty_url>
  <para_id>899429</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>901913</id>
  <title>Precision Medicine Initiative&amp;reg; and Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Precision Medicine Initiative&amp;reg; and Cancer Research</field_short_title>
  <field_page_description>Under the Precision Medicine Initiative, NCI is working to accelerate the pace of research that will help identify which treatments work best for which patients.</field_page_description>
  <field_feature_card_description>This initiative accelerates a more individual molecular approach to cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-30</field_date_posted>
  <field_date_reviewed>2015-01-30</field_date_reviewed>
  <field_pretty_url>precision-medicine-initiative-2016</field_pretty_url>
  <para_id>901913</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899926</term_id>
  <id>902108</id>
  <title>Nausea and Vomiting in People with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Nausea and Vomiting</field_short_title>
  <field_page_description>Types of nausea and vomiting caused by cancer treatment include: anticipatory, acute, and delayed. Controlling these side effects will help to prevent serious problems such as malnutrition and dehydration in people with cancer.</field_page_description>
  <field_list_description>Information about what causes nausea and vomiting, side effects of some cancer treatments, and ways to manage it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-01-30</field_date_reviewed>
  <para_id>902108</para_id>
  <related_resource_ids>7092074</related_resource_ids>
  <related_resource_ids>7092076</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>903672</id>
  <title>Genome Study Yields Clues to Head and Neck Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Genome Study Yields Clues to Head and Neck Cancers</field_short_title>
  <field_page_description>Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease, including in patients whose cancer is associated with the human papillomavirus (HPV). </field_page_description>
  <field_feature_card_description>Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-03</field_date_posted>
  <field_date_reviewed>2015-02-03</field_date_reviewed>
  <field_pretty_url>tcga-head-and-neck-hpv</field_pretty_url>
  <para_id>903672</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074837</term_id>
  <id>1119620</id>
  <title>Requests for TCGA Materials</title>
  <langcode>en</langcode>
  <field_short_title>Requests for TCGA Materials</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-09</field_date_posted>
  <field_date_reviewed>2018-07-09</field_date_reviewed>
  <field_pretty_url>material-requests</field_pretty_url>
  <para_id>1119620</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952656</term_id>
  <id>14106</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Supportive and Palliative Care</title>
  <langcode>en</langcode>
  <field_short_title>Supportive &amp;amp; Palliative Care</field_short_title>
  <field_page_description>Side effects of cancer treatment, management of cancer-related complications and pain, and psychosocial concerns.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14106</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>14147</id>
  <title>Antioxidants and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Antioxidants and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet about antioxidants, substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer.</field_page_description>
  <field_list_description>A fact sheet about antioxidants, substances that may protect cells from the damage caused by unstable molecules known as free radicals.  Free radical damage may lead to cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-01-17</field_date_posted>
  <field_date_reviewed>2017-02-06</field_date_reviewed>
  <field_pretty_url>antioxidants-fact-sheet</field_pretty_url>
  <para_id>14147</para_id>
  <related_resource_id>6919702</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>817860</term_id>
  <id>14175</id>
  <title>Social Media at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Social Media at NCI</field_short_title>
  <field_page_description>The National Cancer Institute (NCI) has a presence on Twitter, YouTube, and Facebook and maintains numerous RSS feeds by which you can automatically receive NCI updates.</field_page_description>
  <field_feature_card_description>Connect with us (in Spanish, too) on one or more of NCI's social media channels.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2010-03-29</field_date_reviewed>
  <para_id>14175</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911160</term_id>
  <id>14336</id>
  <title>Palliative Care in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Palliative Care in Cancer</field_short_title>
  <field_page_description>A fact sheet that describes the role of palliative care, which is comfort care given to patients from the time of cancer diagnosis and throughout the course of illness. </field_page_description>
  <field_feature_card_description>A fact sheet about palliative care, which is comfort care given to those with a serious or life-threatening disease.</field_feature_card_description>
  <field_list_description>A fact sheet that describes the role of palliative care, which is comfort care given to a patient who has a serious or life-threatening disease, such as cancer, from the time of diagnosis and throughout the course of illness.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-12</field_date_posted>
  <field_date_reviewed>2017-10-20</field_date_reviewed>
  <field_pretty_url>palliative-care-fact-sheet</field_pretty_url>
  <para_id>14336</para_id>
  <related_resource_ids>7228378</related_resource_ids>
  <related_resource_ids>7228379</related_resource_ids>
  <related_resource_ids>7228380</related_resource_ids>
  <related_resource_ids>7228381</related_resource_ids>
  <related_resource_ids>7228382</related_resource_ids>
  <related_resource_ids>7228387</related_resource_ids>
  <related_resource_ids>7228388</related_resource_ids>
  <related_resource_ids>7228389</related_resource_ids>
  <related_resource_ids>7228390</related_resource_ids>
  <related_resource_ids>7228391</related_resource_ids>
  <related_resource_ids>7228392</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>14388</id>
  <title>Smokeless Tobacco and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Smokeless Tobacco and Cancer</field_short_title>
  <field_page_description>A fact sheet about the health risks associated with the use of smokeless tobacco.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-08-18</field_date_posted>
  <field_date_reviewed>2010-10-25</field_date_reviewed>
  <field_pretty_url>smokeless-fact-sheet</field_pretty_url>
  <para_id>14388</para_id>
  <related_resource_ids>6625671</related_resource_ids>
  <related_resource_ids>6625672</related_resource_ids>
  <related_resource_ids>6625673</related_resource_ids>
  <related_resource_ids>6625674</related_resource_ids>
  <related_resource_ids>6625675</related_resource_ids>
  <related_resource_ids>6625687</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>10952</term_id>
  <id>14423</id>
  <title>About NCI</title>
  <langcode>en</langcode>
  <field_short_title>About NCI</field_short_title>
  <field_page_description>Information about the National Cancer Institute, including information about NCI's organization, budget, advisory boards, and employment opportunities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14423</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11950</term_id>
  <id>14435</id>
  <title>Pheochromocytoma and Paraganglioma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Pheochromocytoma and Paraganglioma</field_short_title>
  <field_page_description>Pheochromocytoma and paraganglioma are rare tumors that can be benign (not cancer) or malignant. Pheochromocytomas form in the adrenal glands, and paragangliomas usually along nerve pathways in the head, neck, and spine. Start here to find information on pheochromocytoma and paraganglioma treatment, and research.</field_page_description>
  <field_list_description>NCI's gateway for information about Pheochromocytoma and Paraganglioma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14435</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952654</term_id>
  <id>14490</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Pediatric Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Treatment</field_short_title>
  <field_page_description>Find treatment information for different types of cancer in children. Includes information about diagnosis, staging, and prognosis.</field_page_description>
  <field_list_description>Treatment options for childhood cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14490</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952670</term_id>
  <id>14510</id>
  <title>PDQ&amp;reg; Adult Treatment Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Adult Treatment Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of medical oncology, radiation oncology, and surgical oncology.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-03-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14510</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>899478</id>
  <title>Strengthening National Cancer Planning Efforts and Building on 20 Years of US-Vietnam Relations</title>
  <langcode>en</langcode>
  <field_short_title>Strengthening National Cancer Planning Efforts and Building on 20 Years of US-Vietnam Relations</field_short_title>
  <field_page_description>CGH's Dr. Paul Pearlman discusses his detail in Vietnam as an Embassy Science Fellow: this detail has given me the opportunity to work side by side with the US Centers for Disease Control and Prevention, the World Health Organization’s Vietnam Country Office, Hospital K, and other key organizations to engage on these i</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-23</field_date_posted>
  <field_date_reviewed>2015-01-23</field_date_reviewed>
  <field_pretty_url>strengthening-us-vietnan-relations</field_pretty_url>
  <para_id>899478</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>901342</id>
  <title>Head and Neck Cancer International Group (HNCIG)</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck International Group (HNIG)</field_short_title>
  <field_page_description>The Head and Neck Cancer International Group was established in 2014 with the mission to promote and conduct high quality head and neck cancer clinical trials worldwide to improve outcomes in patients diagnosed with these diseases. </field_page_description>
  <field_feature_card_description>The Head and Neck Cancer International Group was established in 2014 with the mission to promote and conduct high quality head and neck cancer clinical trials worldwide. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-28</field_date_posted>
  <field_date_reviewed>2015-01-28</field_date_reviewed>
  <field_pretty_url>hncig</field_pretty_url>
  <para_id>901342</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899934</term_id>
  <id>901824</id>
  <title>Mouth and Throat Problems during Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Mouth and Throat Problems</field_short_title>
  <field_page_description>Cancer treatments may cause dental, mouth, and throat side effects such as changes in taste (dysgeusia), dry mouth (xerostomia), infections, mouth sores, pain or swelling in your mouth (oral mucositis), sensitivity to foods, and swallowing problems.</field_page_description>
  <field_feature_card_description>Cancer treatment can cause oral complications. Learn what causes oral problems and ways to prevent or manage them.</field_feature_card_description>
  <field_list_description>Information about what causes mouth and throat problems, a side effect of some cancer treatments, and ways to prevent or manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-05-03</field_date_reviewed>
  <para_id>901824</para_id>
  <related_resource_id>7166420</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>762611</term_id>
  <id>902260</id>
  <title>CGH Celebrates World Cancer Day 2015</title>
  <langcode>en</langcode>
  <field_short_title>CGH Celebrates World Cancer Day 2015</field_short_title>
  <field_page_description>CGH activities celebrating World Cancer Day 2015</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-30</field_date_posted>
  <field_date_reviewed>2015-01-30</field_date_reviewed>
  <field_pretty_url>wcd-2015</field_pretty_url>
  <para_id>902260</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903596</term_id>
  <id>903600</id>
  <title>Support Services</title>
  <langcode>en</langcode>
  <field_short_title>Support Services</field_short_title>
  <field_page_description>Various services to help you cope during and after your cancer treatment.</field_page_description>
  <field_feature_card_description>Various services to help you cope during and after your cancer treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-10</field_date_posted>
  <field_date_reviewed>2015-02-02</field_date_reviewed>
  <para_id>903600</para_id>
  <related_resource_ids>6670606</related_resource_ids>
  <related_resource_ids>6670607</related_resource_ids>
  <related_resource_ids>6670610</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903757</term_id>
  <id>903755</id>
  <title>Memory or Concentration Problems and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Memory or Concentration Problems</field_short_title>
  <field_page_description>Cancer treatments, such as chemo, may cause difficulty thinking, concentrating, or other cognitive problems. Learn about steps people with cancer can take to manage these side effects. See a list of helpful questions for families to ask the doctor.</field_page_description>
  <field_list_description>Information about what causes memory or concentration problems, a side effect of some cancer treatments, and ways to manage it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-02-04</field_date_reviewed>
  <para_id>903755</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>904556</id>
  <title>Medicare to Cover Annual Lung Cancer Screening for Some Beneficiaries</title>
  <langcode>en</langcode>
  <field_short_title>Medicare to Cover Annual Lung Cancer Screening for Some Beneficiaries</field_short_title>
  <field_page_description>For the first time, Medicare will cover the costs of lung cancer screening for some beneficiaries, the Centers for Medicare and Medicaid Services (CMS) announced on February 5.</field_page_description>
  <field_feature_card_description>For the first time, Medicare will cover the costs of lung cancer screening for some beneficiaries, the Centers for Medicare and Medicaid Services (CMS) announced on February 5.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-06</field_date_posted>
  <field_date_reviewed>2015-02-06</field_date_reviewed>
  <field_pretty_url>medicare-lung-cancer-screening</field_pretty_url>
  <para_id>904556</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>901011</term_id>
  <id>903727</id>
  <title>Pain in People with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Pain</field_short_title>
  <field_page_description>Controlling pain is an important part of your cancer treatment plan. Learn how to track levels of pain. Find out how pain, a side effect of cancer treatment, is treated using acupuncture, biofeedback, and physical therapy. </field_page_description>
  <field_list_description>What causes pain? How can I treat or lessen pain during cancer treatment? Pain is a side effect of some cancer treatments. Learn how to prevent pain, treat pain, or lessen pain in cancer patients. Get a list of questions to ask your doctor about pain.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-12-04</field_date_reviewed>
  <para_id>903727</para_id>
  <related_resource_ids>7105815</related_resource_ids>
  <related_resource_ids>7105820</related_resource_ids>
  <related_resource_ids>7105821</related_resource_ids>
  <related_resource_ids>7105822</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899924</term_id>
  <id>903729</id>
  <title>Urinary and Bladder Problems</title>
  <langcode>en</langcode>
  <field_short_title>Urinary and Bladder Problems</field_short_title>
  <field_page_description>Problems such as radiation cystitis and urinary tract infections, which are sometimes caused by cancer treatments, are discussed along with ways to prevent or manage them.</field_page_description>
  <field_list_description>Information about the causes and symptoms of urinary and bladder problems, a side effect of some cancer treatments, and ways to prevent or manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-02-04</field_date_reviewed>
  <para_id>903729</para_id>
  <related_resource_id>7107101</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903735</term_id>
  <id>903736</id>
  <title>Edema (Swelling) and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Edema (Swelling)</field_short_title>
  <field_page_description>Edema is a condition in which fluid builds up in your body’s tissues. The swelling may be caused by chemotherapy, cancer, and conditions not related to cancer. Learn about signs of edema, including swelling in your feet, ankles, and legs.  </field_page_description>
  <field_list_description>Information about what causes edema, a side effect of some cancer treatments, and ways to prevent or lessen it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-03-14</field_date_reviewed>
  <para_id>903736</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1093752</term_id>
  <id>1093757</id>
  <title>Sexual Health Issues in Men with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Sexual Health Issues in Men</field_short_title>
  <field_page_description>Cancer treatments such as chemotherapy, radiation therapy and prostate surgery may affect a man’s sexual function, lower libido, and make it difficult to get an erection. Learn how to manage and treat these sexual problems, during cancer treatment.</field_page_description>
  <field_feature_card_description>Cancer treatment may have side effects that affect a man's sexual life, but there are ways to manage.  </field_feature_card_description>
  <field_list_description>Men receiving cancer treatment may have side effects that affect their sexual life. Learn about factors that determine whether sexual health is affected and ways to manage changes during treatment for cancer.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-22</field_date_posted>
  <field_date_reviewed>2017-08-28</field_date_reviewed>
  <para_id>1093757</para_id>
  <related_resource_ids>7107053</related_resource_ids>
  <related_resource_ids>7107054</related_resource_ids>
  <related_resource_ids>7107068</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1093820</id>
  <title>Modified Stem Cells Deliver Chemotherapy to Metastatic Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Stem Cells Deliver Chemo to Metastatic Breast Cancer</field_short_title>
  <field_page_description>Using modified stem cells, researchers delivered a cancer drug selectively to metastatic breast cancer tumors in mice, as this NCI Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Treatment targets ‘stiff’ environment around metastases.</field_feature_card_description>
  <field_list_description>Researchers have used modified stem cells to deliver a cancer drug selectively to metastatic breast cancer tumors in mice. The stem cells target metastatic tumors by homing in on the stiff environment that typically surrounds them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-30</field_date_posted>
  <field_date_reviewed>2017-08-30</field_date_reviewed>
  <field_pretty_url>breast-metastases-targeting-stem-cells</field_pretty_url>
  <para_id>1093820</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1090265</term_id>
  <id>1094047</id>
  <title>Cancer Prevention Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Prevention Steering Committee Roster</field_short_title>
  <field_page_description>Roster of members on the Cancer Prevention Steering Committee.</field_page_description>
  <field_feature_card_description>Roster of members on the Cancer Prevention Steering Committee.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-28</field_date_posted>
  <field_date_reviewed>2017-09-28</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>1094047</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1096343</id>
  <title>Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar</title>
  <langcode>en</langcode>
  <field_short_title>Dr. John M. Carethers to Deliver CURE Distinguished Scholars Seminar</field_short_title>
  <field_page_description>Dr. John M. Carethers will deliver the second CURE Distinguished Scholars Seminar on Oct. 5, 2017. </field_page_description>
  <field_feature_card_description>On October 5, 2017, Dr. John M. Carethers will deliver the second CURE Distinguished Scholars Seminar. </field_feature_card_description>
  <field_list_description>On October 5, 2017, Dr. John M. Carethers will deliver the second CURE Distinguished Scholars Seminar. Dr. Carethers will present highlights from his research in hereditary colon cancer, tumor progression, and colorectal cancer disparities.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-19</field_date_posted>
  <field_date_reviewed>2017-09-19</field_date_reviewed>
  <field_pretty_url>carethers-seminar</field_pretty_url>
  <para_id>1096343</para_id>
  <related_resource_ids>6703325</related_resource_ids>
  <related_resource_ids>6703326</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1096585</id>
  <title>FDA Expands Approval of Fulvestrant for Advanced Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Expands Approval of Fulvestrant for Breast Cancer</field_short_title>
  <field_page_description>Fulvestrant (Faslodex®) has been approved by FDA for some women with advanced breast cancer, this Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>Approval is for fulvestrant alone in some women with advanced breast cancer.</field_feature_card_description>
  <field_list_description>FDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-22</field_date_posted>
  <field_date_reviewed>2017-09-21</field_date_reviewed>
  <field_pretty_url>fda-fulvestrant-breast-cancer</field_pretty_url>
  <para_id>1096585</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1112440</id>
  <title>OncoArray Links Dozens of DNA Variants to Risk for Common Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Linking DNA Variants and Cancer Risk</field_short_title>
  <field_page_description>Researchers with the NCI-supported GAME-ON initiative and OncoArray Network are publishing studies identifying dozens of new genetic variants associated with the risk for developing some of the most common cancers, as this Cancer Currents blog post reports.</field_page_description>
  <field_feature_card_description>An NCI-supported network is unearthing data on genetic links to common cancers. </field_feature_card_description>
  <field_list_description>Researchers with the NCI-supported GAME-ON initiative and OncoArray Network are publishing studies identifying dozens of new genetic variants associated with the risk for developing some of the most common cancers. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-12</field_date_posted>
  <field_date_reviewed>2018-04-06</field_date_reviewed>
  <field_pretty_url>oncoarray-genetic-variants-cancer-risk</field_pretty_url>
  <para_id>1112440</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1113235</term_id>
  <id>1113237</id>
  <title>Access to Experimental Cancer Drugs</title>
  <langcode>en</langcode>
  <field_short_title>Access to Experimental Cancer Drugs</field_short_title>
  <field_page_description> An experimental drug has been tested in the lab and with animals and approved for testing in people by the FDA, but can’t yet be advertised, sold, or prescribed. Experimental drugs may be available through clinical trials or expanded access programs - learn more about these programs and how to talk to your doctor.</field_page_description>
  <field_feature_card_description>Learn how you might gain access to drugs that have been approved for testing in people but can't yet be advertised, sold, or prescribed.</field_feature_card_description>
  <field_list_description>An experimental drug is one that has been tested in the lab and with animals and approved for testing in people by the U.S. Food and Drug Administration (FDA), but can’t yet be advertised, sold, or prescribed. Experimental drugs may be available through clinical trials or expanded access programs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-17</field_date_posted>
  <field_date_reviewed>2018-04-17</field_date_reviewed>
  <para_id>1113237</para_id>
  <related_resource_ids>7062812</related_resource_ids>
  <related_resource_ids>7062813</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>936689</term_id>
  <id>172407</id>
  <title>Questions to Ask Your Doctor about Your Diagnosis</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask about Your Diagnosis</field_short_title>
  <field_page_description>Suggested questions for patients to ask their doctors when they learn they have cancer and want to know what to expect next. </field_page_description>
  <field_feature_card_description>These questions may help you learn more about your cancer and what you can expect next.</field_feature_card_description>
  <field_list_description>These questions may help you learn more about your cancer what you can expect next.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2018-08-09</field_date_reviewed>
  <para_id>172407</para_id>
  <related_resource_ids>7091985</related_resource_ids>
  <related_resource_ids>7091988</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>936649</term_id>
  <id>176775</id>
  <title>Questions to Ask Your Doctor about Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask Your Doctor about Cancer</field_short_title>
  <field_page_description>Sets of questions, organized by topic, that cancer patients may want to ask their doctors or other members of their health care team to learn more about their cancer and what to expect.</field_page_description>
  <field_feature_card_description>When you meet with your doctor or other members of your health care team, take a list of questions with you.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-02-01</field_date_posted>
  <field_date_reviewed>2012-01-30</field_date_reviewed>
  <para_id>176775</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1117583</term_id>
  <id>1117584</id>
  <title>Carryover Unobligated Funds</title>
  <langcode>en</langcode>
  <field_short_title>Carryover Unobligated Funds</field_short_title>
  <field_page_description>Carryover is the process by which unobligated funds remaining at the end of a budget period may be carried forward to cover allowable costs in the next budget period. Learn more about how to carryover NCI grants.</field_page_description>
  <field_feature_card_description>Carryover is the process by which unobligated funds remaining at the end of a budget period may be carried forward to cover allowable costs in the next budget period. Learn more about how to carryover NCI grants.</field_feature_card_description>
  <field_list_description>Carryover is the process by which unobligated funds remaining at the end of a budget period may be carried forward to cover allowable costs in the next budget period. The carryover of funds enables recipients to use unexpended prior year grant funds in another budget period. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-13</field_date_posted>
  <field_date_reviewed>2018-06-13</field_date_reviewed>
  <para_id>1117584</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1117621</term_id>
  <id>1117628</id>
  <title>NAVIGATE: NCI and VA Interagency Group to Accelerate Trials Enrollment</title>
  <langcode>en</langcode>
  <field_short_title>NAVIGATE</field_short_title>
  <field_page_description>The NAVIGATE program will make it easier for veterans to access promising new cancer treatments via clinical trials. This partnership between NCI and the VHA will increase the number of VA Medical Centers participating in and conducting NCI-supported cancer clinical trials.</field_page_description>
  <field_list_description>The NAVIGATE program is a partnership between NCI and the Veterans Health Administration (VHA) to facilitate enrollment of veterans into NCI funded clinical trials. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-14</field_date_posted>
  <field_date_reviewed>2018-06-14</field_date_reviewed>
  <para_id>1117628</para_id>
  <related_resource_id>7204930</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1118079</id>
  <title>Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors?</title>
  <langcode>en</langcode>
  <field_short_title>Do Frequent Follow-Up Tests Help Colorectal Cancer Survivors?</field_short_title>
  <field_page_description>Two studies of colorectal cancer survivors examined whether more frequent follow-up testing for recurrence improved how long people lived. Read this Cancer Currents blog post to learn whether testing frequency affects survival.</field_page_description>
  <field_feature_card_description>Studies show testing more than once a year doesn’t improve survival.</field_feature_card_description>
  <field_list_description>Two studies examined the impact of more frequent follow-up testing for cancer recurrence in colorectal cancer survivors. Learn whether the studies showed that frequent testing improved survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-20</field_date_posted>
  <field_date_reviewed>2018-06-20</field_date_reviewed>
  <field_pretty_url>colorectal-cancer-follow-up-testing</field_pretty_url>
  <para_id>1118079</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>14222</id>
  <title>A to Z List of Cancer Drugs</title>
  <langcode>en</langcode>
  <field_short_title>A to Z List of Cancer Drugs</field_short_title>
  <field_page_description>List of cancer drug information summaries providing details about cancer drugs and cancer drug combinations.</field_page_description>
  <field_feature_card_description>Consumer-friendly information about drugs and drug combinations used to prevent and treat cancer.</field_feature_card_description>
  <field_list_description>Consumer-friendly information about cancer drugs and drug combinations used to prevent and treat cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-01-30</field_date_posted>
  <field_date_reviewed>2006-09-28</field_date_reviewed>
  <para_id>14222</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>816951</term_id>
  <id>816969</id>
  <title>RAS Image-Based Screens</title>
  <langcode>en</langcode>
  <field_short_title>Image-Based Screens</field_short_title>
  <field_page_description>This laboratory develops screens based on live cell imaging of labeled RAS molecules.</field_page_description>
  <field_feature_card_description>This laboratory develops screens based on live cell imaging of labeled RAS molecules.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-08-19</field_date_reviewed>
  <para_id>816969</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>816958</term_id>
  <id>817097</id>
  <title>RAS Informatics</title>
  <langcode>en</langcode>
  <field_short_title>RAS Informatics</field_short_title>
  <field_page_description>The RAS Informatics lab group develops tools to track and analyze “big data” from the RAS Initiative, as well as analyzes data from external projects. By integrating internal and external data, this group helps improve understanding of RAS-driven cancers.</field_page_description>
  <field_feature_card_description>This lab group develops tools to track and analyze “big data” from the RAS Initiative and the larger RAS community.</field_feature_card_description>
  <field_list_description>This lab group develops tools to track and analyze “big data” from the RAS Initiative and the larger RAS community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-08-20</field_date_reviewed>
  <para_id>817097</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>1032039</id>
  <title>NCI Scientists Identify New Gene Mutation that Predisposes Families to Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>NCI Scientists Identify New Gene Mutation that Predisposes Families to Melanoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-03-31</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>gene-mutation-predisposes-melanoma</field_pretty_url>
  <para_id>1032039</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>1032054</id>
  <title>Modeling Different Breast Cancer Screening Strategies</title>
  <langcode>en</langcode>
  <field_short_title>Modeling Different Breast Cancer Screening Strategies</field_short_title>
  <field_page_description>A modeling study for breast cancer screening found that regular mammography screening for women ages 50 to 74 reduces the risk of dying due to breast cancer, with a smaller benefit for women 40 to 49.</field_page_description>
  <field_list_description>A study that uses modeling to summarize the benefits and harms of breast cancer screening finds that regular mammography screening for women ages 50 to 74 reduces the risk of dying due to breast cancer, with a smaller benefit for women 40 to 49.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-11-18</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>modeling-breast-cancer-screening</field_pretty_url>
  <para_id>1032054</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1033570</id>
  <title>Three New Therapies Approved for Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Three New Therapies Approved for Multiple Myeloma</field_short_title>
  <field_page_description>In November 2015, the FDA approved three new therapies for patients with multiple myeloma.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-06</field_date_posted>
  <field_date_reviewed>2016-01-05</field_date_reviewed>
  <field_pretty_url>fda-threedrugs-myeloma</field_pretty_url>
  <para_id>1033570</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1033860</id>
  <title>Mutation-Specific Approaches to KRAS Cancers: What We Can Learn from G12C-Directed Inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Mutation-specific Approaches to KRAS Cancers</field_short_title>
  <field_page_description>Dr. Sharon Campbell discusses recent advances in targeting specific mutant forms of KRAS proteins in cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-12</field_date_posted>
  <field_date_reviewed>2016-01-12</field_date_reviewed>
  <field_pretty_url>kras-g12c-inhibitors</field_pretty_url>
  <para_id>1033860</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1047145</id>
  <title>Strengthening relations with Latin American countries through health diplomacy</title>
  <langcode>en</langcode>
  <field_short_title>Strengthening relations with Latin American countries through health diplomacy</field_short_title>
  <field_page_description>Ambassador of Peru to the United States, Luis Miguel Castilla, visited the Center for Global Health (CGH) at the National Cancer Institute a year ago with the objective of strengthening collaboration between US NCI and the Instituto Nacional de Enfermedades Neoplasicas of Peru and Ministry of Health of Peru. As part of</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-22</field_date_posted>
  <field_date_reviewed>2016-04-22</field_date_reviewed>
  <field_pretty_url>diplomacy</field_pretty_url>
  <para_id>1047145</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047410</id>
  <title>Venetoclax Approved for Some Patients with Chronic Lymphocytic Leukemia </title>
  <langcode>en</langcode>
  <field_short_title>Venetoclax for Chronic Lymphocytic Leukemia</field_short_title>
  <field_page_description>The FDA has approved venetoclax for patients with chronic lymphocytic leukemia (CLL) whose tumors have a specific genetic alteration.</field_page_description>
  <field_feature_card_description>Treatment led to substantial, enduring tumor responses.</field_feature_card_description>
  <field_list_description>The FDA has approved venetoclax for patients with chronic lymphocytic leukemia whose tumors have a specific genetic alteration.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-04</field_date_posted>
  <field_date_reviewed>2016-04-27</field_date_reviewed>
  <field_pretty_url>venetoclax-cll</field_pretty_url>
  <para_id>1047410</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1002055</term_id>
  <id>1047991</id>
  <title>Genomic Data Sharing (GDS) Policy</title>
  <langcode>en</langcode>
  <field_short_title>Genomic Data Sharing Policy</field_short_title>
  <field_page_description>The NIH Genomic Data Sharing (GDS) Policy was issued to promote broad sharing of genomic research data and ensure oversight and protections for research involving human data. </field_page_description>
  <field_feature_card_description>Learn about this policy, which applies to all NIH-funded research that generates large-scale genomic data.</field_feature_card_description>
  <field_list_description>The NIH Genomic Data Sharing (GDS) Policy was issued to promote broad and robust sharing of genomic research data and ensure proper oversight and appropriate protections for research involving human data.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-06</field_date_posted>
  <field_date_reviewed>2016-05-06</field_date_reviewed>
  <para_id>1047991</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1050939</id>
  <title>Online Tool Helps Users Distinguish Moles from Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Online Tool Helps Users Distinguish Moles from Melanoma</field_short_title>
  <field_page_description>“Moles to Melanoma: Recognizing the ABCDE Features” presents photos that show changes in individual pigmented lesions over time, and describes the different appearances of moles, dysplastic nevi, and melanomas.</field_page_description>
  <field_feature_card_description>An online tool presents photos that show changes in individual pigmented lesions over time.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-23</field_date_posted>
  <field_date_reviewed>2016-05-23</field_date_reviewed>
  <field_pretty_url>moles-to-melanoma</field_pretty_url>
  <para_id>1050939</para_id>
  <related_resource_ids>6611713</related_resource_ids>
  <related_resource_ids>6611714</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916998</term_id>
  <id>1051328</id>
  <title>Clinical Trial Registration, Amendments, and Updates</title>
  <langcode>en</langcode>
  <field_short_title>Trial Registration, Amendments, and Updates</field_short_title>
  <field_page_description>Policies on clinical trial registration, amendments and updates related to CTRP.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-25</field_date_posted>
  <field_date_reviewed>2016-05-25</field_date_reviewed>
  <para_id>1051328</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1051445</id>
  <title>The Genomic Data Commons Launches</title>
  <langcode>en</langcode>
  <field_short_title>NCI Genomic Data Commons Launches</field_short_title>
  <field_page_description>The NCI Genomic Data Commons is a next generation knowledge network that enables the access, analysis, and submission of cancer genomic data. The GDC facilitates data sharing and promotes precision medicine in oncology. </field_page_description>
  <field_feature_card_description>The NCI GDC, a data sharing platform to facilitate precision oncology, lauches today. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-06</field_date_posted>
  <field_date_reviewed>2016-05-26</field_date_reviewed>
  <field_pretty_url>gdc-launches</field_pretty_url>
  <para_id>1051445</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1052064</id>
  <title>Tumor Microenvironment Influences Metabolism of Cancer Cells</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Microenvironment Influences Metabolism of Cancer Cells</field_short_title>
  <field_page_description>In a new blog post in RAS Dialogue, Dr. Cosimo Commisso discusses how the metabolism of cancer cells might be different in different parts of solid tumors.</field_page_description>
  <field_feature_card_description>In a new blog post in RAS Dialogue, Dr. Cosimo Commisso discusses how the metabolism of cancer cells might be different in different parts of solid tumors.</field_feature_card_description>
  <field_list_description>Solid tumors have disregulated blood, oxygen, and nutrient supplies that influence metabolism in different parts of the tumors.  Attacking these differences will require an intimate knowledge of how cancer cells detect and adapt to their environment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-06</field_date_posted>
  <field_date_reviewed>2016-06-06</field_date_reviewed>
  <field_pretty_url>metabolic-heterogeneity-solid-tumors</field_pretty_url>
  <para_id>1052064</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1117737</id>
  <title>TCGA's Study of Breast Lobular Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Breast Lobular Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Breast Lobular Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Breast Lobular Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of invasive breast lobular carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-15</field_date_posted>
  <field_date_reviewed>2018-06-15</field_date_reviewed>
  <field_pretty_url>breast-lobular</field_pretty_url>
  <para_id>1117737</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1117904</id>
  <title>Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs Expire </title>
  <langcode>en</langcode>
  <field_short_title>Biosimilar Drugs for Cancer Emerge </field_short_title>
  <field_page_description>As the patents on widely used biological drugs to treat cancer expire, biosimilar drugs are being developed for the treatment of patients with cancer. You can learn how biosimilars may expand treatment options in this Cancer Currents blog post.  </field_page_description>
  <field_feature_card_description>Biosimilars could potentially enable greater access to biological therapies.</field_feature_card_description>
  <field_list_description>As the patents on some widely used drugs to treat cancer expire in the coming years, biosimilar drugs are being developed for the treatment of patients with cancer. Are biosimilars effective and will they expand treatment options for patients? </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-18</field_date_posted>
  <field_date_reviewed>2018-06-18</field_date_reviewed>
  <field_pretty_url>biosimilars-cancer-treatment</field_pretty_url>
  <para_id>1117904</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1119354</id>
  <title>Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research Stalwart, Dies</title>
  <langcode>en</langcode>
  <field_short_title>Long-Time NCI Deputy Director Dr. Alan Rabson Dies</field_short_title>
  <field_page_description>Long-time NCI senior leader Alan Rabson, M.D., passed away on July 4, at the age of 92. His career spanned 6 decades, including research on tumor virology and cancer pathology and senior NCI leadership roles.</field_page_description>
  <field_feature_card_description>Revered scientist and leader’s career at NCI spanned 6 decades.</field_feature_card_description>
  <field_list_description>Many in the cancer research and NIH community are mourning the loss of long-time NCI senior leader Alan Rabson, M.D., who passed away on July 4, at the age of 92. His career spanned 6 decades, including research on tumor virology and cancer pathology and senior NCI leadership roles.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-05</field_date_posted>
  <field_date_reviewed>2018-07-05</field_date_reviewed>
  <field_pretty_url>alan-rabson-passes-away</field_pretty_url>
  <para_id>1119354</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1119645</id>
  <title>Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children</title>
  <langcode>en</langcode>
  <field_short_title>Drug Prevents Chemo-Related Hearing Loss in Some Children</field_short_title>
  <field_page_description>Sodium thiosulfate protected cisplatin-related hearing loss in children with a form of liver cancer, results from a clinical trial show. As this Cancer Currents post explains, the findings should affect clinical practice.</field_page_description>
  <field_feature_card_description>Treatment addresses common side effect of chemo drug cisplatin. </field_feature_card_description>
  <field_list_description>The drug sodium thiosulfate can protect the hearing of children with cancer undergoing treatment with the chemotherapy drug cisplatin, results from a new clinical trial show. The trial involved children with a form of liver cancer called hepatoblastoma.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-13</field_date_posted>
  <field_date_reviewed>2018-07-11</field_date_reviewed>
  <field_pretty_url>cisplatin-hearing-loss-sodium-thiosulfate</field_pretty_url>
  <para_id>1119645</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11924</term_id>
  <id>14121</id>
  <title>Liver and Bile Duct Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Liver and Bile Duct Cancer</field_short_title>
  <field_page_description>Liver cancer includes hepatocellular carcinoma and bile duct cancer (cholangiocarcinoma). Risk factors for HCC include chronic infection with hepatitis B or C and cirrhosis of the liver. Start here to find information on liver and bile duct cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about liver and bile cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14121</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12598</term_id>
  <id>14165</id>
  <title>E-mail Us</title>
  <langcode>en</langcode>
  <field_short_title>E-mail Us</field_short_title>
  <field_page_description>NCI Web e-mail contact form.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-03-29</field_date_reviewed>
  <field_pretty_url>email-us</field_pretty_url>
  <para_id>14165</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11482</term_id>
  <id>14304</id>
  <title>NCI Organization</title>
  <langcode>en</langcode>
  <field_short_title>NCI Organization</field_short_title>
  <field_page_description>Links to NCI's 30 divisions, offices, and centers who work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda.</field_page_description>
  <field_feature_card_description>Links to NCI's divisions, offices, and centers.</field_feature_card_description>
  <field_list_description>As the nation's leading federal agency for cancer research, NCI has 30 divisions, offices, and centers who work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14304</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911142</term_id>
  <id>14362</id>
  <title>Diethylstilbestrol (DES) and Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Diethylstilbestrol (DES) and Cancer </field_short_title>
  <field_page_description>A fact sheet about DES (a synthetic form of estrogen) and the health problems of children who were exposed to DES while in the womb.</field_page_description>
  <field_feature_card_description>A fact sheet about DES (a synthetic form of estrogen) and the health problems of children who were exposed to DES while in the womb.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-10-05</field_date_posted>
  <field_date_reviewed>2011-10-05</field_date_reviewed>
  <field_pretty_url>des-fact-sheet</field_pretty_url>
  <para_id>14362</para_id>
  <related_resource_id>6934388</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1074434</id>
  <title>CGH Hosts the Regional Centers of Research Excellence Program Launch Meeting for Cohort 1 Investigators</title>
  <langcode>en</langcode>
  <field_short_title>CGH Hosts the Regional Centers of Research Excellence Program Launch Meeting for Cohort 1 Investigat</field_short_title>
  <field_page_description>CGH convened the first meeting of the principal investigators funded in the first cohort.  These investigators gathered to share their Research Center plans and provide feedback to one another. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-01</field_date_posted>
  <field_date_reviewed>2017-03-01</field_date_reviewed>
  <field_pretty_url>rcre-launch</field_pretty_url>
  <para_id>1074434</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074837</term_id>
  <id>1074843</id>
  <title>Structural Genomics Research</title>
  <langcode>en</langcode>
  <field_short_title>Structural Genomics Research</field_short_title>
  <field_page_description>NCI's Center for Cancer Genomics uses structural cancer genomics to identify genomic alterations that contribute to cancer growth, metastasis, and recurrence.</field_page_description>
  <field_feature_card_description>Structural genomics identifies alterations in cancer that contribute to cancer growth, metastasis, and recurrence. </field_feature_card_description>
  <field_list_description>Structural genomics identifies alterations in cancer that contribute to cancer growth, metastasis, and recurrence. CCG's structural genomics programs include The Cancer Genome Atlas and TARGET.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-03-06</field_date_reviewed>
  <para_id>1074843</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078424</term_id>
  <id>1078666</id>
  <title>About the Office of HIV and AIDS Malignancy</title>
  <langcode>en</langcode>
  <field_short_title>About the Office of HIV and AIDS Malignancy</field_short_title>
  <field_page_description>The Office of HIV and AIDS Malignancy (OHAM) enhances NCI’s research in the field of HIV/AIDS and facilitates coordination of this effort. Learn more about the clinical and programmatic initiatives that OHAM oversees.</field_page_description>
  <field_feature_card_description>Learn how OHAM enhances and facilitates NCI’s HIV/AIDS research initiatives. </field_feature_card_description>
  <field_list_description>The Office of HIV and AIDS Malignancy enhances NCI’s research in the field of HIV/AIDS and facilitates the NCI-wide coordination of this effort. Learn more about the clinical and programmatic initiatives that OHAM oversees.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078666</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1080448</id>
  <title>A Panel of Isogenic RAS-Dependent Cell Lines Developed at the Frederick National Laboratory</title>
  <langcode>en</langcode>
  <field_short_title>A Panel of Isogenic RAS-Dependent Cell Lines Developed at the Frederick National Laboratory</field_short_title>
  <field_page_description>Cells lacking all RAS genes but those that have been modified and introduced by viral transduction are highly useful for drug screens.</field_page_description>
  <field_feature_card_description>Cell lines engineered to express single RAS isoforms and mutants are available from the FNL.</field_feature_card_description>
  <field_list_description>Mouse embryonic fibroblasts have been engineered to lack all RAS genes on demand.  Then individual RAS genes can be introduced.  Such cells allow effects of drugs to be tested with more precision.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-06</field_date_posted>
  <field_date_reviewed>2017-04-06</field_date_reviewed>
  <field_pretty_url>rasless-mefs-drug-screens</field_pretty_url>
  <para_id>1080448</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1080960</id>
  <title>FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on the FDA’s approval of niraparib as maintenance therapy for some women with recurrent ovarian cancer.</field_page_description>
  <field_feature_card_description>FDA approval is for patients with or without BRCA mutations.</field_feature_card_description>
  <field_list_description>The FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-12</field_date_posted>
  <field_date_reviewed>2017-04-11</field_date_reviewed>
  <field_pretty_url>fda-niraparib-ovarian</field_pretty_url>
  <para_id>1080960</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1081004</id>
  <title>Multiple Myeloma Awareness and African American Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Multiple Myeloma Awareness and African American Disparities</field_short_title>
  <field_page_description>As part of National Minority Cancer Awareness Week, we discuss multiple myeloma, a cancer that disproportionately affect minorities, and awareness of this cancer in African American communities.</field_page_description>
  <field_feature_card_description>Learn about multiple myeloma and disparities in the African American community.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-13</field_date_posted>
  <field_date_reviewed>2017-04-13</field_date_reviewed>
  <field_pretty_url>multiple-myeloma-disparities</field_pretty_url>
  <para_id>1081004</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074837</term_id>
  <id>1081662</id>
  <title>Cancer Driver Discovery Program</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Driver Discovery</field_short_title>
  <field_page_description>The Cancer Driver Discovery Program aims to sequence a large number of cancer cases in order to increase statistical power for identifying recurrent driver mutations.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-04-17</field_date_reviewed>
  <field_pretty_url>driver-discovery</field_pretty_url>
  <para_id>1081662</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1084121</id>
  <title>FDA Approves Immunotherapy Drugs for Patients with Bladder Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Drugs Approved for Bladder Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on the FDA’s approval of four immunotherapy drugs for patients with bladder cancer. </field_page_description>
  <field_feature_card_description>Approvals for four checkpoint inhibitors expand treatment options for patients.</field_feature_card_description>
  <field_list_description>The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-30</field_date_posted>
  <field_date_reviewed>2017-05-09</field_date_reviewed>
  <field_pretty_url>approvals-fda-checkpoint-bladder</field_pretty_url>
  <para_id>1084121</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>778027</term_id>
  <id>772091</id>
  <title>Clinical Trial Concept Submission Guidelines</title>
  <langcode>en</langcode>
  <field_short_title>Concept Submission Guidelines</field_short_title>
  <field_page_description>A guide to current NCI procedures for submitting phase 3 or large phase 2 clinical trial concepts to be evaluated by Scientific Steering Committees.</field_page_description>
  <field_feature_card_description>A guide to current NCI procedures for submitting phase 3 or large phase 2 clinical trial concepts to be evaluated by Scientific Steering Committees.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772091</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772008</term_id>
  <id>772126</id>
  <title>Clinical Imaging Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Imaging Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772126</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>777640</term_id>
  <id>777641</id>
  <title>NCI Summer Curriculum in Cancer Prevention - Additional Lectures for International Participants</title>
  <langcode>en</langcode>
  <field_short_title>NCI Summer Curriculum in Cancer Prevention - Additional Lectures for International Participants</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2013-07-22</field_date_reviewed>
  <para_id>777641</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>792795</term_id>
  <id>791265</id>
  <title>NCI Congressional Justification</title>
  <langcode>en</langcode>
  <field_short_title>NCI Congressional Justification</field_short_title>
  <field_page_description>The NCI budget Congressional Justification is prepared to justify the President's annual budget request to Congress. View and download the 2018 Congressional Justification.</field_page_description>
  <field_feature_card_description>Take a look at the FY 2019 NCI Congressional Justification to see an outline of our goals and objectives for the coming fiscal year. </field_feature_card_description>
  <field_list_description>The Congressional Justification is a document that justifies the President’s budget request by explaining NCI’s mission, outlining the institute’s goals and objectives for the coming fiscal year, and providing comparative data and analysis for the previous, current, and proposed budgets.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-21</field_date_posted>
  <field_date_reviewed>2014-06-13</field_date_reviewed>
  <para_id>791265</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>799307</term_id>
  <id>799373</id>
  <title>RAS Target Identification at FNLCR</title>
  <langcode>en</langcode>
  <field_short_title>RAS Target Identification</field_short_title>
  <field_page_description>Discover the cutting edge technologies being used to better define target vulnerabilities in RAS proteins and pathways essential to cancer cells.</field_page_description>
  <field_feature_card_description>Discover the cutting edge technologies being used to better define target vulnerabilities in RAS proteins and pathways essential to cancer cells.</field_feature_card_description>
  <field_list_description>The RAS Initiative is using cutting edge technologies to better define target vulnerabilities in RAS proteins, complexes of RAS proteins with its effector and regulatory partners, cell surface proteins that are enriched in cancer cells driven by mutant RAS, and pathways that are essential to cancer cells but not normal cells.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <para_id>799373</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogSeries</CONTENTTYPENAME>
  <term_id>799459</term_id>
  <id>799464</id>
  <title>RAS Dialogue</title>
  <langcode>en</langcode>
  <field_short_title>RAS Dialogue</field_short_title>
  <field_page_description>Post comments, ask questions, share information, and stay up-to-date with expert Rasologists.</field_page_description>
  <field_feature_card_description>Post comments, ask questions, and share information with RAS experts.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-30</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919531</term_id>
  <id>799547</id>
  <title>RAS Meetings and Videos</title>
  <langcode>en</langcode>
  <field_short_title>Meetings &amp; Videos</field_short_title>
  <field_page_description>Find upcoming RAS-related workshops, seminars, and conferences and previously recorded webcasts of such events.</field_page_description>
  <field_feature_card_description>Explore upcoming RAS-related workshops, seminars, and conferences and previously recorded webcasts of such events.</field_feature_card_description>
  <field_list_description>Explore upcoming RAS-related workshops, seminars, and conferences and previously recorded webcasts of such events.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-06</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <para_id>799547</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917268</term_id>
  <id>800098</id>
  <title>The NCI Outstanding Investigator Award (R35)</title>
  <langcode>en</langcode>
  <field_short_title>Outstanding Investigator Award</field_short_title>
  <field_page_description>The NCI Outstanding Investigator Award (OIA) supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research. </field_page_description>
  <field_feature_card_description>NCI established the Outstanding Investigator Award (R35) for principal investigators who have achieved significant research accomplishments. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-02</field_date_posted>
  <field_date_reviewed>2014-07-02</field_date_reviewed>
  <para_id>800098</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770469</term_id>
  <id>770498</id>
  <title>Head and Neck Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770498</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771997</term_id>
  <id>772112</id>
  <title>Pediatric and Adolescent Solid Tumor Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric and Adolescent Solid Tumor Steering Committee</field_short_title>
  <field_page_description>The Pediatric and Adolescent Solid Tumor Steering Committee addresses the design, prioritization and evaluation of concepts for large phase 2 and phase 3 clinical trials in extracranial solid tumors of children and youth. </field_page_description>
  <field_feature_card_description>The Pediatric and Adolescent Solid Tumor Steering Committee evaluates and prioritizes concepts for therapeutic clinical trials.   </field_feature_card_description>
  <field_list_description>The Pediatric and Adolescent Solid Tumor Steering Committee evaluates and prioritizes concepts for clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN).  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772112</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>792909</id>
  <title>CGH’s Third Year with NCI: Progress, Partnerships, &amp; Possibilities</title>
  <langcode>en</langcode>
  <field_short_title>CGH’s Third Year with NCI: Progress, Partnerships, &amp; Possibilities</field_short_title>
  <field_page_description>The Center for Global Health is embarking on its third year within the National Cancer Institute, and I am pleased with the extraordinary progress and achievements made in this time by our dedicated staff members.  CGH has established new, and strengthened ongoing, initiatives and programs with great success, including</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-06-17</field_date_reviewed>
  <field_pretty_url>welcome</field_pretty_url>
  <para_id>792909</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>792910</id>
  <title>2013 Awardees: Request for Proposals for Pilot Collaborations with Low- and Mid-Income Countries (LMICs) in Global Cancer Research or Global Health Research at NCI-Designated Cancer Centers</title>
  <langcode>en</langcode>
  <field_short_title>2013 CGH Awardees</field_short_title>
  <field_page_description>The National cancer institute, CENTER FOR GLOBAL HEALTH, in collaboration with the OFFICE OF CANCER CENTERS, is pleased to announce the 2013 awardees of the Request for Proposals for Pilot Collaborations with Low- and Mid-Income Countries (LMICs) in Global Cancer Research or Global Health Research at NCI-Designated Can</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-06-17</field_date_reviewed>
  <field_pretty_url>2013-cgh-awardees</field_pretty_url>
  <para_id>792910</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>799624</id>
  <title>Redefining Adjuvant Therapy for Stage III Resected Colon Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Redefining Adjuvant Therapy for Stage III Resected Colon Cancer</field_short_title>
  <field_page_description>In this trial, patients with resected stage III colon cancer are being randomly assigned to receive FOLFOX chemotherapy for either 3 or 6 months and to take either a pill called celecoxib or a matching placebo pill for 3 years. </field_page_description>
  <field_feature_card_description>In this trial, patients with resected stage III colon cancer are being randomly assigned to receive FOLFOX chemotherapy for either 3 or 6 months and to take either a pill called celecoxib or a matching placebo pill for 3 years. </field_feature_card_description>
  <field_list_description>In this trial, patients with resected stage III colon cancer are being randomly assigned to receive a type of chemotherapy called FOLFOX for either 3 months or 6 months and to take either an aspirin-like pill called celecoxib (Celebrex®) or a matching placebo pill for 3 years. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-07-03</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <field_pretty_url>folfox-celecoxib</field_pretty_url>
  <para_id>799624</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1053529</id>
  <title>The Cancer Moonshot Summit: Reaching New Heights</title>
  <langcode>en</langcode>
  <field_short_title>The Cancer Moonshot Summit: Reaching New Heights</field_short_title>
  <field_page_description>An NCI Cancer Currents blog from acting NCI Director Dr. Doug Lowy on the Cancer Moonshot national summit hosted by Vice President Joe Biden in Washington, D.C., including a summary of the NCI-related activities stimulated by the Cancer Moonshot.</field_page_description>
  <field_feature_card_description>Vice President Biden urges participants, cancer community to double rate of research progress.</field_feature_card_description>
  <field_list_description>A recap of the Cancer Moonshot national summit hosted by Vice President Joe Biden in Washington, D.C., on June 29, 2016, including a summary of the NCI-related activities that have been stimulated by the Cancer Moonshot.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-30</field_date_posted>
  <field_date_reviewed>2016-06-30</field_date_reviewed>
  <field_pretty_url>moonshot-summit</field_pretty_url>
  <para_id>1053529</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1056793</id>
  <title>Inherited Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Inherited Mutations Identified in Advanced Prostate Cancers</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about the discovery in men with advanced prostate cancer of inherited mutations in genes that play a role in repairing damaged DNA. </field_page_description>
  <field_feature_card_description>In the future, men who have prostate cancer with these inherited mutations may be candidates for particular treatments.</field_feature_card_description>
  <field_list_description>Researchers estimate that nearly 12% of men with advanced prostate cancer have inherited mutations in genes that play a role in repairing damaged DNA. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-25</field_date_posted>
  <field_date_reviewed>2016-07-25</field_date_reviewed>
  <field_pretty_url>dna-repair-mutations-prostate</field_pretty_url>
  <para_id>1056793</para_id>
  <related_resource_id>6598350</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1056870</id>
  <title>Partner-Aided Skin Exams Increase Early Detection of New Melanomas</title>
  <langcode>en</langcode>
  <field_short_title>Partner-Aided Skin Exams Increase Early Detection of New Melanomas</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study which showed that people previously treated for melanoma can team up with a partner and be trained to find new melanomas.</field_page_description>
  <field_feature_card_description>Training helps family, friends detect new melanomas in previously treated patients. </field_feature_card_description>
  <field_list_description>People previously treated for melanoma can team up with a spouse, family member, or a friend and be trained to find new melanomas, a new study shows.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-27</field_date_posted>
  <field_date_reviewed>2016-07-26</field_date_reviewed>
  <field_pretty_url>partner-skin-exams-melanoma</field_pretty_url>
  <para_id>1056870</para_id>
  <related_resource_ids>6624885</related_resource_ids>
  <related_resource_ids>6624886</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>822143</term_id>
  <id>1057079</id>
  <title>RAS Spokes/Funding</title>
  <langcode>en</langcode>
  <field_short_title>Spokes/Funding</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-27</field_date_posted>
  <field_date_reviewed>2016-07-27</field_date_reviewed>
  <para_id>1057079</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1057582</id>
  <title>Nanoparticle Delivers Cancer Drugs to Tumor Blood Vessels</title>
  <langcode>en</langcode>
  <field_short_title>Nanoparticle Delivers Cancer Drugs to Tumor Blood Vessels</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study showing that, in cancer mouse models, nanoparticles that target P-selectin on tumor blood vessels shrank tumors and extended survival.</field_page_description>
  <field_feature_card_description>In mice, treatment approach improved delivery of cancer drugs to tumors.</field_feature_card_description>
  <field_list_description>In cancer mouse models, nanoparticles that bind to a protein called P-selectin on tumor blood vessels shrank tumors and extended survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-01</field_date_posted>
  <field_date_reviewed>2016-07-29</field_date_reviewed>
  <field_pretty_url>nanoparticle-tumor-vessels</field_pretty_url>
  <para_id>1057582</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061367</id>
  <title>Approach May Allow for Stem Cell Transplant without Radiation, Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Study Tests Safer Stem Cell Transplant</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a study testing a potentially safer way to perform stem cell transplants for treating cancer and other diseases.</field_page_description>
  <field_feature_card_description>In mice, a new approach produces stem cell transplantation without using high-dose chemotherapy or radiation.</field_feature_card_description>
  <field_list_description>In a recent study, researchers showed that a new approach may provide a safer way to perform stem cell transplants for treating cancer and other diseases.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-07</field_date_posted>
  <field_date_reviewed>2016-09-06</field_date_reviewed>
  <field_pretty_url>safer-stem-cell-transplant</field_pretty_url>
  <para_id>1061367</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1035790</id>
  <title>CGH Supports World Cancer Day Every Day</title>
  <langcode>en</langcode>
  <field_short_title>CGH Supports World Cancer Day Every Day</field_short_title>
  <field_page_description>We celebrate World Cancer Day every year on February 4th. This year the theme “We can. I can.” invites us to think not only about how we can work with one another to reduce the global burden of cancer, but how we as individuals can make a difference. Every day the staff at CGH work to establish and build upon programs </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-04</field_date_posted>
  <field_date_reviewed>2016-02-04</field_date_reviewed>
  <field_pretty_url>wcd-every-day</field_pretty_url>
  <para_id>1035790</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1035900</id>
  <title>Faint Light at the End of the Tunnel</title>
  <langcode>en</langcode>
  <field_short_title>Faint Light at the End of the Tunnel</field_short_title>
  <field_page_description>Gideon Bollag describes progress and some of the challenges in inhibiting RAF, the primary effector of RAS in the MAPK pathway.</field_page_description>
  <field_feature_card_description>In a new blog in RAS Dialogue, Dr. Gideon Bollag discusses the challenges and opportunities of drugging the RAS pathway.</field_feature_card_description>
  <field_list_description>Many cancers are dependent on an overactive MAPK pathway. While progress in inhibiting mutant RAS proteins is still in its early phase, third-generation drugs that inhibit the next protein in the pathway, RAF, are being tested. Gideon Bollag of Plexxikon describes some of the challenges of developing inhibitors of RAF.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-08</field_date_posted>
  <field_date_reviewed>2016-02-05</field_date_reviewed>
  <field_pretty_url>bollag-raf-inhibitors</field_pretty_url>
  <para_id>1035900</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1036653</id>
  <title>FDA Approves Eribulin Mesylate for Advanced Liposarcoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Eribulin Mesylate for Advanced Liposarcoma</field_short_title>
  <field_page_description>The FDA has approved eribulin mesylate for patients with liposarcoma whose cancers are advanced or cannot be removed by surgery and are no longer responding to anthracycline-based chemotherapy.</field_page_description>
  <field_feature_card_description>Offers new option for patients for whom there are few effective therapies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-11</field_date_posted>
  <field_date_reviewed>2016-02-09</field_date_reviewed>
  <field_pretty_url>fda-eribulin-mesylate</field_pretty_url>
  <para_id>1036653</para_id>
  <related_resource_id>6598521</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1037153</term_id>
  <id>1037684</id>
  <title>Learning to Relax</title>
  <langcode>en</langcode>
  <field_short_title>Learning to Relax</field_short_title>
  <field_page_description>Relaxation and imagery exercises to help reduce pain and stress from cancer and its treatment.</field_page_description>
  <field_feature_card_description>Relaxation and imagery exercises can help cancer patients cope with pain and stress.</field_feature_card_description>
  <field_list_description>Relaxation and imagery exercises to help reduce pain and stress. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-29</field_date_posted>
  <field_date_reviewed>2016-02-17</field_date_reviewed>
  <para_id>1037684</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1038005</term_id>
  <id>1038006</id>
  <title>Cancer Moonshot&amp;#8480; Blue Ribbon Panel</title>
  <langcode>en</langcode>
  <field_short_title>Blue Ribbon Panel</field_short_title>
  <field_page_description>The Blue Ribbon Panel Report outlines 10 recommendations to accelerate progress against cancer. The panel was established to ensure that the Cancer Moonshot's approaches are grounded in the best science.</field_page_description>
  <field_feature_card_description>The Blue Ribbon Panel (BRP) outlined 10 research recommendations to accelerate progress against cancer. Learn about the panel and its report.</field_feature_card_description>
  <field_list_description>A Blue Ribbon Panel of experts was established as a working group of the NCAB to ensure that the Cancer Moonshot's approaches are grounded in the best science. Their report outlines 10 recommendations to accelerate progress against cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-04</field_date_posted>
  <field_date_reviewed>2016-02-18</field_date_reviewed>
  <para_id>1038006</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1038331</id>
  <title>A Milestone in Cancer Research and Treatment in India</title>
  <langcode>en</langcode>
  <field_short_title>A Milestone in Cancer Research and Treatment in India</field_short_title>
  <field_page_description>Tata Memorial Center is celebrating 75 years of leadership service towards cancer control and research in India.  In honor of this anniversary, TMC is hosting A Conference of New Ideas in Cancer – Challenging Dogmas on February 26-28th, 2016 as part of its platinum jubilee events.  CGH Director, Dr. Ted Trimble, will g</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-19</field_date_posted>
  <field_date_reviewed>2016-02-19</field_date_reviewed>
  <field_pretty_url>tmc_jubilee</field_pretty_url>
  <para_id>1038331</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1038908</id>
  <title>BRCA Testing Rates High in Young Women with Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>BRCA Testing Increasing in Young Breast Cancer Patients</field_short_title>
  <field_page_description>Testing for genetic mutations strongly associated with an increased breast cancer risk has risen dramatically among women younger than age 40 who are diagnosed with the disease, according to a new study.</field_page_description>
  <field_feature_card_description>Testing for genetic mutations associated with breast cancer risk has risen dramatically among young women diagnosed with the disease. </field_feature_card_description>
  <field_list_description>Testing for genetic mutations strongly associated with an increased risk of breast cancer has risen dramatically among women younger than age 40 who are diagnosed with the disease, according to a new study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-01</field_date_posted>
  <field_date_reviewed>2016-03-01</field_date_reviewed>
  <field_pretty_url>brca-testing-breast-cancer</field_pretty_url>
  <para_id>1038908</para_id>
  <related_resource_id>6611769</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1038904</term_id>
  <id>1038929</id>
  <title>Center for Research Strategy (CRS)</title>
  <langcode>en</langcode>
  <field_short_title>Center for Research Strategy (CRS)</field_short_title>
  <field_page_description>CRS develops recommendations on scientific opportunity, funding gaps and mechanisms, while monitoring the direction and application of knowledge and resources.</field_page_description>
  <field_feature_card_description>Identifies research opportunities and funding gaps while monitoring the direction and application of NCI’s scientific knowledge and resources.</field_feature_card_description>
  <field_list_description>The Center for Research Strategy (CRS) develops recommendations for addressing scientific opportunity, identifying funding gaps, and managing funding mechanisms, while monitoring the direction and application of scientific knowledge and resources.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-03-29</field_date_posted>
  <field_date_reviewed>2016-03-02</field_date_reviewed>
  <para_id>1038929</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084772</id>
  <title>Screening and Early Detection - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Screening &amp; Early Detection</field_short_title>
  <field_page_description>Blog posts on cancer screening and early detection research—including diagnostic biomarkers and advances or trends in screening practices—from NCI Cancer Currents. </field_page_description>
  <field_feature_card_description>Cancer screening and early detection research blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>screening-early-detection</field_pretty_url>
  <para_id>1084772</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084774</id>
  <title>Survivorship and Supportive Care - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Survivorship &amp; Supportive Care</field_short_title>
  <field_page_description>Blog posts on survivorship and supportive care research—including the physical, psychosocial, and economic issues faced by cancer survivors and their caregivers—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Survivorship and supportive care research blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>survivorship-supportive-care</field_pretty_url>
  <para_id>1084774</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086212</id>
  <title>Study Identifies Genetic Mutations in Tumors From 10,000 Patients with Metastatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Mutations in 10,000 Patients with Metastatic Cancer</field_short_title>
  <field_page_description>Researchers have reported the results of an initiative to characterize the genetic mutations in tumors from more than 10,000 patients with advanced cancer treated at the center.</field_page_description>
  <field_feature_card_description>The genetic information was used to match hundreds of patients to treatments or clinical trials.</field_feature_card_description>
  <field_list_description>Researchers at Memorial Sloan Kettering Cancer Center have reported the results of an initiative to characterize the genetic mutations in tumors from more than 10,000 patients with advanced cancer treated at the center. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-31</field_date_posted>
  <field_date_reviewed>2017-05-25</field_date_reviewed>
  <field_pretty_url>mutations-metastatic-cancer</field_pretty_url>
  <para_id>1086212</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086924</id>
  <title>Less Chemotherapy May Be Best Choice for Some Patients with Colon Cancer, Study Shows</title>
  <langcode>en</langcode>
  <field_short_title>Less Adjuvant Chemotherapy for Colon Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on a study which showed a shorter chemotherapy course following surgery may be preferred for some patients with colon cancer.</field_page_description>
  <field_feature_card_description>Shorter post-surgery chemotherapy may be safer, equally effective for patients at low risk of recurrence.</field_feature_card_description>
  <field_list_description>A shorter course of chemotherapy following surgery may be preferred to longer treatment for some patients with colon cancer, results of an international collaborative study suggest.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-07</field_date_posted>
  <field_date_reviewed>2017-06-07</field_date_reviewed>
  <field_pretty_url>adjuvant-chemo-colorectal</field_pretty_url>
  <para_id>1086924</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1087027</id>
  <title>Powering Off Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Powering Off Cancer</field_short_title>
  <field_page_description>Many cancers are more dependent on metabolic reactions that occur in mitochondria than normal cells. New therapies that target these reactions are being tested.</field_page_description>
  <field_feature_card_description>The laboratory of Dr. Costas Lyssiotis is investigating how the metabolism of mitochondria in cancer cells can be targeted.</field_feature_card_description>
  <field_list_description>The uncontrolled growth of cancers is dependent on altered metabolism.  For example, many cancers are highly dependent on the altered metabolic reactions that occur in their mitochondria. New therapies that target these reactions are being tested.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-09</field_date_posted>
  <field_date_reviewed>2017-06-08</field_date_reviewed>
  <field_pretty_url>targeting-mitochondria</field_pretty_url>
  <para_id>1087027</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>801793</term_id>
  <id>801796</id>
  <title>RAS Reference Reagents</title>
  <langcode>en</langcode>
  <field_short_title>Reference Reagents</field_short_title>
  <field_page_description>NCI researchers have developed unique and powerful reagents at the NCI labs. Learn about and purchase the latest RAS pathways and reagents.</field_page_description>
  <field_feature_card_description>Learn about and purchase the latest RAS pathways and reagents.</field_feature_card_description>
  <field_list_description>RAS Initiative researchers have developed unique reagents at the FNLCR. We hope that by widely distributing these to the larger RAS community, we can increase the efficiency of all research on RAS.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-07-07</field_date_reviewed>
  <para_id>801796</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>801793</term_id>
  <id>802095</id>
  <title>RAS Cell Lines</title>
  <langcode>en</langcode>
  <field_short_title>Mutant KRAS Cell Lines</field_short_title>
  <field_page_description>Cell lines expressing mutant RAS genes are essential tools for finding ways to intervene in RAS cancers. Learn about the work of NCI RAS Initiative scientists to engineer and characterize these cell lines, creating a reliable resource.</field_page_description>
  <field_list_description>Cell lines expressing mutant RAS genes are essential tools for finding ways to intervene in RAS cancers. NCI's RAS Initiative scientists have devoted significant effort to engineering and characterizing these cell lines so they will be a reliable resource for themselves and the larger RAS community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-28</field_date_posted>
  <field_date_reviewed>2014-07-10</field_date_reviewed>
  <field_pretty_url>cell-lines</field_pretty_url>
  <para_id>802095</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919492</term_id>
  <id>805062</id>
  <title>About the Office of Budget and Finance </title>
  <langcode>en</langcode>
  <field_short_title>About OBF</field_short_title>
  <field_page_description>The Office of Budget and Finance (OBF) advises the NCI Office of the Director and senior NCI staff on the effective management of financial and other resources to ensure that NCI operates in an efficient and fiscally responsible manner.</field_page_description>
  <field_feature_card_description>Learn more about who we are, what we do, and why.</field_feature_card_description>
  <field_list_description>OBF advises the NCI Office of the Director and senior NCI staff on the effective management of financial, personnel and other resources to ensure that NCI operates in an efficient and fiscally responsible manner.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-21</field_date_posted>
  <field_date_reviewed>2014-07-17</field_date_reviewed>
  <para_id>805062</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>809153</id>
  <title>Reducing the Burden of Cancer in East Africa</title>
  <langcode>en</langcode>
  <field_short_title>Reducing the Burden of Cancer in East Africa</field_short_title>
  <field_page_description>The mission of CGH is to advance global cancer research, build expertise, and leverage resources across nations to reduce cancer deaths worldwide. To carry out that mission, we facilitate the sharing of knowledge and expertise. CGH's latest effort, the East Africa Cancer Control Leadership Forum, carried out this missi</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-29</field_date_posted>
  <field_date_reviewed>2014-07-29</field_date_reviewed>
  <field_pretty_url>east-africa</field_pretty_url>
  <para_id>809153</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>810259</term_id>
  <id>810260</id>
  <title>Office of Communications and Public Liaison</title>
  <langcode>en</langcode>
  <field_short_title>Office of Communications and Public Liaison</field_short_title>
  <field_page_description>The NCI Office of Communications and Public Liaison (OCPL) supports NCI by disseminating cancer research findings, providing evidence-based information on cancer for the public, including patients, caregivers, health professionals, researchers, advocates, the news media, and other stakeholders, and disseminating cancer</field_page_description>
  <field_feature_card_description>Information about NCI's Office of Communications and Public Liaison (OCPL)</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-04</field_date_posted>
  <field_date_reviewed>2014-08-04</field_date_reviewed>
  <para_id>810260</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1031741</term_id>
  <id>1031742</id>
  <title>Managing Costs and Medical Information </title>
  <langcode>en</langcode>
  <field_short_title>Managing Medical Care and Costs</field_short_title>
  <field_page_description>People with cancer may face major financial challenges and need help dealing with the high costs of care. Cancer treatment can be very expensive, even when you have insurance. Learn ways to manage medical information, paperwork, bills, and other records.</field_page_description>
  <field_feature_card_description>Learn ways to manage healthcare information, paperwork, bills, and other records.</field_feature_card_description>
  <field_list_description>People with cancer and their families may face major financial challenges. Cancer treatment can be very expensive, even when you have insurance. Learn ways to manage and track tests and treatments, paperwork, bills, and other records.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-19</field_date_posted>
  <field_date_reviewed>2016-10-18</field_date_reviewed>
  <para_id>1031742</para_id>
  <related_resource_ids>7185227</related_resource_ids>
  <related_resource_ids>7185228</related_resource_ids>
  <related_resource_ids>7185229</related_resource_ids>
  <related_resource_ids>7185230</related_resource_ids>
  <related_resource_ids>7185231</related_resource_ids>
  <related_resource_ids>7185234</related_resource_ids>
  <related_resource_ids>7185239</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>1032053</id>
  <title>A Harmful Trend: Increased Waterpipe Smoking</title>
  <langcode>en</langcode>
  <field_short_title>A Harmful Trend: Increased Waterpipe Smoking</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-05-18</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>waterpipe-smoking</field_pretty_url>
  <para_id>1032053</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1007397</term_id>
  <id>1033175</id>
  <title>Profiles in Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Profiles in Cancer Research</field_short_title>
  <field_page_description>Written profiles highlighting the work of NCI and NCI-funded researchers, clinicians, and others who contribute to cancer research.</field_page_description>
  <field_feature_card_description>Meet a few of the NCI-funded researchers, clinicians, and others at work in cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-22</field_date_posted>
  <field_date_reviewed>2015-12-22</field_date_reviewed>
  <para_id>1033175</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1011698</term_id>
  <id>1033573</id>
  <title>Cancer Immunology, Hematology, and Etiology Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Immunology, Hematology, and Etiology Research</field_short_title>
  <field_page_description>Part of NCI’s Division of Cancer Biology’s research portfolio, studies supported include the characterization of basic mechanisms relevant to anti-tumor immune responses and hematologic malignancies. </field_page_description>
  <field_feature_card_description>Studies supported include the characterization of basic mechanisms relevant to anti-tumor immune responses and hematologic malignancies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <para_id>1033573</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1033671</id>
  <title>Researcher Interview: Jinghui Zhang</title>
  <langcode>en</langcode>
  <field_short_title>Researcher Interview: Jinghui Zhang</field_short_title>
  <field_page_description>Center for Cancer Genomics Interview with Jinghui Zhang, Ph.D.</field_page_description>
  <field_feature_card_description>Researcher Interview: Jinghui Zhang</field_feature_card_description>
  <field_list_description>In this interview, Jinghui Zhang, Ph.D., Chair of Computational Biology at St. Jude Children’s Research Hospital, discusses why developing new computational methods is critical to progress against cancer. She also explains how differences between adult and pediatric cancers impact the way they are studied.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-01-12</field_date_posted>
  <field_date_reviewed>2016-01-08</field_date_reviewed>
  <field_pretty_url>jinghui-zhang-interview</field_pretty_url>
  <para_id>1033671</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1034077</term_id>
  <id>1034078</id>
  <title>Recurrent Cancer: When Cancer Comes Back</title>
  <langcode>en</langcode>
  <field_short_title>When Cancer Comes Back</field_short_title>
  <field_page_description>Cancer can recur when treatment doesn’t fully remove or destroy all the cancer cells. Learn about the different types of recurrence and how recurrent cancer is restaged and treated.</field_page_description>
  <field_feature_card_description>Learn the different types of recurrent cancer and why it returns.</field_feature_card_description>
  <field_list_description>Cancer can come back, or recur, when treatment doesn’t fully remove or destroy all the cancer cells. Learn about the different types of recurrence and how recurrent cancer is restaged and treated.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-18</field_date_posted>
  <field_date_reviewed>2016-01-18</field_date_reviewed>
  <para_id>1034078</para_id>
  <related_resource_ids>6200022</related_resource_ids>
  <related_resource_ids>6200023</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1034464</term_id>
  <id>1034951</id>
  <title>Cancer Moonshot&amp;#8480;</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot&amp;#8480;</field_short_title>
  <field_page_description>The Cancer Moonshot is marshalling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention, detection, and treatment.</field_page_description>
  <field_feature_card_description>This broad-based effort is making new investments to accelerate progress against cancer.</field_feature_card_description>
  <field_list_description>An introduction to the Cancer Moonshot, which is marshalling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention, detection, and treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-01</field_date_posted>
  <field_date_reviewed>2016-01-29</field_date_reviewed>
  <para_id>1034951</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1035196</id>
  <title>The ‘Crisis’ of Low HPV Vaccination Rates: A Conversation with Dr. Noel Brewer</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation about the HPV Vaccination Crisis</field_short_title>
  <field_page_description>Following the release of a consensus statement from the NCI-Designated Cancer Centers urging HPV vaccination in the United States, Dr. Noel Brewer discusses the country’s low vaccination rates and how clinicians can help to improve them.</field_page_description>
  <field_feature_card_description>Dr. Noel Brewer discusses how clinicians can help to improve the country’s low vaccination rates.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-02</field_date_posted>
  <field_date_reviewed>2016-02-02</field_date_reviewed>
  <field_pretty_url>hpv-vaccination-rates</field_pretty_url>
  <para_id>1035196</para_id>
  <related_resource_ids>7238924</related_resource_ids>
  <related_resource_ids>7238925</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1035894</id>
  <title>Mouse Study Points to Mechanism Linking Obesity and Colorectal Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Mouse Study Points to Mechanism Linking Obesity and Colorectal Cancer Risk</field_short_title>
  <field_page_description>A missing hormone in obese mice may help explain a longstanding association between obesity and an increased risk of colorectal cancer in humans.</field_page_description>
  <field_feature_card_description>Study points to mechanism linking obesity and colorectal cancer risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-08</field_date_posted>
  <field_date_reviewed>2016-02-05</field_date_reviewed>
  <field_pretty_url>obesity-mechanism-colorectal</field_pretty_url>
  <para_id>1035894</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1040879</id>
  <title>A Conversation with Elizabeth Jaffee</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation with Elizabeth Jaffee</field_short_title>
  <field_page_description>In this RAS Dialogue blost post, Dr. Elizabeth Jaffee talks about her career developing immunotherapies for cancer.</field_page_description>
  <field_feature_card_description>In a new blog in RAS Dialogue, Dr. Elizabeth Jaffee discusses the recent increased interest in harnessing patients' own immune systems to treat cancer.</field_feature_card_description>
  <field_list_description>Immunotherapy uses the patient's own immune system to fight cancer, but some tumors lack significant numbers of immune cells. Elizabeth Jaffee has invented new therapies that are designed to attract immune cells to penetrate tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-07</field_date_posted>
  <field_date_reviewed>2016-03-07</field_date_reviewed>
  <field_pretty_url>elizabeth-jaffee-interview</field_pretty_url>
  <para_id>1040879</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1040907</term_id>
  <id>1040908</id>
  <title>Reports</title>
  <langcode>en</langcode>
  <field_short_title>Reports</field_short_title>
  <field_page_description>Information about major NCI reports as well as other reports released by government health agencies and nonprofit groups that provide information about cancer.</field_page_description>
  <field_feature_card_description>Information about major NCI reports as well as other reports released by government health agencies and nonprofit groups that provide information about cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-03-08</field_date_posted>
  <field_date_reviewed>2016-03-08</field_date_reviewed>
  <para_id>1040908</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1041747</id>
  <title>What’s New on NCI’s Websites?</title>
  <langcode>en</langcode>
  <field_short_title>What’s New on NCI’s Websites?</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description> NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-18</field_date_posted>
  <field_date_reviewed>2016-03-17</field_date_reviewed>
  <field_pretty_url>new-online-march-2016</field_pretty_url>
  <para_id>1041747</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1041998</id>
  <title>Crizotinib Approval Expanded for Advanced Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Crizotinib Approval Expanded for Lung Cancer </field_short_title>
  <field_page_description>The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.</field_page_description>
  <field_feature_card_description>Approval covers patients whose tumors have specific genetic changes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-22</field_date_posted>
  <field_date_reviewed>2016-03-22</field_date_reviewed>
  <field_pretty_url>fda-crizotinib-ros1</field_pretty_url>
  <para_id>1041998</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1043475</id>
  <title>Drug Combination Shrinks Duodenal Polyps in People with Familial Adenomatous Polyposis</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combo Shrinks Duodenal Polyps in FAP</field_short_title>
  <field_page_description>In a small clinical trial of people with an inherited condition that greatly increases gastrointestinal cancer risk, a two-drug combination shrank precancerous lesions in the duodenum.</field_page_description>
  <field_feature_card_description>Study result raises possibility of lowering duodenal cancer risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-07</field_date_posted>
  <field_date_reviewed>2016-04-06</field_date_reviewed>
  <field_pretty_url>erlotinib-sulindac-fap</field_pretty_url>
  <para_id>1043475</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1043875</id>
  <title>Nanoparticle Generator Slips Chemotherapy Past Tumor Cells’ Protective Barriers</title>
  <langcode>en</langcode>
  <field_short_title>Nanoparticle Generator Targets Metastatic Breast Cancer</field_short_title>
  <field_page_description>Researchers have developed a new injectable nanoparticle-generating technology that can deliver a cancer drug to the nucleus of metastatic breast cancer cells.</field_page_description>
  <field_feature_card_description>Technology delivers cancer drugs directly to lung, liver metastases.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-11</field_date_posted>
  <field_date_reviewed>2016-04-08</field_date_reviewed>
  <field_pretty_url>nanoparticle-generator-metastases</field_pretty_url>
  <para_id>1043875</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1044411</id>
  <title>Vitamin D Deficiency May Promote Spread of Some Breast Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Vitamin D Deficiency May Promote Spread of Some Breast Cancers</field_short_title>
  <field_page_description>Low vitamin D levels are associated with metastasis in women with breast cancer, suggests a new study.</field_page_description>
  <field_feature_card_description>Study also identifies association between vitamin D and a cancer-causing gene.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-14</field_date_posted>
  <field_date_reviewed>2016-04-13</field_date_reviewed>
  <field_pretty_url>vitamin-d-metastasis</field_pretty_url>
  <para_id>1044411</para_id>
  <related_resource_id>6583642</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1048172</id>
  <title>Improving Public Health through Increased Tobacco Regulation</title>
  <langcode>en</langcode>
  <field_short_title>Improving Public Health with Increased Tobacco Regulation</field_short_title>
  <field_page_description>NCI’s Dr. Robert Croyle discusses the Food and Drug Administration’s release of a rule that extends its regulatory authority over tobacco products to include cigars, e-cigarettes, hookah tobacco, and others.</field_page_description>
  <field_feature_card_description>FDA extends its regulatory authority over tobacco products.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Robert Croyle discusses the Food and Drug Administration’s release of a rule that extends its regulatory authority over tobacco products to include cigars, e-cigarettes, hookah (waterpipe) tobacco.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-10</field_date_posted>
  <field_date_reviewed>2016-05-09</field_date_reviewed>
  <field_pretty_url>fda-rule-tobacco</field_pretty_url>
  <para_id>1048172</para_id>
  <related_resource_ids>6598426</related_resource_ids>
  <related_resource_ids>6598428</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>1048366</term_id>
  <id>1048367</id>
  <title>Adrenocortical Carcinoma Research</title>
  <langcode>en</langcode>
  <field_short_title>Adrenocortical Carcinoma Research</field_short_title>
  <field_page_description>Find research articles on adrenocortical carcinoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-12</field_date_posted>
  <field_date_reviewed>2016-05-12</field_date_reviewed>
  <para_id>1048367</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1051624</id>
  <title>Colorectal Cancer Survival Linked to Primary Tumor Location</title>
  <langcode>en</langcode>
  <field_short_title>Colorectal Cancer Survival Linked to Primary Tumor Location</field_short_title>
  <field_page_description> In patients with metastatic colorectal cancer, the location in the colon where the tumor originated appears to strongly influence how long patients live, according to a new study.</field_page_description>
  <field_feature_card_description>Patients whose tumors originated in left colon lived longer after treatment.</field_feature_card_description>
  <field_list_description>A blog post on a study showing that in patients with metastatic colorectal cancer, the location in the colon where the tumor originated appears to strongly influence how long patients live.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-27</field_date_posted>
  <field_date_reviewed>2016-05-27</field_date_reviewed>
  <field_pretty_url>colorectal-survival-location</field_pretty_url>
  <para_id>1051624</para_id>
  <related_resource_id>6612044</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1051984</id>
  <title>Two New Therapies Approved by FDA for Advanced Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Two New Therapies Approved for Advanced Kidney Cancer</field_short_title>
  <field_page_description>An NCI’s Cancer Currents blog on the FDA’s recent approval of cabozantinib (Cometriq®) and lenvatinib (Lenvima®) for the treatment of patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies. </field_page_description>
  <field_feature_card_description>Both approvals are for patients whose cancers have progressed after prior treatment with drugs that block tumor blood vessel growth. </field_feature_card_description>
  <field_list_description>The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-03</field_date_posted>
  <field_date_reviewed>2016-06-03</field_date_reviewed>
  <field_pretty_url>fda-cabozantinib-lenvatinib-kidney</field_pretty_url>
  <para_id>1051984</para_id>
  <related_resource_id>6598553</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1052062</id>
  <title>NCI and the Chinese National Cancer Center pursue new collaborations in cancer research</title>
  <langcode>en</langcode>
  <field_short_title>NCI and the Chinese National Cancer Center pursue new collaborations in cancer research</field_short_title>
  <field_page_description>CGH Director, Dr. Ted Trimble, and East Asia Program Director, Dr. Ann Chao, traveled to Beijing with Mr. Matthew Brown from the Department of Health and Human Services Office of Global Affairs to attend the Joint Meeting of the NCC and the U.S. NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-06</field_date_posted>
  <field_date_reviewed>2016-06-06</field_date_reviewed>
  <field_pretty_url>ncc_collaboration</field_pretty_url>
  <para_id>1052062</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1052813</id>
  <title>The Genomic Data Commons Expands with New Data Sharing Agreement</title>
  <langcode>en</langcode>
  <field_short_title>GDC grows with new data</field_short_title>
  <field_page_description>The Genomic Data Commons (GDC) will gain data from 18,000 patients through an agreement signed today with Foundation Medicine, Inc.</field_page_description>
  <field_feature_card_description>The GDC will gain data from 18,000 patients through an agreement signed today with Foundation Medicine, Inc.</field_feature_card_description>
  <field_list_description>Foundation Medicine, Inc., a molecular profiling company, will contribute data from 18,000 patients in the FoundationOne database to the Genomic Data Commons (GDC).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-29</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <field_pretty_url>genomic-data-commons-foundation-medicine</field_pretty_url>
  <para_id>1052813</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052954</id>
  <title>The Moonshot Blue Ribbon Panel: Moving Toward a Final Report</title>
  <langcode>en</langcode>
  <field_short_title>Moonshot Blue Ribbon Panel Moving Toward Final Report</field_short_title>
  <field_page_description>An NCI Cancer Currents blog from acting NCI Director Dr. Doug Lowy providing an update on the activities of the National Cancer Moonshot Initiative’s Blue Ribbon Panel and its work to develop a final report.</field_page_description>
  <field_feature_card_description>The panel's working groups are reviewing ideas and will present final recommendations in August.</field_feature_card_description>
  <field_list_description>An update on the activities of the National Cancer Moonshot Initiative’s Blue Ribbon Panel and its work to develop a final report for research ideas to be pursued under this initiative.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-23</field_date_posted>
  <field_date_reviewed>2016-06-23</field_date_reviewed>
  <field_pretty_url>moonshot-blue-ribbon-update</field_pretty_url>
  <para_id>1052954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1054541</id>
  <title>Mouse Study Illuminates the Spread of Breast Cancer to Bone</title>
  <langcode>en</langcode>
  <field_short_title>Mouse Study Illuminates the Spread of Breast Cancer to Bone</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about research into the mechanisms that allow breast cancer cells to invade bone and remain there for years before emerging to cause cancer.</field_page_description>
  <field_feature_card_description>Study provides clues on how cancer cells move in and out of bone.</field_feature_card_description>
  <field_list_description>Researchers have identified proteins that may regulate the movement of breast cancer cells into and out of bone marrow.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-07</field_date_posted>
  <field_date_reviewed>2016-07-06</field_date_reviewed>
  <field_pretty_url>breast-cancer-bone-metastasis</field_pretty_url>
  <para_id>1054541</para_id>
  <related_resource_id>6624967</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1059229</id>
  <title>Adolescents Who Wouldn’t Have Smoked May Be Drawn to E-Cigarettes</title>
  <langcode>en</langcode>
  <field_short_title>Adolescents Who Wouldn’t Have Smoked May Be Drawn to E-Cigarettes</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on a recent study that suggest adolescents are not just using e-cigarettes as a substitute for conventional cigarettes but that e-cigarettes are attracting new users to tobacco products.</field_page_description>
  <field_feature_card_description>E-cigarettes may be attracting adolescents who wouldn't have smoked to conventional tobacco products.</field_feature_card_description>
  <field_list_description>The findings from a recent study suggest that adolescents are not just using e-cigarettes as a substitute for conventional cigarettes but that e-cigarettes are attracting new users to tobacco products.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-11</field_date_posted>
  <field_date_reviewed>2016-08-10</field_date_reviewed>
  <field_pretty_url>adolescents-e-cigarettes</field_pretty_url>
  <para_id>1059229</para_id>
  <related_resource_id>6598419</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1060803</id>
  <title>TCGA Data Leveraged for Developing FDA-Designated Breakthrough Therapy</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Data Inform LOXO-101 Drug Development</field_short_title>
  <field_page_description>Pharmaceutical company Loxo Oncology used TCGA data in research that led them to develop FDA-designated breakthrough therapy LOXO-101, a targeted therapy. </field_page_description>
  <field_list_description>Pharmaceutical company Loxo Oncology used TCGA data in research that led them to develop FDA-designated breakthrough therapy LOXO-101, a promising new targeted therapy for treating cancers with TRK fusions. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-06</field_date_posted>
  <field_date_reviewed>2016-08-24</field_date_reviewed>
  <field_pretty_url>tcga-loxo-101-targeted-therapy-development</field_pretty_url>
  <para_id>1060803</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061588</id>
  <title>Blue Ribbon Panel Report: The Power of the Cancer Community Coming Together</title>
  <langcode>en</langcode>
  <field_short_title>Blue Ribbon Panel Report: The Power of Coming Together</field_short_title>
  <field_page_description>An NCI Cancer Currents blog by the NCI acting director thanking the cancer community for contributing to the Cancer Moonshot Blue Ribbon Panel report, which was presented to the National Cancer Advisory Board on September 7.</field_page_description>
  <field_feature_card_description>The NCI acting director thanks the cancer community for contributing to the Cancer Moonshot Blue Ribbon Panel report.</field_feature_card_description>
  <field_list_description>NCI Acting Director Dr. Douglas R. Lowy, M.D., thanks the cancer community for contributing to the Cancer Moonshot Blue Ribbon Panel report, which was presented to the National Cancer Advisory Board on September 7.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-09</field_date_posted>
  <field_date_reviewed>2016-09-09</field_date_reviewed>
  <field_pretty_url>brp-report-ncab</field_pretty_url>
  <para_id>1061588</para_id>
  <related_resource_id>6611678</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061698</id>
  <title>The Impact and Future of the Childhood Cancer Survivor Study: An Interview with Greg Armstrong, M.D.</title>
  <langcode>en</langcode>
  <field_short_title>Impact and Future of the Childhood Cancer Survivor Study</field_short_title>
  <field_page_description>Dr. Greg Armstrong of the Childhood Cancer Survivor Study discusses this long-running study and its future.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-14</field_date_posted>
  <field_date_reviewed>2016-09-13</field_date_reviewed>
  <field_pretty_url>childhood-survivor-study</field_pretty_url>
  <para_id>1061698</para_id>
  <related_resource_ids>6598464</related_resource_ids>
  <related_resource_ids>6598465</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1061725</term_id>
  <id>1061727</id>
  <title>RAS Screens and Assays at FNLCR</title>
  <langcode>en</langcode>
  <field_short_title>RAS Screens &amp; Assays</field_short_title>
  <field_page_description>A primary goal of the RAS Initiative is to develop assays for RAS activity, localization, and signaling and adapt those assays so they can be used for finding new drug candidates. Explore the work leading to highly validated screening protocols.</field_page_description>
  <field_feature_card_description>Learn about the groups working to both develop assays for RAS activity, localization, and signaling and then adapt those assays to be used for finding new drug candidates.</field_feature_card_description>
  <field_list_description>A primary goal of the RAS Initiative at the Frederick National Laboratory for Cancer Research (FNLCR) is to develop assays for RAS activity, localization, and signaling and adapt those assays so they can be used for finding new drug candidates.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-14</field_date_posted>
  <field_date_reviewed>2016-09-14</field_date_reviewed>
  <para_id>1061727</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1062505</id>
  <title>Chromosomal Instability Score May Predict Response to Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Novel Cancer Biomarker May Predict Prognosis, Treatment Response</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a study of a new type of cancer biomarker that measures the extent of chromosomal instability as a way to potentially predict patient prognosis and help guide cancer treatment choices.</field_page_description>
  <field_feature_card_description>Approach that measures extent of chromosomal instability may provide insight into tumor behavior.</field_feature_card_description>
  <field_list_description>A new study suggests that a chromosomal instability score may help guide treatment choices for patients with cancer.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-23</field_date_posted>
  <field_date_reviewed>2016-09-23</field_date_reviewed>
  <field_pretty_url>chromosomal-instability</field_pretty_url>
  <para_id>1062505</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938231</term_id>
  <id>953354</id>
  <title>Treatment Prevents Chemotherapy Side Effects for Children with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Treatment Prevents Chemotherapy Side Effects for Children with Cancer</field_short_title>
  <field_page_description>Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children. </field_page_description>
  <field_feature_card_description>Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children. </field_feature_card_description>
  <field_list_description>Final results from a phase III randomized clinical trial show that addition of aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in pediatric patients. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-13</field_date_posted>
  <field_date_reviewed>2015-05-13</field_date_reviewed>
  <field_pretty_url>aprepitant-side-effects</field_pretty_url>
  <para_id>953354</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1090852</term_id>
  <id>956477</id>
  <title>NCI and the Precision Medicine Initiative&amp;reg;</title>
  <langcode>en</langcode>
  <field_short_title>NCI and the Precision Medicine Initiative&amp;reg;</field_short_title>
  <field_page_description>NCI's activities related to precision medicine focuses on new and expanded precision medicine clinical trials; mechanisms to overcome drug resistance to cancer treatments; and developing a shared digital repository of precision medicine trials data.</field_page_description>
  <field_feature_card_description>To improve patient outcomes, NCI is accelerating research on the molecular abnormalities that drive cancer.</field_feature_card_description>
  <field_list_description>Under this initiative, NCI is focusing on four broad areas: new and expanded precision medicine clinical trials; overcoming drug resistance to cancer treatments; developing new laboratory models for cancer research; and building and sharing a digital repository of data resulting from NCI-sponsored precision medicine clinical trials, all with the aim of bringing precision medicine into everyday clinical practice.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-19</field_date_posted>
  <field_date_reviewed>2015-05-19</field_date_reviewed>
  <para_id>956477</para_id>
  <related_resource_ids>6648376</related_resource_ids>
  <related_resource_ids>6648382</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>963824</id>
  <title>Nanotechnology for Treating Cancer: Pitfalls and Bridges on the Path to Nanomedicines</title>
  <langcode>en</langcode>
  <field_short_title>Nanotechnology for Treating Cancer: Pitfalls and Bridges on the Path to Nanomedicines</field_short_title>
  <field_page_description>Despite their promise, only a few nano-formulated drugs are used in humans. The NCI Nanotechnology Characterization Lab helps companies and academic investigators maximize their chance of successful clinical use.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-08</field_date_posted>
  <field_date_reviewed>2015-06-08</field_date_reviewed>
  <field_pretty_url>nanomedicines</field_pretty_url>
  <para_id>963824</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>966540</id>
  <title>TAS-102 Improves Overall Survival in Patients with Metastatic Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>TAS-102 for Metastatic Colorectal Cancer</field_short_title>
  <field_page_description>A summary of results from an international phase III trial that compared TAS-102 with placebo in patients with metastatic colorectal cancer whose disease progressed following prior treatment.</field_page_description>
  <field_feature_card_description>The drug extended the lives of patients whose disease had progressed following standard therapy. </field_feature_card_description>
  <field_list_description>In an international randomized phase III trial, the investigational drug TAS-102 extended the lives of patients with metastatic colorectal cancer whose disease had progressed following standard therapies. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-12</field_date_posted>
  <field_date_reviewed>2015-06-12</field_date_reviewed>
  <field_pretty_url>TAS-102-overall-survival</field_pretty_url>
  <para_id>966540</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>768744</term_id>
  <id>966689</id>
  <title>Webinar Summary: A Conversation with NCI Acting Director, Dr. Douglas R Lowy</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation with NCI Acting Director, Dr. Douglas R. Lowy</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-15</field_date_posted>
  <field_date_reviewed>2015-06-15</field_date_reviewed>
  <field_pretty_url>lowy-precision-medicine-webinar</field_pretty_url>
  <para_id>966689</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969898</term_id>
  <id>969899</id>
  <title>Extramural Funding</title>
  <langcode>en</langcode>
  <field_short_title>Extramural Funding</field_short_title>
  <field_page_description>Find details about obligations  for the NCI extramural research program, including grants and contracts.</field_page_description>
  <field_feature_card_description>Find details about obligations  for grants and contracts this fiscal year.</field_feature_card_description>
  <field_list_description>See the dollar amount and percent of NCI budget for grants and contracts.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969899</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969907</term_id>
  <id>969908</id>
  <title>Special Sources of Funds</title>
  <langcode>en</langcode>
  <field_short_title>Special Sources of Funds</field_short_title>
  <field_page_description>Find details about Cooperative Research and Development Agreements (CRADAs) and other special funding sources, including the Stamp Out Breast Cancer Act. </field_page_description>
  <field_feature_card_description>Find details about Cooperative Research and Development Agreements (CRADAs) and other special funding sources. </field_feature_card_description>
  <field_list_description>Find budget information for Cooperative Research and Development Agreements (CRADAs), royalty income, and the Stamp Out Breast Cancer Act funding.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969908</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938231</term_id>
  <id>971650</id>
  <title>Childhood Cancer Genomics Gaps and Opportunities: Identification of Research Priorities Workshop Summary</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancer Genomics Gaps and Opportunities - Workshop Summary</field_short_title>
  <field_page_description>NCI convened a workshop of representative research teams that have been leaders in defining the genomic landscape of childhood cancers to discuss the influence of genomic discoveries on the future of childhood cancer research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-17</field_date_posted>
  <field_date_reviewed>2015-07-01</field_date_reviewed>
  <field_pretty_url>childhood-genomics-workshop-summary</field_pretty_url>
  <para_id>971650</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974318</term_id>
  <id>974319</id>
  <title>NCI Historical Trends</title>
  <langcode>en</langcode>
  <field_short_title>Historical Trends</field_short_title>
  <field_page_description>Find information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.</field_page_description>
  <field_feature_card_description>Information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.</field_feature_card_description>
  <field_list_description>Since its establishment in 1937, the National Cancer Institute has served as a scientific cornerstone of the National Institutes of Health. Find information about the history of NCI appropriations and the Professional Judgment (Bypass) Budget, as well as data on funding trends and staffing levels.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974319</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>81826</id>
  <title>Drugs Approved for Bone Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Bone Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for bone cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-06-09</field_date_posted>
  <field_date_reviewed>2011-05-23</field_date_reviewed>
  <field_pretty_url>bone</field_pretty_url>
  <para_id>81826</para_id>
  <related_resource_ids>6996771</related_resource_ids>
  <related_resource_ids>6996777</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>84773</id>
  <title>Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Tool Weighs Benefits, Risks of Raloxifene or Tamoxifen to Prevent Breast Cancer</field_short_title>
  <field_page_description>Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk. </field_page_description>
  <field_feature_card_description>Researchers have developed a benefit-risk index to help guide decisions on whether postmenopausal women at increased risk of developing breast cancer should take raloxifene or tamoxifen to reduce that risk. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-14</field_date_posted>
  <field_date_reviewed>2011-06-14</field_date_reviewed>
  <field_pretty_url>benefit-risk-tool</field_pretty_url>
  <para_id>84773</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>84829</id>
  <title>Drugs Approved for Malignant Mesothelioma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Malignant Mesothelioma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for malignant mesothelioma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-06-17</field_date_posted>
  <field_date_reviewed>2011-06-17</field_date_reviewed>
  <field_pretty_url>mesothelioma</field_pretty_url>
  <para_id>84829</para_id>
  <related_resource_ids>6424035</related_resource_ids>
  <related_resource_ids>6424036</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>88731</id>
  <title>Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Multiple Myeloma </field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for multiple myeloma and other plasma cell neoplasms. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-26</field_date_posted>
  <field_date_reviewed>2011-07-07</field_date_reviewed>
  <field_pretty_url>multiple-myeloma</field_pretty_url>
  <para_id>88731</para_id>
  <related_resource_ids>6994508</related_resource_ids>
  <related_resource_ids>6994528</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938242</term_id>
  <id>312165</id>
  <title>Combining Angiogenesis-Targeted Treatments for Liver Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Combining Angiogenesis-Targeted Treatments for Liver Cancer</field_short_title>
  <field_page_description>In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for a liver transplant or other local therapies will be given oral sorafenib at the standard approved dose and intravenous TRC105. </field_page_description>
  <field_feature_card_description>In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for a liver transplant or other local therapies will be given oral sorafenib at the standard approved dose and intravenous TRC105. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-05-29</field_date_posted>
  <field_date_reviewed>2012-05-30</field_date_reviewed>
  <field_pretty_url>trc105-sorafenib</field_pretty_url>
  <para_id>312165</para_id>
  <related_resource_ids>6494686</related_resource_ids>
  <related_resource_ids>6494687</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>315512</id>
  <title>Sigmoidoscopy Proves to Be Effective Screening Tool for Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Sigmoidoscopy Proves to Be Effective Screening Tool for Colorectal Cancer</field_short_title>
  <field_page_description>In a large randomized trial involving healthy men and women aged 55 to 74, sigmoidoscopy substantially reduced the incidence of and mortality from colorectal cancer.</field_page_description>
  <field_feature_card_description>In a large randomized trial involving healthy men and women aged 55 to 74, sigmoidoscopy substantially reduced the incidence of and mortality from colorectal cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-07</field_date_posted>
  <field_date_reviewed>2012-06-07</field_date_reviewed>
  <field_pretty_url>screening-sigmoidoscopy</field_pretty_url>
  <para_id>315512</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>317040</id>
  <title>Study Shows Drug Is Effective for Cancer Patients with Peripheral Neuropathy</title>
  <langcode>en</langcode>
  <field_short_title>Study Shows Drug Is Effective for Cancer Patients with Peripheral Neuropathy</field_short_title>
  <field_page_description>Results of a phase III trial (CALGB-170601) show that duloxetine (Cymbalta) effectively treats painful peripheral neuropathy caused by certain types of chemotherapy.</field_page_description>
  <field_feature_card_description>Results of a phase III trial (CALGB-170601) show that duloxetine (Cymbalta) effectively treats painful peripheral neuropathy caused by certain types of chemotherapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-13</field_date_posted>
  <field_date_reviewed>2012-06-13</field_date_reviewed>
  <field_pretty_url>neuropathy</field_pretty_url>
  <para_id>317040</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>903752</term_id>
  <id>323202</id>
  <title>Tumor Markers</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Markers</field_short_title>
  <field_page_description>A fact sheet that defines tumor markers and describes how they can be used to aid diagnosis and treatment.</field_page_description>
  <field_feature_card_description>Learn about  tumor markers and their importance to cancer diagnosis and treatment. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-09</field_date_posted>
  <field_date_reviewed>2015-11-04</field_date_reviewed>
  <field_pretty_url>tumor-markers-fact-sheet</field_pretty_url>
  <para_id>323202</para_id>
  <related_resource_ids>6932771</related_resource_ids>
  <related_resource_ids>6932772</related_resource_ids>
  <related_resource_ids>6932779</related_resource_ids>
  <related_resource_ids>6932780</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396053</term_id>
  <id>396065</id>
  <title>Randomization and Bias in Cancer Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Randomization</field_short_title>
  <field_page_description>Information about randomization and bias in cancer clinical trials. </field_page_description>
  <field_feature_card_description>Information about randomization and bias in cancer clinical trials. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>396065</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>922401</id>
  <title>Results of the National CT Colonography Trial: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Results of the National CT Colonography Trial: Questions and Answers</field_short_title>
  <field_page_description>Learn the results of the National Computerized Tomographic Colonography (CTC) clinical trial, which evaluated how well CTC identifies participants with at least one significantly large polyp using colonoscopy as the gold (or reference) standard.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2008-09-17</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>virtual-colonoscopy-results-qa</field_pretty_url>
  <para_id>922401</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>923365</term_id>
  <id>923366</id>
  <title>Cancer Statistics</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Statistics</field_short_title>
  <field_page_description>Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses.</field_page_description>
  <field_feature_card_description>Basic information about cancer statistics in the U.S. and how they are used.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-04-02</field_date_reviewed>
  <para_id>923366</para_id>
  <related_resource_ids>7132457</related_resource_ids>
  <related_resource_ids>7132458</related_resource_ids>
  <related_resource_ids>7132464</related_resource_ids>
  <related_resource_ids>7132465</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929807</term_id>
  <id>929808</id>
  <title>About This Website</title>
  <langcode>en</langcode>
  <field_short_title>About This Website</field_short_title>
  <field_page_description>The National Cancer Institute (NCI) website serves to disseminate authoritative, evidence-based, and up-to-date information about cancer and NCI-supported cancer research. Much of the information is available for content reuse and syndication.</field_page_description>
  <field_feature_card_description>This website serves to disseminate authoritative, evidence-based, and up-to-date information about cancer and NCI-supported cancer research.</field_feature_card_description>
  <field_list_description>NCI is the U.S. government's principal agency for cancer research. This website serves to disseminate authoritative, evidence-based, and up-to-date information about cancer and NCI-supported cancer research. Much of the information is available for content reuse and syndication.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-10</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <para_id>929808</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>936434</id>
  <title>Immune-Based Treatment Shows Promise against Metastatic Cervical Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy for Cervical Cancer</field_short_title>
  <field_page_description>In an early phase NCI clinical trial, two patients with metastatic cervical cancer had a complete disappearance of their tumors after receiving treatment with a form of immunotherapy called adoptive cell transfer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-16</field_date_posted>
  <field_date_reviewed>2015-04-16</field_date_reviewed>
  <field_pretty_url>immunotherapy-cervical</field_pretty_url>
  <para_id>936434</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936435</id>
  <title>Grantee Spotlight: Elisa Rodriguez, Ph.D., M.S. - Community-based Education and Outreach Can Increase Biospecimen Donations among Hispanics and African Americans </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Elisa Rodriguez, Ph.D., M.S.</field_short_title>
  <field_page_description>Dr. Elisa M. Rodriguez tests the feasibility of community-based participatory research approaches to engaging Hispanics, African Americans, and the medically underserved in the Buffalo, NY area in biospecimen donation for cancer research.</field_page_description>
  <field_feature_card_description>Dr. Rodriguez tests approaches to engaging the underserved in biospecimen donation.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-25</field_date_posted>
  <field_date_reviewed>2014-06-25</field_date_reviewed>
  <field_pretty_url>rodriguez-spotlight-blog</field_pretty_url>
  <para_id>936435</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>938053</id>
  <title>Program Spotlight: National Outreach Network's Community Health Educators Provide Much-Needed Support to Cancer Survivors from Racially/Ethnically Diverse Communities</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: National Outreach Network's Community Health Educators </field_short_title>
  <field_page_description>National Outreach Network of Community Health Educators located at Community Network Program Centers, Partnerships to Advance Cancer Health Equity, and NCI-designated cancer centers help patients and their families receive survivorship support.</field_page_description>
  <field_feature_card_description>National Outreach Network CHEs help patients &amp; families receive survivorship support.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-17</field_date_posted>
  <field_date_reviewed>2014-04-17</field_date_reviewed>
  <field_pretty_url>survivorship-spotlight</field_pretty_url>
  <para_id>938053</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>938140</id>
  <title>July Spotlight: Cancer Awareness Highlights</title>
  <langcode>en</langcode>
  <field_short_title>July Spotlight: Cancer Awareness Highlights</field_short_title>
  <field_page_description>CRCHD recognizes Sarcoma Awareness Month in July by featuring two investigators researching sarcoma as well as highlighting other cancers with low incidence rates and childhood cancers.</field_page_description>
  <field_feature_card_description>CRCHD recognizes Sarcoma Awareness Month in July.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-01</field_date_posted>
  <field_date_reviewed>2014-07-01</field_date_reviewed>
  <field_pretty_url>july2014-spotlight</field_pretty_url>
  <para_id>938140</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>938159</id>
  <title>Special Spotlight: Asian American and Pacific Islander Heritage Month </title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: Asian American and Pacific Islander Heritage Month </field_short_title>
  <field_page_description>CRCHD celebrates Asian American and Pacific Islander Heritage Month by recognizing the contributions of NIH/NCI-supported investigators and community health educators.</field_page_description>
  <field_feature_card_description>CRCHD celebrates Asian American and Pacific Islander Heritage Month.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-01</field_date_posted>
  <field_date_reviewed>2014-05-01</field_date_reviewed>
  <field_pretty_url>may2014-spotlight</field_pretty_url>
  <para_id>938159</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938223</term_id>
  <id>939893</id>
  <title>Bone Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on bone cancers, such as osteosarcoma and Ewing sarcoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939893</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940001</term_id>
  <id>940006</id>
  <title>Carcinoma of Unknown Primary—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Carcinoma of Unknown Primary</field_short_title>
  <field_page_description>Carcinoma of unknown primary (CUP) is a rare disease in which malignant cells are found in the body but the site of the primary cancer is not known. Most CUPs are adenocarcinomas, or undifferentiated tumors. Find evidence-based information on the treatment for carcinoma of unknown primary.</field_page_description>
  <field_list_description>NCI's gateway for information about Carcinoma of Unknown Primary.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>940006</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938195</term_id>
  <id>940117</id>
  <title>Esophageal Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on esophageal cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940117</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1045410</id>
  <title>Pembrolizumab Shows Promise in Patients with Rare Form of Skin Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Shows Promise against Rare Skin Cancer</field_short_title>
  <field_page_description>In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab.</field_page_description>
  <field_feature_card_description>Long-lasting tumor responses seen in small clinical trial studying Merkel cell carcinoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-19</field_date_posted>
  <field_date_reviewed>2016-04-18</field_date_reviewed>
  <field_pretty_url>pembrolizumab-merkel-cell</field_pretty_url>
  <para_id>1045410</para_id>
  <related_resource_ids>6890255</related_resource_ids>
  <related_resource_ids>6890260</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1047416</term_id>
  <id>1047417</id>
  <title>Diversity Career Development Program</title>
  <langcode>en</langcode>
  <field_short_title>Diversity Career Development Program</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-19</field_date_posted>
  <field_date_reviewed>2016-04-27</field_date_reviewed>
  <para_id>1047417</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1048207</id>
  <title>Bringing global cancer leaders together at the 4th Annual Symposium on Global Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Bringing global cancer leaders together at the 4th Annual Symposium on Global Cancer Research</field_short_title>
  <field_page_description>The Annual Symposium on Global Cancer Research held in April 2016 was developed with a special focus on innovative and low-cost technologies in global cancer control, and brought inspiring keynote speakers such as John Seffrin, Former CEO of the American Cancer Society, and Tom Bollyky, Senior Fellow for Global Health </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-09</field_date_posted>
  <field_date_reviewed>2016-05-09</field_date_reviewed>
  <field_pretty_url>symposium</field_pretty_url>
  <para_id>1048207</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1048482</id>
  <title>New Treatment Target Identified for Diffuse Large B-Cell Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Study Identifies Potential Lymphoma Treatment Target</field_short_title>
  <field_page_description>NCI researchers have identified new therapeutic targets for diffuse large B-cell lymphoma. Drugs that hit these targets are under clinical development and the researchers hope to begin testing them in clinical trials of patients with DLBCL.</field_page_description>
  <field_feature_card_description>NCI researchers hope to initiate human trials of possible new therapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-13</field_date_posted>
  <field_date_reviewed>2016-05-13</field_date_reviewed>
  <field_pretty_url>dlbcl-smac-mimetics</field_pretty_url>
  <para_id>1048482</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1049998</id>
  <title>Improving Cancer Control in Rural Communities: An Interview with Dr. Robert Croyle</title>
  <langcode>en</langcode>
  <field_short_title>Improving Cancer Control in Rural Communities</field_short_title>
  <field_page_description>NCI’s Dr. Robert Croyle discusses some of the issues related to cancer control faced by rural communities and how NCI is approaching this important problem.</field_page_description>
  <field_feature_card_description>Fewer physicians, distant health care facilities, high rates of tobacco use are among the factors affecting people in rural areas.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-18</field_date_posted>
  <field_date_reviewed>2016-05-18</field_date_reviewed>
  <field_pretty_url>cancer-control-rural</field_pretty_url>
  <para_id>1049998</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1050940</id>
  <title>Charting a Course toward Precision Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Charting a Course toward Precision Cancer Prevention</field_short_title>
  <field_page_description>Cancer researchers are increasingly exploring how cancer risk is influenced by genetic predisposition to cancer and the effects of environmental exposures, and what this means for cancer prevention.</field_page_description>
  <field_feature_card_description>Researchers are exploring ways to develop tailored approaches to reducing cancer risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-26</field_date_posted>
  <field_date_reviewed>2016-05-23</field_date_reviewed>
  <field_pretty_url>precision-prevention-chanock</field_pretty_url>
  <para_id>1050940</para_id>
  <related_resource_ids>6611746</related_resource_ids>
  <related_resource_ids>6611747</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1051834</id>
  <title>FDA Approves First Immunotherapy for Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves First Immunotherapy for Lymphoma</field_short_title>
  <field_page_description>The FDA has approved nivolumab (Opdivo®) for the treatment of patients with classical Hodgkin lymphoma whose disease has relapsed or worsened after receiving an autologous hematopoietic stem cell transplantation followed by brentuximab vedotin (Adcetris®)</field_page_description>
  <field_feature_card_description>First checkpoint inhibitor approved for any type of lymphoma.</field_feature_card_description>
  <field_list_description>A blog post on the FDA approval of the immunotherapy drug nivolumab for the treatment of some patients with Hodgkin lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-31</field_date_posted>
  <field_date_reviewed>2016-05-31</field_date_reviewed>
  <field_pretty_url>fda-nivolumab-lymphoma</field_pretty_url>
  <para_id>1051834</para_id>
  <related_resource_id>6598549</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052076</id>
  <title>FDA Approves New Immunotherapy Drug for Bladder Cancer </title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Atezolizumab for Bladder Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on the FDA approval of atezolizumab (Tecentriq®) for the treatment of patients with the most common type of bladder cancer.</field_page_description>
  <field_feature_card_description>The checkpoint inhibitor is the first new treatment approved for bladder cancer in two decades. </field_feature_card_description>
  <field_list_description>The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-07</field_date_posted>
  <field_date_reviewed>2016-06-06</field_date_reviewed>
  <field_pretty_url>fda-atezolizumab-bladder</field_pretty_url>
  <para_id>1052076</para_id>
  <related_resource_ids>6598558</related_resource_ids>
  <related_resource_ids>6598559</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052101</id>
  <title>Trials Produce Practice-Changing Results for Brain Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Trials Produce Practice-Changing Results for Brain Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about two clinical trials that showed treatment with temozolomide plus radiation increased overall and progression-free survival.</field_page_description>
  <field_feature_card_description>For two types of brain cancer, adding temozolomide to radiation therapy increased survival.</field_feature_card_description>
  <field_list_description>Results from two clinical trials show that treating patients with the chemotherapy drug temozolomide in addition to radiation therapy increased overall and progression-free survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-09</field_date_posted>
  <field_date_reviewed>2016-06-07</field_date_reviewed>
  <field_pretty_url>asco-temozolomide-brain</field_pretty_url>
  <para_id>1052101</para_id>
  <related_resource_id>6611959</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>988383</term_id>
  <id>1052650</id>
  <title>Division of Cancer Biology Research Portfolio</title>
  <langcode>en</langcode>
  <field_short_title>DCB Research Portfolio</field_short_title>
  <field_page_description>Explore the broad range of investigator-initiated research and programs funded by the Division of Cancer Biology (DCB) to advance existing and emerging research areas in cancer biology.</field_page_description>
  <field_feature_card_description>Explore the broad range of investigator-initiated research and programs funded by DCB to advance existing and emerging research areas in cancer biology.</field_feature_card_description>
  <field_list_description>Explore the broad range of investigator-initiated research and programs funded by the Division of Cancer Biology to advance existing and emerging research areas in cancer biology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-06-16</field_date_reviewed>
  <para_id>1052650</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052682</id>
  <title>Early-Stage Cancer Trials Support Promise of Precision Medicine, Immunotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Early-Stage Trials ASCO 2016</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on promising findings from several early-stage clinical trials featured at the 2016 American Society of Clinical Oncology annual meeting in Chicago.</field_page_description>
  <field_feature_card_description>Encouraging results from early-stage trials of targeted and immune-based therapies. </field_feature_card_description>
  <field_list_description>Encouraging findings from several early-stage clinical trials featured at the 2016 American Society of Clinical Oncology annual meeting support the promise of precision medicine and immunotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-17</field_date_posted>
  <field_date_reviewed>2016-06-17</field_date_reviewed>
  <field_pretty_url>asco-2016-early-trials</field_pretty_url>
  <para_id>1052682</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1053904</id>
  <title>Setting the Stage for the Next Decade of Tobacco Control Research</title>
  <langcode>en</langcode>
  <field_short_title>Setting the Stage for the Next Decade of Tobacco Control Research</field_short_title>
  <field_page_description>An NCI Cancer Currents blog by Dr. Robert Croyle on a new report that lays out recommended priorities to help shape NCI’s future tobacco control research portfolio.</field_page_description>
  <field_feature_card_description>NCI working group highlights key research areas for next decade.</field_feature_card_description>
  <field_list_description>A new report from an NCI working group lays out recommended priorities to help shape the institute’s future tobacco control research portfolio.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-05</field_date_posted>
  <field_date_reviewed>2016-07-01</field_date_reviewed>
  <field_pretty_url>tobacco-control-plan</field_pretty_url>
  <para_id>1053904</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1056234</term_id>
  <id>1056236</id>
  <title>National Cancer Reporting Fellowships</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Reporting Fellowships</field_short_title>
  <field_page_description>A four-day seminar to help U.S.-based journalists increase their understanding of scientific research and ability to report accurately on complex scientific findings.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-27</field_date_posted>
  <field_date_reviewed>2016-09-27</field_date_reviewed>
  <para_id>1056236</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061095</id>
  <title>New on NCI’s Websites for August 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for August 2016</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-29</field_date_posted>
  <field_date_reviewed>2016-08-29</field_date_reviewed>
  <field_pretty_url>new-online-august-2016</field_pretty_url>
  <para_id>1061095</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061536</id>
  <title>Pancreatic Cancer Cells May Obtain Nutrients from Neighboring Cells</title>
  <langcode>en</langcode>
  <field_short_title>Pancreatic Cancer Cells Rely on Neighbors for Nutrients</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a study which showed that pancreatic cancer cells instruct healthy cells around them to provide nutrients they need to survive and grow.</field_page_description>
  <field_feature_card_description>Study identifies potential key energy source for tumor survival, growth.</field_feature_card_description>
  <field_list_description>Pancreatic cancer cells instruct healthy cells around them to provide nutrients they need to survive and grow, a new study suggests.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-12</field_date_posted>
  <field_date_reviewed>2016-09-08</field_date_reviewed>
  <field_pretty_url>pancreatic-metabolism</field_pretty_url>
  <para_id>1061536</para_id>
  <related_resource_id>6583657</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1063033</id>
  <title>TARGET Initiative Fueling Progress Against Childhood Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Initiative Fueling Progress Against Childhood Leukemia</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about how TARGET, an NCI-funded initiative, has led to the launch of clinical trials of targeted therapies for childhood leukemia.</field_page_description>
  <field_feature_card_description>TARGET initiative leads to clinical trials of targeted therapies.</field_feature_card_description>
  <field_list_description>Research from TARGET, an NCI-funded program supporting genomic analyses of childhood cancers, has led to the launch of several clinical trials of targeted therapies to treat children with acute lymphoblastic leukemia.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-30</field_date_posted>
  <field_date_reviewed>2016-09-30</field_date_reviewed>
  <field_pretty_url>target-leukemia</field_pretty_url>
  <para_id>1063033</para_id>
  <related_resource_id>6598441</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1063058</id>
  <title>Educating Patients about Genetic Test Results: An Interview with Carol Weil about the COMET Study</title>
  <langcode>en</langcode>
  <field_short_title>Educating Patients about Genetic Test Results</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about the COMET study, which will examine the impact of counseling patients about the results of their tumor profiling results.</field_page_description>
  <field_feature_card_description>New study will explore how to help patients understand their tumor profile results, with less stress. </field_feature_card_description>
  <field_list_description>The recently launched COMET study will examine whether educating patients with cancer about genetic testing will increase their knowledge and reduce their stress levels after receiving genomic testing results.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-14</field_date_posted>
  <field_date_reviewed>2016-09-30</field_date_reviewed>
  <field_pretty_url>comet-study</field_pretty_url>
  <para_id>1063058</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1063059</id>
  <title>Supporting the development of affordable technologies for cancer detection, diagnosis, and treatment in LMICs</title>
  <langcode>en</langcode>
  <field_short_title>Supporting the development of affordable technologies for cancer detection</field_short_title>
  <field_page_description>Supporting the development of affordable technologies for cancer detection</field_page_description>
  <field_feature_card_description>Supporting the development of affordable technologies for cancer detection, diagnosis, and treatment in LMICs.</field_feature_card_description>
  <field_list_description>Supporting the development of affordable technologies for cancer detection, diagnosis, and treatment in LMICs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-30</field_date_posted>
  <field_date_reviewed>2016-09-30</field_date_reviewed>
  <para_id>1063059</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1063214</id>
  <title>Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Avelumab Shrinks Merkel Cell Tumors</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about results from a phase II clinical trial showing durable tumor responses to the immunotherapy drug avelumab in patients with metastatic Merkel cell carcinoma.</field_page_description>
  <field_feature_card_description>One-third of patients with metastatic Merkel cell carcinoma had durable tumor responses to avelumab.</field_feature_card_description>
  <field_list_description>In a phase II clinical trial, some patients with metastatic Merkel cell carcinoma whose cancer has progressed despite treatment with chemotherapy had durable tumor responses to the immunotherapy drug avelumab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-06</field_date_posted>
  <field_date_reviewed>2016-10-05</field_date_reviewed>
  <field_pretty_url>avelumab-merkel-cell</field_pretty_url>
  <para_id>1063214</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>917537</term_id>
  <id>13593</id>
  <title>VPH y el cáncer</title>
  <langcode>es</langcode>
  <field_short_title>VPH y el cáncer</field_short_title>
  <field_page_description>Hoja informativa acerca de la relación entre la infección por los virus del papiloma humano (VPH) y el cáncer. </field_page_description>
  <field_feature_card_description>Aprenda sobre la relación entre la infección por los virus del papiloma humano (VPH) y el cáncer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-02</field_date_posted>
  <field_date_reviewed>2015-02-19</field_date_reviewed>
  <field_pretty_url>hoja-informativa-vph</field_pretty_url>
  <para_id>13593</para_id>
  <related_resource_ids>7087011</related_resource_ids>
  <related_resource_ids>7087012</related_resource_ids>
  <related_resource_ids>7087032</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>913439</term_id>
  <id>919123</id>
  <title>Formulación y aprobación de medicamentos</title>
  <langcode>es</langcode>
  <field_short_title>Formulación y aprobación de medicamentos</field_short_title>
  <field_page_description>Información sobre medicamentos específicos y la formulación y aprobación de medicamentos.</field_page_description>
  <field_feature_card_description>Información para el consumidor acerca de los fármacos y las combinaciones de fármacos que se usan para prevenir y tratar el cáncer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-24</field_date_posted>
  <field_date_reviewed>2015-03-24</field_date_reviewed>
  <para_id>919123</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>939927</term_id>
  <id>1038792</id>
  <title>Anormalidad genética predice beneficio de tratamiento en pacientes con raro tumor cerebral</title>
  <langcode>es</langcode>
  <field_short_title>Anormalidad genética predice beneficio de tratamiento en pacientes con raro tumor cerebral</field_short_title>
  <field_page_description>La mediana del tiempo de supervivencia en pacientes con una forma altamente maligna de oligodendroglioma, un raro tumor cerebral, se duplicó cuando se añadió quimioterapia a la radioterapia.</field_page_description>
  <field_feature_card_description>La mediana del tiempo de supervivencia en pacientes con una forma altamente maligna de oligodendroglioma, un raro tumor cerebral, se duplicó cuando se añadió quimioterapia a la radioterapia.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-02-09</field_date_posted>
  <field_date_reviewed>2012-02-09</field_date_reviewed>
  <field_pretty_url>predice-beneficio-tratamiento</field_pretty_url>
  <para_id>1038792</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>953685</term_id>
  <id>898426</id>
  <title>Sumarios del PDQ® de información sobre el cáncer: Terapias integrales, alternativas y complementarias</title>
  <langcode>es</langcode>
  <field_short_title>Terapias integrales</field_short_title>
  <field_page_description>Información sobre las terapias integrales, alternativas y complementarias de tratamiento para pacientes con cáncer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2018-10-09</field_date_reviewed>
  <para_id>898426</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>969513</term_id>
  <id>982943</id>
  <title>Preguntas y respuestas: ¿Qué es el sobrediagnóstico del cáncer?</title>
  <langcode>es</langcode>
  <field_short_title>Preguntas y respuestas: ¿Qué es el sobrediagnóstico del cáncer?</field_short_title>
  <field_page_description>El tratamiento de cánceres que no crecerían lo suficiente como para causar problemas médicos puede hacer más daño que beneficio.</field_page_description>
  <field_feature_card_description>El tratamiento de cánceres que no crecerían lo suficiente como para causar problemas médicos puede hacer más daño que beneficio.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-08-03</field_date_posted>
  <field_date_reviewed>2015-08-03</field_date_reviewed>
  <field_pretty_url>sobrediagnostico</field_pretty_url>
  <para_id>982943</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16404</term_id>
  <id>16405</id>
  <title>Resultados</title>
  <langcode>es</langcode>
  <field_short_title>Resultados</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16405</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>940552</term_id>
  <id>1038809</id>
  <title>Efectos tardíos no justificarían añadir radioterapia a la quimioterapia para el linfoma de Hodgkin en estadio inicial</title>
  <langcode>es</langcode>
  <field_short_title>Efectos tardíos y el linfoma de Hodgkin en estadio inicial</field_short_title>
  <field_page_description>Los pacientes con linfoma de Hodgkin en estadio inicial que recibieron varios fármacos de quimioterapia como único tratamiento, tenían más probabilidad de sobrevivir 12 años después que los pacientes que recibieron tratamiento que incluía radioterapia.</field_page_description>
  <field_feature_card_description>Los pacientes con linfoma de Hodgkin en estadio inicial que recibieron varios fármacos de quimioterapia como único tratamiento, tenían más probabilidad de sobrevivir 12 años después que los pacientes que recibieron tratamiento que incluía radioterapia.</field_feature_card_description>
  <field_list_description>Los pacientes con linfoma de Hodgkin en estadio inicial que recibieron varios fármacos de quimioterapia como único tratamiento, tenían más probabilidad de sobrevivir 12 años después que los pacientes que recibieron tratamiento que incluía radioterapia, de acuerdo con los resultados de un estudio clínico de fase III.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-22</field_date_posted>
  <field_date_reviewed>2011-12-22</field_date_reviewed>
  <field_pretty_url>efectos-tardios-radioterapia</field_pretty_url>
  <para_id>1038809</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>929678</term_id>
  <id>840870</id>
  <title>Muchos adolescentes y adultos jóvenes supervivientes de cáncer tienen problemas crónicos de salud y conductas no saludables</title>
  <langcode>es</langcode>
  <field_short_title>Muchos adolescentes y adultos jóvenes supervivientes de cáncer tienen problemas crónicos de salud</field_short_title>
  <field_page_description>Un estudio de 2002 mostró que las personas que tuvieron cáncer cuando eran adolescentes y adultos jóvenes eran más propensas en la actualidad a fumar, ser obesas, padecer diferentes enfermedades crónicas, estar discapacitadas y tener una salud mental y física precaria. Los resultados subrayan la importancia de abordar </field_page_description>
  <field_feature_card_description>Artículo sobre los resultados de un estudio realizado en 2012 que subrayan la importancia de abordar las necesidades especiales e inquietudes de los adolescentes y adultos jóvenes supervivientes de cáncer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-26</field_date_posted>
  <field_date_reviewed>2014-09-05</field_date_reviewed>
  <field_pretty_url>adolescentes-adultos-jovenes-problemas-salud</field_pretty_url>
  <para_id>840870</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1091194</term_id>
  <id>697302</id>
  <title>Atlas del Genoma del Cáncer: Antecedentes </title>
  <langcode>es</langcode>
  <field_short_title>Atlas del Genoma del Cáncer: Antecedentes </field_short_title>
  <field_page_description>El Atlas del Genoma del Cáncer es una iniciativa de los Institutos Nacionales de la Salud (NIH) para crear mapas multidimensionales completos de los cambios genómicos clave en los tipos y subtipos principales de cáncer.</field_page_description>
  <field_feature_card_description>El Atlas del Genoma del Cáncer es una iniciativa de los Institutos Nacionales de la Salud (NIH) para crear mapas multidimensionales completos de los cambios genómicos clave en los tipos y subtipos principales de cáncer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-27</field_date_posted>
  <field_date_reviewed>2014-01-27</field_date_reviewed>
  <para_id>697302</para_id>
  <related_resource_ids>5249175</related_resource_ids>
  <related_resource_ids>5249176</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>63163</term_id>
  <id>697303</id>
  <title>Atlas del Genoma del Cáncer - Estudio de caso: cáncer cerebral </title>
  <langcode>es</langcode>
  <field_short_title>Atlas del Genoma del Cáncer - Estudio de caso: cáncer cerebral </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-27</field_date_posted>
  <field_date_reviewed>2014-01-27</field_date_reviewed>
  <para_id>697303</para_id>
  <related_resource_ids>5249187</related_resource_ids>
  <related_resource_ids>5249188</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>78747</id>
  <title>Starting Hormone Therapy at Menopause Increases Breast Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Starting Hormone Therapy at Menopause Increases Breast Cancer Risk</field_short_title>
  <field_page_description>According to a January 28, 2011 article in the Journal of the National Cancer Institute, women who start taking menopausal hormone therapy around the time of menopause have a higher risk of breast cancer than women who begin taking hormones a few years later.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-11</field_date_posted>
  <field_date_reviewed>2011-05-11</field_date_reviewed>
  <field_pretty_url>menopausal-ht-risk</field_pretty_url>
  <para_id>78747</para_id>
  <related_resource_id>5421363</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>79693</id>
  <title>Drugs Approved for Anal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Anal Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the FDA for use in anal cancer. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-26</field_date_posted>
  <field_date_reviewed>2011-05-20</field_date_reviewed>
  <field_pretty_url>anal</field_pretty_url>
  <para_id>79693</para_id>
  <related_resource_ids>6423450</related_resource_ids>
  <related_resource_ids>6423452</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>79721</id>
  <title>Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests</title>
  <langcode>en</langcode>
  <field_short_title>Menopausal Estrogen Therapy Benefits and Risks Vary by Age, WHI Analysis Suggests</field_short_title>
  <field_page_description>Long-term follow-up data from the Women’s Health Initiative (WHI) provide new information about the potential risks and benefits of hormone therapy to treat symptoms related to menopause, including its effect on breast cancer risk,</field_page_description>
  <field_feature_card_description>Long-term follow-up data from the Women’s Health Initiative (WHI) provide new information about the potential risks and benefits of hormone therapy to treat symptoms related to menopause, including its effect on breast cancer risk,</field_feature_card_description>
  <field_list_description>Long-term follow-up data from the Women’s Health Initiative (WHI) provide important new information about the potential risks and benefits of hormone therapy to treat symptoms or conditions related to menopause, including its effect on breast cancer risk, according to results published April 5, 2011, in the Journal of the American Medical Association.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-05-20</field_date_posted>
  <field_date_reviewed>2011-05-20</field_date_reviewed>
  <field_pretty_url>ert-benefits-risks-age</field_pretty_url>
  <para_id>79721</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>84042</id>
  <title>Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Five Years of Tamoxifen Continues to Benefit Women 15 Years after Treatment</field_short_title>
  <field_page_description>In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy. </field_page_description>
  <field_feature_card_description>In a large randomized clinical trial, women with early-stage breast cancer who received 5 years of adjuvant treatment with tamoxifen had better outcomes up to 15 years after the start of treatment than those who received 2 years of tamoxifen therapy. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-03</field_date_posted>
  <field_date_reviewed>2011-06-03</field_date_reviewed>
  <field_pretty_url>tamoxifen-15-year-benefits</field_pretty_url>
  <para_id>84042</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>89610</id>
  <title>Drugs Approved for Myeloproliferative Neoplasms</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Myeloproliferative Neoplasms</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for myeloproliferative neoplasms. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-26</field_date_posted>
  <field_date_reviewed>2011-07-12</field_date_reviewed>
  <field_pretty_url>myeloproliferative-neoplasms</field_pretty_url>
  <para_id>89610</para_id>
  <related_resource_ids>6994542</related_resource_ids>
  <related_resource_ids>6994556</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>283901</id>
  <title>Hormone Therapy for Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Hormone Therapy for Breast Cancer</field_short_title>
  <field_page_description>A fact sheet that describes types of hormone therapy, its role in preventing and treating breast cancer, and possible side effects.</field_page_description>
  <field_feature_card_description>A fact sheet that describes hormone therapy and its role in preventing and treating breast cancer.</field_feature_card_description>
  <field_list_description>A fact sheet that describes hormone therapy (including antiestrogens, LH-RH agonists, aromatase inhibitors, and SERMs) and its role in preventing and treating breast cancer. Includes information about possible side effects.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-03</field_date_posted>
  <field_date_reviewed>2017-02-14</field_date_reviewed>
  <field_pretty_url>breast-hormone-therapy-fact-sheet</field_pretty_url>
  <para_id>283901</para_id>
  <related_resource_ids>6934476</related_resource_ids>
  <related_resource_ids>6934507</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>298554</id>
  <title>Many Patients with Cancer Need Better Treatments for Pain</title>
  <langcode>en</langcode>
  <field_short_title>Many Patients with Cancer Need Better Treatments for Pain</field_short_title>
  <field_page_description>Inadequate pain treatment in patients with cancer remains a significant problem and appears to be more frequent among minorities, according to a new study published online April 16, 2012, in the Journal of Clinical Oncology.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-05-09</field_date_posted>
  <field_date_reviewed>2012-05-08</field_date_reviewed>
  <field_pretty_url>pain-management</field_pretty_url>
  <para_id>298554</para_id>
  <related_resource_id>6451433</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938161</term_id>
  <id>300494</id>
  <title>Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery</title>
  <langcode>en</langcode>
  <field_short_title>Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical Surgery</field_short_title>
  <field_page_description>Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.</field_page_description>
  <field_feature_card_description>Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-05-14</field_date_posted>
  <field_date_reviewed>2012-05-14</field_date_reviewed>
  <field_pretty_url>chemoradiation</field_pretty_url>
  <para_id>300494</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>317031</id>
  <title>For Some Breast Cancers, New Drug May Be Treatment Option</title>
  <langcode>en</langcode>
  <field_short_title>For Some Breast Cancers, New Drug May Be Treatment Option</field_short_title>
  <field_page_description>Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option.</field_page_description>
  <field_feature_card_description>Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option.</field_feature_card_description>
  <field_list_description>Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-13</field_date_posted>
  <field_date_reviewed>2012-06-13</field_date_reviewed>
  <field_pretty_url>t-dm1</field_pretty_url>
  <para_id>317031</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>417551</term_id>
  <id>321610</id>
  <title>CCCT Contact and Staff Information</title>
  <langcode>en</langcode>
  <field_short_title>Contact CCCT</field_short_title>
  <field_page_description>Contact and staff information for NCI's Coordinating Center for Clinical Trials (CCCT).</field_page_description>
  <field_feature_card_description>Contact the Coordinating Center for Clinical Trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-06-21</field_date_posted>
  <field_date_reviewed>2012-06-21</field_date_reviewed>
  <para_id>321610</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938227</term_id>
  <id>394026</id>
  <title>Genetically Engineered Immunotherapy for Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Genetically Engineered Immunotherapy for Advanced Cancer</field_short_title>
  <field_page_description>In this trial, doctors will collect T lymphocytes from patients with advanced mesothelin-expressing cancer and genetically engineer them to recognize mesothelin. The gene-engineered cells will be multiplied and infused into the patient to fight the cancer</field_page_description>
  <field_feature_card_description>In this trial, doctors will collect T lymphocytes from patients with advanced mesothelin-expressing cancer and genetically engineer them to recognize mesothelin. The gene-engineered cells will be multiplied and infused into the patient to fight the cancer</field_feature_card_description>
  <field_list_description>In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-08-07</field_date_posted>
  <field_date_reviewed>2012-08-08</field_date_reviewed>
  <field_pretty_url>immunotherapy-target-mesothelin</field_pretty_url>
  <para_id>394026</para_id>
  <related_resource_ids>6494730</related_resource_ids>
  <related_resource_ids>6494731</related_resource_ids>
  <related_resource_ids>6494732</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>920814</id>
  <title>Dr. Dinah Singer: Increasing Diversity in Cancer Research: One Lab at a Time</title>
  <langcode>en</langcode>
  <field_short_title>Dr. Dinah Singer: Increasing Diversity in Cancer Research: One Lab at a Time</field_short_title>
  <field_page_description>As part of the series “Increasing Diversity in Cancer Research,” CRCHD spoke with Dr. Dinah Singer, Director of NCI’s Division of Cancer Biology, about training and mentorship, and the role it plays in attracting and retaining students and investigators underrepresented in cancer research.</field_page_description>
  <field_feature_card_description>Dr. Dinah Singer discusses training, mentorship, and the role it plays in cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-27</field_date_posted>
  <field_date_reviewed>2015-03-27</field_date_reviewed>
  <field_pretty_url>singer-spotlight</field_pretty_url>
  <para_id>920814</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>922313</id>
  <title>The Importance of Cancer Prevention Research and its Challenges</title>
  <langcode>en</langcode>
  <field_short_title>The Importance of Cancer Prevention Research and its Challenges</field_short_title>
  <field_page_description>Barry Kramer, M.D., M.P.H., talks about NCI's efforts for improving cancer prevention and early detection, two topics discussed in the documentary film, Cancer: The Emperor of All Maladies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-01</field_date_posted>
  <field_date_reviewed>2015-03-31</field_date_reviewed>
  <field_pretty_url>cancer-prevention-research-importance</field_pretty_url>
  <para_id>922313</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>922408</id>
  <title>The Study of Tamoxifen and Raloxifene (STAR): Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>The Study of Tamoxifen and Raloxifene (STAR): Questions and Answers</field_short_title>
  <field_page_description>Learn about the Study of Tamoxifen and Raloxifene (STAR) clinical trial, which is comparing the drug raloxifene (Evista®) with the drug tamoxifen (Nolvadex®) in reducing the incidence of breast cancer in at-risk postmenopausal women.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2006-04-17</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>star-trial-results-qa</field_pretty_url>
  <para_id>922408</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>844114</term_id>
  <id>922513</id>
  <title>Publications</title>
  <langcode>en</langcode>
  <field_short_title>Publications</field_short_title>
  <field_page_description>Information about NCI publications including PDQ cancer information for patients and health professionals, patient-education publications, fact sheets, dictionaries, NCI blogs and newsletters and major reports.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-01</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <para_id>922513</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>922515</id>
  <title>A Message to the Cancer Research Community</title>
  <langcode>en</langcode>
  <field_short_title>A Message to the Cancer Research Community</field_short_title>
  <field_page_description>Doug Lowy, M.D., a long-time researcher and leader at NCI, greats the cancer research community as the institute's new acting director.</field_page_description>
  <field_feature_card_description>Doug Lowy, M.D., a long-time researcher and leader at NCI, greats the cancer research community as the institute's new acting director.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-01</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>lowy-message</field_pretty_url>
  <para_id>922515</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922597</term_id>
  <id>922598</id>
  <title>Immunosuppression</title>
  <langcode>en</langcode>
  <field_short_title>Immunosuppression</field_short_title>
  <field_page_description>Information about how a suppressed immune system can influence cancer risk.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-02</field_date_reviewed>
  <para_id>922598</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>935795</id>
  <title>RAS Insight</title>
  <langcode>en</langcode>
  <field_short_title>RAS Insight</field_short_title>
  <field_page_description>David Heimbrook, now CEO of the Frederick National Laboratory for Cancer Research, played a major role in a large pharma as it tried to develop an anti-RAS drug. Lessons from that failure inform the RAS Initiative today.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-04-13</field_date_reviewed>
  <field_pretty_url>ras-insight</field_pretty_url>
  <para_id>935795</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>349491</term_id>
  <id>936257</id>
  <title>2012 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2012 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2012.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <para_id>936257</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>349493</term_id>
  <id>936261</id>
  <title>2013 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2013 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2013.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <para_id>936261</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>936775</id>
  <title>Future Directions for NCI’s Surveillance Research Program</title>
  <langcode>en</langcode>
  <field_short_title>Future Directions for NCI’s Surveillance Research Program</field_short_title>
  <field_page_description>Since the early 1970s, NCI’s SEER program has been an invaluable resource for statistics on cancer in the United States. For the past several years, SEER researchers have been working toward a much broader and comprehensive goal for providing cancer stati</field_page_description>
  <field_feature_card_description>SEER researchers are working toward a much broader and comprehensive goal for providing nationwide cancer statistics.</field_feature_card_description>
  <field_list_description>Since the early 1970s, NCI’s SEER program has been an invaluable resource for statistics on cancer in the United States. For the past several years, SEER researchers have been working toward a much broader and comprehensive goal for providing cancer statistics on a nationwide basis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-17</field_date_posted>
  <field_date_reviewed>2015-04-17</field_date_reviewed>
  <field_pretty_url>seer-future</field_pretty_url>
  <para_id>936775</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>937767</id>
  <title>Program Spotlight: Dana Farber/Harvard Cancer Center Partnership Receives $8 Million Grant to Start Center for Personalized Cancer Therapy </title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: Dana Farber/Harvard Cancer Center Partnership Receives $8 Million Grant </field_short_title>
  <field_page_description>The UMass Boston and Dana Farber/Harvard Cancer Center PACHE Partnership received a grant to start-up a Center for Personalized Cancer Therapy on the UMass Boston campus.  The center is deigned to train underrepresented students to work in cancer research.</field_page_description>
  <field_feature_card_description>UMass Boston and Dana Farber/Harvard Cancer Center partnership receives start-up grant.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-10</field_date_posted>
  <field_date_reviewed>2014-04-10</field_date_reviewed>
  <field_pretty_url>DF-HCC-spotlight</field_pretty_url>
  <para_id>937767</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939921</term_id>
  <id>939928</id>
  <title>Brain Tumors—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Brain Tumors </field_short_title>
  <field_page_description>Brain and spinal cord tumors include anaplastic astrocytomas and glioblastomas, meningiomas, pituitary tumors, schwannomas, ependymomas, and sarcomas. Find evidence-based information on brain tumor treatment, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about brain tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939928</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940027</term_id>
  <id>940034</id>
  <title>Cervical Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Cervical Cancer </field_short_title>
  <field_page_description>The primary risk factor for cervical cancer is human papillomavirus (HPV) infection. Most cases of cervical cancer are preventable by routine screening and by treatment of precancerous lesions. Find evidence-based information on cervical cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about cervical cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>940034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940173</term_id>
  <id>940178</id>
  <title>Extragonadal Germ Cell Tumors—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Extragonadal Germ Cell Tumors</field_short_title>
  <field_page_description>Extragonadal germ cell tumors are rare and account for only a small percentage of all germ cell tumors. However, the true incidence of these tumors may be higher than originally thought because of failure to diagnose them properly. Find evidence-based information on extragonadal germ cell tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Extragonadal Germ Cell Tumor .</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940178</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940502</term_id>
  <id>940507</id>
  <title>Lung Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Lung Cancer </field_short_title>
  <field_page_description>Lung cancer appears in two main types. Non-small cell (squamous cell carcinoma, large cell carcinoma, and adenocarcinoma), and small cell lung cancer (oat cell cancer and combined small cell carcinoma). Find evidence-based information on lung cancer treatment, causes and prevention, research, screening, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about lung cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940507</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940578</term_id>
  <id>940587</id>
  <title>Malignant Mesothelioma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Malignant Mesothelioma </field_short_title>
  <field_page_description>Epithelial mesothelioma is the most common type of malignant mesothelioma, which forms in the cells that line organs. The other types begin in spindle-shaped cells called sarcomatoid cells or are a mixture of both cell types. Find evidence-based information on malignant mesothelioma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Malignant Mesothelioma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940587</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940610</term_id>
  <id>940617</id>
  <title>Plasma Cell Neoplasms (Including Multiple Myeloma)—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Plasma Cell Neoplasms (Including Multiple Myeloma)</field_short_title>
  <field_page_description>There are several types of plasma cell neoplasms, including monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, extramedullary plasmacytoma, and multiple myeloma. Find evidence-based information on plasma cell neoplasms treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Multiple Myeloma and Other Plasma Cell Neoplasms.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940617</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940674</term_id>
  <id>940681</id>
  <title>Neuroblastoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Neuroblastoma</field_short_title>
  <field_page_description>Neuroblastoma is a disease in which malignant cells form in the neuroblasts of the adrenal glands and paraspinal nerve tissue from the neck to the pelvis. Find evidence-based information on neuroblastoma treatment, screening, research, and genetics.</field_page_description>
  <field_list_description>NCI's gateway for information about Neuroblastoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940681</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938350</term_id>
  <id>940682</id>
  <title>Neuroblastoma Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on neuroblastoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940682</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>15312</id>
  <title>Artificial Sweeteners and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Artificial Sweeteners and Cancer</field_short_title>
  <field_page_description>A fact sheet that reviews research studies on the possible connection between artificial sweeteners and cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-08-18</field_date_posted>
  <field_date_reviewed>2016-08-10</field_date_reviewed>
  <field_pretty_url>artificial-sweeteners-fact-sheet</field_pretty_url>
  <para_id>15312</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11910</term_id>
  <id>15315</id>
  <title>Gastrointestinal Carcinoid Tumors—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Gastrointestinal Carcinoid Tumors</field_short_title>
  <field_page_description>Gastrointestinal (GI) carcinoid tumors are slow-growing tumors that form in the neuroendocrine cells in the GI tract. The GI tract includes the stomach, small intestine, colon, rectum, appendix, and other organs. Start here to find treatment information and research on gastrointestinal carcinoid tumors.</field_page_description>
  <field_list_description>NCI's gateway for information about Gastrointestinal Carcinoid.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15315</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>857987</term_id>
  <id>15333</id>
  <title>Psychological Stress and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Psychological Stress and Cancer</field_short_title>
  <field_page_description>A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress.</field_page_description>
  <field_feature_card_description>A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-10</field_date_reviewed>
  <field_pretty_url>stress-fact-sheet</field_pretty_url>
  <para_id>15333</para_id>
  <related_resource_ids>5211083</related_resource_ids>
  <related_resource_ids>5211084</related_resource_ids>
  <related_resource_ids>5211086</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>15500</id>
  <title>Where To Get Help When You Decide To Quit Smoking</title>
  <langcode>en</langcode>
  <field_short_title>Where To Get Help When You Decide To Quit Smoking</field_short_title>
  <field_page_description>This fact sheet provides information about helpful resources for people who have decided to quit smoking.</field_page_description>
  <field_feature_card_description>Quitting smoking isn’t easy, but we have information and resources to help you succeed.</field_feature_card_description>
  <field_list_description>A fact sheet that provides information about helpful resources for people who have decided to quit smoking.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-10-28</field_date_posted>
  <field_date_reviewed>2010-10-28</field_date_reviewed>
  <field_pretty_url>help-quitting-fact-sheet</field_pretty_url>
  <para_id>15500</para_id>
  <related_resource_ids>6625638</related_resource_ids>
  <related_resource_ids>6625639</related_resource_ids>
  <related_resource_ids>6625640</related_resource_ids>
  <related_resource_ids>6625641</related_resource_ids>
  <related_resource_ids>6625642</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11884</term_id>
  <id>15597</id>
  <title>Brain Tumors—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Brain Tumors </field_short_title>
  <field_page_description>Brain tumors are growths of malignant cells in tissues of the brain. Tumors that start in the brain are called primary brain tumors. Tumors that spread to the brain are called metastatic brain tumors. Start here to find information on brain cancer treatment, research, and statistics.</field_page_description>
  <field_feature_card_description>NCI's gateway for information about brain tumors, including treatment, clinical trials, research, statistics, and more.</field_feature_card_description>
  <field_list_description>Information about brain tumor treatment, clinical trials, research, statistics, and other topics.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15597</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>12742</term_id>
  <id>16143</id>
  <title>Funding for Extramural Cancer Training by the Cancer Training Branch</title>
  <langcode>en</langcode>
  <field_short_title>Funding for Cancer Training</field_short_title>
  <field_page_description>Find funding for training grants, fellowships, research career development awards, and education research grants for students and scientists at universities and institutions across the country. </field_page_description>
  <field_feature_card_description>Find funding for training grants, fellowships, research career development awards, and education research grants for students and scientists at universities and institutions across the country. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2008-11-14</field_date_reviewed>
  <para_id>16143</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11882</term_id>
  <id>15577</id>
  <title>Bone Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Bone Cancer</field_short_title>
  <field_page_description>Bone cancer is rare and includes several types. Some bone cancers, including osteosarcoma and Ewing sarcoma, are seen most often in children and young adults. Start here to find information on bone cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about bone cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15577</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11890</term_id>
  <id>15596</id>
  <title>HPV and Pap Testing</title>
  <langcode>en</langcode>
  <field_short_title>HPV and Pap Testing</field_short_title>
  <field_page_description>Pap tests detect abnormal cervical cells, including precancerous cervical lesions, as well as early cervical cancers. HPV tests detect HPV infections that can cause cervical cell abnormalities. Learn how Pap and HPV tests are done, how often testing should be done, and how are HPV test results are reported.</field_page_description>
  <field_list_description>A fact sheet that describes cervical cancer screening, which includes the Pap test and HPV testing. The fact sheet includes information about cervical cancer screening guidelines.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-01</field_date_posted>
  <field_date_reviewed>2019-02-06</field_date_reviewed>
  <field_pretty_url>pap-hpv-testing-fact-sheet</field_pretty_url>
  <para_id>15596</para_id>
  <related_resource_ids>7267773</related_resource_ids>
  <related_resource_ids>7267774</related_resource_ids>
  <related_resource_ids>7267775</related_resource_ids>
  <related_resource_ids>7267790</related_resource_ids>
  <related_resource_ids>7267791</related_resource_ids>
  <related_resource_ids>7267806</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>906093</term_id>
  <id>15646</id>
  <title>Sentinel Lymph Node Biopsy</title>
  <langcode>en</langcode>
  <field_short_title>Sentinel Lymph Node Biopsy</field_short_title>
  <field_page_description>A fact sheet that describes the sentinel lymph node biopsy procedure and details two clinical trials evaluating the effectiveness of this procedure.</field_page_description>
  <field_list_description>A fact sheet that describes the sentinel lymph node biopsy (SLNB) procedure, its use in determining the extent, or stage, of cancer in the body, and the results of research on the use of SLNB in breast cancer and melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-08-11</field_date_posted>
  <field_date_reviewed>2011-08-11</field_date_reviewed>
  <field_pretty_url>sentinel-node-biopsy-fact-sheet</field_pretty_url>
  <para_id>15646</para_id>
  <related_resource_id>7229066</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>929549</term_id>
  <id>15684</id>
  <title>BRCA Mutations: Cancer Risk and Genetic Testing</title>
  <langcode>en</langcode>
  <field_short_title>BRCA Mutations: Cancer Risk &amp; Genetic Testing</field_short_title>
  <field_page_description>A fact sheet about the BRCA1 and BRCA2 genes, what to do if a person tests positive for alterations in one of these genes, and consequences of genetic testing.</field_page_description>
  <field_feature_card_description>What to know about the cancer risks of, and genetic testing for, mutations of the BRCA1 and BRCA2 genes.</field_feature_card_description>
  <field_list_description>A fact sheet about the BRCA1 and BRCA2 genes, how BRCA1 and BRCA2 gene mutations (changes) affect a person's risk of cancer, genetic testing for cancer risk, interpreting test results, and the benefits and risks of genetic testing.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-05</field_date_posted>
  <field_date_reviewed>2018-01-30</field_date_reviewed>
  <field_pretty_url>brca-fact-sheet</field_pretty_url>
  <para_id>15684</para_id>
  <related_resource_ids>7203606</related_resource_ids>
  <related_resource_ids>7203641</related_resource_ids>
  <related_resource_ids>7203642</related_resource_ids>
  <related_resource_ids>7203647</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11904</term_id>
  <id>15711</id>
  <title>Extracranial Germ Cell Tumors—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Extracranial Germ Cell Tumors</field_short_title>
  <field_page_description>Extracranial germ cell tumors are tumors that develop from germ cells (fetal cells that give rise to sperm and eggs) and can form in many parts of the body. They are most common in teenagers and can often be cured. Start here to find information on extracranial germ cell tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about extracranial germ cell tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15711</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127288</term_id>
  <id>57469</id>
  <title>Terminology Resources</title>
  <langcode>en</langcode>
  <field_short_title>Terminology Resources</field_short_title>
  <field_page_description>NCI's reference terminology and related vocabulary resources to help researchers, clinicians, and administrators identify types of cancer, treatments, and other cancer-related topics.</field_page_description>
  <field_feature_card_description>NCI's reference terminology and related vocabulary resources to help researchers, clinicians, and administrators identify types of cancer, treatments, and other cancer-related topics.</field_feature_card_description>
  <field_list_description>NCI's reference terminology and related vocabulary resources to help patients, researchers, clinicians, and administrators identify types of cancer, treatments, and other cancer-related topics.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-07</field_date_posted>
  <field_date_reviewed>2015-06-12</field_date_reviewed>
  <para_id>57469</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>929549</term_id>
  <id>550781</id>
  <title>Genetic Testing for Hereditary Cancer Syndromes</title>
  <langcode>en</langcode>
  <field_short_title>Genetic Testing for Hereditary Cancer Syndromes</field_short_title>
  <field_page_description>A fact sheet about genetic testing for inherited cancer risk. Includes types of tests, who should consider testing, and how to understand test results.</field_page_description>
  <field_feature_card_description>A fact sheet about genetic testing for inherited cancer risk, including information about at-home, or direct-to-consumer, genetic tests.</field_feature_card_description>
  <field_list_description>A fact sheet about genetic testing for inherited cancer risk, including types of tests, who should consider testing, how to understand test results, and who has access to a person’s test results. Also contains information about at-home, or direct-to-consumer, genetic tests. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-04-22</field_date_posted>
  <field_date_reviewed>2013-04-11</field_date_reviewed>
  <field_pretty_url>genetic-testing-fact-sheet</field_pretty_url>
  <para_id>550781</para_id>
  <related_resource_ids>6667572</related_resource_ids>
  <related_resource_ids>6667573</related_resource_ids>
  <related_resource_ids>6667576</related_resource_ids>
  <related_resource_ids>6667577</related_resource_ids>
  <related_resource_ids>6667578</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941018</term_id>
  <id>941025</id>
  <title>Soft Tissue Sarcoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Soft Tissue Sarcoma </field_short_title>
  <field_page_description>Soft tissue sarcomas are malignant tumors that arise in any of the mesodermal tissues of the extremities, trunk and retroperitoneum, or head and neck. Soft tissue sarcomas may be heterogeneous. Find evidence-based information on soft tissue sarcoma treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about soft tissue sarcoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941025</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941050</term_id>
  <id>941055</id>
  <title>Testicular Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Testicular Cancer </field_short_title>
  <field_page_description>Most testicular cancers are germ cell tumors. Germ cell tumors are divided into seminomas and nonseminomas. Nonseminomas tend to grow and spread more quickly than seminomas. Find evidence-based information on testicular cancer treatment, screening, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about testicular cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941055</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>937897</term_id>
  <id>941394</id>
  <title>Advanced Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on advanced cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941394</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917299</term_id>
  <id>941622</id>
  <title>Resources for International Partners</title>
  <langcode>en</langcode>
  <field_short_title>Resources for International Partners</field_short_title>
  <field_page_description>Resources for foreign governments, non-governmental organizations, and other U.S. government agencies to address the challenges of cancer research and reduce the global burden of cancer.</field_page_description>
  <field_feature_card_description>Learn about NCI's Center for Global Health, which facilitates global collaboration by leveraging research resources with U.S. government agencies, foreign governments, non-government organizations, and pharmaceutical and biotechnology companies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941622</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505615</term_id>
  <id>505753</id>
  <title>Accessibility Policy</title>
  <langcode>en</langcode>
  <field_short_title>Accessibility</field_short_title>
  <field_page_description>Learn about the accessibility policy for the NCI website, including information about Section 508 of the Rehabilitation Act. </field_page_description>
  <field_feature_card_description>Information about the accessibility policy for the NCI website. </field_feature_card_description>
  <field_list_description>Information about the accessibility policy for the NCI website. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2013-02-05</field_date_reviewed>
  <para_id>505753</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>571449</id>
  <title>More Research Is Needed on What Patients Being Treated for Cancer Should Eat</title>
  <langcode>en</langcode>
  <field_short_title>Diet Recommendations for Cancer Patients</field_short_title>
  <field_page_description>An article about the need for new research on the optimal nutrition for patients being treated for cancer.</field_page_description>
  <field_feature_card_description>An article about the need for new research on the optimal nutrition for patients who have been treated for cancer.</field_feature_card_description>
  <field_list_description>A survey of online recommendations shows there is a need for more research on the optimal nutritional approaches for patients being treated for cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-05-14</field_date_posted>
  <field_date_reviewed>2013-05-14</field_date_reviewed>
  <field_pretty_url>nutrition-during-after-treatment</field_pretty_url>
  <para_id>571449</para_id>
  <related_resource_id>7235261</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940922</term_id>
  <id>940927</id>
  <title>Retinoblastoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Retinoblastoma</field_short_title>
  <field_page_description>Retinoblastoma is a pediatric cancer. For patients with extraocular retinoblastoma, intensive chemotherapy is required, including high-dose chemotherapy and autologous hematopoietic stem cell rescue. Find evidence-based information on retinoblastoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Retinoblastoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940927</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>76380</id>
  <title>Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Node-Negative Breast Cancer Patients</title>
  <langcode>en</langcode>
  <field_short_title>Sentinel Lymph Node Occult Metastases Have Minimal Survival Effect in Some Breast Cancer Patients</field_short_title>
  <field_page_description>Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small</field_page_description>
  <field_feature_card_description>Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small</field_feature_card_description>
  <field_list_description>Detailed examination of sentinel lymph node tissue from breast cancer patients revealed previously unidentified metastases in about 16% of the samples, but the difference in 5-year survival between patients with and without these metastases was very small and likely not clinically meaningful. The results were published in the February 3, 2011 New England Journal of Medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-26</field_date_posted>
  <field_date_reviewed>2011-04-26</field_date_reviewed>
  <field_pretty_url>occult-mets</field_pretty_url>
  <para_id>76380</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>79694</id>
  <title>Drugs Approved for Cervical Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Cervical Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for cervical cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-06-10</field_date_posted>
  <field_date_reviewed>2011-05-20</field_date_reviewed>
  <field_pretty_url>cervical</field_pretty_url>
  <para_id>79694</para_id>
  <related_resource_ids>7065102</related_resource_ids>
  <related_resource_ids>7065107</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>83997</id>
  <title>Drugs Approved for Kaposi Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Kaposi Sarcoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Kaposi sarcoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-12</field_date_posted>
  <field_date_reviewed>2011-06-01</field_date_reviewed>
  <field_pretty_url>kaposi-sarcoma</field_pretty_url>
  <para_id>83997</para_id>
  <related_resource_ids>7130950</related_resource_ids>
  <related_resource_ids>7130951</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396047</term_id>
  <id>396060</id>
  <title>What Are Clinical Trials? </title>
  <langcode>en</langcode>
  <field_short_title>What Are Clinical Trials? </field_short_title>
  <field_page_description>Information about the basics of cancer clinical trials.</field_page_description>
  <field_feature_card_description>Information covering the basics of cancer clinical trials, including what they are, where they take place, and the types of clinical trials. Also, explains phases, randomization, placebo, and members of the research team.</field_feature_card_description>
  <field_list_description>Information covering the basics of cancer clinical trials, including what they are, where they take place, and the types of clinical trials. Also, explains phases, randomization, placebo, and members of the research team.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2012-08-10</field_date_reviewed>
  <para_id>396060</para_id>
  <related_resource_ids>7252215</related_resource_ids>
  <related_resource_ids>7252216</related_resource_ids>
  <related_resource_ids>7252217</related_resource_ids>
  <related_resource_ids>7252218</related_resource_ids>
  <related_resource_ids>7252219</related_resource_ids>
  <related_resource_ids>7252222</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396049</term_id>
  <id>396061</id>
  <title>Types of Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Types of Clinical Trials</field_short_title>
  <field_page_description>Information about the several types of cancer clinical trials, including treatment trials, prevention trials, screening trials, supportive and palliative care trials. Each type of trial is designed to answer different research questions.</field_page_description>
  <field_feature_card_description>Information about the several types of cancer clinical trials, including treatment trials, prevention trials, screening trials, supportive and palliative care trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2012-08-10</field_date_reviewed>
  <para_id>396061</para_id>
  <related_resource_ids>6324001</related_resource_ids>
  <related_resource_ids>6324002</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396057</term_id>
  <id>396117</id>
  <title>Deciding to Take Part in a Clinical Trial</title>
  <langcode>en</langcode>
  <field_short_title>Deciding to Take Part</field_short_title>
  <field_page_description>Information to help people think about whether taking part in a cancer clinical trial is right for them. Covers benefits and risks of taking part, as well as eligibility criteria.</field_page_description>
  <field_feature_card_description>Like all treatment options, clinical trials have possible benefits and risks. By looking closely at all options, you are taking an active role in a decision that affects your life. Find information you can use when making your decision.</field_feature_card_description>
  <field_list_description>Like all treatment options, clinical trials have possible benefits and risks. Find information you can use when making your decision about whether taking part in a trial is right for you.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>396117</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>922824</term_id>
  <id>951178</id>
  <title>Scientific Conferences Where NCI Exhibits</title>
  <langcode>en</langcode>
  <field_short_title>Conferences</field_short_title>
  <field_page_description>Scientific conferences where NCI will be exhibiting, including ASCO, AACR, BIO, and APHA.</field_page_description>
  <field_feature_card_description>Scientific conferences where NCI will be exhibiting, including ASCO, AACR, BIO, and APHA.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-06</field_date_posted>
  <field_date_reviewed>2015-05-06</field_date_reviewed>
  <para_id>951178</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>951268</term_id>
  <id>951269</id>
  <title>Scientific Meetings and Lectures</title>
  <langcode>en</langcode>
  <field_short_title>Scientific Meetings and Lectures</field_short_title>
  <field_page_description>Scientific meetings and lectures hosted at NCI.</field_page_description>
  <field_feature_card_description>Upcoming scientific meetings and lectures hosted at NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-06</field_date_posted>
  <field_date_reviewed>2015-05-06</field_date_reviewed>
  <para_id>951269</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>959427</id>
  <title>Screening Rates for Several Cancers Miss Their Targets</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Screening Rates Missing Targets</field_short_title>
  <field_page_description>Screening rates for breast, colorectal, and cervical cancer are lagging behind target rates set by the Healthy People 2020 program, according to a new study. </field_page_description>
  <field_feature_card_description>Screening rates for several common cancers are falling short of their targets.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-26</field_date_posted>
  <field_date_reviewed>2015-05-26</field_date_reviewed>
  <field_pretty_url>screening-targets</field_pretty_url>
  <para_id>959427</para_id>
  <related_resource_ids>6572960</related_resource_ids>
  <related_resource_ids>6572962</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>959841</term_id>
  <id>959842</id>
  <title>NCI-COG Pediatric MATCH</title>
  <langcode>en</langcode>
  <field_short_title>NCI-COG Pediatric MATCH</field_short_title>
  <field_page_description>In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have certain genetic mutations will be treated with drugs that are matched to those mutations.</field_page_description>
  <field_feature_card_description>This trial is studying treatments targeted to tumor alterations in children and adolescents with advanced cancer.</field_feature_card_description>
  <field_list_description>In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have particular genetic mutations are being treated with drugs designed to target those mutations.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-01</field_date_posted>
  <field_date_reviewed>2015-05-27</field_date_reviewed>
  <para_id>959842</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>962853</id>
  <title>Grantee Spotlight: Marta Torroella-Kouri, Ph.D. – Studying the Role of Obesity and Breast Fat Tissue Inflammation in African American Women with Breast Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Marta Torroella-Kouri – Studying the Role of Obesity in African American Women</field_short_title>
  <field_page_description>Dr. Marta Torroella-Kouri, a CRCHD-NCI R21 grantee, is studying the role of obesity and breast fat tissue inflammation in breast cancer. </field_page_description>
  <field_feature_card_description>Dr. Torroella-Kouri studies obesity and breast fat tissue inflammation in breast cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-02</field_date_posted>
  <field_date_reviewed>2015-06-02</field_date_reviewed>
  <field_pretty_url>torroella-kouri-spotlight</field_pretty_url>
  <para_id>962853</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>963035</id>
  <title>The Playing Field for Cancer Checkpoint Inhibitors Is Expanding</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Checkpoint Inhibitor Use Expanding</field_short_title>
  <field_page_description>The list of cancers that may be susceptible to checkpoint inhibitors is quickly expanding, according to findings from clinical trials presented at the ASCO annual meeting.</field_page_description>
  <field_feature_card_description>More cancer types may be susceptible to checkpoint inhibitors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-04</field_date_posted>
  <field_date_reviewed>2015-06-04</field_date_reviewed>
  <field_pretty_url>pd1-trials</field_pretty_url>
  <para_id>963035</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969901</term_id>
  <id>969902</id>
  <title>Obligations by Budget Mechanism and Division</title>
  <langcode>en</langcode>
  <field_short_title>NCI and Division Obligations</field_short_title>
  <field_page_description>See obligations for the 2018 fiscal year by budget mechanism and division, including grants, contracts, training fellowships, intramural research, and management and support. </field_page_description>
  <field_feature_card_description>See obligations for the 2018 fiscal year by budget mechanism and division. </field_feature_card_description>
  <field_list_description>See obligations for grants, contracts, training fellowships, intramural research, and management and support, including the number of grant awards, funding amounts, and percent of the total NCI budget.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969902</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969904</term_id>
  <id>969905</id>
  <title>NIH Management Fund, Service and Supply Fund (SSF), and GSA Rent</title>
  <langcode>en</langcode>
  <field_short_title>NIH Management Fund</field_short_title>
  <field_page_description>See the distribution of NCI's payment for common research and support activities required by NIH, including GSA rent and the Service and Supply Fund.  </field_page_description>
  <field_feature_card_description>See the distribution of NCI's payment for common research and support activities required by NIH. </field_feature_card_description>
  <field_list_description>See the funding amount and percent for the NCI portion of costs that are shared among all NIH Institutes and centers, and includes descriptions of each support activity.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969905</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127296</term_id>
  <id>57474</id>
  <title>NCPDP Terminology</title>
  <langcode>en</langcode>
  <field_short_title>NCPDP Terminology</field_short_title>
  <field_page_description>NCPDP Terminology developed with NCI EVS for prescription drugs.</field_page_description>
  <field_feature_card_description>NCPDP works with NCI to provide standard terminology for transfer of data related to medications, supplies, and services within the healthcare system.</field_feature_card_description>
  <field_list_description>National Council for Prescription Drug Programs (NCPDP) works with NCI to provide standard terminology for transfer of data related to medications, supplies, and services within the healthcare system.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-07</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>57474</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937922</term_id>
  <id>495557</id>
  <title>Cancer Education Webinars for Multicultural Media </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Education Webinars for Multicultural Media </field_short_title>
  <field_page_description>These webinars from NCI are intended to educate multicultural media professionals about the impact of cancer and other diseases on special populations, including African American, Hispanic, Asian American, and American Indian/Alaska Native communities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-01-25</field_date_posted>
  <field_date_reviewed>2013-01-21</field_date_reviewed>
  <para_id>495557</para_id>
  <related_resource_id>5418989</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16387</term_id>
  <id>16388</id>
  <title>NCI Drug Dictionary</title>
  <langcode>en</langcode>
  <field_short_title>NCI Drug Dictionary</field_short_title>
  <field_page_description>Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials.</field_page_description>
  <field_feature_card_description>Definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16388</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>11738</term_id>
  <id>16394</id>
  <title>Cancer Genetics Professionals</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genetics Professionals</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <field_pretty_url>view</field_pretty_url>
  <para_id>16394</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16399</term_id>
  <id>16400</id>
  <title>NCI Search Results</title>
  <langcode>en</langcode>
  <field_short_title>NCI Search Results</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16400</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127290</term_id>
  <id>57473</id>
  <title>CDISC Terminology</title>
  <langcode>en</langcode>
  <field_short_title>CDISC Terminology</field_short_title>
  <field_page_description>Clinical Data Interchange Standards Consortium (CDISC) is an international, non-profit organization that develops and supports global data standards for medical research. CDISC is working actively with EVS to develop and support controlled terminology in several areas, notably CDISC's Study Data Tabulation Model (SDTM)</field_page_description>
  <field_feature_card_description>CDISC and NCI EVS partner to develop global terminology and data standards for biomedical research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-07</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>57473</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505617</term_id>
  <id>505759</id>
  <title>Website Linking Policy</title>
  <langcode>en</langcode>
  <field_short_title>Website Linking</field_short_title>
  <field_page_description>Learn about linking to the website of the National Cancer Institute (NCI) and about NCI's policy for links on its site.</field_page_description>
  <field_feature_card_description>Information about linking to the NCI website and about NCI's policy for links on its site.</field_feature_card_description>
  <field_list_description>Information about linking to the NCI website and about NCI's policy for links on its site.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <para_id>505759</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>530168</id>
  <title>Drugs Approved for Soft Tissue Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Soft Tissue Sarcoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for soft tissue sarcoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_feature_card_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for soft tissue sarcoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-03-13</field_date_posted>
  <field_date_reviewed>2013-03-08</field_date_reviewed>
  <field_pretty_url>soft-tissue-sarcoma</field_pretty_url>
  <para_id>530168</para_id>
  <related_resource_ids>6425036</related_resource_ids>
  <related_resource_ids>6425037</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>538205</id>
  <title>Ten Years of Tamoxifen Reduces Breast Cancer Recurrences, Improves Survival</title>
  <langcode>en</langcode>
  <field_short_title>Ten Years of Tamoxifen Reduces Breast Cancer Recurrences, Improves Survival</field_short_title>
  <field_page_description>Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.</field_page_description>
  <field_feature_card_description>Taking adjuvant tamoxifen for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-03-20</field_date_posted>
  <field_date_reviewed>2013-03-20</field_date_reviewed>
  <field_pretty_url>10-years-tamoxifen</field_pretty_url>
  <para_id>538205</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911152</term_id>
  <id>584571</id>
  <title>Alcohol and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Alcohol and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers.</field_page_description>
  <field_feature_card_description>A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers.</field_feature_card_description>
  <field_list_description>A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers, such as a person’s genes and tobacco use.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-17</field_date_posted>
  <field_date_reviewed>2018-09-13</field_date_reviewed>
  <field_pretty_url>alcohol-fact-sheet</field_pretty_url>
  <para_id>584571</para_id>
  <related_resource_ids>7121949</related_resource_ids>
  <related_resource_ids>7121951</related_resource_ids>
  <related_resource_ids>7121952</related_resource_ids>
  <related_resource_ids>7121953</related_resource_ids>
  <related_resource_ids>7121957</related_resource_ids>
  <related_resource_ids>7121958</related_resource_ids>
  <related_resource_ids>7121959</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937920</term_id>
  <id>15305</id>
  <title>Multicultural Media Outreach Program</title>
  <langcode>en</langcode>
  <field_short_title>Multicultural Media Outreach Program</field_short_title>
  <field_page_description>NCI's Multicultural Media Outreach Program works with the ethnic media to reach minority communities with culturally relevant cancer news and information.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2010-11-05</field_date_posted>
  <field_date_reviewed>2010-08-23</field_date_reviewed>
  <para_id>15305</para_id>
  <related_resource_ids>6784842</related_resource_ids>
  <related_resource_ids>6784843</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11502</term_id>
  <id>15309</id>
  <title>National Cancer Institute Overview and Mission </title>
  <langcode>en</langcode>
  <field_short_title>NCI Overview</field_short_title>
  <field_page_description>Learn about the National Cancer Institute and what we do, our impact, and our future plans.</field_page_description>
  <field_feature_card_description>Learn about who we are, what we do, and our future plans.</field_feature_card_description>
  <field_list_description>Learn about who we are, what we do, and our future plans.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15309</para_id>
  <related_resource_ids>7217996</related_resource_ids>
  <related_resource_ids>7217997</related_resource_ids>
  <related_resource_ids>7217998</related_resource_ids>
  <related_resource_ids>7218003</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16384</term_id>
  <id>16385</id>
  <title>NCI Dictionary of Cancer Terms</title>
  <langcode>en</langcode>
  <field_short_title>NCI Dictionary of Cancer Terms</field_short_title>
  <field_page_description>NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.</field_page_description>
  <field_feature_card_description>Look up easy-to-understand definitions for words and phrases related to cancer and medicine.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16385</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505613</term_id>
  <id>505758</id>
  <title>Privacy and Security Policy</title>
  <langcode>en</langcode>
  <field_short_title>Privacy and Security</field_short_title>
  <field_page_description>Learn about the privacy and security policies for the National Cancer Institute (NCI) website.</field_page_description>
  <field_feature_card_description>Information about privacy and security policies for the NCI website.</field_feature_card_description>
  <field_list_description>Information about privacy and security policies for the NCI website.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2013-02-05</field_date_reviewed>
  <para_id>505758</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938142</term_id>
  <id>941115</id>
  <title>Thyroid Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on thyroid cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941115</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941205</term_id>
  <id>941210</id>
  <title>Vaginal Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Vaginal Cancer </field_short_title>
  <field_page_description> Vaginal cancer is often squamous cell carcinoma. Other types of vaginal cancer are adenocarcinoma, melanoma, and sarcoma. Infection with certain types of human papillomavirus (HPV) causes most vaginal cancer. Find evidence-based information on vaginal cancer treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about vaginal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941210</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>915373</term_id>
  <id>941397</id>
  <title>Diagnosis and Staging Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on cancer diagnosis and staging, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941397</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>939964</id>
  <title>Breast Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on breast cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939964</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>940072</id>
  <title>Colorectal Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on colorectal cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940072</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938269</term_id>
  <id>940383</id>
  <title>Kidney Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on kidney cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940383</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938242</term_id>
  <id>940478</id>
  <title>Liver and Bile Duct Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on liver cancer and bile duct cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940478</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940738</term_id>
  <id>940745</id>
  <title>Pancreatic Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Pancreatic Cancer </field_short_title>
  <field_page_description>Exocrine pancreatic cancer is cancer of the exocrine gland of the pancreas, whereas cancer of the endocrine gland usually forms as a collection of tumor cell types referred to as pancreatic neuroendocrine tumors. Find evidence-based information on pancreatic cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Pancreatic Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940745</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938135</term_id>
  <id>940746</id>
  <title>Pancreatic Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on pancreatic cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940746</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940775</term_id>
  <id>940780</id>
  <title>Parathyroid Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Parathyroid Cancer</field_short_title>
  <field_page_description>Parathyroid cancer often presents as a benign adenoma, though malignant carcinomas are possible. Parathyroid adenomas represent a common endocrine problem, whereas parathyroid carcinomas are very rare tumors. Find evidence-based information on parathyroid cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Parathyroid Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940780</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11960</term_id>
  <id>13658</id>
  <title>Small Intestine Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Small Intestine Cancer</field_short_title>
  <field_page_description>Small intestine cancer usually begins in an area of the intestine called the duodenum. This cancer is rarer than cancers in other parts of the gastrointestinal system, such as the colon and stomach. Explore the links on this page to learn more about small intestine cancer treatment, statistics, research, and clinical t</field_page_description>
  <field_list_description>NCI's gateway for information about Small Intestine Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2007-05-14</field_date_reviewed>
  <para_id>13658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11948</term_id>
  <id>13695</id>
  <title>Penile Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Penile Cancer</field_short_title>
  <field_page_description>Penile cancer usually forms on or under the foreskin. Human papillomavirus (HPV) causes about one-third of penile cancer cases. When found early, penile cancer is usually curable. Start here to find information on penile cancer treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about Penile Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13695</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>586656</id>
  <title>Coping with Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Coping with Advanced Cancer</field_short_title>
  <field_page_description>Covers the choices for care and symptom control for the patient with late-stage cancer, along with the emotional and communication issues it brings.</field_page_description>
  <field_feature_card_description>Covers the choices for care and symptom control for the patient with late-stage cancer, along with the emotional and communication issues it brings.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2013-06-11</field_date_reviewed>
  <field_pretty_url>advanced-cancer</field_pretty_url>
  <para_id>586656</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>586657</id>
  <title>When Someone You Love Is Being Treated for Cancer: Support for Caregivers</title>
  <langcode>en</langcode>
  <field_short_title>When Someone You Love Is Being Treated for Cancer</field_short_title>
  <field_page_description>Covers practical, coping, and communication tips for friends and family members caring for loved ones with cancer.</field_page_description>
  <field_feature_card_description>Covers practical, coping, and communication tips for friends and family members caring for loved ones with cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2013-06-11</field_date_reviewed>
  <field_pretty_url>when-someone-you-love-is-being-treated</field_pretty_url>
  <para_id>586657</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>586922</id>
  <title>Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer (Updated)</title>
  <langcode>en</langcode>
  <field_short_title>Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer</field_short_title>
  <field_page_description>A summary of results from an international phase III clinical trial that compared crizotinib versus chemotherapy in previously treated patients with advanced lung cancer whose tumors have an EML4-ALK fusion gene.</field_page_description>
  <field_feature_card_description>Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.</field_feature_card_description>
  <field_list_description>Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-06-17</field_date_posted>
  <field_date_reviewed>2013-06-17</field_date_reviewed>
  <field_pretty_url>crizotinib</field_pretty_url>
  <para_id>586922</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940990</term_id>
  <id>940995</id>
  <title>Small Intestine Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Small Intestine Cancer</field_short_title>
  <field_page_description>Adenocarcinoma is the most common type of small intestine cancer. Other types of small intestine cancer are sarcomas, carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Find evidence-based information on small intestine cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Small Intestine Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940995</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941107</term_id>
  <id>941114</id>
  <title>Thyroid Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Thyroid Cancer </field_short_title>
  <field_page_description>There are four types of thyroid cancer. These are papillary, follicular, medullary, and anaplastic thyroid cancer. Papillary is the most common type of thyroid cancer. Find evidence-based information on thyroid cancer treatment, screening, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about thyroid cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941114</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>915370</term_id>
  <id>941396</id>
  <title>Research on Coping with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on coping with cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941396</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917295</term_id>
  <id>941591</id>
  <title>Resources for Caregivers</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Caregivers</field_short_title>
  <field_page_description>Information to help you care for the cancer patient in your life and take care of yourself, as well as general information about cancer and the latest cancer research.</field_page_description>
  <field_feature_card_description>Information to help you care for yourself as well as the cancer patient in your life.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941591</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917301</term_id>
  <id>941619</id>
  <title>Resources for Industry</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Industry</field_short_title>
  <field_page_description>Resources for private sector partners, including the pharmaceutical and biotechnology industry, in NCI’s efforts to develop approaches and technologies to prevent, diagnose, and treat cancer.</field_page_description>
  <field_feature_card_description>NCI develops and commercializes novel technologies and products to prevent, diagnose, and treat cancer through its Small Business Innovation Research and Small Business Technology Transfer programs. Find links to these programs and resources.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941619</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>530170</id>
  <title>Drugs Approved for Gastrointestinal Stromal Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Gastrointestinal Stromal Tumors</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for gastrointestinal stromal tumors (GIST). The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_feature_card_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for gastrointestinal stromal tumors (GIST).</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-03-08</field_date_posted>
  <field_date_reviewed>2013-03-08</field_date_reviewed>
  <field_pretty_url>gist</field_pretty_url>
  <para_id>530170</para_id>
  <related_resource_ids>6423688</related_resource_ids>
  <related_resource_ids>6423689</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>941393</id>
  <title>Screening Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on cancer screening, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941393</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11884</term_id>
  <id>941586</id>
  <title>Clinical Trials to Treat Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Brain Tumors</field_short_title>
  <field_page_description>A list of open treatment clinical trials for adult and childhood brain tumors.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <field_pretty_url>clinical-trials</field_pretty_url>
  <para_id>941586</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904030</term_id>
  <id>962800</id>
  <title>Jonathan S. Wiest, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Jonathan S. Wiest, Ph.D.</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-02</field_date_posted>
  <field_date_reviewed>2015-06-02</field_date_reviewed>
  <field_pretty_url>wiest-bio</field_pretty_url>
  <para_id>962800</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>963862</id>
  <title>Better Care for Children with Cancer Linked to Longer Lifespans</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancer Survivors Are Living Longer</field_short_title>
  <field_page_description>New data from the Childhood Cancer Survivor Study suggest that refinements in pediatric cancer treatment over the last few decades have helped to extend the lifespans of many survivors of childhood cancer.</field_page_description>
  <field_feature_card_description>Refinements in care have extended the lifespans of many survivors of childhood cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-11</field_date_posted>
  <field_date_reviewed>2015-06-11</field_date_reviewed>
  <field_pretty_url>longer-childhood-survivor-lifespans</field_pretty_url>
  <para_id>963862</para_id>
  <related_resource_ids>6572600</related_resource_ids>
  <related_resource_ids>6572601</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11966</term_id>
  <id>12880</id>
  <title>Testicular Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Testicular Cancer</field_short_title>
  <field_page_description>Testicular cancer most often begins in germ cells (cells that make sperm). It is rare and is most frequently diagnosed in men 20-34 years old. Most testicular cancers can be cured, even if diagnosed at an advanced stage. Start here to find information on testicular cancer treatment, screening, and statistics.</field_page_description>
  <field_feature_card_description>Most testicular cancers can be cured even if they are diagnosed at an advanced stage. Learn more.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about testicular cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>12880</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>929956</id>
  <title>A Story of Discovery: Natural Compound Helps Treat Breast and Ovarian Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Science and Nature Team Up Against Breast and Ovarian Cancers</field_short_title>
  <field_page_description>NCI Story of Discovery describes how researchers discover the lifesaving compound Taxol, a drug now commonly used to treat breast and ovarian cancers.</field_page_description>
  <field_list_description>Nature provides NCI researchers with one of the best cancer drugs currently available to treat breast and ovarian cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-31</field_date_posted>
  <field_date_reviewed>2015-04-08</field_date_reviewed>
  <field_pretty_url>taxol</field_pretty_url>
  <para_id>929956</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>930347</id>
  <title>Facilitating Research, Fueling Collaboration: Dr. Frank McCormick on the RAS Initiative</title>
  <langcode>en</langcode>
  <field_short_title>Facilitating Research, Fueling Collaboration: Dr. Frank McCormick on the RAS Initiative</field_short_title>
  <field_page_description>Frank McCormick, Ph.D., talks about the history, the challenges, and the future of research on RAS gene mutations, which drive more than 30 percent of all human cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-09</field_date_posted>
  <field_date_reviewed>2015-04-09</field_date_reviewed>
  <field_pretty_url>mccormick-qa</field_pretty_url>
  <para_id>930347</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>930560</id>
  <title>Grantee Spotlight: Jennie Williams, Ph.D. - Investigating Genetic Biomarkers for Colon Cancer in African Americans</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Jennie Williams, Ph.D.</field_short_title>
  <field_page_description>Dr. Jennie Williams is investigating, through an NCI-supported R01 grant, what role molecular genetics plays in the initiation of colon cancer in African-Americans and cancer health disparities.</field_page_description>
  <field_feature_card_description>Dr. J. Williams investigates molecular genetics in colon cancer in African-Americans. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-09</field_date_posted>
  <field_date_reviewed>2015-04-09</field_date_reviewed>
  <field_pretty_url>williams-spotlight</field_pretty_url>
  <para_id>930560</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936147</id>
  <title>Grantee Spotlight: Rafael E. Guerrero-Preston, Dr.P.H., M.P.H. - Exploring Genetic and Epigenetic Factors Underlying Head and Neck Cancer Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Rafael E. Guerrero-Preston, Dr.P.H., M.P.H.  </field_short_title>
  <field_page_description>Dr. Rafael E. Guerrero-Preston, an NCI/CRCHD K01 grantee, presented findings from his research on epigenomic biomarkers to improve head and neck cancer early detection and clinical management, and reduce survival disparities.</field_page_description>
  <field_feature_card_description>Dr. Guerrero-Preston presented findings from his epigenomic research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-11</field_date_posted>
  <field_date_reviewed>2014-08-11</field_date_reviewed>
  <field_pretty_url>preston-spotlight-blog</field_pretty_url>
  <para_id>936147</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>937762</id>
  <title>Special Spotlight: Levi A. Garraway, M.D., Ph.D., Receives Prestigious Jane Cooke Wright Award from American Association for Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: Levi A. Garraway, M.D., Ph.D.</field_short_title>
  <field_page_description>Dr. Levi A. Garraway, a former CRCHD CURE trainee, received the prestigious Jane Cooke Wright Lectureship Award at the 2014 meeting of the American Association for Cancer Research and presented "The Cancer Genome in Biology, Therapy, and Drug Resistance.”</field_page_description>
  <field_feature_card_description>Dr. Garraway received the 2014 Jane Cooke Wright Lectureship Award.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-17</field_date_posted>
  <field_date_reviewed>2014-04-17</field_date_reviewed>
  <field_pretty_url>garraway-spotlight</field_pretty_url>
  <para_id>937762</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939329</id>
  <title>Scientific Cooperation Between the U.S. and the Republic of South Africa Funds 7 Cancer-Specific Projects</title>
  <langcode>en</langcode>
  <field_short_title>Scientific Cooperation Between the U.S. and the Republic of South Africa Funds 7 Cancer-Specific Pro</field_short_title>
  <field_page_description>The NIH has recently awarded its first round of grants in a parallel U.S.-South Africa funding opportunity. Initiatives funded through this program will advance biomedical research for tuberculosis and HIV/AIDS in not only the US and South Africa, but will contribute to the global wealth of knowledge of these diseases.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-27</field_date_posted>
  <field_date_reviewed>2015-04-27</field_date_reviewed>
  <field_pretty_url>southafrica-collaboration</field_pretty_url>
  <para_id>939329</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939440</id>
  <title>Advancing Global Cancer Research @ AACR 2015</title>
  <langcode>en</langcode>
  <field_short_title>Advancing Global Cancer Research @ AACR 2015</field_short_title>
  <field_page_description>Research Priorities for NCI’s Center for Global Health' and included presentations on our mission, objectives, currently funded programs, and future programs given by Dr. Lisa Stevens and Paul Pearlman, as well as three special presentations by NCI grantees. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-27</field_date_posted>
  <field_date_reviewed>2015-04-27</field_date_reviewed>
  <field_pretty_url>AACR</field_pretty_url>
  <para_id>939440</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939851</term_id>
  <id>939858</id>
  <title>Bladder Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Bladder Cancer </field_short_title>
  <field_page_description>Transitional cell carcinoma of the bladder can be low-grade or high-grade. Bladder cancer is also divided into muscle-invasive and nonmuscle-invasive disease. Find evidence-based information on bladder cancer including treatment, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Bladder Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939858</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938032</term_id>
  <id>939929</id>
  <title>Brain Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on brain cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939929</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121491</id>
  <title>TCGA's Study of Endometrial Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Endometrial Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Endometrial Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Endometrial Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of endometrial (uterine) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-06</field_date_posted>
  <field_date_reviewed>2018-08-06</field_date_reviewed>
  <field_pretty_url>uterine</field_pretty_url>
  <para_id>1121491</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121494</term_id>
  <id>1121495</id>
  <title>Establish a Network for Direct Patient Engagement</title>
  <langcode>en</langcode>
  <field_short_title>Direct Patient Engagement Network</field_short_title>
  <field_page_description>This Cancer Moonshot initiative will engage patients to contribute their tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer. A patient’s genomic data may guide treatment decisions.</field_page_description>
  <field_feature_card_description>Engaging patients to contribute their tumor profile data will improve data sharing and expand knowledge about cancer and its outcomes across patient populations.</field_feature_card_description>
  <field_list_description>Engage patients to contribute their comprehensive tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-06</field_date_reviewed>
  <para_id>1121495</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121591</id>
  <title>TCGA's Study of Urothelial Bladder Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Urothelial Bladder Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Urothelial Bladder Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Urothelial Bladder Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of muscle-invasive urothelial bladder carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-07</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>bladder</field_pretty_url>
  <para_id>1121591</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121684</term_id>
  <id>1121685</id>
  <title>Generation of Human Tumor Atlases</title>
  <langcode>en</langcode>
  <field_short_title>Generation of Human Tumor Atlases</field_short_title>
  <field_page_description>Human tumor atlases act as maps that describe the multidimensional cellular, structural, and molecular characteristics of human cancers over time. This information will improve understanding of how cancers develop and respond to treatment, ultimately improving care.</field_page_description>
  <field_feature_card_description>The development of tumor atlases will help researchers better understand how tumors progress over time and respond to treatment.</field_feature_card_description>
  <field_list_description>Create dynamic 3D maps of human tumor evolution to document the genetic lesions and cellular interactions of each tumor as it evolves from a precancerous lesion to advanced cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-09</field_date_reviewed>
  <para_id>1121685</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1123624</term_id>
  <id>1123625</id>
  <title>NCI Community Oncology Research Program (NCORP)</title>
  <langcode>en</langcode>
  <field_short_title>NCI Community Oncology Research Program (NCORP)</field_short_title>
  <field_page_description>The NCI Community Oncology Research Program (NCORP) is a community-based program that brings cancer clinical trials and cancer care delivery research to individuals in their own communities.</field_page_description>
  <field_feature_card_description>NCORP brings cancer trials and care delivery research to people in their communities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-27</field_date_posted>
  <field_date_reviewed>2018-08-27</field_date_reviewed>
  <para_id>1123625</para_id>
  <related_resource_ids>7123515</related_resource_ids>
  <related_resource_ids>7123516</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>762611</term_id>
  <id>1124223</id>
  <title>2018 World Cancer Congress</title>
  <langcode>en</langcode>
  <field_short_title>2018 World Cancer Congress</field_short_title>
  <field_page_description>The 2018 World Cancer Congress features the latest successful interventions in cancer prevention, diagnosis, treatment and care. View a schedule of NCI activities at this year's Congress.  </field_page_description>
  <field_list_description>NCI activities at the 2018 World Cancer Congress</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-14</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <field_pretty_url>wcc2018</field_pretty_url>
  <para_id>1124223</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916971</term_id>
  <id>587661</id>
  <title>Contributing to Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Contributing to Cancer Research</field_short_title>
  <field_page_description>Information about donating money to cancer research and contributing in other ways, such as volunteering, donating tissue, or participating in a research study.</field_page_description>
  <field_feature_card_description>Information about donating money to cancer research and contributing in other ways.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-21</field_date_posted>
  <field_date_reviewed>2013-06-18</field_date_reviewed>
  <para_id>587661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941081</term_id>
  <id>941086</id>
  <title>Thymoma and Thymic Carcinoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Thymoma and Thymic Carcinoma </field_short_title>
  <field_page_description>Thymomas and thymic carcinomas are epithelial tumors of the thymus. A thymic epithelial tumor that exhibits cytologic atypia and histologic features no longer specific to the thymus is known as a thymic carcinoma. Find evidence-based information on thymoma and thymic carcinoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about thymoma and thymic carcinoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941086</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>941168</term_id>
  <id>941176</id>
  <title>Uterine Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on uterine cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941176</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>922517</term_id>
  <id>941434</id>
  <title>NCI Senior Leadership</title>
  <langcode>en</langcode>
  <field_short_title>NCI Senior Leadership</field_short_title>
  <field_page_description>Information about NCI Director and other senior NCI leaders.</field_page_description>
  <field_feature_card_description>Information about NCI Director Norman Sharpless, M.D., and other senior NCI leaders.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941434</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>280109</term_id>
  <id>953974</id>
  <title>Digital Standards for NCI Websites and Social Media</title>
  <langcode>en</langcode>
  <field_short_title>NCI Digital Standards</field_short_title>
  <field_page_description>NCI digital standards provide content managers and developers guidance on content standards, visual design and branding, and policies and procedures in effect for NCI digital media. </field_page_description>
  <field_feature_card_description>Content standards, visual design and branding standards, and policies and procedures in effect for NCI digital media. </field_feature_card_description>
  <field_list_description>The National Cancer Institute's digital standards provide content managers and developers guidance on content standards, visual design and branding standards, as well as policies and procedures in effect for NCI digital media. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-14</field_date_posted>
  <field_date_reviewed>2015-05-14</field_date_reviewed>
  <para_id>953974</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>959693</id>
  <title>Pembrolizumab Improves Overall Survival in Patients with Advanced Melanoma </title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab for Advanced Melanoma</field_short_title>
  <field_page_description>A summary of results from a randomized phase III study that showed pembrolizumab (Keytruda®) improved survival in patients with advanced melanoma compared with Ipilimumab (Yervoy®).</field_page_description>
  <field_feature_card_description>Pembrolizumab (Keytruda®) improves survival in patients with advanced melanoma compared with Ipilimumab (Yervoy®).</field_feature_card_description>
  <field_list_description>In a randomized phase III study, pembrolizumab (Keytruda®) improved survival in patients with advanced melanoma compared with Ipilimumab (Yervoy®).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-26</field_date_posted>
  <field_date_reviewed>2015-05-26</field_date_reviewed>
  <field_pretty_url>pembrolizumab</field_pretty_url>
  <para_id>959693</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916844</term_id>
  <id>966144</id>
  <title>Download the NCI FYI Mobile App</title>
  <langcode>en</langcode>
  <field_short_title>Download the NCI FYI Mobile App</field_short_title>
  <field_page_description>The NCI FYI mobile application offers a centralized source of available resources to fellows and trainees working at NCI in Maryland.</field_page_description>
  <field_feature_card_description>The NCI FYI mobile application offers a centralized source of available resources to fellows and trainees working on the NIH main Campus in Bethesda, MD, off campus in the surrounding area in Rockville, MD and Frederick, MD.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-10</field_date_posted>
  <field_date_reviewed>2015-06-10</field_date_reviewed>
  <field_pretty_url>fyi-app</field_pretty_url>
  <para_id>966144</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>966169</id>
  <title>CURE Spotlight: Cesar Castro, M.D. Develops Smartphone Technology for Cancer Detection in Underserved Communities</title>
  <langcode>en</langcode>
  <field_short_title>CURE Spotlight: Cesar Castro, M.D. </field_short_title>
  <field_page_description>Dr. Cesar Castro, a former K12 CURE scholar, and a team of researchers have developed a smartphone-based technology that converts a smartphone into a tool for cancer diagnosis.</field_page_description>
  <field_feature_card_description>Dr. Castro developed technology that uses a smartphone as cancer diagnosis tool.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-10</field_date_posted>
  <field_date_reviewed>2015-06-10</field_date_reviewed>
  <field_pretty_url>castro-spotlight</field_pretty_url>
  <para_id>966169</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>588480</id>
  <title>Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors</field_short_title>
  <field_page_description>In this phase III trial, people who have had curative surgery for colon cancer will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months.</field_page_description>
  <field_feature_card_description>In this phase III trial, people who have had curative surgery for colon cancer will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months.</field_feature_card_description>
  <field_list_description>In this phase III trial, people who have undergone curative surgery for stage 0-3 colon cancer, with or without adjuvant chemotherapy, will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-06-20</field_date_posted>
  <field_date_reviewed>2013-06-20</field_date_reviewed>
  <field_pretty_url>eflornithine-sulindac</field_pretty_url>
  <para_id>588480</para_id>
  <related_resource_ids>6494577</related_resource_ids>
  <related_resource_ids>6494578</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938139</term_id>
  <id>941026</id>
  <title>Soft Tissue Sarcoma Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on soft tissue sarcoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941026</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941166</term_id>
  <id>941175</id>
  <title>Uterine Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Uterine Cancer</field_short_title>
  <field_page_description>Most uterine cancers start in the endometrium, which is called endometrial cancer. Uterine sarcoma is a form of uterine cancer of the muscle and tissue that support the uterus. Find evidence-based information on uterine cancer treatment, causes and prevention, screening, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about uterine cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941175</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941229</term_id>
  <id>941234</id>
  <title>Vulvar Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Vulvar Cancer </field_short_title>
  <field_page_description>Vulvar cancer forms in a woman's external genitalia, and most often affects the outer vaginal lips. Having vulvar intraepithelial neoplasia or HPV infection can affect the risk of vulvar cancer. Find evidence-based information on vulvar cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about vulvar cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941234</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>915352</term_id>
  <id>941395</id>
  <title>Causes and Prevention Research</title>
  <langcode>en</langcode>
  <field_short_title>Causes and Prevention Research</field_short_title>
  <field_page_description>Find the latest research articles on cancer causes and risk factors for cancers and how some cancers may be prevented.</field_page_description>
  <field_feature_card_description>The latest research on causes and risk factors for cancers and how some cancers may be prevented.</field_feature_card_description>
  <field_list_description>Find research articles on cancer causes and prevention, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941395</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917293</term_id>
  <id>941581</id>
  <title>Resources for Patients</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Patients</field_short_title>
  <field_page_description>Authoritative information about your type of cancer, as well as information on a wide range of cancer topics and the latest cancer research. </field_page_description>
  <field_feature_card_description>We offer authoritative information about your type of cancer as well as general information about cancer, coping and other supportive care resources, and the latest cancer research. Also find NCI-supported clinical trials. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917291</term_id>
  <id>941598</id>
  <title>Information for the Cancer Research Community </title>
  <langcode>en</langcode>
  <field_short_title>Resources for the Cancer Research Community </field_short_title>
  <field_page_description>Find research and development tools, datasets, information about research training programs, and basics about applying for and managing grants.</field_page_description>
  <field_feature_card_description>Find NCI grants, training opportunities, information about the NCI grants process, and the latest research news.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941598</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>953644</id>
  <title>Welcome to the New Cancer.gov</title>
  <langcode>en</langcode>
  <field_short_title>Welcome to the New Cancer.gov</field_short_title>
  <field_page_description>NCI has launched a new, dynamic, and easier-to-use version of NCI’s main websites, Cancer.gov and its counterpart in Spanish, Cancer.gov/espanol.</field_page_description>
  <field_feature_card_description>What’s true for cancer research is true for websites: there’s no progress without change.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2015-05-14</field_date_reviewed>
  <field_pretty_url>new-website</field_pretty_url>
  <para_id>953644</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>962601</term_id>
  <id>962602</id>
  <title>Building a Diverse Workforce</title>
  <langcode>en</langcode>
  <field_short_title>Building a Diverse Workforce</field_short_title>
  <field_page_description>Find information about cancer research training for those from backgrounds underrepresented in cancer biomedical and behavioral sciences.</field_page_description>
  <field_feature_card_description>Learn about training opportunities for those from populations typically underrepresented in cancer research careers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-01</field_date_posted>
  <field_date_reviewed>2015-06-01</field_date_reviewed>
  <para_id>962602</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>962855</id>
  <title>Whole Brain Radiation for Some Patients with Brain Metastases Worsens Cognitive Decline </title>
  <langcode>en</langcode>
  <field_short_title>Brain Metastases Treatment Worsens Cognitive Decline </field_short_title>
  <field_page_description>In some patients with cancer that has spread to the brain, whole brain radiation following radiosurgery causes more severe cognitive decline and does not improve survival compared with radiosurgery alone, a new study has found.</field_page_description>
  <field_feature_card_description>Treating brain metastases with two forms of radiation may cause worse cognitive decline than just using one.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-02</field_date_posted>
  <field_date_reviewed>2015-06-02</field_date_reviewed>
  <field_pretty_url>brainmets-radiation</field_pretty_url>
  <para_id>962855</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>966675</id>
  <title>Enhancing the Clinical Trials Search Function on Cancer.gov</title>
  <langcode>en</langcode>
  <field_short_title>Enhancing the Clinical Trials Search Function on Cancer.gov</field_short_title>
  <field_page_description>The enhanced clinical trials search function on Cancer.gov will allow users to more easily find accurate and timely information about active and recruiting NCI-supported clinical trials.</field_page_description>
  <field_feature_card_description>Find accurate, timely information about NCI-supported clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-16</field_date_posted>
  <field_date_reviewed>2015-06-16</field_date_reviewed>
  <field_pretty_url>trials-search</field_pretty_url>
  <para_id>966675</para_id>
  <related_resource_id>6613694</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917216</term_id>
  <id>1126631</id>
  <title>Using Tandem Transplants to Treat Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Using Tandem Transplants to Treat Neuroblastoma-Julie Park, M.D.</field_short_title>
  <field_page_description>Learn how an NCI-supported trial led by Julie Park established a new standard of care for children with high-risk neuroblastoma. </field_page_description>
  <field_feature_card_description>Julie Park, M.D., led a trial for neuroblastoma that changed the way the disease is treated in the United States.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>julie-park-tandem-transplants-treat-neuroblastoma</field_pretty_url>
  <para_id>1126631</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1130980</id>
  <title>Meticulous Reconstructions of Tumor Origins With Single-Cell DNA Sequencing: Researcher Interview with Nicholas Navin</title>
  <langcode>en</langcode>
  <field_short_title>Nicholas Navin on Single-Cell DNA Sequencing</field_short_title>
  <field_page_description>A pioneer in single-cell DNA sequencing talks about the technology and the research it enables.</field_page_description>
  <field_feature_card_description>Researcher Interview on Single-Cell DNA Sequencing </field_feature_card_description>
  <field_list_description>Dr. Nicholas Navin talks about single-cell DNA sequencing and his research, considerations for working in the single-cell sequencing space, and what’s next for his lab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-11-27</field_date_posted>
  <field_date_reviewed>2018-11-14</field_date_reviewed>
  <field_pretty_url>interview-scDNA-seq</field_pretty_url>
  <para_id>1130980</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1131168</id>
  <title>Olaparib after Initial Treatment Delays Ovarian Cancer Progression</title>
  <langcode>en</langcode>
  <field_short_title>Olaparib Maintenance Therapy Delays Ovarian Cancer Progression</field_short_title>
  <field_page_description>Could results from the SOLO-1 trial change the standard of care for women with newly diagnosed ovarian cancer that harbors a BRCA mutation?</field_page_description>
  <field_feature_card_description>The PARP inhibitor delayed progression of tumors with a BRCA mutation.</field_feature_card_description>
  <field_list_description>In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of chemotherapy. Could the findings change the standard of care for newly diagnosed ovarian cancer with a BRCA mutation?</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-20</field_date_posted>
  <field_date_reviewed>2018-11-16</field_date_reviewed>
  <field_pretty_url>ovarian-cancer-olaparib-maintenance-therapy</field_pretty_url>
  <para_id>1131168</para_id>
  <related_resource_id>7195298</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1132090</term_id>
  <id>1132069</id>
  <title>National CryoEM Facility Acknowledged User Publications</title>
  <langcode>en</langcode>
  <field_short_title>Acknowledged Publications from National CryoEM Facility’s Users</field_short_title>
  <field_page_description> The National CryoEM Facility provides cancer researchers access to the latest technology for high resolution imaging. View a list of acknowledged publications from National CryoEM Facility’s users.</field_page_description>
  <field_feature_card_description>View a list of acknowledged publications from National CryoEM Facility’s users.</field_feature_card_description>
  <field_list_description>View a list of acknowledged publications from National CryoEM Facility’s users. The National CryoEM Facility provides cancer researchers access to the latest technology for high resolution imaging.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-03</field_date_posted>
  <field_date_reviewed>2018-12-03</field_date_reviewed>
  <field_pretty_url>ncef-publications</field_pretty_url>
  <para_id>1132069</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1132182</term_id>
  <id>1132183</id>
  <title>TCGA Contact Information</title>
  <langcode>en</langcode>
  <field_short_title>Contact TCGA</field_short_title>
  <field_page_description>Find contact information for The Cancer Genome Atlas Program.</field_page_description>
  <field_list_description>For more information about The Cancer Genome Atlas program, reach out to a member of the team.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-12-05</field_date_reviewed>
  <para_id>1132183</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1132190</id>
  <title>Teaching in Medical Education</title>
  <langcode>en</langcode>
  <field_short_title>Teaching in Medical Education</field_short_title>
  <field_page_description>The Teaching in Medical Education (TIME) course provides NCI postdoctoral fellows with basic knowledge in teaching methods, course planning, writing a syllabus and developing examinations. This course is for postdoctoral fellows interested in pursing an academic career at a medical school.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-05</field_date_posted>
  <field_date_reviewed>2018-12-05</field_date_reviewed>
  <field_pretty_url>teaching-medical-education</field_pretty_url>
  <para_id>1132190</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1132734</id>
  <title>Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows</title>
  <langcode>en</langcode>
  <field_short_title>Vitamin D Supplements Don’t Reduce Cancer Incidence</field_short_title>
  <field_page_description>Taking vitamin D supplements doesn’t decrease cancer risk, according to results from VITAL, the largest-ever clinical trial of vitamin D for cancer prevention. </field_page_description>
  <field_feature_card_description>In the VITAL trial, the supplement did not lower the risk of developing cancer.</field_feature_card_description>
  <field_list_description>In the largest-ever randomized trial testing vitamin D for cancer prevention, the supplement did not lower the risk of developing cancer. The Vitamin D and Omega-3 Trial (VITAL) includes a nationally representative sample of nearly 26,000 participants.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-13</field_date_posted>
  <field_date_reviewed>2018-12-12</field_date_reviewed>
  <field_pretty_url>vitamin-d-supplement-cancer-prevention</field_pretty_url>
  <para_id>1132734</para_id>
  <related_resource_id>7186031</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917505</term_id>
  <id>917508</id>
  <title>Complementary and Alternative Medicine for Health Professionals</title>
  <langcode>en</langcode>
  <field_short_title>CAM for Health Professionals</field_short_title>
  <field_page_description>Health professional information about healing philosophies, approaches, and therapies used in complementary and alternative medicine (CAM) in cancer care.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-10</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917508</para_id>
  <related_resource_ids>7162476</related_resource_ids>
  <related_resource_ids>7162477</related_resource_ids>
  <related_resource_ids>7162478</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>917548</id>
  <title>Grantee Spotlight: Sunday O. Akintoye, B.D.S., D.D.S., M.S.- Studying the Biology of Bone Cells to Reduce Head and Neck Cancer Treatment Complications </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Sunday O. Akintoye, B.D.S., D.D.S., M.S.- Studying the Biology of Bone Cells </field_short_title>
  <field_page_description>Dr. Sunday O. Akintoye, a CRCHD CURE grantee, is studying the behavior of jaw bone stem cells and complications related to cancer treatment. </field_page_description>
  <field_feature_card_description>Dr. Akintoye studies jaw bone stem cells and cancer-related complications.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-20</field_date_posted>
  <field_date_reviewed>2014-08-20</field_date_reviewed>
  <field_pretty_url>akintoye-blog</field_pretty_url>
  <para_id>917548</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>918999</term_id>
  <id>919000</id>
  <title>Resources for News Media</title>
  <langcode>en</langcode>
  <field_short_title>Resources for News Media</field_short_title>
  <field_page_description>Resources to help the news media provide accurate, timely information and disseminate cancer research news. </field_page_description>
  <field_feature_card_description>Resources to help the news media provide accurate, timely information and disseminate cancer research news. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-23</field_date_posted>
  <field_date_reviewed>2015-03-23</field_date_reviewed>
  <para_id>919000</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>919120</id>
  <title>Who Will Respond to PD-1 Inhibition? Study Provides Clues</title>
  <langcode>en</langcode>
  <field_short_title>Who Will Respond to PD-1 Inhibition? Study Provides Clues</field_short_title>
  <field_page_description>A new study shows that specific DNA changes in a tumor may help determine which patients are most likely to respond to treatment with PD-1 inhibitors</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-24</field_date_posted>
  <field_date_reviewed>2015-03-24</field_date_reviewed>
  <field_pretty_url>pd-1-inhibition</field_pretty_url>
  <para_id>919120</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>919564</id>
  <title>Mapping International Cancer Activities – Global Cancer Project Map Launch</title>
  <langcode>en</langcode>
  <field_short_title>Mapping International Cancer Activities – Global Cancer Project Map Launch</field_short_title>
  <field_page_description>CGH’s Dr. Sudha Sivaram, Dr. Makeda Williams, and Ms. Kalina Duncan have partnered with Drs. Ami Bhatt and Franklin Huang at Global Oncology, Inc. (GO) to develop the Global Cancer Project Map - a web-based tool designed to facilitate cancer research and control activity planning.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-25</field_date_posted>
  <field_date_reviewed>2015-03-25</field_date_reviewed>
  <field_pretty_url>gcpm</field_pretty_url>
  <para_id>919564</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919680</term_id>
  <id>919682</id>
  <title>Blogs and Newsletters</title>
  <langcode>en</langcode>
  <field_short_title>Blogs and Newsletters</field_short_title>
  <field_page_description>Blogs and newsletters featured on the Cancer.gov website.</field_page_description>
  <field_feature_card_description>Blogs and newsletters featured on Cancer.gov.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-16</field_date_posted>
  <field_date_reviewed>2015-03-25</field_date_reviewed>
  <para_id>919682</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129047</term_id>
  <id>1120005</id>
  <title>Data Types Collected by TCGA</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Data Types</field_short_title>
  <field_page_description>Learn about the molecular and clinical data generated for TCGA samples.</field_page_description>
  <field_list_description>Documentation of sample processing and the molecular and clinical data generated for TCGA's samples, including case enrollment, processing of biospeciments into molecular analytes, and the different types of molecular characterization.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-07-17</field_date_reviewed>
  <para_id>1120005</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120760</id>
  <title>TCGA's Study of Clear Cell Renal Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Clear Cell Renal Cell Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Clear Cell Renal Cell Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Clear Cell Renal Cell Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of clear cell renal cell (kidney) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-27</field_date_posted>
  <field_date_reviewed>2018-07-27</field_date_reviewed>
  <field_pretty_url>renal-cell-clear-cell</field_pretty_url>
  <para_id>1120760</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>919139</id>
  <title>FDA Approves First Immunotherapy Treatment for Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves First Immunotherapy Treatment for Lung Cancer</field_short_title>
  <field_page_description>The FDA has approved nivolumab to treat patients with advanced non-small cell lung cancer that has progressed during or after treatment with platinum-based chemotherapy.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-24</field_date_posted>
  <field_date_reviewed>2015-03-24</field_date_reviewed>
  <field_pretty_url>fda-opdivo</field_pretty_url>
  <para_id>919139</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919143</term_id>
  <id>919144</id>
  <title>Sleep Problems (Insomnia) and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Sleep Problems</field_short_title>
  <field_page_description>Sleep problems are a common side effect during cancer treatment. Learn how a polysomnogram can assess sleep problems. Learn about the benefits of managing sleep disorders in men and women with cancer. </field_page_description>
  <field_list_description>Information about sleep problems, a side effect of some cancer treatments, and ways to manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-04-11</field_date_reviewed>
  <para_id>919144</para_id>
  <related_resource_id>7091853</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>899356</term_id>
  <id>920152</id>
  <title>Annual Report to the Nation on the Status of Cancer, 1975 -2011: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Annual Report to the Nation on the Status of Cancer, 1975 -2011: Questions and Answers</field_short_title>
  <field_page_description>This report provides a yearly update of cancer incidence (new cases) and mortality (death) rates, and trends in these rates in the United States. The special feature section of this year’s report highlights the incidence of breast cancer subtypes by race,</field_page_description>
  <field_list_description>This report provides a yearly update of cancer incidence (new cases) and mortality (death) rates, and trends in these rates in the United States. The special feature section of this year’s report highlights the incidence of breast cancer subtypes by race, ethnicity, poverty level and state.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-26</field_date_reviewed>
  <field_pretty_url>report-nation-march-2015-qanda</field_pretty_url>
  <para_id>920152</para_id>
  <related_resource_ids>5269498</related_resource_ids>
  <related_resource_ids>5269499</related_resource_ids>
  <related_resource_ids>5269502</related_resource_ids>
  <related_resource_ids>5269503</related_resource_ids>
  <related_resource_ids>5269693</related_resource_ids>
  <related_resource_ids>5269694</related_resource_ids>
  <related_resource_ids>5269696</related_resource_ids>
  <related_resource_ids>5269697</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121522</id>
  <title>TCGA's Study of Head and Neck Squamous Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Head and Neck Squamous Cell Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Head and Neck Squamous Cell Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Head and Neck Squamous Cell Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of head and neck squamous cell carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-07</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>head-and-neck</field_pretty_url>
  <para_id>1121522</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1121561</id>
  <title>Tailored Psychotherapy Eases Depression in People with Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Easing Depression in People with Advanced Cancer</field_short_title>
  <field_page_description>In people recently diagnosed with advanced cancer, a tailored psychotherapy approach called CALM lessened symptoms of depression, results from a clinical trial show. The approach also may help prevent depression, this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Tailored psychotherapy approach helps combat common problem.</field_feature_card_description>
  <field_list_description>Just three to six sessions of a tailored psychotherapy approach called CALM helped to lessen symptoms of depression in people recently diagnosed with advanced cancer, results from a clinical trial show. The approach also may help prevent depression, researchers found.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-09</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>advanced-cancer-calm-therapy-reduces-depression</field_pretty_url>
  <para_id>1121561</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1123401</id>
  <title>Enhancements to NCI’s SEER Program Creating New Research Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>SEER Creating New Research Opportunities</field_short_title>
  <field_page_description>NCI’s SEER program is expanding and operating a series of pilot studies that, as Dr. Lynne Penberthy explains, are focused on the routine collection of more clinical and genomic data to help researchers better understand cancer and its impact.</field_page_description>
  <field_feature_card_description>Pilot studies focused on collecting more clinical, genomic data.</field_feature_card_description>
  <field_list_description>NCI’s SEER program is expanding in size and operating a series of innovative pilot studies. As Dr. Lynne Penberthy explains, these studies are setting the stage for the routine collection of more clinical and genomic data that will help researchers better understand cancer and its impact.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-23</field_date_posted>
  <field_date_reviewed>2018-08-23</field_date_reviewed>
  <field_pretty_url>nci-seer-enhancements-creating-opportunities</field_pretty_url>
  <para_id>1123401</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1123783</id>
  <title>Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combination Blocks Driver of Breast and Other Cancers</field_short_title>
  <field_page_description>Arsenic trioxide and retinoic acid work together to target Pin1, a master regulator protein that drives breast and other cancers. The findings could spur clinical trials, as this Cancer Currents blog explains.</field_page_description>
  <field_feature_card_description>Drugs work together to slow triple-negative breast cancer in mice.</field_feature_card_description>
  <field_list_description>Arsenic trioxide and retinoic acid work together to target the master regulator protein Pin1, a new study shows. In cancer cell lines and mice, the drug combination slowed the growth of triple-negative breast cancer tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-04</field_date_posted>
  <field_date_reviewed>2018-09-04</field_date_reviewed>
  <field_pretty_url>arsenic-retinoic-acid-cancer-master-regulator</field_pretty_url>
  <para_id>1123783</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915624</term_id>
  <id>915663</id>
  <title>Public Health Research and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Public Health Research and Cancer</field_short_title>
  <field_page_description>Population-based cancer research can provide important information that influences practices, policies, and programs that directly affect and could improve public health.</field_page_description>
  <field_feature_card_description>Studying cancer and its burden on a population-wide scale can provide information that directly affects the health of millions of people.</field_feature_card_description>
  <field_list_description>Studying cancer and its burden on a population-wide scale can provide important information that influences practices, policies, and programs that directly affect the health of millions of people in the United States each year.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-07</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915663</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915801</term_id>
  <id>916017</id>
  <title>Talking about Your Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Talking about Your Advanced Cancer</field_short_title>
  <field_feature_card_description>Knowing your options and sharing them with others will make it easier for you to move forward with your care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916017</para_id>
  <related_resource_ids>7042107</related_resource_ids>
  <related_resource_ids>7042108</related_resource_ids>
  <related_resource_ids>7042116</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915813</term_id>
  <id>916031</id>
  <title>Advanced Cancer and Caregivers</title>
  <langcode>en</langcode>
  <field_short_title>Advanced Cancer and Caregivers</field_short_title>
  <field_page_description>Learn tips for taking care of yourself, coping with your feelings and grief, asking for help, ,communicating with your loved one about their wishes for care, talking to children about death</field_page_description>
  <field_list_description>Being a caregiver an advanced or metastatic cancer patient can be very hard and challenging in many ways. Learn tips for taking care of yourself and how to handle the challenges that arise during this time.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916031</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>941787</term_id>
  <id>916034</id>
  <title>Planning for the Caregiver</title>
  <langcode>en</langcode>
  <field_short_title>Planning for the Caregiver</field_short_title>
  <field_page_description>Caring for someone with advanced cancer brings its own challenges and concerns. Here are some planning tips that may help. </field_page_description>
  <field_feature_card_description>Caring for someone with advanced cancer brings its own challenges and concerns. Here are some planning tips that may help.  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916034</para_id>
  <related_resource_ids>6761369</related_resource_ids>
  <related_resource_ids>6761370</related_resource_ids>
  <related_resource_ids>6761371</related_resource_ids>
  <related_resource_ids>6761375</related_resource_ids>
  <related_resource_ids>6761376</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917000</term_id>
  <id>917205</id>
  <title>Accrual Reporting </title>
  <langcode>en</langcode>
  <field_short_title>Accrual Reporting </field_short_title>
  <field_page_description>An overview of accrual reporting requirements of clinical trials into the Clinical Trial Reporting Program.</field_page_description>
  <field_feature_card_description>An overview of accrual reporting requirements of clinical trials.   </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-17</field_date_posted>
  <field_date_reviewed>2015-03-17</field_date_reviewed>
  <para_id>917205</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917503</term_id>
  <id>917507</id>
  <title>Complementary and Alternative Medicine for Patients</title>
  <langcode>en</langcode>
  <field_short_title>CAM for Patients</field_short_title>
  <field_page_description>Patient information about philosophies, approaches, and therapies used in complementary and alternative medicine (CAM) in cancer care.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-10</field_date_posted>
  <field_date_reviewed>2015-03-18</field_date_reviewed>
  <para_id>917507</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>917513</id>
  <title>DNA "Minicircles" Could Improve Cancer Detection, Study Suggests</title>
  <langcode>en</langcode>
  <field_short_title>DNA "Minicircles" Could Improve Cancer Detection, Study Suggests</field_short_title>
  <field_page_description>Injecting customized DNA “rings” into tumor-bearing mice caused the tumor cells to release a biomarker that can be detected with a simple blood test.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-19</field_date_posted>
  <field_date_reviewed>2015-03-19</field_date_reviewed>
  <field_pretty_url>dna-minicircles</field_pretty_url>
  <para_id>917513</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918914</term_id>
  <id>918915</id>
  <title>Previous NCI Directors</title>
  <langcode>en</langcode>
  <field_short_title>Previous NCI Directors</field_short_title>
  <field_page_description>Find a listing of the previous directors of NCI.</field_page_description>
  <field_feature_card_description>Find a listing of the previous directors of NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-23</field_date_reviewed>
  <para_id>918915</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>919126</id>
  <title>The Exceptional Responders Initiative: Welcoming More Cases</title>
  <langcode>en</langcode>
  <field_short_title>The Exceptional Responders Initiative: Welcoming More Cases</field_short_title>
  <field_page_description>The initiative is studying tissue, clinical, and genomic data from patients with cancer who have had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-24</field_date_posted>
  <field_date_reviewed>2015-03-24</field_date_reviewed>
  <field_pretty_url>exceptional-responders-initiative</field_pretty_url>
  <para_id>919126</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1120154</id>
  <title>Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy </title>
  <langcode>en</langcode>
  <field_short_title>Immune Cells Linked to Diarrhea Caused by Chemotherapy</field_short_title>
  <field_page_description>A study in mice sheds light onto how some chemotherapies cause diarrhea. The findings could be the basis for developing new treatments for patients with cancer who develop gastrointestinal side effects from chemotherapy, explains this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>The findings in mice may lead to new treatments for this common side effect.</field_feature_card_description>
  <field_list_description>A study in mice sheds light onto how some chemotherapies cause diarrhea. The findings could be the basis for developing new treatments for patients with cancer who develop gastrointestinal side effects from chemotherapy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-20</field_date_posted>
  <field_date_reviewed>2018-07-19</field_date_reviewed>
  <field_pretty_url>macrophages-chemotherapy-induced-diarrhea</field_pretty_url>
  <para_id>1120154</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>675725</id>
  <title>CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers</title>
  <langcode>en</langcode>
  <field_short_title>CAR T Cells: Engineering Immune Cells to Treat Cancer</field_short_title>
  <field_page_description>Research on CAR T-cell therapy—a rapidly emerging form of cancer treatment, primarily for blood cancers like leukemia and lymphoma—is moving at a swift pace.</field_page_description>
  <field_feature_card_description>The field is poised to deliver new approved treatments.</field_feature_card_description>
  <field_list_description>CAR T-cell therapy is a rapidly emerging form of cancer treatment, primarily for blood cancers like leukemia and lymphoma. An article about research to improve CAR T-cell therapy and expand its use.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-12-06</field_date_posted>
  <field_date_reviewed>2013-12-04</field_date_reviewed>
  <field_pretty_url>car-t-cells</field_pretty_url>
  <para_id>675725</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919486</term_id>
  <id>722578</id>
  <title>Contact the Office of Advocacy Relations</title>
  <langcode>en</langcode>
  <field_short_title>Contact OAR</field_short_title>
  <field_page_description>Contact information for the Office of Advocacy Relations, including staff directory.</field_page_description>
  <field_feature_card_description>OAR contact information, including staff directory.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-11</field_date_posted>
  <field_date_reviewed>2014-03-11</field_date_reviewed>
  <para_id>722578</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974495</term_id>
  <id>974496</id>
  <title>Research Career Awards “K” Program</title>
  <langcode>en</langcode>
  <field_short_title>Research Career “K” Awards</field_short_title>
  <field_page_description>Career development "K" awards are a significant component of NCI’s training effort. See funding amounts and the percentage of total research career award funding.</field_page_description>
  <field_feature_card_description>Find information about "K" awards and the percentage of total research career award funding.</field_feature_card_description>
  <field_list_description>See the number and dollar amount for career development "K" awards and the percent of total research career award funding.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974496</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>979441</id>
  <title>Program Spotlight: CURE Scholars Participate in Annual Mock Grant Review to Prepare for Independent Research Careers</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: CURE Scholars Participate in Annual Mock Grant Review</field_short_title>
  <field_page_description>As part of its 2015 Professional Development Workshop, CRCHD held a mock review session for CURE scholars, trainees, and investigators to enhance their understanding of the grant review process and provide insight on successful grant applications.</field_page_description>
  <field_feature_card_description>CRCHD held a mock grant review to enhance understanding of the grant review process.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-23</field_date_posted>
  <field_date_reviewed>2015-07-23</field_date_reviewed>
  <field_pretty_url>MockReview-2015</field_pretty_url>
  <para_id>979441</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120758</id>
  <title>TCGA's Study of Cholangiocarcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Cholangiocarcinoma</field_short_title>
  <field_page_description>TCGA's Study of Cholangiocarcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Cholangiocarcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of cholangiocarcinoma (bile duct cancer), including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-27</field_date_posted>
  <field_date_reviewed>2018-07-27</field_date_reviewed>
  <field_pretty_url>cholangiocarcinoma</field_pretty_url>
  <para_id>1120758</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121294</id>
  <title>TCGA's Study of Colorectal Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Colorectal Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Colorectal Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Colorectal Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of colorectal (colon and rectal) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-03</field_date_posted>
  <field_date_reviewed>2018-08-03</field_date_reviewed>
  <field_pretty_url>colorectal</field_pretty_url>
  <para_id>1121294</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121521</id>
  <title>TCGA's Study of Glioblastoma Multiforme</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Glioblastoma Multiforme</field_short_title>
  <field_page_description>TCGA's Study of Glioblastoma Multiforme</field_page_description>
  <field_feature_card_description>TCGA's Study of Glioblastoma Multiforme</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of glioblastoma multiforme brain tumors, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-07</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>glioblastoma</field_pretty_url>
  <para_id>1121521</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1121562</id>
  <title>Clinical Trials to Treat Thymoma and Thymic Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Thymoma and Thymic Carcinoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-08-07</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>thymoma-thymic-carcinoma</field_pretty_url>
  <para_id>1121562</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1122430</id>
  <title>The International Rare Cancer Initiative</title>
  <langcode>en</langcode>
  <field_short_title>The International Rare Cancer Initiative</field_short_title>
  <field_page_description>The International Rare cancer Initiative focuses on rare cancers because they are a pressing public health priority. Read more to learn about how CGH pushes for practice-changing clinical trials in rare cancers.</field_page_description>
  <field_list_description>The International Rare cancer Initiative focuses on rare cancers because they are a pressing public health priority, and pushes for practice-changing clinical trials in rare cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-15</field_date_posted>
  <field_date_reviewed>2018-08-15</field_date_reviewed>
  <field_pretty_url>irci</field_pretty_url>
  <para_id>1122430</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1124101</term_id>
  <id>1124102</id>
  <title>Create a Pediatric Immunotherapy Discovery and Development Network (PI-DDN)</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Immunotherapy Network</field_short_title>
  <field_page_description>This Cancer Moonshot initiative aims to establish a pediatric cancer immunotherapy network to discover and characterize new targets for immunotherapies and ultimately develop new, effective immunotherapy treatments for children and adolescents with cancer.</field_page_description>
  <field_list_description>Generate a cancer immunotherapy research network to overcome challenges in the development of immunotherapies for childhood cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2017-10-30</field_date_reviewed>
  <para_id>1124102</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124216</id>
  <title>Moxetumomab Approved by FDA for Hairy Cell Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Moxetumomab Approved for Hairy Cell Leukemia</field_short_title>
  <field_page_description>FDA has approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the treatment of hairy cell leukemia (HCL). The approval covers the use of moxetumomab in patients with HCL who have already undergone standard treatments.</field_page_description>
  <field_feature_card_description>Bacterial-toxin based drug developed at NCI.</field_feature_card_description>
  <field_list_description>The FDA has approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the treatment of some patients with hairy cell leukemia (HCL). Moxetumomab is approved to treat patients with HCL who have already undergone at least two lines of standard treatments.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-14</field_date_posted>
  <field_date_reviewed>2018-09-13</field_date_reviewed>
  <field_pretty_url>moxetumomab-fda-hairy-cell-leukemia</field_pretty_url>
  <para_id>1124216</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1129127</id>
  <title>Reflections on My First Year as NCI Director</title>
  <langcode>en</langcode>
  <field_short_title>Reflections on My First Year as NCI Director</field_short_title>
  <field_page_description>October 2018 marked Dr. Norman Sharpless’s one-year anniversary as NCI director. He reflects on noteworthy events from the past 12 months.</field_page_description>
  <field_feature_card_description>Norman Sharpless, M.D., reflects on noteworthy events from the past 12 months.</field_feature_card_description>
  <field_list_description>October 2018 marked Dr. Norman Sharpless’s one-year anniversary as NCI director. He reflects on noteworthy events from the past 12 months and his excitement about leading NCI at such a critical juncture in the history of cancer research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-01</field_date_posted>
  <field_date_reviewed>2018-11-01</field_date_reviewed>
  <field_pretty_url>sharpless-first-year-nci-director</field_pretty_url>
  <para_id>1129127</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1130390</id>
  <title>Eight Factors May Link Disparities in Cancer Death Rates and Income</title>
  <langcode>en</langcode>
  <field_short_title>Factors May Link Disparities in Cancer Death Rates, Income</field_short_title>
  <field_page_description>Eight factors may explain more than 80% of the relationship between poverty and disparities in cancer death rates, according to a new study.</field_page_description>
  <field_feature_card_description>Eight factors may explain the link between poverty and cancer death disparities.</field_feature_card_description>
  <field_list_description>Eight factors may explain more than 80% of the relationship between poverty and disparities in cancer death rates at the county level, according to a new study. The largest mediator was a surprise to the researchers.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-08</field_date_posted>
  <field_date_reviewed>2018-11-08</field_date_reviewed>
  <field_pretty_url>factors-linking-cancer-death-income-disparities</field_pretty_url>
  <para_id>1130390</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1131543</id>
  <title>Study Improves the Quality of Biopsy Specimens for Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Improving the Quality of Cancer Research Biopsy Specimens </field_short_title>
  <field_page_description>NCI researchers have developed and tested recommendations for improving the quality of biopsy specimens collected from patients in cancer clinical trials.</field_page_description>
  <field_feature_card_description>Study provides recommendations for research teams.</field_feature_card_description>
  <field_list_description>An NCI-led team of researchers has developed and tested recommendations for improving the quality of biopsy specimens collected from patients participating in cancer clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-23</field_date_posted>
  <field_date_reviewed>2018-11-27</field_date_reviewed>
  <field_pretty_url>improving-cancer-research-biopsies</field_pretty_url>
  <para_id>1131543</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133180</term_id>
  <id>1133232</id>
  <title>SDH-deficient gastrointestinal stromal tumor (GIST)</title>
  <langcode>en</langcode>
  <field_short_title>SDH-deficient gastrointestinal stromal tumor (GIST)</field_short_title>
  <field_page_description>SDH-deficient gastrointestinal stromal tumor, or SDH-deficient GIST, is a type of digestive tract cancer. GIST is a fairly common type of cancer, but SDH-deficient GIST makes up only about 6% of GIST diagnoses. Learn more about how this tumor an run in families, the treatment, and the prognosis. </field_page_description>
  <field_list_description>SDH-deficient gastrointestinal stromal tumor, or SDH-deficient GIST, is a type of digestive tract cancer. GIST is a fairly common type of cancer, but SDH-deficient GIST makes up only about 6% of GIST diagnoses.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>sdh-deficient-gastrointestinal-stromal-tumor-gist</field_pretty_url>
  <para_id>1133232</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134576</term_id>
  <id>1133249</id>
  <title>Rare Tumor Workshops</title>
  <langcode>en</langcode>
  <field_short_title>Rare Tumor Workshops</field_short_title>
  <field_page_description>MyPART holds workshops to help scientists learn what to study about rare cancer and share research. Also, advocates discuss issues important to patients, clinicians share their experience treating the rare cancer, and FDA representatives help design experiments and clinical trials.</field_page_description>
  <field_feature_card_description>Workshops help scientists learn what to study about rare cancer and connect them with advocates, clinicians, and FDA representatives.</field_feature_card_description>
  <field_list_description>We hold workshops in the Center for Cancer Research to help scientists learn what to study about rare cancer. During the workshops, scientists share research, advocates discuss issues important to patients, clinicians share their experience treating the rare cancer, and FDA representatives help design experiments and clinical trials with the best chance of drug approval.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133249</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133222</id>
  <title>Alveolar soft part sarcomas</title>
  <langcode>en</langcode>
  <field_short_title>Alveolar soft part sarcomas</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>alveolar-soft-part-sarcomas</field_pretty_url>
  <para_id>1133222</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133225</id>
  <title>Inflammatory myofibroblastic tumor</title>
  <langcode>en</langcode>
  <field_short_title>Inflammatory myofibroblastic tumor</field_short_title>
  <field_page_description>Inflammatory myofibroblastic tumor, or IMT, forms in tissues called mucosal surfaces and mesentery. IMT usually starts in the lung, but it can also begin in many other places. IMTs are mostly found in children and young adults but can occur at any age. Learn more about treatment and the prognosis for IMT.</field_page_description>
  <field_feature_card_description>Inflammatory myofibroblastic tumor, or IMT, forms in tissues called mucosal surfaces and mesentery. IMTs are mostly found in children and young adults but can occur at any age.</field_feature_card_description>
  <field_list_description>Inflammatory myofibroblastic tumor, or IMT, forms in tissues called mucosal surfaces and mesentery. IMT usually starts in the lung, but it can also begin in many other places, including the bladder, uterus, larynx, stomach, liver, and intestine. IMTs are mostly found in children and young adults but can occur at any age.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>inflammatory-myofibroblastic-tumor</field_pretty_url>
  <para_id>1133225</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133184</term_id>
  <id>1133239</id>
  <title>Epithelioid hemangioendothelioma</title>
  <langcode>en</langcode>
  <field_short_title>Epithelioid hemangioendothelioma</field_short_title>
  <field_page_description>Epithelioid hemangioendothelioma (EHE or eHAE), is a rare cancer that grows from the cells that make up blood vessels.Because EHE is so rare, there is no standard treatment. Learn more about the diagnosis, treatment, and prognosis for this rare tumor.</field_page_description>
  <field_feature_card_description>Epithelioid hemangioendothelioma (EHE or eHAE), is a rare cancer that grows from the cells that make up blood vessels.</field_feature_card_description>
  <field_list_description>Epithelioid hemangioendothelioma (EHE or eHAE), is a rare cancer that grows from the cells that make up blood vessels. This cancer can occur anywhere in the body with the most common sites being the bones, liver, and lungs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>epithelioid-hemangioendothelioma</field_pretty_url>
  <para_id>1133239</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133468</term_id>
  <id>1133251</id>
  <title>Natural History Study of Rare Solid Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Natural History Study of Rare Solid Tumors</field_short_title>
  <field_page_description>By taking part in a natural history study, you can speed up the development of new treatments by giving researchers the tools they need to understand how cancer forms and grows and to find new treatments. </field_page_description>
  <field_feature_card_description>You can help speed up the development of new treatments by giving researchers the tools they need.</field_feature_card_description>
  <field_list_description>The purpose of a natural history study is to collect information, tissue and tumor samples, and data from patients to better understand how cancer develops and grows. When researchers don’t know how cancer grows it is much harder to design trials to test new treatments. Natural history studies help researchers understand cancer better.  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133251</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133198</term_id>
  <id>1133258</id>
  <title>New Research</title>
  <langcode>en</langcode>
  <field_short_title>New Research</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>new-research</field_pretty_url>
  <para_id>1133258</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133174</term_id>
  <id>1133525</id>
  <title>Rare Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Rare Tumors</field_short_title>
  <field_page_description>Rare tumors can form anywhere in the body. MyPART is studying tumors in several different body systems. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <para_id>1133525</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133192</term_id>
  <id>1133526</id>
  <title>Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>MyPART is working to address the challenges researchers face in studying rare cancers so we can find new treatments faster.</field_page_description>
  <field_feature_card_description>MyPART is working to address the challenges researchers face in studying rare cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <para_id>1133526</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133724</term_id>
  <id>1133725</id>
  <title>The Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)</title>
  <langcode>en</langcode>
  <field_short_title>New Early K99/R00 Award</field_short_title>
  <field_page_description>The early K99/R00 will help researchers to complete n needed mentored training and transition in a timely manner to independent, tenure-track or equivalent. </field_page_description>
  <field_list_description>The NIH Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) supports outstanding postdoctoral researchers who do not require extended periods of mentored research training beyond their doctoral degrees before
transitioning to research independence, which is common for those working in data science and cancer control science.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-27</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <para_id>1133725</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133753</term_id>
  <id>1133757</id>
  <title>NIH Fellows Editorial Board Editorial Process Guidelines</title>
  <langcode>en</langcode>
  <field_short_title>Editorial Process Guidelines</field_short_title>
  <field_page_description>Board members will review submitted documents following an editorial process and prepare final reports.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-21</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <field_pretty_url>editorial-process</field_pretty_url>
  <para_id>1133757</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1123937</id>
  <title>TCGA's Study of Lung Squamous Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Lung Squamous Cell Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Lung Squamous Cell Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Lung Squamous Cell Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of lung squamous cell carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-09-05</field_date_reviewed>
  <field_pretty_url>lung-squamous</field_pretty_url>
  <para_id>1123937</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124474</id>
  <title>Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the Brain</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Drugs Shrink Brain Metastases from Melanoma</field_short_title>
  <field_page_description>In patients with melanoma that has spread to the brain, the combination of the immune checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors, an early phase clinical trial shows. </field_page_description>
  <field_feature_card_description>Tumors shrink in some patients treated with checkpoint inhibitor combination.</field_feature_card_description>
  <field_list_description>Results from a clinical trial show that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors in more than half of participants with melanoma that had spread to the brain.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-20</field_date_posted>
  <field_date_reviewed>2018-09-18</field_date_reviewed>
  <field_pretty_url>melanoma-brain-metastases-nivolumab-ipilimumab</field_pretty_url>
  <para_id>1124474</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1090878</term_id>
  <id>1124679</id>
  <title>Annual Plan and Budget Proposal FY 2020 Coming Soon</title>
  <langcode>en</langcode>
  <field_short_title>Annual Plan and Budget Proposal FY 2020 Coming Soon</field_short_title>
  <field_page_description>Annual Plan and Budget Proposal FY 2020 Coming Soon</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-20</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <field_pretty_url>placeholder</field_pretty_url>
  <para_id>1124679</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1125012</id>
  <title>The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce</title>
  <langcode>en</langcode>
  <field_short_title>Ensuring a Stable Cancer Research Workforce</field_short_title>
  <field_page_description>NCI’s R50 Research Specialist Award was launched in 2016 to help sustain a stable workforce of experienced scientists who can take fullest advantage of advanced technologies and the era of big data.</field_page_description>
  <field_feature_card_description>R50 award supports experienced cancer research specialists.</field_feature_card_description>
  <field_list_description>With the increasing reliance on advanced technologies and the rise of big data in cancer research, NCI launched the R50 Research Specialist Award to help sustain a stable workforce of experienced scientists who can take fullest advantage of these tools and resources.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-27</field_date_posted>
  <field_date_reviewed>2018-09-27</field_date_reviewed>
  <field_pretty_url>nci-r50-research-specialist-award</field_pretty_url>
  <para_id>1125012</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>916700</term_id>
  <id>1126528</id>
  <title>Resources for Researchers</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Researchers</field_short_title>
  <field_page_description>Resources for Researchers is a directory of NCI-supported tools and services for cancer researchers. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-15</field_date_posted>
  <field_date_reviewed>2018-10-15</field_date_reviewed>
  <para_id>1126528</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915603</term_id>
  <id>1126609</id>
  <title>Shining a Spotlight on Tumor Exosomes</title>
  <langcode>en</langcode>
  <field_short_title>Shining a Spotlight on Tumor Exosomes-David Lyden M.D., Ph.D.</field_short_title>
  <field_page_description>Learn how NCI support is helping researcher David Lyden understand how cancer cell exosomes create a nurturing environment for the growth of metastatic tumors.</field_page_description>
  <field_feature_card_description>Pediatric neuro-oncologist David Lyden, M.D., Ph.D., studies exosomes to uncover the steps of cancer cell metastasis.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>david-lyden-exosomes-metastasis</field_pretty_url>
  <para_id>1126609</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915624</term_id>
  <id>1126634</id>
  <title>Working to Reduce the Cancer Burden Caused by Tobacco</title>
  <langcode>en</langcode>
  <field_short_title>Working to Reduce the Cancer Burden Caused by Tobacco-Michael Fiore, M.D., M.P.H., M.B.A.</field_short_title>
  <field_page_description>Tobacco use in the US continues to cause great harm. Learn about Dr. Michael Fiore and his NCI working group’s recommendations on Tobacco Control Research Priorities for the Next Decade.</field_page_description>
  <field_feature_card_description>Michael Fiore, M.D., M.P.H., M.B.A., helped to spearhead an NCI working group that recommended tobacco research priorities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>michael-fiore-reducing-tobacco-cancer-burden</field_pretty_url>
  <para_id>1126634</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1121282</id>
  <title>Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Combination Approved for Colorectal Cancer</field_short_title>
  <field_page_description>The combination of the immune checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) has been approved by FDA for the treatment of patients with metastatic colorectal cancer whose tumor cells have DNA repair defects.</field_page_description>
  <field_feature_card_description>Ipilimumab plus nivolumab approved to treat tumors with DNA repair defects.</field_feature_card_description>
  <field_list_description>The FDA has approved the combination of the immune checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) for the treatment of patients with metastatic colorectal cancer whose tumor cells have defects that affect their ability to repair DNA.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-03</field_date_posted>
  <field_date_reviewed>2018-08-03</field_date_reviewed>
  <field_pretty_url>fda-ipilimumab-nivolumab-colorectal-dna-repair</field_pretty_url>
  <para_id>1121282</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121484</id>
  <title>TCGA's Study of Cutaneous Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Cutaneous Melanoma</field_short_title>
  <field_page_description>TCGA's Study of Cutaneous Melanoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Cutaneous Melanoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of cutaneous (skin) melanoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-06</field_date_posted>
  <field_date_reviewed>2018-08-06</field_date_reviewed>
  <field_pretty_url>melanoma-skin</field_pretty_url>
  <para_id>1121484</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121667</id>
  <title>TCGA's Study of Lower Grade Glioma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Lower Grade Glioma</field_short_title>
  <field_page_description>TCGA's Study of Lower Grade Glioma</field_page_description>
  <field_feature_card_description>TCGA's Study of Lower Grade Glioma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of lower grade glioma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-08</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <field_pretty_url>glioma</field_pretty_url>
  <para_id>1121667</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1121733</id>
  <title>Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations</title>
  <langcode>en</langcode>
  <field_short_title>Ivosidenib Approved for Acute Myeloid Leukemia</field_short_title>
  <field_page_description>FDA has approved ivosidenib (Tibsovo) for the treatment of adults with acute myeloid leukemia (AML) that has a specific mutation in a gene called IDH1. Ivosidenib becomes the first FDA-approved treatment that targets IDH1. </field_page_description>
  <field_feature_card_description>First FDA-approved drug that targets IDH1 gene mutations.</field_feature_card_description>
  <field_list_description>The FDA has approved ivosidenib (Tibsovo) for the treatment of adults with acute myeloid leukemia (AML) that has a specific mutation in a gene called IDH1. Ivosidenib becomes the first FDA-approved IDH1-targeted treatment.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-13</field_date_posted>
  <field_date_reviewed>2018-08-10</field_date_reviewed>
  <field_pretty_url>ivosidenib-aml-fda-approval</field_pretty_url>
  <para_id>1121733</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>1123473</id>
  <title>Drugs Approved for Pheochromocytoma and Paraganglioma </title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Pheochromocytoma and Paraganglioma </field_short_title>
  <field_page_description>Find information about drugs for Pheochromocytoma and Paraganglioma. The drugs listed have been approved by the Food and Drug Administration (FDA) and include both generic and brand names.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-08-24</field_date_posted>
  <field_date_reviewed>2018-08-24</field_date_reviewed>
  <field_pretty_url>pheochromocytoma-paraganglioma</field_pretty_url>
  <para_id>1123473</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1123732</id>
  <title>Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Closer Look at Postmenopausal Bleeding and Endometrial Cancer</field_short_title>
  <field_page_description>A new study shows that 90% of postmenopausal women diagnosed with endometrial cancer reported vaginal bleeding before their diagnosis. Approximately 9% of women who saw a doctor for bleeding, the study showed, later received an endometrial cancer diagnosis.</field_page_description>
  <field_feature_card_description>Bleeding after menopause common prior to diagnosis.</field_feature_card_description>
  <field_list_description>A new study has found that 90% of postmenopausal women diagnosed with endometrial cancer reported vaginal bleeding before their diagnosis. Approximately 9% of postmenopausal women who saw a doctor for bleeding, the study showed, later received an endometrial cancer diagnosis.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-29</field_date_posted>
  <field_date_reviewed>2018-08-28</field_date_reviewed>
  <field_pretty_url>endometrial-cancer-bleeding-common-symptom</field_pretty_url>
  <para_id>1123732</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>979474</id>
  <title>Program Spotlight: 2015 Scientific Poster Winners at CRCHD Professional Development Workshop</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: 2015 Scientific Poster Winners</field_short_title>
  <field_page_description>As part of its 2015 Professional Development Workshop, CURE scholars, trainees, and investigators participated in a competitive poster session – providing participants with an opportunity to present research findings and future research plans.</field_page_description>
  <field_feature_card_description>CURE scholars participated in a poster session at the 2015 PDW.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-23</field_date_posted>
  <field_date_reviewed>2015-07-23</field_date_reviewed>
  <field_pretty_url>Poster-Winners-2015</field_pretty_url>
  <para_id>979474</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>979827</id>
  <title>U.S. Indoor Tanning Rates Are Dropping, But Still High</title>
  <langcode>en</langcode>
  <field_short_title>U.S. Indoor Tanning Rates Are Dropping, But Still High</field_short_title>
  <field_page_description>Study estimates about 1.6 million fewer women and 400,000 fewer men tan indoors, but it’s still a common practice. </field_page_description>
  <field_feature_card_description>Millions of women and men continue to use devices such as tanning beds that raise the risk of skin cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-24</field_date_posted>
  <field_date_reviewed>2015-07-24</field_date_reviewed>
  <field_pretty_url>indoor-tanning</field_pretty_url>
  <para_id>979827</para_id>
  <related_resource_id>6572884</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>983684</id>
  <title>NCI-Designated Cancer Centers Expand, Four Awarded Comprehensive Designation </title>
  <langcode>en</langcode>
  <field_short_title>NCI-Designated Cancer Centers Expand, Four Awarded Comprehensive Designation </field_short_title>
  <field_page_description>NCI’s cancer centers program added a new institution and awarded the comprehensive designation to four existing NCI-designated centers.</field_page_description>
  <field_feature_card_description>The program has added a new institution and awarded the comprehensive designation to four existing NCI cancer centers.</field_feature_card_description>
  <field_list_description>In July 2015, the NCI’s cancer centers program expanded by adding a new institution and awarding the comprehensive designation to four existing NCI-designated cancer centers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-06</field_date_posted>
  <field_date_reviewed>2015-08-06</field_date_reviewed>
  <field_pretty_url>new-cancer-centers</field_pretty_url>
  <para_id>983684</para_id>
  <related_resource_id>6613731</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1027726</id>
  <title>FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves T-VEC to Treat Metastatic Melanoma</field_short_title>
  <field_page_description>The FDA has approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC). The drug was approved for the treatment of metastatic melanoma that cannot be removed surgically.</field_page_description>
  <field_feature_card_description>The drug is the first oncolytic virus therapy to be approved.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-25</field_date_posted>
  <field_date_reviewed>2015-11-25</field_date_reviewed>
  <field_pretty_url>t-vec-melanoma</field_pretty_url>
  <para_id>1027726</para_id>
  <related_resource_id>6572740</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1030591</term_id>
  <id>1030592</id>
  <title>Public Health Service Act</title>
  <langcode>en</langcode>
  <field_short_title>Public Health Service Act</field_short_title>
  <field_page_description>Information on the Public Health Service Act and related legislation that directly impacted the mission of NCI.</field_page_description>
  <field_feature_card_description>Public Health Service Act</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-12-10</field_date_reviewed>
  <para_id>1030592</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>919157</term_id>
  <id>63861</id>
  <title>NCI's Clinical Trials Programs and Initiatives</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials</field_short_title>
  <field_page_description>Information about NCI programs and initiatives that sponsor, conduct, develop, or support clinical trials, including NCI’s Clinical Trial Network (NCTN) and NCI Community Oncology Research Program (NCORP) initiatives.</field_page_description>
  <field_feature_card_description>Information about NCI programs and initiatives that sponsor, conduct, develop, or support clinical trials. </field_feature_card_description>
  <field_list_description>Information about NCI programs and initiatives that sponsor, conduct, develop, or support clinical trials, including NCI’s Clinical Trial Network (NCTN)  and  NCI Community Oncology Research Program (NCORP) initiatives to transform cancer clinical trials to be more flexible and responsive to the rapid advances being made in oncologic sciences.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-24</field_date_posted>
  <field_date_reviewed>2011-02-24</field_date_reviewed>
  <para_id>63861</para_id>
  <related_resource_ids>7251347</related_resource_ids>
  <related_resource_ids>7251350</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>63867</id>
  <title>Clinical Trials Information for Patients and Caregivers</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials Information for Patients and Caregivers</field_short_title>
  <field_page_description>Explains clinical trials, including what they are, why they are important, things to think about when deciding to take part, and questions to ask your doctor.</field_page_description>
  <field_feature_card_description>What clinical trials are, why they are important, and things to think about and ask when deciding to take part.</field_feature_card_description>
  <field_list_description>This section contains basic information about clinical trials, including why clinical trials are important, things to think about when deciding to take part, and questions to ask your doctor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2011-02-24</field_date_reviewed>
  <para_id>63867</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>63868</id>
  <title>Treating Multiply Relapsed or Refractory Hairy Cell Leukemia </title>
  <langcode>en</langcode>
  <field_short_title>Treating Multiply Relapsed or Refractory Hairy Cell Leukemia </field_short_title>
  <field_page_description>In this trial, patients with hairy cell leukemia who have not responded or relapsed after initial chemotherapy will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine. </field_page_description>
  <field_feature_card_description>In this trial, patients with hairy cell leukemia who have not responded or relapsed after initial chemotherapy will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine. </field_feature_card_description>
  <field_list_description>In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-22</field_date_posted>
  <field_date_reviewed>2011-02-24</field_date_reviewed>
  <field_pretty_url>pentostatin-bendamustine-hairy-cell</field_pretty_url>
  <para_id>63868</para_id>
  <related_resource_ids>6320302</related_resource_ids>
  <related_resource_ids>6320306</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65902</term_id>
  <id>65947</id>
  <title>Cancer Research Education Grants Program (R25)</title>
  <langcode>en</langcode>
  <field_short_title>NCI R25 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-18</field_date_posted>
  <field_date_reviewed>2011-03-18</field_date_reviewed>
  <para_id>65947</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>65904</term_id>
  <id>65952</id>
  <title>Cancer Education and Career Development Program (R25T)</title>
  <langcode>en</langcode>
  <field_short_title>NCI R25T Award</field_short_title>
  <field_page_description>Institutional award for predoctoral or postdoctoral candidates or mentored junior faculty who are pursuing careers in cancer prevention, control, behavioral, and population sciences or transdisciplinary sciences.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-18</field_date_posted>
  <field_date_reviewed>2011-03-18</field_date_reviewed>
  <para_id>65952</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1047605</term_id>
  <id>68415</id>
  <title>Mentored Quantitative Research Career Award (K25)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K25 Award</field_short_title>
  <field_page_description>For postdoctoral candidates, mentored junior faculty and senior faculty who are pursuing careers in transdisciplinary sciences.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-22</field_date_reviewed>
  <para_id>68415</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68510</term_id>
  <id>68595</id>
  <title>Established  Investigator Award in Cancer Prevention and Control (K05)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K05 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-22</field_date_reviewed>
  <para_id>68595</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>463787</id>
  <title>Eating Hints: Before, during, and after Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Eating Hints: Before, during, and after Cancer Treatment</field_short_title>
  <field_page_description>Eating Hints covers eating problems that may be caused by cancer and its treatment. Learn about common eating problems and ways to manage them.</field_page_description>
  <field_feature_card_description>Information about eating problems patients may have during treatment for cancer and ways to manage.</field_feature_card_description>
  <field_list_description>Covers eating problems that patients may have during treatment for cancer and ways to manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-20</field_date_reviewed>
  <field_pretty_url>eating-hints</field_pretty_url>
  <para_id>463787</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938032</term_id>
  <id>468217</id>
  <title>Adding Chemotherapy to Radiation Improves Survival for Some Patients with Rare Brain Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Adding Chemotherapy to Radiation Improves Survival for Some Patients with Rare Brain Cancer</field_short_title>
  <field_page_description>Long-term results from two clinical trials confirm that certain patients with anaplastic oligodendrogliomas live substantially longer if they are treated with a combination of chemotherapy and radiation therapy rather than radiatiation alone.</field_page_description>
  <field_feature_card_description>Long-term results from two clinical trials confirm that certain patients with anaplastic oligodendrogliomas live substantially longer if they are treated with a combination of chemotherapy and radiation therapy rather than radiatiation alone.</field_feature_card_description>
  <field_list_description>Long-term results from two clinical trials confirm that certain patients with rare brain tumors called anaplastic oligodendrogliomas live substantially longer if they are treated with a combination of chemotherapy and radiation therapy rather than radiation alone.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-11-29</field_date_posted>
  <field_date_reviewed>2012-11-28</field_date_reviewed>
  <field_pretty_url>chemotherapy-improves-survival</field_pretty_url>
  <para_id>468217</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938229</term_id>
  <id>1070678</id>
  <title>Daratumumab Improves Progression-Free Survival for Patients with Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Daratumumab for Multiple Myeloma Improves Progression-Free Survival</field_short_title>
  <field_page_description>A summary of clinical trial results showing that daratumumab plus lenalidomide and dexamethasone improved progression-free survival for patients with relapsed or refractory disease.</field_page_description>
  <field_feature_card_description>Daratumumab plus lenalidomide and dexamethasone improved survival for patients with relapsed or refractory disease.</field_feature_card_description>
  <field_list_description>Results from a phase III trial showed that adding daratumumab to lenalidomide and dexamethasone improved progression-free survival among patients with relapsed or refractory disease, compared with lenalidomide and dexamethasone alone.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-04</field_date_posted>
  <field_date_reviewed>2017-01-04</field_date_reviewed>
  <field_pretty_url>daratumumab-castor-pollux</field_pretty_url>
  <para_id>1070678</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1099303</term_id>
  <id>1073407</id>
  <title>Selected Interviews with Dr. Doug Lowy</title>
  <langcode>en</langcode>
  <field_short_title>Selected Interviews with Doug Lowy</field_short_title>
  <field_page_description>In these selected interviews, Douglas R. Lowy, M.D., Deputy Director of the National Cancer Institute (NCI), talks with media and scientific institutions about basic science, clinical research, and the work of NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-28</field_date_posted>
  <field_date_reviewed>2017-02-15</field_date_reviewed>
  <para_id>1073407</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073548</id>
  <title>U.S. Cancer Mortality Rates Falling, But Some Regions Left Behind, Study Finds</title>
  <langcode>en</langcode>
  <field_short_title>County-Level Disparities Found in Cancer Deaths</field_short_title>
  <field_page_description>A &lt;i&gt;Cancer Currents&lt;/i&gt; blog post on a study that showed the rate of cancer deaths in the U.S. is declining overall but increasing in some counties.</field_page_description>
  <field_feature_card_description>Despite overall improvements, study shows deaths from cancer distributed unequally in the U.S.</field_feature_card_description>
  <field_list_description>A study of nationwide mortality data found that, while cancer deaths in the U.S. dropped between 1980 and 2014, disparities persisted, and in 160 counties cancer mortality rose substantially.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-21</field_date_posted>
  <field_date_reviewed>2017-02-17</field_date_reviewed>
  <field_pretty_url>cancer-death-disparities</field_pretty_url>
  <para_id>1073548</para_id>
  <related_resource_id>6612523</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1090419</term_id>
  <id>1074402</id>
  <title>TMEN Investigators</title>
  <langcode>en</langcode>
  <field_short_title>TMEN Investigators</field_short_title>
  <field_page_description>TMEN funded cancer research grants investigating the mechanisms of a tumor’s interaction with its surrounding environment.</field_page_description>
  <field_feature_card_description>Research Projects studying the tumor microenvironment funded by TMEN</field_feature_card_description>
  <field_list_description>A list of grants funded by the Tumor Microenvironment Network to conduct cancer research investigating the mechanisms of tumor-host interactions in human cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-21</field_date_posted>
  <field_date_reviewed>2017-02-28</field_date_reviewed>
  <para_id>1074402</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1078445</term_id>
  <id>1078446</id>
  <title>2016 Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>2016 Social Media Events</field_short_title>
  <field_page_description>Find past social media events involving NCI and its partners from 2016.</field_page_description>
  <field_feature_card_description>Find past social media events involving NCI and its partners from 2016.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-28</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <para_id>1078446</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1078552</id>
  <title>Regional Centers of Research Excellence Program</title>
  <langcode>en</langcode>
  <field_short_title>Regional Centers of Research Excellence Program</field_short_title>
  <field_page_description>Regional Centers of Research Excellence Program</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-30</field_date_posted>
  <field_date_reviewed>2017-03-30</field_date_reviewed>
  <field_pretty_url>rcres-program</field_pretty_url>
  <para_id>1078552</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078782</term_id>
  <id>1078794</id>
  <title>OHAM Research Activities</title>
  <langcode>en</langcode>
  <field_short_title>OHAM Research Activities</field_short_title>
  <field_page_description>OHAM manages HIV/AIDS research and shares oversight for activities across NCI and NIH. Learn how OHAM is addressing the diverse population of HIV/AIDS patients. </field_page_description>
  <field_feature_card_description>OHAM manages four research programs and shares oversight for HIV/AIDS research activities across NCI and NIH.</field_feature_card_description>
  <field_list_description>OHAM manages four research programs and shares oversight for trans-NIH and international activities that extend across the spectrum of research, training, international studies, and clinical trials to address the diverse population of HIV/AIDS patients. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078794</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974455</term_id>
  <id>974489</id>
  <title>Specialized Programs of Research Excellence (SPOREs)</title>
  <langcode>en</langcode>
  <field_short_title>Specialized Programs of Research Excellence</field_short_title>
  <field_page_description>SPOREs enable the rapid movement of basic findings into clinical settings and help determine the biological basis for research observations. See funding for SPORE programs by mechanism and cancer site. </field_page_description>
  <field_feature_card_description>See funding for SPORE programs by mechanism and cancer site. </field_feature_card_description>
  <field_list_description>Displays the number and dollar amount of P50 and co-funded SPOREs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974489</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974530</term_id>
  <id>974533</id>
  <title>NCI Funding Trends</title>
  <langcode>en</langcode>
  <field_short_title>Funding Trends</field_short_title>
  <field_page_description>Find information about NCI funding in past fiscal years, including percent growth by mechanism and percent share by mechanism.</field_page_description>
  <field_feature_card_description>Find information about funding by mechanism in past fiscal years. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974533</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>981038</id>
  <title>What’s New Online from NCI?</title>
  <langcode>en</langcode>
  <field_short_title>What’s New Online from NCI?</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>Update about new websites and online content from NCI</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-06</field_date_posted>
  <field_date_reviewed>2015-08-06</field_date_reviewed>
  <field_pretty_url>new-online-july-2015</field_pretty_url>
  <para_id>981038</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>1001476</id>
  <title>Improved Strategies for Cancer Prevention and Early Detection</title>
  <langcode>en</langcode>
  <field_short_title>Improved Strategies for Cancer Prevention and Early Detection</field_short_title>
  <field_page_description>The prevention of cancer and the development of more effective strategies to detect cancer precursors and early stage cancers, when treatment may be most effective, remain critical goals.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-11</field_date_posted>
  <field_date_reviewed>2015-09-11</field_date_reviewed>
  <field_pretty_url>strategies-prevention-early-detection</field_pretty_url>
  <para_id>1001476</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1002027</term_id>
  <id>1002028</id>
  <title>Bioinformatics, Big Data, and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Bioinformatics, Big Data, and Cancer</field_short_title>
  <field_page_description>Researchers take on challenges and opportunities to mine big data for answers to complex biological questions. Learn how bioinformatics uses advanced computing, mathematics, and technological platforms to store, manage, analyze, and understand data.</field_page_description>
  <field_feature_card_description>Researchers take on challenges and opportunities to mine big data for answers to complex biological questions.</field_feature_card_description>
  <field_list_description>The focus of bioinformatics is to establish an infrastructure to store, analyze, integrate, and visualize large amounts of biological data and related information—big data—as well as provide access to it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-14</field_date_posted>
  <field_date_reviewed>2015-09-14</field_date_reviewed>
  <para_id>1002028</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1004569</term_id>
  <id>1004570</id>
  <title>Genomic Data Access</title>
  <langcode>en</langcode>
  <field_short_title>Data Access</field_short_title>
  <field_page_description>Information for NIH staff and extramural investigators on how to get a dbGaP account and how to request controlled-access data.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-10</field_date_posted>
  <field_date_reviewed>2015-09-23</field_date_reviewed>
  <para_id>1004570</para_id>
  <related_resource_ids>6677498</related_resource_ids>
  <related_resource_ids>6677499</related_resource_ids>
  <related_resource_ids>6677500</related_resource_ids>
  <related_resource_ids>6677501</related_resource_ids>
  <related_resource_ids>6677502</related_resource_ids>
  <related_resource_ids>6677503</related_resource_ids>
  <related_resource_ids>6677504</related_resource_ids>
  <related_resource_ids>6677505</related_resource_ids>
  <related_resource_ids>6677506</related_resource_ids>
  <related_resource_ids>6677508</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1004580</term_id>
  <id>1004581</id>
  <title>Advisory Board Meetings</title>
  <langcode>en</langcode>
  <field_short_title>Advisory Board Meetings</field_short_title>
  <field_page_description>Upcoming meetings and recent meeting proceedings for NCAB and BSA.</field_page_description>
  <field_feature_card_description>Stay up to date on upcoming meetings and recent meeting proceedings for advisory boards that advise the National Cancer Institute and the NCI Director.</field_feature_card_description>
  <field_list_description>Stay up to date on upcoming meetings and recent meeting proceedings for the National Cancer Advisory Board (NCAB) and the Board of Scientific Advisors (BSA).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-23</field_date_posted>
  <field_date_reviewed>2015-09-23</field_date_reviewed>
  <para_id>1004581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>1004820</id>
  <title>TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurrence May Forgo Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>TAILORx Trial Shows Women at Low Risk for Breast Cancer Recurring May Forgo Chemo</field_short_title>
  <field_page_description>A summary of results from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.</field_page_description>
  <field_feature_card_description>The TAILORx trial finds that a molecular test associated with breast cancer recurrence can predict who may benefit from chemotherapy.</field_feature_card_description>
  <field_list_description>Initial findings from the Trial Assigning Individualized Options for Treatment, or TAILORx, finds that women with early-stage hormone receptor-positive breast cancer have a low risk of recurrence based on a test for the expression of 21 genes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-28</field_date_posted>
  <field_date_reviewed>2015-09-25</field_date_reviewed>
  <field_pretty_url>tailorx-low-risk</field_pretty_url>
  <para_id>1004820</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>1007342</id>
  <title>Targeting RAL-GEF signaling and cytokines in KRAS driven lung cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeting RAL-GEF signaling and cytokines in KRAS driven lung cancer</field_short_title>
  <field_page_description>David Barbie's laboratory seeks to understand how cytokine production stimulated by mutant KRAS influences cancer growth. Inhibitors could improve treatments of cancers driven by mutant KRAS.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-09</field_date_posted>
  <field_date_reviewed>2015-09-30</field_date_reviewed>
  <field_pretty_url>targeting-ral-gef</field_pretty_url>
  <para_id>1007342</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938042</term_id>
  <id>1014731</id>
  <title>Hormone Replacement Therapy May Improve Survival for Women with Ovarian Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Hormone Replacement Therapy May Improve Survival for Women with Ovarian Cancer </field_short_title>
  <field_page_description>The randomized, controlled Adjuvant Hormone Therapy trial was launched in 1990 to assess the effects of estrogen-alone hormone replacement therapy in women treated for epithelial ovarian cancer.</field_page_description>
  <field_feature_card_description>Estrogen may benefit women treated for ovarian cancer </field_feature_card_description>
  <field_list_description>Study suggests that the use of estrogen-alone hormone replacement therapy may improve overall survival of women treated for epithelial ovarian cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-21</field_date_posted>
  <field_date_reviewed>2015-10-16</field_date_reviewed>
  <field_pretty_url>hrt-survival</field_pretty_url>
  <para_id>1014731</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1016185</id>
  <title>Funding Opportunity: Genomic Data Analysis Network Centers</title>
  <langcode>en</langcode>
  <field_short_title>Funding Opportunity: Genomic Data Centers</field_short_title>
  <field_page_description>Funding Opportunity CCG, Funding Opportunity Center for Cancer Genomics, CCG, Center for Cancer Genomics, CCG RFA, Center for cancer genomics rfa, genomic data analysis network, genomic data analysis network centers,</field_page_description>
  <field_feature_card_description>The National Cancer Institute (NCI) has published three companion Funding Opportunity Announcements (FOAs) for Genomic Data Analysis Network Centers to support programs of the Center for Cancer Genomics (CCG).</field_feature_card_description>
  <field_list_description>The National Cancer Institute (NCI) has published three companion Funding Opportunity Announcements (FOAs) for Genomic Data Analysis Network Centers to support programs of the Center for Cancer Genomics (CCG). The FOAs are managed by CCG and solicit applications for a Processing Genomic Data Center, a Visualization Genomic Data Center, and a Specialized Genomic Data Center.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-10-29</field_date_posted>
  <field_date_reviewed>2015-10-23</field_date_reviewed>
  <field_pretty_url>fundinggdan</field_pretty_url>
  <para_id>1016185</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>1019525</id>
  <title>Shared Decision Making to Improve Cancer Screening Choices</title>
  <langcode>en</langcode>
  <field_short_title>Shared Decision Making in Cancer Screening </field_short_title>
  <field_page_description>A research update article about helping patients make informed decisions about cancer screening that reflect their own values and preferences.</field_page_description>
  <field_feature_card_description>Shared decision making helps patients make informed decisions about cancer screening that reflect their own values and preferences.</field_feature_card_description>
  <field_list_description>In an effort to help patients make informed decisions and involve them more directly in critical medical decisions related to cancer screening, experts are turning to shared decision making.         </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-03</field_date_posted>
  <field_date_reviewed>2015-11-03</field_date_reviewed>
  <field_pretty_url>shared-decision-making</field_pretty_url>
  <para_id>1019525</para_id>
  <related_resource_id>7250724</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1023341</term_id>
  <id>1023342</id>
  <title>NCI Research Specialist Award (R50)</title>
  <langcode>en</langcode>
  <field_short_title>NCI Research Specialist Award (R50)</field_short_title>
  <field_page_description>Award enables scientists to pursue stable research careers within an existing cancer research program, but not serve as independent investigators.</field_page_description>
  <field_feature_card_description>Enables scientists to pursue stable careers within an existing, NCI-funded cancer research program. Applications due by Jan. 11, 2019.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-06</field_date_posted>
  <field_date_reviewed>2015-11-06</field_date_reviewed>
  <para_id>1023342</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1025854</id>
  <title>FDA Approves Nivolumab for Some Melanomas and Lung Cancers</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Nivolumab for Some Melanomas and Lung Cancers</field_short_title>
  <field_page_description>The FDA has approved nivolumab in combination with ipilimumab for advanced melanoma and nivolumab alone for advanced nonsquamous lung cancer.</field_page_description>
  <field_feature_card_description>The FDA has approved nivolumab for use against some melanomas and lung cancers. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-10</field_date_posted>
  <field_date_reviewed>2015-11-10</field_date_reviewed>
  <field_pretty_url>nivolumab-expanded</field_pretty_url>
  <para_id>1025854</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1026032</term_id>
  <id>1026781</id>
  <title>Legislative Activities </title>
  <langcode>en</langcode>
  <field_short_title>Legislative Activities </field_short_title>
  <field_page_description>Find information on current and past legislation along with resources to learn more on congressional activities impacting NCI.</field_page_description>
  <field_feature_card_description>Learn about NCI-specific legislation, past and present, and related congressional information.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <para_id>1026781</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026059</term_id>
  <id>1026898</id>
  <title>Legislative Resources</title>
  <langcode>en</langcode>
  <field_short_title>Legislative Resources</field_short_title>
  <field_page_description>Find external resources as well as a glossary of commons legislative terms.</field_page_description>
  <field_feature_card_description>Find external resources as well as a glossary of commons legislative terms.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026898</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026796</term_id>
  <id>1026914</id>
  <title>Cancer Research Legislation</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Research Legislation</field_short_title>
  <field_page_description>Legislation from the current Congress dealing with cancer research related to NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026914</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026802</term_id>
  <id>1026926</id>
  <title>Congressional Resolutions</title>
  <langcode>en</langcode>
  <field_short_title>Congressional Resolutions</field_short_title>
  <field_page_description>Congressional resolutions from the current Congress related to NCI's mission.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026926</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026932</term_id>
  <id>1026934</id>
  <title>Legislative History Timeline</title>
  <langcode>en</langcode>
  <field_short_title>Legislative History Timeline</field_short_title>
  <field_page_description>A timeline of important legislation related to cancer research, public health or NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026934</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1027658</id>
  <title>FDA Approves Irinotecan Liposome to Treat Pancreatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Irinotecan Liposome to Treat Pancreatic Cancer</field_short_title>
  <field_page_description>Patients with metastatic pancreatic cancer that has progressed after receiving gemcitabine-based chemotherapy now have a new treatment option: irinotecan liposome in combination with fluorouracil and leucovorin.</field_page_description>
  <field_feature_card_description>When combined with fluorouracil and leucovorin, the three-drug combination is used to treat pancreatic cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-24</field_date_posted>
  <field_date_reviewed>2015-11-23</field_date_reviewed>
  <field_pretty_url>irinotecan-liposome-pancreatic</field_pretty_url>
  <para_id>1027658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1028125</id>
  <title>The Cancer Genome Atlas: More Than a Large Collection of Data</title>
  <langcode>en</langcode>
  <field_short_title>TCGA: More Than a Large Collection of Data</field_short_title>
  <field_page_description>Though TCGA will wrap up in 2016 with a concluding symposium, cancer genomics projects built upon the success of TCGA will continue to play a major part in the NCI’s mission to better understand and treat cancer in the years to come.</field_page_description>
  <field_feature_card_description>TCGA: More Than a Large Collection of Data</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-12-07</field_date_posted>
  <field_date_reviewed>2015-12-01</field_date_reviewed>
  <field_pretty_url>zenklusen-leadership-update</field_pretty_url>
  <para_id>1028125</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478616</id>
  <title>Concept Checklist  </title>
  <langcode>en</langcode>
  <field_short_title>Concept Checklist  </field_short_title>
  <field_page_description>Instructions for what to include in a Biomarker, Imaging, Quality of Life, or Cost-Effectiveness Studies Funding Program (BIQSFP) proposal. </field_page_description>
  <field_feature_card_description>What to include in a Biomarker, Imaging, Quality of Life and Cost-Effectiveness Analysis Studies Funding Program (BIQSFP) proposal. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>concept-checklists</field_pretty_url>
  <para_id>478616</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478617</id>
  <title>Evaluator Resources</title>
  <langcode>en</langcode>
  <field_short_title>Evaluator Resources</field_short_title>
  <field_page_description>Resources for Biomarker, Imaging, Quality of Life and Cost Effectiveness Analysis Studies Funding Program (BIQSFP) evaluators.
</field_page_description>
  <field_feature_card_description>Resources for Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP) evaluators. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>evaluator-resources</field_pretty_url>
  <para_id>478617</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1075067</term_id>
  <id>817904</id>
  <title>NCI Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>Social Media Events</field_short_title>
  <field_page_description>Learn about NCI's upcoming and recent social media events.</field_page_description>
  <field_feature_card_description>Learn about NCI's upcoming and recent social media events.</field_feature_card_description>
  <field_list_description>A listing of past and present NCI and partner social media events.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-22</field_date_posted>
  <field_date_reviewed>2018-10-15</field_date_reviewed>
  <para_id>817904</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>819947</id>
  <title>Questions to Ask Your Doctor about Cancer Screening</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask Your Doctor about Cancer Screening</field_short_title>
  <field_page_description>In this audio clip, Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy discuss the benefits and harms of cancer screening and highlight popular misconceptions about cancer screening statistics.</field_page_description>
  <field_feature_card_description>An audio clip of Drs. Lisa Schwartz and Steven Woloshin of the Dartmouth Institute for Health Policy discussing the benefits and harms of cancer screening.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-11-27</field_date_posted>
  <field_date_reviewed>2014-08-27</field_date_reviewed>
  <field_pretty_url>questions-screening-audio</field_pretty_url>
  <para_id>819947</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>822289</id>
  <title>Tackling the Conundrum of Cachexia in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Tackling the Conundrum of Cachexia in Cancer</field_short_title>
  <field_page_description>An article about why and how some patients with cancer develop a wasting syndrome that causes dramatic loss of muscle mass and substantial weight loss.</field_page_description>
  <field_feature_card_description>An article about why and how some patients with cancer develop a wasting syndrome that causes dramatic loss of muscle mass and substantial weight loss.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-11-01</field_date_posted>
  <field_date_reviewed>2014-09-04</field_date_reviewed>
  <field_pretty_url>cachexia</field_pretty_url>
  <para_id>822289</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>827981</term_id>
  <id>828020</id>
  <title>NCI Center to Reduce Cancer Health Disparities (CRCHD)</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD</field_short_title>
  <field_page_description>The Center to Reduce Cancer Health Disparities (CRCHD) is central to NCI’s efforts to reduce the unequal burden of cancer in our society via basic and community research, as well as networks, and to train the next generation of competitive researchers from diverse populations in cancer and cancer health disparities res</field_page_description>
  <field_feature_card_description>The NCI established CRCHD to help reduce the unequal burden of cancer in our society.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2018-05-17</field_date_reviewed>
  <para_id>828020</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>828586</id>
  <title>Cancer Detection, Diagnosis, and Treatment Technologies for Global Health: Supporting the development of low-cost technologies for LMICs </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Detection, Diagnosis, and Treatment Technologies for Global Health</field_short_title>
  <field_page_description>NCI, Center for Global Health supports the development and validation of low-cost, portable technologies that can improve cancer detection, diagnosis, and treatment in low-and middle-income countries.</field_page_description>
  <field_feature_card_description>NCI, CGH supports low-cost technology awards</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <field_pretty_url>low-cost-technologies</field_pretty_url>
  <para_id>828586</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904111</term_id>
  <id>828593</id>
  <title>CRCHD Offices and Branches</title>
  <langcode>en</langcode>
  <field_short_title>Offices and Branches</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828593</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>919383</term_id>
  <id>833192</id>
  <title>CRCHD Integrated Networks</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Integrated Networks</field_short_title>
  <field_page_description>INB supports two network-based programs—the National Outreach Network (NON) and the Geographic Management of Cancer Health Disparities Program (GMaP)—as well as advising on women’s health and sexual and gender minority opportunities within and across the NCI. </field_page_description>
  <field_feature_card_description>INB supports the National Outreach Network, the Geographic Management of Cancer Health Disparities Program, and advises on women’s health and sexual and gender minority opportunities within and across NCI. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833192</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836256</id>
  <title>If You Want to Find Ways to Prevent Cancer...Learn About Prevention Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>If You Want to Find Ways to Prevent Cancer...Learn About Prevention Clinical Trials</field_short_title>
  <field_page_description>Covers things you should know when deciding to take part in a clinical trial that may help find ways to prevent cancer.</field_page_description>
  <field_feature_card_description>Covers things you should know when deciding to take part in a clinical trial that may help find ways to prevent cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>about-prevention-trials</field_pretty_url>
  <para_id>836256</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>986218</id>
  <title>With FDA Approval, Gefitinib Returns to U.S. Market for Some Patients with Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Gefitinib Approved for Some Lung Cancer Patients</field_short_title>
  <field_page_description>The FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.</field_page_description>
  <field_feature_card_description>The FDA has approved gefitinib as an initial treatment for lung cancer patients whose tumors have EGFR mutations.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-18</field_date_posted>
  <field_date_reviewed>2015-08-13</field_date_reviewed>
  <field_pretty_url>fda-gefitinib</field_pretty_url>
  <para_id>986218</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>988387</term_id>
  <id>988388</id>
  <title>About the Division of Cancer Biology</title>
  <langcode>en</langcode>
  <field_short_title>About DCB</field_short_title>
  <field_page_description>Learn about DCB’s offices and branches as well as how it prioritizes programs, facilitates research, and communicates with scientists.</field_page_description>
  <field_feature_card_description>Learn about DCB’s offices and branches as well as how it prioritizes programs, facilitates research, and communicates with scientists.</field_feature_card_description>
  <field_list_description>Learn about DCB's offices and branches as well as how it prioritizes programs, facilitates research, and communicates with scientists.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-08-26</field_date_reviewed>
  <para_id>988388</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915634</term_id>
  <id>1001483</id>
  <title>Enhancing Drug Discovery and Development</title>
  <langcode>en</langcode>
  <field_short_title>Enhancing Drug Discovery and Development</field_short_title>
  <field_page_description>Cancer drug discovery and development has long been a priority for the National Cancer Institute, most importantly in areas of need  that are not being adequately addressed by the private sector.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-11</field_date_posted>
  <field_date_reviewed>2015-09-11</field_date_reviewed>
  <field_pretty_url>enhancing-drug-discovery</field_pretty_url>
  <para_id>1001483</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1002421</id>
  <title>NCI Releases Budget Proposal for Fiscal Year 2017</title>
  <langcode>en</langcode>
  <field_short_title>NCI Releases FY2017 Annual Plan &amp; Budget Proposal</field_short_title>
  <field_page_description>The NCI Annual Plan and Budget Proposal for Fiscal Year 2017 provides an overview of NCI’s priorities and key initiatives and the institute’s funding request.</field_page_description>
  <field_feature_card_description>Acting Director Doug Lowy, M.D., calls this a "transformational moment" in cancer research, requests sustained budget increases.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-17</field_date_posted>
  <field_date_reviewed>2015-09-16</field_date_reviewed>
  <field_pretty_url>lowy-annual-plan-2017</field_pretty_url>
  <para_id>1002421</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>1004456</id>
  <title>Regional Centers of Research Excellence in Non-communicable Diseases in LMICs FAQs</title>
  <langcode>en</langcode>
  <field_short_title>Regional Centers of Research Excellence in Non-communicable Diseases in LMICs FAQs</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-22</field_date_posted>
  <field_date_reviewed>2015-09-22</field_date_reviewed>
  <field_pretty_url>rcre-faq</field_pretty_url>
  <para_id>1004456</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1007397</term_id>
  <id>1007710</id>
  <title>David Q. Matus, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>David Q. Matus, Ph.D.</field_short_title>
  <field_page_description>David Matus studies cellular invasion--a characteristic behavior of metastatic cancer cells--in an evolutionary context. </field_page_description>
  <field_feature_card_description>The Stony Brook University evolutionary developmental biologist studies cellular invasion, a characteristic behavior of metastatic cancer cells. </field_feature_card_description>
  <field_list_description>David Matus studies cellular invasion during normal development in the worm, C. elegans, as a model for understanding this behavior in metastatic cancer cells.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-01</field_date_posted>
  <field_date_reviewed>2015-10-01</field_date_reviewed>
  <field_pretty_url>david-matus</field_pretty_url>
  <para_id>1007710</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1016859</id>
  <title>Patients with Advanced Cancer May Benefit from Discussing Prognosis with Physicians</title>
  <langcode>en</langcode>
  <field_short_title>Patients with Advanced Cancer May Benefit from Discussing Prognosis with Physicians</field_short_title>
  <field_page_description>Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.</field_page_description>
  <field_feature_card_description>Patients with advanced cancer may benefit from having discussions about their prognoses with their physicians.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-30</field_date_posted>
  <field_date_reviewed>2015-10-28</field_date_reviewed>
  <field_pretty_url>prognosis-discussion</field_pretty_url>
  <para_id>1016859</para_id>
  <related_resource_id>6572910</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1025858</id>
  <title>Antioxidants Accelerate the Growth and Invasiveness of Tumors in Mice </title>
  <langcode>en</langcode>
  <field_short_title>Antioxidants Accelerate the Growth and Invasiveness of Tumors in Mice </field_short_title>
  <field_page_description>Metastatic tumor cells are particularly sensitive to oxidative stress, and antioxidant supplementation increases their ability to grow and metastasize. </field_page_description>
  <field_feature_card_description>Studies in mice show that antioxidant supplements may help tumors to grow and metastasize. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-12</field_date_posted>
  <field_date_reviewed>2015-11-10</field_date_reviewed>
  <field_pretty_url>antioxidants-metastasis</field_pretty_url>
  <para_id>1025858</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1026867</id>
  <title>How Genomics Is Shaping Precision Medicine in Oncology</title>
  <langcode>en</langcode>
  <field_short_title>How Genomics Is Shaping Precision Medicine in Oncology</field_short_title>
  <field_page_description>In laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.</field_page_description>
  <field_feature_card_description>The director of NCI’s Center for Cancer Genomics discusses precision medicine and its use in the treatment of lymphoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-19</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <field_pretty_url>understanding-precision-medicine</field_pretty_url>
  <para_id>1026867</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65187</id>
  <title>Drugs Approved for Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Brain Tumors</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the FDA for use in brain tumors. The drug names link to NCI's Cancer Drug Information summaries. The list includes generic names and brand names. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-03-02</field_date_posted>
  <field_date_reviewed>2011-03-09</field_date_reviewed>
  <field_pretty_url>brain</field_pretty_url>
  <para_id>65187</para_id>
  <related_resource_ids>6991004</related_resource_ids>
  <related_resource_ids>6991015</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1096587</term_id>
  <id>65192</id>
  <title>About the Annual Plan and Budget Proposal</title>
  <langcode>en</langcode>
  <field_short_title>About the Annual Plan &amp; Budget Proposal</field_short_title>
  <field_page_description>Learn about the annual budget plan and proposal NCI submits to the President and Congress each fiscal year, including an archive of plans from previous years.</field_page_description>
  <field_feature_card_description>Learn about the annual budget plan NCI submits to the President and Congress each fiscal year.</field_feature_card_description>
  <field_list_description>Learn about the annual budget plan and proposal NCI submits to the President and Congress each fiscal year and find an archive of plans from previous years.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-17</field_date_posted>
  <field_date_reviewed>2011-03-09</field_date_reviewed>
  <para_id>65192</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65252</term_id>
  <id>65973</id>
  <title>Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellows (F31) </title>
  <langcode>en</langcode>
  <field_short_title>NCI F31 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-18</field_date_posted>
  <field_date_reviewed>2011-03-18</field_date_reviewed>
  <para_id>65973</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>74367</id>
  <title>Accidents at Nuclear Power Plants and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Accidents at Nuclear Power Plants and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet about cancer risks associated with accidents at nuclear power plants. </field_page_description>
  <field_list_description>A fact sheet about cancer risks associated with accidents at nuclear power plants.  Includes information for cancer patients who live in an area that may be affected by a nuclear power plant accident.  Also contains links to information about NCI-supported research on ionizing radiation and cancer risk. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-19</field_date_posted>
  <field_date_reviewed>2011-04-19</field_date_reviewed>
  <field_pretty_url>nuclear-accidents-fact-sheet</field_pretty_url>
  <para_id>74367</para_id>
  <related_resource_id>6933920</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420514</term_id>
  <id>420515</id>
  <title>Federal Government Programs</title>
  <langcode>en</langcode>
  <field_short_title>Federal Government Programs</field_short_title>
  <field_page_description>Information about government health programs that may cover some costs associated with clinical trial participation.</field_page_description>
  <field_feature_card_description>Government health programs that may cover some costs associated with clinical trial participation.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>420515</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>430360</id>
  <title>Treating KSHV-Associated Multicentric Castleman Disease</title>
  <langcode>en</langcode>
  <field_short_title>Treating KSHV-Associated Multicentric Castleman Disease</field_short_title>
  <field_page_description>In this study, patients with KSHV-associated multicentric Castleman disease will receive IV tocilizumab every other week for up to 12 weeks. Patients who do not benefit may go on to receive high-dose AZT and valganciclovir as well.</field_page_description>
  <field_feature_card_description>In this study, patients with KSHV-associated multicentric Castleman disease will receive IV tocilizumab every other week for up to 12 weeks. Patients who do not benefit may go on to receive high-dose AZT and valganciclovir as well.</field_feature_card_description>
  <field_list_description>In this pilot study, patients with KSHV-associated multicentric Castleman disease will receive intravenous tocilizumab every other week for up to 12 weeks. Patients who do not benefit from tocilizumab therapy alone may go on to receive high-dose AZT and valganciclovir in addition to tocilizumab. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-09-18</field_date_posted>
  <field_date_reviewed>2012-09-20</field_date_reviewed>
  <field_pretty_url>kshv-multicentric-castleman-disease</field_pretty_url>
  <para_id>430360</para_id>
  <related_resource_ids>6509678</related_resource_ids>
  <related_resource_ids>6509679</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>463788</id>
  <title>Facing Forward: Life After Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Facing Forward: Life After Cancer Treatment</field_short_title>
  <field_page_description>Covers both the physical and emotional post-treatment issues for cancer survivors.</field_page_description>
  <field_feature_card_description>Covers both the physical and emotional post-treatment issues for cancer survivors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-20</field_date_reviewed>
  <field_pretty_url>facing-forward</field_pretty_url>
  <para_id>463788</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>898587</term_id>
  <id>818142</id>
  <title>Milestones in Cancer Research and Discovery</title>
  <langcode>en</langcode>
  <field_short_title>Milestones in Cancer Research and Discovery</field_short_title>
  <field_page_description>During the past 250 years, we have witnessed many landmark discoveries in our efforts to make progress against cancer, an affliction known to humanity for thousands of years. This timeline shows a few key milestones in the history of cancer research.</field_page_description>
  <field_feature_card_description>Timeline featuring selected milestones in 250 years of cancer research and discovery.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-21</field_date_posted>
  <field_date_reviewed>2014-08-22</field_date_reviewed>
  <para_id>818142</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1080972</id>
  <title>Celebrating National Minority Health Month 2017</title>
  <langcode>en</langcode>
  <field_short_title>Celebrating National Minority Health Month 2017</field_short_title>
  <field_page_description>NCI and other organizations recognize National Minority Health Month in April 2017.</field_page_description>
  <field_feature_card_description>Find out how NCI and other organizations recognized National Minority Health Month in April 2017.</field_feature_card_description>
  <field_list_description>In recognition of National Minority Health Month, learn more about NCI programs, funding mechanisms, tools, and events that focus on cancer health disparities research, cancer types and disparities, and building a diverse biomedical workforce.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-12</field_date_posted>
  <field_date_reviewed>2017-04-12</field_date_reviewed>
  <field_pretty_url>nci-nmhm-2017</field_pretty_url>
  <para_id>1080972</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1081765</id>
  <title>Mentor Spotlight: Elva M. Arredondo, PhD</title>
  <langcode>en</langcode>
  <field_short_title>Mentor Spotlight: Elva M. Arredondo, PhD</field_short_title>
  <field_page_description>Lilian G. Perez shares how her mentor, Dr. Elva M. Arredondo, has supported her career development.</field_page_description>
  <field_feature_card_description>Lilian G. Perez shares how her mentor, Dr. Elva M. Arredondo, has supported her career development.</field_feature_card_description>
  <field_list_description>Lilian G. Perez, MPH, a fifth-year PhD Candidate, shares how being mentored by Elva M. Arredondo, PhD, a Professor in the Division of Health Promotion and Behavioral Science at San Diego State University, has positively influenced her career development.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-18</field_date_posted>
  <field_date_reviewed>2017-04-18</field_date_reviewed>
  <field_pretty_url>mentor-spotlight-arredondo</field_pretty_url>
  <para_id>1081765</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084766</id>
  <title>Leadership and Expert Views - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Leadership &amp; Expert Views</field_short_title>
  <field_page_description>Blog posts featuring the views of NCI leaders and other scientific experts—including first-person commentaries and Q&amp;As about research trends and new research programs—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Views of NCI leaders and other scientific experts posted on NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>leadership-expert-views</field_pretty_url>
  <para_id>1084766</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1086589</id>
  <title>TRACERx: Trailblazing Longitudinal Cancer Genomics</title>
  <langcode>en</langcode>
  <field_short_title>TRACERx Longitudinal Cancer Genomics Study</field_short_title>
  <field_page_description>The Center for Cancer Genomics is supporting TRACERx, a longitudinal lung cancer genomics study.</field_page_description>
  <field_feature_card_description>Learn about TRACERx, a novel longitudinal cancer genomics study.</field_feature_card_description>
  <field_list_description>The Cancer Genome Atlas (TCGA) has been analyzed in more than one thousand scientific publications and enabled countless discoveries, but mostly using cross-sectional studies. To study in depth how cancer evolves and progresses, NCI's Center for Cancer Genomics (CCG) is supporting the innovative, longitudinal study Tracking Non-Small-Cell Lung Cancer Evolution through Therapy (TRACERx).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-01</field_date_posted>
  <field_date_reviewed>2017-05-30</field_date_reviewed>
  <field_pretty_url>tracerx-longitudinal-lung-study</field_pretty_url>
  <para_id>1086589</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086813</id>
  <title>FDA Expands Approval of Pembrolizumab for First-Line Treatment of Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Expands Approval of Pembrolizumab for Lung Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog post on FDA’s approval of pembrolizumab (Keytruda®) to be used with chemotherapy as a first-line treatment for non-small cell lung cancer.</field_page_description>
  <field_feature_card_description>The immunotherapy is used with chemotherapy as a first-line treatment for NSCLC.</field_feature_card_description>
  <field_list_description>FDA approved the immune checkpoint inhibitor pembrolizumab to be used with chemotherapy as a first-line treatment for non-small cell lung cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-06</field_date_posted>
  <field_date_reviewed>2017-06-05</field_date_reviewed>
  <field_pretty_url>fda-pembrolizumab-lung-expanded</field_pretty_url>
  <para_id>1086813</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1077678</id>
  <title>Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson</title>
  <langcode>en</langcode>
  <field_short_title>Colorectal Cancer Incidence Rising in Young Adults </field_short_title>
  <field_page_description>An interview with NCI’s Drs. Philip Rosenberg and William Anderson on NCI’s Cancer Currents blog about a new study showing rising colorectal cancer incidence rates in adults under age 50. </field_page_description>
  <field_feature_card_description>NCI experts discuss recent findings and their implications for future research.</field_feature_card_description>
  <field_list_description>Drs. Philip Rosenberg and William Anderson of NCI discuss a recent study on which they were coauthors that reported an increase in colorectal cancer incidence among adults under age 50 in the United States. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-23</field_date_posted>
  <field_date_reviewed>2017-03-23</field_date_reviewed>
  <field_pretty_url>young-adult-colorectal-incidence-increasing</field_pretty_url>
  <para_id>1077678</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1078441</term_id>
  <id>1078449</id>
  <title>2014 Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>2014 Social Media Events</field_short_title>
  <field_page_description>Find past social media events involving NCI and its partners from 2014.</field_page_description>
  <field_feature_card_description>Find past social media events involving NCI and its partners from 2014.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-28</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <para_id>1078449</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1078454</id>
  <title>Screen to Save Community Spotlight: UT Health San Antonio </title>
  <langcode>en</langcode>
  <field_short_title>Screen to Save Spotlight: UT Health San Antonio </field_short_title>
  <field_page_description>As Screen to Save outreach activities are in progress, CRCHD will highlight education and outreach activities taking place in communities across the country. This week, CRCHD is spotlighting the work of our community health educators at the Cancer Therapy and Research Center of the University of Texas Health Science Ce</field_page_description>
  <field_feature_card_description>CRCHD spotlights community health educators at the Cancer Therapy and Research Center of the University of Texas Health Science Center at San Antonio.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-28</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <field_pretty_url>s2s-uthsa</field_pretty_url>
  <para_id>1078454</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1082594</term_id>
  <id>1080219</id>
  <title>AIDS and Cancer Specimen Resource</title>
  <langcode>en</langcode>
  <field_short_title>AIDS and Cancer Specimen Resource</field_short_title>
  <field_page_description>The AIDS Cancer Specimen Resource (ACSR) is a biorepository for HIV-infected human biospecimens. Learn how ACSR encourages pivotal understanding of the epidemic and its impact on cancer incidence.</field_page_description>
  <field_feature_card_description>Learn how ACSR encourages pivotal study of the HIV/AIDS epidemic and its impact on cancer incidence.</field_feature_card_description>
  <field_list_description>The AIDS Cancer Specimen Resource (ACSR) is a biorepository for HIV-infected human biospecimens and associated clinical information. Learn how ACSR encourages pivotal understanding of the HIV/AIDS epidemic and its impact on cancer incidence. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080219</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>901950</term_id>
  <id>901860</id>
  <title>Bleeding and Bruising (Thrombocytopenia) and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Bleeding and Bruising (Thrombocytopenia)</field_short_title>
  <field_page_description>Cancer treatments, such as chemotherapy and targeted therapy, can increase patients’ risk of bleeding and bruising, also called thrombocytopenia. Learn about steps to take if you are at increased risk of a low platelet count.</field_page_description>
  <field_list_description>Information about what causes bleeding and bruising, a side effect of some cancer treatments, and ways to manage it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <para_id>901860</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>904676</id>
  <title>Special Spotlight: World Cancer Day - Ending Cancer Health Disparities is Not Beyond Us</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: World Cancer Day - Ending Cancer Health Disparities is Not Beyond Us</field_short_title>
  <field_page_description>CRCHD observes World Cancer Day 2015, joining the global fight against cancer and cancer health disparities so that everyone can live healthy lives.</field_page_description>
  <field_feature_card_description>CRCHD observes World Cancer Day 2015</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-04</field_date_posted>
  <field_date_reviewed>2015-02-04</field_date_reviewed>
  <field_pretty_url>worldcancerday2015-spotlight-blog</field_pretty_url>
  <para_id>904676</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1094195</id>
  <title>Crizotinib Shows Promise for Childhood Cancers </title>
  <langcode>en</langcode>
  <field_short_title>Crizotinib Shows Promise for Childhood Cancers </field_short_title>
  <field_page_description>Crizotinib (Xalkori®) shrank tumors in children with anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMT).</field_page_description>
  <field_feature_card_description>In early-stage trial, crizotinib shrank tumors in most patients. </field_feature_card_description>
  <field_list_description>In a small clinical trial, the drug crizotinib shrank tumors in children with cancers that have alterations in the ALK gene. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-05</field_date_posted>
  <field_date_reviewed>2017-09-05</field_date_reviewed>
  <field_pretty_url>crizotinib-childhood-cancers</field_pretty_url>
  <para_id>1094195</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1095911</id>
  <title>FDA Approves Inotuzumab for Adults with B-Cell Acute Lymphoblastic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Inotuzumab Approved for Adults with B-Cell ALL</field_short_title>
  <field_page_description>Inotuzumab (Besponsa®) has been approved by FDA for some adults with B-cell acute lymphoblastic leukemia (ALL) that has returned or doesn’t respond to chemotherapy.</field_page_description>
  <field_feature_card_description>Adds another option for patients with ALL that has returned.</field_feature_card_description>
  <field_list_description>FDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-18</field_date_posted>
  <field_date_reviewed>2017-09-13</field_date_reviewed>
  <field_pretty_url>fda-inotuzumab-leukemia</field_pretty_url>
  <para_id>1095911</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097627</id>
  <title>Study Identifies Crucial Characteristic of High-Risk HPV</title>
  <langcode>en</langcode>
  <field_short_title>Study Identifies Crucial Characteristic of High-Risk HPV</field_short_title>
  <field_page_description>For human papillomavirus type 16 (HPV16) to cause cervical cancer, a precise DNA sequence of the E7 gene may be required, this Cancer Currents post on a new study explains.</field_page_description>
  <field_feature_card_description>Researchers identified the sequence of the specific gene linked to the cancer-causing ability of HPV16.</field_feature_card_description>
  <field_list_description>By comparing the genomes of women infected with a high-risk type of human papillomavirus (HPV), researchers have found that a precise DNA sequence of a viral gene is associated with cervical cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-05</field_date_posted>
  <field_date_reviewed>2017-10-05</field_date_reviewed>
  <field_pretty_url>hpv-viral-gene</field_pretty_url>
  <para_id>1097627</para_id>
  <related_resource_id>7267067</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097890</id>
  <title>Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Trial Provides Insights on Lymph Node Removal in Breast Cancer</field_short_title>
  <field_page_description>For some women with early-stage breast cancer who have a lumpectomy, a sentinel node biopsy is sufficient, as this Cancer Currents article explains.</field_page_description>
  <field_feature_card_description>In some women with early-stage disease, conservative approach sufficient, study shows.</field_feature_card_description>
  <field_list_description>Long-term results from a large clinical trial confirm that, for some women with early-stage breast cancer who have lumpectomy as their surgical treatment, a less extensive lymph node biopsy approach is sufficient.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-10</field_date_posted>
  <field_date_reviewed>2017-10-10</field_date_reviewed>
  <field_pretty_url>breast-cancer-lymph-node-removal</field_pretty_url>
  <para_id>1097890</para_id>
  <related_resource_id>6745618</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917216</term_id>
  <id>1126632</id>
  <title>Searching for Less-Toxic Cancer Treatments for Kids</title>
  <langcode>en</langcode>
  <field_short_title>Searching for Less-Toxic Cancer Treatments for Kids-Gregory Aune, M.D., Ph.D.</field_short_title>
  <field_page_description>Frustration with the toxicities of chemotherapy and radiation spurs cancer survivor and investigator Greg Aune to look for less-toxic therapies for children.</field_page_description>
  <field_feature_card_description>Gregory Aune, M.D., Ph.D., focuses on identifying biomarkers of toxicity caused by powerful cancer drugs.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>gregory-aune-less-toxic-cancer-treatments-kids</field_pretty_url>
  <para_id>1126632</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1132070</id>
  <title>Conversation with Dr. Shiva Malek and Dr. Christiaan Klijn</title>
  <langcode>en</langcode>
  <field_short_title>Conversation with Dr. Shiva Malek and Dr. Christiaan Klijn</field_short_title>
  <field_page_description>Inhibiting MEK re-wires regulation of MAPK signaling so that inhibitors of RAF kinases are more effective against cells driven by mutant KRAS.</field_page_description>
  <field_feature_card_description>Combined inhibition of MEK and RAF inhibits cells driven by mutant KRAS.</field_feature_card_description>
  <field_list_description>Signaling downstream of RAS is subject to many levels of regulation. Inhibiting MEK seems to re-wire that regulation so that inhibitors of RAF kinases are more effective against cells driven by mutant KRAS.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-06</field_date_posted>
  <field_date_reviewed>2018-12-03</field_date_reviewed>
  <field_pretty_url>shiva-malek</field_pretty_url>
  <para_id>1132070</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1132206</term_id>
  <id>1132207</id>
  <title>Trichloroethylene (TCE)</title>
  <langcode>en</langcode>
  <field_short_title>Trichloroethylene </field_short_title>
  <field_page_description>Trichloroethylene (TCE) is a chemical used to make refrigerants and as a metal degreaser. It may be found in contaminated soil or water near military bases and in some commercial and household cleaning products. TCE exposure may cause kidney cancer and increase the risk of lymphoma and liver cancer.</field_page_description>
  <field_feature_card_description>Trichloroethylene (TCE) is widely used as a degreasing agent and may accumulate in soil and groundwater near places it is used. TCE exposure may cause kidney cancer and increase the risk of lymphoma and liver cancer.  </field_feature_card_description>
  <field_list_description>Learn about trichloroethylene (TCE), a chemical used to make refrigerants and as a degreaser. Exposure to TCE may cause kidney cancer and increase the risk of lymphoma and liver cancer.  Although most TCE in the United States is used in manufacturing refrigerants, it may be found in contaminated soil or groundwater near military bases and in some commercial and household cleaning products.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-10</field_date_posted>
  <field_date_reviewed>2018-12-05</field_date_reviewed>
  <para_id>1132207</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133143</id>
  <title>Plans for NCI’s Fiscal Year 2019 Budget</title>
  <langcode>en</langcode>
  <field_short_title>Plans for NCI’s Fiscal Year 2019 Budget</field_short_title>
  <field_page_description>NCI Director Dr. Ned Sharpless on NCI’s FY2019 budget and important budgetary decisions, including those related to the Cancer Moonshot and young investigators.</field_page_description>
  <field_feature_card_description>NCI Director Dr. Ned Sharpless explains important decisions for the coming fiscal year.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Ned Sharpless describes important decisions NCI leaders have recently made with respect to the institute’s fiscal year 2019 budget, including those related to the Cancer Moonshot and early-stage investigators.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-18</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>sharpless-nci-fy2019-budget</field_pretty_url>
  <para_id>1133143</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133484</term_id>
  <id>1133216</id>
  <title>About Rare Cancers</title>
  <langcode>en</langcode>
  <field_short_title>About Rare Cancers</field_short_title>
  <field_page_description>Rare cancers are those that affect fewer than 40,000 people per year in the U.S. As a group, they make up just over a quarter of all cancers. Because rates of cancer in children are very low, all children’s cancers are considered rare. A quarter of all cancer deaths each year are due to rare cancers. Although new treat</field_page_description>
  <field_feature_card_description>Rare cancers are those that affect fewer than 40,000 people per year in the U.S. As a group, they make up just over a quarter of all cancers. The MyPART network was started to make it easier to find treatments for rare cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133216</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133180</term_id>
  <id>1133231</id>
  <title>Fibrolamellar hepatocellular carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Fibrolamellar hepatocellular carcinoma</field_short_title>
  <field_page_description>Fibrolamellar hepatocellular carcinoma, or FLHCC, is a rare cancer of the liver that usually grows in teens and adults under 40 years old. It is unsusal because it occurs in people who have healthy livers. Learn more about how this cancer forms, is treated, and the prognosis. </field_page_description>
  <field_feature_card_description>Fibrolamellar hepatocellular carcinoma, or FLHCC, is a rare cancer of the liver that usually grows in teens and adults under 40 years old. It is unsusal because it occurs in people who have healthy livers. </field_feature_card_description>
  <field_list_description>Fibrolamellar hepatocellular carcinoma, or FLHCC, is a rare cancer of the liver that usually grows in teens and adults under 40 years old. It is unsusal because it occurs in people who have healthy livers. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>fibrolamellar-hepatocellular-carcinoma</field_pretty_url>
  <para_id>1133231</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911172</term_id>
  <id>14759</id>
  <title>Human Papillomavirus (HPV) Vaccines</title>
  <langcode>en</langcode>
  <field_short_title>Human Papillomavirus (HPV) Vaccines</field_short_title>
  <field_page_description>A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer.</field_page_description>
  <field_feature_card_description>Learn about HPV vaccines, which protect against infections that cause cervical cancer and several other types of cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-16</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-fact-sheet</field_pretty_url>
  <para_id>14759</para_id>
  <related_resource_ids>7267736</related_resource_ids>
  <related_resource_ids>7267737</related_resource_ids>
  <related_resource_ids>7267770</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>914480</term_id>
  <id>14778</id>
  <title>Lymphoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Lymphoma</field_short_title>
  <field_page_description>Lymphoma is cancer that begins in cells of the lymph system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma can often be cured. The prognosis of NHL depends on the specific type. Start here to find information about lymphoma treatment, research, and statistics.</field_page_description>
  <field_list_description>Information about non-Hodgkin lymphoma and Hodgkin lymphoma treatment, clinical trials, research, statistics, and other topics from the National Cancer Institute.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14778</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916790</term_id>
  <id>14824</id>
  <title>Research Funding Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Research Funding Opportunities</field_short_title>
  <field_page_description>Find a wide range of funding announcements to support cancer research and training, organized by topic and by funding mechanism.</field_page_description>
  <field_list_description>Find a wide range of funding announcements to support cancer research, organized by topic and alternatively by funding mechanism.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14824</para_id>
  <related_resource_ids>7107641</related_resource_ids>
  <related_resource_ids>7107642</related_resource_ids>
  <related_resource_ids>7107643</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>929549</term_id>
  <id>14890</id>
  <title>The Genetics of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Genetics</field_short_title>
  <field_page_description>Information about genetic changes, how they may be inherited or acquired during a person's life, how they can increase cancer risk, and genetic testing for mutations.</field_page_description>
  <field_feature_card_description>Genetic changes, which may be inherited or acquired during a person's life, can increase cancer risk.</field_feature_card_description>
  <field_list_description>Information about genetic changes, how they may be inherited or acquired during a person's life, and how they can increase cancer risk.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-22</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14890</para_id>
  <related_resource_ids>7123583</related_resource_ids>
  <related_resource_ids>7123584</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11976</term_id>
  <id>15005</id>
  <title>Carcinoma of Unknown Primary—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Carcinoma of Unknown Primary</field_short_title>
  <field_page_description>Carcinoma of unknown primary (CUP) occurs when cancer cells have spread in the body and formed metastatic tumors but the site of the primary cancer is not known. There are a number of reasons why the primary cancer may not be found. Start here to find treatment information for carcinoma of unknown primary.</field_page_description>
  <field_list_description>NCI's gateway for information about Carcinoma of Unknown Primary.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15005</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911145</term_id>
  <id>15113</id>
  <title>Obesity</title>
  <langcode>en</langcode>
  <field_short_title>Obesity</field_short_title>
  <field_page_description>People who are obese may have an increased risk of several types of cancer, whereas eating a healthy diet, being physically active, and keeping a healthy weight may help reduce risk of some cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15113</para_id>
  <related_resource_ids>6888275</related_resource_ids>
  <related_resource_ids>6888276</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>917500</term_id>
  <id>15132</id>
  <title>Complementary and Alternative Medicine</title>
  <langcode>en</langcode>
  <field_short_title>Complementary and Alternative Medicine</field_short_title>
  <field_page_description>Healing philosophies, approaches, and therapies used in&amp;nbsp;complementary and alternative medicine (CAM) in cancer care.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15132</para_id>
  <related_resource_ids>6528401</related_resource_ids>
  <related_resource_ids>6528402</related_resource_ids>
  <related_resource_ids>6528403</related_resource_ids>
  <related_resource_ids>6528404</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>200019</id>
  <title>Vitamin D and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Vitamin D and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet that summarizes the results of studies on vitamin D and cancer prevention.  It includes information about dietary recommendations for vitamin D.</field_page_description>
  <field_feature_card_description>A fact sheet that summarizes the results of studies on vitamin D and cancer prevention.  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-10-28</field_date_posted>
  <field_date_reviewed>2013-10-21</field_date_reviewed>
  <field_pretty_url>vitamin-d-fact-sheet</field_pretty_url>
  <para_id>200019</para_id>
  <related_resource_ids>6478177</related_resource_ids>
  <related_resource_ids>6478178</related_resource_ids>
  <related_resource_ids>6478179</related_resource_ids>
  <related_resource_ids>6478197</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1074540</id>
  <title>Study Shows Platelets Can Deliver Immunotherapy, Reduce Tumor Regrowth</title>
  <langcode>en</langcode>
  <field_short_title>Platelets Deliver Immunotherapy, Slow Tumor Growth</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on an experimental adjuvant therapy using blood platelets engineered to deliver an immune checkpoint inhibitor.</field_page_description>
  <field_feature_card_description>In mouse studies, the treatment prevented cancer cells from growing after surgery.</field_feature_card_description>
  <field_list_description>In experiments in mice, researchers show platelets linked to an immunotherapy drug can help eliminate residual cancer cells that remain after surgery. The engineered platelets may also prevent leftover cancer cells from spreading.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-03</field_date_posted>
  <field_date_reviewed>2017-03-02</field_date_reviewed>
  <field_pretty_url>platelet-immunotherapy</field_pretty_url>
  <para_id>1074540</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074835</term_id>
  <id>1074840</id>
  <title>Functional Genomics Research</title>
  <langcode>en</langcode>
  <field_short_title>Functional Genomics Research</field_short_title>
  <field_page_description>NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.</field_page_description>
  <field_feature_card_description>Functional genomics studies the role of particular cancer genes and pathways, and develops therapeutic strategies to target them. CCG's related research includes the Cancer Target Discovery and Development Network and the Human Cancer Models Initiative.</field_feature_card_description>
  <field_list_description>Functional genomics studies the role of particular cancer genes and pathways, and develops therapeutic strategies to target them. CCG's functional genomics research includes the Cancer Target Discovery and Development Network and the Human Cancer Models Initiative.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-03-06</field_date_reviewed>
  <para_id>1074840</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420501</term_id>
  <id>1074857</id>
  <title>Cancer Clinical Trials at the National Institutes of Health Clinical Center</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Clinical Trials at the NIH Clinical Center </field_short_title>
  <field_page_description>Information about cancer clinical trials at the NIH Clinical Center in Bethesda, Maryland.</field_page_description>
  <field_feature_card_description>NCI trials in Bethesda, Maryland, aim to solve important problems in cancer research and patient care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-08</field_date_posted>
  <field_date_reviewed>2017-05-25</field_date_reviewed>
  <field_pretty_url>clinical-center</field_pretty_url>
  <para_id>1074857</para_id>
  <related_resource_ids>6802453</related_resource_ids>
  <related_resource_ids>6802454</related_resource_ids>
  <related_resource_ids>6802455</related_resource_ids>
  <related_resource_ids>6802456</related_resource_ids>
  <related_resource_ids>6802460</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1078474</id>
  <title>Blinatumomab Extends Survival for Patients with Advanced ALL</title>
  <langcode>en</langcode>
  <field_short_title>Blinatumomab Improves Survival in Advanced ALL</field_short_title>
  <field_page_description>A Cancer Currents blog post on a large clinical trial showing that blinatumomab improves survival and causes fewer side effects than standard chemotherapy.</field_page_description>
  <field_feature_card_description>The immunotherapy drug also caused fewer side effects than chemotherapy.</field_feature_card_description>
  <field_list_description>Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-30</field_date_posted>
  <field_date_reviewed>2017-03-29</field_date_reviewed>
  <field_pretty_url>blinatumomab-leukemia</field_pretty_url>
  <para_id>1078474</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078426</term_id>
  <id>1078672</id>
  <title>NCI Funding for HIV and AIDS Malignancies Research</title>
  <langcode>en</langcode>
  <field_short_title>NCI Funding for HIV/AIDS Malignancies Research</field_short_title>
  <field_page_description>OHAM supports funding to advance the study of HIV/AIDS-related cancers. Find funding to investigate HIV/AIDS infection, transmission, and treatment. </field_page_description>
  <field_feature_card_description>Explore funding opportunities to investigate infection, transmission, and treatment of HIV and HIV/AIDS-related malignancies. </field_feature_card_description>
  <field_list_description>Find funding for research to advance the study of HIV/AIDS-related cancers, including the application of big data and multidisciplinary studies that investigate treatment, co-infection, and aids-defining or non-aids-defining cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078672</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080196</term_id>
  <id>1080199</id>
  <title>Cancer Moonshot&amp;#8480; Research Initiatives</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot&amp;#8480; Research Initiatives</field_short_title>
  <field_page_description>Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-26</field_date_posted>
  <field_date_reviewed>2017-04-03</field_date_reviewed>
  <para_id>1080199</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080223</term_id>
  <id>1080234</id>
  <title>NCI HIV and AIDS Research Coordinated by OHAM</title>
  <langcode>en</langcode>
  <field_short_title>NCI HIV/AIDS Research Coordinated by OHAM</field_short_title>
  <field_page_description>NCI scientists have made a number of critical contributions to HIV/AIDS research since the beginning of the AIDS epidemic. Learn more about intramural and extramural research supported by NCI. </field_page_description>
  <field_feature_card_description>Scientists working at NCI campuses conduct an active research program in HIV/AIDS malignancies, and NCI supports extramural research focused on HIV/AIDS. </field_feature_card_description>
  <field_list_description>An active research program in HIV/AIDS and HIV malignancies is conducted by scientists working at the NCI campuses in Bethesda, Rockville, and Frederick, Maryland. In addition, extramural research focused on HIV malignancies is supported by the NCI.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080234</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089455</id>
  <title>New Rituximab Formulation Approved for Some Lymphomas, Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Subcutaneous Rituximab for Some Blood Cancers</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on FDA’s approval of a new formulation of rituximab, Rituxan Hycela, for some patients with lymphoma and leukemia.</field_page_description>
  <field_feature_card_description>The drug can now be given via injection, greatly speeding up administration.</field_feature_card_description>
  <field_list_description>The FDA has approved a new formulation of rituximab, Rituxan Hycela, that reduces treatment administration time for patients with several types of blood cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-14</field_date_posted>
  <field_date_reviewed>2017-07-13</field_date_reviewed>
  <field_pretty_url>fda-rituxan-hycela</field_pretty_url>
  <para_id>1089455</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1089582</term_id>
  <id>1089583</id>
  <title>Cancer Moonshot&amp;#8480; Funding Opportunities Resources</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot&amp;#8480; FOAs Resources</field_short_title>
  <field_page_description>Funding opportunities that address the goals of the Blue Ribbon Panel are available. Learn more about these FOAs and pre-application webinars.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-18</field_date_posted>
  <field_date_reviewed>2017-07-14</field_date_reviewed>
  <para_id>1089583</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>921989</term_id>
  <id>14652</id>
  <title>Cancer in Children and Adolescents</title>
  <langcode>en</langcode>
  <field_short_title>Cancer in Children and Adolescents</field_short_title>
  <field_page_description>A fact sheet about statistics, types, causes, and treatment of childhood cancers in the United States.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-01</field_date_posted>
  <field_date_reviewed>2018-10-08</field_date_reviewed>
  <field_pretty_url>child-adolescent-cancers-fact-sheet</field_pretty_url>
  <para_id>14652</para_id>
  <related_resource_ids>7233043</related_resource_ids>
  <related_resource_ids>7233044</related_resource_ids>
  <related_resource_ids>7233046</related_resource_ids>
  <related_resource_ids>7233047</related_resource_ids>
  <related_resource_ids>7233049</related_resource_ids>
  <related_resource_ids>7233050</related_resource_ids>
  <related_resource_ids>7233053</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11596</term_id>
  <id>14703</id>
  <title>Professional Resources for Cancer Patient Education</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Cancer Patient Education</field_short_title>
  <field_page_description>Information about the NCI listserv for cancer patient educators, and the Cancer Patient Education Network.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2005-07-01</field_date_posted>
  <field_date_reviewed>2009-11-16</field_date_reviewed>
  <field_pretty_url>cancer-patient-education-resource</field_pretty_url>
  <para_id>14703</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11896</term_id>
  <id>14718</id>
  <title>Tests to Detect Colorectal Cancer and Polyps</title>
  <langcode>en</langcode>
  <field_short_title>Tests to Detect Colorectal Cancer and Polyps</field_short_title>
  <field_page_description>A fact sheet that discusses the advantages and disadvantages of several colorectal cancer screening tests.</field_page_description>
  <field_feature_card_description>This fact sheet discusses the advantages and disadvantages of several colorectal cancer screening tests.  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-13</field_date_posted>
  <field_date_reviewed>2016-07-07</field_date_reviewed>
  <field_pretty_url>screening-fact-sheet</field_pretty_url>
  <para_id>14718</para_id>
  <related_resource_ids>6995378</related_resource_ids>
  <related_resource_ids>6995379</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11922</term_id>
  <id>14790</id>
  <title>Leukemia—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Leukemia</field_short_title>
  <field_page_description>Leukemia is a broad term for cancers of the blood cells. The type of leukemia depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. Start here to find information on leukemia treatment, research, and statistics.</field_page_description>
  <field_list_description>Information about leukemia treatment, clinical trials, research, statistics, and other topics.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14790</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>14942</id>
  <title>Garlic and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Garlic and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet that summarizes the results of studies on the consumption of garlic for cancer prevention.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2008-01-22</field_date_posted>
  <field_date_reviewed>2008-01-22</field_date_reviewed>
  <field_pretty_url>garlic-fact-sheet</field_pretty_url>
  <para_id>14942</para_id>
  <related_resource_id>7099772</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>882432</term_id>
  <id>15302</id>
  <title>Radon and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Radon and Cancer</field_short_title>
  <field_page_description>A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home.</field_page_description>
  <field_feature_card_description>A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-06</field_date_posted>
  <field_date_reviewed>2011-12-06</field_date_reviewed>
  <field_pretty_url>radon-fact-sheet</field_pretty_url>
  <para_id>15302</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>211442</id>
  <title>Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening</title>
  <langcode>en</langcode>
  <field_short_title>Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening</field_short_title>
  <field_page_description>Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination</field_page_description>
  <field_feature_card_description>Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination</field_feature_card_description>
  <field_list_description>Thirteen year follow-up data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial show higher incidence but similar mortality among men screened annually with the prostate-specific antigen (PSA) test and digital rectal examination (DRE).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-02-17</field_date_posted>
  <field_date_reviewed>2012-02-17</field_date_reviewed>
  <field_pretty_url>screening-psa-dre</field_pretty_url>
  <para_id>211442</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1075562</id>
  <title>FDA Approves New Use for Lenalidomide in Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves New Use for Lenalidomide in Multiple Myeloma</field_short_title>
  <field_page_description>A Cancer Currents blog on the approval of lenalidomide as maintenance therapy for patients with multiple myeloma who have received an autologous stem cell transplant.</field_page_description>
  <field_feature_card_description>Drug approved as maintenance therapy after a stem cell transplant.</field_feature_card_description>
  <field_list_description>The FDA has approved lenalidomide for use as a maintenance therapy in patients with multiple myeloma who have undergone an autologous stem cell transplant, to help keep the cancer from coming back.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-16</field_date_posted>
  <field_date_reviewed>2017-03-16</field_date_reviewed>
  <field_pretty_url>fda-lenalidomide-myeloma-maintenance</field_pretty_url>
  <para_id>1075562</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1077659</id>
  <title>Stem-Cell Based Tool May Help Measure Heart Toxicity of Cancer Drugs</title>
  <langcode>en</langcode>
  <field_short_title>Stem Cell-Based Tool Ranks Heart Toxicity of Cancer Drugs</field_short_title>
  <field_page_description>A Cancer Currents blog post on a new research study that uses a type of adult stem cell to assess the heart toxicity of cancer drugs known as tyrosine kinase inhibitors.</field_page_description>
  <field_feature_card_description>The "cardiac safety index" may help identify drugs that cause side effects earlier in the drug development process.</field_feature_card_description>
  <field_list_description>Researchers have used adult stem cells to create a tool for ranking how toxic a group of cancer drugs, called tyrosine kinase inhibitors, are to human heart cells. Such a test could potentially identify toxic side effects earlier in the drug development process.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-21</field_date_posted>
  <field_date_reviewed>2017-03-21</field_date_reviewed>
  <field_pretty_url>heart-toxicity-index</field_pretty_url>
  <para_id>1077659</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078422</term_id>
  <id>1078650</id>
  <title>Office of HIV and AIDS Malignancy</title>
  <langcode>en</langcode>
  <field_short_title>Office of HIV and AIDS Malignancy</field_short_title>
  <field_page_description>OHAM conducts HIV and AIDS-associated research and coordinates related research activities across NCI. Learn more about key discoveries made by NCI scientists. </field_page_description>
  <field_feature_card_description>OHAM conducts HIV and AIDS-associated research and coordinates related research activities across NCI.</field_feature_card_description>
  <field_list_description>OHAM conducts HIV and AIDS-associated research and coordinates related research activities across NCI. OHAM includes two programs, the AIDS Malignancy Program and the AIDS Cancer Clinical Program.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-31</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078650</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1082592</term_id>
  <id>1080218</id>
  <title>AIDS Malignancy Consortium</title>
  <langcode>en</langcode>
  <field_short_title>AIDS Malignancy Consortium</field_short_title>
  <field_page_description>AMC was founded in 1995 to support trial innovation. Learn more about AMC’s commitment to enhancing therapeutic options for patients with HIV-associated malignancies.</field_page_description>
  <field_feature_card_description>Learn more about AMC’s commitment to supporting innovation in clinical trials.</field_feature_card_description>
  <field_list_description>The AIDS Malignancy Consortium is an NCI-supported clinical trials group founded in 1995 to support trial innovation. Learn more about this group of clinical centers committed to enhancing therapeutic options for patients with HIV-associated malignancies.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080218</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1082565</id>
  <title>Program Spotlight: Training Navigation</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: Training Navigation </field_short_title>
  <field_page_description>Dr. Hana Odeh talks about CRCHD’s new training navigation initiative and her role as training navigator.  </field_page_description>
  <field_feature_card_description>Dr. Hana Odeh talks about CRCHD’s new training navigation initiative and her role as training navigator.  </field_feature_card_description>
  <field_list_description>Dr. Hana Odeh talks about CRCHD’s new training navigation initiative and her role as training navigator.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-26</field_date_posted>
  <field_date_reviewed>2017-04-26</field_date_reviewed>
  <field_pretty_url>training-navigation</field_pretty_url>
  <para_id>1082565</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>1083954</id>
  <title>In an Era of Precision Medicine, Testing New Approaches to Breast Cancer Screening</title>
  <langcode>en</langcode>
  <field_short_title>Testing Precision Screening for Breast Cancer</field_short_title>
  <field_page_description>An NCI research article about individualized approaches that could help identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk.</field_page_description>
  <field_feature_card_description>Identifying appropriate screening tests and screening intervals for each person’s level of risk.</field_feature_card_description>
  <field_list_description>Researchers are testing individualized approaches that could identify those at risk of breast cancer who need to be screened and testing screening intervals that are appropriate for each person’s level of risk.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-09</field_date_posted>
  <field_date_reviewed>2017-05-08</field_date_reviewed>
  <field_pretty_url>precision-screening-breast</field_pretty_url>
  <para_id>1083954</para_id>
  <related_resource_ids>6813932</related_resource_ids>
  <related_resource_ids>6813934</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1080375</id>
  <title>Advancing the Potential and Promise of Total-Body PET Imaging</title>
  <langcode>en</langcode>
  <field_short_title>Advancing the Promise of Total-Body PET Imaging</field_short_title>
  <field_page_description>A Cancer Currents blog on how NCI is supporting a total-body PET scanner and the institute’s role in advancing new research and cancer care-related technologies.</field_page_description>
  <field_feature_card_description>Still under development, scanner could fundamentally alter cancer care.</field_feature_card_description>
  <field_list_description>A total-body PET scanner under development is an ideal example of how NCI and NIH are supporting the development of new research and cancer care-related technologies. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-07</field_date_posted>
  <field_date_reviewed>2017-04-06</field_date_reviewed>
  <field_pretty_url>total-body-pet</field_pretty_url>
  <para_id>1080375</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1080475</id>
  <title>April Spotlight: National Minority Health Month</title>
  <langcode>en</langcode>
  <field_short_title>April Spotlight: National Minority Health Month</field_short_title>
  <field_page_description>Each April, we recognize National Minority Health Month and National Minority Cancer Awareness Week. Dr. Peter Ogunbiyi shares how CRCHD’s work is related to the 2017 theme: Bridging Health Equity Across Communities.</field_page_description>
  <field_feature_card_description>Each April, we recognize National Minority Health Month and National Minority Cancer Awareness Week. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-07</field_date_posted>
  <field_date_reviewed>2017-04-06</field_date_reviewed>
  <field_pretty_url>nmhm17</field_pretty_url>
  <para_id>1080475</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1074837</term_id>
  <id>1081666</id>
  <title>Clinical Trial Sequencing Project</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trial Sequencing</field_short_title>
  <field_page_description>The Clinical Trial Sequencing Project performs genomic characterization of samples from NCI-sponsored trials with the goal of improving the understanding and treatment of various cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-04-17</field_date_reviewed>
  <field_pretty_url>clinical-trial-sequencing</field_pretty_url>
  <para_id>1081666</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1083491</term_id>
  <id>1083492</id>
  <title>Tumor Metastasis Research</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Metastasis Research</field_short_title>
  <field_page_description>Tumor metastasis research examines the mechanisms that allow cancer cells to leave the primary tumor and spread to another part of the body. Learn about recent tumor metastasis research studies supported by the Division of Cancer Biology.</field_page_description>
  <field_feature_card_description>A research area that defines the mechanisms of tumor metastasis which allow tumor cells to leave the primary tumor, survive and travel through the circulation or lymph and ultimately enter distant tissues and expand.</field_feature_card_description>
  <field_list_description>A research area that defines the mechanisms of tumor metastasis which allow tumor cells to leave the primary tumor, survive and travel through the circulation or lymph and ultimately enter distant tissues and expand.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-01</field_date_posted>
  <field_date_reviewed>2017-05-05</field_date_reviewed>
  <para_id>1083492</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1083493</id>
  <title>Nanoparticles Create Effective CAR T Cells in Living Mice</title>
  <langcode>en</langcode>
  <field_short_title>Nanoparticles Create Effective CAR T Cells in Mice</field_short_title>
  <field_page_description>A Cancer Currents blog on the development of a method to genetically engineer cancer-fighting immune cells, known as CAR T cells, in living animals using nanoparticles that carry DNA. </field_page_description>
  <field_feature_card_description>Engineered immune cells eliminated leukemia in the animals.</field_feature_card_description>
  <field_list_description>Researchers have developed a method to genetically engineer cancer-fighting immune cells in living animals using nanoparticles that carry DNA. The new study shows that the resulting immune cells, known as CAR T cells, eliminated leukemia in mice.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-05</field_date_posted>
  <field_date_reviewed>2017-05-05</field_date_reviewed>
  <field_pretty_url>nanoparticles-engineer-immune-cells</field_pretty_url>
  <para_id>1083493</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084754</id>
  <title>Cancer Risk - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Risk</field_short_title>
  <field_page_description>Blog posts on research related to cancer risk—including inherited, behavioral, and environmental risks and studies about decreasing risk—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer risk-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_list_description>Blog posts on research related to cancer risk—including inherited, behavioral, and environmental risks and studies about decreasing risk—from NCI Cancer Currents.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>cancer-risk</field_pretty_url>
  <para_id>1084754</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084762</id>
  <title>FDA Approvals - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approvals</field_short_title>
  <field_page_description>Blog posts on cancer drugs and devices approved by the Food and Drug Administration—including summaries of the evidence to support the approvals and what they mean for patients—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Summaries of FDA approvals of cancer drugs and devices from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>fda-approvals</field_pretty_url>
  <para_id>1084762</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1098083</id>
  <title>Copanlisib Approved for Follicular Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Copanlisib Approved for Follicular Lymphoma</field_short_title>
  <field_page_description>Copanlisib (Aliqopa®), a type of PI3K inhibitor, has been approved by the FDA for the treatment of patients with advanced follicular lymphoma.</field_page_description>
  <field_feature_card_description>Now second PI3K inhibitor approved for patients with advanced follicular lymphoma.</field_feature_card_description>
  <field_list_description>FDA has granted accelerated approval to copanlisib (Aliqopa®) for the treatment of patients with follicular lymphoma, a form of non-Hodgkin lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-16</field_date_posted>
  <field_date_reviewed>2017-10-13</field_date_reviewed>
  <field_pretty_url>aliqopa-fda-follicular-lymphoma</field_pretty_url>
  <para_id>1098083</para_id>
  <related_resource_id>6750782</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1098890</id>
  <title>Study Uses Open Data to Analyze “Normal” Tissue Near Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Tissue adjacent to tumors may not be “normal,” study finds</field_short_title>
  <field_page_description>The tissue immediately surrounding a tumor may not be normal, even if it appears normal under the microscope, as this Cancer Currents article explains.</field_page_description>
  <field_feature_card_description>Findings suggest extensive tumor interaction with surrounding tissue.</field_feature_card_description>
  <field_list_description>The tissue immediately surrounding a tumor may not be normal, even if it appears normal under the microscope, according to an analysis of data from two genomic databases.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-23</field_date_posted>
  <field_date_reviewed>2017-10-23</field_date_reviewed>
  <field_pretty_url>tumor-adjacent-tissue</field_pretty_url>
  <para_id>1098890</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100622</id>
  <title>Expanding Smoking Cessation Services at NCI-Designated Cancer Centers: An Interview with Dr. Glen Morgan</title>
  <langcode>en</langcode>
  <field_short_title>Expanding Smoking Cessation at NCI-Designated Cancer Centers</field_short_title>
  <field_page_description>A new smoking cessation initiative will support NCI-Designated Cancer Centers efforts to help more patients quit smoking, as Dr. Glen Morgan explains in this Cancer Currents interview.</field_page_description>
  <field_feature_card_description>Initiative is aimed at helping cancer patients to stop smoking.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Glen Morgan discusses NCI’s Cancer Center Cessation Initiative, including how and why this smoking cessation initiative was developed and its long-term goals.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-22</field_date_posted>
  <field_date_reviewed>2017-11-22</field_date_reviewed>
  <field_pretty_url>smoking-cessation-nci-cancer-centers</field_pretty_url>
  <para_id>1100622</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1101951</id>
  <title>Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Acalabrutinib Approved for Mantle Cell Lymphoma</field_short_title>
  <field_page_description>Acalabrutinib (Calquence®) has been granted accelerated approval by FDA for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.</field_page_description>
  <field_feature_card_description>Approval based on promising results in early phase clinical trial.</field_feature_card_description>
  <field_list_description>The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-12</field_date_posted>
  <field_date_reviewed>2017-12-11</field_date_reviewed>
  <field_pretty_url>acalabrutinib-fda-mantle-cell-lymphoma</field_pretty_url>
  <para_id>1101951</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1102376</term_id>
  <id>1102381</id>
  <title>Selected Publications by the NCI Director</title>
  <langcode>en</langcode>
  <field_short_title>Selected Publications by the NCI Director</field_short_title>
  <field_page_description>Dr. Norman Sharpless's written work on cancer research appears in many leading scientific journals, as well as a variety of other publications. This page lists some of the articles published by Dr. Sharpless since becoming NCI director.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-19</field_date_posted>
  <field_date_reviewed>2017-12-18</field_date_reviewed>
  <para_id>1102381</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1102407</id>
  <title>Strengthening CGH’s partnerships in cancer research and control in Africa: AORTIC 2017</title>
  <langcode>en</langcode>
  <field_short_title>Strengthening CGH’s partnerships in cancer research and control in Africa: AORTIC 2017</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-20</field_date_posted>
  <field_date_reviewed>2017-12-20</field_date_reviewed>
  <field_pretty_url>aortic-2017</field_pretty_url>
  <para_id>1102407</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1102706</term_id>
  <id>1102704</id>
  <title>Selected Interviews with the NCI Director</title>
  <langcode>en</langcode>
  <field_short_title>Selected Interviews by the NCI Director</field_short_title>
  <field_page_description>See interviews given by Dr. Norman “Ned” Sharpless during his time as NCI director.</field_page_description>
  <field_feature_card_description>The National Cancer Institute director is frequently interviewed by media, scientific, and nonprofit organizations about a variety of topics of interest to the cancer community.</field_feature_card_description>
  <field_list_description>The National Cancer Institute director is frequently interviewed by media, scientific, and nonprofit organizations about a variety of topics of interest to the cancer community. See interviews given by Dr. Norman "Ned" Sharpless during his time as NCI director.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-07</field_date_posted>
  <field_date_reviewed>2017-12-27</field_date_reviewed>
  <para_id>1102704</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916472</term_id>
  <id>882446</id>
  <title>Hexavalent Chromium Compounds</title>
  <langcode>en</langcode>
  <field_short_title>Hexavalent Chromium Compounds</field_short_title>
  <field_page_description>Learn about chromium, exposure to which can increase your risk of lung cancer and cancer of the paranasal sinuses and nasal cavity. Hexavalent chromium compounds have been used as corrosion inhibitors in a wide variety of products and processes.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <para_id>882446</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882606</term_id>
  <id>882607</id>
  <title>Benzene</title>
  <langcode>en</langcode>
  <field_short_title>Benzene</field_short_title>
  <field_page_description>Learn about benzene, a component of crude oil and other substances. Exposure to benzene may increase the risk of leukemia and other blood disorders.  Among smokers, 90 percent of benzene exposure comes from smoking. Benzene may also be found in glues, adhesives, and paint or cleaning products.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-01-14</field_date_reviewed>
  <para_id>882607</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882613</term_id>
  <id>882624</id>
  <title>Beryllium</title>
  <langcode>en</langcode>
  <field_short_title>Beryllium</field_short_title>
  <field_page_description>Learn about beryllium, exposure to which can increase your risk of lung cancer. Beryllium is a naturally occurring, light-weight metal used in products such as aerospace components, transistors, nuclear reactors, and golf clubs. Most exposures occur to workers who produce such products.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-01-31</field_date_reviewed>
  <para_id>882624</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882651</term_id>
  <id>882656</id>
  <title>Coal Tar and Coal-Tar Pitch</title>
  <langcode>en</langcode>
  <field_short_title>Coal Tar and Coal-Tar Pitch</field_short_title>
  <field_page_description>Learn about coal-tar products, which can raise your risk of skin cancer, lung cancer, and other types of cancer. Examples of coal-tar products include creosote, coal-tar pitch, and certain preparations used to treat skin conditions such as eczema, psoriasis, and dandruff.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2018-12-28</field_date_reviewed>
  <para_id>882656</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882655</term_id>
  <id>882658</id>
  <title>Crystalline Silica</title>
  <langcode>en</langcode>
  <field_short_title>Crystalline Silica</field_short_title>
  <field_page_description>Learn about crystalline silica (quartz dust), which can raise your risk of lung cancer. Crystalline silica is present in certain construction materials such as concrete, masonry, and brick and also in commercial products such as some cleansers, cosmetics, pet litter, talcum powder, caulk, and paint.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-01</field_date_reviewed>
  <para_id>882658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>884837</id>
  <title>Global Prostate Cancer Disparities in Black Men</title>
  <langcode>en</langcode>
  <field_short_title>Global Prostate Cancer Disparities in Black Men</field_short_title>
  <field_page_description>Global Prostate Cancer Disparities in Black Men</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-18</field_date_posted>
  <field_date_reviewed>2014-12-18</field_date_reviewed>
  <field_pretty_url>global-prostate-cancer-disparities-in-black-men</field_pretty_url>
  <para_id>884837</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>890811</id>
  <title>Combining Two Types of Targeted Therapy Improves Survival in Some Patients with Advanced Melanoma (Updated)</title>
  <langcode>en</langcode>
  <field_short_title>Dabrafenib Plus Trametinib for Advanced Melanoma</field_short_title>
  <field_page_description>A summary of results from two phase III trials show that patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a</field_page_description>
  <field_feature_card_description>In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following t</field_feature_card_description>
  <field_list_description>In two phase III trials, patients with metastatic melanoma whose tumors have specific mutations in the BRAF gene lived longer following treatment with dabrafenib (Tafinlar®), a BRAF inhibitor, plus trametinib (Mekinist®), a MEK inhibitor, than following treatment with a BRAF inhibitor alone.

</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-06</field_date_posted>
  <field_date_reviewed>2015-01-06</field_date_reviewed>
  <field_pretty_url>dabrafenib-trametinib</field_pretty_url>
  <para_id>890811</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1080925</id>
  <title>FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Ribociclib, Palbociclib for Metastatic Breast Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on the FDA’s approval of two targeted therapies, ribociclib and palbociclib, for women with metastatic breast cancer.</field_page_description>
  <field_feature_card_description>Two targeted therapies are approved for use with an aromatase inhibitor.</field_feature_card_description>
  <field_list_description>The FDA has approved a new targeted therapy, ribociclib, and expanded its earlier approval of another targeted therapy, palbociclib, for some women with metastatic breast cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-10</field_date_posted>
  <field_date_reviewed>2017-04-10</field_date_reviewed>
  <field_pretty_url>fda-ribociclib-palbociclib-breast-cancer</field_pretty_url>
  <para_id>1080925</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1083418</id>
  <title>Collection of Patient-Reported Outcomes Feasible in Cancer Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Collecting Patient-Reported Outcomes in Cancer Clinical Trials</field_short_title>
  <field_page_description>A &lt;i&gt;Cancer Currents&lt;/i&gt; blog post on a study showing that patient-reported outcomes, or PROs, can be successfully collected during cancer clinical trials</field_page_description>
  <field_feature_card_description>Patient-reported outcomes may help clarify how new drugs affect quality of life.</field_feature_card_description>
  <field_list_description>Cancer patients, even those who are undergoing difficult treatments, are willing to devote time to completing thorough assessments of the side effects they encounter in clinical trials, a new study finds.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-10</field_date_posted>
  <field_date_reviewed>2017-05-03</field_date_reviewed>
  <field_pretty_url>patient-reported-outcomes-clinical-trials</field_pretty_url>
  <para_id>1083418</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1084559</id>
  <title>NCI ALMANAC: A New Tool for Research on Cancer Drug Combinations</title>
  <langcode>en</langcode>
  <field_short_title>NCI ALMANAC Tool for Research on Cancer Drug Combinations</field_short_title>
  <field_page_description>A Cancer Currents blog post on the NCI ALMANAC, a new resource that provides data showing how well pairs of FDA-approved cancer drugs performed in killing tumor cells from NCI-60 Human Tumor Cell Lines.</field_page_description>
  <field_feature_card_description>The resource provides data showing how well pairs of FDA-approved drugs kill tumor cells.</field_feature_card_description>
  <field_list_description>NCI has released a new, easy-to-use resource called the NCI ALMANAC to help researchers identify potentially promising combinations of cancer drugs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>nci-almanac-drug-combinations</field_pretty_url>
  <para_id>1084559</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084768</id>
  <title>Prevention - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Prevention</field_short_title>
  <field_page_description>Blog posts on cancer prevention research—including behavioral interventions and other ways to prevent cancer and prevention-related research programs—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer prevention-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>prevention</field_pretty_url>
  <para_id>1084768</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1113308</id>
  <title>April Spotlight: National Minority Health Month</title>
  <langcode>en</langcode>
  <field_short_title>April Spotlight: National Minority Health Month</field_short_title>
  <field_page_description>Each April, we recognize National Minority Health Month (NMHM) because of its direct relevance to us at the National Cancer Institute’s Center to Reduce Cancer Health Disparities (NCI CRCHD). This year’s NMHM theme, Partnering for Health Equity, brings attention to the need for individuals, institutions, and communitie</field_page_description>
  <field_feature_card_description>Each April, we recognize National Minority Health Month (NMHM).  This year’s theme is Partnering for Health Equity.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-04-17</field_date_posted>
  <field_date_reviewed>2018-04-17</field_date_reviewed>
  <field_pretty_url>nmhm18</field_pretty_url>
  <para_id>1113308</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1113457</id>
  <title>A Conversation About RAS Dimers</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation About RAS Dimers</field_short_title>
  <field_page_description>RAS proteins seem to be dimeric in living cells, but monomeric in vitro. Understanding RAS dimers may be important for finding treatments for RAS cancers.</field_page_description>
  <field_feature_card_description>Understanding RAS dimers may enable treatments for RAS cancers.</field_feature_card_description>
  <field_list_description>Data are persuasive that RAS proteins are dimeric in living cells, but monomeric in vitro. Pasi Jänne, Chiara Ambrogio, and Frank McCormick discuss the significance of understanding RAS dimers for finding treatments for RAS cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-04-20</field_date_posted>
  <field_date_reviewed>2018-04-19</field_date_reviewed>
  <field_pretty_url>ras-dimers</field_pretty_url>
  <para_id>1113457</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113875</id>
  <title>Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival</title>
  <langcode>en</langcode>
  <field_short_title>Low Muscle Mass Linked with Worse Cancer Survival</field_short_title>
  <field_page_description>In a new study, researchers compared the risk of death for women with breast cancer who had low skeletal muscle mass, or sarcopenia, at diagnosis and women who had adequate muscle mass. Learn what they found and what it might mean for patients in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>A high percentage of women had the condition at time of diagnosis.</field_feature_card_description>
  <field_list_description>Researchers compared the risk of death for women with breast cancer who had low skeletal muscle mass, or sarcopenia, at the time of their cancer diagnosis and women who had adequate muscle mass.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-30</field_date_posted>
  <field_date_reviewed>2018-04-26</field_date_reviewed>
  <field_pretty_url>sarcopenia-breast-cancer-prognosis</field_pretty_url>
  <para_id>1113875</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113970</id>
  <title>Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Expands Lung Cancer Treatment Options</field_short_title>
  <field_page_description>Results from a large clinical trial show combining the immune checkpoint inhibitor pembrolizumab (Keytruda) with chemotherapy helped some patients with advanced cancer live longer. As this Cancer Currents post explains, the results will immediately affect patient care.</field_page_description>
  <field_feature_card_description>Results of a large clinical trial will immediately affect patient care.</field_feature_card_description>
  <field_list_description>Results from a large clinical trial show combining an immune checkpoint inhibitor with chemotherapy helped some patients with advanced lung cancer live longer than chemotherapy alone. How will this change the lung cancer treatment landscape?</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-27</field_date_posted>
  <field_date_reviewed>2018-04-27</field_date_reviewed>
  <field_pretty_url>pembrolizumab-lung-cancer-first-line</field_pretty_url>
  <para_id>1113970</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>982343</term_id>
  <id>982346</id>
  <title>Vaginal Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on vaginal cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-31</field_date_posted>
  <field_date_reviewed>2015-07-31</field_date_reviewed>
  <para_id>982346</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>986192</id>
  <title>Gene Therapy Approach for Ovarian Cancer Shows Encouraging Signs in Animal Model</title>
  <langcode>en</langcode>
  <field_short_title>Gene Therapy in Mouse Model of Ovarian Cancer</field_short_title>
  <field_page_description>A single injection of a gene therapy viral vector inhibited tumor growth of some mouse tumors derived from patients with recurrent ovarian cancer.</field_page_description>
  <field_feature_card_description>A gene therapy approach blocked tumor growth in mice with ovarian cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-14</field_date_posted>
  <field_date_reviewed>2015-08-14</field_date_reviewed>
  <field_pretty_url>genetherapy-ovarian</field_pretty_url>
  <para_id>986192</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>988385</term_id>
  <id>988476</id>
  <title>DCB Funding</title>
  <langcode>en</langcode>
  <field_short_title>DCB Funding</field_short_title>
  <field_page_description>The Division of Cancer Biology (DCB) funds and supports extramural basic research that investigates the fundamental biology behind cancer. Find out more about DCB's grants process and funding opportunities.</field_page_description>
  <field_feature_card_description>Find out more about DCB's grants process and funding opportunities.</field_feature_card_description>
  <field_list_description>The Division of Cancer Biology funds and supports extramural basic research that investigates the fundamental biology behind cancer. Find out more about DCB's grants process and funding opportunities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-08-26</field_date_reviewed>
  <para_id>988476</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1004257</id>
  <title>New Planning Grant Announced Promotes NCD Research</title>
  <langcode>en</langcode>
  <field_short_title>New Planning Grant Announced Promotes NCD Research</field_short_title>
  <field_page_description>NCI launches the Regional Centers of Research Excellence (RCRE) program.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-21</field_date_posted>
  <field_date_reviewed>2015-09-21</field_date_reviewed>
  <field_pretty_url>NCD_FOA</field_pretty_url>
  <para_id>1004257</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1004623</id>
  <title>Cancer Trends: Influencing Care and Research Priorities</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Trends: Influencing Care and Research Priorities</field_short_title>
  <field_page_description>Many of the trends being seen in cancer are changing how we view cancer and how we address it, from prompting research to identify the underlying causes of cancers increasing in incidence to informing research on treatment and prevention.</field_page_description>
  <field_feature_card_description>SEER, NCI’s chief means of monitoring key trends, is being enhanced to better serve research needs.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-24</field_date_posted>
  <field_date_reviewed>2015-09-24</field_date_reviewed>
  <field_pretty_url>cancer-trends</field_pretty_url>
  <para_id>1004623</para_id>
  <related_resource_ids>6940306</related_resource_ids>
  <related_resource_ids>6940308</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1025849</id>
  <title>Bringing Precision to Screening for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Bringing Precision to Screening for Cancer</field_short_title>
  <field_page_description>A recent NCI-sponsored conference brought together leading screening and cancer control researchers to discuss the state of the science of precision screening for five cancers.</field_page_description>
  <field_feature_card_description>Researchers seek better ways to determine who will benefit from regular cancer screening.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-17</field_date_posted>
  <field_date_reviewed>2015-11-10</field_date_reviewed>
  <field_pretty_url>precision-screening</field_pretty_url>
  <para_id>1025849</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1026924</id>
  <title>Cancer Informatics: Expanding Access to Cancer Genomics Data</title>
  <langcode>en</langcode>
  <field_short_title>Expanding Data Access</field_short_title>
  <field_page_description>The NCI Genomic Data Commons and Cloud Pilots expand access to cancer genomics data by compiling and harmonzed data into a central data repository.</field_page_description>
  <field_feature_card_description>Genomic Data Commons and Cloud Pilots Expand Access to Data</field_feature_card_description>
  <field_list_description>Drs. Staudt and Kibbe discuss the NCI’s major initiatives to improve both the accessibility and usability of cancer genomics data. Top among the NCI’s priorities are the Genomic Data Commons, a service that will bring together and harmonize cancer genomic data sets from NCI programs and non-NCI data submitters, and the Cancer Genomics Cloud Pilots.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-12-02</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <field_pretty_url>cancer-informatics-hangout</field_pretty_url>
  <para_id>1026924</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1027131</id>
  <title>What an Indian Proverb Can Teach Us About Communication</title>
  <langcode>en</langcode>
  <field_short_title>What an Indian Proverb Can Teach Us About Communication</field_short_title>
  <field_page_description>Cancer Research in the Media: International Workshop for Scientific Journalism (CRiM), held last month in India - a partnership of the NCI Office of Communications and Public Liaison (OCPL) and NCI Center for Global Health (CGH).</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-11-20</field_date_posted>
  <field_date_reviewed>2015-11-20</field_date_reviewed>
  <field_pretty_url>crim_india</field_pretty_url>
  <para_id>1027131</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>1030529</id>
  <title>A Conversation with Allan Balmain</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation with Allan Balmain</field_short_title>
  <field_page_description>Dr. Allan Balmain talks about his career path as a pioneer in RAS biology.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-10</field_date_posted>
  <field_date_reviewed>2015-12-10</field_date_reviewed>
  <field_pretty_url>allan-balmain-interview</field_pretty_url>
  <para_id>1030529</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918927</term_id>
  <id>65156</id>
  <title>Drugs Approved for Conditions Related to Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Conditions Related to Cancer</field_short_title>
  <field_page_description>People with cancer may have other conditions caused by the cancer or its treatment. Drugs approved by the FDA for some of these cancer-related conditions are listed on this page, and link to NCI's Cancer Drug Information Summaries. </field_page_description>
  <field_list_description>Conditions related to cancer are listed with links to information about drugs used in those conditions. The drug names link to NCI's Cancer Drug Information summaries. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-18</field_date_posted>
  <field_date_reviewed>2011-03-08</field_date_reviewed>
  <para_id>65156</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899932</term_id>
  <id>903722</id>
  <title>Diarrhea and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Diarrhea</field_short_title>
  <field_page_description>Diarrhea, a side effect of cancer treatment, may cause symptoms such as loose, watery stools. Diarrhea can lead to dehydration and malnutrition in cancer patients. Learn about ways to treat and manage diarrhea during cancer treatment.</field_page_description>
  <field_list_description>Information about what causes diarrhea, a side effect of cancer treatment, and ways to manage it. Symptoms and treatments to manage diarrhea are also explained for cancer patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-12-04</field_date_reviewed>
  <para_id>903722</para_id>
  <related_resource_id>7106974</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>916488</term_id>
  <id>905791</id>
  <title>NCI’s Role in Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s Role in Cancer Research</field_short_title>
  <field_feature_card_description>NCI supports and advances cancer research in many ways.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-19</field_date_posted>
  <field_date_reviewed>2015-02-09</field_date_reviewed>
  <para_id>905791</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1093795</id>
  <title>Bringing the Investigational Breast Cancer Drug Endoxifen from Bench to Bedside with NCI Support</title>
  <langcode>en</langcode>
  <field_short_title>Bringing Endoxifen from Bench to Bedside</field_short_title>
  <field_page_description>Endoxifen, a breast cancer drug being tested in clinical trials, had critical support from NCI, the Mayo Clinic’s Dr. Matthew Goetz writes in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Early-phase clinical trials of endoxifen show promising results.</field_feature_card_description>
  <field_list_description>Researchers recognized the potential of endoxifen as a treatment for breast cancer and, with NCI support, developed the compound into a drug now being tested in clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-31</field_date_posted>
  <field_date_reviewed>2017-08-29</field_date_reviewed>
  <field_pretty_url>endoxifen-breast-cancer-NCI-support</field_pretty_url>
  <para_id>1093795</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1094911</id>
  <title>Forgoing Conventional Cancer Treatments for Alternative Medicine Increases Risk of Death</title>
  <langcode>en</langcode>
  <field_short_title>Alternative Medicine for Cancer Treatment Raises Mortality Risk</field_short_title>
  <field_page_description>Choosing alternative medicine as an initial cancer treatment led to substantially worse survival than patients who received conventional cancer treatments, this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Survival much lower in patients choosing alternative therapies over conventional treatments.</field_feature_card_description>
  <field_list_description>In a large study, patients with nonmetastatic breast, lung, or colorectal cancer who chose alternative therapies had substantially worse survival than patients who received conventional cancer treatments.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-12</field_date_posted>
  <field_date_reviewed>2017-09-07</field_date_reviewed>
  <field_pretty_url>alternative-medicine-cancer-survival</field_pretty_url>
  <para_id>1094911</para_id>
  <related_resource_ids>6749757</related_resource_ids>
  <related_resource_ids>6749758</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1095674</id>
  <title>A Brief Tour of DAVE: The Genomic Data Commons Analysis Toolkit</title>
  <langcode>en</langcode>
  <field_short_title>A tour of GDC DAVE</field_short_title>
  <field_page_description>Get a tour of GDC's genomic analysis and visualization tools</field_page_description>
  <field_feature_card_description>Get a tour of GDC's DAVE: Data Analysis, Visualization &amp; Exploration Tools</field_feature_card_description>
  <field_list_description>The Genomic Data Commons (GDC) gives a brief tour of DAVE: Data Analysis, Visualization, and Exploration Tools. GDC welcomes user questions and feedback to help build an accessible and valuable genomic data resource.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-12</field_date_posted>
  <field_date_reviewed>2017-09-12</field_date_reviewed>
  <field_pretty_url>gdc-dave-tour</field_pretty_url>
  <para_id>1095674</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097905</id>
  <title>Pembrolizumab Secures FDA Approval in Stomach Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab Secures FDA Approval in Stomach Cancer</field_short_title>
  <field_page_description>FDA has approved the immunotherapy drug pembrolizumab (Keytruda®) for use in some patients with advanced gastric (stomach) cancer that is PD-L1 positive.</field_page_description>
  <field_feature_card_description>Approval is for some patients with advanced cancer that is PD-L1 positive.</field_feature_card_description>
  <field_list_description>The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-12</field_date_posted>
  <field_date_reviewed>2017-10-11</field_date_reviewed>
  <field_pretty_url>gastric-cancer-fda-keytruda</field_pretty_url>
  <para_id>1097905</para_id>
  <related_resource_id>6747146</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099018</id>
  <title>Abemaciclib Approved by FDA for Advanced or Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Abemaciclib Approved for Breast Cancer</field_short_title>
  <field_page_description>Abemaciclib (Verzenio™), a type of CDK4/6 inhibitor, has been approved by FDA for some patients with advanced or metastatic breast cancer.</field_page_description>
  <field_feature_card_description>Approval is for some patients with advanced or metastatic breast cancer.</field_feature_card_description>
  <field_list_description>FDA approved abemaciclib (Verzenio™) for the treatment of some people with advanced or metastatic HR-positive, HER2-negative breast cancer whose disease has progressed after treatment with hormone therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-26</field_date_posted>
  <field_date_reviewed>2017-10-24</field_date_reviewed>
  <field_pretty_url>fda-abemaciclib-breast-cancer</field_pretty_url>
  <para_id>1099018</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>936692</term_id>
  <id>171104</id>
  <title>Questions to Ask Your Doctor about Your Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask about Your Treatment</field_short_title>
  <field_page_description>Suggested questions for cancer patients to ask their doctors about treatment choices and the possible side effects of cancer treatment.</field_page_description>
  <field_feature_card_description>Suggested questions to ask your doctor about treatment choices and the possible side effects of treatment. </field_feature_card_description>
  <field_list_description>Suggested questions to ask your doctor about treatment choices and the possible side effects of cancer treatment. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-02-14</field_date_posted>
  <field_date_reviewed>2018-08-09</field_date_reviewed>
  <para_id>171104</para_id>
  <related_resource_ids>7093740</related_resource_ids>
  <related_resource_ids>7093741</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772002</term_id>
  <id>772119</id>
  <title>Thoracic Malignancy Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Thoracic Malignancy Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772119</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069528</term_id>
  <id>799467</id>
  <title>A Message from Dr. Frank McCormick</title>
  <langcode>en</langcode>
  <field_short_title>A Message from Dr. Frank McCormick</field_short_title>
  <field_page_description>Frank McCormick, pioneering RAS researcher and former head of the UCSF cancer center, describes the problem with RAS cancers and how the NCI RAS Initiative will attack them.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <field_pretty_url>mccormick-message</field_pretty_url>
  <para_id>799467</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917270</term_id>
  <id>804860</id>
  <title>NCI Outstanding Investigator Award (R35) Frequently Asked Questions</title>
  <langcode>en</langcode>
  <field_short_title>FAQs</field_short_title>
  <field_page_description>Frequently asked questions for the NCI Outstanding Investigator Award.</field_page_description>
  <field_feature_card_description>Frequently asked questions for the NCI Outstanding Investigator Award.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-15</field_date_posted>
  <field_date_reviewed>2014-07-15</field_date_reviewed>
  <para_id>804860</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919505</term_id>
  <id>805068</id>
  <title>Contact the Office of Budget and Finance</title>
  <langcode>en</langcode>
  <field_short_title>Contact OBF</field_short_title>
  <field_page_description>Address and phone number for NCI's Office of Budget and Finance.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-21</field_date_posted>
  <field_date_reviewed>2014-07-17</field_date_reviewed>
  <para_id>805068</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>816960</term_id>
  <id>817099</id>
  <title>RAS Structural Biology</title>
  <langcode>en</langcode>
  <field_short_title>RAS Structural Biology</field_short_title>
  <field_page_description>The RAS Structural Biology group determines the structures of RAS proteins, alone and in complex with important effectors.</field_page_description>
  <field_feature_card_description>This group aims to provide structural insights into oncogenic mutants of RAS, RAS-effector, and RAS-interactor complexes.</field_feature_card_description>
  <field_list_description>This group aims to provide structural insights into oncogenic mutants of RAS, RAS-effector, and RAS-interactor complexes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2014-08-20</field_date_reviewed>
  <para_id>817099</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915352</term_id>
  <id>1032044</id>
  <title>Microbes within Our Bodies May Cause or Contribute to Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Microbes within Our Bodies May Cause or Contribute to Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-12</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>microbes-cancer-link</field_pretty_url>
  <para_id>1032044</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1007397</term_id>
  <id>1033164</id>
  <title>Christal Sohl, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Christal Sohl, Ph.D.</field_short_title>
  <field_page_description>The San Diego State University biologist uses a variety of methods, including structural, computational, and kinetic analyses, to study enzymes that may play a role in cancer.</field_page_description>
  <field_feature_card_description>The San Diego State University biologist studies enzymes that may play a role in cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-22</field_date_posted>
  <field_date_reviewed>2015-12-21</field_date_reviewed>
  <field_pretty_url>christal-sohl</field_pretty_url>
  <para_id>1033164</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1033306</term_id>
  <id>1033307</id>
  <title>The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)</title>
  <langcode>en</langcode>
  <field_short_title>The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)</field_short_title>
  <field_page_description>Apply for the NCI F99/K00 Award that helps late-stage doctoral candidates finish their training and then transition into cancer-focused research positions.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-29</field_date_posted>
  <field_date_reviewed>2016-01-26</field_date_reviewed>
  <para_id>1033307</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1105290</id>
  <title>Olaparib Approved for Treating Some Breast Cancers with BRCA Gene Mutations</title>
  <langcode>en</langcode>
  <field_short_title>Olaparib Approved for Breast Cancers with BRCA Gene Mutations</field_short_title>
  <field_page_description>The Food and Drug Administration has approved olaparib (Lynparza®) to treat metastatic breast cancers that have inherited mutations in the BRCA1 or BRCA2 genes as well as a companion diagnostic test for selecting candidates for the therapy.</field_page_description>
  <field_feature_card_description>In the trial that led to approval, the drug caused fewer side effects than standard chemotherapy.</field_feature_card_description>
  <field_list_description>The drug olaparib (Lynparza®) is the first treatment approved by the Food and Drug Administration for patients with metastatic breast cancer who have inherited mutations in the BRCA1 or BRCA2 genes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-29</field_date_posted>
  <field_date_reviewed>2018-01-29</field_date_reviewed>
  <field_pretty_url>fda-olaparib-breast-brca-mutations</field_pretty_url>
  <para_id>1105290</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107079</id>
  <title>For Rare Melanoma, Checkpoint Inhibitors May Hold Substantial Promise</title>
  <langcode>en</langcode>
  <field_short_title>Checkpoint Inhibitors Hold Promise for Rare Melanoma</field_short_title>
  <field_page_description>Patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from immune checkpoint inhibitors, a new study shows. As this Cancer Currents post explains, an NCI-sponsored clinical trial is already testing one such drug, pembrolizumab (Keytruda) in patients with this cancer.</field_page_description>
  <field_feature_card_description>Patients with desmoplastic melanoma may be particularly likely to benefit.</field_feature_card_description>
  <field_list_description>A new study suggests that patients with a rare form of melanoma, called desmoplastic melanoma, may be particularly likely to benefit from treatments known as immune checkpoint inhibitors. An NCI-sponsored clinical trial is already testing one such drug in patients with this cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>desmoplastic-melanoma-checkpoint-inhibitors</field_pretty_url>
  <para_id>1107079</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107109</id>
  <title>Clinical Trials for Childhood Brain Stem Glioma</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials for Childhood Brain Stem Glioma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>childhood-brainstem-glioma</field_pretty_url>
  <para_id>1107109</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109800</id>
  <title>Drug May Help Prevent Resistance to Toxin-Based Leukemia Therapy</title>
  <langcode>en</langcode>
  <field_short_title>Drug May Help Prevent Resistance to Toxin-Based Leukemia Therapy</field_short_title>
  <field_page_description>Adding the drug 5-AZA to moxetumomab pasudotox, a toxin-based cancer drug, may improve its efficacy in acute lymphoblastic leukemia (ALL). As this Cancer Currents blog post explains, in mice, both drugs were more effective than moxetumomab alone.</field_page_description>
  <field_feature_card_description>In mice, giving 5-AZA along with moxetumomab improved its efficacy.</field_feature_card_description>
  <field_list_description>A new study has identified a possible strategy for improving the efficacy of a toxin-based cancer treatment, moxetumomab pasudotox, in some patients with acute lymphoblastic leukemia (ALL).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-12</field_date_posted>
  <field_date_reviewed>2018-03-09</field_date_reviewed>
  <field_pretty_url>moxetumomab-leukemia-overcoming-resistance</field_pretty_url>
  <para_id>1109800</para_id>
  <related_resource_ids>6914494</related_resource_ids>
  <related_resource_ids>6914495</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1114660</id>
  <title>Assessing the International Landscape of Cancer Research through Successful Partnership</title>
  <langcode>en</langcode>
  <field_short_title>Assessing the International Landscape</field_short_title>
  <field_page_description>On April 11th, 2018 the NCI Center for Research Strategy, in coordination with CGH, hosted the Annual Meeting of the International Cancer Research Partnership (ICRP). The meeting marked 18 years of a successful partnership, representing 124 organizations that fund cancer research projects in 145 countries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-04</field_date_posted>
  <field_date_reviewed>2018-05-04</field_date_reviewed>
  <field_pretty_url>icrp-2018</field_pretty_url>
  <para_id>1114660</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114844</term_id>
  <id>1114850</id>
  <title>Get Involved: Community Groups for Trainees and Fellows</title>
  <langcode>en</langcode>
  <field_short_title>Get Involved: Community Groups</field_short_title>
  <field_page_description>Cancer research fellows and trainees will find information about special interest groups at NCI and NIH. Learn more about how to get involved. </field_page_description>
  <field_feature_card_description>Trainees will find information and resources to support their NCI fellowship. </field_feature_card_description>
  <field_list_description>Learn about community groups, committees, and leadership opportunities at NCI and NIH. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-04</field_date_reviewed>
  <para_id>1114850</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114842</term_id>
  <id>1115079</id>
  <title>New to NCI: Information for New Trainees and Fellows</title>
  <langcode>en</langcode>
  <field_short_title>New to NCI: Information for New Trainees</field_short_title>
  <field_page_description>Fellows and cancer research trainees will find information to support their onboarding at NCI, including stipend and tax information and NIH rules and regulations. Learn more about orientation for NCI trainees. </field_page_description>
  <field_feature_card_description>Trainees will find information to support their onboarding experience. </field_feature_card_description>
  <field_list_description>Find information to support onboarding at NCI, including stipend and tax information and NIH rules and regulations.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-09</field_date_reviewed>
  <para_id>1115079</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>886985</term_id>
  <id>905020</id>
  <title>Screening Tests</title>
  <langcode>en</langcode>
  <field_short_title>Screening Tests</field_short_title>
  <field_page_description>Information about tests such as mammography and colonoscopy that may be used to screen for cancer in people without symptoms of disease.  </field_page_description>
  <field_feature_card_description>Information about cancer screening and the types of tests used to find cancer.</field_feature_card_description>
  <field_list_description>Information about tests that may be used to screen for cancer in people without symptoms of disease.  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-24</field_date_posted>
  <field_date_reviewed>2015-02-06</field_date_reviewed>
  <para_id>905020</para_id>
  <related_resource_ids>7214563</related_resource_ids>
  <related_resource_ids>7214564</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1096317</id>
  <title>Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan</title>
  <langcode>en</langcode>
  <field_short_title>Overcoming the Challenges of Metastatic Cancer</field_short_title>
  <field_page_description>NCI’s Dr. Rosandra Kaplan discusses metastatic cancer research and new ideas for treating and preventing metastatic cancer.</field_page_description>
  <field_feature_card_description>NCI’s Dr. Rosandra Kaplan on important trends in metastatic cancer research.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-20</field_date_posted>
  <field_date_reviewed>2017-09-18</field_date_reviewed>
  <field_pretty_url>metastatic-cancer-kaplan</field_pretty_url>
  <para_id>1096317</para_id>
  <related_resource_id>6713323</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097043</id>
  <title>Kids First Pediatric Research Program Moves Forward</title>
  <langcode>en</langcode>
  <field_short_title>Kids First Pediatric Research Program Moves Forward</field_short_title>
  <field_page_description>A new data resource center is being developed for the Gabriella Miller Kids First Research Program, so investigators can better collaborate on childhood cancers and birth defect research.</field_page_description>
  <field_feature_card_description>Researchers developing central resource for data sharing.</field_feature_card_description>
  <field_list_description>Progress continues to be made with the Gabriella Miller Kids First Research Program, which is creating opportunities for investigators from different research communities to share resources and collaborate on research into childhood cancers and certain birth defects.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-29</field_date_posted>
  <field_date_reviewed>2017-09-28</field_date_reviewed>
  <field_pretty_url>kidsfirst-childhood-cancer-moving-forward</field_pretty_url>
  <para_id>1097043</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1097589</term_id>
  <id>1097590</id>
  <title>Identifying Strategic Scientific Opportunities at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Identifying Strategic Scientific Opportunities</field_short_title>
  <field_page_description>As NCI's central scientific strategy office, CRS collaborates with the institute's divisions, offices, and centers to identify research opportunities to advance NCI's vision for the future of cancer research.</field_page_description>
  <field_feature_card_description>CRS collaborates with NCI's DOCs to identify research opportunities to advance NCI's vision for hte future of cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-13</field_date_posted>
  <field_date_reviewed>2017-10-04</field_date_reviewed>
  <para_id>1097590</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>45782</term_id>
  <id>1097904</id>
  <title>Susan Perkins, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Susan Perkins, Ph.D.</field_short_title>
  <field_page_description>Read more about Cancer Training Branch Deputy Chief Susan Perkins, Ph.D.</field_page_description>
  <field_list_description>Biography of Susan Perkins, Ph.D.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-10</field_date_posted>
  <field_date_reviewed>2017-10-10</field_date_reviewed>
  <field_pretty_url>susan-perkins</field_pretty_url>
  <para_id>1097904</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1117063</id>
  <title>Dr. Levi Garraway to Deliver NCI CURE Distinguished Scholars Seminar</title>
  <langcode>en</langcode>
  <field_short_title>Dr. Levi Garraway to Deliver NCI CURE Distinguished Scholars Seminar</field_short_title>
  <field_page_description>On July 24, 2018, Dr. Levi Garraway will deliver the next CURE Distinguished Scholars Seminar. Dr. Garraway will present on the Molecular and Genomic Characterization of Human Solid Tumors.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-05</field_date_posted>
  <field_date_reviewed>2018-06-05</field_date_reviewed>
  <field_pretty_url>garraway-seminar</field_pretty_url>
  <para_id>1117063</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1117120</id>
  <title>Selumetinib Continues to Show Promise in Children with NF1</title>
  <langcode>en</langcode>
  <field_short_title>Selumetinib Shrinks Tumors in Children with NF1</field_short_title>
  <field_page_description>The investigational drug selumetinib shrank tumors in some children with a genetic syndrome called neurofibromatosis type 1 (NF1). As this Cancer Currents post explains, the drug also improved symptoms related to tumors known as neurofibromas, which can cause pain, difficulty breathing or walking, and disfigurement. </field_page_description>
  <field_feature_card_description>The tumors can cause pain, difficulty breathing or walking, and disfigurement.</field_feature_card_description>
  <field_list_description>In a phase 2 clinical trial, the investigational drug selumetinib shrank tumors in some children with the genetic syndrome neurofibromatosis type 1 (NF1). The tumors, called neurofibromas, can cause pain, difficulty breathing or walking, and disfigurement.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-08</field_date_posted>
  <field_date_reviewed>2018-06-07</field_date_reviewed>
  <field_pretty_url>selumetinib-nf1-neurofibromas</field_pretty_url>
  <para_id>1117120</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1104028</term_id>
  <id>1117581</id>
  <title>Respondent Burden</title>
  <langcode>en</langcode>
  <field_short_title>Respondent Burden</field_short_title>
  <field_page_description>The respondent burden for those participating in Intramural Continuing Umbrella of Research Experiences (iCURE). </field_page_description>
  <field_feature_card_description>iCure Respondent Burden</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-13</field_date_posted>
  <field_date_reviewed>2018-06-13</field_date_reviewed>
  <field_pretty_url>respondent-burden</field_pretty_url>
  <para_id>1117581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1126555</term_id>
  <id>1117590</id>
  <title>The Cancer Genome Atlas Program</title>
  <langcode>en</langcode>
  <field_short_title>The Cancer Genome Atlas</field_short_title>
  <field_page_description>The Cancer Genome Atlas (TCGA) is a landmark cancer genomics program that sequenced and molecularly characterized over 11,000 cases of primary cancer samples. Learn more about how the program transformed the cancer research community and beyond.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-13</field_date_posted>
  <field_date_reviewed>2018-06-13</field_date_reviewed>
  <para_id>1117590</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1118100</id>
  <title>Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia</field_short_title>
  <field_page_description>FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.</field_page_description>
  <field_feature_card_description>Approval now includes patients without the deletion 17p gene alteration.</field_feature_card_description>
  <field_list_description>FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-22</field_date_posted>
  <field_date_reviewed>2018-06-20</field_date_reviewed>
  <field_pretty_url>venetoclax-fda-cll-expanded-approval</field_pretty_url>
  <para_id>1118100</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129043</term_id>
  <id>1118194</id>
  <title>TCGA Computational Tools</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Computational Tools</field_short_title>
  <field_page_description>Some of the data processing, visualization, and other computational tools developed by TCGA network researchers and collaborators.</field_page_description>
  <field_feature_card_description>Some of the tools developed by TCGA network researchers and collaborators</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-06-22</field_date_reviewed>
  <para_id>1118194</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>941579</term_id>
  <id>14272</id>
  <title>Selected NCI-Supported Trials</title>
  <langcode>en</langcode>
  <field_short_title>Selected NCI-Supported Trials</field_short_title>
  <field_page_description>Information about selected NCI-supported clinical trials, open or closed to patient enrollment.</field_page_description>
  <field_feature_card_description>This page describes some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods.</field_feature_card_description>
  <field_list_description>This page describes some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2006-12-19</field_date_posted>
  <field_date_reviewed>2006-12-19</field_date_reviewed>
  <para_id>14272</para_id>
  <related_resource_ids>7117725</related_resource_ids>
  <related_resource_ids>7117727</related_resource_ids>
  <related_resource_ids>7117729</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919678</term_id>
  <id>14404</id>
  <title>Site Map</title>
  <langcode>en</langcode>
  <field_short_title>Site Map</field_short_title>
  <field_page_description>Site map for the National Cancer Institute website.</field_page_description>
  <field_list_description>Site map for the National Cancer Institute website (www.cancer.gov).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14404</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11880</term_id>
  <id>14454</id>
  <title>Bladder Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Bladder Cancer</field_short_title>
  <field_page_description>The most common type of bladder cancer is transitional cell carcinoma, also called urothelial carcinoma. Smoking is a major risk factor for bladder cancer. Bladder cancer is often diagnosed at an early stage. Start here to find information on bladder cancer treatment, screening, research, and statistics.</field_page_description>
  <field_feature_card_description>Our evidence-based information covers treatment, causes, screening, and more.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about Bladder Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14454</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65193</id>
  <title>Drugs Approved for Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Lung Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for lung cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-09</field_date_reviewed>
  <field_pretty_url>lung</field_pretty_url>
  <para_id>65193</para_id>
  <related_resource_ids>7181325</related_resource_ids>
  <related_resource_ids>7181345</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65323</id>
  <title>Drugs Approved for Kidney (Renal Cell) Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Kidney (Renal Cell) Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for kidney (renal cell) cancer. The list includes generic names and brand names. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-11</field_date_reviewed>
  <field_pretty_url>kidney</field_pretty_url>
  <para_id>65323</para_id>
  <related_resource_ids>6950338</related_resource_ids>
  <related_resource_ids>6950341</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65325</id>
  <title>Drugs Approved for Pancreatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Pancreatic Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for pancreatic cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-11</field_date_reviewed>
  <field_pretty_url>pancreatic</field_pretty_url>
  <para_id>65325</para_id>
  <related_resource_ids>6994698</related_resource_ids>
  <related_resource_ids>6994709</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65908</term_id>
  <id>65964</id>
  <title>Sallie Rosen Kaplan (SRK) Postdoctoral Fellowship for Women Scientists</title>
  <langcode>en</langcode>
  <field_short_title>NCI SRK Award</field_short_title>
  <field_page_description>The SRK Fellowship is a highly competitive, unpaid, and annual, one-year program that provides additional mentoring opportunities, networking, seminars, and workshops to help prepare NCI’s female postdoctoral fellows for the competitive nature of the job market and help them remain in a biomedical research career. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-18</field_date_posted>
  <field_date_reviewed>2011-03-18</field_date_reviewed>
  <para_id>65964</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68334</term_id>
  <id>68353</id>
  <title>Paul Calabresi Career Development Award for Clinical Oncology (K12)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K12 Award</field_short_title>
  <field_page_description>Institutional award for postdoctoral candidates or mentored junior faculty who are clinical scientists pursuing careers in patient-oriented research.</field_page_description>
  <field_feature_card_description>Institutional award for postdoctoral candidates or mentored junior faculty who are clinical scientists pursuing careers in patient-oriented research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-21</field_date_posted>
  <field_date_reviewed>2011-03-21</field_date_reviewed>
  <para_id>68353</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68512</term_id>
  <id>68601</id>
  <title>Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K07 Award</field_short_title>
  <field_page_description>For postdoctoral candidates or mentored junior faculty who are pursuing careers in cancer prevention, control, behavioral, and population sciences.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-22</field_date_reviewed>
  <para_id>68601</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>70026</id>
  <title>When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death</title>
  <langcode>en</langcode>
  <field_short_title>When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death</field_short_title>
  <field_page_description>Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2,</field_page_description>
  <field_feature_card_description>Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2,</field_feature_card_description>
  <field_list_description>Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-03-30</field_date_posted>
  <field_date_reviewed>2011-03-30</field_date_reviewed>
  <field_pretty_url>bevacizumab-severe-side-effects</field_pretty_url>
  <para_id>70026</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>73712</id>
  <title>PSA Velocity Does Not Improve Prostate Cancer Detection</title>
  <langcode>en</langcode>
  <field_short_title>PSA Velocity Does Not Improve Prostate Cancer Detection</field_short_title>
  <field_page_description>A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute.</field_page_description>
  <field_feature_card_description>A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24, 2011, in the Journal of the National Cancer Institute.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-13</field_date_posted>
  <field_date_reviewed>2011-04-13</field_date_reviewed>
  <field_pretty_url>psa-velocity-detection</field_pretty_url>
  <para_id>73712</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>74351</id>
  <title>Drugs Approved for Non-Hodgkin Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Non-Hodgkin Lymphoma</field_short_title>
  <field_page_description>A list of cancer drugs approved by the Food and Drug Administration (FDA) for non-Hodgkin lymphoma. The list includes generic names, brand names, and common drug combinations.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2013-06-10</field_date_reviewed>
  <field_pretty_url>non-hodgkin</field_pretty_url>
  <para_id>74351</para_id>
  <related_resource_ids>7143849</related_resource_ids>
  <related_resource_ids>7143851</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1101055</term_id>
  <id>1101059</id>
  <title>Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade</title>
  <langcode>en</langcode>
  <field_short_title>Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Block</field_short_title>
  <field_page_description>This study seeks to better predict patient-derived tumor responsiveness to immune checkpoint blockade.</field_page_description>
  <field_list_description>This study hypothesizes that physiologic modeling of the tumor microenvironment through microfluidic culture will enhance the ability to predict patient-derived tumor responsiveness to immune checkpoint blockade.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-19</field_date_posted>
  <field_date_reviewed>2017-12-01</field_date_reviewed>
  <para_id>1101059</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1101415</id>
  <title>FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Alectinib for Untreated ALK-Positive Lung Cancer</field_short_title>
  <field_page_description>Alectinib (Alcensa) has been approved by the FDA for untreated ALK-positive non-small cell lung cancer (NSCLC), based on results from the ALEX trial. </field_page_description>
  <field_feature_card_description>Approval offers new option for patients whose tumors are ALK positive.</field_feature_card_description>
  <field_list_description>FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-06</field_date_posted>
  <field_date_reviewed>2017-12-05</field_date_reviewed>
  <field_pretty_url>alectinib-fda-untreated-lung-cancer</field_pretty_url>
  <para_id>1101415</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1101493</id>
  <title>With Advances in Cancer Immunotherapy, Scientists Discuss Need to Develop New Mouse Models</title>
  <langcode>en</langcode>
  <field_short_title>Researchers Discuss Developing Better Cancer Immunotherapy Models</field_short_title>
  <field_page_description>Developing better cancer immunotherapy mouse models was the focus of a recent NCI-sponsored meeting, including current challenges and future opportunities. </field_page_description>
  <field_feature_card_description>Research symposium addresses need for new models to advance immune-based treatments. </field_feature_card_description>
  <field_list_description>A recent NCI symposium focused on developing new and better mouse models for testing treatments that harness the immune system against cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-08</field_date_posted>
  <field_date_reviewed>2017-12-07</field_date_reviewed>
  <field_pretty_url>immunotherapy-mouse-models-meeting</field_pretty_url>
  <para_id>1101493</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102509</id>
  <title>Genomic Profiling Tests Cleared by FDA Can Help Guide Cancer Treatment, Clinical Trial Enrollment</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Two Genomic Profiling Tests for Cancer</field_short_title>
  <field_page_description>FDA has approved two genomic profiling tests for tumors. One of the tests, FoundationOne CDx (F1CDx), can be used as a companion diagnostic for some cancer therapies.</field_page_description>
  <field_feature_card_description>Tests can identify different cancer-associated genetic alterations.</field_feature_card_description>
  <field_list_description>The FDA has recently approved two tests to identify genetic alterations in tumors. One of the tests can be used to identify patients who may be candidates to receive specific targeted therapies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-21</field_date_posted>
  <field_date_reviewed>2017-12-21</field_date_reviewed>
  <field_pretty_url>genomic-profiling-tests-cancer</field_pretty_url>
  <para_id>1102509</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102692</id>
  <title>Fusobacterium May Help Colorectal Cancer Grow and Spread</title>
  <langcode>en</langcode>
  <field_short_title>Bacteria May Aid Growth of Colorectal Cancer</field_short_title>
  <field_page_description>The bacteria Fusobacterium may help fuel the growth of colorectal cancer, and antibiotics may help to treat it, a new study suggests.</field_page_description>
  <field_feature_card_description>Study links specific bacterial species to growth, spread of this common cancer.</field_feature_card_description>
  <field_list_description>Fusobacterium, found in the stomach and intestines, may help fuel the growth of colorectal cancer and metastases. In a mouse model of colorectal cancer, using antibiotics to kill these bacteria slowed tumor growth.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-29</field_date_posted>
  <field_date_reviewed>2017-12-26</field_date_reviewed>
  <field_pretty_url>bacteria-colorectal-cancer</field_pretty_url>
  <para_id>1102692</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1102943</term_id>
  <id>1102955</id>
  <title>NCI Scientists in the Community</title>
  <langcode>en</langcode>
  <field_short_title>NCI Scientists in the Community</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-05</field_date_reviewed>
  <para_id>1102955</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1103889</term_id>
  <id>1104010</id>
  <title>Treatment of Head and Neck Cancer in Adults—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer Treatment in Adults</field_short_title>
  <field_page_description>Find diagnosis, staging, and treatment information for these head and neck cancers: hypopharynx, larynx, lip and oral cavity, neck cancer with occult primary, nasopharynx, oropharynx, paranasal sinus and nasal cavity, and salivary gland cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-15</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104010</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1033564</id>
  <title>Asia-Pacific Economic Cooperation (APEC)</title>
  <langcode>en</langcode>
  <field_short_title>Asia-Pacific Economic Cooperation (APEC)</field_short_title>
  <field_page_description>As the leading economic forum in the Asia-Pacific region, APEC facilitates economic growth and prosperity in the Asia-Pacific region through trade and investment liberalization, business facilitation, and economic and technical cooperation.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-05</field_date_posted>
  <field_date_reviewed>2016-01-05</field_date_reviewed>
  <field_pretty_url>apec</field_pretty_url>
  <para_id>1033564</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1011704</term_id>
  <id>1033575</id>
  <title>Structural Biology and Molecular Applications Research</title>
  <langcode>en</langcode>
  <field_short_title>Structural Biology and Molecular Applications Research</field_short_title>
  <field_page_description>Part of NCI's Division of Cancer Biology's research portfolio, research and development in this area focuses on enabling technologies, models, and methodologies to support basic and applied cancer research. </field_page_description>
  <field_feature_card_description>Cancer research and development in this area focuses on enabling technologies, models, and methodologies to support basic and applied cancer research.  </field_feature_card_description>
  <field_list_description>Cancer research and discovery in this area focuses on technology development and molecular applications, biophysical biology, and computational/mathematical methods and bioinformatics development.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <para_id>1033575</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1011706</term_id>
  <id>1033576</id>
  <title>Tumor Biology and Microenvironment Research</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Biology and Microenvironment Research</field_short_title>
  <field_page_description>Part of NCI's Division of Cancer Biology's research portfolio, research in this area seeks to understand the role of tumor cells and the tumor microenvironment (TME) in driving cancer initiation, progression, maintenance and recurrence.</field_page_description>
  <field_feature_card_description>Research in this area seeks to understand the role of tumor cells and the tumor microenvironment (TME) in driving cancer initiation, progression, maintenance and recurrence.</field_feature_card_description>
  <field_list_description>Research in this area seeks to understand the role of tumor cells and the tumor microenvironment in driving cancer processes.  Understanding the cellular, molecular, and biochemical interactions of tumors within their microenvironment is essential to improving cancer diagnosis and treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <para_id>1033576</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>762611</term_id>
  <id>1035658</id>
  <title>CGH Celebrates World Cancer Day 2017</title>
  <langcode>en</langcode>
  <field_short_title>CGH Celebrates World Cancer Day 2017</field_short_title>
  <field_page_description>The NCI Center for Global Health participated in a number of events to celebrate World Cancer Day.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-01-31</field_date_posted>
  <field_date_reviewed>2016-02-03</field_date_reviewed>
  <field_pretty_url>WCD2017</field_pretty_url>
  <para_id>1035658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1035659</id>
  <title>Persistent Peripheral Neuropathy Increases Fall Risk among Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Persistent Peripheral Neuropathy Increases Fall Risk among Cancer Survivors</field_short_title>
  <field_page_description>Many female cancer survivors have problems with mobility and other physical functioning as a result of persistent peripheral neuropathy caused by chemotherapy treatment, according to a new study. </field_page_description>
  <field_feature_card_description>Persistent neuropathy caused by chemotherapy impairs physical functioning and increases fall risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-05</field_date_posted>
  <field_date_reviewed>2016-02-03</field_date_reviewed>
  <field_pretty_url>peripheral-neuropathy-falls</field_pretty_url>
  <para_id>1035659</para_id>
  <related_resource_id>6611780</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1088594</id>
  <title>Extensive Lymph Node Surgery Does Not Increase Survival in Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Trial Provides Guidance on Lymph Node Surgery in Melanoma</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on results from a clinical trial which show that a conservative approach to lymph node removal surgery may be best for some patients with melanoma.</field_page_description>
  <field_feature_card_description>For some patients, a conservative approach may be best option.</field_feature_card_description>
  <field_list_description>A conservative approach to lymph node removal surgery may be best for people with melanoma that has spread from the skin to one or a small number of nearby lymph nodes, new results from a large international clinical trial suggest. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-30</field_date_posted>
  <field_date_reviewed>2017-06-29</field_date_reviewed>
  <field_pretty_url>lymph-node-surgery-melanoma</field_pretty_url>
  <para_id>1088594</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1088987</id>
  <title>Cancer Researchers Report Progress in Studying Exceptional Responders</title>
  <langcode>en</langcode>
  <field_short_title>Exceptional Responders Initiative Moving Forward</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a recent NCI-sponsored meeting to discuss research on exceptional responders—patients with cancer who have dramatic and long-lasting treatment responses.</field_page_description>
  <field_feature_card_description>Researchers are trying to identify factors behind unique, dramatic treatment responses.</field_feature_card_description>
  <field_list_description>Researchers who study exceptional responders—patients who have dramatic and long-lasting responses to treatments for cancer that were not effective for most similar patients—met recently to discuss the state of the science in this emerging field. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-06</field_date_posted>
  <field_date_reviewed>2017-07-06</field_date_reviewed>
  <field_pretty_url>exceptional-responders-progress</field_pretty_url>
  <para_id>1088987</para_id>
  <related_resource_id>6625498</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>763331</term_id>
  <id>814107</id>
  <title>Understanding Cervical Changes: Next Steps After an Abnormal Screening Test</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Cervical Changes</field_short_title>
  <field_page_description>Explains abnormal Pap test, HPV test, and Pap/HPV cotest results. Treatment and follow-up care for abnormal cervical cancer screening results including ASC-US, AGC, LSIL, ASC-H, HSIL, AIS. Learn about colposcopy, types of biopsies, CIN, and HPV vaccine.</field_page_description>
  <field_feature_card_description>Explains HPV Infection; cervical cancer screening tests including Pap test, HPV test, and Pap/HPV cotesting; new cervical cancer screening guidelines; possible Pap test results and Pap/HPV cotest results; follow-up testing; treatment; and HPV vaccination.</field_feature_card_description>
  <field_list_description>Learn what test results mean if a recent Pap test showed cell changes in the cervix or an HPV test was positive, including that not all cervical changes mean cancer; find out the importance of follow-up care and treatment for abnormal results. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-01-16</field_date_posted>
  <field_date_reviewed>2014-01-16</field_date_reviewed>
  <para_id>814107</para_id>
  <related_resource_ids>7118465</related_resource_ids>
  <related_resource_ids>7118474</related_resource_ids>
  <related_resource_ids>7118475</related_resource_ids>
  <related_resource_ids>7118477</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911288</term_id>
  <id>814466</id>
  <title>Targeted Therapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Therapy</field_short_title>
  <field_page_description>Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread. Learn how targeted therapy works against cancer and about side effects that may occur.</field_page_description>
  <field_feature_card_description>Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread. Learn how targeted therapy works against cancer and about side effects that may occur.</field_feature_card_description>
  <field_list_description>Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread. Learn how targeted therapy works against cancer and about common side effects that may occur.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-08-15</field_date_posted>
  <field_date_reviewed>2014-08-14</field_date_reviewed>
  <para_id>814466</para_id>
  <related_resource_id>7170538</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1031954</id>
  <title>Checking In on Cancer Checkpoint Inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Checking In on Cancer Checkpoint Inhibitors</field_short_title>
  <field_page_description>NCI’s Dr. James Gulley discusses cancer checkpoint inhibitors, their impact on patient care, and future directions for these therapies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-18</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>gulley-checkpoint</field_pretty_url>
  <para_id>1031954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1033176</id>
  <title>Cancer Can Lead to Financial Hardship, Study Confirms</title>
  <langcode>en</langcode>
  <field_short_title>Study of Cancer and Financial Hardship</field_short_title>
  <field_page_description>A substantial number of working-age cancer survivors report material or psychological financial hardship associated with their cancer.</field_page_description>
  <field_feature_card_description>Many working-age cancer survivors report financial hardship associated with their cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-23</field_date_posted>
  <field_date_reviewed>2015-12-22</field_date_reviewed>
  <field_pretty_url>cancer-financial-hardship</field_pretty_url>
  <para_id>1033176</para_id>
  <related_resource_id>6572996</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1034108</id>
  <title>DNA Misfolding Revealed as Novel Oncogenic Mechanism</title>
  <langcode>en</langcode>
  <field_short_title>DNA Misfolding Revealed as Novel Oncogenic Mechanism</field_short_title>
  <field_page_description>Researchers studying IDH-mutant brain tumors have identified a previously unknown genetic mechanism that may contribute to cancer. A change in how DNA is arranged, or packaged, in the cell nucleus may inappropriately activate a gene associated with brain cancer.</field_page_description>
  <field_feature_card_description>DNA Misfolding Revealed as Novel Oncogenic Mechanism</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-01</field_date_posted>
  <field_date_reviewed>2016-01-19</field_date_reviewed>
  <field_pretty_url>gliomas-reveal-dna-misfolding</field_pretty_url>
  <para_id>1034108</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>1034200</term_id>
  <id>1034201</id>
  <title>Penile Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Penile Cancer Research</field_short_title>
  <field_page_description>Find research articles on penile cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_feature_card_description>Find research articles on penile cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-01-20</field_date_posted>
  <field_date_reviewed>2016-01-20</field_date_reviewed>
  <para_id>1034201</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>14376</id>
  <title>Breast Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer</field_short_title>
  <field_page_description>Breast cancer is the second most common cancer in women after skin cancer. Mammograms can detect breast cancer early, possibly before it has spread. Start here to find information on breast cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_feature_card_description>Information about breast cancer prevention, screening, treatment, statistics, research, clinical trials, and more.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14376</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911286</term_id>
  <id>14411</id>
  <title>Lasers in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Lasers in Cancer Treatment</field_short_title>
  <field_page_description>A fact sheet that describes use of high-intensity light in cancer treatment, its advantages and disadvantages, and types of procedures that use it.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-09-13</field_date_posted>
  <field_date_reviewed>2011-09-13</field_date_reviewed>
  <field_pretty_url>lasers-fact-sheet</field_pretty_url>
  <para_id>14411</para_id>
  <related_resource_ids>7232703</related_resource_ids>
  <related_resource_ids>7232704</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>915528</term_id>
  <id>14524</id>
  <title>Angiogenesis Inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Angiogenesis Inhibitors</field_short_title>
  <field_page_description>A fact sheet that describes cancer-fighting agents that block the growth of blood vessels that support tumor growth.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-01</field_date_posted>
  <field_date_reviewed>2018-04-02</field_date_reviewed>
  <field_pretty_url>angiogenesis-inhibitors-fact-sheet</field_pretty_url>
  <para_id>14524</para_id>
  <related_resource_ids>7229086</related_resource_ids>
  <related_resource_ids>7229087</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12598</term_id>
  <id>14539</id>
  <title>Contact Us for Help</title>
  <langcode>en</langcode>
  <field_short_title>Contact Us for Help</field_short_title>
  <field_page_description>Cancer information specialists can answer your questions about cancer and help you with quitting smoking. They also respond to questions and requests for information about NCI and its programs.</field_page_description>
  <field_feature_card_description>NCI offers free information on cancer topics in English and Spanish. Get live help at 1-800-4-CANCER.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14539</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>139015</id>
  <title>Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients</title>
  <langcode>en</langcode>
  <field_short_title>Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients</field_short_title>
  <field_page_description>A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin.</field_page_description>
  <field_feature_card_description>A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin.</field_feature_card_description>
  <field_list_description>A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin in terms of overall survival, according to a report published online October 21 in The Lancet.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-02</field_date_posted>
  <field_date_reviewed>2011-12-02</field_date_reviewed>
  <field_pretty_url>smaller-margins</field_pretty_url>
  <para_id>139015</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938142</term_id>
  <id>139034</id>
  <title>Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Therapy Shows Benefit in Rare Type of Thyroid Cancer</field_short_title>
  <field_page_description>Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.</field_page_description>
  <field_feature_card_description>Treatment with the multitargeted agent vandetanib (Caprelsa) improved progression-free survival in patients with medullary thyroid cancer (MTC), according to findings from a randomized clinical trial.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-02</field_date_posted>
  <field_date_reviewed>2011-12-02</field_date_reviewed>
  <field_pretty_url>vandetanib</field_pretty_url>
  <para_id>139034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>936684</term_id>
  <id>170976</id>
  <title>Questions to Ask Your Doctor When You Have Finished Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask Your Doctor When You Have Finished Treatment</field_short_title>
  <field_page_description>Suggested questions for cancer patients to ask their doctors after treatment is finished and they are planning for follow-up care and next steps. </field_page_description>
  <field_feature_card_description>Suggested questions for cancer patients to ask their doctors after treatment is finished and they are planning for follow-up care and next steps. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-02-14</field_date_posted>
  <field_date_reviewed>2012-01-23</field_date_reviewed>
  <para_id>170976</para_id>
  <related_resource_ids>6636725</related_resource_ids>
  <related_resource_ids>6636726</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>816956</term_id>
  <id>817098</id>
  <title>RAS Reagents</title>
  <langcode>en</langcode>
  <field_short_title>RAS Reagents</field_short_title>
  <field_page_description>The RAS Reagents group prepares proteins, DNAs, and cell lines, all of which are required to attack cancers caused by mutant RAS.</field_page_description>
  <field_feature_card_description>Attacking cancers caused by mutant RAS requires proteins, DNAs, and cell lines prepared by this group.</field_feature_card_description>
  <field_list_description>Attacking cancers caused by mutant RAS requires proteins, DNAs, and cell lines prepared by this group.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-08-20</field_date_reviewed>
  <para_id>817098</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1031697</id>
  <title>FDA Approves Cobimetinib as Part of Drug Combination for Advanced Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Cobimetinib Approved for Advanced Melanoma</field_short_title>
  <field_page_description>The FDA has approved the targeted drug cobimetinib, in combination with another targeted therapy, to treat patients with advanced melanoma whose tumors have specific genetic mutations.</field_page_description>
  <field_feature_card_description>Drug combination targets the same signaling pathway in cancer cells.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-15</field_date_posted>
  <field_date_reviewed>2015-12-15</field_date_reviewed>
  <field_pretty_url>cobimetinib-melanoma</field_pretty_url>
  <para_id>1031697</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1031743</id>
  <title>Returning to Vietnam – Building on Collaborations in Cancer Control and Research</title>
  <langcode>en</langcode>
  <field_short_title>Returning to Vietnam – Building on Collaborations in Cancer Control and Research</field_short_title>
  <field_page_description>Dr. Paul Pearlman presented at the 9th US-Vietnam Joint Committee Meeting on Science and Technology Cooperation, held in Ho Chi Minh City by the Ministry of Science and Technology, and at a national cancer stakeholder meeting in Hanoi, held by the Ministry of Health.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-12-15</field_date_posted>
  <field_date_reviewed>2015-12-15</field_date_reviewed>
  <field_pretty_url>vietnam_jcm</field_pretty_url>
  <para_id>1031743</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938231</term_id>
  <id>1032050</id>
  <title>Overcoming Global Cultural and Financial Disparities to Treat Children with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Overcoming Global Cultural and Financial Disparities to Treat Children with Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-18</field_date_posted>
  <field_date_reviewed>2015-12-18</field_date_reviewed>
  <field_pretty_url>overcoming-global-health-disparities</field_pretty_url>
  <para_id>1032050</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1033636</id>
  <title>Driving New Approaches to Cancer Prevention and Early Detection</title>
  <langcode>en</langcode>
  <field_short_title>Driving New Approaches to Cancer Prevention and Early Detection</field_short_title>
  <field_page_description>Researchers are pioneering new approaches to preventing and screening for cancer, and the management of very early-stage disease.</field_page_description>
  <field_feature_card_description>Researchers are pioneering new approaches to cancer screening and prevention, and the management of early-stage disease.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-13</field_date_posted>
  <field_date_reviewed>2016-01-08</field_date_reviewed>
  <field_pretty_url>new-approaches-prevention</field_pretty_url>
  <para_id>1033636</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1061552</term_id>
  <id>1061553</id>
  <title>RAS Biochemistry and Biophysics</title>
  <langcode>en</langcode>
  <field_short_title>Biochemistry and Biophysics</field_short_title>
  <field_page_description>This RAS Biochemistry and Biophysics lab investigates signaling by RAS proteins, which is regulated by the interactions with substrates, protein partners, and membranes.</field_page_description>
  <field_feature_card_description>Signaling by RAS proteins is regulated by the interactions with substrates, protein partners, and membranes that are investigated by this lab.</field_feature_card_description>
  <field_list_description>Signaling by RAS proteins is regulated by the interactions with substrates, protein partners, and membranes that are investigated by this lab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-08</field_date_posted>
  <field_date_reviewed>2016-09-08</field_date_reviewed>
  <para_id>1061553</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061909</id>
  <title>Meeting Patients Where They Are: Liberating Clinical Trials Data Under the Cancer Moonshot</title>
  <langcode>en</langcode>
  <field_short_title>Liberating NCI Clinical Trials Data</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a new application programming interface (API) that allows anyone to build online tools that help people find NCI-supported clinical trials.</field_page_description>
  <field_feature_card_description>NCI’s clinical trials application programming interface (API) allows anyone to build online tools that help people find NCI-supported clinical trials.</field_feature_card_description>
  <field_list_description>NCI’s new application programming interface (API) that allows anyone to build online tools that help people find NCI-supported clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-16</field_date_posted>
  <field_date_reviewed>2016-09-16</field_date_reviewed>
  <field_pretty_url>clinical-trials-api</field_pretty_url>
  <para_id>1061909</para_id>
  <related_resource_ids>6611860</related_resource_ids>
  <related_resource_ids>6611862</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1062106</id>
  <title>Message from Dr. Lowy</title>
  <langcode>en</langcode>
  <field_short_title>Message from Dr. Lowy</field_short_title>
  <field_page_description>A message from NCI Acting Director, Douglas Lowy, about the progress of the RAS Initiative and its goal to create a virtual network of scientists working collaboratively to solve the RAS problem.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-04</field_date_posted>
  <field_date_reviewed>2016-09-19</field_date_reviewed>
  <field_pretty_url>dr-lowy-message</field_pretty_url>
  <para_id>1062106</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894082</term_id>
  <id>1062753</id>
  <title>Program Spotlight: 2016 NCI/CRCHD Professional Development Workshop Scientific Poster Winners</title>
  <langcode>en</langcode>
  <field_short_title>2016 PDW Scientific Poster Winners</field_short_title>
  <field_page_description>Professional Development and Mock Review Workshop 2016, 2016 PDW, Poster Session, Winners </field_page_description>
  <field_feature_card_description>CRCHD invited young and early stage investigators participating in the workshop to present their research findings and plans for future research in this competitive session. </field_feature_card_description>
  <field_list_description>A highlight of the Professional Development and Mock Review Workshop is always the interactive poster session. CRCHD invited young and early stage investigators participating in the workshop to present their research findings and plans for future research in this competitive session. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-26</field_date_posted>
  <field_date_reviewed>2016-09-26</field_date_reviewed>
  <field_pretty_url>Poster-Winners-2016</field_pretty_url>
  <para_id>1062753</para_id>
  <related_resource_ids>6459565</related_resource_ids>
  <related_resource_ids>6459569</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1062765</id>
  <title>IEEE-NIH 2016 Special Topics Conference on Healthcare Innovations and Point-of-Care Technologies</title>
  <langcode>en</langcode>
  <field_short_title>IEEE-NIH 2016 Special Topics Conference</field_short_title>
  <field_page_description>Institute of Electrical and Electronics Engineers, Incorporated (IEEE)-NIH 2016 Special Topics Conference on Healthcare Innovations and Point-of-Care Technologies</field_page_description>
  <field_feature_card_description>Institute of Electrical and Electronics Engineers, Incorporated (IEEE)-NIH 2016 Special Topics Conference on Healthcare Innovations and Point-of-Care Technologies (http://hipt.embs.org/2016/), Cancun Mexico, November 9 to 11, 2016</field_feature_card_description>
  <field_list_description>As we approach the upcoming Institute of Electrical and Electronics Engineers, Incorporated (IEEE)-NIH 2016 Special Topics Conference on Healthcare Innovations and Point-of-Care Technologies (http://hipt.embs.org/2016/) to be held in Cancun, Mexico November 9th to 11th, it's a good opportunity to reflect on what it is we’re trying to accomplish here and why individuals should attend.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-26</field_date_posted>
  <field_date_reviewed>2016-09-26</field_date_reviewed>
  <field_pretty_url>ieee-special-topics-conference</field_pretty_url>
  <para_id>1062765</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1062777</id>
  <title>Many Cancer Caregivers Report Feeling Unprepared for Caregiving Challenges</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Caregivers Feel Unprepared for Some Challenges</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a new study that showed cancer caregivers play multiple roles and need more information to help their loved ones.  </field_page_description>
  <field_feature_card_description>Many cancer caregivers do not feel adequately prepared for the tasks they assume.</field_feature_card_description>
  <field_list_description>Many family members who care for loved ones with cancer do not feel adequately prepared for the caregiving tasks they assume and need help to make informed decisions about end-of-life care, according to a new study. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-27</field_date_posted>
  <field_date_reviewed>2016-09-27</field_date_reviewed>
  <field_pretty_url>caregivers-needs-challenges</field_pretty_url>
  <para_id>1062777</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1090915</id>
  <title>Glioblastoma—Unraveling the Threads: A Q&amp;A with Drs. Mark Gilbert and Terri Armstrong of the NIH Neuro-Oncology Branch</title>
  <langcode>en</langcode>
  <field_short_title>Unraveling the Threads: Making Progress against Glioblastoma</field_short_title>
  <field_page_description>Progress against the brain cancer glioblastoma has been slow. In this Cancer Currents post, Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss what’s being done to change that.</field_page_description>
  <field_feature_card_description>Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss challenges in glioblastoma research.</field_feature_card_description>
  <field_list_description>Progress against the brain cancer glioblastoma has been slow. Drs. Mark Gilbert and Terri Armstrong of NCI’s Neuro-Oncology Branch discuss why and what’s being done to change that.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-03</field_date_posted>
  <field_date_reviewed>2017-08-02</field_date_reviewed>
  <field_pretty_url>glioblastoma-research-making-progress</field_pretty_url>
  <para_id>1090915</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1093691</id>
  <title>Two New Therapies Approved for Acute Myeloid Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Two New Therapies Approved for Acute Myeloid Leukemia</field_short_title>
  <field_page_description>Two new treatments for adults with acute myeloid leukemia (AML) have been approved by FDA: enasidenib (Idhifa®) and cytarabine-daunorubicin CPX-351 (Vyxeos®), as this Cancer Currents post explains</field_page_description>
  <field_feature_card_description>Approvals include first drug to target tumors with IDH mutations.</field_feature_card_description>
  <field_list_description>FDA has approved two new treatments for some adult patients with acute myeloid leukemia (AML): enasidenib (Idhifa®), which targets the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos®), a two-drug chemotherapy combination encapsulated in liposomes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-28</field_date_posted>
  <field_date_reviewed>2017-08-28</field_date_reviewed>
  <field_pretty_url>fda-enasidenib-vyxeos-aml</field_pretty_url>
  <para_id>1093691</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911184</term_id>
  <id>14648</id>
  <title>Hair Dyes and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Hair Dyes and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.</field_page_description>
  <field_feature_card_description>A fact sheet that reviews research about hair dye use and cancer risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-13</field_date_posted>
  <field_date_reviewed>2016-08-18</field_date_reviewed>
  <field_pretty_url>hair-dyes-fact-sheet</field_pretty_url>
  <para_id>14648</para_id>
  <related_resource_ids>6934145</related_resource_ids>
  <related_resource_ids>6934146</related_resource_ids>
  <related_resource_ids>6934147</related_resource_ids>
  <related_resource_ids>6934172</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911142</term_id>
  <id>14676</id>
  <title>Menopausal Hormone Therapy and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Menopausal Hormone Therapy and Cancer</field_short_title>
  <field_page_description>A fact sheet about the results of research on menopausal hormone therapy (MHT). Includes information about the effect of MHT on the body and benefits and risks of using menopausal hormones.</field_page_description>
  <field_feature_card_description>A fact sheet about the results of research on menopausal hormone therapy. Includes information about the effect of menopausal hormone therapy on the body. Also outlines the benefits and risks of using menopausal hormones.</field_feature_card_description>
  <field_list_description>A fact sheet about the results of research on menopausal hormone therapy. Includes information about the effect of menopausal hormone therapy on the body. Also outlines the benefits and risks of using menopausal hormones.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-05</field_date_posted>
  <field_date_reviewed>2018-07-17</field_date_reviewed>
  <field_pretty_url>mht-fact-sheet</field_pretty_url>
  <para_id>14676</para_id>
  <related_resource_ids>7165667</related_resource_ids>
  <related_resource_ids>7165668</related_resource_ids>
  <related_resource_ids>7165669</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>939391</term_id>
  <id>14798</id>
  <title>PDQ&amp;reg; - NCI's Comprehensive Database</title>
  <langcode>en</langcode>
  <field_short_title>PDQ&amp;reg; </field_short_title>
  <field_page_description>An NCI database that contains the latest information about cancer treatment, screening, prevention, genetics, supportive care, and complementary and alternative medicine, plus drug information and a dictionary of cancer terms.</field_page_description>
  <field_feature_card_description>Use our evidence-based information summaries and other PDQ resources to answer questions on a wide range of cancer topics.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14798</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952681</term_id>
  <id>15008</id>
  <title>PDQ&amp;reg; Screening and Prevention Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Screening &amp;amp; Prevention Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of oncology, cancer prevention, hematology, radiology, urology, statistics, epidemiology, and economics.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-05-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15008</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1040909</id>
  <title>HPV Infections Targeted by Vaccine Decrease in U.S.</title>
  <langcode>en</langcode>
  <field_short_title>HPV Infections Drop in the U.S.</field_short_title>
  <field_page_description>Infection with human papillomavirus (HPV) types targeted by the quadrivalent HPV vaccine has declined by nearly two-thirds among teenage girls since HPV vaccination was recommended in the United States.</field_page_description>
  <field_feature_card_description>Infection with human papillomavirus (HPV) types targeted by vaccine declined among teenage girls and young women in the U.S. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-09</field_date_posted>
  <field_date_reviewed>2016-03-08</field_date_reviewed>
  <field_pretty_url>hpv-infections-decreased</field_pretty_url>
  <para_id>1040909</para_id>
  <related_resource_id>6611704</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1042230</id>
  <title>New Strategy for Treating Advanced Ovarian Cancer Shows Promise in Mice </title>
  <langcode>en</langcode>
  <field_short_title>New Strategy for Treating Advanced Ovarian Cancer Shows Promise in Mice </field_short_title>
  <field_page_description>The use of a protein fragment to stimulate cells in the tumor microenvironment against cancer shows promise in animal models of metastatic ovarian cancer. </field_page_description>
  <field_feature_card_description>Stimulating cells in the tumor microenvironment against ovarian cancer shows promise in mice.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-28</field_date_posted>
  <field_date_reviewed>2016-03-28</field_date_reviewed>
  <field_pretty_url>ovarian-cancer-prosaposin</field_pretty_url>
  <para_id>1042230</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1042262</id>
  <title>Nutritional Requirements of Pancreatic Cancers - A Conversation with Dafna Bar-Sagi</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation with Dafna Bar-Sagi</field_short_title>
  <field_page_description>In a new RAS Dialogue blog post, Dr. Dafna Bar-Sagi discusses the new interest in her 1986 discovery of the unexpected dietary preference of pancreatic cancer cells.</field_page_description>
  <field_feature_card_description>In a new blog in RAS Dialogue, Dr. Dafna Bar-Sagi discusses the new interest in her 1986 discovery of the unexpected dietary preference of pancreatic cancer cells.</field_feature_card_description>
  <field_list_description>Solid tumors in humans develop primarily from epithelial cells, which have different functions in different tissues. Pancreatic cancers derive much of their nutrition from proteins consumed from their environment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-30</field_date_posted>
  <field_date_reviewed>2016-03-29</field_date_reviewed>
  <field_pretty_url>dafna-bar-sagi-interview</field_pretty_url>
  <para_id>1042262</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1043594</term_id>
  <id>1043595</id>
  <title>Understanding Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Cancer</field_short_title>
  <field_page_description>This page is a gateway to basic information about how cancer develops, trends in cancer cases and deaths, and how cancer affects different populations.</field_page_description>
  <field_feature_card_description>Start learning about cancer with our resources that explain how it develops and is categorized and who is affected.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-07</field_date_posted>
  <field_date_reviewed>2016-04-07</field_date_reviewed>
  <para_id>1043595</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1045533</id>
  <title>A Shared Commitment for Accelerating Progress with the Cancer Moonshot</title>
  <langcode>en</langcode>
  <field_short_title>A Shared Commitment to the Cancer Moonshot</field_short_title>
  <field_page_description>At the AACR annual meeting, Vice President Biden spoke about the National Cancer Moonshot Initiative and the critical role the entire research community will play in accelerating progress against cancer.</field_page_description>
  <field_feature_card_description>Vice President Biden spoke at a major cancer meeting about the critical role to be played by the entire research community.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-20</field_date_posted>
  <field_date_reviewed>2016-04-20</field_date_reviewed>
  <field_pretty_url>moonshot-biden-aacr</field_pretty_url>
  <para_id>1045533</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1048220</id>
  <title>Healthy Kids; Healthy World - Take Your Child to Work Day 2016</title>
  <langcode>en</langcode>
  <field_short_title>Healthy Kids; Healthy World - Take Your Child to Work Day 2016</field_short_title>
  <field_page_description>On April 28th CGH joined several NCI offices at the Shady Grove campus to celebrate Take Your Child to Work Day 2016. Volunteers hosted three activity stations, each offering creative fun with a message: With healthy kids, we can create a healthier world.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-10</field_date_posted>
  <field_date_reviewed>2016-05-10</field_date_reviewed>
  <field_pretty_url>tyctwd2016</field_pretty_url>
  <para_id>1048220</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1049936</id>
  <title>Crosstalk between Cancer Cells and Neighboring Cells May Contribute to Tumor Growth</title>
  <langcode>en</langcode>
  <field_short_title>Molecular Crosstalk Promotes Pancreatic Tumor Growth</field_short_title>
  <field_page_description>Pancreatic cancer cells and neighboring normal cells engage in a two-way molecular conversation that helps drive malignant behavior in the cancer cells, according to new study results.</field_page_description>
  <field_feature_card_description>This two-way communication can activate a chain of events that helps tumor cells survive and multiply.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-16</field_date_posted>
  <field_date_reviewed>2016-05-16</field_date_reviewed>
  <field_pretty_url>crosstalk-pancreatic</field_pretty_url>
  <para_id>1049936</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770500</term_id>
  <id>770501</id>
  <title>Leukemia Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Leukemia Steering Committee</field_short_title>
  <field_page_description>The Leukemia Steering Committee addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult leukemia cancer.</field_page_description>
  <field_feature_card_description>The Leukemia Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials. </field_feature_card_description>
  <field_list_description>The Leukemia Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770501</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771995</term_id>
  <id>772095</id>
  <title>Myeloma Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Myeloma Steering Committee</field_short_title>
  <field_page_description>The Myeloma Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_page_description>
  <field_feature_card_description>The Myeloma Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_feature_card_description>
  <field_list_description>The Myeloma Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772095</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771999</term_id>
  <id>772116</id>
  <title>Pediatric Leukemia and Lymphoma Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Leukemia and Lymphoma Steering Committee</field_short_title>
  <field_page_description>The Pediatric Leukemia and Lymphoma Steering Committee addresses the design, prioritization, and evaluation of concepts for phase II and phase III clinical trials in pediatric hematologic cancers.</field_page_description>
  <field_feature_card_description>The Pediatric Leukemia and Lymphoma Steering Committee evaluates and prioritizes concepts for therapeutic clinical trials. </field_feature_card_description>
  <field_list_description>The Pediatric Leukemia and Lymphoma Steering Committee evaluates and prioritizes concepts for clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772116</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772002</term_id>
  <id>772118</id>
  <title>Thoracic Malignancy Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Thoracic Malignancy Steering Committee</field_short_title>
  <field_page_description>The Thoracic Malignancy Steering Committee addresses the design, prioritization, and evaluation of concepts for phase II and phase III clinical trials in chest malignancies.</field_page_description>
  <field_feature_card_description>The Thoracic Malignancy Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_feature_card_description>
  <field_list_description>The Thoracic Malignancy Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772118</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772004</term_id>
  <id>772120</id>
  <title>Investigational Drug Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Investigational Drug Steering Committee</field_short_title>
  <field_page_description>The Investigational Drug Steering Committee (IDSC) collaborates with NCI in the design and prioritization of early phase drug development trials conducted by the Experimental Therapeutics Clinical Trials Network (ETCTN).</field_page_description>
  <field_feature_card_description>The IDSC works with NCI in the design and prioritization of early phase drug development trials.</field_feature_card_description>
  <field_list_description>The IDSC collaborates with NCI in the design and prioritization of early phase drug development trials conducted by the Experimental Therapeutics Clinical Trials Network (ETCTN).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772120</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772004</term_id>
  <id>772121</id>
  <title>Investigational Drug Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Investigational Drug Steering Committee Roster</field_short_title>
  <field_page_description>The Investigational Drug Steering Committee collaborates with NCI in the design and prioritization of early phase drug development clinical trials. View the committee member roster.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2018-04-04</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772121</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1033900</id>
  <title>Two Drugs Show Efficacy against Common Form of Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Two Drugs Show Efficacy against Common Form of Leukemia</field_short_title>
  <field_page_description>Reports from early-stage trials of two new oral drugs provide hope for patients with high-risk chronic lymphocytic leukemia.</field_page_description>
  <field_feature_card_description>Early-stage trial results provide hope for patients with high-risk chronic lymphocytic leukemia.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-15</field_date_posted>
  <field_date_reviewed>2016-01-14</field_date_reviewed>
  <field_pretty_url>cll-new-drugs</field_pretty_url>
  <para_id>1033900</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1034081</id>
  <title>FDA Approves Alectinib for ALK-Positive Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Alectinib Approved for ALK-Positive NSCLC</field_short_title>
  <field_page_description>The FDA has approved alectinib to treat patients with metastatic ALK-positive non-small cell lung cancer who have stopped responding to or who are unable to tolerate crizotinib.</field_page_description>
  <field_feature_card_description>Drug approval provides another option for some patients with lung cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-19</field_date_posted>
  <field_date_reviewed>2016-01-19</field_date_reviewed>
  <field_pretty_url>fda-alectinib-nsclc</field_pretty_url>
  <para_id>1034081</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1034329</id>
  <title>Novel Treatment Approach Shrinks Ovarian Tumors in Mice</title>
  <langcode>en</langcode>
  <field_short_title>Novel Treatment Shrinks Ovarian Tumors in Mice</field_short_title>
  <field_page_description>Researchers have developed a new approach for treating tumors that express mutant versions of the p53 protein, which are present in more than half of all cancers, including an aggressive and common subtype of ovarian cancer.</field_page_description>
  <field_feature_card_description>Treatment shrank tumors by as much as 90 percent with no evidence of side effects.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-25</field_date_posted>
  <field_date_reviewed>2016-01-22</field_date_reviewed>
  <field_pretty_url>p53-aggregation-blocker</field_pretty_url>
  <para_id>1034329</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1034916</id>
  <title>January is Cervical Cancer Awareness Month</title>
  <langcode>en</langcode>
  <field_short_title>January is Cervical Cancer Awareness Month</field_short_title>
  <field_page_description>The Center for Global Health supports global activities to advance global cancer research, build expertise, and leverage resources across nations to address the challenges of cancer and reduce cancer deaths worldwide. Towards these aims, NCI has partnered with Pink Ribbon Red Ribbon, a global organization founded on pu</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-01-28</field_date_posted>
  <field_date_reviewed>2016-01-28</field_date_reviewed>
  <field_pretty_url>cervical-cancer</field_pretty_url>
  <para_id>1034916</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1038738</id>
  <title>Missed Radiation Therapy Sessions Increase Risk of Cancer Recurrence</title>
  <langcode>en</langcode>
  <field_short_title>Missed Radiation Therapy Sessions Increase Risk of Cancer Recurrence</field_short_title>
  <field_page_description>Patients who miss radiation therapy sessions during cancer treatment have an increased risk of their disease returning, even if they eventually complete their course of radiation treatment, according to a new study.</field_page_description>
  <field_feature_card_description>Patients who miss radiation therapy sessions during cancer treatment have an increased risk of their disease returning.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-26</field_date_posted>
  <field_date_reviewed>2016-02-26</field_date_reviewed>
  <field_pretty_url>missed-radiation-therapy</field_pretty_url>
  <para_id>1038738</para_id>
  <related_resource_id>6611898</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1040845</id>
  <title>Fueling Basic Discovery: NCI’s Cooperative Human Tissue Network</title>
  <langcode>en</langcode>
  <field_short_title>Fueling Basic Discovery: NCI’s Cooperative Human Tissue Network</field_short_title>
  <field_page_description>Quality biospecimens are a foundational resource for cancer research. One of NCI’s longest running biospecimen programs is the Cooperative Human Tissue Network, a resource mainly for basic discovery and early translational research.</field_page_description>
  <field_feature_card_description>The Cooperative Human Tissue Network provides tissue for biomarker studies and other early research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-07</field_date_posted>
  <field_date_reviewed>2016-03-07</field_date_reviewed>
  <field_pretty_url>chtn-biospecimens</field_pretty_url>
  <para_id>1040845</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1041539</term_id>
  <id>1041540</id>
  <title>Delirium and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Diagnosing and Treating Delirium in Cancer Patients</field_short_title>
  <field_page_description>Delirium is a confused mental state. Symptoms may include changes in thinking and sleeping. In cancer patients, it may be caused by medicine, dehydration, or happen at the end of life. Delirium may be mistaken for depression or dementia.</field_page_description>
  <field_list_description>Delirium during cancer treatment is explained, including what causes it and how it is treated. Hypoactive delirium, hyperactive delirium, and mixed delirium are explained. Questions to ask your family member's doctor are also included.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-01</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <para_id>1041540</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1035818</term_id>
  <id>1034875</id>
  <title>Genomic Data Commons</title>
  <langcode>en</langcode>
  <field_short_title>Genomic Data Commons</field_short_title>
  <field_page_description>The NCI Genomic Data Commons (GDC) is a unified cancer genomics knowledge base that promotes data sharing and facilitates precision medicine in oncology.</field_page_description>
  <field_feature_card_description>This NCI-supported knowledge system for cancer genomic and clinical data fosters precision medicine in oncology.</field_feature_card_description>
  <field_list_description>NCI’s Genomic Data Commons (GDC) is a unified cancer genomics knowledge base that promotes sharing of genomic and clinical data between researchers and facilitates precision medicine in oncology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-01</field_date_posted>
  <field_date_reviewed>2016-01-28</field_date_reviewed>
  <para_id>1034875</para_id>
  <related_resource_ids>7227921</related_resource_ids>
  <related_resource_ids>7227922</related_resource_ids>
  <related_resource_ids>7227923</related_resource_ids>
  <related_resource_ids>7227926</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1034962</id>
  <title>Opportunities in Cancer Nanotechnology: A Conversation with NCI’s Dr. Piotr Grodzinski </title>
  <langcode>en</langcode>
  <field_short_title>Opportunities in Cancer Nanotechnology: A Conversation with NCI’s Dr. Piotr Grodzinski</field_short_title>
  <field_page_description>The director of NCI's Office of Cancer Nanotechnology Research discusses the Cancer Nanotechnology Plan 2015, as well as new developments and clinical opportunities in the field.</field_page_description>
  <field_feature_card_description>NCI’s Dr. Piotr Grodzinski discusses new developments and clinical opportunities in the field of cancer nanotechnology.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-29</field_date_posted>
  <field_date_reviewed>2016-01-29</field_date_reviewed>
  <field_pretty_url>grodzinski-nanotechnology</field_pretty_url>
  <para_id>1034962</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1036622</id>
  <title>President Obama’s Budget Request Affirms Commitment to Progress against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Budget Request Includes Funds for Cancer Initiative</field_short_title>
  <field_page_description>President Obama’s FY 2017 Budget Request includes $680 million to support Vice President Biden’s cancer research initiative.</field_page_description>
  <field_feature_card_description>This undertaking will identify promising ways to leverage new resources and accelerate progress against cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-10</field_date_posted>
  <field_date_reviewed>2016-02-09</field_date_reviewed>
  <field_pretty_url>moonshot-budget-request</field_pretty_url>
  <para_id>1036622</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1036897</id>
  <title>Prospective Study Links HPV Detection in the Mouth to Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Study Confirms Oral HPV Infection Precedes Head and Neck Cancer </field_short_title>
  <field_page_description>A new study confirms that infection with HPV 16 precedes the development of head and neck cancer.</field_page_description>
  <field_feature_card_description>Study also links additional HPV types to oropharyngeal cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-12</field_date_posted>
  <field_date_reviewed>2016-02-11</field_date_reviewed>
  <field_pretty_url>hpv-head-and-neck-cancer</field_pretty_url>
  <para_id>1036897</para_id>
  <related_resource_ids>7267793</related_resource_ids>
  <related_resource_ids>7267797</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1038482</id>
  <title>Gene Fusion May Drive Rare Childhood Brain Tumor</title>
  <langcode>en</langcode>
  <field_short_title>Genomic Study Identifies Gene Fusion in Rare Childhood Brain Tumor</field_short_title>
  <field_page_description>Researchers have identified a genetic rearrangement that may drive the development of a rare benign brain tumor in children through three distinct biological mechanisms simultaneously.</field_page_description>
  <field_feature_card_description>Researchers have found a genetic rearrangement that may drive the development of a rare brain tumor in children.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-22</field_date_posted>
  <field_date_reviewed>2016-02-22</field_date_reviewed>
  <field_pretty_url>gene-fusion-pediatric-glioma</field_pretty_url>
  <para_id>1038482</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1041142</term_id>
  <id>1041143</id>
  <title>National Cryo-Electron Microscopy Facility</title>
  <langcode>en</langcode>
  <field_short_title>National Program for Cryo-Em</field_short_title>
  <field_page_description>Information about the National Cryo-EM Facility at NCI, created to provide researchers access to the latest cryo-EM technology for high resolution imaging. Includes timeline for installation and how to access the facility.</field_page_description>
  <field_feature_card_description>Cancer researchers can submit samples for high-resolution imaging by the Titan Krios microscope.</field_feature_card_description>
  <field_list_description>Home page for the National Cryo-Electron Microscopy Facility at NCI, open to cancer researchers in structural biology cryo-EM research without sufficient access to high resolution microscopes. The user facility is expected to be available for use by May 15, 2017.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-03-22</field_date_posted>
  <field_date_reviewed>2016-03-11</field_date_reviewed>
  <para_id>1041143</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>216653</id>
  <title>Additional Surgery after Breast-Conserving Surgery Varies Widely</title>
  <langcode>en</langcode>
  <field_short_title>Additional Surgery after Breast-Conserving Surgery Varies Widely</field_short_title>
  <field_page_description>A study published in the Feb. 1, 2012, issue of JAMA found that the number of women who have one or more additional surgeries to remove suspected residual tumor tissue (re-excisions) following breast-conserving surgery (BCS) for breast cancer varies widely across surgeons and hospitals.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-02-28</field_date_posted>
  <field_date_reviewed>2012-02-28</field_date_reviewed>
  <field_pretty_url>additional-surgery-variation</field_pretty_url>
  <para_id>216653</para_id>
  <related_resource_id>5421544</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940287</term_id>
  <id>940292</id>
  <title>Gestational Trophoblastic Disease—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Gestational Trophoblastic Disease</field_short_title>
  <field_page_description>Gestational trophoblastic disease (GTD) is a broad term encompassing both benign and malignant growths arising from products of conception in the uterus. GTDs contain paternal chromosomes and are placental in origin. Find evidence-based information on gestational trophoblastic disease treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about gestational trophoblastic disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940292</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940349</term_id>
  <id>940354</id>
  <title>Intraocular (Eye) Melanoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Intraocular (Eye) Melanoma</field_short_title>
  <field_page_description>Intraocular (uveal) melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. Find evidence-based information on intraocular melanoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about intraocular (eye) melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940354</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>914484</term_id>
  <id>940417</id>
  <title>Langerhans Cell Histiocytosis—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Langerhans Cell Histiocytosis</field_short_title>
  <field_page_description>Langerhans cell histiocytosis is a rare blood cancer that forms when a type of white blood cell called Langerhans cells becomes abnormal and grows in different parts of the body. LCH is most common in young children but can occur at any age. Start here to find information on Langerhans cell histiocytosis treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about langerhans cell histiocytosis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940417</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940412</term_id>
  <id>940418</id>
  <title>Langerhans Cell Histiocytosis—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Langerhans Cell Histiocytosis</field_short_title>
  <field_page_description>Histiocytic diseases, like Langerhans cell histiocytosis (LCH) and myeloid-derived dendritic cell disorder, in children and adults are caused by an abnormal accumulation of cells of the mononuclear phagocytic system. Find evidence-based information on Langerhans cell histiocytosis treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about langerhans cell histiocytosis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940418</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940827</term_id>
  <id>940836</id>
  <title>Pheochromocytoma and Paraganglioma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Pheochromocytoma and Paraganglioma</field_short_title>
  <field_page_description>Pheochromocytomas and extra-adrenal paragangliomas are rare tumors arising from neural crest tissue that develops into sympathetic and parasympathetic paraganglia throughout the body. Find evidence-based information on pheochromocytoma and paraganglioma treatment, research, and genetics.</field_page_description>
  <field_list_description>NCI's gateway for information about Pheochromocytoma and Paraganglioma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940836</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940885</term_id>
  <id>940890</id>
  <title>Prostate Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Prostate Cancer </field_short_title>
  <field_page_description>Prostate cancers are often adenocarcinomas. Prostatic intraepithelial neoplasia is often present in association with prostatic adenocarcinoma. Find evidence-based information on prostate cancer including treatment, causes and prevention, screening, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Prostate Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940890</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11926</term_id>
  <id>12897</id>
  <title>Lung Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Lung Cancer</field_short_title>
  <field_page_description>The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. Smoking causes most lung cancers, but nonsmokers can also develop lung cancer. Start here to find information on lung cancer treatment, causes and prevention, screening, research, and statistics on lung cancer.</field_page_description>
  <field_feature_card_description>Smoking causes most lung cancers, but nonsmokers can also develop lung cancer. </field_feature_card_description>
  <field_list_description>NCI's gateway for information about lung cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>12897</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11900</term_id>
  <id>12963</id>
  <title>Esophageal Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Esophageal Cancer</field_short_title>
  <field_page_description>The most common types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. These forms of esophageal cancer develop in some parts of the esophagus and are driven by genetic changes. Start here to find information on esophageal cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about esophageal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>12963</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>11646</term_id>
  <id>13054</id>
  <title>Coping with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Coping with Cancer</field_short_title>
  <field_page_description>Information for patients, families, and caregivers to help manage emotional and lifestyle effects of cancer, treatment, and life after treatment.</field_page_description>
  <field_feature_card_description>Supportive information on managing the physical and emotional effects of cancer and treatment for both patients and caregivers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2009-10-08</field_date_reviewed>
  <para_id>13054</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>13193</id>
  <title>The ALTTO Breast Cancer Trial</title>
  <langcode>en</langcode>
  <field_short_title>The ALTTO Breast Cancer Trial</field_short_title>
  <field_page_description>A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive br</field_page_description>
  <field_list_description>A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2008-03-14</field_date_posted>
  <field_date_reviewed>2015-07-24</field_date_reviewed>
  <field_pretty_url>altto</field_pretty_url>
  <para_id>13193</para_id>
  <related_resource_id>6214811</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938026</term_id>
  <id>13750</id>
  <title>Second HPV Vaccine Shows Early Positive Results</title>
  <langcode>en</langcode>
  <field_short_title>Second HPV Vaccine Shows Early Results</field_short_title>
  <field_page_description>The vaccine Cervarix® was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.</field_page_description>
  <field_list_description>The vaccine Cervarix&amp;reg; was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2007-07-17</field_date_posted>
  <field_date_reviewed>2007-07-17</field_date_reviewed>
  <field_pretty_url>cervarix-prevents-hpv</field_pretty_url>
  <para_id>13750</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929824</term_id>
  <id>13790</id>
  <title>Subscribe to Cancer.gov RSS Feeds</title>
  <langcode>en</langcode>
  <field_short_title>Subscribe to Cancer.gov RSS Feeds</field_short_title>
  <field_page_description>Subscribe to NCI RSS feeds to get news releases, summaries of clinical trial results, NCI Fact Sheets, and other information.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2009-09-08</field_date_reviewed>
  <para_id>13790</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>915538</term_id>
  <id>13918</id>
  <title>Blood-Forming Stem Cell Transplants</title>
  <langcode>en</langcode>
  <field_short_title>Blood-Forming Stem Cell Transplants</field_short_title>
  <field_page_description>A fact sheet that explains the step-by-step procedures of two types of transplantations used with high-dose chemotherapy, including their risks and benefits.  </field_page_description>
  <field_feature_card_description>A fact sheet that explains the step-by-step procedures of two types of transplantations used with high-dose chemotherapy, including their risks and benefits.  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-09-09</field_date_posted>
  <field_date_reviewed>2013-08-12</field_date_reviewed>
  <field_pretty_url>stem-cell-fact-sheet</field_pretty_url>
  <para_id>13918</para_id>
  <related_resource_ids>7103871</related_resource_ids>
  <related_resource_ids>7103872</related_resource_ids>
  <related_resource_ids>7103873</related_resource_ids>
  <related_resource_ids>7103874</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>723108</id>
  <title>Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia</field_short_title>
  <field_page_description>A summary of results from an international double-blind phase III trial that compared the combination of idelalisib plus rituximab (Rituxan®) versus placebo plus rituximab. </field_page_description>
  <field_feature_card_description>In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rituximab (Rituxan®) lived substantially longer without th</field_feature_card_description>
  <field_list_description>In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rituximab (Rituxan®) lived substantially longer without their disease getting worse than patients who received a placebo plus rituximab.

Overall survival was also improved in patients who received idelalisib plus rituximab. Patients who received idelalisib and rituximab were also more likely to live 12 months after beginning treatment and to have their cancer regress compared with patients who received a placebo plus rituximab.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-03-12</field_date_posted>
  <field_date_reviewed>2014-03-12</field_date_reviewed>
  <field_pretty_url>idelalisib-rituximab-cll</field_pretty_url>
  <para_id>723108</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919349</term_id>
  <id>748306</id>
  <title>About NCI Center for Global Health</title>
  <langcode>en</langcode>
  <field_short_title>About NCI Center for Global Health</field_short_title>
  <field_page_description>Provides assistance and guidance to nations as they develop and implement cancer control plans, trains international investigators, and strengthens U.S. national, regional, multilateral, and bilateral collaboration.</field_page_description>
  <field_list_description>Learn more about who we are, what we do, and why.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <para_id>748306</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>754654</id>
  <title>TARGET Initiative Leading the Way to New and Exciting Discoveries in Childhood Cancers</title>
  <langcode>en</langcode>
  <field_short_title>New Discoveries in Childhood Cancers</field_short_title>
  <field_page_description>Tapping into collaborative science: NCI's TARGET initiative makes discoveries in childhood cancers possible, such as genetic tests to address blood cancer</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-28</field_date_posted>
  <field_date_reviewed>2014-04-16</field_date_reviewed>
  <field_pretty_url>target-initiative</field_pretty_url>
  <para_id>754654</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770431</term_id>
  <id>770432</id>
  <title>Gastrointestinal Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Gastrointestinal Steering Committee</field_short_title>
  <field_page_description>The Gastrointestinal Steering Committee addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 clinical trials in adult gastrointestinal cancers. </field_page_description>
  <field_feature_card_description>The Gastrointestinal Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_feature_card_description>
  <field_list_description>The Gastrointestinal Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770432</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11708</term_id>
  <id>909853</id>
  <title>NCI Fact Sheets</title>
  <langcode>en</langcode>
  <field_short_title>Fact Sheets</field_short_title>
  <field_page_description>Nearly 100 fact sheets on a wide array of cancer topics. Fact sheets address risk factors, prevention, support, treatment, and more. </field_page_description>
  <field_feature_card_description>NCI's fact sheets address questions about risk factors, prevention, support, treatment, and more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-19</field_date_posted>
  <field_date_reviewed>2015-02-19</field_date_reviewed>
  <para_id>909853</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>910289</id>
  <title>Grantee Spotlight: Dr. David Turner - Investigating the Role of Nutrition in Cancer Growth for African Americans Living with Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Dr. David Turner - Role of Nutrition in Cancer Growth for African Americans</field_short_title>
  <field_page_description>Dr. David Turner, a Partnerships to Advance Cancer Health Equity (PACHE) researcher, studies the role of nutrition in cancer growth among African Americans with prostate cancer.</field_page_description>
  <field_feature_card_description>Dr. Turner studies nutrition in cancer growth among African Americans with prostate cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-20</field_date_posted>
  <field_date_reviewed>2015-02-20</field_date_reviewed>
  <field_pretty_url>turner-spotlight-blog</field_pretty_url>
  <para_id>910289</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>912334</id>
  <title>Ras Mitogenic Signaling: p53 Enters the Stage</title>
  <langcode>en</langcode>
  <field_short_title>Ras Mitogenic Signaling: p53 Enters the Stage</field_short_title>
  <field_page_description>Mariano Barbacid and Matthias Drosten describe experiments that reveal a new role for the p53/p21Clp1/Rb axis in controling MAPK signaling.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-09</field_date_posted>
  <field_date_reviewed>2015-03-02</field_date_reviewed>
  <field_pretty_url>ras-mitogenic-signaling</field_pretty_url>
  <para_id>912334</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>912836</term_id>
  <id>912839</id>
  <title>Chemotherapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Chemotherapy </field_short_title>
  <field_page_description>Chemotherapy is a type of cancer treatment that uses drugs to kill cancer cells. Learn how chemotherapy works against cancer, why it causes side effects, and how it is used with other cancer treatments.</field_page_description>
  <field_feature_card_description>Learn how chemotherapy works against cancer, why it causes side effects, and how it is used with other cancer treatments.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-17</field_date_reviewed>
  <para_id>912839</para_id>
  <related_resource_ids>7106304</related_resource_ids>
  <related_resource_ids>7106305</related_resource_ids>
  <related_resource_ids>7106307</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914818</term_id>
  <id>915049</id>
  <title>Step 4: Award Negotiation &amp; Issuance</title>
  <langcode>en</langcode>
  <field_short_title>Step 4: Award Negotiation &amp; Issuance</field_short_title>
  <field_page_description>Before a grant can be awarded and accepted, several pre-award activities must happen to formalize the partnership. Ensuring compliance with federal laws, a review of costs and a negotiation of the appropriate funding level must all happen in order to receive a grant.</field_page_description>
  <field_feature_card_description>When an agency awards a grant, it is formalizing its partnership with the recipient (institution) to ensure compliance with federal laws, regulations and policies, and to protect the overall scientific endeavor.</field_feature_card_description>
  <field_list_description>Before a grant can be awarded and accepted, several pre-award activities must happen to formalize the partnership. Ensuring compliance with federal laws, a review of costs and a negotiation of the appropriate funding level must all happen in order to receive a grant.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915049</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>915113</id>
  <title>Researchers use Modified CRISPR Systems to Modulate Gene Expression on a Genomic Scale</title>
  <langcode>en</langcode>
  <field_short_title>Researchers use Modified CRISPR Systems to Modulate Gene Expression on a Genomic Scale</field_short_title>
  <field_page_description>Cancer Target Discovery and Development Network (CTD&lt;sup&gt;2&lt;/sup&gt;) researchers at the University of California, San Francisco, developed a CRISPR system that can regulate both gene repression and activation with fewer off-target effects.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <field_pretty_url>CRISPRa</field_pretty_url>
  <para_id>915113</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>915269</id>
  <title>Grantee Spotlight: Habtom Ressom, Ph.D. - Multi-Omic Approaches for the Early Detection of Liver Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Habtom Ressom, Ph.D.</field_short_title>
  <field_page_description>Dr. Habtom W. Ressom, an NCI CRCHD R21 grantee, works to identify a method for detecting liver cancer early by employing bioinformatic technologies to collect, and make sense of, multi-omic data from liver cancer cases and patients with liver cirrhosis.</field_page_description>
  <field_feature_card_description>Dr. Ressom researches bioinformatic technologies to detect liver cancer early. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-18</field_date_posted>
  <field_date_reviewed>2014-12-18</field_date_reviewed>
  <field_pretty_url>ressom-spotlight-blog</field_pretty_url>
  <para_id>915269</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>915266</term_id>
  <id>915271</id>
  <title>Grants Policies and Process</title>
  <langcode>en</langcode>
  <field_short_title>Grants Policies and Process</field_short_title>
  <field_page_description>NIH prior approval is required for the transfer of a grant. Learn more about transferring a cancer research grant from one entity to another.</field_page_description>
  <field_feature_card_description>Learn about NCI's grants administration process, including legal, regulatory, and policy requirements.</field_feature_card_description>
  <field_list_description>Research grants are subject to a variety of policy requirements. Learn about the NCI Office of Grants Administration process, including legal, regulatory, and policy requirements.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-12</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915271</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>911158</term_id>
  <id>915971</id>
  <title>Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Advanced Cancer</field_short_title>
  <field_page_description>Information to help with talking about and coping with advanced cancer, making choices about care, and planning for the end of life.</field_page_description>
  <field_feature_card_description>Information to help with talking about and coping with advanced cancer, making choices about care, and planning for the end of life.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915971</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915818</term_id>
  <id>916033</id>
  <title>Taking Care of Yourself</title>
  <langcode>en</langcode>
  <field_short_title>Taking Care of Yourself</field_short_title>
  <field_page_description>Caring for someone with advanced cancer brings new challenges and concerns. It's important to take care of yourself and reach out for help. Find tips specific to caregivers of patients with advanced cancer.</field_page_description>
  <field_feature_card_description>Tips specific to caregivers of patients with advanced cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>916033</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916854</term_id>
  <id>916855</id>
  <title>History of the National Cancer Institute</title>
  <langcode>en</langcode>
  <field_short_title>History</field_short_title>
  <field_page_description>Since its establishment in 1937, the National Cancer Institute has supported and advanced cancer research in many ways.</field_page_description>
  <field_feature_card_description>Since its formation in 1937, the National Cancer Institute has supported and advanced cancer research in many ways. </field_feature_card_description>
  <field_list_description>Major milestones in the history of the National Cancer Institute, the federal government's primary agency to address cancer research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916855</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917279</term_id>
  <id>919802</id>
  <title>Cancer Care Delivery Research Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Care Delivery Research Steering Committee Roster</field_short_title>
  <field_page_description>Roster of members on the Cancer Care Delivery Research Steering Committee.</field_page_description>
  <field_feature_card_description>Roster of members on the Cancer Care Delivery Research Steering Committee.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-26</field_date_posted>
  <field_date_reviewed>2015-03-26</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>919802</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129051</term_id>
  <id>1119790</id>
  <title>Citing TCGA in Publications and Presentations</title>
  <langcode>en</langcode>
  <field_short_title>Citing TCGA</field_short_title>
  <field_page_description>Guidelines for citing The Cancer Genome Atlas or The Cancer Genome Atlas Research Network in your research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-07-13</field_date_reviewed>
  <para_id>1119790</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1119977</id>
  <title>Combination Screens for Cancer Vulnerabilities: A Conversation with Kris Wood</title>
  <langcode>en</langcode>
  <field_short_title>Combination Screens for Cancer Vulnerabilities: A Conversation with Kris Wood</field_short_title>
  <field_page_description>Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted.</field_page_description>
  <field_feature_card_description>Cancers driven by mutant KRAS are difficult to treat. Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted.</field_feature_card_description>
  <field_list_description>Cancers driven by mutant KRAS are difficult to treat. Combining genetic screens with drugs that work downstream of mutant KRAS reveals cellular adaptations to uncontrolled growth that may be targeted.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-07-19</field_date_posted>
  <field_date_reviewed>2018-07-17</field_date_reviewed>
  <field_pretty_url>kris-wood</field_pretty_url>
  <para_id>1119977</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120620</id>
  <title>TCGA's Study of Acute Myeloid Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Acute Myeloid Leukemia</field_short_title>
  <field_page_description>TCGA's Study of Acute Myeloid Leukemia</field_page_description>
  <field_feature_card_description>TCGA's Study of Acute Myeloid Leukemia</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of acute myeloid leukemia (AML), including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-26</field_date_posted>
  <field_date_reviewed>2018-07-26</field_date_reviewed>
  <field_pretty_url>acute-myeloid-leukemia</field_pretty_url>
  <para_id>1120620</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120759</id>
  <title>TCGA's Study of Chromophobe Renal Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Chromophobe Renal Cell Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Chromophobe Renal Cell Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Chromophobe Renal Cell Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of chromophobe renal cell (kidney) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-27</field_date_posted>
  <field_date_reviewed>2018-07-27</field_date_reviewed>
  <field_pretty_url>renal-cell-chromophobe</field_pretty_url>
  <para_id>1120759</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1121520</id>
  <title>High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer Drug</title>
  <langcode>en</langcode>
  <field_short_title>Enhancing PI3K Inhibitor Response with Diet, Diabetes Drug</field_short_title>
  <field_page_description>Combining targeted cancer drugs known as PI3K inhibitors with a high-fat (ketogenic) diet or a diabetes drug may overcome P13K inhibitor resistance, a new study in mice suggests.</field_page_description>
  <field_feature_card_description>Study combined high-fat diet or diabetes medication with PI3K inhibitors.</field_feature_card_description>
  <field_list_description>A study in mice may have identified a way to help overcome resistance to targeted cancer drugs known as PI3K inhibitors. The approach appears to work by reducing insulin levels in patients receiving these drugs.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-08</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>pi3k-resistance-ketogenic-diet-diabetes-drug</field_pretty_url>
  <para_id>1121520</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1123942</id>
  <title>TCGA's Study of Pancreatic Ductal Adenocarcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Pancreatic Ductal Adenocarcinoma</field_short_title>
  <field_page_description>TCGA's Study of Pancreatic Ductal Adenocarcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Pancreatic Ductal Adenocarcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of pancreatic ductal adenocarcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-09-05</field_date_reviewed>
  <field_pretty_url>pancreatic</field_pretty_url>
  <para_id>1123942</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124128</id>
  <title>Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya Mohile</title>
  <langcode>en</langcode>
  <field_short_title>Integrating Geriatric Assessment into Cancer Care</field_short_title>
  <field_page_description>Dr. Supriya Mohile discusses efforts to incorporate geriatric assessment into the cancer care of older patients, including the recent publication of ASCO clinical guidelines on geriatric cancer care. </field_page_description>
  <field_feature_card_description>Dr. Supriya Mohile discusses efforts to improve the care of older patients.</field_feature_card_description>
  <field_list_description>Dr. Supriya Mohile discusses the unique issues experienced by older adults with cancer and efforts to incorporate geriatric assessment into patient care, including the publication of recent ASCO clinical guidelines on geriatric cancer care.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-11</field_date_posted>
  <field_date_reviewed>2018-09-11</field_date_reviewed>
  <field_pretty_url>geriatric-assessment-cancer-care-mohile</field_pretty_url>
  <para_id>1124128</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124129</id>
  <title>Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows</title>
  <langcode>en</langcode>
  <field_short_title>Appendix Cancers Genetically Distinct from Other GI Cancers</field_short_title>
  <field_page_description>Appendix cancers are distinct from colorectal and other gastrointestinal cancers, the largest-ever genomic study of its kind has shown. As this Cancer Currents post explains, specific mutations may help identify aggressive appendix tumors.</field_page_description>
  <field_feature_card_description>Specific mutations may identify aggressive appendix tumors.</field_feature_card_description>
  <field_list_description>The largest-ever study of DNA changes in appendix cancer shows that it is distinct from colorectal and other gastrointestinal cancers and suggests that specific mutations in appendix tumors may help predict whether they may be aggressive.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-12</field_date_posted>
  <field_date_reviewed>2018-09-11</field_date_reviewed>
  <field_pretty_url>appendix-cancer-genetic-distinct</field_pretty_url>
  <para_id>1124129</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1124184</term_id>
  <id>1124201</id>
  <title>Publications from the RAS Initiative</title>
  <langcode>en</langcode>
  <field_short_title>RAS Initiative Publications</field_short_title>
  <field_page_description>This list of publications from the RAS Initiative reflects the balance between the public responsibilities of the National Cancer Institute and the requirements of our external partners.</field_page_description>
  <field_feature_card_description>This list of RAS Initiative publications reflects the balance between the public responsibilities of NCI and the requirements of external partners.</field_feature_card_description>
  <field_list_description>This list of RAS Initiative publications reflects the balance between the public responsibilities of NCI and the requirements of external partners.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-16</field_date_posted>
  <field_date_reviewed>2018-09-12</field_date_reviewed>
  <para_id>1124201</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1124678</id>
  <title>Dr. Chanita Hughes-Halbert to Deliver NCI CURE Distinguished Scholars Seminar</title>
  <langcode>en</langcode>
  <field_short_title>Dr. Chanita Hughes-Halbert to Deliver NCI CURE Distinguished Scholars Seminar</field_short_title>
  <field_page_description>On October 17, 2018, Dr. Chanita Hughes-Halbert will deliver the next CURE Distinguished Scholars Seminar. Dr. Hughes-Halbert will present on Translational Issues in Cancer Health Disparities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-20</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <field_pretty_url>Hughes-Halbert-Seminar</field_pretty_url>
  <para_id>1124678</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915605</term_id>
  <id>1124701</id>
  <title>Brushing the Airway to Detect Lung Cancer Earlier</title>
  <langcode>en</langcode>
  <field_short_title>Brushing the Airway to Detect Lung Cancer Earlier</field_short_title>
  <field_page_description>Learn how NCI support enabled pulmonologist Avrum Spira to develop a minimally invasive test to tell whether smokers with suspicious lung lesions have cancer.</field_page_description>
  <field_feature_card_description>Avrum Spira, M.D., M.Sc., is transforming the paradigm of early lung cancer detection and screening.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-09-21</field_date_reviewed>
  <field_pretty_url>avrum-spira-early-detection-lung-cancer</field_pretty_url>
  <para_id>1124701</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917216</term_id>
  <id>1124707</id>
  <title>Improving Outcomes for Patients with NF1</title>
  <langcode>en</langcode>
  <field_short_title>Improving Outcomes for Patients with NF1</field_short_title>
  <field_page_description>Read about Philip Moss who participated in an NCI clinical trial led by Brigitte Widemann that is showing promise in treating children with NF1.</field_page_description>
  <field_feature_card_description>Philip Moss had run out of treatment options for his neurofibroma tumors when he joined a clinical trial at NIH.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-09-21</field_date_reviewed>
  <field_pretty_url>philip-moss-improving-outcomes-nf1-neurofibromas</field_pretty_url>
  <para_id>1124707</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915609</term_id>
  <id>1126636</id>
  <title>Bringing Research to the Community to Reduce Cancer Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Bringing Research to the Community to Reduce Cancer Disparities-Chanita Hughes-Halbert, Ph.D.</field_short_title>
  <field_page_description>Read about how NCI is working to reduce cancer disparities by bringing clinical trials to minority and underserved communities.</field_page_description>
  <field_feature_card_description>Chanita Hughes-Halbert, Ph.D., leads one of NCORP’s minority/underserved community sites.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>chanita-hughes-halbert-clinical-trials-community-access</field_pretty_url>
  <para_id>1126636</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1126643</id>
  <title>APACT &amp; WCC 2018: Tobacco Control, Oral Cancer and the Sustainable Development Goals in the Asia-Pacific </title>
  <langcode>en</langcode>
  <field_short_title>APACT &amp; WCC 2018: Tobacco Control, Oral Cancer and Sustainable Development in the Asia-Pacific </field_short_title>
  <field_page_description>Want to learn more about tobacco control, oral cancer and sustainable development in the Asia-Pacific? Read CGH's Spotlight Blog: Tobacco Control, Oral Cancer and Sustainable Development in the Asia-Pacific. </field_page_description>
  <field_list_description>Tobacco Control, Oral Cancer and Sustainable Development in the Asia-Pacific </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-16</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>tobacco</field_pretty_url>
  <para_id>1126643</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1126837</id>
  <title>Using World RePORT to Measure How Much HPV-related Research is Being Funded Throughout the World</title>
  <langcode>en</langcode>
  <field_short_title>Using World Report to Measure How Much HPV-related Research is Being Funded Throughout the World</field_short_title>
  <field_page_description>Interested in learning in more about HPV-related research? Read: Using World RePORT to Measure How Much HPV-related Research is Being Funded Throughout the World to find out more.</field_page_description>
  <field_list_description>World RePORT, an open-access and interactive database of international research projects, grants, and collaborations dedicated to improving health, compiles data submitted by the U.S. National Institutes of Health (NIH), the UK’s medical research council (MRC), the European Commission (EC), the Canadian Institutes of Health Research (CIHR), the Bill and Melinda Gates Foundation, and the Wellcome Trust. We use this database to determine where research on HPV is taking place.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-19</field_date_posted>
  <field_date_reviewed>2018-10-19</field_date_reviewed>
  <field_pretty_url>world-report</field_pretty_url>
  <para_id>1126837</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1128965</id>
  <title>New on NCI Websites for October 2018</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI Websites for October 2018</field_short_title>
  <field_page_description>See selected content that has been added to NCI’s websites as of October 2018, in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of October 2018.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-30</field_date_posted>
  <field_date_reviewed>2018-10-29</field_date_reviewed>
  <field_pretty_url>new-online-Oct-2018</field_pretty_url>
  <para_id>1128965</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1131335</id>
  <title>Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function</title>
  <langcode>en</langcode>
  <field_short_title>Tailored Radiation for Brain Metastases Reduces Cognitive Impact</field_short_title>
  <field_page_description>For treating brain metastases, a radiation therapy technique called hippocampal avoidance limits the radiation’s cognitive impact, a clinical trial shows.</field_page_description>
  <field_feature_card_description>Hippocampal avoidance limits harm without affecting treatment’s effect on tumors.</field_feature_card_description>
  <field_list_description>Results from a clinical trial suggest that, in patients with brain metastases, an advanced radiotherapy technique limits harm to patients’ cognitive function without affecting the treatment’s effect on tumors.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-26</field_date_posted>
  <field_date_reviewed>2018-11-20</field_date_reviewed>
  <field_pretty_url>brain-metastases-radiation-therapy-hippocampal-avoidance</field_pretty_url>
  <para_id>1131335</para_id>
  <related_resource_id>7168224</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1132884</id>
  <title>iCURE Welcomes First Scholars to the NCI</title>
  <langcode>en</langcode>
  <field_short_title>iCURE Welcomes First Scholars to the NCI</field_short_title>
  <field_page_description>The Intramural Continuing Umbrella of Research Experiences (iCURE) program is thrilled to announce that the inaugural cohort of iCURE scholars has been selected. </field_page_description>
  <field_feature_card_description>The iCURE program has selected the inaugural cohort of iCURE scholars.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-14</field_date_posted>
  <field_date_reviewed>2018-12-14</field_date_reviewed>
  <field_pretty_url>icure-welcomes-scholars</field_pretty_url>
  <para_id>1132884</para_id>
  <related_resource_ids>7183459</related_resource_ids>
  <related_resource_ids>7183460</related_resource_ids>
  <related_resource_ids>7183490</related_resource_ids>
  <related_resource_ids>7183491</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>1133170</id>
  <title>Drugs Approved for Solid Tumors Anywhere in the Body</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Solid Tumors Anywhere in the Body</field_short_title>
  <field_page_description>A list of cancer drugs approved by the FDA for the treatment of solid tumors.</field_page_description>
  <field_list_description>A list of cancer drugs approved by the Food and Drug Administration (FDA) for for the treatment of solid tumors based on their genetic features and not on where the tumors originated in the body. The list includes generic names and brand names.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>solid-tumors</field_pretty_url>
  <para_id>1133170</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133176</term_id>
  <id>1133220</id>
  <title>Chordoma</title>
  <langcode>en</langcode>
  <field_short_title>Chordoma</field_short_title>
  <field_page_description>Chordoma is a slow growing cancer of tissue found inside the spine, formed from the left-over cells that were important in the development of the spine before birth. Learn more about chrodomas, how they are diagnosed, and how they are treated.</field_page_description>
  <field_list_description>Chordoma is a slow growing cancer of tissue found inside the spine, formed from the left-over cells that were important in the development of the spine before birth. Most people are diagnosed with chordoma in their 50s and 60s - pediatric chordomas make up 5% of all chordoma diagnoses.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>chordoma</field_pretty_url>
  <para_id>1133220</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133227</id>
  <title>Synovial sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Synovial sarcoma</field_short_title>
  <field_page_description>Synovial sarcoma is a cancer that can come from different types of soft tissue, such as muscle or ligaments. One third of patients with synovial sarcoma will be diagnosed under the age of 30. It is somewhat more common in males. Learn more about the tumor, diagnosis, and prognosis from the MyPART project. </field_page_description>
  <field_list_description>Synovial sarcoma is a cancer that can come from different types of soft tissue, such as muscle or ligaments. One third of patients with synovial sarcoma will be diagnosed under the age of 30. It is somewhat more common in males.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>synovial-sarcoma</field_pretty_url>
  <para_id>1133227</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134558</term_id>
  <id>1133234</id>
  <title>Adrenocortical carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Adrenocortical carcinoma</field_short_title>
  <field_page_description>Adrenocortical carcinoma, or ACC, is a cancer of the adrenal glands, which are two small triangular-shaped glands that sit on top of each kidney. It is very rare, afffecting around one in one million people in the US annually.  Learn more about diagnosis, treatement, and prognosis of this disease. </field_page_description>
  <field_list_description>Adrenocortical carcinoma, or ACC, is a cancer of the adrenal glands, which are two small triangular-shaped glands that sit on top of each kidney. It is very rare, afffecting around one in one million people in the US annually. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>adrenocortical-carcinoma</field_pretty_url>
  <para_id>1133234</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>1133190</term_id>
  <id>1133245</id>
  <title>Other Rare Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Other Rare Tumors</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133245</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133439</id>
  <title>FDA Approvals Bring New Options for Older Patients with AML</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approvals Bring New Options for Older Patients with AML</field_short_title>
  <field_page_description>FDA has approved venetoclax (Venclexta) and glasdegib (Daurismo) for older patients with AML and those who can’t tolerate the standard chemotherapy treatment.</field_page_description>
  <field_feature_card_description>Glasdegib and venetoclax provide choices for those who can’t tolerate standard treatment.</field_feature_card_description>
  <field_list_description>FDA has approved venetoclax (Venclexta) and glasdegib (Daurismo) for use in people with acute myeloid leukemia aged 75 and older and those with health conditions that prevent them from receiving the intensive chemotherapy regimen that is the standard initial treatment.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-27</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <field_pretty_url>fda-approval-glasdegib-venetoclax-aml-older</field_pretty_url>
  <para_id>1133439</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133194</term_id>
  <id>1133502</id>
  <title>Participate</title>
  <langcode>en</langcode>
  <field_short_title>Participate</field_short_title>
  <field_page_description>Patients, families, and advocacy organizations can participate in MyPART’s work to improve the lives of children, teens, and young adults with rare cancers.</field_page_description>
  <field_feature_card_description>The MyPART network works best when patients, families, and advocacy organizations work together.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <para_id>1133502</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133753</term_id>
  <id>1133756</id>
  <title>Join the NIH Fellows Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Join the NIH Fellows Editorial Board</field_short_title>
  <field_page_description>The NIH Fellows Editorial Board offers fellows a free, confidential scientific document-editing service and gives fellows who join the Board editorial training and experience. The Fellows Editoral Board is by volunteer only of fellows and other professionals  to edit scientific documents and grant applications. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-21</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <para_id>1133756</para_id>
  <related_resource_ids>7192973</related_resource_ids>
  <related_resource_ids>7192974</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133783</term_id>
  <id>1133781</id>
  <title>Submissions to the NIH Fellows Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Submissions to the NIH Fellows Editorial Board</field_short_title>
  <field_page_description>The NIH Fellows Editorial Board offers a free, confidential scientific document-editing service for any current NIH or FDA fellow. The all-volunteer Editorial Board of fellows and other professionals edit fellows’ scientific documents—typically manuscripts and grant applications—for grammar, form, and clarity. The edit</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-21</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <para_id>1133781</para_id>
  <related_resource_id>7193154</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134381</id>
  <title>Cancer Biotechnology </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Biotechnology Course</field_short_title>
  <field_page_description>The Cancer Biotechnology course educates NCI fellows on new methodologies focusing on the latest advances in DNA, protein and image analysis. This course is targeted to clinical and postdoctoral fellows who want to learn about new biotechnology advances in science.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <field_pretty_url>cancer-biotechnology</field_pretty_url>
  <para_id>1134381</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134382</id>
  <title>Non-Academic Jobs for Fellows in Law Firms, Patent and Trademark Office and Scientific Intellectual Property </title>
  <langcode>en</langcode>
  <field_short_title>Non-Academic Jobs for Fellows</field_short_title>
  <field_page_description>The Non-Academic Jobs for Fellows in Law Firms, Patent and Trademark Office and Scientific Intellectual Property workshop assists NCI Fellows, Staff Scientists, and Staff Clinicians in positioning themselves for job opportunites.</field_page_description>
  <field_list_description>The Non-Academic Jobs for Fellows in Law Firms, Patent and Trademark Office and Scientific Intellectual Property workshop assists NCI Fellows, Staff Scientists, and Staff Clinicians in positioning themselves for job opportunites at  law firms, patent and trademark, and intellectual property protection across the biotechnology and pharmaceutical industries.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <field_pretty_url>non-academic-jobs</field_pretty_url>
  <para_id>1134382</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134424</id>
  <title>Translational Research in Clinical Oncology</title>
  <langcode>en</langcode>
  <field_short_title>Translational Research in Clinical Oncology</field_short_title>
  <field_page_description>This course is designed to provide NIH postdoctoral and clinical fellows an overview of general principles of cancer biology and treatment, epidemiology, genomics, precision medicine, mechanisms of resistance, use of preclinical models, and identification of novel molecular targets. </field_page_description>
  <field_list_description>The Translational Research in Clinical Oncology (TRACO) course is designed to provide NIH postdoctoral and clinical fellows an overview of general principles of cancer biology and treatment, epidemiology, genomics, precision medicine, mechanisms of resistance, use of preclinical models, and identification of novel molecular targets.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-04</field_date_posted>
  <field_date_reviewed>2019-01-04</field_date_reviewed>
  <field_pretty_url>translational-research-clinical-oncology</field_pretty_url>
  <para_id>1134424</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133186</term_id>
  <id>1134556</id>
  <title>What are rare kidney tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Kidney Tumors</field_short_title>
  <field_page_description>Kidney tumors may also be called renal tumors. Specific rare tumors are named by where they form in the kidney and the type of cells they look like. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134556</para_id>
  <related_resource_id>7196831</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134630</term_id>
  <id>1134631</id>
  <title>Modeling and Druggable-Genome Screening of Glioblastoma Invasion Using Regional Biopsy-Guided Biomaterials Systems</title>
  <langcode>en</langcode>
  <field_short_title>Modeling and Druggable-Genome Screening of Glioblastoma Invasion</field_short_title>
  <field_page_description>TEC funded grant which will uncover mechanisms by which glioblastoma tumor cells and their microenvironment are altered to drive increased invasiveness as cells migrate away from the tumor core.</field_page_description>
  <field_list_description>This TEC funded grant has combined site-directed biopsies from GBM with tissue engineered platforms to study invasion in vitro. Our studies will uncover mechanisms by which tumor cells and their microenvironment are altered to drive increased invasiveness as cells migrate away from the tumor core.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-08</field_date_posted>
  <field_date_reviewed>2017-06-28</field_date_reviewed>
  <para_id>1134631</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1135266</term_id>
  <id>1135267</id>
  <title>Office of Acquisitions (OA)</title>
  <langcode>en</langcode>
  <field_short_title>Office of Acquisitions (OA)</field_short_title>
  <field_page_description>The National Cancer Institute Office of Acquisitions negotiates, awards, and administers contracts and simplified acquisitions, while ensuring that customer service is paramount, communications are open and continuous, positive relationships are fostered, sound business judgment is employed, and acquisition strategies </field_page_description>
  <field_list_description>OA negotiates, awards, and administers contracts and simplified acquisitions in support of NCI’s mission to prevent, diagnose, and treat cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-15</field_date_posted>
  <field_date_reviewed>2019-01-15</field_date_reviewed>
  <para_id>1135267</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1135722</id>
  <title>African American Men More Likely to Die from Low-Grade Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>For Black Men, Disparities in Death from Low-Grade Prostate Cancer</field_short_title>
  <field_page_description>African American men with low-grade prostate cancer are more likely to die from the disease than men of other races, a new study shows.</field_page_description>
  <field_feature_card_description>African American men have higher death risk than men of other races.</field_feature_card_description>
  <field_list_description>For African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the increase, the risk is still small.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-28</field_date_posted>
  <field_date_reviewed>2019-01-24</field_date_reviewed>
  <field_pretty_url>prostate-cancer-death-disparities-black-men</field_pretty_url>
  <para_id>1135722</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1136868</term_id>
  <id>1136877</id>
  <title>FNLCR Acquisition Resources</title>
  <langcode>en</langcode>
  <field_short_title>FNLCR Resources</field_short_title>
  <field_page_description>Browse the NCI Frederick National Laboratory for Cancer Research Acquisition Resources.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-05</field_date_posted>
  <field_date_reviewed>2019-02-05</field_date_reviewed>
  <para_id>1136877</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1137221</id>
  <title>HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies</title>
  <langcode>en</langcode>
  <field_short_title>HTAN: Mapping Tumors across Space and Time</field_short_title>
  <field_page_description>The Human Tumor Atlas Network is using the latest technologies to create detailed maps that capture cancer’s physical features and how tumors evolve over time. </field_page_description>
  <field_feature_card_description>A new NCI program will create maps of cancers with unprecedented detail.</field_feature_card_description>
  <field_list_description>The Human Tumor Atlas Network, an NCI-led collaborative research project, is creating detailed maps of cancers that will be used to learn how cancer develops, spreads, and responds to treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-12</field_date_posted>
  <field_pretty_url>human-tumor-atlas-network-cancer-maps</field_pretty_url>
  <para_id>1137221</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1137532</term_id>
  <id>1137533</id>
  <title>NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24)</title>
  <langcode>en</langcode>
  <field_short_title>NCI U24 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-12</field_date_reviewed>
  <para_id>1137533</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1137581</term_id>
  <id>1137582</id>
  <title>Subcontracting Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Subcontracting Opportunities</field_short_title>
  <field_page_description>Explore the different ways to find NCI subcontracting opportunities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-11</field_date_posted>
  <field_date_reviewed>2019-02-11</field_date_reviewed>
  <para_id>1137582</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1135698</term_id>
  <id>1137608</id>
  <title>An NCI Affordable Cancer Technologies project selected as one of Physics World’s Top Ten Breakthroughs of 2018</title>
  <langcode>en</langcode>
  <field_short_title>An NCI Affordable Cancer Technologies project selected as one of Physics World’s Top Ten</field_short_title>
  <field_page_description>Interested in technology devices for LMICs? Read how Eric Ford from the University of Washington and his team have recently been recognized by Physics World for his NCI-funded work to bring intensity-modulate radiotherapy (IMRT) to low- and middle-income settings.</field_page_description>
  <field_list_description>Eric Ford from the University of Washington and his team have recently been recognized by Physics World for his NCI-funded work to bring intensity-modulate radiotherapy (IMRT) to low- and middle-income settings.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-12</field_date_posted>
  <field_date_reviewed>2019-02-12</field_date_reviewed>
  <field_pretty_url>eric-ford</field_pretty_url>
  <para_id>1137608</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1137978</term_id>
  <id>1137914</id>
  <title>Activities at NCI Exhibit Booth #2111</title>
  <langcode>en</langcode>
  <field_short_title>Activities at NCI Exhibit Booth #2111</field_short_title>
  <field_page_description>Stop by NCI’s Exhibit Booth at AACR 2019 to connect with NCI experts, order free publications, and learn about NCI programs and initiatives.</field_page_description>
  <field_feature_card_description>Connect with NCI experts, order free publications, and learn about NCI programs and initiatives at interactive kiosks. In addition, check out our schedule of Meet the Expert sessions.</field_feature_card_description>
  <field_list_description>Connect with NCI experts, order free publications, and learn about NCI programs and initiatives at interactive kiosks. In addition, check out our schedule of Meet the Expert sessions.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-22</field_date_posted>
  <field_date_reviewed>2018-03-26</field_date_reviewed>
  <para_id>1137914</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1139367</id>
  <title>NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s Rare Cancer Clinics Fostering Collaboration</field_short_title>
  <field_page_description>To advance progress against rare cancers like GIST and brain cancers, NCI has created special clinics that bring together clinicians, patients, and advocates.</field_page_description>
  <field_feature_card_description>Clinics bring together clinicians, patients, and advocates.</field_feature_card_description>
  <field_list_description>NCI has created special clinics that bring together clinicians, patients, and advocates to promote more rapid progress against rare cancers. The effort includes both rare pediatric cancers and central nervous system tumors in adults.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-28</field_date_posted>
  <field_date_reviewed>2019-02-26</field_date_reviewed>
  <field_pretty_url>rare-cancer-clinics-nci</field_pretty_url>
  <para_id>1139367</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1136415</term_id>
  <id>1139997</id>
  <title>Initiative Spotlight: A Conversation with Frank McCormick</title>
  <langcode>en</langcode>
  <field_short_title>Initiative Spotlight: A Conversation with Frank McCormick</field_short_title>
  <field_page_description>Recent discoveries and new approaches are chipping away at the cancers caused by mutant RAS genes.</field_page_description>
  <field_feature_card_description>For the first time cancers caused by RAS are being directly targeted.</field_feature_card_description>
  <field_list_description>Recent discoveries and new approaches are chipping away at the cancers caused by mutant RAS genes.  For the first time drugs that target RAS directly are in human clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2019-03-01</field_date_reviewed>
  <field_pretty_url>frank-mccormick</field_pretty_url>
  <para_id>1139997</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1140154</id>
  <title>Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Eliminating Racial Disparities in Lung Cancer Treatment</field_short_title>
  <field_page_description>For black and white patients with early-stage lung cancer, a multipronged approach implemented in hospitals improved treatment rates, a new study shows.</field_page_description>
  <field_feature_card_description>Approach improved treatment rate for black and white patients.</field_feature_card_description>
  <field_list_description>Use of a multipronged approach within hospitals, including community centers, not only  eliminated treatment disparities among black and white patients with early-stage lung cancer, it also improved treatment rates for all patients, results from a new study show.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-05</field_date_posted>
  <field_date_reviewed>2019-03-05</field_date_reviewed>
  <field_pretty_url>lung-cancer-treatment-disparities-eliminated</field_pretty_url>
  <para_id>1140154</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>93513</id>
  <title>Drugs Approved for Testicular Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Testicular Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for testicular cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-25</field_date_posted>
  <field_date_reviewed>2011-07-19</field_date_reviewed>
  <field_pretty_url>testicular</field_pretty_url>
  <para_id>93513</para_id>
  <related_resource_ids>6994894</related_resource_ids>
  <related_resource_ids>6994902</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11738</term_id>
  <id>109060</id>
  <title>Application Form for NCI Cancer Genetics Services Directory</title>
  <langcode>en</langcode>
  <field_short_title>Application Form for NCI Cancer Genetics Services Directory</field_short_title>
  <field_page_description>Professionals who provide services related to cancer genetics (cancer risk assessment, genetic counseling, genetic susceptibility testing, and others) may fill out this application form to be listed in the National Cancer Institute's Cancer Genetics Services Directory. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-09-12</field_date_posted>
  <field_date_reviewed>2011-09-12</field_date_reviewed>
  <field_pretty_url>application-form</field_pretty_url>
  <para_id>109060</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>637652</id>
  <title>Harnessing the Power of Our Immune Systems to Treat Neuroblastoma: Discovery of Ch14.18 Immunotherapy </title>
  <langcode>en</langcode>
  <field_short_title>Ch14.18 Immunotherapy to Treat Neuroblastoma</field_short_title>
  <field_page_description>Neuroblastoma is rare yet it's the most common cancer affecting infants. Prior to a discovery 20 years in the making, there was little hope for survival in children with advanced stages of the disease. Today, research is leading to a brighter outlook.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-07</field_date_posted>
  <field_date_reviewed>2013-09-17</field_date_reviewed>
  <field_pretty_url>neuroblastoma</field_pretty_url>
  <para_id>637652</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938229</term_id>
  <id>637658</id>
  <title>Pomalidomide plus Low-Dose Dexamethasone Improves Survival for Patients with Multiple Myeloma </title>
  <langcode>en</langcode>
  <field_short_title>Pomalidomide for Multiple Myeloma</field_short_title>
  <field_page_description>A summary of results from a phase III trial that compared the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone versus high-dose dexamethasone alone in patients with multiple myeloma that has progressed despite other treatments. </field_page_description>
  <field_feature_card_description>Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed despite other treatments. </field_feature_card_description>
  <field_list_description>Results from a randomized phase III trial show that the combination of pomalidomide (Pomalyst®) and low-dose dexamethasone may benefit some patients with multiple myeloma that has progressed (worsened) despite other treatments. Patients who received the combination therapy lived longer without the disease getting worse than patients who received high-dose dexamethasone alone. Overall survival was also improved in the group that received the combination therapy compared with the other group.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-09-19</field_date_posted>
  <field_date_reviewed>2013-09-19</field_date_reviewed>
  <field_pretty_url>pomalidomide-dexamethasone</field_pretty_url>
  <para_id>637658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>974292</id>
  <title>Setting the Course: Genomics Workshop on Childhood Cancers Identifies Research Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Genomics Workshop on Childhood Cancers Identifies Research Opportunities</field_short_title>
  <field_page_description>NCI recently convened a workshop to discuss the status of genomic characterization for childhood cancers and to identify opportunities for future research.</field_page_description>
  <field_feature_card_description>Genomic studies can provide new insights into childhood cancers</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-17</field_date_posted>
  <field_date_reviewed>2015-07-06</field_date_reviewed>
  <field_pretty_url>childhood-genomic-workshop</field_pretty_url>
  <para_id>974292</para_id>
  <related_resource_ids>6572545</related_resource_ids>
  <related_resource_ids>6572546</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>78414</id>
  <title>Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer</field_short_title>
  <field_page_description>Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, </field_page_description>
  <field_feature_card_description>Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, </field_feature_card_description>
  <field_list_description>Treatment with trastuzumab for 1 year following standard chemotherapy improved disease-free survival in women with HER2-positive early breast cancer, according to 4-year follow-up results of the Herceptin Adjuvant (HERA) trial reported February 25, 2011, in Lancet Oncology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-05-06</field_date_posted>
  <field_date_reviewed>2011-05-06</field_date_reviewed>
  <field_pretty_url>trastuzumab-after-chemo</field_pretty_url>
  <para_id>78414</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>79028</id>
  <title>Drugs Approved for Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Leukemia</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the FDA for use in leukemia. The drug names link to NCI's Cancer Drug Information summaries.  The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-20</field_date_posted>
  <field_date_reviewed>2011-05-12</field_date_reviewed>
  <field_pretty_url>leukemia</field_pretty_url>
  <para_id>79028</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938032</term_id>
  <id>79346</id>
  <title>Lenalidomide and Radiation for Children with Brain Cancers </title>
  <langcode>en</langcode>
  <field_short_title>Lenalidomide and Radiation for Children with Brain Cancers </field_short_title>
  <field_page_description>n this trial, patients up to age 18 who are newly diagnosed with diffuse intrinsic pontine gliomas (DIPG) or who have other incompletely resected high-grade gliomas will undergo radiation therapy and receive oral lenalidomide, followed by lenalidomide. </field_page_description>
  <field_feature_card_description>In this trial, patients up to age 18 who are newly diagnosed with diffuse intrinsic pontine gliomas (DIPG) or who have other incompletely resected high-grade gliomas will undergo radiation therapy and receive oral lenalidomide, followed by lenalidomide. </field_feature_card_description>
  <field_list_description>In this trial, patients up to age 18 who are newly diagnosed with diffuse intrinsic pontine gliomas (DIPG) or who have other high-grade gliomas that could not be completely resected will undergo radiation therapy and receive oral lenalidomide at increasing doses daily for 6 weeks, followed by lenalidomide alone. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-17</field_date_posted>
  <field_date_reviewed>2011-05-17</field_date_reviewed>
  <field_pretty_url>children-lenalidomide-radiation</field_pretty_url>
  <para_id>79346</para_id>
  <related_resource_ids>6494120</related_resource_ids>
  <related_resource_ids>6494121</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>81827</id>
  <title>Drugs Approved for Gestational Trophoblastic Disease</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Gestational Trophoblastic Disease</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for gestational trophoblastic disease. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-06-10</field_date_posted>
  <field_date_reviewed>2011-05-23</field_date_reviewed>
  <field_pretty_url>gestationaldisease</field_pretty_url>
  <para_id>81827</para_id>
  <related_resource_ids>6996763</related_resource_ids>
  <related_resource_ids>6996768</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938135</term_id>
  <id>84128</id>
  <title>Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients</title>
  <langcode>en</langcode>
  <field_short_title>Chemotherapy Regimen Extends Survival in Advanced Pancreatic Cancer Patients</field_short_title>
  <field_page_description>A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer. </field_page_description>
  <field_feature_card_description>A four-drug chemotherapy regimen has produced the longest improvement in survival ever seen in a phase III clinical trial of patients with metastatic pancreatic cancer, one of the deadliest types of cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-07</field_date_posted>
  <field_date_reviewed>2011-06-07</field_date_reviewed>
  <field_pretty_url>folfirinox</field_pretty_url>
  <para_id>84128</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>84738</id>
  <title>Drugs Approved for Hodgkin Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Hodgkin Lymphoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Hodgkin lymphoma. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-12</field_date_posted>
  <field_date_reviewed>2011-06-13</field_date_reviewed>
  <field_pretty_url>hodgkin-lymphoma</field_pretty_url>
  <para_id>84738</para_id>
  <related_resource_ids>6997007</related_resource_ids>
  <related_resource_ids>6997008</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>89699</id>
  <title>Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for ovarian cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-12-05</field_date_posted>
  <field_date_reviewed>2011-07-14</field_date_reviewed>
  <field_pretty_url>ovarian</field_pretty_url>
  <para_id>89699</para_id>
  <related_resource_ids>6994742</related_resource_ids>
  <related_resource_ids>6994753</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940946</term_id>
  <id>940953</id>
  <title>Skin Cancer (Including Melanoma)—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Skin Cancer</field_short_title>
  <field_page_description>Basal cell carcinoma and squamous cell carcinoma are referred to as nonmelanoma skin cancers. Melanoma is a malignant tumor of melanocytes, which make the melanin. Find evidence-based information on skin cancer treatment, causes and prevention, screening, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Skin Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940953</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>940954</id>
  <title>Skin Cancer (Including Melanoma) Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on skin cancer, including melanoma, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>941142</term_id>
  <id>941147</id>
  <title>Urethral Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Urethral Cancer </field_short_title>
  <field_page_description>Urethral cancer is a rare cancer. There are three types of urethral cancer. Squamous cell carcinoma is the most common type. Transitional cell carcinoma of the urethra, and adenocarcinoma in the glands around the urethra are less common. Find evidence-based information on urethral cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about urethral cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941147</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11922</term_id>
  <id>941596</id>
  <title>Clinical Trials to Treat Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Leukemia</field_short_title>
  <field_page_description>A list of leukemia treatment trials accepting patients. </field_page_description>
  <field_feature_card_description>A list of leukemia treatment trials accepting patients. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <field_pretty_url>clinical-trials</field_pretty_url>
  <para_id>941596</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938231</term_id>
  <id>953384</id>
  <title>Research on Childhood Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Research on Childhood Cancers</field_short_title>
  <field_page_description>Find research articles on childhood cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-13</field_date_posted>
  <field_date_reviewed>2015-05-13</field_date_reviewed>
  <para_id>953384</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>967894</id>
  <title>Using Gene Expression to Diagnose Lung Cancer More Accurately</title>
  <langcode>en</langcode>
  <field_short_title>Gene Classifier May Help to Diagnose Lung Cancer</field_short_title>
  <field_page_description>A pattern of gene expression in the cells of the upper airways of patients with suspected lung cancer can help to diagnose lung cancer more accurately than bronchoscopy alone.</field_page_description>
  <field_feature_card_description>When combined with bronchoscopy, this test may more accurately identify patients without cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-19</field_date_posted>
  <field_date_reviewed>2015-06-19</field_date_reviewed>
  <field_pretty_url>lung-genomic-classifier</field_pretty_url>
  <para_id>967894</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>969678</id>
  <title>International Collaboration Enhances Cancer Screening Efforts</title>
  <langcode>en</langcode>
  <field_short_title>International Collaboration Enhances Cancer Screening Efforts</field_short_title>
  <field_page_description>CGH is working with the International Agency for Research on CancerExit Disclaimer (IARC) and the Pan American Health Organization (PAHO) on the ESTAMPA Study, a multi-centric study of cervical cancer screening and triage with HPV testing.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-23</field_date_posted>
  <field_date_reviewed>2015-06-23</field_date_reviewed>
  <field_pretty_url>international-collaboration</field_pretty_url>
  <para_id>969678</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>969698</term_id>
  <id>969699</id>
  <title>NCI Budget Fact Book</title>
  <langcode>en</langcode>
  <field_short_title>NCI Budget Fact Book</field_short_title>
  <field_page_description>The NCI Budget Fact Book summarizes the recent NCI fiscal year budget, including research funding and overall spending. Review the highlights of NCI's 2018 Fiscal Year Budget.</field_page_description>
  <field_feature_card_description>A summary of NCI’s expenditures for FY 2018, as well as funding policies related to research grant awards.</field_feature_card_description>
  <field_list_description>The Fact Book contains distribution of the NCI fiscal year budget among various research programs and funding mechanisms, funding policies influencing grant awards, comparisons with prior year allocations, overall budget data, and historical trends.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969699</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929672</term_id>
  <id>929673</id>
  <title>Office of Management Policy and Compliance </title>
  <langcode>en</langcode>
  <field_short_title>Office of Management Policy and Compliance</field_short_title>
  <field_page_description>NCI’s Office of Management Policy and Compliance is responsible for NCI-wide evaluation and implementation of HHS, NIH and NCI policies, guidelines and regulations with oversight in the areas of Risk and Records Management, Organizational Change, PRA/OMB Clearance, Policy, and Delegated Authorities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-06</field_date_posted>
  <field_date_reviewed>2015-04-06</field_date_reviewed>
  <para_id>929673</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929695</term_id>
  <id>929700</id>
  <title>Multimedia from NCI</title>
  <langcode>en</langcode>
  <field_short_title>Multimedia from NCI</field_short_title>
  <field_page_description>The National Cancer Institute’s collection of multimedia includes photography, illustrations, videos, infographics, and apps.</field_page_description>
  <field_feature_card_description>A collection of videos, photos, infographics, and more from NCI.</field_feature_card_description>
  <field_list_description>A collection of videos, photos, infographics, and more from NCI.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-06</field_date_posted>
  <field_date_reviewed>2015-04-06</field_date_reviewed>
  <para_id>929700</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>931040</id>
  <title>Take Action to Decrease Your Cancer Risk - Obesity and Its Role in Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Take Action to Decrease Your Cancer Risk - Obesity and Its Role in Cancer Health Disparities</field_short_title>
  <field_page_description>In support of this year’s National Minority Health Month theme “Prevention is Power: Taking Action for Health Equity!”, CRCHD is highlighting the role of obesity in cancer health disparities among diverse population groups in the U.S.</field_page_description>
  <field_feature_card_description>CRCHD highlights the role of obesity in cancer health disparities during National Minority Health Month.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-10</field_date_posted>
  <field_date_reviewed>2015-04-10</field_date_reviewed>
  <field_pretty_url>nmhm15-spotlight</field_pretty_url>
  <para_id>931040</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>937180</id>
  <title>Targeted Agents Active Against HER2-positive Breast Cancer: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Agents Active Against Breast Cancer: Q&amp;A</field_short_title>
  <field_page_description>ALTTO was a clinical trial designed to determine whether the combination of the monoclonal antibody trastuzumab (Herceptin) and the drug lapatinib (Tykerb) was more effective in treating HER2/ErbB2-positive breast cancer when combined with chemotherapy than either agent alone. Results from ALTTO did not show additional</field_page_description>
  <field_feature_card_description>ALTTO was a clinical trial designed to determine whether the combination of the monoclonal antibody trastuzumab (Herceptin) and the drug lapatinib (Tykerb) was more effective in treating HER2/ErbB2-positive breast cancer when combined with chemotherapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-17</field_date_posted>
  <field_date_reviewed>2015-04-17</field_date_reviewed>
  <field_pretty_url>altto-qa</field_pretty_url>
  <para_id>937180</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>937783</id>
  <title>At NCI, A Continued Commitment to Supporting the Best Science</title>
  <langcode>en</langcode>
  <field_short_title>At NCI, Supporting the Best Science</field_short_title>
  <field_page_description>Yesterday, at the AACR annual meeting, Dr. Doug Lowy spoke directly to the research community about his goals as NCI Acting Director. Dr. Lowy said that he plans to continue many of the programs launched by his predecessor, Dr. Harold Varmus, and to sharp</field_page_description>
  <field_feature_card_description>At the AACR annual meeting, Dr. Doug Lowy laid out his goals as NCI Acting Director.</field_feature_card_description>
  <field_list_description>Yesterday, at the AACR annual meeting, Dr. Doug Lowy spoke directly to the research community about his goals as NCI Acting Director. Dr. Lowy said that he plans to continue many of the programs launched by his predecessor, Dr. Harold Varmus, and to sharpen the institute’s focus in several areas where he believes greater progress can offer significant dividends.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-21</field_date_posted>
  <field_date_reviewed>2015-04-21</field_date_reviewed>
  <field_pretty_url>Lowy-AACR</field_pretty_url>
  <para_id>937783</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>937997</id>
  <title>Study Forecasts New Breast Cancer Cases by 2030</title>
  <langcode>en</langcode>
  <field_short_title>Study Forecasts New Breast Cancer Cases by 2030</field_short_title>
  <field_page_description>A new study from NCI researchers is forecasting important trends in the types and molecular makeup of breast cancer cases through 2030, including a reduction in the proportion of cases that are considered to be difficult to treat.</field_page_description>
  <field_feature_card_description>A new study from NCI researchers is forecasting important trends in the types and molecular makeup of breast cancer cases through 2030.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-23</field_date_posted>
  <field_date_reviewed>2015-04-23</field_date_reviewed>
  <field_pretty_url>breast-forecast</field_pretty_url>
  <para_id>937997</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>938462</id>
  <title>Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker</title>
  <langcode>en</langcode>
  <field_short_title>Trial Yields Positive Data on Pembrolizumab for Lung Cancer</field_short_title>
  <field_page_description>Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab (Keytruda®). </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-27</field_date_posted>
  <field_date_reviewed>2015-04-24</field_date_reviewed>
  <field_pretty_url>pembrolizumab-biomarker</field_pretty_url>
  <para_id>938462</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938195</term_id>
  <id>87572</id>
  <title>Adding Targeted Therapy to Treatment for Esophageal Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Adding Targeted Therapy to Treatment for Esophageal Cancer </field_short_title>
  <field_page_description>In this phase III clinical trial, people with confirmed HER2-positive locally advanced esophageal cancer will be randomly assigned to receive preoperative radiation therapy and chemotherapy, with or without trastuzumab. </field_page_description>
  <field_feature_card_description>In this phase III clinical trial, people with confirmed HER2-positive locally advanced esophageal cancer will be randomly assigned to receive preoperative radiation therapy and chemotherapy, with or without trastuzumab. </field_feature_card_description>
  <field_list_description>In this phase III clinical trial, people with confirmed HER2-positive locally advanced esophageal cancer will be randomly assigned to receive preoperative radiation therapy and chemotherapy, with or without trastuzumab. Following surgery, patients assigned to the trastuzumab arm of the study will receive maintenance therapy with trastuzumab for 1 year. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-06-28</field_date_posted>
  <field_date_reviewed>2011-06-29</field_date_reviewed>
  <field_pretty_url>trastuzumab</field_pretty_url>
  <para_id>87572</para_id>
  <related_resource_ids>6494643</related_resource_ids>
  <related_resource_ids>6494644</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938269</term_id>
  <id>316878</id>
  <title>Adjuvant Everolimus for Resected Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Adjuvant Everolimus for Resected Kidney Cancer</field_short_title>
  <field_page_description>In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54 weeks. </field_page_description>
  <field_feature_card_description>In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54 weeks. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-12</field_date_posted>
  <field_date_reviewed>2012-06-12</field_date_reviewed>
  <field_pretty_url>adjuvant-everolimus</field_pretty_url>
  <para_id>316878</para_id>
  <related_resource_ids>6494662</related_resource_ids>
  <related_resource_ids>6494663</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938231</term_id>
  <id>327274</id>
  <title>Study Finds Small Increase in Cancer Risk after Childhood CT Scans</title>
  <langcode>en</langcode>
  <field_short_title>Study Finds Small Increase in Cancer Risk after Childhood CT Scans</field_short_title>
  <field_page_description>A study published in the June 6, 2012, issue of The Lancet shows that radiation exposure from computed tomography (CT) scans in childhood results in very small but increased risks of leukemia and brain tumors in the first decade after exposure.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-07-10</field_date_posted>
  <field_date_reviewed>2012-07-10</field_date_reviewed>
  <field_pretty_url>ct-scans-risk</field_pretty_url>
  <para_id>327274</para_id>
  <related_resource_ids>6485669</related_resource_ids>
  <related_resource_ids>6485670</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938142</term_id>
  <id>315480</id>
  <title>Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery</title>
  <langcode>en</langcode>
  <field_short_title>Low-Dose Radioactive Iodine Destroys Thyroid Tissue Left after Surgery</field_short_title>
  <field_page_description>A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two randomized controlled trials.</field_page_description>
  <field_feature_card_description>A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two randomized controlled trials.</field_feature_card_description>
  <field_list_description>A low dose of radioactive iodine given after surgery for thyroid cancer destroyed (ablated) residual thyroid tissue as effectively as a higher dose, with fewer side effects and less exposure to radiation, according to two European randomized controlled trials published May 3, 2012 in the New England Journal of Medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-07</field_date_posted>
  <field_date_reviewed>2012-06-07</field_date_reviewed>
  <field_pretty_url>low-dose-radiation</field_pretty_url>
  <para_id>315480</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>318053</id>
  <title>Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Expanding the Playing Field: Immune-Based Therapy Shows Potential for Lung, Other Cancers</field_short_title>
  <field_page_description>Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers. </field_page_description>
  <field_feature_card_description>Results from two early-phase clinical trials presented at the 2012 American Society of Clinical Oncology annual meeting provide further evidence that priming the immune system to attack tumors has potential as a treatment for certain cancers. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-15</field_date_posted>
  <field_date_reviewed>2012-06-15</field_date_reviewed>
  <field_pretty_url>pd-1-immunotherapy</field_pretty_url>
  <para_id>318053</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917232</term_id>
  <id>321611</id>
  <title>Clinical Trials and Translational Research Advisory Committee </title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials and Translational Research Advisory Committee </field_short_title>
  <field_page_description>Clinical Trials and Translational Research Advisory Committee, CTAC, is an external oversight committee that advises NCI leadership on its clinical and translational research enterprises.</field_page_description>
  <field_feature_card_description>CTAC advises NCI on its clinical and translational research enterprises.</field_feature_card_description>
  <field_list_description>Learn about CTAC, an external oversight committee that advises NCI leadership on its clinical and translational research enterprises.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-06-21</field_date_posted>
  <field_date_reviewed>2012-06-21</field_date_reviewed>
  <para_id>321611</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>920991</id>
  <title>The RAS Reference Reagents Program: Sharing Resources and Enabling RAS Research</title>
  <langcode>en</langcode>
  <field_short_title>The RAS Reference Reagents Program: Sharing Resources and Enabling RAS Research</field_short_title>
  <field_page_description>Dominic Esposito describes how the preparation of highly qualified reagents for use in the RAS Initiative also supports research in the broader RAS community</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-27</field_date_reviewed>
  <field_pretty_url>ras-reference-reagents-program</field_pretty_url>
  <para_id>920991</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>882603</term_id>
  <id>15428</id>
  <title>Asbestos Exposure and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Asbestos Exposure and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet about asbestos, asbestos-related diseases, and who to contact for more information. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-15</field_date_posted>
  <field_date_reviewed>2017-06-07</field_date_reviewed>
  <field_pretty_url>asbestos-fact-sheet</field_pretty_url>
  <para_id>15428</para_id>
  <related_resource_ids>6934312</related_resource_ids>
  <related_resource_ids>6934313</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>937903</term_id>
  <id>16365</id>
  <title>Adolescents and Young Adults with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>AYA</field_short_title>
  <field_page_description>Information about cancer in adolescents and young adults (AYAs), including treatment, follow-up care, coping, and related research.</field_page_description>
  <field_feature_card_description>Nearly 70,000 people between ages 15 and 39 are diagnosed with cancer each year. Learn about treatment, follow-up care, coping, and related research concerning cancer patients in this age group.</field_feature_card_description>
  <field_list_description>Information about cancer in adolescents and young adults, including treatment, follow-up care, coping, and related research. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2018-01-31</field_date_reviewed>
  <para_id>16365</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>11738</term_id>
  <id>16392</id>
  <title>NCI Cancer Genetics Services Directory</title>
  <langcode>en</langcode>
  <field_short_title>NCI Cancer Genetics Services Directory</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <para_id>16392</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>279438</term_id>
  <id>505608</id>
  <title>Lymphedema and Breast Cancer Surgery</title>
  <langcode>en</langcode>
  <field_short_title>Lymphedema and Breast Cancer Surgery</field_short_title>
  <field_page_description>Lymphedema is a problem that can happen when lymph nodes are removed during breast cancer surgery. Sentinel lymph node biopsy can help lower the chances of lymphedema.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-03-01</field_date_posted>
  <field_date_reviewed>2013-02-05</field_date_reviewed>
  <field_pretty_url>lymphedema</field_pretty_url>
  <para_id>505608</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505611</term_id>
  <id>505752</id>
  <title>Disclaimer of Endorsement and Liability</title>
  <langcode>en</langcode>
  <field_short_title>Disclaimer</field_short_title>
  <field_page_description>As detailed in this disclaimer policy, the National Cancer Institute does not endorse or recommend any commercial product or activity on its websites.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <para_id>505752</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>530171</id>
  <title>Drugs Approved for Rhabdomyosarcoma </title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Rhabdomyosarcoma </field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for rhabdomyosarcoma. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. There may be drugs used in rhabdomyosarcoma that are not listed here.</field_page_description>
  <field_feature_card_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for rhabdomyosarcoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-03-13</field_date_posted>
  <field_date_reviewed>2013-03-08</field_date_reviewed>
  <field_pretty_url>rhabdomyosarcoma</field_pretty_url>
  <para_id>530171</para_id>
  <related_resource_ids>6994924</related_resource_ids>
  <related_resource_ids>6994925</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>532546</id>
  <title>Surgery Choices for Women with DCIS or Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Surgery Choices for Women with DCIS or Breast Cancer</field_short_title>
  <field_page_description>Covers the types of breast surgery, such as breast-sparing surgery and mastectomy, and helps women decide which surgery is the best choice for them.</field_page_description>
  <field_feature_card_description>Covers the types of breast surgery, such as breast-sparing surgery and mastectomy, and helps women decide which surgery is the best choice for them.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2013-03-11</field_date_reviewed>
  <field_pretty_url>surgery-choices</field_pretty_url>
  <para_id>532546</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974316</term_id>
  <id>974320</id>
  <title>Grants to NCI-Designated Cancer Centers</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Centers</field_short_title>
  <field_page_description>NCI Cancer Centers develop more effective approaches to prevent, diagnose, and treat cancer. See the number and dollar amount of Cancer Center awards by state.</field_page_description>
  <field_feature_card_description>See the number and dollar amount of Cancer Center awards, by state.</field_feature_card_description>
  <field_list_description>See the number and dollar amount of Cancer Center awards, by state.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974320</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11914</term_id>
  <id>12879</id>
  <title>Head and Neck Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancers</field_short_title>
  <field_page_description>A fact sheet about the risk factors, symptoms, diagnosis, treatment, follow-up, and rehabilitation for cancers of the head and neck. </field_page_description>
  <field_feature_card_description>A fact sheet about the risk factors, symptoms, diagnosis, treatment, follow-up, and rehabilitation for cancers of the head and neck.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-02-11</field_date_posted>
  <field_date_reviewed>2017-03-29</field_date_reviewed>
  <field_pretty_url>head-neck-fact-sheet</field_pretty_url>
  <para_id>12879</para_id>
  <related_resource_ids>7267828</related_resource_ids>
  <related_resource_ids>7267860</related_resource_ids>
  <related_resource_ids>7267862</related_resource_ids>
  <related_resource_ids>7267863</related_resource_ids>
  <related_resource_ids>7267864</related_resource_ids>
  <related_resource_ids>7267865</related_resource_ids>
  <related_resource_ids>7267901</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>11796</term_id>
  <id>12954</id>
  <title>Cancer Screening</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Screening</field_short_title>
  <field_page_description>Cancer screening is checking for cancer in people who don't have symptoms. Screening tests can help doctors find and treat several types of cancer early, but cancer screening can have harms as well as benefits. </field_page_description>
  <field_list_description>Screening tests can help doctors find and treat several types of cancer early, before they cause symptoms. But screening for cancer can have harms as well as benefits. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2010-09-14</field_date_reviewed>
  <para_id>12954</para_id>
  <related_resource_id>7197131</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>13327</id>
  <title>Tea and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Tea and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet that summarizes the results of studies about tea and cancer prevention. Includes information about the ingredients of tea and safety considerations regarding tea consumption.</field_page_description>
  <field_list_description>A fact sheet that summarizes the results of studies about tea and cancer prevention. It includes information about the ingredients of tea and safety considerations regarding tea consumption.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-11-17</field_date_posted>
  <field_date_reviewed>2010-11-17</field_date_reviewed>
  <field_pretty_url>tea-fact-sheet</field_pretty_url>
  <para_id>13327</para_id>
  <related_resource_ids>6242631</related_resource_ids>
  <related_resource_ids>6242632</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>13782</id>
  <title>Abortion, Miscarriage, and Breast Cancer Risk: 2003 Workshop</title>
  <langcode>en</langcode>
  <field_short_title>Abortion, Miscarriage, and Breast Cancer Risk: 2003 Workshop</field_short_title>
  <field_page_description>Information about an NCI Workshop convened February 24-26, 2003, to provide an integrated scientific assessment of the association between reproductive events and the risk of breast cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2003-02-20</field_date_posted>
  <field_date_reviewed>2010-01-12</field_date_reviewed>
  <field_pretty_url>abortion-miscarriage-risk</field_pretty_url>
  <para_id>13782</para_id>
  <related_resource_ids>6498235</related_resource_ids>
  <related_resource_ids>6498236</related_resource_ids>
  <related_resource_ids>6498237</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>14017</id>
  <title>Electromagnetic Fields and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Electromagnetic Fields and Cancer</field_short_title>
  <field_page_description>A fact sheet about research on electric and magnetic fields and studies examining their potential connection with cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2016-04-04</field_date_reviewed>
  <field_pretty_url>electromagnetic-fields-fact-sheet</field_pretty_url>
  <para_id>14017</para_id>
  <related_resource_id>7196716</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>746613</term_id>
  <id>747150</id>
  <title>NCI Center for Global Health (CGH)</title>
  <langcode>en</langcode>
  <field_short_title>NCI Center for Global Health (CGH)</field_short_title>
  <field_page_description>NCI’s Center for Global Health coordinates research and works with national and international partners to understand and address the burden of cancer worldwide.</field_page_description>
  <field_feature_card_description>Coordinates research and works with partners worldwide to understand and address the global burden of cancer.</field_feature_card_description>
  <field_list_description>The Center for Global Health coordinates research and partners with others worldwide to understand and address the global burden of cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-08</field_date_posted>
  <field_date_reviewed>2014-04-08</field_date_reviewed>
  <para_id>747150</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938103</term_id>
  <id>317032</id>
  <title>Study Suggests New Treatment Option for Some Lymphomas</title>
  <langcode>en</langcode>
  <field_short_title>Study Suggests New Treatment Option for Some Lymphomas</field_short_title>
  <field_page_description>Updated findings from a large European clinical trial indicate that patients with some types of lymphoma could initially be treated with the chemotherapy drug bendamustine (Treanda) and the targeted agent rituximab (Rituxan).</field_page_description>
  <field_feature_card_description>Updated findings from a large European clinical trial indicate that patients with some types of lymphoma could initially be treated with the chemotherapy drug bendamustine (Treanda) and the targeted agent rituximab (Rituxan).</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-13</field_date_posted>
  <field_date_reviewed>2012-06-13</field_date_reviewed>
  <field_pretty_url>bendamustine-rituximab</field_pretty_url>
  <para_id>317032</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938195</term_id>
  <id>317771</id>
  <title>Preoperative Chemotherapy, Radiation Improve Survival in Esophageal Cancer (Updated)</title>
  <langcode>en</langcode>
  <field_short_title>Preoperative Chemotherapy, Radiation Improve Survival in Esophageal Cancer (Updated)</field_short_title>
  <field_page_description>Patients with esophageal cancer who received chemotherapy and radiation before surgery survived, on average, nearly twice as long as patients treated with surgery alone, according to results of a randomized clinical trial published May 31, 2012, in NEJM.</field_page_description>
  <field_feature_card_description>Patients with esophageal cancer who received chemotherapy and radiation before surgery survived, on average, nearly twice as long as patients treated with surgery alone, according to results of a randomized clinical trial published May 31, 2012, in NEJM.</field_feature_card_description>
  <field_list_description>Patients with esophageal cancer who received chemotherapy and radiation before surgery survived, on average, nearly twice as long as patients treated with surgery alone, according to results of a randomized clinical trial published May 31, 2012, in the &lt;i&gt;New England Journal of Medicine&lt;/i&gt;. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-14</field_date_posted>
  <field_date_reviewed>2012-06-14</field_date_reviewed>
  <field_pretty_url>preop-treatment-improves-survival</field_pretty_url>
  <para_id>317771</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>921723</id>
  <title>Making Sense of Key Cancer Reports</title>
  <langcode>en</langcode>
  <field_short_title>Making Sense of Key Cancer Reports</field_short_title>
  <field_page_description>Several regularly released reports, including the Annual Report to the Nation—which is jointly released by NCI and several other organizations—provide information on important cancer trends in the United States.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-30</field_date_reviewed>
  <field_pretty_url>cancer-reports</field_pretty_url>
  <para_id>921723</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>82012</id>
  <title>Drugs Approved for Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Head and Neck Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for head and neck cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-07-12</field_date_posted>
  <field_date_reviewed>2011-05-27</field_date_reviewed>
  <field_pretty_url>head-neck</field_pretty_url>
  <para_id>82012</para_id>
  <related_resource_ids>6991254</related_resource_ids>
  <related_resource_ids>6991262</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>84176</id>
  <title>Eribulin Improves Survival of Women with Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Eribulin Improves Survival of Women with Metastatic Breast Cancer</field_short_title>
  <field_page_description>Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE. </field_page_description>
  <field_feature_card_description>Treatment with eribulin (Halaven™) improved overall survival in women with metastatic breast cancer whose disease progressed despite multiple rounds of prior chemotherapy, according to the results of a phase III clinical trial called EMBRACE. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-10</field_date_posted>
  <field_date_reviewed>2011-06-10</field_date_reviewed>
  <field_pretty_url>eribulin-improves-survival</field_pretty_url>
  <para_id>84176</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938042</term_id>
  <id>87570</id>
  <title>Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients</title>
  <langcode>en</langcode>
  <field_short_title>Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients</field_short_title>
  <field_page_description>Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival. </field_page_description>
  <field_feature_card_description>Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-06-29</field_date_posted>
  <field_date_reviewed>2011-06-29</field_date_reviewed>
  <field_pretty_url>bevacizumab-combo-chemo</field_pretty_url>
  <para_id>87570</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>312922</id>
  <title>Cruciferous Vegetables and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Cruciferous Vegetables and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet that summarizes the results of studies about cruciferous vegetables and cancer. Includes a list of cruciferous vegetables and dietary recommendations.</field_page_description>
  <field_feature_card_description>A fact sheet that summarizes the results of studies about cruciferous vegetables and cancer. It includes a list of cruciferous vegetables and outlines dietary recommendations for vegetables.</field_feature_card_description>
  <field_list_description>A fact sheet that summarizes the results of studies about cruciferous vegetables and cancer. It includes a list of cruciferous vegetables and outlines dietary recommendations for vegetables.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-15</field_date_posted>
  <field_date_reviewed>2012-06-07</field_date_reviewed>
  <field_pretty_url>cruciferous-vegetables-fact-sheet</field_pretty_url>
  <para_id>312922</para_id>
  <related_resource_ids>6187344</related_resource_ids>
  <related_resource_ids>6187347</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939555</id>
  <title>Mexico’s National Cancer Control Plan: From Development to Implementation</title>
  <langcode>en</langcode>
  <field_short_title>Mexico’s National Cancer Control Plan: From Development to Implementation</field_short_title>
  <field_page_description>The National Cancer Institute and the Center for Global Health have had a long-standing and successful partnership with INCan, and at their request are identifying new or enhanced ways to provide technical support by way of resources, training, and collaborative programs to facilitate the implementation of the NCCP.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-29</field_date_reviewed>
  <field_pretty_url>mexico-nccp</field_pretty_url>
  <para_id>939555</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>939623</id>
  <title>Empowering Women through Education and Advocacy in Breast and Cervical Cancer Prevention and Control</title>
  <langcode>en</langcode>
  <field_short_title>Empowering Women through Education and Advocacy in Breast and Cervical Cancer Prevention and Control</field_short_title>
  <field_page_description>Through partnerships with the Peruvian Ministry of Health and the Pan American Health Organization regional office, CGH co-supported the first Women’s Cancer Summit was held in Lima, Peru. This unique training workshop brought primary-level health care providers from 26 districts together with patient advocates and sur</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <field_pretty_url>wcs-peru</field_pretty_url>
  <para_id>939623</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>968013</id>
  <title>Linking International Cancer Screening Efforts</title>
  <langcode>en</langcode>
  <field_short_title>Linking International Cancer Screening Efforts</field_short_title>
  <field_page_description>Drs. Sudha Sivaram and Steve Taplin speak at the International Cancer Screening Network (ICSN) Meeting, which brings together individuals involved in cancer screening research and cancer screening programs from the ICSN’s member countries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-18</field_date_posted>
  <field_date_reviewed>2015-06-18</field_date_reviewed>
  <field_pretty_url>ICSN</field_pretty_url>
  <para_id>968013</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>969383</id>
  <title>Nivolumab Improves Survival for Some Patients with Advanced Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Nivolumab Improves Survival for Some Patients with Advanced Melanoma</field_short_title>
  <field_page_description>A summary of results from an international, double-blind, randomized phase III trial testing the combination of  nivolumab (Opdivo®) and ipilimumab (Yervoy®) against nivolumab alone and ipilimumab alone in patients with advanced melanoma.</field_page_description>
  <field_feature_card_description>Nivolumab plus ipilimumab improves progression-free survival for some patients with advanced melanoma. </field_feature_card_description>
  <field_list_description>In an international, double-blind, randomized phase III trial, the combination of nivolumab and ipilimumab improved progression-free survival compared with ipilimumab alone for patients with advanced melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-26</field_date_posted>
  <field_date_reviewed>2015-06-22</field_date_reviewed>
  <field_pretty_url>nivolumab-checkmate067</field_pretty_url>
  <para_id>969383</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969710</term_id>
  <id>969896</id>
  <title>Funding Allocated to Major NCI Program Areas</title>
  <langcode>en</langcode>
  <field_short_title>Program Structure</field_short_title>
  <field_page_description>See obligations to major NCI program areas, including research; resource development; cancer prevention and control; and program management and support.</field_page_description>
  <field_feature_card_description>See obligations to major NCI program areas  for the 2018 fiscal year.</field_feature_card_description>
  <field_list_description>Find the dollar amount and percent of the total NCI budget by area of budget activity: research, resource development, cancer prevention and control, program management and support.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969896</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>970222</term_id>
  <id>970255</id>
  <title>Research Project Grants (RPGs)</title>
  <langcode>en</langcode>
  <field_short_title>Research Project Grants</field_short_title>
  <field_page_description>See the number of grants requested and awarded by activity code and funding mechanism.</field_page_description>
  <field_feature_card_description>See the number of grants requested and awarded by activity code and funding mechanism.</field_feature_card_description>
  <field_list_description>Find RPG summary data, including the number of RPG awards; RPGs requested, awarded, and the success rate; RPG awards by grant activity codes; and RPGs by funding mechanisms.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-26</field_date_reviewed>
  <para_id>970255</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11876</term_id>
  <id>13937</id>
  <title>Anal Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Anal Cancer</field_short_title>
  <field_page_description>Anal cancer cases have been increasing over several decades. Infection with human papillomavirus (HPV) is the major risk factor for anal cancer. Start here to find information on anal cancer treatment, causes and prevention, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about anal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13937</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>11844</term_id>
  <id>14034</id>
  <title>Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Treatment</field_short_title>
  <field_page_description>Information on cancer treatment methods, specific anticancer drugs, and drug development and approval. Research updates, cancer treatment facilities, and other topics also covered. </field_page_description>
  <field_feature_card_description>Information about types of treatment, side effects, clinical trials, drugs, research updates, and more.</field_feature_card_description>
  <field_list_description>Learn about the different types of cancer treatment, including clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>10978</term_id>
  <id>112133</id>
  <title>Emergency Resources for the Cancer Community</title>
  <langcode>en</langcode>
  <field_short_title>Emergency Resources for the Cancer Community</field_short_title>
  <field_page_description>Information to help prepare for an emergency. Includes resources to continue cancer care, to prepare and update NCI employees and contractors, and NCI contacts for grantees.</field_page_description>
  <field_feature_card_description>Resources for patients and health care providers to continue cancer care, and information for NCI grantees and staff.</field_feature_card_description>
  <field_list_description>Information to help prepare for an emergency. Includes resources for patients and health care providers to continue cancer care, NCI contacts for grantees, and resources to prepare and update NCI employees and contractors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-10-03</field_date_posted>
  <field_date_reviewed>2011-10-03</field_date_reviewed>
  <para_id>112133</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>728762</id>
  <title>Treatment of Solid Tumor Cancers with the Chemotherapy Drug Methotrexate</title>
  <langcode>en</langcode>
  <field_short_title>Methotrexate: Chemotherapy Treatment for Cancer</field_short_title>
  <field_page_description>Prior to the 1950s, treatment for the majority of cancers was limited to either surgery or the use of radiation. The discovery of the use of methotrexate in curing a rare cancer marked the first time a cancer had been cured. This led to the development of many of today’s common cancer treatments. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-30</field_date_posted>
  <field_date_reviewed>2014-03-28</field_date_reviewed>
  <field_pretty_url>methotrexate</field_pretty_url>
  <para_id>728762</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748303</id>
  <title>Funding for Global Research and Training</title>
  <langcode>en</langcode>
  <field_short_title>Funding for Global Research and Training</field_short_title>
  <field_page_description>Find research and training opportunities from NCI's Center for Global Health (CGH).</field_page_description>
  <field_feature_card_description>Explore the research and training opportunities we support globally.</field_feature_card_description>
  <field_list_description>Explore the research and training opportunities we support globally.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <para_id>748303</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>762611</term_id>
  <id>748304</id>
  <title>Global Health Events</title>
  <langcode>en</langcode>
  <field_short_title>Global Health Events</field_short_title>
  <field_page_description>CGH sponsors a number of global health events for both national and international audiences, focused on the open exchange of scientific knowledge.</field_page_description>
  <field_feature_card_description>Discover the latest national and international events that focus on the open exchange of scientific knowledge.</field_feature_card_description>
  <field_list_description>Discover the latest national and international events that focus on the open exchange of scientific knowledge.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <para_id>748304</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915352</term_id>
  <id>759574</id>
  <title>Aspirin to Reduce Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Aspirin to Reduce Cancer Risk</field_short_title>
  <field_page_description>A federal advisory panel supports aspirin to reduce the risk of colorectal cancer, while researchers are investigating whether it may help reduce the risk of other cancers.</field_page_description>
  <field_feature_card_description>Aspirin may reduce colorectal cancer risk, but what about other cancers?</field_feature_card_description>
  <field_list_description>Even as a federal advisory panel has supported the use of aspirin to reduce the risk of colorectal cancer in some people, researchers are investigating how aspirin works against cancer and whether it may help reduce the risk of other cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-04-21</field_date_posted>
  <field_date_reviewed>2014-04-21</field_date_reviewed>
  <field_pretty_url>aspirin-cancer-risk</field_pretty_url>
  <para_id>759574</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>762580</id>
  <title>Lung Cancer Screening Saves Lives: The National Lung Screening Trial</title>
  <langcode>en</langcode>
  <field_short_title>Lung Cancer Screening Saves Lives</field_short_title>
  <field_page_description>NCI funded the National Lung Screening Trial, an eight-year study that used new technology to detect small, aggressive tumors early enough to surgically remove them. This approach reduced lung cancer deaths among participants by 20 percent.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-31</field_date_posted>
  <field_date_reviewed>2014-07-31</field_date_reviewed>
  <field_pretty_url>NLST</field_pretty_url>
  <para_id>762580</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>768744</term_id>
  <id>768770</id>
  <title>Advocacy Announcements and Resources</title>
  <langcode>en</langcode>
  <field_short_title>Announcements and Resources</field_short_title>
  <field_page_description>Get updates from the Office of Advocacy Relations (OAR) and find resources for cancer research advocates.</field_page_description>
  <field_feature_card_description>Updates from OAR and a list of NCI resources for cancer research advocates.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-15</field_date_posted>
  <field_date_reviewed>2014-05-15</field_date_reviewed>
  <para_id>768770</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940066</term_id>
  <id>940071</id>
  <title>Colorectal Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Colorectal Cancer</field_short_title>
  <field_page_description>Colorectal cancer studies often consider colon and rectal cancer together. Worldwide, colorectal cancer is the third most common form of cancer. Find evidence-based information on colon and rectal cancer treatment, causes and prevention, screening, research, genetics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about colorectal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940071</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938028</term_id>
  <id>940233</id>
  <title>Stomach Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on stomach cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940233</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940438</term_id>
  <id>940445</id>
  <title>Leukemia—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Leukemia</field_short_title>
  <field_page_description>There are different types of leukemia, including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia. Find evidence-based information on leukemia treatment, research, genomics, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about leukemia.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940445</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940345</term_id>
  <id>12915</id>
  <title>Intraocular (Eye) Melanoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Intraocular (Eye) Melanoma</field_short_title>
  <field_page_description>Intraocular (uveal) melanoma is a rare cancer that forms in the eye. It usually has no early signs or symptoms. As with melanoma of the skin, risk factors include having fair skin and light-colored eyes. Start here to find information on intraocular melanoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about intraocular (eye) melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>12915</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916666</term_id>
  <id>13184</id>
  <title>Extramural Research</title>
  <langcode>en</langcode>
  <field_short_title>Extramural Research</field_short_title>
  <field_page_description>Five extramural research divisions and several offices and centers monitor and administer NCI’s extramural grant and contract research activities.</field_page_description>
  <field_feature_card_description>Learn how NCI monitors and administers extramural grants and contract research activities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-08</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13184</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952672</term_id>
  <id>13270</id>
  <title>PDQ&amp;reg; Pediatric Treatment Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Treatment Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of pediatric oncology, pediatric surgery, pediatric neuro-oncology, and radiation oncology.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-05-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13270</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>13362</id>
  <title>Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers</title>
  <langcode>en</langcode>
  <field_short_title>Radiation Risks and Pediatric Computed Tomography</field_short_title>
  <field_page_description>Information on the use of pediatric computed tomography (CT), why it is important to minimize the radiation dose to children, and strategies to minimize CT radiation exposure to children.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2002-08-20</field_date_posted>
  <field_date_reviewed>2018-09-04</field_date_reviewed>
  <field_pretty_url>pediatric-ct-scans</field_pretty_url>
  <para_id>13362</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11936</term_id>
  <id>13495</id>
  <title>Neuroblastoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Neuroblastoma</field_short_title>
  <field_page_description>Neuroblastoma is a cancer of immature nerve cells that most often occurs in young children. It usually begins in the adrenal glands but can form in the neck, chest, abdomen, and spine. Start here to find information on neuroblastoma treatment, screening, and research.</field_page_description>
  <field_list_description>NCI's gateway for information about Neuroblastoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13495</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938028</term_id>
  <id>13591</id>
  <title>Chemotherapy Before Surgery May Increase Survival in Stomach Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Chemo Before Surgery May Help Stomach Cancer</field_short_title>
  <field_page_description>Chemotherapy given before surgery for cancer of the lower esophagus and stomach increased the number of patients surviving for five years compared to surgery alone, according to findings presented at the 2007 ASCO meeting in Chicago.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2007-07-09</field_date_posted>
  <field_date_reviewed>2011-10-19</field_date_reviewed>
  <field_pretty_url>preop-chemo</field_pretty_url>
  <para_id>13591</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciHome</CONTENTTYPENAME>
  <term_id>12614</term_id>
  <id>13019</id>
  <title>Cancer.gov Home Page</title>
  <langcode>en</langcode>
  <field_short_title>Comprehensive Cancer Information</field_short_title>
  <field_page_description>Accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13019</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11970</term_id>
  <id>13211</id>
  <title>Thymoma and Thymic Carcinoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Thymoma and Thymic Carcinoma</field_short_title>
  <field_page_description>Thymomas and thymic carcinomas are rare tumors that form in cells on the thymus. Thymomas grow slowly and rarely spread beyond the thymus. Thymic carcinoma grows faster, often spreads to other parts of the body, and is harder to treat. Start here to find information on thymoma and thymic carcinoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about thymoma and thymic carcinoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13211</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11896</term_id>
  <id>13420</id>
  <title>Colorectal Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Colorectal Cancer</field_short_title>
  <field_page_description>Colorectal cancer often begins as a growth called a polyp inside the colon or rectum. Finding and removing polyps can prevent colorectal cancer. Start here to find information on colon and rectal cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about colorectal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13420</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11882</term_id>
  <id>13598</id>
  <title>Primary Bone Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Primary Bone Cancer</field_short_title>
  <field_page_description>A fact sheet about the diagnosis and treatment of cancers that develop in the bones.</field_page_description>
  <field_feature_card_description>A fact sheet about the diagnosis and treatment of cancers that develop in the bones.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-06</field_date_posted>
  <field_date_reviewed>2018-11-20</field_date_reviewed>
  <field_pretty_url>bone-fact-sheet</field_pretty_url>
  <para_id>13598</para_id>
  <related_resource_ids>7241091</related_resource_ids>
  <related_resource_ids>7241092</related_resource_ids>
  <related_resource_ids>7241093</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11964</term_id>
  <id>13641</id>
  <title>Stomach (Gastric) Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Stomach (Gastric) Cancer</field_short_title>
  <field_page_description>Stomach (gastric) cancer occurs when cancer cells form in the lining of the stomach. Risk factors include smoking, infection with H. pylori bacteria, and certain inherited conditions. Start here to find information on stomach (gastric) cancer treatment, causes and prevention, screening, research, and statistics. </field_page_description>
  <field_feature_card_description>Risk factors include &lt;i&gt;Helicobacter pylori&lt;/i&gt; infection of the stomach, smoking, and a diet high in salted or smoked foods.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about stomach (gastric) cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13641</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>13720</id>
  <title>Early Reproductive Events and Breast Cancer: Workshop Statement</title>
  <langcode>en</langcode>
  <field_short_title>Early Reproductive Events/Breast Cancer Statement</field_short_title>
  <field_page_description>This scientific workshop was convened by the National Cancer Institute in 2003 to present and review the information available on the risk of breast cancer associated with pregnancy. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2003-02-26</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <field_pretty_url>ere-workshop-statement</field_pretty_url>
  <para_id>13720</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911160</term_id>
  <id>13730</id>
  <title>End-of-Life Care for People Who Have Cancer</title>
  <langcode>en</langcode>
  <field_short_title>End-of-Life Care</field_short_title>
  <field_page_description>A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life.</field_page_description>
  <field_feature_card_description>A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-09-01</field_date_posted>
  <field_date_reviewed>2012-05-10</field_date_reviewed>
  <field_pretty_url>care-fact-sheet</field_pretty_url>
  <para_id>13730</para_id>
  <related_resource_ids>7123360</related_resource_ids>
  <related_resource_ids>7123361</related_resource_ids>
  <related_resource_ids>7123365</related_resource_ids>
  <related_resource_ids>7123366</related_resource_ids>
  <related_resource_ids>7123368</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11954</term_id>
  <id>13780</id>
  <title>Prostate Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Prostate Cancer</field_short_title>
  <field_page_description>Prostate cancer is the most common cancer among men in the United States. Prostate cancer usually grows very slowly, and finding and treating it before symptoms occur may not improve men’s health. Start here to find information on prostate cancer treatment, research, causes and prevention, screening, and statistics.</field_page_description>
  <field_feature_card_description>Prostate cancer is the most common cancer in men, but often has no early symptoms. </field_feature_card_description>
  <field_list_description>NCI's gateway for information about Prostate Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13780</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>922822</term_id>
  <id>951125</id>
  <title>NCI Events</title>
  <langcode>en</langcode>
  <field_short_title>Events</field_short_title>
  <field_page_description>Find upcoming scientific conferences where NCI will be exhibiting, NCI-hosted lectures, scientific meetings, board meetings, and live social media Twitter chat events involving NCI and our partners.</field_page_description>
  <field_feature_card_description>NCI hosts scientific meetings and lectures, advisory board meetings, and other events, including live social media Twitter chats, throughout the year.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-05</field_date_posted>
  <field_date_reviewed>2015-05-05</field_date_reviewed>
  <para_id>951125</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938227</term_id>
  <id>952011</id>
  <title>Metastatic Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Metastatic Cancer Research</field_short_title>
  <field_page_description>Find research articles about metastatic cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-12</field_date_posted>
  <field_date_reviewed>2015-05-08</field_date_reviewed>
  <para_id>952011</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>954351</id>
  <title>Grantee Spotlight: Monica Baskin, Ph.D. - Studying Weight Loss for Cancer Prevention in African-American Women</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Monica Baskin, Ph.D. - Studying Weight Loss for Cancer Prevention</field_short_title>
  <field_page_description>Dr. Monica Baskin tests the efficacy of evidence-based community strategies for obesity prevention and elimination of cancer health disparities among African-American women living in the Deep South.</field_page_description>
  <field_feature_card_description>Dr. Baskin researches obesity prevention &amp; cancer health disparities elimination.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2015-05-15</field_date_reviewed>
  <field_pretty_url>baskin-spotlight</field_pretty_url>
  <para_id>954351</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>961751</id>
  <title>Most American Adults Do Not Use Sunscreen Regularly </title>
  <langcode>en</langcode>
  <field_short_title>American Adults Not Using Sunscreen</field_short_title>
  <field_page_description>The majority of Americans are not using sunscreen regularly to protect their skin from damage caused by the sun’s ultraviolet (UV) rays, according to a new survey.</field_page_description>
  <field_feature_card_description>Many Americans are not using sunscreen regularly to protect their skin from sun damage.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-01</field_date_posted>
  <field_date_reviewed>2015-05-29</field_date_reviewed>
  <field_pretty_url>no-sunscreen</field_pretty_url>
  <para_id>961751</para_id>
  <related_resource_id>6572878</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>962982</id>
  <title>International Partnerships for Clinical Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>International Partnerships for Clinical Cancer Research</field_short_title>
  <field_page_description>CGH co-sponsors the 2015 International Symposium on Cancer Clinical Trials and related meetings held in partnership with the Japanese National Cancer Center (JNCC) and Embassies of France, Korea, United Kingdom (UK), and United States (US) in Tokyo on May 14 - 15, 2015.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-03</field_date_posted>
  <field_date_reviewed>2015-06-03</field_date_reviewed>
  <field_pretty_url>clinicalcancerresearch</field_pretty_url>
  <para_id>962982</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>963867</id>
  <title>Study Finds Storytelling Helps Overcome Cervical Cancer Screening Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Storytelling Helps Overcome Cervical Cancer Screening Disparities</field_short_title>
  <field_page_description>Using a storytelling approach to educate women about cervical cancer screening eliminated disparities in attitudes toward screening and behavior, according to a new study.</field_page_description>
  <field_feature_card_description>A storytelling approach to educate women about cervical cancer screening eliminated disparities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-10</field_date_posted>
  <field_date_reviewed>2015-06-10</field_date_reviewed>
  <field_pretty_url>cervical-screening-narrative-video</field_pretty_url>
  <para_id>963867</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969704</term_id>
  <id>969705</id>
  <title>Most Recent Reported Fiscal Year Budget</title>
  <langcode>en</langcode>
  <field_short_title>Recent Fiscal Year Budget</field_short_title>
  <field_page_description>See NCI obligations resulting from appropriated and reimbursable funding for the recently reported fiscal year.</field_page_description>
  <field_feature_card_description>See actual NCI obligations for the recently reported fiscal year.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969705</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>969990</id>
  <title>Special Spotlight: The Alabama Project Celebrates Survivors and Their Communities</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: The Alabama Project Celebrates Survivors and Their Communities</field_short_title>
  <field_page_description>In recognition of cancer survivors and their families, CRCHD celebrates cancer survivorship with a focus in on The Alabama Project and its visual storytelling of the powerful impact of community in survivorship.</field_page_description>
  <field_feature_card_description>CRCHD celebrates cancer survivorship with a focus in on The Alabama Project.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-25</field_date_posted>
  <field_date_reviewed>2015-06-25</field_date_reviewed>
  <field_pretty_url>alabama-project</field_pretty_url>
  <para_id>969990</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1124596</term_id>
  <id>1124649</id>
  <title>Three-dimensional Organoid Models to Study Breast Cancer Progression</title>
  <langcode>en</langcode>
  <field_short_title>3D Organoid Models to Study Breast Cancer Progression </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-31</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <para_id>1124649</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1126287</term_id>
  <id>1126299</id>
  <title>Cancer Moonshot&amp;#8480; – FY 2017, FY 2018 and FY 2019 Funding Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot - Closed Funding Opportunities </field_short_title>
  <field_page_description>Find funding opportunities that were available in previous fiscal years to align with the efforts of the Cancer Moonshot. </field_page_description>
  <field_list_description>This page highlights the funding opportunities that were available in previous fiscal years to align with the efforts of the Cancer Moonshot."</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-10-11</field_date_reviewed>
  <para_id>1126299</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919157</term_id>
  <id>1127125</id>
  <title>Stopping Multiple Myeloma in Its Tracks</title>
  <langcode>en</langcode>
  <field_short_title>Stopping Multiple Myeloma in Its Tracks-Valerie Winston</field_short_title>
  <field_page_description>The results of standard tests indicated that Valerie Winston was at risk for multiple myeloma. Read how an NCI combination therapy clinical trial helped her avoid the full impact of multiple myeloma.</field_page_description>
  <field_feature_card_description>Thanks to a clinical trial, Valerie Winston never had to experience multiple myeloma’s full impact. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <field_pretty_url>valerie-winston-clinical-trial-multiple-myeloma</field_pretty_url>
  <para_id>1127125</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1107074</term_id>
  <id>1127139</id>
  <title>Developing the First Precision Immunotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Developing the First Precision Immunotherapy</field_short_title>
  <field_page_description>Learn about the NCI-funded research that enabled the first FDA approved precision medicine- the immune checkpoint inhibitor pembrolizumab.</field_page_description>
  <field_feature_card_description>In May 2017, FDA approved the first drug to treat tumors based on their genetic characteristics, regardless of where in the body the cancer originated.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <field_pretty_url>pembrolizumab-first-precision-immunotherapy</field_pretty_url>
  <para_id>1127139</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129040</term_id>
  <id>1129041</id>
  <title>Using TCGA Data, Resources, and Materials</title>
  <langcode>en</langcode>
  <field_short_title>Using TCGA Data, Resources, and Materials</field_short_title>
  <field_page_description>Using TCGA in your research? Learn about the data and other resources available.</field_page_description>
  <field_feature_card_description>Learn about the data and resources available for using TCGA in your research.</field_feature_card_description>
  <field_list_description>An overview of information relevant to using TCGA data and resources in your research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-10-30</field_date_reviewed>
  <para_id>1129041</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1130551</id>
  <title>Gene Tied to Alzheimer’s May Be Associated with Cancer-Related Cognitive Problems</title>
  <langcode>en</langcode>
  <field_short_title>Alzheimer’s Gene May Play Role in Chemobrain </field_short_title>
  <field_page_description>Findings from a clinical study and a mouse study may shed light on genetic risk factors for developing cancer-related cognitive problems in older breast cancer survivors. The results suggest a gene associated with Alzheimer’s disease may play a role.
</field_page_description>
  <field_feature_card_description>Studies identify potential genetic factor for cancer-related cognitive problems.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-09</field_date_posted>
  <field_date_reviewed>2018-11-09</field_date_reviewed>
  <field_pretty_url>chemobrain-cancer-survivors-alzheimers-gene</field_pretty_url>
  <para_id>1130551</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>1130633</id>
  <title>TEST - What's New in Lung Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>TEST - What's New in Lung Cancer Research</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-29</field_date_posted>
  <field_date_reviewed>2018-11-09</field_date_reviewed>
  <field_pretty_url>draft</field_pretty_url>
  <para_id>1130633</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133223</id>
  <title>Desmoid tumor</title>
  <langcode>en</langcode>
  <field_short_title>Desmoid tumor</field_short_title>
  <field_page_description>Desmoid tumors grow from the connective tissue in your body. Desmoid tumors are benign, which means they are not cancer, but they are very difficult to get rid of and can be painful to live with. Learn more about diagnosis, treatments, and prognosis for desmoid tumors.</field_page_description>
  <field_list_description>Desmoid tumors grow from the connective tissue in your body. Desmoid tumors are benign, which means they are not cancer, but they are very difficult to get rid of and can be painful to live with.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>desmoid-tumor</field_pretty_url>
  <para_id>1133223</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133224</id>
  <title>Desmoplastic small round cell tumor</title>
  <langcode>en</langcode>
  <field_short_title>Desmoplastic small round cell tumor</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>desmoplastic-small-round-cell-tumor</field_pretty_url>
  <para_id>1133224</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>969476</id>
  <title>Many Women with Dense Breasts May Not Need Additional Screening</title>
  <langcode>en</langcode>
  <field_short_title>Many Women with Dense Breasts May Not Need Additional Screening</field_short_title>
  <field_page_description>Breast density is just one of several factors that should be taken into account in determining the need for additional cancer screening, study suggests.</field_page_description>
  <field_feature_card_description>Inclusion of risk model helps identify need for further screening.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-22</field_date_posted>
  <field_date_reviewed>2015-06-22</field_date_reviewed>
  <field_pretty_url>dense-breasts-screening</field_pretty_url>
  <para_id>969476</para_id>
  <related_resource_ids>6915576</related_resource_ids>
  <related_resource_ids>6915603</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>969701</term_id>
  <id>969702</id>
  <title>NCI Budget Summary Data</title>
  <langcode>en</langcode>
  <field_short_title>Budget Summary Data</field_short_title>
  <field_page_description>Find detailed data about funds available to NCI and information about how NCI obligated its funding this fiscal year.</field_page_description>
  <field_feature_card_description>Find a listing of data about how  NCI obligated its funding this fiscal year.</field_feature_card_description>
  <field_list_description>A listing of detailed data about funds available to NCI and information about how NCI obligated its funding this year. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-24</field_date_reviewed>
  <para_id>969702</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>970159</term_id>
  <id>970160</id>
  <title>NCI Extramural Programs</title>
  <langcode>en</langcode>
  <field_short_title>Extramural Programs</field_short_title>
  <field_page_description>The majority of NCI's budget funds extramural grants and contracts.  Find information about extramural funding by grant activity, institution, state, and country.</field_page_description>
  <field_feature_card_description>Find information about NCI extramural funding by grant activity, institution, state, and country.</field_feature_card_description>
  <field_list_description>The majority of NCI's budget funds extramural grants and contracts. Find information about funding by grant activity, institution, state, and country.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-06-26</field_date_reviewed>
  <para_id>970160</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>12891</id>
  <title>Cell Phones and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Cell Phones and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that outlines the available evidence regarding use of cellular/mobile telephones and cancer risk.</field_page_description>
  <field_feature_card_description>A fact sheet that outlines evidence about use of cellular/mobile telephones and cancer risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-14</field_date_posted>
  <field_date_reviewed>2018-11-01</field_date_reviewed>
  <field_pretty_url>cell-phones-fact-sheet</field_pretty_url>
  <para_id>12891</para_id>
  <related_resource_ids>7204778</related_resource_ids>
  <related_resource_ids>7204780</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915370</term_id>
  <id>13089</id>
  <title>Home Care Nursing Improves Cancer Symptom Management</title>
  <langcode>en</langcode>
  <field_short_title>Home Care Nursing Improves Cancer Symptom Management</field_short_title>
  <field_page_description>Home care nursing (HCN) improves the management of symptoms in breast and colorectal cancer patients who take the oral chemotherapy drug capecitabine, according to a study published online November 16 in the &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt;.</field_page_description>
  <field_list_description>Home care nursing (HCN) improves the management of symptoms in breast and colorectal cancer patients who take the oral chemotherapy drug capecitabine, according to a study published online November 16, 2009, in the &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt;.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-12-16</field_date_posted>
  <field_date_reviewed>2009-12-16</field_date_reviewed>
  <field_pretty_url>home-care-symptom-management</field_pretty_url>
  <para_id>13089</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>13128</id>
  <title>Inflammatory Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Inflammatory Breast Cancer</field_short_title>
  <field_page_description>A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-15</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <field_pretty_url>ibc-fact-sheet</field_pretty_url>
  <para_id>13128</para_id>
  <related_resource_ids>7233001</related_resource_ids>
  <related_resource_ids>7233011</related_resource_ids>
  <related_resource_ids>7233027</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>903750</term_id>
  <id>13674</id>
  <title>Understanding Laboratory Tests</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Laboratory Tests</field_short_title>
  <field_page_description>A fact sheet that describes the role of screening and diagnostic laboratory tests. Lists the common tests used in cancer medicine and discusses how to interpret test results.</field_page_description>
  <field_feature_card_description>Understanding Laboratory Tests</field_feature_card_description>
  <field_list_description>A fact sheet that describes the role of screening and diagnostic laboratory tests. Includes a list of the common tests used in cancer medicine and a brief discussion of how to interpret test results.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-12-30</field_date_posted>
  <field_date_reviewed>2013-12-11</field_date_reviewed>
  <field_pretty_url>understanding-lab-tests-fact-sheet</field_pretty_url>
  <para_id>13674</para_id>
  <related_resource_ids>6188066</related_resource_ids>
  <related_resource_ids>6188067</related_resource_ids>
  <related_resource_ids>6188068</related_resource_ids>
  <related_resource_ids>6188069</related_resource_ids>
  <related_resource_ids>6188070</related_resource_ids>
  <related_resource_ids>6188071</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>910891</term_id>
  <id>13704</id>
  <title>What Is Cancer?</title>
  <langcode>en</langcode>
  <field_short_title>What Is Cancer?</field_short_title>
  <field_page_description>Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.</field_page_description>
  <field_feature_card_description>Understand how cancer cells differ from normal cells and why they grow and spread.</field_feature_card_description>
  <field_list_description>Understand how cancer cells differ from normal cells and genetics changes that cause cancer to grow and spread.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2007-09-17</field_date_posted>
  <field_date_reviewed>2007-03-28</field_date_reviewed>
  <para_id>13704</para_id>
  <related_resource_ids>7267630</related_resource_ids>
  <related_resource_ids>7267631</related_resource_ids>
  <related_resource_ids>7267633</related_resource_ids>
  <related_resource_ids>7267648</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>13001</id>
  <title>"Light" Cigarettes and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>"Light" Cigarettes and Cancer Risk</field_short_title>
  <field_page_description>This fact sheet answers questions about the health effects of smoking "low-tar," "mild," or "light" cigarettes.</field_page_description>
  <field_list_description>A fact sheet that answers questions about the health effects of smoking "low-tar," "mild," or "light" cigarettes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-08-18</field_date_posted>
  <field_date_reviewed>2010-10-28</field_date_reviewed>
  <field_pretty_url>light-cigarettes-fact-sheet</field_pretty_url>
  <para_id>13001</para_id>
  <related_resource_ids>6147625</related_resource_ids>
  <related_resource_ids>6147626</related_resource_ids>
  <related_resource_ids>6147627</related_resource_ids>
  <related_resource_ids>6147628</related_resource_ids>
  <related_resource_ids>6147629</related_resource_ids>
  <related_resource_ids>6147630</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>829</term_id>
  <id>13367</id>
  <title>About Cancer</title>
  <langcode>en</langcode>
  <field_short_title>About Cancer</field_short_title>
  <field_page_description>Information from the National Cancer Institute about cancer treatment, prevention, screening, genetics, causes, and how to cope with cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13367</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952658</term_id>
  <id>13866</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Screening/Detection (Testing for Cancer)</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Screening</field_short_title>
  <field_page_description>Tests or procedures that detect specific types of cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13866</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952664</term_id>
  <id>13879</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Integrative, Alternative, and Complementary Therapies</title>
  <langcode>en</langcode>
  <field_short_title>Integrative Therapies</field_short_title>
  <field_page_description>Information about complementary and alternative forms of medicine, or CAM, for cancer patients. </field_page_description>
  <field_list_description>Information about complementary and alternative forms of treatment for cancer patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-01</field_date_posted>
  <field_date_reviewed>2016-04-12</field_date_reviewed>
  <para_id>13879</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>930690</term_id>
  <id>13917</id>
  <title>Visitor Information</title>
  <langcode>en</langcode>
  <field_short_title>Visitor Information</field_short_title>
  <field_page_description>Visitor information including directions by car and public transportation to NCI in Rockville, MD, and contact details for NCI campuses and the National Institutes of Health in Bethesda, MD.</field_page_description>
  <field_list_description>Planning to visit NCI in Rockville, MD or the National Institutes of Health (NIH) in Bethesda, MD? Find helpful visitor information including directions and contact details.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2010-02-22</field_date_reviewed>
  <para_id>13917</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11958</term_id>
  <id>109372</id>
  <title>What Does Melanoma Look Like?</title>
  <langcode>en</langcode>
  <field_short_title>What Does Melanoma Look Like?</field_short_title>
  <field_page_description>Several photographs of melanoma, the deadliest form of skin cancer. </field_page_description>
  <field_feature_card_description>Several photographs of melanoma, the deadliest form of skin cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-13</field_date_posted>
  <field_pretty_url>melanoma-photos</field_pretty_url>
  <para_id>109372</para_id>
  <related_resource_ids>6562568</related_resource_ids>
  <related_resource_ids>6562570</related_resource_ids>
  <related_resource_ids>6562571</related_resource_ids>
  <related_resource_ids>6562577</related_resource_ids>
  <related_resource_ids>6562578</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11958</term_id>
  <id>119953</id>
  <title>Common Moles, Dysplastic Nevi, and Risk of Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Common Moles, Dysplastic Nevi, and Risk of Melanoma</field_short_title>
  <field_page_description>A fact sheet about moles and how some moles may be related to melanoma, the most serious type of skin cancer. Includes photos of differences between moles and cancer.</field_page_description>
  <field_feature_card_description>Photos and facts about moles, cancer, and the risk factors for melanoma.</field_feature_card_description>
  <field_list_description>A fact sheet about moles and how some moles may be related to melanoma, which is the most serious type of skin cancer. The fact sheet includes photos of differences between moles and cancer, and discusses risk factors for melanoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-02</field_date_posted>
  <field_date_reviewed>2018-04-27</field_date_reviewed>
  <field_pretty_url>moles-fact-sheet</field_pretty_url>
  <para_id>119953</para_id>
  <related_resource_ids>6955616</related_resource_ids>
  <related_resource_ids>6955617</related_resource_ids>
  <related_resource_ids>6955618</related_resource_ids>
  <related_resource_ids>6955619</related_resource_ids>
  <related_resource_ids>6955620</related_resource_ids>
  <related_resource_ids>6955785</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>730874</id>
  <title>Preventing Cervical Cancer: The Development of HPV Vaccines</title>
  <langcode>en</langcode>
  <field_short_title>Preventing Cervical Cancer with HPV Vaccines</field_short_title>
  <field_page_description>Cervical cancer can be prevented with HPV vaccines. NCI-supported researchers helped establish HPV as a cause of cervical cancer. They also helped create the first HPV vaccines, were involved in the vaccine trials, and contribute to ongoing studies. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-04-03</field_date_posted>
  <field_date_reviewed>2014-03-31</field_date_reviewed>
  <field_pretty_url>hpv-vaccines</field_pretty_url>
  <para_id>730874</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762660</id>
  <title>NCI Affordable Cancer Technologies Program </title>
  <langcode>en</langcode>
  <field_short_title>Affordable Technologies</field_short_title>
  <field_page_description>CGH supports the development and validation of affordable technology to increase access to cancer prevention, screening, detection, diagnosis and treatment in LMICs.</field_page_description>
  <field_feature_card_description>CGH supports the development and validation of low-cost technology to increase access to cancer prevention, screening, detection, diagnosis and treatment in LMICs.</field_feature_card_description>
  <field_list_description>CGH supports the development and validation of affordable technology to increase access to cancer prevention, screening, detection, diagnosis and treatment in LMICs, especially in rural areas with limited infrastructure. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-16</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>affordable-cancer-technology</field_pretty_url>
  <para_id>762660</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762661</id>
  <title>Trans-NIH Regional Grant Writing &amp; Scientific Peer Review Workshops</title>
  <langcode>en</langcode>
  <field_short_title>Trans-NIH Regional Grant Writing &amp; Scientific Peer Review Workshops</field_short_title>
  <field_page_description>The Trans-NIH Regional Grant Writing &amp; Scientific Peer Review Workshops increase the participation of scientists from LMICs in the research grant process.</field_page_description>
  <field_feature_card_description>The Trans-NIH Regional Grant Writing &amp; Scientific Peer Review Workshops increase the participation of scientists from LMICs in the research grant process.</field_feature_card_description>
  <field_list_description>CGH organizes The Regional Grant Writing &amp; Scientific Peer Review Workshops in coordination with several Institutes and Centers across NIH to increase the participation of scientists from LMICs in the research grant process; develop strategies for sustainable research support and collaborations; and use competitive research as a tool to address global health issues. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>trans-nih-regional-workshops</field_pretty_url>
  <para_id>762661</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770112</term_id>
  <id>770110</id>
  <title>What We Do</title>
  <langcode>en</langcode>
  <field_short_title>What We Do</field_short_title>
  <field_page_description>To advance global cancer research, build expertise, improve cancer prevention and cancer screening in low to middle income countries (LMICs), and reduce cancer deaths worldwide, CGH facilitates research efforts through collaboration with U.S. government agencies, foreign governments, non-government organizations, and p</field_page_description>
  <field_feature_card_description>CGH advances global cancer research to reduce cancer deaths worldwide</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-05-19</field_date_reviewed>
  <para_id>770110</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770439</term_id>
  <id>770467</id>
  <title>Gynecologic Cancer Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Gynecologic Cancer Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770467</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>912173</id>
  <title>FDA Approves Lenvatinib for Radioactive Iodine-Refractory Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Lenvatinib for Radioactive Iodine-Refractory Thyroid Cancer</field_short_title>
  <field_page_description>The FDA has approved lenvatinib (Lenvima) to treat some patients with the most common type of thyroid cancer.</field_page_description>
  <field_feature_card_description>The FDA has approved lenvatinib (Lenvima) to treat some patients with the most common type of thyroid cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-02</field_date_posted>
  <field_date_reviewed>2015-03-02</field_date_reviewed>
  <field_pretty_url>fda-approves-lenvima</field_pretty_url>
  <para_id>912173</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916947</term_id>
  <id>912885</id>
  <title>Radiation Therapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Radiation Therapy </field_short_title>
  <field_page_description>Radiation therapy is a type of cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. Learn about the types of radiation, why side effects happen, which ones you might have, and more.</field_page_description>
  <field_feature_card_description>Learn about the types of radiation used to treat cancer, why side effects happen, which ones you might have, and more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-05-01</field_date_reviewed>
  <para_id>912885</para_id>
  <related_resource_ids>7262313</related_resource_ids>
  <related_resource_ids>7262314</related_resource_ids>
  <related_resource_ids>7262317</related_resource_ids>
  <related_resource_ids>7262324</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>914470</id>
  <title>Conference Report: Pursuing Progress Against HIV-Related Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Conference Report: Pursuing Progress Against HIV-Related Cancers</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on the recent annual Conference on Retroviruses and Opportunistic Infections, where investigators presented important new findings on HIV-related cancers.</field_page_description>
  <field_list_description>At the recent annual Conference on Retroviruses and Opportunistic Infections, several NCI researchers and NCI-funded investigators presented important new findings on HIV-related cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-09</field_date_posted>
  <field_date_reviewed>2015-03-09</field_date_reviewed>
  <field_pretty_url>conference-report-hiv</field_pretty_url>
  <para_id>914470</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914806</term_id>
  <id>915261</id>
  <title>Introduction to the Grants Process</title>
  <langcode>en</langcode>
  <field_short_title>Introduction to Grants Process</field_short_title>
  <field_page_description>Information about the NCI grants process, including recipient eligibility, the different people involved, and information about funding.</field_page_description>
  <field_feature_card_description>This overview includes information about recipient eligibility, funding types, applying for a grant, and more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915261</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915355</term_id>
  <id>915356</id>
  <title>Age and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Age</field_short_title>
  <field_page_description>Advancing age is the most important risk factor for cancer overall, and for many individual cancer types.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915356</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911172</term_id>
  <id>915359</id>
  <title>Infectious Agents</title>
  <langcode>en</langcode>
  <field_short_title>Infectious Agents</field_short_title>
  <field_page_description>Certain infectious agents, including viruses, bacteria, and parasites, can cause cancer in infected people or increase the risk that cancer will form.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915359</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915634</term_id>
  <id>915680</id>
  <title>Cancer Treatment Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Treatment Research</field_short_title>
  <field_page_description>The development of more effective and less toxic treatments is fundamental to improving outcomes for patients with cancer. NCI is leading efforts on several fronts to develop and evaluate new cancer treatments.</field_page_description>
  <field_feature_card_description>NCI is leading efforts on several fronts to develop and evaluate new cancer treatments.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-07</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915680</para_id>
  <related_resource_ids>7227884</related_resource_ids>
  <related_resource_ids>7227887</related_resource_ids>
  <related_resource_ids>7227891</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>916489</id>
  <title>More Evidence That a Wild-Type KRAS Allele Plays a Role in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>More Evidence That a Wild-Type KRAS Allele Plays a Role in Cancer</field_short_title>
  <field_page_description>Jim Hartley of the RAS Initiative discusses evidence from mouse models that a wild type KRAS allele modulates early selection of Q61L or Q61R mutants in lung cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <field_pretty_url>kras-allele</field_pretty_url>
  <para_id>916489</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>916659</id>
  <title>Grantee Spotlight: Katherine Briant, MPH, CHES - Bridging Community Cancer Education Efforts with Health Disparities Research</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Katherine Briant, MPH, CHES</field_short_title>
  <field_page_description>Katherine Briant, MPH, CHES, is Community Health Educator in NCI’s National Outreach Network links NCI-supported outreach and community education efforts and cancer health disparities research and training programs.</field_page_description>
  <field_feature_card_description>Ms. Briant links outreach/community education efforts and cancer health disparities research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-22</field_date_posted>
  <field_date_reviewed>2014-08-22</field_date_reviewed>
  <field_pretty_url>briant-spotlight-blog</field_pretty_url>
  <para_id>916659</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11962</term_id>
  <id>13832</id>
  <title>Soft Tissue Sarcoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Soft Tissue Sarcoma</field_short_title>
  <field_page_description>Soft tissue sarcoma is a cancer that starts in soft tissues like muscle, tendons, fat, lymph vessels, blood vessels, and nerves. These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. Start here to find information on soft tissue sarcoma treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about soft tissue sarcoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13832</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11942</term_id>
  <id>13916</id>
  <title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Ovarian, Fallopian Tube, and Primary Peritoneal Cancer</field_short_title>
  <field_page_description>Ovarian epithelial cancer is the most common type of ovarian cancer. Cancer can also form at the end of the fallopian tube near the ovary or the peritoneum and spread to the ovary. Start here to find information on ovarian cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_feature_card_description>Because it's hard to diagnose early, ovarian cancer is often found at an advanced stage. Read about treatment, research, and more.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13916</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11738</term_id>
  <id>13982</id>
  <title>Description of NCI Cancer Genetics Services Directory</title>
  <langcode>en</langcode>
  <field_short_title>Description of NCI Cancer Genetics Services Directory</field_short_title>
  <field_page_description>Background and Purpose of PDQ Cancer Genetics Services Directory</field_page_description>
  <field_list_description>Description of the cancer genetics services directory and the qualifications of the professionals who are included.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <field_pretty_url>description</field_pretty_url>
  <para_id>13982</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911142</term_id>
  <id>13986</id>
  <title>Oral Contraceptives and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Oral Contraceptives and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet about research on the association of oral contraceptive use (birth control pills) with risk of various cancers.</field_page_description>
  <field_feature_card_description>Learn what the research says about cancer risk associated with the use of birth control pills. </field_feature_card_description>
  <field_list_description>A fact sheet about research on the association of oral contraceptive use with risk of various cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-01</field_date_posted>
  <field_date_reviewed>2018-02-22</field_date_reviewed>
  <field_pretty_url>oral-contraceptives-fact-sheet</field_pretty_url>
  <para_id>13986</para_id>
  <related_resource_id>7267936</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11958</term_id>
  <id>109373</id>
  <title>What Does a Mole Look Like?</title>
  <langcode>en</langcode>
  <field_short_title>What Does a Mole Look Like?</field_short_title>
  <field_page_description>Photographs of Common Moles and Dysplastic Nevi.</field_page_description>
  <field_feature_card_description>Photographs of Common Moles and Dysplastic Nevi.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-13</field_date_posted>
  <field_pretty_url>mole-photos</field_pretty_url>
  <para_id>109373</para_id>
  <related_resource_ids>6562552</related_resource_ids>
  <related_resource_ids>6562553</related_resource_ids>
  <related_resource_ids>6562555</related_resource_ids>
  <related_resource_ids>6562567</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748499</id>
  <title>CGH Short Term Scientist Exchange Program (STSEP)</title>
  <langcode>en</langcode>
  <field_short_title>CGH Short Term Scientist Exchange Program (STSEP)</field_short_title>
  <field_page_description>STSEP promotes collaborative research between established U.S. and foreign scientists from low, middle, and upper-middle income countries (LMICs) by supporting, in part, exchange visits of cancer researchers between U.S. and foreign laboratories.</field_page_description>
  <field_feature_card_description>STSEP promotes collaborative research between established U.S. and foreign scientists from LMICs by supporting exchange visits of cancer researchers between U.S. and foreign laboratories.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <field_pretty_url>stsep</field_pretty_url>
  <para_id>748499</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748890</id>
  <title>Cancer Prevention Fellowship Program</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Prevention Fellowship Program</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-10</field_date_reviewed>
  <field_pretty_url>prevention-fellowship</field_pretty_url>
  <para_id>748890</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>989278</id>
  <title>FDA Approves Sonidegib for Some Patients with Advanced Basal Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Sonidegib Approved for Advanced Basal Cell Carcinoma</field_short_title>
  <field_page_description>The FDA has approved sonidegib for the treatment of patients with locally advanced basal cell carcinoma.</field_page_description>
  <field_feature_card_description>FDA approval provides a new option for this hard-to-treat skin cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-02</field_date_posted>
  <field_date_reviewed>2015-09-02</field_date_reviewed>
  <field_pretty_url>sonidegib-BCC</field_pretty_url>
  <para_id>989278</para_id>
  <related_resource_id>6572686</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>1002050</id>
  <title>Improving Chronic Disease in the Caribbean through Evidence-based Behavioral and Social Interventions</title>
  <langcode>en</langcode>
  <field_short_title>Improving Chronic Disease in the Caribbean through Evidence-based Behavioral and Social In</field_short_title>
  <field_page_description>The Office for Behavioral and Social Sciences Research and the NCI’s Center for Global Health held a workshop entitled “Improving Chronic Disease in the Caribbean through Evidence-based Behavioral and Social Interventions”, which took place in Bridgetown, Barbados from July 21 to 24, 2015. The objectives of the worksho</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-15</field_date_posted>
  <field_date_reviewed>2015-09-15</field_date_reviewed>
  <field_pretty_url>chronic_disease</field_pretty_url>
  <para_id>1002050</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1002112</id>
  <title>For Some Children with Cancer, Genomic Information May Help Guide Treatment Decisions</title>
  <langcode>en</langcode>
  <field_short_title>Using Genomic Tools to Analyze Tumors in Children</field_short_title>
  <field_page_description>Genomic methods, such as DNA sequencing, may help doctors manage the treatment of children and young adults with cancer. </field_page_description>
  <field_feature_card_description>This study tested the use of DNA and RNA sequencing to inform the treatment of younger patients with rare and aggressive cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-18</field_date_posted>
  <field_date_reviewed>2015-09-15</field_date_reviewed>
  <field_pretty_url>sequencing-pediatric</field_pretty_url>
  <para_id>1002112</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915352</term_id>
  <id>1004582</id>
  <title>CRISPR: Genome Editing Comes of Age</title>
  <langcode>en</langcode>
  <field_short_title>CRISPR: Genome Editing Comes of Age</field_short_title>
  <field_page_description>A research article about a technique for gene editing known as CRISPR-Cas9. The technique has made it much easier and faster for cancer researchers to study mutations and test new therapeutic targets.</field_page_description>
  <field_feature_card_description>An easier, faster way to study cancer mutations and test new therapeutic targets.</field_feature_card_description>
  <field_list_description>A technique for gene editing known as CRISPR-Cas9 has made it much easier and faster for cancer researchers to study mutations and test new therapeutic targets.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-23</field_date_posted>
  <field_date_reviewed>2015-09-23</field_date_reviewed>
  <field_pretty_url>crispr</field_pretty_url>
  <para_id>1004582</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1120791</id>
  <title>New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab Approved for Cervical Cancer, Rare Lymphoma</field_short_title>
  <field_page_description>The FDA has approved pembrolizumab (Keytruda) for some women with advanced cervical cancer and for some patients with primary mediastinal large B-cell lymphoma (PMBCL), a rare type of non-Hodgkin lymphoma.</field_page_description>
  <field_feature_card_description>Immunotherapy drug pembrolizumab cleared for advanced forms of both cancers.</field_feature_card_description>
  <field_list_description>FDA has approved pembrolizumab (Keytruda) for some women with advanced cervical cancer and some patients with primary mediastinal large B-cell lymphoma (PMBCL), a rare type of non-Hodgkin lymphoma. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-02</field_date_posted>
  <field_date_reviewed>2018-07-27</field_date_reviewed>
  <field_pretty_url>pembrolizumab-approved-fda-cervical-pmbcl</field_pretty_url>
  <para_id>1120791</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121514</id>
  <title>TCGA's Study of Esophageal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Esophageal Cancer</field_short_title>
  <field_page_description>TCGA's Study of Esophageal Cancer</field_page_description>
  <field_feature_card_description>TCGA's Study of Esophageal Cancer</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of esophageal squamous cell and adenocarcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-07</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <field_pretty_url>esophageal</field_pretty_url>
  <para_id>1121514</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121524</term_id>
  <id>1121525</id>
  <title>OMB Burden Statements for NCI Information Collections</title>
  <langcode>en</langcode>
  <field_short_title>OMB Burden Statements</field_short_title>
  <field_page_description>Under the Paperwork Reduction Act, information collections approved by the Office of Management and Budget (OMB) are linked to OMB Burden Statements that explain more about the specific collection and who to contact for more information. Burden statements for information collection by NCI are kept here. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-24</field_date_posted>
  <field_date_reviewed>2018-08-07</field_date_reviewed>
  <para_id>1121525</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1121660</term_id>
  <id>1121661</id>
  <title>Build a National Cancer Data Ecosystem</title>
  <langcode>en</langcode>
  <field_short_title>Build a National Cancer Data Ecosystem</field_short_title>
  <field_page_description>Researchers, clinicians, and patients across the country will need to share their collective data and knowledge to enable the development of new technologies and reduce the burden of cancer. This Cancer Moonshot initiative empowers and encourages such collaboration.</field_page_description>
  <field_feature_card_description>This Cancer Moonshot initiative aims to enable and encourage stakeholders to share, access, combine, and analyze data that will enable new discoveries and reduce the burden of cancer. </field_feature_card_description>
  <field_list_description>Create a national ecosystem for sharing and analyzing cancer data so that researchers, clinicians and patients will be able to contribute data, which will facilitate efficient data analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <para_id>1121661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1125566</id>
  <title>For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival</title>
  <langcode>en</langcode>
  <field_short_title>For Small Cell Lung Cancer, Immunotherapy Drug Improves Survival</field_short_title>
  <field_page_description>In a clinical trial of patients with advanced small cell lung cancer (SCLC), atezolizumab (Tecentriq), combined with standard chemotherapy, modestly increased survival—the first trial in more than 20 years to show a survival improvement in this cancer. </field_page_description>
  <field_feature_card_description>First trial in decades to show patients with this cancer lived longer.</field_feature_card_description>
  <field_list_description>In a large clinical trial, the immunotherapy drug atezolizumab (Tecentriq), combined with a standard chemotherapy regimen, modestly increased survival in patients with advanced small cell lung cancer (SCLC). The trial is the first in more than 20 years to show a survival improvement in this cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-03</field_date_posted>
  <field_date_reviewed>2018-10-02</field_date_reviewed>
  <field_pretty_url>small-cell-lung-cancer-atezolizumab-survival</field_pretty_url>
  <para_id>1125566</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916700</term_id>
  <id>1127109</id>
  <title>About Resources for Researchers </title>
  <langcode>en</langcode>
  <field_short_title>About Resources for Researchers </field_short_title>
  <field_page_description>Find contact information to add or edit a resource in the Resources for Researchers tool. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <field_pretty_url>about</field_pretty_url>
  <para_id>1127109</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1127126</id>
  <title>TCGA Cancers Selected for Study</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Cancers Selected for Study</field_short_title>
  <field_page_description>An overview of the 33 cancers selected for molecular characterization and the criteria TCGA used to select them.</field_page_description>
  <field_feature_card_description>An overview of the 33 cancers selected for study by TCGA.</field_feature_card_description>
  <field_list_description>An overview of the 33 different cancers types TCGA selected for study and the criteria used to select them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <para_id>1127126</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>1133172</term_id>
  <id>1133417</id>
  <title>Pediatric and Adult Rare Tumor Network</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric and Adult Rare Tumor Network</field_short_title>
  <field_page_description>The network of scientists, healthcare providers, advocates, patients, and family members, is working on solid rare tumors that have no cures.</field_page_description>
  <field_feature_card_description>Engages patients, advocates, and researchers to improve the lives of young people with rare cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-25</field_date_posted>
  <field_date_reviewed>2016-05-25</field_date_reviewed>
  <para_id>1133417</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133200</term_id>
  <id>1133447</id>
  <title>About MyPART</title>
  <langcode>en</langcode>
  <field_short_title>About</field_short_title>
  <field_page_description>MyPART, the My Pediatric and Adult Rare Tumor network, is a group of scientists, patients, family members, advocates, and healthcare providers who want to help find treatments for rare cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <para_id>1133447</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133753</term_id>
  <id>1133758</id>
  <title>By-Laws for the NIH Fellows Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>NIH Fellows Editorial Board By-Laws</field_short_title>
  <field_page_description>The NIH Fellows Editorial Board (FEB) offers a free and confidential editorial service for NIH fellows. The Board members edit manuscripts, abstracts, book chapters, clinical protocols, and grant submissions and offer suggestions for grammar, structure, and style, but not for scientific content. The Board provides valu</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-21</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <field_pretty_url>by-laws</field_pretty_url>
  <para_id>1133758</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133783</term_id>
  <id>1133798</id>
  <title>Manuscript Preparation Guidelines</title>
  <langcode>en</langcode>
  <field_short_title>Manuscript Preparation Guidelines</field_short_title>
  <field_page_description>The NIH Fellows Editorial Board has written guidelines on how to prepare a manuscript for submission.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-21</field_date_posted>
  <field_date_reviewed>2018-12-21</field_date_reviewed>
  <field_pretty_url>manuscript-preparation-guidelines</field_pretty_url>
  <para_id>1133798</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1134353</id>
  <title>For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target</title>
  <langcode>en</langcode>
  <field_short_title>New Biomarker, Treatment Target for Early-Stage Lung Cancer?</field_short_title>
  <field_page_description>A potential biomarker and treatment target for early-stage non-small cell lung cancer may have been found, results from a new study suggest.</field_page_description>
  <field_feature_card_description>Marker is a protein involved in transporting glucose into cells.</field_feature_card_description>
  <field_list_description>A new study has identified a potential biomarker of early-stage non–small cell lung cancer (NSCLC). The biomarker, the study’s leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-02</field_date_reviewed>
  <field_pretty_url>early-stage-lung-cancer-biomarker</field_pretty_url>
  <para_id>1134353</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134383</id>
  <title>Redox Biology </title>
  <langcode>en</langcode>
  <field_short_title>Redox Biology Course</field_short_title>
  <field_page_description>The Redox Biology course provides NIH postdoctoral and clinical fellows with an overview of how redox-active species and radicals are generated, their effects on the cellular and physiological level, and how they alter carcinogenesis, angiogenesis and proliferation in animal models of cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <field_pretty_url>redox-biology</field_pretty_url>
  <para_id>1134383</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133180</term_id>
  <id>1134553</id>
  <title>What are rare digestive system tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Digestive System Tumors</field_short_title>
  <field_page_description>Rare digestive system tumors form in organs that are important for digesting food and drinks, including the esophagus, stomach, intestines, liver, and pancreas.</field_page_description>
  <field_feature_card_description>Rare digestive system tumors form in organs that are important for digesting food and drinks, including the esophagus, stomach, intestines, liver, and pancreas.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134553</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1135273</term_id>
  <id>1135289</id>
  <title>Acquisition Resources</title>
  <langcode>en</langcode>
  <field_short_title>Acquisition Resources</field_short_title>
  <field_page_description>There are many different systems for acquiring grants or contracts from the National Cancer Institute, and regulations that manage their execution. </field_page_description>
  <field_list_description>Find helpful information relevant to federal contracting processes as conducted by NCI.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-16</field_date_posted>
  <field_date_reviewed>2019-01-16</field_date_reviewed>
  <para_id>1135289</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134584</term_id>
  <id>1137544</id>
  <title>Beat AML 1.0: A Collaborative Program for Functional Genomic Data Integration</title>
  <langcode>en</langcode>
  <field_short_title>Beat AML Functional Genomic Study</field_short_title>
  <field_page_description>The Beat AML program publishes an extensive genomic, drug response, and clinical dataset on acute myeloid leukemia. A lead author describes the collaborative effort and future steps.</field_page_description>
  <field_feature_card_description>Beat AML Functional Genomics </field_feature_card_description>
  <field_list_description>The Beat AML project integrates molecular, drug response, and clinical data for progress towards individualized therapies for acute myeloid leukemia patients. Dr. Jeffrey Tyner from Oregon Health and Science University describes the collaborative effort.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-11</field_date_posted>
  <field_date_reviewed>2019-02-11</field_date_reviewed>
  <field_pretty_url>beataml</field_pretty_url>
  <para_id>1137544</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137761</id>
  <title>TCGA's Study of Mesothelioma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Mesothelioma</field_short_title>
  <field_page_description>A summary of TCGA's study of mesothelioma, including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Mesothelioma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-14</field_date_posted>
  <field_date_reviewed>2019-02-14</field_date_reviewed>
  <field_pretty_url>mesothelioma</field_pretty_url>
  <para_id>1137761</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1124602</id>
  <title>Getting to Know the Complexities of Cancer: A 2018 TCGA Symposium Preview</title>
  <langcode>en</langcode>
  <field_short_title>2018 TCGA Symposium Preview</field_short_title>
  <field_page_description>A preview of some of the research to be presented at the 2018 Cell Symposium, TCGA Legacy: Multi-Omic Studies in Cancer.</field_page_description>
  <field_feature_card_description>TCGA Symposium 2018</field_feature_card_description>
  <field_list_description>At the 2018 Cell Symposium, TCGA Legacy: Multi-Omic Studies in Cancer, cancer genomics experts will discuss the latest research in molecularly characterizing cancer, classifying the disease, and the development of targeted therapy. A preview of how some researchers are starting to understand the complex and dynamic aspects of cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-24</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <field_pretty_url>2018-tcga-symposium</field_pretty_url>
  <para_id>1124602</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1124931</id>
  <title>Hope and Challenge: The NCI Annual Plan and Budget Proposal for Fiscal Year 2020</title>
  <langcode>en</langcode>
  <field_short_title>NCI FY 2020 Annual Plan and Budget Proposal Released</field_short_title>
  <field_page_description>NCI Director Dr. Ned Sharpless announces the release of the institute’s Fiscal Year 2020 Annual Plan and Budget Proposal. The plan represents NCI’s best professional judgement on the optimum funding needed to make the most rapid progress against cancer.</field_page_description>
  <field_feature_card_description>Plan helps inform federal budget planning.</field_feature_card_description>
  <field_list_description>NCI has released its Fiscal Year 2020 Annual Plan and Budget Proposal. The plan represents NCI’s best professional judgement on the optimum funding needed to make the most rapid progress against cancer.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-24</field_date_posted>
  <field_date_reviewed>2018-09-24</field_date_reviewed>
  <field_pretty_url>sharpless-nci-annual-plan-2020</field_pretty_url>
  <para_id>1124931</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1125053</id>
  <title>Conversation with Scott Kopetz: RAS in Colorectal Cancer, Initiation and Resistance</title>
  <langcode>en</langcode>
  <field_short_title>Conversation with Scott Kopetz: RAS in Colorectal Cancer, Initiation and Resistance</field_short_title>
  <field_page_description>Mutated RAS genes are an important cause of colorectal cancers, and play a role in resistance to current drug therapies.</field_page_description>
  <field_feature_card_description>Mutated RAS genes are drivers of colorectal cancer and drug resistance.</field_feature_card_description>
  <field_list_description>Mutated RAS genes are an important cause of colorectal cancers, and play a role in resistance to current drug therapies.  Remarkably, patients whose cancer is progressing despite treatment often have multiple different RAS mutations in their tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-28</field_date_posted>
  <field_date_reviewed>2018-09-27</field_date_reviewed>
  <field_pretty_url>scott-kopetz</field_pretty_url>
  <para_id>1125053</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1125675</id>
  <title>Vaping Pods Produce High Nicotine Levels in Young Users</title>
  <langcode>en</langcode>
  <field_short_title>Vaping Pods Produce High Nicotine Levels in Young Users</field_short_title>
  <field_page_description>Pod-style e-cigarettes produce higher levels of nicotine in the body than conventional cigarettes. Learn why this finding in young users is so concerning.</field_page_description>
  <field_feature_card_description>Learn the reasons why this finding is so concerning.</field_feature_card_description>
  <field_list_description>Adolescents who use pod-style e-cigarettes had higher levels of nicotine in their bodies than is typically found in adolescents who smoke conventional cigarettes, a new study has found. The study's findings are concerning for several reasons.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-05</field_date_posted>
  <field_date_reviewed>2018-10-04</field_date_reviewed>
  <field_pretty_url>youth-vaping-high-nicotine-levels</field_pretty_url>
  <para_id>1125675</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1126201</id>
  <title>For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up</title>
  <langcode>en</langcode>
  <field_short_title>For HPV-Positive Women, Test Can Guide Screening Follow-Up</field_short_title>
  <field_page_description>For women who test HPV-positive during cervical cancer screening, the dual stain test is better than the Pap test at identifying those at increased risk of developing precancers over the next 5 years and can better guide follow-up care. </field_page_description>
  <field_feature_card_description>Dual-stain test better than Pap at identifying cervical precancer risk.</field_feature_card_description>
  <field_list_description>A new test can help to improve the clinical management of women who screen positive for HPV infection during routine cervical cancer screening, an NCI-led study has shown.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-11</field_date_posted>
  <field_date_reviewed>2018-10-11</field_date_reviewed>
  <field_pretty_url>dual-stain-test-cervical-hpv-positive</field_pretty_url>
  <para_id>1126201</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915634</term_id>
  <id>1126608</id>
  <title>Thinking Chemically to Discover New Targeted Cancer Drugs</title>
  <langcode>en</langcode>
  <field_short_title>Thinking Chemically to Discover New Targeted Cancer Drugs-Kevan Shokat, Ph.D.</field_short_title>
  <field_page_description>About a third of all cancers are driven by mutations in RAS genes. Learn how NCI funding is helping Dr. Kevan Shokat develop drugs that inactivate molecular drivers of cancer such as RAS.</field_page_description>
  <field_feature_card_description>Chemical biologist Kevan Shokat, Ph.D., uses his unique perspective to develop molecularly targeted therapies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>kevan-shokat-targeted-drug-discovery</field_pretty_url>
  <para_id>1126608</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134343</term_id>
  <id>1134344</id>
  <title>Preparing for Science-Based Non-Traditional Careers</title>
  <langcode>en</langcode>
  <field_short_title>Preparing for Science-Based Non-Traditional Careers</field_short_title>
  <field_page_description>The Preparing for Science-Based Non-Traditional Careers workshop assist and inform NCI Fellows, Staff Scientists, and Staff Clinicians about exploring various science-based career opportunities outside of independent academic research. This 7 week workshop will provide best practices for getting a job, setting work exp</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-16</field_date_posted>
  <field_date_reviewed>2019-01-02</field_date_reviewed>
  <para_id>1134344</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133176</term_id>
  <id>1134393</id>
  <title>What are rare bone tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Bone Tumors</field_short_title>
  <field_page_description>Rare bone tumors include bone cancer and cartilage cancer. They can be called by different names depending on where they are in the body. Particulare types of rare bone tumors affect children, adolescents, and young adults.</field_page_description>
  <field_list_description>Rare bone tumors include cancer of the bone and cartilage. They get more specific names depending on where they are located in the body.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <para_id>1134393</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134418</id>
  <title>K Grant Writing Workshop</title>
  <langcode>en</langcode>
  <field_short_title>K Grant Writing Workshop</field_short_title>
  <field_page_description>The Writing Cancer Grant Applications course focuses on how to write clear and persuasive grant applications. This course aims to increase the quality of grant applications by successfully communicating scientific data and ideas.</field_page_description>
  <field_list_description>K Grant Writing Workshop focuses on how to write clear and persuasive grant applications. This course aims to increase the quality of grant applications by successfully communicating scientific data and ideas.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-04</field_date_posted>
  <field_date_reviewed>2019-01-04</field_date_reviewed>
  <field_pretty_url>writing-cancer-grant-applications</field_pretty_url>
  <para_id>1134418</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1134542</term_id>
  <id>1134543</id>
  <title>2018 Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>2018 Social Media Events</field_short_title>
  <field_page_description>Find past social media events involving NCI and its partners from 2018.</field_page_description>
  <field_feature_card_description>Find past social media events involving NCI and its partners from 2018.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-03</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <para_id>1134543</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1135698</term_id>
  <id>1135760</id>
  <title>CGH Recognizes World Cancer Day 2019</title>
  <langcode>en</langcode>
  <field_short_title>CGH Recognizes World Cancer Day 2019</field_short_title>
  <field_page_description>Want to know more about World Cancer Day?  Read how the NCI Center for Global Health promotes knowledge sharing in global cancer research and cancer control. </field_page_description>
  <field_feature_card_description>NCI’s Center for Global Health joins partners around the world to reduce the impact of cancer.</field_feature_card_description>
  <field_list_description>On Monday, February 4, the National Cancer Institute (NCI) will recognize World Cancer Day, (WCD) an initiative of the Union for International Cancer Control (UICC). The Center for Global Health (CGH) joins partners across the globe to build awareness about progress against cancer and promote knowledge sharing in cancer research and cancer control.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-25</field_date_posted>
  <field_date_reviewed>2019-01-25</field_date_reviewed>
  <field_pretty_url>wcd</field_pretty_url>
  <para_id>1135760</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1137664</id>
  <title>A CAR T-Cell Therapy for Multiple Childhood Cancers?</title>
  <langcode>en</langcode>
  <field_short_title>CAR T-Cell Study Suggests Promise for Childhood Cancers</field_short_title>
  <field_page_description>A CAR T-cell therapy targeting the B7-H3 protein may have potential as a treatment for several childhood cancers, results from a study in mice suggest.</field_page_description>
  <field_feature_card_description>In mouse models of common pediatric cancers, treatment shrank or eradicated tumors.</field_feature_card_description>
  <field_list_description>An experimental CAR T-cell therapy may have potential as a treatment for several types of childhood cancer, results from a new study in mice suggest. The CAR T cells eradicated tumors in mouse models of several different childhood cancers, including two forms of sarcoma and medulloblastoma.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-14</field_date_posted>
  <field_date_reviewed>2019-02-13</field_date_reviewed>
  <field_pretty_url>car-t-cell-childhood-cancers</field_pretty_url>
  <para_id>1137664</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137852</id>
  <title>TCGA's Study of Testicular Germ Cell Cancer</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Testicular Germ Cell Cancer</field_short_title>
  <field_page_description>A summary of TCGA's study of testicular germ cell cancer, including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Testicular Germ Cell Cancer</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>testicular-germ-cell</field_pretty_url>
  <para_id>1137852</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1138850</id>
  <title>Dormant Tumor Cells Can Be Sensitized to Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Sensitizing Dormant Tumor Cells to Chemotherapy</field_short_title>
  <field_page_description>Strategy looks to slow or prevent metastatic breast cancer by targeting hidden, dormant cancer cells.</field_page_description>
  <field_feature_card_description>Approach targets hidden cancer cells linked to metastasis.</field_feature_card_description>
  <field_list_description>A new study in mice shows that disrupting the relationship between breast cancer cells that spread to bone and normal cells surrounding them makes the cancer cells sensitive to treatment.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-20</field_date_posted>
  <field_date_reviewed>2019-02-19</field_date_reviewed>
  <field_pretty_url>breast-cancer-chemotherapy-sensitizing-dormant-cells</field_pretty_url>
  <para_id>1138850</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1127246</id>
  <title>Studying “Total Diet” and Its Impact on Health, Including Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Studying the Impact of Total Diet on Cancer Risk</field_short_title>
  <field_page_description>Dr. Jill Reedy explains a shift in diet and cancer risk studies, with researchers using a holistic approach that analyzes dietary patterns across the lifespan.</field_page_description>
  <field_feature_card_description>Researchers are changing how they assess the effect of diet on cancer, health. </field_feature_card_description>
  <field_list_description>Researchers are shifting how they assess diet and cancer risk, looking beyond the impact of individual foods or nutrients on health, and taking a more holistic approach, considering dietary patterns across the lifespan. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-25</field_date_posted>
  <field_date_reviewed>2018-10-24</field_date_reviewed>
  <field_pretty_url>cancer-risk-total-diet</field_pretty_url>
  <para_id>1127246</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127269</term_id>
  <id>1127270</id>
  <title>Engineered ECM Platforms to Analyze Progression in High Grade Serous Ovarian Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Engineered ECM Platforms Analyze Progression in High Grade Serous Ovarian Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-31</field_date_posted>
  <field_date_reviewed>2018-09-20</field_date_reviewed>
  <para_id>1127270</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1131832</id>
  <title>Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery</title>
  <langcode>en</langcode>
  <field_short_title>Test Identifies Thyroid Nodules That Don’t Require Surgery </field_short_title>
  <field_page_description>A new test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer.</field_page_description>
  <field_feature_card_description>Test measures genomic changes that have been linked to thyroid cancer. </field_feature_card_description>
  <field_list_description>The test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer. A study showed the test accurately identified samples that, after surgery, were found to be benign.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-30</field_date_posted>
  <field_date_reviewed>2018-11-29</field_date_reviewed>
  <field_pretty_url>thyroid-cancer-diagnostic-genomic-test</field_pretty_url>
  <para_id>1131832</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1132343</id>
  <title>Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Treatment for Rare GI Cancers May Extend Survival</field_short_title>
  <field_page_description>In patients with biliary tract cancer with a BRAF mutation, treatment with dabrafenib plus trametinib shrank tumors, results from a phase 2 trial show.</field_page_description>
  <field_feature_card_description>Dabrafenib plus trametinib shrank tumors with a specific BRAF gene mutation.</field_feature_card_description>
  <field_list_description>In an early-phase trial, dabrafenib plus trametinib shrank tumors in patients with biliary tract cancer and adenocarcinoma of the small intestine whose tumors had a specific mutation in the BRAF gene.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-07</field_date_posted>
  <field_date_reviewed>2018-12-07</field_date_reviewed>
  <field_pretty_url>biliary-tract-cancer-dabrafenib-trametinib</field_pretty_url>
  <para_id>1132343</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133176</term_id>
  <id>1133218</id>
  <title>Adamantinoma</title>
  <langcode>en</langcode>
  <field_short_title>Adamantinoma</field_short_title>
  <field_page_description>Adamantinoma is a rare bone cancer, which mostly grows in the lower leg, tough it can apear in the forearm, jaw, hands, or feet. Adamantinoma is a serious condition. Treatment is important for survival, but it is possible to make a full recovery.</field_page_description>
  <field_list_description>Adamantinoma is a rare bone cancer, which mostly grows in the lower leg, tough it can apear in the forearm, jaw, hands, or feet. Adamantinoma is a serious condition. Treatment is important for survival, but it is possible to make a full recovery.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>adamantinoma</field_pretty_url>
  <para_id>1133218</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134558</term_id>
  <id>1133236</id>
  <title>Medullary thyroid cancer</title>
  <langcode>en</langcode>
  <field_short_title>Medullary thyroid cancer</field_short_title>
  <field_page_description>Medullary thyroid cancer, or MTC, is a cancer that forms in the medulla, or the inside of the thyroid. It is the rarest type of thyroid cancer. Learn more about the diagnosis, treatment, and prognosis of MTC.</field_page_description>
  <field_list_description>Medullary thyroid cancer, or MTC, is a cancer that forms in the medulla, or the inside of the thyroid. It is the rarest type of thyroid cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>medullary-thyroid-cancer</field_pretty_url>
  <para_id>1133236</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133465</term_id>
  <id>1133261</id>
  <title>Who is MyPART?</title>
  <langcode>en</langcode>
  <field_short_title>MyPART Team</field_short_title>
  <field_page_description>The team of doctors, nurses, scientists, and other staff who make up MyPART are working together to improve the lives of children, adolescents, and young adults with rare solid tumors. Learn more about us!</field_page_description>
  <field_feature_card_description>MyPART is made up of a team of doctors, nurses, scientists, and other staff.</field_feature_card_description>
  <field_list_description>The team of doctors, nurses, scientists, and other staff who make up MyPART are working together to improve the lives of children, adolescents, and young adults with rare solid tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133261</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133449</term_id>
  <id>1133262</id>
  <title>Contact MyPART</title>
  <langcode>en</langcode>
  <field_short_title>Contact MyPART</field_short_title>
  <field_page_description>Get in touch with the scientists and staff of MyPART, the My Pediatric and Adult Rare Tumor network.</field_page_description>
  <field_feature_card_description>There are several ways to get in touch with us and learn more about MyPART.</field_feature_card_description>
  <field_list_description>There are several ways to get in touch with us and learn more about MyPART.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133262</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1004902</term_id>
  <id>1004971</id>
  <title>Contact the Division of Cancer Biology</title>
  <langcode>en</langcode>
  <field_short_title>DCB Contact and Staff</field_short_title>
  <field_page_description>Find staff and contact information for DCB's offices and branches.</field_page_description>
  <field_feature_card_description>Find staff and contact information for DCB's offices and branches.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-09-25</field_date_reviewed>
  <para_id>1004971</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1007348</id>
  <title>Persistence of Genetic Mutations after Chemotherapy Linked to Poor Outcomes in Some Patients with AML</title>
  <langcode>en</langcode>
  <field_short_title>Mutation Persistence after Chemotherapy Linked to Poor Outcomes in AML</field_short_title>
  <field_page_description>The persistence of genetic mutations in some patients with acute myeloid leukemia may allow physicians to better classify their risk of recurrence.</field_page_description>
  <field_feature_card_description>Survival, time to relapse substantially greater when no post-treatment mutations detected.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-02</field_date_posted>
  <field_date_reviewed>2015-09-30</field_date_reviewed>
  <field_pretty_url>aml-mutations</field_pretty_url>
  <para_id>1007348</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1014606</id>
  <title>New on NCI’s Websites</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites</field_short_title>
  <field_page_description>An update about new websites and online content from NCI </field_page_description>
  <field_feature_card_description>An update about new websites and online content from NCI </field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-16</field_date_posted>
  <field_date_reviewed>2015-10-16</field_date_reviewed>
  <field_pretty_url>new-online-Oct2015</field_pretty_url>
  <para_id>1014606</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1015931</id>
  <title>Bringing Cancer Research to the Public: NCI’s Networks and Programs</title>
  <langcode>en</langcode>
  <field_short_title>Bringing Cancer Research to the Public: NCI’s Networks and Programs</field_short_title>
  <field_page_description>A number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.</field_page_description>
  <field_feature_card_description>Networks ensure NCI can respond to changes in knowledge, technology, and policy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-22</field_date_posted>
  <field_date_reviewed>2015-10-22</field_date_reviewed>
  <field_pretty_url>research-to-public</field_pretty_url>
  <para_id>1015931</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1026063</term_id>
  <id>1026249</id>
  <title>Office of Government and Congressional Relations (OGCR)</title>
  <langcode>en</langcode>
  <field_short_title>Office of Government and Congressional Relations (OGCR)</field_short_title>
  <field_page_description>The Office of Government and Congressional Relations (OGCR) advises the NCI Director, staff, and advisory boards on legislative and Congressional activities as they relate to the NCI mission.</field_page_description>
  <field_feature_card_description>Advises NCI staff and advisory boards on legislative and Congressional activities as they relate to the NCI mission.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-13</field_date_reviewed>
  <para_id>1026249</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1026836</id>
  <title>FDA Approves Pembrolizumab for Patients with Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Pembrolizumab to Treat Non-Small Cell Lung Cancer</field_short_title>
  <field_page_description>The FDA has approved the drug pembrolizumab to treat patients with advanced non-small cell lung cancer (NSCLC) whose tumors express a protein called PD-L1.</field_page_description>
  <field_feature_card_description>The drug is used to treat patients whose tumors express a protein called PD-L1. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-18</field_date_posted>
  <field_date_reviewed>2015-11-17</field_date_reviewed>
  <field_pretty_url>pembrolizumab-nsclc</field_pretty_url>
  <para_id>1026836</para_id>
  <related_resource_id>6572719</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>63848</term_id>
  <id>63858</id>
  <title>Patient Safety in Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Patient Safety in Clinical Trials</field_short_title>
  <field_page_description>Information about how the rights and safety of people who take part in clinical trials are protected. </field_page_description>
  <field_feature_card_description>There are federal rules in place to help ensure the safety and ethics of clinical trials. </field_feature_card_description>
  <field_list_description>There are federal rules in place to help protect the rights and safety of people who take part in clinical trials. Learn about informed consent, institutional review boards (IRB's), and how trials are closely monitored.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-24</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>63858</para_id>
  <related_resource_ids>7090735</related_resource_ids>
  <related_resource_ids>7090736</related_resource_ids>
  <related_resource_ids>7090737</related_resource_ids>
  <related_resource_ids>7090738</related_resource_ids>
  <related_resource_ids>7090739</related_resource_ids>
  <related_resource_ids>7090741</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65326</id>
  <title>Drugs Approved for Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Prostate Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for prostate cancer. The list includes generic names and brand names. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-11</field_date_reviewed>
  <field_pretty_url>prostate</field_pretty_url>
  <para_id>65326</para_id>
  <related_resource_ids>6994662</related_resource_ids>
  <related_resource_ids>6994674</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915634</term_id>
  <id>1127128</id>
  <title>Combining Immunotherapy and Radiation against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Combining Immunotherapy and Radiation against Cancer</field_short_title>
  <field_page_description>Read how an NCI-funded team led by Robert Vonderheide showed the promise of combining immune checkpoint inhibitors and radiation therapy in melanoma.</field_page_description>
  <field_feature_card_description>A cross-disciplinary team is demonstrating the promise of combining radiation and checkpoint inhibitors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <field_pretty_url>vonderheide-minn-twyman-saint-victor-radiation-checkpoint-inhibitors</field_pretty_url>
  <para_id>1127128</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1129034</id>
  <title>NCI Summer Curriculum: Strengthening Global Cancer Research Capacity</title>
  <langcode>en</langcode>
  <field_short_title>NCI Summer Curriculum: Strengthening Global Cancer Research Capacity</field_short_title>
  <field_page_description>Interested in learning about principles and practice of cancer prevention and control and molecular prevention? Read NCI Summer Curriculum: Strengthening Global Cancer Research Capacity and learn details about 2019 courses.</field_page_description>
  <field_list_description>Cancer Prevention Fellowship Program (CPFP) hosts the 2018 NCI Summer Curriculum featuring two courses: The Principles and Practice of Cancer Prevention and Control (PPCPC) and the Molecular Prevention Course. The program provides a multidisciplinary overview of the principles and practices of cancer prevention and control from both, the public health and the basic biology perspectives.  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-30</field_date_posted>
  <field_date_reviewed>2018-10-30</field_date_reviewed>
  <field_pretty_url>summer-curriculum</field_pretty_url>
  <para_id>1129034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1132043</id>
  <title>Can Topical Drugs Help Prevent Breast Cancer?</title>
  <langcode>en</langcode>
  <field_short_title>Can Topical Drugs Help Prevent Breast Cancer?</field_short_title>
  <field_page_description>A topical form of tamoxifen, called 4-OHT, is being tested to see if it can prevent breast cancer as effectively as oral tamoxifen but with fewer side effects.</field_page_description>
  <field_feature_card_description>A gel form of tamoxifen is being tested in clinical trials.</field_feature_card_description>
  <field_list_description>Researchers are testing a topical-gel form of the drug tamoxifen to see if it can help prevent breast cancer as effectively as the oral form of the drug but with fewer side effects. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-04</field_date_posted>
  <field_date_reviewed>2018-12-03</field_date_reviewed>
  <field_pretty_url>tamoxifen-gel-breast-cancer-prevention</field_pretty_url>
  <para_id>1132043</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133022</id>
  <title>Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combination May Target Metabolism of Leukemia Stem Cells</field_short_title>
  <field_page_description>In AML, the drugs venetoclax (Venclexta) and azacitidine (Vidaza) team up to block the unique metabolism of leukemia stem cells, two studies show.</field_page_description>
  <field_feature_card_description>Two studies may explain why the drugs generate lasting responses in people with AML.</field_feature_card_description>
  <field_list_description>Two new studies show how the drugs venetoclax (Venclexta) and azacitidine (Vidaza) team up to block the unique metabolism of leukemia stem cells and may explain why the drug combination is effective against acute myeloid leukemia.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-14</field_date_posted>
  <field_date_reviewed>2018-12-14</field_date_reviewed>
  <field_pretty_url>aml-venetoclax-azacitidine-target-leukemia-stem-cells</field_pretty_url>
  <para_id>1133022</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134558</term_id>
  <id>1133235</id>
  <title>Anaplastic thyroid cancer</title>
  <langcode>en</langcode>
  <field_short_title>Anaplastic thyroid cancer</field_short_title>
  <field_page_description>Anaplastic thyroid cancer, or ATC, is a type of thyroid cancer. It is a rare type, making up 1% to 2% of thyroid cancer cases. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>anaplastic-thyroid-cancer</field_pretty_url>
  <para_id>1133235</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133188</term_id>
  <id>1133244</id>
  <title>Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Neuroblastoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>neuroblastoma</field_pretty_url>
  <para_id>1133244</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133190</term_id>
  <id>1133246</id>
  <title>NUT midline carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>NUT midline carcinoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>nut-midline-carcinoma</field_pretty_url>
  <para_id>1133246</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134568</term_id>
  <id>1133257</id>
  <title>Center for Cancer Research Rare Tumor Clinics</title>
  <langcode>en</langcode>
  <field_short_title>Rare Tumor Clinics</field_short_title>
  <field_page_description>Each year, the MyPART team hosts clinics on select rare tumors at the NIH Clinical Center in Bethesda, MD. During these one to three-day meetings, people with the rare tumor and experts from around the country meet to learn more about the tumor from each other.</field_page_description>
  <field_feature_card_description>The MyPART team hosts clinics where patients and experts meet to learn more about the tumor from each other.</field_feature_card_description>
  <field_list_description>Each year, the MyPART team hosts clinics on select rare tumors at the NIH Clinical Center in Bethesda, MD. During these one- to three-day meetings, people with the rare tumor and experts from around the country meet to learn more about the tumor from each other.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133257</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>929499</term_id>
  <id>1134348</id>
  <title>Cancer Research Interns</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Research Interns</field_short_title>
  <field_page_description>The Cancer Research Interns (CRI) summer program goal is to train a diverse number of students in labs and branches across the Center for Cancer Research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-16</field_date_posted>
  <field_date_reviewed>2019-01-02</field_date_reviewed>
  <field_pretty_url>cancer-research-interns</field_pretty_url>
  <para_id>1134348</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137929</id>
  <title>TCGA's Study of Uveal Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Uveal Melanoma</field_short_title>
  <field_page_description>A summary of TCGA's study of uveal (intraocular or eye) melanoma, including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Uveal Melanoma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>melanoma-eye</field_pretty_url>
  <para_id>1137929</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1140634</term_id>
  <id>1140635</id>
  <title>Patient-Derived Models Consortium</title>
  <langcode>en</langcode>
  <field_short_title>Patient-Derived Models Consortium</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2019-03-06</field_date_reviewed>
  <para_id>1140635</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>678485</id>
  <title>Using the Immune System in the Fight Against Cancer: Discovery of Rituximab</title>
  <langcode>en</langcode>
  <field_short_title>Discovery of Rituximab</field_short_title>
  <field_page_description>NCI funded the development of rituximab, one of the first monoclonal antibody cancer treatments. With the discovery of rituximab, more than 70 percent of patients diagnosed with non-hodgkin lymphoma now live five years past their initial diagnosis.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-07</field_date_posted>
  <field_date_reviewed>2013-12-11</field_date_reviewed>
  <field_pretty_url>blood-cancer</field_pretty_url>
  <para_id>678485</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>918930</term_id>
  <id>684821</id>
  <title>Off-Label Drug Use in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Off-Label Drug Use in Cancer Treatment</field_short_title>
  <field_page_description>Learn what off-label drug use is and its role in cancer treatment. </field_page_description>
  <field_feature_card_description>Learn what off-label drug use is and its role in cancer treatment. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-01</field_date_posted>
  <field_date_reviewed>2013-12-23</field_date_reviewed>
  <para_id>684821</para_id>
  <related_resource_id>5264395</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>695703</term_id>
  <id>695704</id>
  <title>Research Advocacy at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Research Advocacy at NCI</field_short_title>
  <field_page_description>Research advocates bring the patient perspective to NCI's work, informing research focus and supporting timely, relevant, and effective advances in cancer research.</field_page_description>
  <field_feature_card_description>Research advocates bring the patient's perspective to NCI's work across the cancer care and cancer research continuum. </field_feature_card_description>
  <field_list_description>The cancer patient perspective that research advocates bring into NCI’s research enterprise helps to inform research focus and support the dissemination of results that lead to new and better cancer prevention, detection, and treatment methods.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-23</field_date_posted>
  <field_date_reviewed>2014-01-23</field_date_reviewed>
  <para_id>695704</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>974642</id>
  <title>Next Round of Grant Solicitations for Provocative Questions Announced</title>
  <langcode>en</langcode>
  <field_short_title>Next Round of Grant Solicitations for Provocative Questions Announced</field_short_title>
  <field_page_description>The next round of grant solicitations for Provocative Questions has been announced.</field_page_description>
  <field_feature_card_description>Grants cover 12 new questions generated by researchers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-10</field_date_posted>
  <field_date_reviewed>2015-07-09</field_date_reviewed>
  <field_pretty_url>provocative-questions-new</field_pretty_url>
  <para_id>974642</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>976521</id>
  <title>Pancreatic Cancer Study Finds Possible Diagnostic Marker in Blood</title>
  <langcode>en</langcode>
  <field_short_title>Possible Diagnostic Marker for Pancreatic Cancer</field_short_title>
  <field_page_description>A protein attached to vesicles circulating in the blood could be a biological marker for detecting early signs of pancreatic cancer.</field_page_description>
  <field_feature_card_description>Study detects exosomes shed by pancreatic cancer cells into the blood.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-15</field_date_posted>
  <field_date_reviewed>2015-07-14</field_date_reviewed>
  <field_pretty_url>pancreatic-exosomes</field_pretty_url>
  <para_id>976521</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>976983</id>
  <title>Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma</field_short_title>
  <field_page_description>In a large clinical trial, the oncolytic virus therapy T-VEC improved the durable response rate and median survival in patients with advanced melanoma.</field_page_description>
  <field_feature_card_description>Treatment also appears to stimulate immune response against cancer cells.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-21</field_date_posted>
  <field_date_reviewed>2015-07-16</field_date_reviewed>
  <field_pretty_url>oncolyticvirus-melanoma</field_pretty_url>
  <para_id>976983</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>978894</term_id>
  <id>978895</id>
  <title>RAS Lab Discussion Forum</title>
  <langcode>en</langcode>
  <field_short_title>RAS Lab Discussion Forum</field_short_title>
  <field_page_description>RAS Lab is an online discussion forum to facilitate the exchange of scientific information among researchers in cancers related to RAS.</field_page_description>
  <field_feature_card_description>RAS Lab is an online discussion forum to facilitate the exchange of scientific information among researchers in cancers related to RAS.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-21</field_date_posted>
  <field_date_reviewed>2015-07-21</field_date_reviewed>
  <para_id>978895</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>981114</term_id>
  <id>980954</id>
  <title>Cancer Research in the Media: International Workshop for Scientific Journalism</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Research in the Media</field_short_title>
  <field_page_description>Cancer Research in the Media (CRiM) is a two-day seminar designed for international journalists to increase their understanding of complex scientific findings, improving their ability to communicate accurate cancer-related information to the public.</field_page_description>
  <field_feature_card_description>CRiM is a two-day seminar designed for international journalists to increase their understanding of complex scientific findings.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-27</field_date_posted>
  <field_date_reviewed>2015-07-27</field_date_reviewed>
  <para_id>980954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914506</term_id>
  <id>1126610</id>
  <title>Pursuing a Cancer Prevention Vaccine</title>
  <langcode>en</langcode>
  <field_short_title>Pursuing a Cancer Prevention Vaccine-Olivera Finn, Ph.D.</field_short_title>
  <field_page_description>Read the story of NCI-funded scientist Olivera Finn whose research led to the first clinical trial of a prevention vaccine for people at high risk for cancer.</field_page_description>
  <field_feature_card_description>Olivera Finn, Ph.D., has pursued this goal since her research team discovered the first tumor antigen.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>olivera-finn-prevention-vaccine</field_pretty_url>
  <para_id>1126610</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915624</term_id>
  <id>1126633</id>
  <title>Running (and Eating) Away from Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Running (and Eating) Away from Cancer-Sue Wharfe</field_short_title>
  <field_page_description>Learn how Sue Wharfe benefitted from taking part in a clinical trial of exercise and nutrition for breast cancer survivors that was supported by NCI funding.</field_page_description>
  <field_feature_card_description>Is obesity associated with worse survival for patients with breast cancer? Sue Wharfe participated in a study to address this question.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>sue-wharfe-lifestyle-exercise-nutrition-study</field_pretty_url>
  <para_id>1126633</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915609</term_id>
  <id>1126635</id>
  <title>Addressing Cancer Disparities in Appalachia</title>
  <langcode>en</langcode>
  <field_short_title>Addressing Cancer Disparities in Appalachia-Electra Paskett, Ph.D.</field_short_title>
  <field_page_description>Dr. Electra Paskett addresses cancer disparities through science and community partnerships. With NCI’s support, her efforts have made improvements in underserved communities.</field_page_description>
  <field_feature_card_description>Electra Paskett, Ph.D., has devoted her career to addressing cancer disparities in the United States.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-16</field_date_reviewed>
  <field_pretty_url>electra-paskett-addressing-cancer-disparities-appalachia</field_pretty_url>
  <para_id>1126635</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919157</term_id>
  <id>1127101</id>
  <title>Combining Drugs to Treat Ovarian Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Combining Drugs to Treat Ovarian Cancer-Betsy Brauser</field_short_title>
  <field_page_description>Approximately 70 percent of women diagnosed with ovarian cancer will die from the disease. Read about the NCI-funded combination drug trial that has successfully treated Betsy Brauser's recurrent cancer.</field_page_description>
  <field_feature_card_description>Betsy Brauser participated in a phase 1 clinical trial testing a drug combination to treat ovarian cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2018-10-22</field_date_reviewed>
  <field_pretty_url>betsy-brauser-combining-drugs-treat-ovarian-cancer</field_pretty_url>
  <para_id>1127101</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1129516</id>
  <title>Blood Test Shows Promise for Detecting Genetic Changes in Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Blood Test May Detect Genetic Changes in Brain Tumors</field_short_title>
  <field_page_description>The minimally invasive test could be used to identify and follow molecular changes in children with highly lethal brain tumors called diffuse midline gliomas.</field_page_description>
  <field_feature_card_description>The minimally invasive test could be used in kids with highly lethal gliomas.</field_feature_card_description>
  <field_list_description>A liquid biopsy blood test can detect DNA from brain tumors called diffuse midline gliomas, researchers have found. This minimally invasive test could be used to identify and follow molecular changes in children with these highly lethal brain tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-05</field_date_posted>
  <field_date_reviewed>2018-11-02</field_date_reviewed>
  <field_pretty_url>liquid-biopsy-childhood-brain-tumors</field_pretty_url>
  <para_id>1129516</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1130666</id>
  <title>The Cancer Moonshot: Moving from Planning to Research</title>
  <langcode>en</langcode>
  <field_short_title>The Cancer Moonshot: Moving from Planning to Research</field_short_title>
  <field_page_description>The Cancer Moonshot is supporting innovative science, as it moves from the planning phase to the research phase, explains NCI’s Dr. Dinah Singer. </field_page_description>
  <field_feature_card_description>An update on the science of the Cancer Moonshot initiative.</field_feature_card_description>
  <field_list_description>Dr. Dinah Singer, co-chair of the Cancer Moonshot Blue Ribbon Panel, provides an update to the cancer community on the science being supported under the Moonshot initiative.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-19</field_date_posted>
  <field_date_reviewed>2018-11-09</field_date_reviewed>
  <field_pretty_url>cancer-moonshot-planning-to-research</field_pretty_url>
  <para_id>1130666</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133172</term_id>
  <id>1139288</id>
  <title>Site Map</title>
  <langcode>en</langcode>
  <field_short_title>Site Map</field_short_title>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-24</field_date_posted>
  <field_date_reviewed>2019-02-24</field_date_reviewed>
  <field_pretty_url>sitemap</field_pretty_url>
  <para_id>1139288</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>93512</id>
  <title>Drugs Approved for Stomach (Gastric) Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Stomach (Gastric) Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for stomach (gastric) cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-08-25</field_date_posted>
  <field_date_reviewed>2011-07-19</field_date_reviewed>
  <field_pretty_url>stomach</field_pretty_url>
  <para_id>93512</para_id>
  <related_resource_ids>7097454</related_resource_ids>
  <related_resource_ids>7097460</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>99815</id>
  <title>Drugs Approved for Vulvar Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Vulvar Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for vulvar cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-25</field_date_posted>
  <field_date_reviewed>2011-07-26</field_date_reviewed>
  <field_pretty_url>vulvar</field_pretty_url>
  <para_id>99815</para_id>
  <related_resource_ids>6994881</related_resource_ids>
  <related_resource_ids>6994884</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087111</id>
  <title>CAR T Cells: Expanding into Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>CAR T Cells Expanding into Multiple Myeloma</field_short_title>
  <field_page_description>CAR T-cell therapy is showing promise in multiple myeloma, according to recently presented data from two early-phase clinical trials. </field_page_description>
  <field_feature_card_description>Patients in two early-phase trials responded to treatment, but longer follow-up is needed.</field_feature_card_description>
  <field_list_description>Results from two early-phase trials presented at the American Society of Clinical Oncology annual meeting suggest that an immunotherapy using genetically engineered immune cells may be effective in patients with advanced multiple myeloma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-12</field_date_posted>
  <field_date_reviewed>2017-06-09</field_date_reviewed>
  <field_pretty_url>car-t-cell-multiple-myeloma</field_pretty_url>
  <para_id>1087111</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080236</term_id>
  <id>1087220</id>
  <title>Mostafa Nokta, M.D., Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Mostafa Nokta, M.D., Ph.D.</field_short_title>
  <field_page_description>Learn more about Mostafa Nokta, M.D., Ph.D., director of the AIDS Cancer Clinical Program in the Office of HIV and AIDS Malignancy. </field_page_description>
  <field_feature_card_description>Learn more about Mostafa Nokta, M.D., Ph.D., director of the AIDS Cancer Clinical Program in the Office of HIV and AIDS Malignancy. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-06-09</field_date_reviewed>
  <field_pretty_url>mostafa-nokta</field_pretty_url>
  <para_id>1087220</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836317</id>
  <title>Taking Part in Cancer Treatment Research Studies</title>
  <langcode>en</langcode>
  <field_short_title>Taking Part in Cancer Treatment Research Studies</field_short_title>
  <field_page_description>Covers things you should know and think about when deciding to take part in a cancer treatment clinical trial.</field_page_description>
  <field_feature_card_description>This updated booklet explains cancer treatment trials and helps you think about whether to take part. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>cancer-treatment-research-studies</field_pretty_url>
  <para_id>836317</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>904030</term_id>
  <id>840882</id>
  <title>Center for Cancer Training (CCT)</title>
  <langcode>en</langcode>
  <field_short_title>About Center for Cancer Training (CCT)</field_short_title>
  <field_page_description>CCT's mission is to catalyze the development of a 21st century workforce capable of advancing cancer research through a scientifically integrated approach. </field_page_description>
  <field_feature_card_description>The mission is to catalyze the development of a 21st century cancer research workforce.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-06</field_date_posted>
  <field_date_reviewed>2014-10-16</field_date_reviewed>
  <para_id>840882</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919680</term_id>
  <id>847655</id>
  <title>About the NCI Cancer Bulletin</title>
  <langcode>en</langcode>
  <field_short_title>About the NCI Cancer Bulletin</field_short_title>
  <field_page_description>The NCI Cancer Bulletin is an award-winning online newsletter published by the National Cancer Institute from January 2004 through January 2013.</field_page_description>
  <field_feature_card_description>Information about the NCI Cancer Bulletin</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-28</field_date_posted>
  <field_date_reviewed>2014-10-28</field_date_reviewed>
  <field_pretty_url>cancer-bulletin</field_pretty_url>
  <para_id>847655</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>848991</term_id>
  <id>849014</id>
  <title>Partnerships to Advance Cancer Health Equity (PACHE)</title>
  <langcode>en</langcode>
  <field_short_title>Partnerships to Advance Cancer Health Equity (PACHE)</field_short_title>
  <field_page_description>PACHE fosters collaboration among institutions serving underserved health disparity populations and NCI-Designated Cancer Centers.</field_page_description>
  <field_feature_card_description>PACHE fosters collaboration among institutions serving underserved health disparity populations and NCI-Designated Cancer Centers.</field_feature_card_description>
  <field_list_description>PACHE fosters collaboration among institutions serving underserved health disparity populations and NCI-Designated Cancer Centers to train scientists and deliver cancer advances to underserved communities.


</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <para_id>849014</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>852822</id>
  <title>Building Partnerships Begins at Home  </title>
  <langcode>en</langcode>
  <field_short_title>Building Partnerships Begins at Home  </field_short_title>
  <field_page_description>Building Partnerships Begins at Home  </field_page_description>
  <field_feature_card_description>Building Partnerships Begins at Home  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-03</field_date_posted>
  <field_date_reviewed>2014-11-03</field_date_reviewed>
  <field_pretty_url>partnerships</field_pretty_url>
  <para_id>852822</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>857649</term_id>
  <id>857634</id>
  <title>Children's Assent</title>
  <langcode>en</langcode>
  <field_short_title>Children's Assent</field_short_title>
  <field_page_description>Assent is the process of involving children in the decision to take part in research studies.</field_page_description>
  <field_feature_card_description>Assent is the process of involving children in the decision to take part in research studies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-13</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>857634</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858170</term_id>
  <id>859589</id>
  <title>Keep Up with Your Daily Routine</title>
  <langcode>en</langcode>
  <field_short_title>Daily Routine</field_short_title>
  <field_page_description>Tips on managing your daily life, incorporating fun, humor, and physical activities.</field_page_description>
  <field_feature_card_description>Manage your daily life, incorporating fun, humor, and physical activities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859589</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858172</term_id>
  <id>859593</id>
  <title>Your Faith and Spirituality</title>
  <langcode>en</langcode>
  <field_short_title>Faith &amp; Spirituality</field_short_title>
  <field_page_description>What spirituality means to you, how cancer may affect and change your spirituality and values, and finding comfort and meaning.</field_page_description>
  <field_feature_card_description>What spirituality means to you, how cancer may affect and change your spirituality and values, and finding comfort and meaning. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859593</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1065468</id>
  <title>Modified Immunotherapy Approach Shows Promise for Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Modified Immunotherapy Approach Shows Promise for Leukemia</field_short_title>
  <field_page_description>A Cancer Currents blog post highlighting a new study of a modified immunotherapy approach that uses immune cells called natural killer cells.</field_page_description>
  <field_feature_card_description>A modified immunotherapy shows promise in some patients with acute myeloid leukemia.</field_feature_card_description>
  <field_list_description>Researchers have developed an immunotherapy approach that uses immune cells whose natural cancer killing abilities have been enhanced in the lab. In a small clinical trial, the treatment led to remissions in about half of patients with acute myeloid leukemia.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-21</field_date_posted>
  <field_date_reviewed>2016-10-20</field_date_reviewed>
  <field_pretty_url>nk-immunotherapy-leukemia</field_pretty_url>
  <para_id>1065468</para_id>
  <related_resource_id>6890290</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1028539</id>
  <title>FDA Approves Trabectedin to Treat Two Types of Soft Tissue Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Trabectedin for Sarcoma</field_short_title>
  <field_page_description>The FDA has approved trabectedin for patients with advanced liposarcoma and leiomyosarcoma whose cancer has progressed after prior treatment.</field_page_description>
  <field_feature_card_description>Approval for two sarcoma subytpes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-04</field_date_posted>
  <field_date_reviewed>2015-12-03</field_date_reviewed>
  <field_pretty_url>fda-trabectedin-sarcoma</field_pretty_url>
  <para_id>1028539</para_id>
  <related_resource_id>6572744</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1030201</id>
  <title>Study Sheds Light on Role of Inherited Mutations in Childhood Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Study Sheds Light on Role of Inherited Mutations in Childhood Cancer</field_short_title>
  <field_page_description>In the most comprehensive study of its kind conducted to date, more than 8 percent of children with cancer were found to have inherited genetic mutations associated with a predisposition to the disease.</field_page_description>
  <field_feature_card_description>Finding may influence patient care, counseling for parents, siblings.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-08</field_date_posted>
  <field_date_reviewed>2015-12-07</field_date_reviewed>
  <field_pretty_url>pediatric-germline</field_pretty_url>
  <para_id>1030201</para_id>
  <related_resource_ids>6572556</related_resource_ids>
  <related_resource_ids>6572557</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65906</term_id>
  <id>65958</id>
  <title>The Ruth L. Kirschstein NRSA Institutional Research Training Grant (T32)</title>
  <langcode>en</langcode>
  <field_short_title>NCI T32 Award</field_short_title>
  <field_page_description>Institutional award for predoctoral or postdoctoral candidates or mentored junior faculty who are pursuing careers in basic science.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-02</field_date_posted>
  <field_date_reviewed>2016-02-02</field_date_reviewed>
  <para_id>65958</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68311</term_id>
  <id>68382</id>
  <title>Mentored Patient-Oriented Research Career Development Award (K23)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K23 Award</field_short_title>
  <field_page_description>For postdoctoral candidates or mentored junior faculty who are clinical scientists pursuing careers in patient-oriented research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-21</field_date_posted>
  <field_date_reviewed>2015-12-14</field_date_reviewed>
  <para_id>68382</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938137</term_id>
  <id>69986</id>
  <title>Vaccine Reduces HPV Infections in Young Men</title>
  <langcode>en</langcode>
  <field_short_title>Vaccine Reduces HPV Infections in Young Men</field_short_title>
  <field_page_description>An international randomized clinical trial has shown that the vaccine Gardasil can reduce the incidence of anogenital human papillomavirus (HPV) infections in young men 16 to 26 years of age at the time of vaccination.</field_page_description>
  <field_feature_card_description>An international randomized clinical trial has shown that the vaccine Gardasil can reduce the incidence of anogenital human papillomavirus (HPV) infections in young men 16 to 26 years of age at the time of vaccination.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-03-29</field_date_posted>
  <field_date_reviewed>2011-03-29</field_date_reviewed>
  <field_pretty_url>quad-hpv-vaccine-men</field_pretty_url>
  <para_id>69986</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938135</term_id>
  <id>70472</id>
  <title>Targeted Therapies Sunitinib and Everolimus Improve Survival for Patients with Rare Type of Pancreatic Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Therapies Improve Survival for Patients with Rare Pancreatic Cancers</field_short_title>
  <field_page_description>In 2011, based on initial findings from two clinical trials, the Food and Drug Administration approved sunitinib and everolimus for patients with pancreatic neuroendocrine tumors. Updated results from the everolimus trial were published in September 2016.</field_page_description>
  <field_feature_card_description>The drugs increased the length of time patients with pancreatic neuroendocrine tumors survived overall and without their disease progressing.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-08</field_date_posted>
  <field_date_reviewed>2011-04-08</field_date_reviewed>
  <field_pretty_url>neuroendocrine-sunitinib-everolimus</field_pretty_url>
  <para_id>70472</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11958</term_id>
  <id>73729</id>
  <title>Anyone Can Get Skin Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Anyone Can Get Skin Cancer</field_short_title>
  <field_page_description>No matter if your skin is light, dark, or somewhere in between, everyone is at risk for skin cancer. Learn what skin cancer looks like, how to find it early, and how to lower the chance of skin cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-26</field_date_posted>
  <field_date_reviewed>2016-04-19</field_date_reviewed>
  <field_pretty_url>anyone-can-get-skin-cancer</field_pretty_url>
  <para_id>73729</para_id>
  <related_resource_ids>6785101</related_resource_ids>
  <related_resource_ids>6785102</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026061</term_id>
  <id>1026882</id>
  <title>Contact OGCR</title>
  <langcode>en</langcode>
  <field_short_title>Contact OGCR</field_short_title>
  <field_page_description>Contact the Office of Government and Congressional Relations (OGCR) if you have any questions or need more information on federal legislation and congressional activity affecting cancer research.</field_page_description>
  <field_feature_card_description>Contact the Office of Government and Congressional Relations (OGCR) if you have any questions or need more information on federal legislation and congressional activity affecting cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-08-08</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026882</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026800</term_id>
  <id>1026918</id>
  <title>Federal Health Legislation</title>
  <langcode>en</langcode>
  <field_short_title>Federal Health Legislation</field_short_title>
  <field_page_description>Legislation from the current Congress dealing with federal health related to NCI.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-19</field_date_reviewed>
  <para_id>1026918</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1028596</term_id>
  <id>1028597</id>
  <title>National Cancer Act of 1971</title>
  <langcode>en</langcode>
  <field_short_title>National Cancer Act of 1971</field_short_title>
  <field_page_description>The National Cancer Act of 1971, signed into law by President Richard Nixon, established the National Cancer Institute in its current form.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-12-04</field_date_reviewed>
  <para_id>1028597</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65188</id>
  <title>Drugs Approved for Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Breast Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for breast cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-09</field_date_reviewed>
  <field_pretty_url>breast</field_pretty_url>
  <para_id>65188</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65327</id>
  <title>Drugs Approved for Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Melanoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for melanoma. The list includes generic names and brand names. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-16</field_date_posted>
  <field_date_reviewed>2011-03-11</field_date_reviewed>
  <field_pretty_url>melanoma</field_pretty_url>
  <para_id>65327</para_id>
  <related_resource_ids>7073414</related_resource_ids>
  <related_resource_ids>7073415</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68370</term_id>
  <id>68379</id>
  <title>The NCI Transition Career Development Award (K22)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K22 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-21</field_date_posted>
  <field_date_reviewed>2012-03-16</field_date_reviewed>
  <para_id>68379</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>73714</id>
  <title>Denosumab Reduces Risk of Bone Side Effects in Advanced Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Denosumab Reduces Risk of Bone Side Effects in Advanced Prostate Cancer</field_short_title>
  <field_page_description>The biological agent denosumab (Xgeva) is more effective than zoledronic acid at decreasing the risk of bone fractures and other skeletal-related events (SRE) in men with castration-resistant metastatic prostate cancer, according to results from a randomi</field_page_description>
  <field_feature_card_description>The biological agent denosumab is more effective than zoledronic acid at decreasing the risk of bone fractures in men with castration-resistant metastatic prostate cancer, according to results from a randomized trial.</field_feature_card_description>
  <field_list_description>The biological agent denosumab (Xgeva) is more effective than zoledronic acid at decreasing the risk of bone fractures and other skeletal-related events (SRE) in men with castration-resistant metastatic prostate cancer, according to results from a randomized clinical trial reported online February 25, 2011, in The Lancet.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-13</field_date_posted>
  <field_date_reviewed>2011-04-13</field_date_reviewed>
  <field_pretty_url>denosumab-bone-fractures</field_pretty_url>
  <para_id>73714</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>419028</term_id>
  <id>419029</id>
  <title>Research Team Members</title>
  <langcode>en</langcode>
  <field_short_title>Research Team Members</field_short_title>
  <field_page_description>Information about the different types of experts involved in designing and running a clinical trial. </field_page_description>
  <field_feature_card_description>Information about the different types of experts involved in designing and running a clinical trial. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-04</field_date_posted>
  <field_date_reviewed>2012-09-04</field_date_reviewed>
  <para_id>419029</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1022100</id>
  <title>Researcher Interview: Matthew Meyerson</title>
  <langcode>en</langcode>
  <field_short_title>Researcher Interview: Matthew Meyerson</field_short_title>
  <field_page_description>CCG Interview with Matthew Meyerson</field_page_description>
  <field_feature_card_description>Researcher Interview: Matthew Meyerson</field_feature_card_description>
  <field_list_description>In this interview, Matthew Meyerson, M.D., Ph.D., Professor of Pathology at Dana-Farber Cancer Institute and Harvard Medical School, talks about the clinical impact of his research on lung cancer and discusses developing technologies and ongoing challenges in the field of cancer genomics. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-11-06</field_date_posted>
  <field_date_reviewed>2015-11-05</field_date_reviewed>
  <field_pretty_url>matthew-meyerson-interview</field_pretty_url>
  <para_id>1022100</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026057</term_id>
  <id>1026866</id>
  <title>Committees of Interest</title>
  <langcode>en</langcode>
  <field_short_title>Committees of Interest</field_short_title>
  <field_page_description>Learn more about the specific committees which appropriate funds, authorize programs, or oversee activities of the National Cancer Institute.</field_page_description>
  <field_feature_card_description>Learn more about the specific committees which appropriate funds, authorize programs, or oversee activities of the National Cancer Institute.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-18</field_date_reviewed>
  <para_id>1026866</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1028622</term_id>
  <id>1028623</id>
  <title>National Cancer Act of 1937</title>
  <langcode>en</langcode>
  <field_short_title>National Cancer Act of 1937</field_short_title>
  <field_page_description>National Cancer Act of 1937, signed into law by President Franklin D. Roosevelt, created the National Cancer Institute. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-12-04</field_date_reviewed>
  <para_id>1028623</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65189</id>
  <title>Drugs Approved for Bladder Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Bladder Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for bladder cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-09</field_date_reviewed>
  <field_pretty_url>bladder</field_pretty_url>
  <para_id>65189</para_id>
  <related_resource_ids>7098158</related_resource_ids>
  <related_resource_ids>7098162</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>65316</id>
  <title>Drugs Approved for Colon and Rectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Colon and Rectal Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for use in colon cancer and rectal cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-05-04</field_date_posted>
  <field_date_reviewed>2011-03-10</field_date_reviewed>
  <field_pretty_url>colorectal</field_pretty_url>
  <para_id>65316</para_id>
  <related_resource_ids>7097547</related_resource_ids>
  <related_resource_ids>7097567</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65207</term_id>
  <id>65887</id>
  <title>Ruth L.  Kirschstein NRSA for Individual Predoctoral MD/PhD Degree Fellows (F30)</title>
  <langcode>en</langcode>
  <field_short_title>NCI F30 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-17</field_date_posted>
  <field_date_reviewed>2011-03-17</field_date_reviewed>
  <para_id>65887</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68317</term_id>
  <id>68483</id>
  <title>The Pathway to Independence Award (K99/R00)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K99 Award</field_short_title>
  <field_page_description>For postdoctoral candidates and mentored junior faculty who have less than 5 years of research experience since earning their doctoral degree.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2016-01-11</field_date_reviewed>
  <para_id>68483</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>68506</term_id>
  <id>68514</id>
  <title>Ruth L. Kirschstein NRSA for Senior Fellows (F33)</title>
  <langcode>en</langcode>
  <field_short_title>NCI F33 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-22</field_date_reviewed>
  <para_id>68514</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>70473</id>
  <title>Certain Physicians Are More Likely to Refer Patients to Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Certain Physicians Are More Likely to Refer Patients to Clinical Trials</field_short_title>
  <field_page_description>According to a survey-based study of more than 1,500 physicians treating patients with lung or colorectal cancer, medical oncologists were the most likely and surgeons the least likely to refer patients to, or enroll them in, clinical trials.</field_page_description>
  <field_feature_card_description>According to a survey-based study of more than 1,500 physicians treating patients with lung or colorectal cancer, medical oncologists were the most likely and surgeons the least likely to refer patients to, or enroll them in, clinical trials.</field_feature_card_description>
  <field_list_description>According to a survey-based study of more than 1,500 physicians treating patients with lung or colorectal cancer published online February 11, 2011 in the Journal of the National Cancer Institute, medical oncologists were the most likely and surgeons the least likely to refer patients to, or enroll them in, clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-04-08</field_date_posted>
  <field_date_reviewed>2011-04-08</field_date_reviewed>
  <field_pretty_url>clinical-trial-referral</field_pretty_url>
  <para_id>70473</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919012</term_id>
  <id>445962</id>
  <title>Spanish-Language Social Media at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Spanish-Language Social Media at NCI</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-10-09</field_date_posted>
  <field_date_reviewed>2012-10-09</field_date_reviewed>
  <para_id>445962</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938139</term_id>
  <id>476523</id>
  <title>New Targeted Treatment May Slow Disease in Patients with Advanced GIST</title>
  <langcode>en</langcode>
  <field_short_title>New Targeted Treatment May Slow Disease in Patients with Advanced GIST</field_short_title>
  <field_page_description>A new oral drug, regorafenib (Stivarga®), may delay the progression of advanced gastrointestinal stromal tumors (GIST) that are resistant to treatment, according to results from an international clinical trial published November 22, 2012, in The Lancet. </field_page_description>
  <field_feature_card_description>A new oral drug, regorafenib (Stivarga®), may delay the progression of advanced gastrointestinal stromal tumors (GIST) that are resistant to treatment, according to results from an international clinical trial published November 22, 2012, in The Lancet. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-12-11</field_date_posted>
  <field_date_reviewed>2012-12-11</field_date_reviewed>
  <field_pretty_url>regorafenib-gist</field_pretty_url>
  <para_id>476523</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478613</id>
  <title>Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)</title>
  <langcode>en</langcode>
  <field_short_title>Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)</field_short_title>
  <field_page_description>Funding for NCTN and NCORP Research Bases to support biomarker, imaging, quality of life and cost-effectiveness studies (BIQSFP) associated with network trials.</field_page_description>
  <field_feature_card_description>Funded NCTN and NCORP Research Bases can apply for special funding.</field_feature_card_description>
  <field_list_description>Funded NCTN and NCORP Research Bases can apply for funding to support biomarker, imaging, and quality of life studies with or without Cost-Effectiveness Analysis (CEA) proposals associated with NCI network trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <para_id>478613</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938350</term_id>
  <id>826428</id>
  <title>Monoclonal Antibody Therapy for Relapsed or Treatment-Resistant Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Monoclonal Antibody Therapy for Relapsed or Treatment-Resistant Neuroblastoma</field_short_title>
  <field_page_description>NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory neuroblastoma.</field_page_description>
  <field_feature_card_description>NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory neuroblastoma.</field_feature_card_description>
  <field_list_description>NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory high-risk neuroblastoma.

</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-09-09</field_date_posted>
  <field_date_reviewed>2014-09-08</field_date_reviewed>
  <field_pretty_url>2-studies-mab</field_pretty_url>
  <para_id>826428</para_id>
  <related_resource_ids>6494749</related_resource_ids>
  <related_resource_ids>6494750</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogSeries</CONTENTTYPENAME>
  <term_id>919767</term_id>
  <id>828591</id>
  <title>CRCHD Dialogue on Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Dialogue on Disparities</field_short_title>
  <field_page_description>Blog from CRCHD. Stay up-to-date with cancer health disparities issues and read CRCHD spotlights on promising research findings and program updates.</field_page_description>
  <field_feature_card_description>Stay up-to-date with cancer health disparities issues and read CRCHD spotlights on promising research findings and program updates.</field_feature_card_description>
  <field_list_description>Stay up-to-date with cancer health disparities issues and read CRCHD spotlights on promising research findings and program updates.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>828650</term_id>
  <id>828697</id>
  <title>About Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>About Cancer Health Disparities</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-18</field_date_reviewed>
  <para_id>828697</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>833172</term_id>
  <id>833173</id>
  <title>Disparities Research</title>
  <langcode>en</langcode>
  <field_short_title>Disparities Research</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833173</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836316</id>
  <title>Providing Your Tissue for Research: What You Need To Know</title>
  <langcode>en</langcode>
  <field_short_title>Providing Your Tissue for Research: What You Need To Know</field_short_title>
  <field_page_description>Covers things you should know and think about when deciding to donate your tissue to research. Tissue can include materials from your body such as skin, hair, nails, blood, and urine.</field_page_description>
  <field_feature_card_description>Covers things you should know and think about when deciding to donate your tissue to research. Tissue can include materials from your body such as skin, hair, nails, blood, and urine.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>providing-tissue</field_pretty_url>
  <para_id>836316</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836754</id>
  <title>Understanding Prostate Changes: A Health Guide for Men</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Prostate Changes: A Health Guide for Men</field_short_title>
  <field_page_description>Explains prostate cancer symptoms, risk factors, the PSA test, and other prostate conditions including BPH and prostatitis.</field_page_description>
  <field_feature_card_description>Explains prostate cancer symptoms, risk factors, the PSA test, and other prostate conditions including BPH and prostatitis.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>understanding-prostate-changes</field_pretty_url>
  <para_id>836754</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1082596</term_id>
  <id>1087413</id>
  <title>Archived International Conference on HIV/AIDS Meeting Materials</title>
  <langcode>en</langcode>
  <field_short_title>Archived International Conference on HIV/AIDS Meeting Materials</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-14</field_date_posted>
  <field_date_reviewed>2017-06-14</field_date_reviewed>
  <field_pretty_url>icmh-archives</field_pretty_url>
  <para_id>1087413</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089297</id>
  <title>Large Study Verifies Cancer Risk for Women Carrying BRCA1 or BRCA2 Mutations</title>
  <langcode>en</langcode>
  <field_short_title>Study Affirms Cancer Risk for Women with BRCA Mutations</field_short_title>
  <field_page_description>A Cancer Currents blog post on a large, prospective study of breast, ovarian, and contralateral breast cancer risks associated with BRCA1 and BRCA2 gene mutations.</field_page_description>
  <field_feature_card_description>High lifetime risks of breast and ovarian cancers confirm earlier findings.</field_feature_card_description>
  <field_list_description>Results from the first large prospective study of breast and ovarian cancer risk in women with inherited mutations in the BRCA 1 or BRCA2 genes confirm the high risks estimated from earlier, retrospective studies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-12</field_date_posted>
  <field_date_reviewed>2017-07-12</field_date_reviewed>
  <field_pretty_url>brca-mutation-cancer-risk</field_pretty_url>
  <para_id>1089297</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089578</id>
  <title>NCI’s Technology Transfer Center—Moving Inventions and Ideas from the Lab to Patients: An Interview with Dr. Michael Salgaller</title>
  <langcode>en</langcode>
  <field_short_title>Technology Transfer: From the Lab to Patients</field_short_title>
  <field_page_description>A Cancer Currents blog post featuring an interview with Dr. Michael Salgaller about how NCI’s Technology Transfer Center helps to move NCI-developed technologies from the lab to the bedside.</field_page_description>
  <field_feature_card_description>NCI's Technology Transfer Center helps to advance inventions ‘across the finish line.’</field_feature_card_description>
  <field_list_description>An interview with Dr. Michael Salgaller about how NCI’s Technology Transfer Center helps to move new technologies developed by NCI and NIH scientists from the lab to the bedside.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-17</field_date_posted>
  <field_date_reviewed>2017-07-14</field_date_reviewed>
  <field_pretty_url>tech-transfer-salgaller</field_pretty_url>
  <para_id>1089578</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1090183</id>
  <title>FDA Clears Wider Use of Cooling Cap to Reduce Hair Loss during Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>FDA Clears Wider Use of Cooling Cap </field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about FDA’s clearance of the DigniCap Scalp Cooling System for use in reducing hair loss during chemotherapy by patients with any type of solid tumor. </field_page_description>
  <field_feature_card_description>The clearance covers patients with any type of solid tumor receiving chemotherapy. </field_feature_card_description>
  <field_list_description>The FDA has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy called the DigniCap Scalp Cooling System—for use by patients with any type of solid tumor. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-21</field_date_posted>
  <field_date_reviewed>2017-07-19</field_date_reviewed>
  <field_pretty_url>fda-cooling-cap-chemotherapy</field_pretty_url>
  <para_id>1090183</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1092400</id>
  <title>FDA Approves Nivolumab for Some Metastatic Colorectal Cancers</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Nivolumab for Colorectal Cancer</field_short_title>
  <field_page_description>FDA has approved nivolumab (Opdivo®) for metastatic colorectal cancer with tumors that have alterations that affect DNA repair, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Approval applies to patients whose tumors have specific genetic alterations.</field_feature_card_description>
  <field_list_description>FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with metastatic colorectal cancer whose tumors have alterations that affect DNA repair.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <field_pretty_url>nivolumab-fda-colorectal</field_pretty_url>
  <para_id>1092400</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1092459</term_id>
  <id>1092471</id>
  <title>Prior Approval Requests</title>
  <langcode>en</langcode>
  <field_short_title>Prior Approval Requests</field_short_title>
  <field_page_description>Approval from NIH may be required before a cancer research grant recipient makes budget modifications or undertakes particular activities. Learn how to request approval.</field_page_description>
  <field_feature_card_description>Prior written approval from NIH may be required before modifying grant budget or activities. </field_feature_card_description>
  <field_list_description>The recipient institution is permitted some flexibility for rebudgeting between budget categories, but some actions require prior approval from the NCI. Requests must be submitted at least 30 days before the proposed change. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <para_id>1092471</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904180</term_id>
  <id>828660</id>
  <title>Health Disparities Resources</title>
  <langcode>en</langcode>
  <field_short_title>Health Disparities Resources</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828660</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>828699</id>
  <title>September Spotlight: Childhood Cancer Awareness Month and other Cancer Awareness Highlights</title>
  <langcode>en</langcode>
  <field_short_title>September Spotlight: Childhood Cancer Awareness Month and other Cancer Awareness Highlights</field_short_title>
  <field_page_description>In September, CRCHD joins the rest of the nation in recognizing Childhood Cancer Awareness Month, Leukemia and Lymphoma Awareness Month, and Prostate Cancer Awareness Month.</field_page_description>
  <field_feature_card_description>In September, CRCHD joins the rest of the nation in recognizing Childhood Cancer Awareness Month, Leukemia and Lymphoma Awareness Month, and Prostate Cancer Awareness Month.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-18</field_date_posted>
  <field_date_reviewed>2014-09-18</field_date_reviewed>
  <field_pretty_url>september-spotlight</field_pretty_url>
  <para_id>828699</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833179</term_id>
  <id>833184</id>
  <title>Community Networks Program (CNP)</title>
  <langcode>en</langcode>
  <field_short_title>CNP </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-24</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833184</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836320</id>
  <title>When Cancer Returns</title>
  <langcode>en</langcode>
  <field_short_title>When Cancer Returns</field_short_title>
  <field_page_description>Covers the physical and emotional issues related to having a cancer recurrence.</field_page_description>
  <field_feature_card_description>Covers the physical and emotional issues related to having a cancer recurrence.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-02</field_date_reviewed>
  <field_pretty_url>when-cancer-returns</field_pretty_url>
  <para_id>836320</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836658</id>
  <title>Facing Forward: When Someone You Love Has Completed Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Facing Forward: When Someone You Love Has Completed Cancer Treatment</field_short_title>
  <field_page_description>Covers coping strategies to help cancer caregivers adjust their focus to the recovery phase once treatment is over for their loved one with cancer.</field_page_description>
  <field_feature_card_description>Covers coping strategies to help cancer caregivers adjust their focus to the recovery phase once treatment is over for their loved one with cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>someone-you-love-completed-cancer-treatment</field_pretty_url>
  <para_id>836658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069528</term_id>
  <id>842460</id>
  <title>What Do We Mean By "RAS Pathway"?</title>
  <langcode>en</langcode>
  <field_short_title>What Do We Mean By "RAS Pathway"?</field_short_title>
  <field_page_description>Frank McCormick, scientific lead of the RAS Initiative, requests input from the RAS community to update our conception of the "RAS pathway".</field_page_description>
  <field_feature_card_description>What Do We Mean By "RAS Pathway"?</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-10-22</field_date_posted>
  <field_date_reviewed>2014-10-22</field_date_reviewed>
  <field_pretty_url>what-do-we-mean-ras-pathway</field_pretty_url>
  <para_id>842460</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858164</term_id>
  <id>858342</id>
  <title>Facing Cancer with Your Spouse or Partner</title>
  <langcode>en</langcode>
  <field_short_title>Facing Cancer with Your Spouse or Partner</field_short_title>
  <field_page_description>Practical and supportive information to help you face cancer with your spouse or partner. Includes tips to help improve communication.</field_page_description>
  <field_feature_card_description>Practical and supportive information to help you face cancer with your spouse or partner.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-14</field_date_reviewed>
  <para_id>858342</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>912419</term_id>
  <id>859634</id>
  <title>Survivorship</title>
  <langcode>en</langcode>
  <field_short_title>Survivorship</field_short_title>
  <field_page_description>After cancer treatment, the transition to a new way of life can be hard. Find out how to plan for follow-up care and adjust to physical, emotional, and family changes.</field_page_description>
  <field_feature_card_description>Many cancer survivors say that once treatment ended, it was hard to make a transition to a new way of life. Find out how to adjust to the new feelings and issues that arise when cancer treatment is over.</field_feature_card_description>
  <field_list_description>Many cancer survivors say that once treatment ended, it was hard to make a transition to a new way of life. Find out how to adjust to physical and emotional changes, deal with common family issues, and plan for follow-up care after treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859634</para_id>
  <related_resource_ids>7250709</related_resource_ids>
  <related_resource_ids>7250710</related_resource_ids>
  <related_resource_ids>7250711</related_resource_ids>
  <related_resource_ids>7250712</related_resource_ids>
  <related_resource_ids>7250715</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1065450</id>
  <title>CCG Welcomes a New Genomic Data Analysis Network</title>
  <langcode>en</langcode>
  <field_short_title>CCG's New Genomic Data Analysis Network</field_short_title>
  <field_page_description>NCI's Center for Cancer Genomics (CCG) awarded a new Genomic Data Analysis Network (GDAN), comprised of thirteen centers of three types: Processing, Specialized, and Visualization. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-10-20</field_date_posted>
  <field_date_reviewed>2016-10-20</field_date_reviewed>
  <field_pretty_url>new-genomic-data-analysis-network</field_pretty_url>
  <para_id>1065450</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1066282</id>
  <title>2nd Annual Intra-NCI Global Cancer Research Day: Highlighting Prevention and Screening </title>
  <langcode>en</langcode>
  <field_short_title>2nd Annual Intra-NCI Global Cancer Research Day</field_short_title>
  <field_page_description>2nd Annual Intra-NCI Global Cancer Research Day: Highlighting Prevention and Screening (GCR2016)</field_page_description>
  <field_feature_card_description>2nd Annual Intra-NCI Global Cancer Research Day: Highlighting Prevention and Screening (GCR2016)</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-02</field_date_posted>
  <field_date_reviewed>2016-11-02</field_date_reviewed>
  <field_pretty_url>intraNCI_global_cancer_research_day_2016</field_pretty_url>
  <para_id>1066282</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>1067315</id>
  <title>Examining the Effects of Presurgical Treatment for Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Effects of Presurgical Treatment for Prostate Cancer</field_short_title>
  <field_page_description>In this study, men diagnosed with androgen-sensitive prostate cancer with intermediate- or high-risk features will be examined with mpMRI, undergo targeted biopsies, and be treated with neoadjuvant androgen deprivation therapy.</field_page_description>
  <field_feature_card_description>In this study, men diagnosed with androgen-sensitive prostate cancer with intermediate- or high-risk features will be examined with mpMRI, undergo targeted biopsies, and be treated with neoadjuvant androgen deprivation therapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-28</field_date_posted>
  <field_date_reviewed>2016-11-28</field_date_reviewed>
  <field_pretty_url>mri-neoadjuvant-prostate</field_pretty_url>
  <para_id>1067315</para_id>
  <related_resource_ids>6496375</related_resource_ids>
  <related_resource_ids>6496376</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068137</term_id>
  <id>1068980</id>
  <title>Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows</title>
  <langcode>en</langcode>
  <field_short_title>IOTF: Cancer Prevention Product Review</field_short_title>
  <field_page_description>NCI and FDA collaborate to train individuals in the medical product development and application process. Learn more about this cancer training program.</field_page_description>
  <field_feature_card_description>Training to facilitate novel approaches to cancer prevention. </field_feature_card_description>
  <field_list_description>This interagency program trains individuals in the medical product development processes and their application to study populations, including healthy subjects, to facilitate the movement of novel approaches from the bench to the community.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-12</field_date_posted>
  <field_date_reviewed>2016-12-12</field_date_reviewed>
  <para_id>1068980</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1068124</term_id>
  <id>1068988</id>
  <title>IOTF Mentors: Track 1 and Track 2</title>
  <langcode>en</langcode>
  <field_short_title>IOTF Mentors: Tracks 1 and 2</field_short_title>
  <field_page_description>While at FDA, fellows are assigned a mentor who is a senior member of FDA scientific review staff. Learn more about mentors for Tracks 1 and 2. </field_page_description>
  <field_feature_card_description>Senior members of FDA scientific review staff mentor IOTF fellows in tracks 1 and 2. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-12</field_date_posted>
  <field_date_reviewed>2016-12-12</field_date_reviewed>
  <field_pretty_url>mentors-track-1-2</field_pretty_url>
  <para_id>1068988</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1069392</id>
  <title>GICR Partners Task Force for Cancer Registration in Vietnam</title>
  <langcode>en</langcode>
  <field_short_title>GICR Partners Task Force for Cancer Registration in Vietnam</field_short_title>
  <field_page_description>Global taskforce aims strengthen population-based cancer registries with improved operations, access to case reports, and cancer surveillance.</field_page_description>
  <field_feature_card_description>Partners aim to improve registry operations and cancer surveillance.</field_feature_card_description>
  <field_list_description>NCI joins global taskforce to strengthen population-based cancer registries with improved registry operations, access to case reports, and cancer surveillance.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-20</field_date_posted>
  <field_date_reviewed>2016-12-19</field_date_reviewed>
  <field_pretty_url>cancer-registration-vietnam</field_pretty_url>
  <para_id>1069392</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>940315</term_id>
  <id>1070677</id>
  <title>Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Nivolumab for Recurrent Head and Neck Cancer Improves Survival</field_short_title>
  <field_page_description>A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.</field_page_description>
  <field_feature_card_description>In a phase III trial, the drug improved overall survival better than chemotherapy.</field_feature_card_description>
  <field_list_description>Results from a phase III trial showed that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-04</field_date_posted>
  <field_date_reviewed>2017-01-04</field_date_reviewed>
  <field_pretty_url>nivolumab-hnscc</field_pretty_url>
  <para_id>1070677</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>445983</id>
  <title>Patient Education Publications</title>
  <langcode>en</langcode>
  <field_short_title>Patient Education Publications</field_short_title>
  <field_page_description>Popular NCI patient education booklets available to download as a PDF or to an e-book device, smartphone, or tablet.</field_page_description>
  <field_feature_card_description>Check out our patient education booklets, available in PDF or as downloads to an e-book device, smartphone, or tablet. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-17</field_date_reviewed>
  <para_id>445983</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>464421</id>
  <title>Understanding Breast Changes: A Health Guide for Women</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Breast Changes: A Health Guide for Women</field_short_title>
  <field_page_description>Explains next steps after an abnormal mammogram result, including information about how conditions are diagnosed and treated.</field_page_description>
  <field_feature_card_description>Explains next steps after an abnormal mammogram result, including information about how conditions are diagnosed and treated.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-23</field_date_reviewed>
  <field_pretty_url>understanding-breast-changes</field_pretty_url>
  <para_id>464421</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916996</term_id>
  <id>819746</id>
  <title>Careers at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Careers at NCI</field_short_title>
  <field_page_description>Employment, fellowship, intern, postdoctoral, and advocacy opportunities at NCI.</field_page_description>
  <field_feature_card_description>Employment, fellowship, intern, postdoctoral, and advocacy opportunities at NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-27</field_date_posted>
  <field_date_reviewed>2014-08-27</field_date_reviewed>
  <para_id>819746</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>819945</id>
  <title>Crunching Numbers: What Cancer Screening Statistics Really Tell Us</title>
  <langcode>en</langcode>
  <field_short_title>Crunching Numbers: What Cancer Screening Statistics Really Tell Us</field_short_title>
  <field_page_description>Cancer screening studies have shown that more screening does not necessarily translate into fewer cancer deaths. This article explains how to interpret the statistics used to describe the results of screening studies.</field_page_description>
  <field_feature_card_description>Learn to interpret the statistical results of cancer screening studies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-05-01</field_date_posted>
  <field_date_reviewed>2014-08-27</field_date_reviewed>
  <field_pretty_url>what-screening-statistics-mean</field_pretty_url>
  <para_id>819945</para_id>
  <related_resource_ids>7071285</related_resource_ids>
  <related_resource_ids>7071286</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>904109</term_id>
  <id>828587</id>
  <title>Contact &amp; Staff Bios</title>
  <langcode>en</langcode>
  <field_short_title>Contact &amp; Staff Bios</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828587</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904113</term_id>
  <id>828648</id>
  <title>CRCHD Programs &amp; Initiatives</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Programs &amp; Initiatives</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828648</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069528</term_id>
  <id>835077</id>
  <title>The RAS Initiative - Welcome</title>
  <langcode>en</langcode>
  <field_short_title>The RAS Initiative - Welcome</field_short_title>
  <field_page_description>Blog post from Dr. Harold Varmus, introducing the collaborative initiative to study RAS and provide better treatment for the many cancers driven by RAS mutations around the world.</field_page_description>
  <field_list_description>Former NCI Director and Nobel Laureate Harold Varmus describes the origins, goals, structure, and oversight of the RAS Initiative. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-10-20</field_date_posted>
  <field_date_reviewed>2014-10-20</field_date_reviewed>
  <field_pretty_url>welcome</field_pretty_url>
  <para_id>835077</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>463786</id>
  <title>Radiation Therapy and You: Support for People With Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Radiation Therapy and You</field_short_title>
  <field_page_description>This booklet explains the different types of radiation therapy, what people can expect during treatment, side effects that may happen and ways to manage them.</field_page_description>
  <field_feature_card_description>Explains the different types of radiation therapy, what people can expect during treatment, side effects that may happen and ways to manage them.</field_feature_card_description>
  <field_list_description>Explains the different types of radiation therapy, what people can expect during treatment, side effects that may happen and ways to manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-20</field_date_reviewed>
  <field_pretty_url>radiation-therapy-and-you</field_pretty_url>
  <para_id>463786</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478615</id>
  <title>BIQSFP FAQs</title>
  <langcode>en</langcode>
  <field_short_title>BIQSFP FAQs</field_short_title>
  <field_page_description>Find a list of frequently asked questions related to Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP).</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>faq</field_pretty_url>
  <para_id>478615</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084770</id>
  <title>Prognosis - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Prognosis</field_short_title>
  <field_page_description>Blog posts on cancer prognosis research—including factors that influence prognosis, prognostic biomarkers, and doctor–patient communication about prognosis—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer prognosis-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>prognosis</field_pretty_url>
  <para_id>1084770</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1084982</id>
  <title>Counseling Improves Survivorship Plan Implementation for Low-Income Breast Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Counseling Improves Survivorship Care Plan Implementation</field_short_title>
  <field_page_description>A Cancer Currents blog post on a randomized trial that showed that low-income women who received counseling and a survivorship care plan got improved follow-up care</field_page_description>
  <field_feature_card_description>Low-income women who role-played talking with their doctor about their plan got better care.</field_feature_card_description>
  <field_list_description>In a randomized trial, low-income women who role-played talking with their doctor about their survivorship care plan in a counseling session reported receiving more of their recommended care than women who did not get counseling.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-16</field_date_posted>
  <field_date_reviewed>2017-05-15</field_date_reviewed>
  <field_pretty_url>counseling-survivorship-care</field_pretty_url>
  <para_id>1084982</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>1085271</id>
  <title>Exceptional Responders Initiative: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Exceptional Responders Initiative: Questions and Answers</field_short_title>
  <field_page_description>NCI has embarked on the Exceptional Responders Initiative to understand the molecular underpinnings of exceptional responses to treatment, primarily via chemotherapy, in cancer patients.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-17</field_date_posted>
  <field_date_reviewed>2017-05-17</field_date_reviewed>
  <field_pretty_url>exceptional-responders-initiative-qa</field_pretty_url>
  <para_id>1085271</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>267257</term_id>
  <id>267267</id>
  <title>Find a Cancer Center</title>
  <langcode>en</langcode>
  <field_short_title>Find an NCI-Designated Cancer Center</field_short_title>
  <field_page_description>Find the locations of NCI-designated cancer centers by area, region, state, or name that includes contact information to help health care providers and cancer patients with referrals to clinical trials.</field_page_description>
  <field_feature_card_description>Use the map or list to find centers by area, region, state, or name.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-13</field_date_posted>
  <field_date_reviewed>2012-04-05</field_date_reviewed>
  <para_id>267267</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>860592</id>
  <title>Approaching Pediatric Cancers through a Global Lens</title>
  <langcode>en</langcode>
  <field_short_title>Approaching Pediatric Cancers through a Global Lens</field_short_title>
  <field_page_description>Since the incidence of pediatric cancer is relatively constant worldwide, strengthening population-based registries to collect data on the extent of disease at diagnosis would be helpful in determining if late diagnosis may explain difference in outcome globally.</field_page_description>
  <field_feature_card_description>Approaching Pediatric Cancers through a Global Lens</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-21</field_date_posted>
  <field_date_reviewed>2014-11-21</field_date_reviewed>
  <field_pretty_url>pediatrics</field_pretty_url>
  <para_id>860592</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916470</term_id>
  <id>882631</id>
  <title>1,3-Butadiene</title>
  <langcode>en</langcode>
  <field_short_title>1,3-Butadiene</field_short_title>
  <field_page_description>Learn about 1,3-butadiene, exposure to which can raise your risk of leukemia. 1,3-Butadiene is a gas used to produce synthetic rubber products, such as tires, resins, and plastics. Other sources of exposure include car exhaust; tobacco smoke; and polluted air and water near industrial facilities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-01-31</field_date_reviewed>
  <para_id>882631</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>883417</id>
  <title>More than 300 million people in at least 70 countries use smokeless tobacco </title>
  <langcode>en</langcode>
  <field_short_title>More than 300 million people in at least 70 countries use smokeless tobacco </field_short_title>
  <field_page_description>More than 300 million people in at least 70 countries use smokeless tobacco </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-16</field_date_posted>
  <field_date_reviewed>2014-12-16</field_date_reviewed>
  <field_pretty_url>smokeless-tobacco</field_pretty_url>
  <para_id>883417</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929838</term_id>
  <id>892302</id>
  <title>CCG Funding Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Funding Opportunities</field_short_title>
  <field_page_description>Center for Cancer Genomics (CCG) Funding Opportunities</field_page_description>
  <field_feature_card_description>CCG Funding Opportunities</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-10-23</field_date_posted>
  <field_date_reviewed>2015-01-08</field_date_reviewed>
  <para_id>892302</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>892471</id>
  <title>January Monthly Spotlight: Cervical Health and Cervical Cancer Disparities</title>
  <langcode>en</langcode>
  <field_short_title>January Monthly Spotlight: Cervical Health and Cervical Cancer Disparities</field_short_title>
  <field_page_description>In January, CRCHD joins the nation in raising awareness for Cervical Health and Cervical Cancer Disparities. This month we share a special focus on NCI/CRCHD research programs that are trying to reduce cervical cancer disparities in underserved communities and the people who are spreading the word about the importance </field_page_description>
  <field_feature_card_description>This month we share a special focus on NCI/CRCHD research programs that are trying to reduce cervical cancer disparities in underserved communitie</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-09</field_date_posted>
  <field_date_reviewed>2015-01-09</field_date_reviewed>
  <field_pretty_url>january-spotlight</field_pretty_url>
  <para_id>892471</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084734</id>
  <title>Biology of Cancer - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Biology of Cancer</field_short_title>
  <field_page_description>Blog posts on cancer biology research—including genomics, the tumor microenvironment, and potential new treatment targets—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer biology-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_list_description>Blog posts on cancer biology research—including genomics, the tumor microenvironment, and potential new treatment targets—from NCI Cancer Currents.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>biology</field_pretty_url>
  <para_id>1084734</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084760</id>
  <title>Cancer Disparities - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Disparities</field_short_title>
  <field_page_description>Blog posts on cancer health disparities research—including factors that influence disparities, disparities-related research efforts, and diversity in the cancer research workforce—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Cancer health disparities-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_list_description>Blog posts on cancer health disparities research—including factors that influence disparities, disparities-related research efforts, and diversity in the cancer research workforce—from NCI Cancer Currents.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>disparities</field_pretty_url>
  <para_id>1084760</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086663</id>
  <title>Midostaurin Approved by FDA for Acute Myeloid Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Midostaurin for AML</field_short_title>
  <field_page_description>A Cancer Currents blog post on the FDA approval of midostaurin for patients with newly diagnosed acute myeloid leukemia (AML) and mutations in the FLT3 gene.</field_page_description>
  <field_feature_card_description>The targeted drug is the first new AML treatment to be approved in decades.</field_feature_card_description>
  <field_list_description>The FDA has approved midostaurin for patients with newly diagnosed acute myeloid leukemia (AML) with mutations in the FLT3 gene. The approval also covers several rare conditions.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-01</field_date_posted>
  <field_date_reviewed>2017-06-01</field_date_reviewed>
  <field_pretty_url>fda-midostaurin-aml</field_pretty_url>
  <para_id>1086663</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1086816</term_id>
  <id>1086817</id>
  <title>NCI Cancer Moonshot&amp;#8480; Public Access and Data Sharing Policy</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot&amp;#8480; Public Access and Data Sharing Policy</field_short_title>
  <field_page_description>NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.</field_page_description>
  <field_feature_card_description>NCI has established a data sharing policy that supports public access to all research and data for projects funded as part of the Cancer Moonshot.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-07</field_date_posted>
  <field_date_reviewed>2017-06-05</field_date_reviewed>
  <para_id>1086817</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1087307</id>
  <title>Intervention Dynamic Trial Listing Page</title>
  <langcode>en</langcode>
  <field_short_title>Intervention Dynamic Trial Listing Page</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-13</field_date_posted>
  <field_date_reviewed>2017-06-13</field_date_reviewed>
  <field_pretty_url>intervention</field_pretty_url>
  <para_id>1087307</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080236</term_id>
  <id>1088803</id>
  <title>Denise Jenkins, M.B.A.</title>
  <langcode>en</langcode>
  <field_short_title>Denise Jenkins, M.B.A.</field_short_title>
  <field_page_description>Learn more about Denise Jenkins, M.B.A., program specialist in the NCI Office of HIV and AIDS Malignancy. </field_page_description>
  <field_feature_card_description>Learn more about Denise Jenkins, M.B.A., program specialist in the Office of HIV and AIDS Malignancy. </field_feature_card_description>
  <field_list_description>Learn more about Denise Jenkins, M.B.A., program specialist in the Office of HIV and AIDS Malignancy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-06-30</field_date_reviewed>
  <field_pretty_url>denise-jenkins</field_pretty_url>
  <para_id>1088803</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1074358</term_id>
  <id>1088972</id>
  <title>Tumor Microenvironment Network</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Microenvironment Network</field_short_title>
  <field_page_description>TMEN funded cancer research investigated mechanisms of a tumor’s interaction with its surrounding environment.</field_page_description>
  <field_feature_card_description>TMEN funded research into the mechanisms of tumor-host interactions in human cancer. </field_feature_card_description>
  <field_list_description>The Tumor Microenvironment Network was an NCI-funded Program that supported research towards better understanding the mechanisms of a tumor’s interaction with its surrounding environment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-21</field_date_posted>
  <field_date_reviewed>2017-02-28</field_date_reviewed>
  <para_id>1088972</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084784</id>
  <title>Treatment - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Treatment</field_short_title>
  <field_page_description>Blog posts on cancer treatment research—including new treatments for cancer and their effects, clinical trial results, and overcoming treatment resistance—from NCI Cancer Currents. </field_page_description>
  <field_feature_card_description>Cancer treatment-related blog posts from NCI Cancer Currents.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>treatment</field_pretty_url>
  <para_id>1084784</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086244</id>
  <title>New on NCI’s Websites for May 2017</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for May 2017</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-30</field_date_posted>
  <field_date_reviewed>2017-05-26</field_date_reviewed>
  <field_pretty_url>new-online-may-2017</field_pretty_url>
  <para_id>1086244</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1087617</term_id>
  <id>1087619</id>
  <title>2015 Outstanding Investigator Award Recipients</title>
  <langcode>en</langcode>
  <field_short_title>2015 Recipients of NCI Outstanding Investigator Awards</field_short_title>
  <field_page_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_page_description>
  <field_feature_card_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-14</field_date_posted>
  <field_date_reviewed>2015-10-14</field_date_reviewed>
  <para_id>1087619</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1087994</id>
  <title>Celebrating 21 Years of the CURE Program</title>
  <langcode>en</langcode>
  <field_short_title>Celebrating 21 Years of the CURE Program</field_short_title>
  <field_page_description>In honor of the 21st anniversary of the Continuing Umbrella of Research Experiences (CURE) program, CRCHD will host “Celebrating 21 Years of the CURE Program” on June 27, 2017.</field_page_description>
  <field_feature_card_description>CRCHD will host “Celebrating 21 Years of the CURE Program” on June 27, 2017.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-21</field_date_posted>
  <field_date_reviewed>2017-06-21</field_date_reviewed>
  <field_pretty_url>celebrating-cure</field_pretty_url>
  <para_id>1087994</para_id>
  <related_resource_ids>6805485</related_resource_ids>
  <related_resource_ids>6805489</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1088562</term_id>
  <id>1088563</id>
  <title>Engineered Invasive Human Breast Tumors with Integrated Capillaries and Lymphatics</title>
  <langcode>en</langcode>
  <field_short_title>Engineered Invasive Human Breast Tumors </field_short_title>
  <field_page_description>This collaborative study seeks to develop and apply new methods of engineering human breast tumors that allow for modular control over key aspects of a tumor and its microenvironment.</field_page_description>
  <field_feature_card_description>NCI-funded grant investigating Engineered Invasive Human Breast Tumors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-21</field_date_posted>
  <field_date_reviewed>2017-06-28</field_date_reviewed>
  <para_id>1088563</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089021</id>
  <title>Improving Cancer Control in Rural Communities: Next Steps</title>
  <langcode>en</langcode>
  <field_short_title>Improving Cancer Control in Rural Communities</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from NCI’s Dr. Robert Croyle on how the institute is working to address disparities in cancer outcomes in US rural communities.</field_page_description>
  <field_feature_card_description>NCI is working on multiple fronts to improve cancer control in rural areas.</field_feature_card_description>
  <field_list_description>Studies continue to show disparities in cancer outcomes for people who live in rural parts of the United States. NCI’s Dr. Robert Croyle explains how the institute is working with multiple partners to better understand and address these disparities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-07</field_date_posted>
  <field_date_reviewed>2017-07-06</field_date_reviewed>
  <field_pretty_url>rural-cancer-disparities-next-steps</field_pretty_url>
  <para_id>1089021</para_id>
  <related_resource_ids>6888169</related_resource_ids>
  <related_resource_ids>6888170</related_resource_ids>
  <related_resource_ids>6888171</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1090265</term_id>
  <id>1090266</id>
  <title>Cancer Prevention Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Prevention SC</field_short_title>
  <field_page_description>The Cancer Prevention Steering Committee reviews innovative cancer prevention, screening, and surveillance concepts.</field_page_description>
  <field_feature_card_description>The Cancer Prevention Steering Committee reviews innovative cancer prevention, screening, and surveillance concepts.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-28</field_date_posted>
  <field_date_reviewed>2017-07-21</field_date_reviewed>
  <para_id>1090266</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1103243</term_id>
  <id>1104011</id>
  <title>Treatment of Head and Neck Cancer in Children and Adolescents—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer Treatment in Children and Adolescents</field_short_title>
  <field_page_description>Find diagnosis, staging, and treatment information for these head and neck cancers: hypopharynx, larynx, lip and oral cavity, neck cancer with occult primary, nasopharynx, oropharynx, paranasal sinus and nasal cavity, and salivary gland cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-15</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104011</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1103853</term_id>
  <id>1104012</id>
  <title>Treatment of Head and Neck Cancer in Adults—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer Treatment in Adults</field_short_title>
  <field_page_description>Find information about prognosis, staging, and treatment for adult head and neck cancer sites: hypopharynx, larynx, lip and oral cavity, neck cancer with occult primary, nasopharynx, oropharynx, paranasal sinus and nasal cavity, and salivary gland cancer.</field_page_description>
  <field_list_description>Find information about incidence, risk factors, prognosis, staging, and treatment of the following head and neck cancer sites in adults: hypopharynx, larynx, lip and oral cavity, neck cancer with occult primary, nasopharynx, oropharynx, paranasal sinus and nasal cavity, and salivary gland cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-15</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104012</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1104019</term_id>
  <id>1104024</id>
  <title>Cancer Moonshot℠ - Recent Fiscal Year Funding</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot Funding for FY 2018</field_short_title>
  <field_page_description>The 21st Century Cures Act authorized $1.8 billion to fund the Cancer Moonshot over a 7-year period. See appropriated funding by fiscal year for the Cancer Moonshot.</field_page_description>
  <field_feature_card_description>See appropriated funding by fiscal year for the Cancer Moonshot.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104024</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1104880</id>
  <title>NCI Launches the Intramural Continuing Umbrella of Research Experiences (iCURE) Program!</title>
  <langcode>en</langcode>
  <field_short_title>NCI Launches iCURE!</field_short_title>
  <field_page_description>The new iCURE program supports students’ and scientists’ mentored research experiences in the NCI research community and encourages participation by underrepresented individuals.</field_page_description>
  <field_feature_card_description>The NCI Intramural Research Program and CRCHD announce the Intramural Continuing Umbrella of Research Experiences program!</field_feature_card_description>
  <field_list_description>The NCI Intramural Research Program and CRCHD announce the new Intramural Continuing Umbrella of Research Experiences (iCURE) program! iCURE supports mentored research experiences within the NCI research community and encourages participation by underrepresented individuals.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-03-16</field_date_posted>
  <field_date_reviewed>2018-01-23</field_date_reviewed>
  <field_pretty_url>icure-launch</field_pretty_url>
  <para_id>1104880</para_id>
  <related_resource_ids>6915692</related_resource_ids>
  <related_resource_ids>6915693</related_resource_ids>
  <related_resource_ids>6917103</related_resource_ids>
  <related_resource_ids>6917104</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107095</id>
  <title>Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>transitional-cell-cancer-renal-pelvis-ureter</field_pretty_url>
  <para_id>1107095</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107101</id>
  <title>Clinical Trials to Treat Adult Metastatic Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Adult Metastatic Brain Tumors</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>adult-metastatic-brain-tumors</field_pretty_url>
  <para_id>1107101</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107102</id>
  <title>Clinical Trials to Treat Childhood Astrocytoma</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Childhood Astrocytoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>childhood-astrocytoma</field_pretty_url>
  <para_id>1107102</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107151</id>
  <title>Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Abiraterone Approval Expanded for Prostate Cancer</field_short_title>
  <field_page_description>The FDA has expanded the approval of abiraterone (Zytiga) to treat men with metastatic prostate cancer. The agency approved abiraterone, in combination with prednisone, for men whose cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) and is at high risk of progressing.</field_page_description>
  <field_feature_card_description>Now approved for use in men with hormone-sensitive disease.</field_feature_card_description>
  <field_list_description>The Food and Drug Administration (FDA) has expanded the approval of abiraterone (Zytiga®) for men with prostate cancer. The agency approved abiraterone, in combination with the steroid prednisone, for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) and is at high risk of progressing.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-15</field_date_posted>
  <field_date_reviewed>2018-02-15</field_date_reviewed>
  <field_pretty_url>abiraterone-fda-prostate-hormone-sensitive</field_pretty_url>
  <para_id>1107151</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1137220</term_id>
  <id>1133248</id>
  <title>Challenges for Rare Tumor Researchers</title>
  <langcode>en</langcode>
  <field_short_title>Challenges for Rare Tumor Researchers</field_short_title>
  <field_page_description>Studying rare tumors is difficult, and MyPART is trying to address those challenges through data and biospecimen collection and sharing, clinics, and workshops.</field_page_description>
  <field_feature_card_description>Studying rare tumors is difficult, and MyPART is trying to address those challenges.</field_feature_card_description>
  <field_list_description>Finding treatments for rare cancer requires a multi-institutional effort to collect specimens for research and accrue patients to clinical trials. Robust model systems often don’t exist. These issues put rare tumor researchers at a disadvantage and discourage innovation in the field. MyPART is trying to address those challenges.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133248</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133314</id>
  <title>Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning</title>
  <langcode>en</langcode>
  <field_short_title>Two Radiation Therapy Approaches Prevent Breast Cancer Recurrences</field_short_title>
  <field_page_description>In women with early-stage breast cancer, whole- and partial-breast radiation therapy effectively prevent cancer from returning after breast-conserving surgery.</field_page_description>
  <field_feature_card_description>Low rates of cancer returning with either form of radiation. </field_feature_card_description>
  <field_list_description>In women with early-stage breast cancer, two clinical trials have shown that both whole- and partial-breast radiation therapy are effective at preventing the cancer from returning after breast-conserving surgery.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-19</field_date_posted>
  <field_date_reviewed>2018-12-18</field_date_reviewed>
  <field_pretty_url>breast-cancer-radiation-therapy-whole-partial-recurrence</field_pretty_url>
  <para_id>1133314</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134384</id>
  <title>Scientific Management Training </title>
  <langcode>en</langcode>
  <field_short_title>Scientific Management Training </field_short_title>
  <field_page_description>The Scientific Management Training (SMT) course provides management skills to NCI Principal Investigators and NCI Fellows focusing on personnel and project management to assist in succesfully leading scientific research laboratories.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <field_pretty_url>scientific-management-training</field_pretty_url>
  <para_id>1134384</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1134386</id>
  <title>Statistical Tutorial </title>
  <langcode>en</langcode>
  <field_short_title>Statistical Tutorial </field_short_title>
  <field_page_description>The Statistical Tutorial (ST) course is designed as a follow up to the Statistical Analysis of Research Data (SARD). This tutorial will apply real-time general principles of statistical analysis of research data.</field_page_description>
  <field_list_description>The Statistical Tutorial (ST) course is designed as a follow up to the Statistical Analysis of Research Data (SARD). This tutorial will apply real-time general principles of statistical analysis of research data including descriptive statistics, z- and t-tests of means and mean differences, simple and multiple linear regression, ANOVA tests, and Chi-Squared distribution.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <field_pretty_url>statistical-tutorial</field_pretty_url>
  <para_id>1134386</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1134545</id>
  <title>Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Atezolizumab Approved for Lung Cancer Initial Treatment</field_short_title>
  <field_page_description>FDA recently approved the immunotherapy drug atezolizumab (Tecentriq) for advanced nonsmall cell lung cancer (NSCLC) that lacks EGFR or ALK mutations.</field_page_description>
  <field_feature_card_description>Approval covers advanced NSCLC lacking specific genetic mutations.</field_feature_card_description>
  <field_list_description>On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <field_pretty_url>atezolizumab-lung-cancer-first-line</field_pretty_url>
  <para_id>1134545</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1134552</id>
  <title>What are rare soft tissue tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Soft Tissue Tumors</field_short_title>
  <field_page_description>Rare soft tissue tumors form in the body’s soft tissues such as muscle, fat, tendons, ligaments, lymph and blood vessels, nerves or other tissue that connects and supports the body. </field_page_description>
  <field_feature_card_description>Rare soft tissue tumors form in the body’s soft tissues such as muscle, fat, tendons, ligaments, lymph and blood vessels, nerves or other tissue that connects and supports the body. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134552</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134558</term_id>
  <id>1134554</id>
  <title>What are rare endocrine tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Endocrine Tumors</field_short_title>
  <field_page_description>Rare tumors can develop in the endocrine glands and other cells that produce horomones,like thyroid, adrenal, and pituitary glands, and cells in your pancreas. There are a few specific tumors that affect children, teens, and young adults.</field_page_description>
  <field_feature_card_description>Rare endocrine tumors form in glands or in cells that produce hormones, like thyroid, adrenal, and pituitary glands, and cells in your pancreas. </field_feature_card_description>
  <field_list_description>Rare endocrine tumors form in glands or in cells that produce hormones, like thyroid, adrenal, and pituitary glands, and cells in your pancreas. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134554</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>892450</id>
  <title>Targeting Ras Membrane Association:  Still an Achilles Heel</title>
  <langcode>en</langcode>
  <field_short_title>Targeting Ras Membrane Association:  Still an Achilles Heel</field_short_title>
  <field_page_description>Mark Philips describes how post-translational modifications of KRAS protein influence trafficking</field_page_description>
  <field_list_description>Mark Philips reviews attempts to drug KRAS, and to influence its translocation to the plasma membrane.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-20</field_date_posted>
  <field_date_reviewed>2015-01-09</field_date_reviewed>
  <field_pretty_url>targeting-ras-membrane-association-still-an-achilles-heel</field_pretty_url>
  <para_id>892450</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>895441</id>
  <title>Program Spotlight: 2014 Professional Development Workshop Scientific Poster Winners</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: 2014 Professional Development Workshop Scientific Poster Winners</field_short_title>
  <field_page_description>CRCHD celebrates its 2014 Professional Development Workshop Scientific Poster winners</field_page_description>
  <field_feature_card_description>CRCHD celebrates its 2014 Professional Development Workshop Scientific Poster winners</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-17</field_date_posted>
  <field_date_reviewed>2014-07-17</field_date_reviewed>
  <field_pretty_url>pwd-spotlight</field_pretty_url>
  <para_id>895441</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>895443</id>
  <title>Program Spotlight: CRCHD Mock Grant Review </title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: CRCHD Mock Grant Review </field_short_title>
  <field_page_description>The NCI Center to Reduce Cancer Health Disparities (CRCHD) held a Professional Development Workshop for its Continuing Umbrella of Research Experience (CURE) scholars on June 23-24, 2014, in Rockville, Maryland.  As part of the workshop, attendees had an opportunity to observe and participate in a Mock Grant Review. </field_page_description>
  <field_feature_card_description>The NCI Center to Reduce Cancer Health Disparities (CRCHD) held a Professional Development Workshop for its Continuing Umbrella of Research Experience (CURE) scholars on June 23-24, 2014, in Rockville, Maryland.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-17</field_date_posted>
  <field_date_reviewed>2014-07-17</field_date_reviewed>
  <field_pretty_url>mock-review</field_pretty_url>
  <para_id>895443</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899446</id>
  <title>Program Spotlight: Partnership for the Advancement of Cancer Research Project Brings Cancer Research Training to Underrepresented Students at New Mexico State University</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: Partnership for the Advancement of Cancer Research Project</field_short_title>
  <field_page_description>The NMSU and FHCRC PACHE partnership is making progress in recruiting and training Native Americans and Hispanics for careers in cancer research and drawing attention to the importance of cancer health disparities research.</field_page_description>
  <field_feature_card_description>PACHE is making progress in training Native Americans and Hispanics for careers in cancer research. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-28</field_date_posted>
  <field_date_reviewed>2014-03-28</field_date_reviewed>
  <field_pretty_url>nmsu-spotlight-blog</field_pretty_url>
  <para_id>899446</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899448</id>
  <title>Program Spotlight: Ground Broken for NCI-supported Cancer Treatment Center in Puerto Rico</title>
  <langcode>en</langcode>
  <field_short_title>Program Spotlight: Ground Broken for NCI-supported Cancer Treatment Center in Puerto Rico</field_short_title>
  <field_page_description>Dr. Sanya A. Springfield represented NCI at the groundbreaking ceremonies for the University of Puerto Rico (UPR) cancer hospital. In her remarks, she acknowledged the driving force behind this development is the UPR and the MD Anderson Cancer Center partnership.</field_page_description>
  <field_feature_card_description>Dr. Springfield represents NCI at the groundbreaking ceremonies for the UPR cancer hospital. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-14</field_date_posted>
  <field_date_reviewed>2014-03-14</field_date_reviewed>
  <field_pretty_url>uprccc-spotlight</field_pretty_url>
  <para_id>899448</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903744</term_id>
  <id>903745</id>
  <title>Infection and Neutropenia during Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Infection and Neutropenia</field_short_title>
  <field_page_description>Infection and neutropenia can be serious side effects during cancer treatment. Chemotherapy can increase your risk. Learn how to prevent infection during treatment. Find out what signs and symptoms to call the doctor about. </field_page_description>
  <field_list_description>Information about what cancer treatments increase the risks of infection and neutropenia, the signs of infection, and ways to prevent it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <para_id>903745</para_id>
  <related_resource_id>7120946</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1086097</id>
  <title>Pathology and Laboratory Medicine Programs</title>
  <langcode>en</langcode>
  <field_short_title>Pathology and Laboratory Medicine Programs</field_short_title>
  <field_page_description>CGH's engagement in pathology and laboratory medicine activities to increase awareness about the need for sustainable and accessible services globally.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-24</field_date_posted>
  <field_date_reviewed>2017-05-24</field_date_reviewed>
  <field_pretty_url>pathology</field_pretty_url>
  <para_id>1086097</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>848639</term_id>
  <id>1087287</id>
  <title>CURE Honors</title>
  <langcode>en</langcode>
  <field_short_title>CURE Honors</field_short_title>
  <field_page_description>In celebration of 21 years of the CURE program, CRCHD honors outstanding CURE scholars, mentors, and champions.</field_page_description>
  <field_feature_card_description>In celebration of 21 years of the CURE program, CRCHD honors outstanding CURE scholars, mentors, and champions.</field_feature_card_description>
  <field_list_description>In celebration of 21 years of the Continuing Umbrella of Research Experiences (CURE) program, CRCHD is honoring some of our most accomplished scholars, mentors, and champions, and their achievements in the CURE program.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-13</field_date_posted>
  <field_date_reviewed>2017-06-13</field_date_reviewed>
  <field_pretty_url>honors</field_pretty_url>
  <para_id>1087287</para_id>
  <related_resource_ids>7066046</related_resource_ids>
  <related_resource_ids>7066047</related_resource_ids>
  <related_resource_ids>7066048</related_resource_ids>
  <related_resource_ids>7066049</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1088503</id>
  <title>FDA Expands Approval of Ceritinib for ALK-Positive Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Expands Ceritinib Approval for Lung Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on the FDA approval of ceritinib for patients with untreated ALK-positive non-small cell lung cancer and a clinical trial of alectinib as a first-line lung cancer treatment.</field_page_description>
  <field_feature_card_description>ALK-targeted drug now approved as an initial treatment.</field_feature_card_description>
  <field_list_description>The FDA has approved the targeted therapy ceritinib as an initial treatment for patients with lung cancer that has a mutation in the ALK gene. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-27</field_date_posted>
  <field_date_reviewed>2017-06-27</field_date_reviewed>
  <field_pretty_url>fda-ceritinib-nsclc</field_pretty_url>
  <para_id>1088503</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1088703</id>
  <title>RAS and MYC: Co-conspirators in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>RAS and MYC: Co-conspirators in Cancer</field_short_title>
  <field_page_description>Inhibiting post-translational modifications of MYC to decrease its transcriptional activity is a new strategy for treating RAS-driven cancers.</field_page_description>
  <field_feature_card_description>The laboratory of Dr. Rosalie Sears is studying how modifications to the MYC transcription factor are dependent on RAS signaling in cancer.</field_feature_card_description>
  <field_list_description>The transcription factor MYC is an important downstream target of mutated RAS genes in human cancers. Inhibiting post-translational modifications of MYC to decrease its transcriptional activity is a new strategy for treating RAS-driven cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-13</field_date_posted>
  <field_date_reviewed>2017-06-29</field_date_reviewed>
  <field_pretty_url>myc-ras</field_pretty_url>
  <para_id>1088703</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1089961</id>
  <title>Two-Drug Combination Approved for Lung Cancers with BRAF Mutations</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Drugs for Lung Cancers with BRAF Mutations</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on FDA’s approval of dabrafenib (Tafinlar®) plus trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer with the BRAF V600E mutation.</field_page_description>
  <field_feature_card_description>Approval is the first for lung cancers with the BRAF V600E mutation.</field_feature_card_description>
  <field_list_description>FDA approved the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-18</field_date_posted>
  <field_date_reviewed>2017-07-17</field_date_reviewed>
  <field_pretty_url>fda-trametinib-dabrafenib-lung-cancer</field_pretty_url>
  <para_id>1089961</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>911277</term_id>
  <id>1090830</id>
  <title>Types of Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Types of Cancer Treatment</field_short_title>
  <field_page_description>This page lists the different cancer treatments, including chemotherapy, radiation therapy, immunotherapy, and targeted therapy and takes you to more information about each type.</field_page_description>
  <field_feature_card_description>Learn about surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and more.</field_feature_card_description>
  <field_list_description>Learn about the different types of cancer treatments, including chemotherapy, radiation therapy, immunotherapy, and targeted therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-31</field_date_posted>
  <field_date_reviewed>2017-07-31</field_date_reviewed>
  <para_id>1090830</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1091320</id>
  <title>Dual-Biomarker Blood Test Shows Promise for Pancreatic Cancer Early Detection</title>
  <langcode>en</langcode>
  <field_short_title>Test Shows Promise for Pancreatic Cancer Early Detection</field_short_title>
  <field_page_description>A new blood test may accurately detect pancreatic cancer at its earliest stages, when it is most likely to respond to treatment, findings from a new study suggest.</field_page_description>
  <field_feature_card_description>Test would only apply to people at high risk for the disease.</field_feature_card_description>
  <field_list_description>A new blood test that measures levels of two specific proteins may be able to accurately detect pancreatic cancer at its earliest stages, when it is most likely to respond to treatment, findings from a new study suggest. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-09</field_date_posted>
  <field_date_reviewed>2017-08-08</field_date_reviewed>
  <field_pretty_url>blood-test-pancreatic-cancer</field_pretty_url>
  <para_id>1091320</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1092506</term_id>
  <id>1092524</id>
  <title>Annual Reporting and Auditing </title>
  <langcode>en</langcode>
  <field_short_title>Annual Reporting and Auditing </field_short_title>
  <field_page_description>Reporting helps ensure desired results are achieved throughout the grants lifecycle. Learn more about reporting and auditing requirements for cancer research grants. </field_page_description>
  <field_feature_card_description>Recipients must submit a variety of reports throughout the award lifecycle.</field_feature_card_description>
  <field_list_description>Recipients must submit a variety of reports during the lifecycle of a grant award. Report types may include the research performance progress report, invention report, and financial progress report.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <para_id>1092524</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>892789</id>
  <title>Grantee Spotlight: Dr. Kolawole Okuyemi - Improving Cervical Cancer Screening Attitudes of African Immigrants and Refugees</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Dr. Kolawole Okuyemi - Improving Cervical Cancer Screening Attitudes</field_short_title>
  <field_page_description>Dr. Kolawole Okuyumi is studying cervical cancer screening attitudes and behaviors of African immigrants and refugees (Ethiopians, Nigerians, and Somalis) in Minnesota, and introducing “cancer” and “cervix” to their everyday vocabulary. </field_page_description>
  <field_feature_card_description>Dr. Kolawole Okuyumi is studying cervical cancer screening attitudes and behaviors of African immigrants and refugees in Minnesota, and introducing “cancer” and “cervix” to their everyday vocabulary. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-05</field_date_posted>
  <field_date_reviewed>2015-01-09</field_date_reviewed>
  <field_pretty_url>okuyemi-spotlight</field_pretty_url>
  <para_id>892789</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>897081</id>
  <title>Bacterial Biofilms Provide Clues into Colorectal Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Bacterial Biofilms Provide Clues into Colorectal Cancer Risk</field_short_title>
  <field_page_description>New data suggest that dense bacterial communities called biofilms may contribute to some colon cancers.</field_page_description>
  <field_feature_card_description>New data suggest that dense bacterial communities called biofilms may contribute to some colon cancers.</field_feature_card_description>
  <field_list_description>A new study suggests that dense bacterial communities called biofilms may promote the development of some colorectal cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-16</field_date_posted>
  <field_date_reviewed>2015-01-16</field_date_reviewed>
  <field_pretty_url>bacterial-biofilms-provide-clues</field_pretty_url>
  <para_id>897081</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>279438</term_id>
  <id>898412</id>
  <title>Surgery Choices for Women with DCIS or Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Surgery Choices for Women with DCIS or Breast Cancer</field_short_title>
  <field_page_description>Women diagnosed with DCIS or breast cancer may face a decision about which surgery to have. The choices of breast-sparing surgery, mastectomy, or mastectomy with reconstruction are explained and compared.</field_page_description>
  <field_feature_card_description>Breast-sparing surgery, mastectomy, or mastectomy with reconstruction are explained and compared.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-19</field_date_posted>
  <field_date_reviewed>2015-01-19</field_date_reviewed>
  <para_id>898412</para_id>
  <related_resource_ids>6264991</related_resource_ids>
  <related_resource_ids>6264992</related_resource_ids>
  <related_resource_ids>6264993</related_resource_ids>
  <related_resource_ids>6264994</related_resource_ids>
  <related_resource_ids>6264995</related_resource_ids>
  <related_resource_ids>6264996</related_resource_ids>
  <related_resource_ids>6264997</related_resource_ids>
  <related_resource_ids>6265000</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>901853</term_id>
  <id>901854</id>
  <title>Appetite Loss and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Appetite Loss</field_short_title>
  <field_page_description>Cancer treatments may lower your appetite. Side effects such as nausea, fatigue, or mouth sores can also making eating difficult. Learn how to eat well to avoid losing weight or becoming dehydrated, so you stay strong during treatment.</field_page_description>
  <field_list_description>Information about what causes appetite loss, a side effect of some cancer treatments, and ways to manage it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-09-14</field_date_reviewed>
  <para_id>901854</para_id>
  <related_resource_id>7127637</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903707</term_id>
  <id>903708</id>
  <title>Constipation and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Constipation</field_short_title>
  <field_page_description>Cancer treatment can cause constipation. Symptoms include hard stools, stomach cramps, bloating, and nausea. Causes also include pain medicine, diet changes, dehydration, and being less active. Prevention and treatment of constipation is explained. </field_page_description>
  <field_list_description>What causes constipation in people with cancer? Constipation is a side effect of cancer treatments. Learn about symptoms, causes, prevention, and treatment of constipation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2018-08-09</field_date_reviewed>
  <para_id>903708</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914566</term_id>
  <id>903713</id>
  <title>Nerve Problems (Peripheral Neuropathy) and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Nerve Problems (Peripheral Neuropathy)</field_short_title>
  <field_page_description>Nerve problems, such as peripheral neuropathy, can be caused by cancer treatment. Learn about signs and symptoms of nerve changes. Find out how to prevent or manage nerve problems during cancer treatment.</field_page_description>
  <field_list_description>Information about what causes nerve problems, a side effect of some cancer treatments, and ways to prevent or manage it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-12-04</field_date_reviewed>
  <para_id>903713</para_id>
  <related_resource_ids>7105809</related_resource_ids>
  <related_resource_ids>7105811</related_resource_ids>
  <related_resource_ids>7105812</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>899928</term_id>
  <id>903737</id>
  <title>Hair Loss (Alopecia) and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Hair Loss (Alopecia) </field_short_title>
  <field_page_description>Hair loss, also called alopecia, is a side effect of cancer treatments, such as chemotherapy and radiation therapy. Learn how to cope with and manage hair loss. Listen to tips from others who have experienced hair loss.</field_page_description>
  <field_list_description>Information about what causes hair loss (also called alopecia), a side effect of some cancer treatments, and ways to manage before and after hair loss.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-12-04</field_date_reviewed>
  <para_id>903737</para_id>
  <related_resource_ids>7107030</related_resource_ids>
  <related_resource_ids>7107032</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>898464</term_id>
  <id>905730</id>
  <title>Side Effects of Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Side Effects of Cancer Treatment</field_short_title>
  <field_page_description>Side effects are problems that occur when cancer treatment affects healthy tissues or organs. Learn about side effects caused by cancer treatment. Know what signs and symptoms to call your doctor about. Learn about treatments for side effects.      </field_page_description>
  <field_feature_card_description>Learn how to manage or treat side effects caused by cancer or cancer treatments. </field_feature_card_description>
  <field_list_description>Find common side effects caused by cancer or cancer treatments. Know what signs and symptoms to call your doctor about, ways to manage these problems, and treatment options. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2017-09-22</field_date_reviewed>
  <para_id>905730</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1092536</term_id>
  <id>1092547</id>
  <title>Transfer of a Grant</title>
  <langcode>en</langcode>
  <field_short_title>Transfer of a Grant</field_short_title>
  <field_page_description>NIH prior approval is required for the transfer of a grant. Learn more about transferring a cancer research grant from one entity to another.</field_page_description>
  <field_feature_card_description>Prior approval is required for the transfer of a grant.</field_feature_card_description>
  <field_list_description>A change of recipient organization may be accomplished under most NIH grants, including construction grants. NIH prior approval is required to transfer a grant-supported project or activity from one entity to another.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <para_id>1092547</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>903754</term_id>
  <id>14586</id>
  <title>Tumor Grade</title>
  <langcode>en</langcode>
  <field_short_title>Tumor Grade</field_short_title>
  <field_page_description>A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-05-09</field_date_posted>
  <field_date_reviewed>2013-05-03</field_date_reviewed>
  <field_pretty_url>tumor-grade-fact-sheet</field_pretty_url>
  <para_id>14586</para_id>
  <related_resource_id>6264645</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>903750</term_id>
  <id>14686</id>
  <title>Computed Tomography (CT) Scans and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Computed Tomography (CT) Scans and Cancer</field_short_title>
  <field_page_description>A fact sheet that describes the CT scan procedure and technology and its uses in screening, diagnosis, and treatment. </field_page_description>
  <field_feature_card_description>A fact sheet that describes the CT scan procedure and technology and its uses in screening, diagnosis, and treatment.</field_feature_card_description>
  <field_list_description>A fact sheet that describes the CT scan procedure and technology and its uses in diagnosis, screening, and treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-07-26</field_date_posted>
  <field_date_reviewed>2013-07-16</field_date_reviewed>
  <field_pretty_url>ct-scans-fact-sheet</field_pretty_url>
  <para_id>14686</para_id>
  <related_resource_ids>6923277</related_resource_ids>
  <related_resource_ids>6923278</related_resource_ids>
  <related_resource_ids>6923292</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1105271</term_id>
  <id>14815</id>
  <title>MERIT Award</title>
  <langcode>en</langcode>
  <field_short_title>MERIT Award</field_short_title>
  <field_page_description>Early Stage Investigators who have submitted R01 applications may be eligible for the Method to Extend Research in Time (MERIT) (R37) Award.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14815</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911145</term_id>
  <id>14822</id>
  <title>Obesity and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Obesity and Cancer </field_short_title>
  <field_page_description>A fact sheet that summarizes the evidence linking overweight and obesity to the risk of various cancers and to cancer survivorship.</field_page_description>
  <field_feature_card_description>Overweight and obesity are linked to increased risks of a number of cancers. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-03</field_date_posted>
  <field_date_reviewed>2017-01-17</field_date_reviewed>
  <field_pretty_url>obesity-fact-sheet</field_pretty_url>
  <para_id>14822</para_id>
  <related_resource_ids>7203735</related_resource_ids>
  <related_resource_ids>7203736</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12770</term_id>
  <id>14868</id>
  <title>Partners and Collaborators</title>
  <langcode>en</langcode>
  <field_short_title>Partners &amp; Collaborators</field_short_title>
  <field_page_description>Working with diverse partners allows NCI to engage in important research opportunities that otherwise might not be possible. </field_page_description>
  <field_feature_card_description>Working with diverse partners allows NCI to engage in important research opportunities that otherwise might not be possible. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-09</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14868</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>921989</term_id>
  <id>15181</id>
  <title>Childhood Cancer Survivor Study: An Overview</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancer Survivor Study: An Overview</field_short_title>
  <field_page_description>Health problems that develop years later as a result of a cancer treatment are known as late effects. The Childhood Cancer Survivor Study (CCSS) was started in 1994 to better understand these late effects.</field_page_description>
  <field_list_description>Health problems that develop years later as a result of a cancer treatment are known as late effects. The Childhood Cancer Survivor Study (CCSS) was started in 1994 to better understand and address these late effects.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2007-01-10</field_date_posted>
  <field_date_reviewed>2017-08-14</field_date_reviewed>
  <field_pretty_url>ccss</field_pretty_url>
  <para_id>15181</para_id>
  <related_resource_ids>7127901</related_resource_ids>
  <related_resource_ids>7127903</related_resource_ids>
  <related_resource_ids>7127904</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>12732</term_id>
  <id>15273</id>
  <title>Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Research</field_short_title>
  <field_page_description>NCI is the nation's leader in cancer research. Learn more about NCI's cancer research areas, key initiatives, progress made in cancer research, and resources for researchers like research tools, specimens and data. </field_page_description>
  <field_feature_card_description>Information from the National Cancer Institute on research conducted or supported by the institute. </field_feature_card_description>
  <field_list_description>Information from the National Cancer Institute on research conducted or supported by the institute. Includes overviews of NCI's research areas, NCI's priority initiatives, and information about NCI's role in cancer research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15273</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>11868</term_id>
  <id>15288</id>
  <title>Cancer Types</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Types</field_short_title>
  <field_page_description>Alphabetical list of all cancers, with links to disease-specific and general information about treatment, coping, screening, prevention, clinical trials, and other topics.</field_page_description>
  <field_feature_card_description>A to Z list of cancer types</field_feature_card_description>
  <field_list_description>A to Z list of cancer types, with links to disease-specific and general information about treatment, supportive care, screening, prevention, clinical trials, and other topics.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2010-07-23</field_date_reviewed>
  <para_id>15288</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1091095</id>
  <title>In Melanoma, Personalized Treatment Vaccines Show Promise</title>
  <langcode>en</langcode>
  <field_short_title>Personalized Treatment Vaccines for Melanoma</field_short_title>
  <field_page_description>In patients with melanoma, a personalized treatment vaccine generated a robust immune response and may have helped prevent a recurrence, the Cancer Currents blog reports.</field_page_description>
  <field_feature_card_description>Treatment vaccine generates robust immune response against tumor cells in trial.</field_feature_card_description>
  <field_list_description>Results of an early-phase trial showed that a treatment vaccine personalized to a specific patient’s cancer generated a robust immune response against the cancer and may have helped to prevent it from returning.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-08-03</field_date_reviewed>
  <field_pretty_url>melanoma-personalized-vaccine</field_pretty_url>
  <para_id>1091095</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1091122</id>
  <title>“First in Human” Documentary Highlights NCI Immunotherapy Research</title>
  <langcode>en</langcode>
  <field_short_title>“First in Human” Highlights NCI Immunotherapy Research</field_short_title>
  <field_page_description>The Discovery Channel documentary, First in Human, will feature some of the groundbreaking work on cancer immunotherapy being done at the NIH Clinical Center.</field_page_description>
  <field_feature_card_description>Three-part documentary shows importance of early stage clinical trials.</field_feature_card_description>
  <field_list_description>The Discovery Channel special, First in Human, will feature some of the groundbreaking work on cancer immunotherapy being done at the NIH Clinical Center, including CAR T-cell therapy and TIL therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-07</field_date_posted>
  <field_date_reviewed>2017-08-04</field_date_reviewed>
  <field_pretty_url>first-in-human-nci-immunotherapy</field_pretty_url>
  <para_id>1091122</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1091773</id>
  <title>Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host Disease</title>
  <langcode>en</langcode>
  <field_short_title>Ibrutinib Approved for Graft-Versus-Host Disease</field_short_title>
  <field_page_description>The FDA has approved ibrutinib for chronic graft-versus-host disease, a common side effect of cancer-related stem cell transplants, NCI’s Cancer Currents blog reports.</field_page_description>
  <field_feature_card_description>Approval is the first for this common stem cell transplant side effect.</field_feature_card_description>
  <field_list_description>A drug used to treat several blood cancers, ibrutinib, has been approved by FDA to treat chronic graft-versus-host disease, making it the first approved therapy for this potentially fatal side effect of cancer-related stem cell transplants.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-11</field_date_posted>
  <field_date_reviewed>2017-08-11</field_date_reviewed>
  <field_pretty_url>ibrutinib-fda-gvhd</field_pretty_url>
  <para_id>1091773</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>1043885</term_id>
  <id>1043891</id>
  <title>Small Intestine Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on small intestine cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-08</field_date_posted>
  <field_date_reviewed>2016-04-08</field_date_reviewed>
  <para_id>1043891</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099487</id>
  <title>New on NCI’s Websites for November 2017</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for November 2017</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-03</field_date_posted>
  <field_date_reviewed>2017-11-01</field_date_reviewed>
  <field_pretty_url>new-online-november-2017</field_pretty_url>
  <para_id>1099487</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099568</id>
  <title>Assuming the Role of NCI Director: Working to Accelerate Progress</title>
  <langcode>en</langcode>
  <field_short_title>As NCI Director, Working to Accelerate Progress</field_short_title>
  <field_page_description>Norman Sharpless, M.D., discusses his appointment as the new National Cancer Institute director and continuing NCI’s tradition of commitment to improving people’s lives.</field_page_description>
  <field_feature_card_description>Norman Sharpless, M.D., discusses his appointment as the director of the National Cancer Institute.</field_feature_card_description>
  <field_list_description>Norman Sharpless, M.D., discusses his appointment as the director of the National Cancer Institute and his plans for continuing NCI’s long tradition of research excellence and commitment to improving people’s lives.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-02</field_date_posted>
  <field_date_reviewed>2017-11-02</field_date_reviewed>
  <field_pretty_url>norman-sharpless-nci-director-new</field_pretty_url>
  <para_id>1099568</para_id>
  <related_resource_id>6799015</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099936</id>
  <title>Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care</field_short_title>
  <field_page_description>Learn how tests that analyze circulating tumor DNA in blood, called liquid biopsies, have the potential to track cancer as it develops and changes in this in-depth Cancer Currents article.</field_page_description>
  <field_feature_card_description>Tumor DNA in blood may hold key information that can help detect, track, and treat cancer.</field_feature_card_description>
  <field_list_description>Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-08</field_date_posted>
  <field_date_reviewed>2017-11-08</field_date_reviewed>
  <field_pretty_url>liquid-biopsy-detects-treats-cancer</field_pretty_url>
  <para_id>1099936</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099974</id>
  <title>Study Identifies Potential Drug Combination for Ewing Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combination May Target Ewing Sarcoma</field_short_title>
  <field_page_description>In Ewing sarcoma, combining YK-4-279, a drug that targets the fusion protein EWS-FLI1, with vincristine may be more effective than either drug alone.</field_page_description>
  <field_feature_card_description>Experimental targeted drug may work with chemo to kill more cancer cells.</field_feature_card_description>
  <field_list_description>From experiments in cells and mice, researchers have identified a two-drug combination that kills more Ewing sarcoma cells than either drug on its own. The study findings could help inform future clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-09</field_date_posted>
  <field_date_reviewed>2017-11-09</field_date_reviewed>
  <field_pretty_url>ewing-sarcoma-drug-combination</field_pretty_url>
  <para_id>1099974</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1101053</term_id>
  <id>1101067</id>
  <title>An Organotypic Model Recapitulating Colon Cancer Microenvironment and Metastasis</title>
  <langcode>en</langcode>
  <field_short_title>An Organotypic Model Recapitulating Colon Cancer Microenvironment and Metastasis</field_short_title>
  <field_page_description>In this study, researchers will engineer three models to examine the microenvironment in both the primary site and metastatic sites of colon cancer.</field_page_description>
  <field_list_description>In this study, researchers will engineer three models to examine key aspects of the microenvironment in both the primary site and metastatic sites of colon cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-19</field_date_posted>
  <field_date_reviewed>2017-12-01</field_date_reviewed>
  <para_id>1101067</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1101983</id>
  <title>NCI Center for Global Health’s Scientific Alliance with Kazakhstan on Women’s Cancer Research </title>
  <langcode>en</langcode>
  <field_short_title>NCI Center for Global Health’s Scientific Alliance with Kazakhstan on Women’s Cancer Research </field_short_title>
  <field_page_description>NCI Center for Global Health’s Scientific Alliance with Kazakhstan on Women’s Cancer Research</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-13</field_date_posted>
  <field_date_reviewed>2017-12-12</field_date_reviewed>
  <field_pretty_url>kazakhstan-womens-cancer</field_pretty_url>
  <para_id>1101983</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1103539</id>
  <title>Planning a Genomic Characterization Study? Tips for Collecting and Processing Biospecimens</title>
  <langcode>en</langcode>
  <field_short_title>Tips for Biospecimen Processing</field_short_title>
  <field_page_description>Guidance and tips for the biospecimen processing aspect of your genomic characterization study</field_page_description>
  <field_feature_card_description>Tips for Biospecimen Processing</field_feature_card_description>
  <field_list_description>The Biospecimen Core Resource (BCR) collects patient samples and readies them for genomic characterization, analysis, and other downstream steps. The CCG, which has managed the BCR for over a decade for use by The Cancer Genome Atlas and other projects, offers tips for researchers who may be planning their own genomic characterization study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-16</field_date_posted>
  <field_date_reviewed>2018-01-16</field_date_reviewed>
  <field_pretty_url>bcr-tips</field_pretty_url>
  <para_id>1103539</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1096930</id>
  <title>Low-Tech Outreach Methods Improve Colorectal Cancer Screening</title>
  <langcode>en</langcode>
  <field_short_title>Outreach Improves Colorectal Cancer Screening</field_short_title>
  <field_page_description>Colorectal cancer screening, completion of the appropriate follow-up was increased by mailed invitations, free test kits, this Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>Mailed invitations, free test kits increase screening initiation and follow-up.</field_feature_card_description>
  <field_list_description>Proactive, low-tech outreach approaches can help increase the number of people who get screened for colorectal cancer with a colonoscopy or home stool test and complete the appropriate follow-up.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-26</field_date_posted>
  <field_date_reviewed>2017-09-25</field_date_reviewed>
  <field_pretty_url>colorectal-cancer-screening-outreach</field_pretty_url>
  <para_id>1096930</para_id>
  <related_resource_ids>6713310</related_resource_ids>
  <related_resource_ids>6713311</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097042</id>
  <title>Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Gemtuzumab Approved by FDA for Acute Myeloid Leukemia</field_short_title>
  <field_page_description>FDA approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and some patients 2 years and older with CD33-positive AML.</field_page_description>
  <field_feature_card_description>Drug re-approved after 2010 voluntary withdrawal.</field_feature_card_description>
  <field_list_description>FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-28</field_date_posted>
  <field_date_reviewed>2017-09-28</field_date_reviewed>
  <field_pretty_url>gemtuzumab-fda-leukemia</field_pretty_url>
  <para_id>1097042</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1097231</term_id>
  <id>1097232</id>
  <title>Tumor DNA Sequencing in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Tumor DNA Sequencing</field_short_title>
  <field_page_description>Tumor DNA sequencing (also called genetic profiling or genetic testing) is a test to identify DNA changes in a patient’s cancer. In some cases, this information can help determine a treatment plan. </field_page_description>
  <field_feature_card_description>Tumor DNA sequencing (also called genetic testing) can identify DNA changes that could help determine the best treatment for a patient.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-05</field_date_posted>
  <field_date_reviewed>2017-09-29</field_date_reviewed>
  <para_id>1097232</para_id>
  <related_resource_ids>6804382</related_resource_ids>
  <related_resource_ids>6804383</related_resource_ids>
  <related_resource_ids>6804384</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1098035</id>
  <title>CTD&lt;sup&gt;2&lt;/sup&gt;: Bridging Genomics to Therapeutics</title>
  <langcode>en</langcode>
  <field_short_title>CTD&lt;sup&gt;2&lt;/sup&gt;: Bridging Genomics to Therapeutics</field_short_title>
  <field_page_description>How the NCI’s CTD&lt;sup&gt;2&lt;/sup&gt; initiative is making strides in turning genomic research into effective cancer treatments.</field_page_description>
  <field_feature_card_description>CTD&lt;sup&gt;2&lt;/sup&gt; accomplishments and goals in precision oncology</field_feature_card_description>
  <field_list_description>The Cancer Target Discovery and Development (CTD&lt;sup&gt;2&lt;/sup&gt;) initiative was established by the National Cancer Institute (NCI) to bridge the gap between cancer genomics and precision oncology and has developed many approaches for identifying therapeutic targets, perturbagens, and biomarkers. CTD&lt;sup&gt;2&lt;/sup&gt; is currently exploring cancer heterogeneities and developing strategies to overcome treatment resistance.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-19</field_date_posted>
  <field_date_reviewed>2017-10-13</field_date_reviewed>
  <field_pretty_url>ctd2-therapeutics</field_pretty_url>
  <para_id>1098035</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1098602</id>
  <title>Studies Identify Therapies That May Delay Melanoma Recurrence after Surgery</title>
  <langcode>en</langcode>
  <field_short_title>Immune, Targeted Therapies May Delay Melanoma Recurrence</field_short_title>
  <field_page_description>In clinical trials, nivolumab (Opdivo®) and the combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®) delayed cancer recurrence in patients with melanoma.</field_page_description>
  <field_feature_card_description>In trials, treatments improved how long patients lived without cancer returning.</field_feature_card_description>
  <field_list_description>Two recent clinical trials have identified treatments that may delay cancer from returning in some patients with melanoma. Patients in both trials had advanced melanoma that was surgically removed, and each trial tested different forms of post-surgical, or adjuvant, therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-19</field_date_posted>
  <field_date_reviewed>2017-10-19</field_date_reviewed>
  <field_pretty_url>melanoma-adjuvant-immunotherapy-targeted-therapy</field_pretty_url>
  <para_id>1098602</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099737</id>
  <title>Levels of Immune Cells within Ovarian Tumors Linked to Survival for Some Patients</title>
  <langcode>en</langcode>
  <field_short_title>Immune Cells in Ovarian Tumors Tied to Survival</field_short_title>
  <field_page_description>In some women with ovarian cancer, levels of tumor-infiltrating lymphocytes (TILs) may be associated with survival, as this Cancer Currents blog post explains.</field_page_description>
  <field_feature_card_description>Strongest association in patients with most common type of ovarian cancer.</field_feature_card_description>
  <field_list_description>A large international study suggests that the presence of certain immune cells within the tumors of some patients with ovarian cancer are associated with improved survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-06</field_date_posted>
  <field_date_reviewed>2017-11-03</field_date_reviewed>
  <field_pretty_url>ovarian-cancer-tils-survival</field_pretty_url>
  <para_id>1099737</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100328</id>
  <title>Experimental Ovarian Cancer Vaccine Shows Promise in Mice</title>
  <langcode>en</langcode>
  <field_short_title>Experimental Ovarian Cancer Vaccine Shows Promise in Mice</field_short_title>
  <field_page_description>The vaccine targets a protein that is present at elevated levels in approximately 90% of the most common type of ovarian cancer, this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>The experimental vaccine targets a protein found at elevated levels in most ovarian cancers.</field_feature_card_description>
  <field_list_description>The experimental vaccine targets a protein found at elevated levels in about 90% of the most common type of ovarian cancer. If validated in human studies, researchers believe the vaccine may be particularly useful for women who carry BRCA1 and BRCA2 gene mutations.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-17</field_date_posted>
  <field_date_reviewed>2017-11-16</field_date_reviewed>
  <field_pretty_url>ovarian-cancer-vaccine</field_pretty_url>
  <para_id>1100328</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1116064</id>
  <title>Conversation with Elizabeth Jaffee: An Immuno-Oncology Update</title>
  <langcode>en</langcode>
  <field_short_title>Conversation with Elizabeth Jaffee: An Immuno-Oncology Update</field_short_title>
  <field_page_description>Immunotherapy has dramatically improved the outlook for some cancer patients. Researchers are striving to increase the proportion of patients that respond.</field_page_description>
  <field_list_description>Immunotherapy is becoming part of the "standard of care" for many cancer patients.  Elizabeth Jaffee describes how we got here and where we need to go in the future.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-21</field_date_posted>
  <field_date_reviewed>2018-05-21</field_date_reviewed>
  <field_pretty_url>jaffee-immunotherapy</field_pretty_url>
  <para_id>1116064</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116320</id>
  <title>Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Dabrafenib Plus Trametinib Approved for Melanoma, Thyroid Cancer</field_short_title>
  <field_page_description>FDA recently approved the combination of dabrafenib (Taflinar) and trametinib (Mekinist) to treat some patients with melanoma and anaplastic thyroid cancer whose tumors have a mutation in the BRAF gene. As this Cancer Currents blog post explains, this is the first treatment approved specifically for anaplastic thyroid </field_page_description>
  <field_feature_card_description>The approval is for tumors with a specific mutation in the BRAF gene.</field_feature_card_description>
  <field_list_description>FDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-24</field_date_reviewed>
  <field_pretty_url>fda-dabrafenib-trametinib-melanoma-thyroid</field_pretty_url>
  <para_id>1116320</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116396</id>
  <title>Experimental Cancer Drug Metarrestin Targets Metastatic Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Experimental Drug Metarrestin Targets Metastatic Tumors</field_short_title>
  <field_page_description>An experimental drug called metarrestin appears to selectively target tumors that have spread to other parts of the body. As this Cancer Currents blog post reports, the drug shrank metastatic tumors and extended survival in in mouse models of pancreatic cancer.</field_page_description>
  <field_feature_card_description>Metarrestin shrank tumors and extended survival in mouse models of pancreatic cancer.</field_feature_card_description>
  <field_list_description>Researchers have struggled to develop therapies to treat tumors that have spread to other parts of the body. In a new study, researchers tested whether the experimental drug metarrestin can selectively shrink metastases in mouse models of aggressive pancreatic cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-29</field_date_posted>
  <field_date_reviewed>2018-05-25</field_date_reviewed>
  <field_pretty_url>metaresstin-metastatic-tumors</field_pretty_url>
  <para_id>1116396</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116537</id>
  <title>New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Treatment May Help Prevent Bladder Cancer Recurrences</field_short_title>
  <field_page_description>Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of the cancer returning, according to the results of a large clinical trial. As this Cancer Currents blog post explains, the treatment approach is for patients with low-grade bladder cancer.</field_page_description>
  <field_feature_card_description>Flushing the bladder with gemcitabine may prevent low-grade disease from recurring.</field_feature_card_description>
  <field_list_description>Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-31</field_date_posted>
  <field_date_reviewed>2018-05-30</field_date_reviewed>
  <field_pretty_url>gemcitabine-bladder-cancer-recurrence</field_pretty_url>
  <para_id>1116537</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11952</term_id>
  <id>14519</id>
  <title>Pituitary Tumors—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Pituitary Tumors</field_short_title>
  <field_page_description>Pituitary tumors are usually not cancer and are called pituitary adenomas. They grow slowly and do not spread. Rarely, pituitary tumors are cancer and they can spread to distant parts of the body. Start here to find information on pituitary tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Pituitary Tumor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14519</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>139071</id>
  <title>Study Shows Aspirin Reduces Colorectal Cancer in Those at High Risk</title>
  <langcode>en</langcode>
  <field_short_title>Study Shows Aspirin Reduces Colorectal Cancer in Those at High Risk</field_short_title>
  <field_page_description>Findings from the first large clinical trial of its kind indicate that taking high doses of aspirin daily for at least 2 years substantially reduces the risk of colorectal cancer among people at increased risk of the disease.</field_page_description>
  <field_feature_card_description>Findings from the first large clinical trial of its kind indicate that taking high doses of aspirin daily for at least 2 years substantially reduces the risk of colorectal cancer among people at increased risk of the disease.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-02</field_date_posted>
  <field_date_reviewed>2011-12-02</field_date_reviewed>
  <field_pretty_url>aspirin-reduces-risk</field_pretty_url>
  <para_id>139071</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770500</term_id>
  <id>770502</id>
  <title>Leukemia Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Leukemia Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770502</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771995</term_id>
  <id>772111</id>
  <title>Myeloma Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Myeloma Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772111</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772128</term_id>
  <id>772129</id>
  <title>Patient Advocate Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Patient Advocate Steering Committee</field_short_title>
  <field_page_description>The Patient Advocate Steering Committee (PASC) works to ensure advocates involved with the Scientific Steering Committees (SSCs) are completely integrated in the development, implementation, and monitoring of clinical trials within those groups.</field_page_description>
  <field_feature_card_description>The PASC works to ensure advocates involved with SSCs are completely integrated in the development, implementation, and monitoring of clinical trials within those groups. </field_feature_card_description>
  <field_list_description>The PASC works to ensure advocates involved with SSCs are completely integrated in the development, implementation, and monitoring of clinical trials within those groups. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-23</field_date_posted>
  <field_date_reviewed>2018-04-04</field_date_reviewed>
  <para_id>772129</para_id>
  <related_resource_id>6928556</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>777590</term_id>
  <id>777638</id>
  <title>Center for Global Health Seminar Series</title>
  <langcode>en</langcode>
  <field_short_title>Center for Global Health Seminar Series</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2013-02-20</field_date_reviewed>
  <para_id>777638</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>802441</term_id>
  <id>802442</id>
  <title>How to Work With Your Health Insurance Plan</title>
  <langcode>en</langcode>
  <field_short_title>How to Work With Your Health Insurance Plan</field_short_title>
  <field_page_description>Insurance plans may cover some costs of taking part in a clinical trial. Learn who to contact for help, questions to ask, and the types of information to collect.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-10</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>802442</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919511</term_id>
  <id>807050</id>
  <title>About the Office of Grants Administration</title>
  <langcode>en</langcode>
  <field_short_title>About the Office of Grants Administration</field_short_title>
  <field_page_description>OGA supports grants and cooperative agreements awarded to scientific institutions, small businesses, and individuals to help build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Learn more about OGA and its program structure.</field_page_description>
  <field_feature_card_description>Learn about OGA’s program structure and how the office helps build, maintain, and enhance a cohesive and comprehensive cancer research agenda.</field_feature_card_description>
  <field_list_description>OGA supports grants and cooperative agreements, helping to build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Learn more about OGA, including program structure and responsibilities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-07-22</field_date_posted>
  <field_date_reviewed>2014-07-22</field_date_reviewed>
  <para_id>807050</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>804863</term_id>
  <id>420512</id>
  <title>Insurance Coverage and Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Insurance Coverage and Clinical Trials</field_short_title>
  <field_page_description>Most health insurance plans are required to cover routine patient care costs in clinical trials under certain conditions. Learn about the conditions that insurance plans take into account and how to work with your insurance company.</field_page_description>
  <field_feature_card_description>Information about factors that insurance companies consider when deciding if they will cover the costs of clinical trials.</field_feature_card_description>
  <field_list_description>Most insurance plans are required to cover routine patient care costs in clinical trials under certain conditions. Learn about the conditions that insurance plans take into account and how to work with your insurance company.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2012-09-11</field_date_reviewed>
  <para_id>420512</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>464420</id>
  <title>Taking Time: Support for People With Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Taking Time: Support for People With Cancer</field_short_title>
  <field_page_description>Covers the feelings and concerns of people with cancer and their families.</field_page_description>
  <field_feature_card_description>Covers the feelings and concerns of people with cancer and their families.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-23</field_date_reviewed>
  <field_pretty_url>taking-time</field_pretty_url>
  <para_id>464420</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937897</term_id>
  <id>821976</id>
  <title>Training Providers and Patients to Talk about End-of-Life Care</title>
  <langcode>en</langcode>
  <field_short_title>Training Providers and Patients to Talk about End-of-Life Care</field_short_title>
  <field_page_description>Failing to discuss the transition from active cancer treatment to end-of-life care can leave doctors unsure of what a patient truly wants. Failing to receive end-of-life care in line with their values and wishes can cause patients and their families great distress. Researchers have developed innovative, evidence-based </field_page_description>
  <field_feature_card_description>An article about innovative, evidence-based programs to help doctors and patients discuss the transition from active cancer treatment to end-of-life care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-03-23</field_date_posted>
  <field_date_reviewed>2014-09-03</field_date_reviewed>
  <field_pretty_url>training-talk-end-of-life-care</field_pretty_url>
  <para_id>821976</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938227</term_id>
  <id>824933</id>
  <title>Matters of the Heart: Why Are Cardiac Tumors So Rare?</title>
  <langcode>en</langcode>
  <field_short_title>Matters of the Heart: Why Are Cardiac Tumors So Rare?</field_short_title>
  <field_page_description>Cardiac tumors that originate in the heart itself are extremely rare. The highly specialized and most abundant cell in the heart may explain why the organ is such an inhospitable host to cancer.</field_page_description>
  <field_feature_card_description>An article about very rare tumors that originate in the heart, and the highly specialized cells that may explain why the organ is so inhospitable to cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-02-10</field_date_posted>
  <field_date_reviewed>2014-09-05</field_date_reviewed>
  <field_pretty_url>cardiac-tumors</field_pretty_url>
  <para_id>824933</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>827181</id>
  <title>HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments </title>
  <langcode>en</langcode>
  <field_short_title>HER2's Genetic Link to Breast Cancer</field_short_title>
  <field_page_description>When researchers discovered the HER2 gene's importance to breast cancer growth, this led to the development of trastuzumab and other treatments that have improved survival for women with HER2-positive breast cancer.</field_page_description>
  <field_feature_card_description>Learn about the development of trastuzumab and other treatments that have improved survival for women with HER2-positive breast cancer.</field_feature_card_description>
  <field_list_description>HER2 is a gene that has been linked to breast cancer growth. Learn about the development of trastuzumab, a monoclonal antibody that blocks the HER2 protein, and other treatments that have improved survival for women with HER2-positive breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-09-15</field_date_posted>
  <field_date_reviewed>2014-09-15</field_date_reviewed>
  <field_pretty_url>HER2</field_pretty_url>
  <para_id>827181</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904178</term_id>
  <id>828659</id>
  <title>Examples of Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Examples of Cancer Health Disparities</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828659</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>904068</term_id>
  <id>828713</id>
  <title>About The Center to Reduce Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>About CRCHD</field_short_title>
  <field_page_description>Learn about what we do at CRCHD and find staff contact information. </field_page_description>
  <field_feature_card_description>Learn about what we do at CRCHD and find staff contact information. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-18</field_date_reviewed>
  <para_id>828713</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1104021</term_id>
  <id>1104025</id>
  <title>Cancer Moonshot℠ - Obligations by Budget Mechanism</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot Obligations</field_short_title>
  <field_page_description>NCI reports Cancer Moonshot obligations by funding mechanism. See obligations for Moonshot grants, intramural research, and contracts, including the number of grant awards, funding amounts, and percentages by mechanism of the total Cancer Moonshot budget.</field_page_description>
  <field_feature_card_description>See obligations for Cancer Moonshot grants  by mechanism.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104025</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>1104089</id>
  <title>TEST - Lung Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>TEST - Lung Cancer Research</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-18</field_date_posted>
  <field_date_reviewed>2018-01-18</field_date_reviewed>
  <field_pretty_url>2</field_pretty_url>
  <para_id>1104089</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1105037</id>
  <title>Study Identifies Potential Cause of Hearing Loss from Cisplatin</title>
  <langcode>en</langcode>
  <field_short_title>Potential Cause of Cisplatin-Linked Hearing Loss Identified</field_short_title>
  <field_page_description>The chemotherapy drug cisplatin is retained in the inner ear for long periods, possibly explaining the hearing loss linked to treatment with the drug.</field_page_description>
  <field_feature_card_description>Commonly used chemotherapy is retained for long periods in the inner ear.</field_feature_card_description>
  <field_list_description>A new study has found the commonly used chemotherapy drug cisplatin is retained in the inner ear of mice and humans for long periods. The finding may explain why many patients treated with the drug develop hearing loss and could point toward potential ways to prevent it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-26</field_date_posted>
  <field_date_reviewed>2018-01-25</field_date_reviewed>
  <field_pretty_url>cisplatin-hearing-loss</field_pretty_url>
  <para_id>1105037</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1105714</id>
  <title>Gut Bacteria Influence Effectiveness of a Type of Immunotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Gut Bacteria Affect Response to Immunotherapy</field_short_title>
  <field_page_description>Three new studies have identified intestinal bacteria that appear to influence the response to checkpoint inhibitors. This Cancer Currents blog post explains how the researchers think their findings could be used to improve patients’ responses to these immunotherapy drugs.</field_page_description>
  <field_feature_card_description>Could altering the gut microbiome turn nonresponders into responders?</field_feature_card_description>
  <field_list_description>Using mouse models of cancer, researchers found that altering the gut microbiome could affect whether tumors responded to checkpoint inhibition.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-05</field_date_posted>
  <field_date_reviewed>2018-02-02</field_date_reviewed>
  <field_pretty_url>gut-bacteria-checkpoint-inhibitors</field_pretty_url>
  <para_id>1105714</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1106258</id>
  <title>2017 Embassy Science Fellowship: Bangkok, Thailand</title>
  <langcode>en</langcode>
  <field_short_title>2017 ESF in Thailand</field_short_title>
  <field_page_description>The Embassy Science Fellow (ESF) program provides U.S. embassies access to the expertise of U.S. government officers in science and technology fields. U.S. embassies request Fellows to assist on science, technology, environment or health issues and related policy development and collaboration.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-08</field_date_posted>
  <field_date_reviewed>2018-02-08</field_date_reviewed>
  <field_pretty_url>2017-esf-thailand</field_pretty_url>
  <para_id>1106258</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1106282</id>
  <title>FDA Approves New Treatment for Certain Neuroendocrine Tumors</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves New Treatment for Neuroendocrine Tumors</field_short_title>
  <field_page_description>FDA has approved Lutathera® for some people with neuroendocrine tumors (NETs) that affect the digestive tract. On January 29, FDA approved Lutathera® for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract, known as GEP-NETs.</field_page_description>
  <field_feature_card_description>Lutathera® approved for NETs in pancreas or gastrointestinal tract.</field_feature_card_description>
  <field_list_description>People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-08</field_date_posted>
  <field_date_reviewed>2018-02-08</field_date_reviewed>
  <field_pretty_url>lutathera-fda-gastrointestinal-nets</field_pretty_url>
  <para_id>1106282</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107097</id>
  <title>Clinical Trials to Treat Testicular Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Testicular Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>testicular-cancer</field_pretty_url>
  <para_id>1107097</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107099</id>
  <title>Clinical Trials to Treat Adult Glioblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Adult Glioblastoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>adult-glioblastoma</field_pretty_url>
  <para_id>1107099</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107845</id>
  <title>Molecular Switch Links High-Fat Diet to Prostate Cancer Metastasis</title>
  <langcode>en</langcode>
  <field_short_title>High-Fat Diet Linked to Prostate Cancer Metastasis</field_short_title>
  <field_page_description>A new study in mice has revealed a molecular link between a high-fat diet and the growth and spread of prostate cancer. As this Cancer Currents post explains, researchers also showed that an anti-obesity drug that targets a protein that controls fat synthesis could potentially be used to treat metastatic prostate cance</field_page_description>
  <field_feature_card_description>Could changes in diet improve treatment outcomes?</field_feature_card_description>
  <field_list_description>A new study in mice has revealed a molecular link between a high-fat diet and the growth and spread of prostate cancer. The findings, the study leaders believe, raise the possibility that changes in diet could potentially improve treatment outcomes in some men. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-22</field_date_posted>
  <field_date_reviewed>2018-02-22</field_date_reviewed>
  <field_pretty_url>high-fat-diet-prostate-metastasis</field_pretty_url>
  <para_id>1107845</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1103047</term_id>
  <id>1104013</id>
  <title>Treatment of Head and Neck Cancer in Children and Adolescents—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer Treatment in Children and Adolescents</field_short_title>
  <field_page_description>Find information about prognosis, staging, and treatment for the following head and neck cancer sites in children: esthesioneuroblastoma, larynx and papillomatosis, nasopharynx, oral cavity, and salivary gland.</field_page_description>
  <field_list_description>Find information about incidence, risk factors, prognosis, staging, and treatment of the following head and neck cancer sites in children and adolescents: hypopharynx, larynx, lip and oral cavity, neck cancer with occult primary, nasopharynx, oropharynx, paranasal sinus and nasal cavity, and salivary gland cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-15</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104013</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1104873</id>
  <title>Study Finds Biological Differences in Lung Tumors of African Americans and Whites</title>
  <langcode>en</langcode>
  <field_short_title>In Black and White Patients, Biological Differences in Lung Tumors</field_short_title>
  <field_page_description>In patients with lung cancer, a new study shows different patterns of gene expression in the tumors of African American and white patients may contribute to racial disparities.</field_page_description>
  <field_feature_card_description>Differences in gene activity may contribute to disparities, study suggests.</field_feature_card_description>
  <field_list_description>Patterns of gene expression may be different in the tumors of some African Americans than in those of whites, a new study has found, and these biological differences may contribute to racial disparities in lung cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-23</field_date_posted>
  <field_date_reviewed>2018-01-23</field_date_reviewed>
  <field_pretty_url>lung-cancer-biologic-differences-race</field_pretty_url>
  <para_id>1104873</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107096</id>
  <title>Clinical Trials to Treat Kidney (Renal Cell) Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Kidney (Renal Cell) Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>kidney-cancer</field_pretty_url>
  <para_id>1107096</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107156</id>
  <title>Retooling NCI MERIT Awards to Support Budding Cancer Researchers</title>
  <langcode>en</langcode>
  <field_short_title>Retooled Award Supports Budding Cancer Researchers</field_short_title>
  <field_page_description>In this Cancer Currents post, NCI Director Dr. Norman Sharpless discusses how NCI is retooling a grant mechanism, called the MERIT R37 Award, to help early-stage investigators by extending the length of time they can receive funding under their first independent NIH grant.</field_page_description>
  <field_feature_card_description>NCI Director Dr. Sharpless discusses changes to NCI’s MERIT Award.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless discusses how NCI is retooling a grant mechanism, called the MERIT R37 Award, to help early-stage investigators by extending the length of time they can receive funding under their first independent NIH grant.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-16</field_date_posted>
  <field_date_reviewed>2018-02-15</field_date_reviewed>
  <field_pretty_url>sharpless-merit-awards</field_pretty_url>
  <para_id>1107156</para_id>
  <related_resource_id>6994338</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1108328</id>
  <title>Recognizing HPV Awareness Day</title>
  <langcode>en</langcode>
  <field_short_title>HPV Awareness Day</field_short_title>
  <field_page_description>On Sunday, March 4, NCI joins organizations around the world, to promote awareness and education about HPV infection and the HPV-associated diseases that can be prevented through vaccination.</field_page_description>
  <field_feature_card_description>Join NCI in raising awareness of the global burden of cancer caused by infection with the human papillomavirus (HPV).  </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-27</field_date_posted>
  <field_date_reviewed>2018-02-27</field_date_reviewed>
  <field_pretty_url>int-hpv</field_pretty_url>
  <para_id>1108328</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109255</id>
  <title>FDA Approves Apalutamide for Some Men with Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Apalutamide for Prostate Cancer</field_short_title>
  <field_page_description>Apalutamide (Erleada) is a hormone therapy that counteracts resistance to androgen deprivation therapy. Learn more about the FDA approval of apalutamide for men with castration-resistant nonmetastatic prostate cancer in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Apalutamide delays metastasis, potentially extends survival.</field_feature_card_description>
  <field_list_description>In the trial that led to the approval, apalutamide (Erleada) delayed cancer metastasis for men with prostate cancer that is resistant to androgen deprivation therapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-08</field_date_posted>
  <field_date_reviewed>2018-03-07</field_date_reviewed>
  <field_pretty_url>apalutamide-fda-nonmetastatic-prostate</field_pretty_url>
  <para_id>1109255</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1117639</id>
  <title>Successful Outreach for Collaboration on Cancer Research in Eurasia</title>
  <langcode>en</langcode>
  <field_short_title>Successful Outreach for Collaboration on Cancer Research in Eurasia</field_short_title>
  <field_page_description>The National Cancer Institute Center for Global Health and N. N. Alexandrov National Cancer Centre of Belarus convened the first Eurasian Cancer Screening Conference on May 17-18th, 2018. Read CGH's Spotlight Blog to learn more about the conference objectives and outcomes.</field_page_description>
  <field_list_description>Together with N. N. Alexandrov National Cancer Centre of Belarus, CGH convened the first Eurasian Cancer Screening Conference, held on May 17-18th, 2018. The event focused on results derived from evaluations of national cancer screening programs, and needs of cancer research and implementation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-14</field_date_posted>
  <field_date_reviewed>2018-06-14</field_date_reviewed>
  <field_pretty_url>ecsc</field_pretty_url>
  <para_id>1117639</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129045</term_id>
  <id>1119406</id>
  <title>TCGA Molecular Characterization Platforms</title>
  <langcode>en</langcode>
  <field_short_title>Molecular Characterization Platforms</field_short_title>
  <field_page_description>Descriptions and supporting materials for each of the sequencing platforms and other technologies used to generate the TCGA dataset.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-07-05</field_date_reviewed>
  <para_id>1119406</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>14073</id>
  <title>Cigar Smoking and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Cigar Smoking and Cancer</field_short_title>
  <field_page_description>A fact sheet about the health risks associated with cigar smoking.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-08-18</field_date_posted>
  <field_date_reviewed>2010-10-27</field_date_reviewed>
  <field_pretty_url>cigars-fact-sheet</field_pretty_url>
  <para_id>14073</para_id>
  <related_resource_ids>6152154</related_resource_ids>
  <related_resource_ids>6152155</related_resource_ids>
  <related_resource_ids>6152156</related_resource_ids>
  <related_resource_ids>6152157</related_resource_ids>
  <related_resource_ids>6152158</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917291</term_id>
  <id>14178</id>
  <title>Certificates of Confidentiality</title>
  <langcode>en</langcode>
  <field_short_title>Certificates of Confidentiality</field_short_title>
  <field_page_description>Background information and application procedures for researchers.</field_page_description>
  <field_feature_card_description>Certificates of Confidentiality contact information</field_feature_card_description>
  <field_list_description>Certificates of confidentiality background information and application procedures for researchers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2000-05-04</field_date_posted>
  <field_date_reviewed>2013-01-23</field_date_reviewed>
  <field_pretty_url>certificates-confidentiality</field_pretty_url>
  <para_id>14178</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>903752</term_id>
  <id>14293</id>
  <title>Pathology Reports</title>
  <langcode>en</langcode>
  <field_short_title>Pathology Reports</field_short_title>
  <field_page_description>A fact sheet describing the information found in a pathology report, the document that contains results of the examination of tissue removed during biopsy or surgery.</field_page_description>
  <field_list_description>A fact sheet that describes the type of information that may be found in a pathology report, the document that contains results of the visual and microscopic examination of tissue removed during a biopsy or surgery.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2007-12-06</field_date_posted>
  <field_date_reviewed>2010-09-23</field_date_reviewed>
  <field_pretty_url>pathology-reports-fact-sheet</field_pretty_url>
  <para_id>14293</para_id>
  <related_resource_ids>6670978</related_resource_ids>
  <related_resource_ids>6670979</related_resource_ids>
  <related_resource_ids>6670980</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>150013</id>
  <title>Combination Therapy Shows Promise for Treating Advanced Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Combination Therapy Shows Promise for Treating Advanced Breast Cancer</field_short_title>
  <field_page_description>Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.</field_page_description>
  <field_feature_card_description>Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-21</field_date_posted>
  <field_date_reviewed>2011-12-21</field_date_reviewed>
  <field_pretty_url>everolimus-plus-exemestane</field_pretty_url>
  <para_id>150013</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100730</id>
  <title>An Important Moment in Tobacco Control </title>
  <langcode>en</langcode>
  <field_short_title>An Important Moment in Tobacco Control</field_short_title>
  <field_page_description>The major tobacco companies have begun publishing corrective statements explaining the harms of smoking, addressing common misconceptions about cigarettes.</field_page_description>
  <field_feature_card_description>Court-ordered statements explain smoking harms, clarify misconceptions.</field_feature_card_description>
  <field_list_description>November 26, 2017, marked a unique moment in US public health history, with the major US tobacco companies issuing the first in a series of court-ordered "corrective statements" about their products. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-28</field_date_posted>
  <field_date_reviewed>2017-11-27</field_date_reviewed>
  <field_pretty_url>tobacco-corrective-statements</field_pretty_url>
  <para_id>1100730</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102628</term_id>
  <id>1102878</id>
  <title>Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t</title>
  <langcode>en</langcode>
  <field_short_title>Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t</field_short_title>
  <field_page_description>How pancreatic cancer cell lines adapt to loss of their mutant KRAS genes suggest how new treatments for pancreatic cancers should be used.</field_page_description>
  <field_feature_card_description>Not all pancreatic cancer cells mind loss of their mutant KRAS genes.</field_feature_card_description>
  <field_list_description>Of all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes.  The adaptations these lines make provide opportunities for treating these deadly cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-04</field_date_reviewed>
  <field_pretty_url>kras-dependence</field_pretty_url>
  <para_id>1102878</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1102949</term_id>
  <id>1102953</id>
  <title>Partnerships</title>
  <langcode>en</langcode>
  <field_short_title>Partnerships</field_short_title>
  <field_page_description>NCI fellows and trainees assist with science needs, workshops, and career guidance for middle school and high school students. Partner with us to enhance science education in your classroom.   </field_page_description>
  <field_feature_card_description>See a list of current partners and learn more about partnership opportunities. </field_feature_card_description>
  <field_list_description>NCI fellows and trainees assist with science needs, workshops, and career guidance for middle school and high school students. See a list of current partners and learn more about partnership opportunities.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-05</field_date_reviewed>
  <para_id>1102953</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1104023</term_id>
  <id>1104026</id>
  <title>Cancer Moonshot℠ - Funding by Research Category</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot Funding by Category</field_short_title>
  <field_page_description>The Cancer Moonshot Blue Ribbon Panel (BRP) provided research recommendations to accelerate progress against cancer. See the NCI obligations for Cancer Moonshot activities by research category.</field_page_description>
  <field_feature_card_description>See obligations for Cancer Moonshot activities by research category.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-01-15</field_date_reviewed>
  <para_id>1104026</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1104097</id>
  <title>CGH Recognizes World Cancer Day 2018</title>
  <langcode>en</langcode>
  <field_short_title>CGH Recognizes World Cancer Day 2018</field_short_title>
  <field_page_description>On Sunday, February 4th, the National Cancer Institute will recognize World Cancer Day, an initiative of the Union for International Cancer Control.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-18</field_date_posted>
  <field_date_reviewed>2018-01-18</field_date_reviewed>
  <field_pretty_url>wcd-2018</field_pretty_url>
  <para_id>1104097</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1106060</term_id>
  <id>1106068</id>
  <title>Dense Breasts: Answers to Commonly Asked Questions</title>
  <langcode>en</langcode>
  <field_short_title>Dense Breasts: Answers to Commonly Asked Questions</field_short_title>
  <field_page_description>Mammograms detect breast density, breast cancer, and breast changes that are not cancer (benign breast changes). Breast density describes the amount of glandular and fibrous tissue, as compared to fatty tissue. Learn what factors are associated with breast density and about other risk factors for breast cancer.</field_page_description>
  <field_feature_card_description>Get answers to commonly asked questions about mammographically dense breasts and a list of questions to ask your doctor.</field_feature_card_description>
  <field_list_description>Explains what breast density is and how it can affect a woman’s risk for breast cancer. Includes questions to help a woman learn more about her personal risk for breast cancer, after a finding of dense breasts on a mammogram.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-16</field_date_posted>
  <field_date_reviewed>2018-02-06</field_date_reviewed>
  <para_id>1106068</para_id>
  <related_resource_ids>7119247</related_resource_ids>
  <related_resource_ids>7119248</related_resource_ids>
  <related_resource_ids>7119250</related_resource_ids>
  <related_resource_ids>7119254</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109910</id>
  <title>The Imperative of Addressing Cancer Drug Costs and Value  </title>
  <langcode>en</langcode>
  <field_short_title>Addressing Cancer Drug Costs and Value  </field_short_title>
  <field_page_description>The President’s Cancer Panel has released its latest report, Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. The report recommends six actions to maximize the value and affordability of cancer drug treatment.</field_page_description>
  <field_feature_card_description>President's Cancer Panel report promotes value and innovation in cancer drug treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-15</field_date_posted>
  <field_date_reviewed>2018-03-13</field_date_reviewed>
  <field_pretty_url>presidents-cancer-panel-drug-prices</field_pretty_url>
  <para_id>1109910</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1044285</id>
  <title>Single-Cell Analysis Zooms in on Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Melanoma Single-Cell RNA Sequencing</field_short_title>
  <field_page_description>Single-Cell RNA Sequencing Study of Melanoma</field_page_description>
  <field_feature_card_description>Single-Cell Analysis Elucidates Melanoma Relapse Mechanism</field_feature_card_description>
  <field_list_description>In a new study, researchers from the Broad Institute analyzed melanoma RNA expression using single-cell sequencing. They found that the simultaneous expression of two different gene expression programs within the same tumor affected therapeutic resistance and relapse.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-26</field_date_posted>
  <field_date_reviewed>2016-04-11</field_date_reviewed>
  <field_pretty_url>melanoma-single-cell</field_pretty_url>
  <para_id>1044285</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047008</id>
  <title>New Treatment Target Identified for Key Prostate Cancer Driver</title>
  <langcode>en</langcode>
  <field_short_title>Study Identifies New Treatment Target for Prostate Cancer</field_short_title>
  <field_page_description>Researchers have identified a potential alternative approach to blocking a key molecular driver of an advanced form of prostate cancer, called androgen-independent or castration-resistant prostate cancer.</field_page_description>
  <field_feature_card_description>Alternative approach blocks key molecular driver of an advanced form of prostate cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-22</field_date_posted>
  <field_date_reviewed>2016-04-21</field_date_reviewed>
  <field_pretty_url>prostate-ror-gamma-inhibitor</field_pretty_url>
  <para_id>1047008</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1048347</id>
  <title>CGH observes National Women’s Health Week </title>
  <langcode>en</langcode>
  <field_short_title>CGH observes National Women’s Health Week </field_short_title>
  <field_page_description>This week, the U.S. Department of Health and Human Services is observing the 17th annual National Women’s Health Week. The goal of the National Women's Health Week is to empower women to make their health a priority. In celebration, the NCI Center for Global Health held a seminar on the Knowledge Summaries for Comprehe</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-12</field_date_posted>
  <field_date_reviewed>2016-05-12</field_date_reviewed>
  <field_pretty_url>womens-health</field_pretty_url>
  <para_id>1048347</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1048571</term_id>
  <id>1048572</id>
  <title>Grantees or Grant Applicants Submitting Data</title>
  <langcode>en</langcode>
  <field_short_title>Grantees or Grant Applicants Submitting Data</field_short_title>
  <field_page_description>In order to be compliant with the Genomic Data Sharing (GDS) Policy, extramural investigators should use the following to guide their steps through the grant life-cycle process.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-13</field_date_posted>
  <field_date_reviewed>2016-05-13</field_date_reviewed>
  <para_id>1048572</para_id>
  <related_resource_id>7083140</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1048574</term_id>
  <id>1048575</id>
  <title>Non-NIH Funded Investigators Submitting Data</title>
  <langcode>en</langcode>
  <field_short_title>Non-NIH Funded Investigators Submitting Data</field_short_title>
  <field_page_description>Learn how non-NIH funded investigators may submit genomic data to the database of Genotypes and Phenotypes (dbGaP) or the Genomic Data Commons (GDC), under the NIH Genomic Data Sharing policy.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-13</field_date_posted>
  <field_date_reviewed>2016-05-13</field_date_reviewed>
  <para_id>1048575</para_id>
  <related_resource_id>7083145</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052662</id>
  <title>New on NCI’s Websites for June 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for June 2016</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-16</field_date_posted>
  <field_date_reviewed>2016-06-16</field_date_reviewed>
  <field_pretty_url>new-online-june-2016</field_pretty_url>
  <para_id>1052662</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1053375</id>
  <title>Prognosis Discussions Improve Understanding of Illness for Patients with Terminal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Prognosis Discussions Improve Understanding of Illness for Patients with Terminal Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on patients with advanced, curable cancer and the effect of discussing their prognosis and their understanding of the serious nature of their illness.</field_page_description>
  <field_feature_card_description>Patients with incurable cancer who discussed their prognosis with doctors better understood their illness.</field_feature_card_description>
  <field_list_description>Many patients with advanced, incurable cancer have a poor understanding of their prognosis or life expectancy, a new study shows. Patients who discussed their prognosis with their doctors were more likely to understand the serious nature of their illness.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-27</field_date_posted>
  <field_date_reviewed>2016-06-27</field_date_reviewed>
  <field_pretty_url>cancer-prognosis-discussions</field_pretty_url>
  <para_id>1053375</para_id>
  <related_resource_id>6797379</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>227641</term_id>
  <id>267255</id>
  <title>NCI-Designated Cancer Centers</title>
  <langcode>en</langcode>
  <field_short_title>NCI-Designated Cancer Centers</field_short_title>
  <field_page_description>NCI-designated cancer centers are at the forefront of NCI-supported cancer research efforts at universities and cancer research centers across the United States.</field_page_description>
  <field_feature_card_description>There are now 70 NCI Cancer Centers serving as the backbone of NCI’s programs for studying and controlling cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-04-05</field_date_posted>
  <field_date_reviewed>2012-04-05</field_date_reviewed>
  <para_id>267255</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858187</term_id>
  <id>859801</id>
  <title>Support for Caregivers of Cancer Patients</title>
  <langcode>en</langcode>
  <field_short_title>Support for Caregivers</field_short_title>
  <field_page_description>Being a caregiver of cancer patients can be stressful. Find out what to expect and how to deal with caring for a loved one with cancer.</field_page_description>
  <field_feature_card_description>Being a caregiver can be stressful. Learn tips for how to care for yourself while caring for others.</field_feature_card_description>
  <field_list_description>If you are helping your family member or friend through cancer treatment, you are a caregiver. Being a caregiver can be very stressful, but you can find ways to care for yourself while caring for others.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859801</para_id>
  <related_resource_ids>7081245</related_resource_ids>
  <related_resource_ids>7081246</related_resource_ids>
  <related_resource_ids>7081247</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>860262</term_id>
  <id>860263</id>
  <title>Human Papillomavirus (HPV) Vaccines: An Interview with Douglas R. Lowy, M.D.</title>
  <langcode>en</langcode>
  <field_short_title>Human Papillomavirus (HPV) Vaccines: An Interview with Douglas R. Lowy, M.D.</field_short_title>
  <field_page_description>NCI’s Dr. Doug Lowy discusses HPV vaccines, including their efficacy, safety, and the development of next-generation vaccines.</field_page_description>
  <field_feature_card_description>NCI’s Dr. Doug Lowy discusses HPV vaccines, including their efficacy, safety, and the development of next-generation vaccines.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-11-20</field_date_posted>
  <field_date_reviewed>2014-11-20</field_date_reviewed>
  <field_pretty_url>hpv-vaccines-lowy</field_pretty_url>
  <para_id>860263</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>762611</term_id>
  <id>861865</id>
  <title>CGH Staff Present at the World Cancer Congress 2014</title>
  <langcode>en</langcode>
  <field_short_title>CGH at World Cancer Congress 2014</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-24</field_date_posted>
  <field_date_reviewed>2014-11-24</field_date_reviewed>
  <field_pretty_url>wcc-2014</field_pretty_url>
  <para_id>861865</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>692708</term_id>
  <id>866188</id>
  <title>The RAS Initiative</title>
  <langcode>en</langcode>
  <field_short_title>The RAS Initiative</field_short_title>
  <field_page_description>NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.</field_page_description>
  <field_feature_card_description>NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of the KRAS gene and to ultimately create effective, new therapies. </field_feature_card_description>
  <field_list_description>NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of the KRAS gene and to ultimately create effective, new therapies. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-01</field_date_posted>
  <field_date_reviewed>2014-12-01</field_date_reviewed>
  <para_id>866188</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>940315</term_id>
  <id>1050504</id>
  <title>PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck </field_short_title>
  <field_page_description>Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.</field_page_description>
  <field_feature_card_description>Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.</field_feature_card_description>
  <field_list_description>Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance after chemoradiation had overall survival rates similar to those of patients who underwent planned neck dissection and chemoradiation. But PET-CT imaging resulted in fewer operations and was more cost-effective than neck dissection.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-20</field_date_posted>
  <field_date_reviewed>2016-05-20</field_date_reviewed>
  <field_pretty_url>pet-ct-surveillance</field_pretty_url>
  <para_id>1050504</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>417543</term_id>
  <id>1051290</id>
  <title>Clinical Trials Reporting Program</title>
  <langcode>en</langcode>
  <field_short_title>CTRP</field_short_title>
  <field_page_description>The Clinical Trials Reporting Program is a comprehensive database of all NCI-supported clinical trials.</field_page_description>
  <field_feature_card_description>Find information about CTRP, a comprehensive database of all NCI-supported clinical trials.</field_feature_card_description>
  <field_list_description>A comprehensive database of all NCI-supported clinical trials. The database exists to identify gaps in clinical research and duplicative studies. CTRP helps prioritize and enhance patient accrual to trials by making physicians aware of relevant opportunities for participation in clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-25</field_date_posted>
  <field_date_reviewed>2016-05-25</field_date_reviewed>
  <para_id>1051290</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16374</term_id>
  <id>1052956</id>
  <title>Clinical Trials Search Results</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials Search Results</field_short_title>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <field_pretty_url>r</field_pretty_url>
  <para_id>1052956</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16374</term_id>
  <id>1052961</id>
  <title>Clinical Trials (PDQ®)</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials (PDQ®)</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-02-02</field_date_posted>
  <field_date_reviewed>2011-02-02</field_date_reviewed>
  <field_pretty_url>v</field_pretty_url>
  <para_id>1052961</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1053426</id>
  <title>Reflections from a Year at the Center for Global Health</title>
  <langcode>en</langcode>
  <field_short_title>Reflections from a Year at the Center for Global Health</field_short_title>
  <field_page_description>The Cancer Research Training Award (CRTA) Fellowship is a one-year fellowship, where a laboratory, a Center or a Division within the National Cancer Institute takes in a post baccalaureate trainee for a year. This trainee is typically someone who has completed their Bachelor’s degree and is ready to put their knowledge</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-28</field_date_posted>
  <field_date_reviewed>2016-06-28</field_date_reviewed>
  <field_pretty_url>crta</field_pretty_url>
  <para_id>1053426</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1054523</id>
  <title>Human Cancer Models Initiative Will Create Next Generation Cancer Models That Have Genomic and Clinical Data</title>
  <langcode>en</langcode>
  <field_short_title>Launch of Human Cancer Models Initiative</field_short_title>
  <field_page_description>The NCI has formed new international collaboration called the Human Cancer Models Initiative to generate better models of human cancers to support cancer research.</field_page_description>
  <field_feature_card_description>An international collaboration called the Human Cancer Models Initiative will create next-generation cancer models for cancer research. </field_feature_card_description>
  <field_list_description>The NCI announced a new international collaboration called the Human Cancer Models Initiative that will generate models of human cancers that more accurately represent tumor biology and the diversity of cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-07-11</field_date_posted>
  <field_date_reviewed>2016-07-06</field_date_reviewed>
  <field_pretty_url>human-cancer-models-initiative-launch</field_pretty_url>
  <para_id>1054523</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1057853</id>
  <title>Researcher Interview: Aviv Regev</title>
  <langcode>en</langcode>
  <field_short_title>Aviv Regev Interview</field_short_title>
  <field_page_description>Amy E. Blum, M.A. spoke with Aviv Regev, Ph.D. in this CCG researcher interview.</field_page_description>
  <field_feature_card_description>CCG Question &amp; Answer with Aviv Regev, Ph.D. </field_feature_card_description>
  <field_list_description>This Researcher Interview between Amy E. Blum, M.A. and Aviv Regev, Ph.D., covers current topics in cancer genomics, including Dr. Regev's lab, recent work, and perspective on the future.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-15</field_date_posted>
  <field_date_reviewed>2016-08-02</field_date_reviewed>
  <field_pretty_url>aviv-regev-interview</field_pretty_url>
  <para_id>1057853</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1058013</term_id>
  <id>1058014</id>
  <title>Cancer Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Disparities</field_short_title>
  <field_page_description>Basic information about cancer disparities in the U.S., factors that contribute to the disproportionate burden of cancer in some groups, and examples of disparities in incidence and mortality among certain populations.</field_page_description>
  <field_feature_card_description>Many factors contribute to the fact that minorities and other groups tend to bear an unequal burden of cancer. </field_feature_card_description>
  <field_list_description>Certain groups bear an unequal burden of cancer. Learn about the factors that contribute to cancer disparities and find examples of disparities in incidence and mortality among certain populations.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-04</field_date_posted>
  <field_date_reviewed>2016-08-03</field_date_reviewed>
  <para_id>1058014</para_id>
  <related_resource_ids>6926598</related_resource_ids>
  <related_resource_ids>6926599</related_resource_ids>
  <related_resource_ids>6926600</related_resource_ids>
  <related_resource_ids>6926620</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1047031</term_id>
  <id>1047038</id>
  <title>DCB Research Resources</title>
  <langcode>en</langcode>
  <field_short_title>DCB Research Resources</field_short_title>
  <field_page_description>A collection of researcher resources specific to cancer biology research.</field_page_description>
  <field_feature_card_description>A collection of researcher resources specific to cancer biology research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-04-22</field_date_reviewed>
  <para_id>1047038</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047286</id>
  <title>Targeted Photoimmunotherapy Approach for Cancer Moves Forward</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Photoimmunotherapy for Cancer Moves Forward</field_short_title>
  <field_page_description>Two new studies from NCI researchers add to growing evidence of the promise of a novel type of cancer immunotherapy that uses infrared light to activate rapid and selective killing of cancer cells.</field_page_description>
  <field_feature_card_description>Results from an early study of a kind of immunotherapy that uses infrared light to activate the selective killing of cancer cells. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-25</field_date_posted>
  <field_date_reviewed>2016-04-25</field_date_reviewed>
  <field_pretty_url>photoimmunotherapy-cancer</field_pretty_url>
  <para_id>1047286</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1047414</term_id>
  <id>1047418</id>
  <title>NCI Graduate Student Recruiting Program</title>
  <langcode>en</langcode>
  <field_short_title>NCI Graduate Student Recruiting Program</field_short_title>
  <field_feature_card_description>NCI is looking for postdoctoral fellows to complete their training in the Intramural Research Program.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-19</field_date_posted>
  <field_date_reviewed>2016-04-27</field_date_reviewed>
  <para_id>1047418</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938227</term_id>
  <id>1050232</id>
  <title>Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer</field_short_title>
  <field_page_description>In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.</field_page_description>
  <field_feature_card_description>HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive pembrolizumab.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-19</field_date_posted>
  <field_date_reviewed>2016-05-19</field_date_reviewed>
  <field_pretty_url>hiv-pembrolizumab-trial</field_pretty_url>
  <para_id>1050232</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1051873</id>
  <title>Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches</title>
  <langcode>en</langcode>
  <field_short_title>Risk Profiling May Improve Lung Cancer Screening </field_short_title>
  <field_page_description>A new modeling study suggests that individualized, risk-based selection of ever-smokers for lung cancer screening may prevent more lung cancer deaths and improve the effectiveness and efficiency of screening compared with current screening recommendations</field_page_description>
  <field_feature_card_description>Risk-based modeling may identify ever-smokers who are most likely to benefit from CT screening for lung cancer. </field_feature_card_description>
  <field_list_description>A blog post on a modeling study from NCI researchers suggesting that individualized, risk-based selection of ever-smokers for lung cancer screening may prevent more lung cancer deaths compared with current screening recommendations.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-02</field_date_posted>
  <field_date_reviewed>2016-06-01</field_date_reviewed>
  <field_pretty_url>risk-profile-lung-screening</field_pretty_url>
  <para_id>1051873</para_id>
  <related_resource_id>6611761</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1052092</id>
  <title>Russian delegation visits NIH and NCI to discuss research collaboration</title>
  <langcode>en</langcode>
  <field_short_title>Russian delegation visits NIH and NCI to discuss research collaboration</field_short_title>
  <field_page_description>The NCI Center for Global Health hosted a delegation from the Russian Foundation for Basic Research to discuss ongoing and future collaborations in cancer research. The delegation was accompanied by representatives from the US Embassy in Moscow and the Embassy of the Russian Federation in Washington DC. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-07</field_date_posted>
  <field_date_reviewed>2016-06-07</field_date_reviewed>
  <field_pretty_url>russia</field_pretty_url>
  <para_id>1052092</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>776903</term_id>
  <id>776914</id>
  <title>Office of Grants Administration (OGA)</title>
  <langcode>en</langcode>
  <field_short_title>Office of Grants Administration (OGA)</field_short_title>
  <field_page_description>OGA manages all NCI business-related activities associated with the negotiation, award, and administration of NCI grants and cooperative agreements to help financially support cancer research activities throughout the United States and around the world.</field_page_description>
  <field_feature_card_description>OGA manages the business aspect of more than $3 billion in grant awards annually.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-28</field_date_posted>
  <field_date_reviewed>2014-05-28</field_date_reviewed>
  <para_id>776914</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917235</term_id>
  <id>777714</id>
  <title>Cancer Clinical Investigator Team Leadership Award (CCITLA)</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Clinical Investigator Team Leadership Award (CCITLA)</field_short_title>
  <field_page_description>NCI’s Cancer Clinical Investigator Team Leadership Awards (CCITLAs) recognize mid-career clinical investigators at NCI Cancer Centers.</field_page_description>
  <field_feature_card_description>Mid-career investigators who are leaders in clinical cancer research at NCI-designated cancer centers can apply for funding to support clinical research activities.</field_feature_card_description>
  <field_list_description>NCI’s Cancer Clinical Investigator Team Leadership Awards (CCITLAs) recognize mid-career clinical investigators at NCI-designated Cancer Centers working to improve the lives of people with cancer through clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-30</field_date_posted>
  <field_date_reviewed>2014-05-30</field_date_reviewed>
  <para_id>777714</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919514</term_id>
  <id>807054</id>
  <title>Contact OGA</title>
  <langcode>en</langcode>
  <field_short_title>Contact OGA</field_short_title>
  <field_page_description>Feel free send us your comments, concerns, and questions regarding general NCI grant-related issues, as well as your experience with the award process.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-04</field_date_posted>
  <field_date_reviewed>2014-07-22</field_date_reviewed>
  <para_id>807054</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>814247</id>
  <title>The ALCHEMIST Lung Cancer Trials</title>
  <langcode>en</langcode>
  <field_short_title>The ALCHEMIST Lung Cancer Trials</field_short_title>
  <field_page_description>A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the &lt;i&gt;EGFR&lt;/i&gt; and &lt;i&gt;ALK&lt;/i&gt; genes, and assign patients with these gene mutations to treatment trials tes</field_page_description>
  <field_feature_card_description>These clinical trials are exploring whether targeted therapy can prevent the recurrence of certain subtypes of early-stage lung cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-08-18</field_date_posted>
  <field_date_reviewed>2014-08-12</field_date_reviewed>
  <field_pretty_url>alchemist</field_pretty_url>
  <para_id>814247</para_id>
  <related_resource_ids>6635735</related_resource_ids>
  <related_resource_ids>6635736</related_resource_ids>
  <related_resource_ids>6635737</related_resource_ids>
  <related_resource_ids>6635738</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1031900</id>
  <title>New Drug for Pediatric Neuroblastoma Shows Promise in Preclinical Studies</title>
  <langcode>en</langcode>
  <field_short_title>Drug Shows Promise for Pediatric Neuroblastoma</field_short_title>
  <field_page_description>An international research team has identified a possible new treatment target for pediatric neuroblastoma and is planning an early-stage clinical trial of a drug that inhibits this target.</field_page_description>
  <field_feature_card_description>Lab studies suggest a new treatment target for this type of childhood cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-17</field_date_posted>
  <field_date_reviewed>2015-12-16</field_date_reviewed>
  <field_pretty_url>fact-target-neuroblastoma</field_pretty_url>
  <para_id>1031900</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1033214</id>
  <title>Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options</title>
  <langcode>en</langcode>
  <field_short_title>Approvals Increase Lung Cancer Treatment Options</field_short_title>
  <field_page_description>The FDA has approved two targeted therapies, osimertinib (Tagrisso™) and necitumumab (Portrazza™), for the treatment of some patients with advanced lung cancer.</field_page_description>
  <field_feature_card_description>The FDA has approved two targeted therapies, osimertinib (Tagrisso™) and necitumumab (Portrazza™), for the treatment of some patients with advanced lung cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-28</field_date_posted>
  <field_date_reviewed>2015-12-23</field_date_reviewed>
  <field_pretty_url>fda-osimertinib-necitumumab</field_pretty_url>
  <para_id>1033214</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1034898</id>
  <title>Video Intervention Helps Prepare Patients to Participate in Cancer Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Video Helps Prepare Patients to Participate in Cancer Clinical Trials</field_short_title>
  <field_page_description>Patients who took part in a tailored, video-based educational program had a better understanding of and fewer concerns about participating in clinical trials than patients who received text-based educational.</field_page_description>
  <field_feature_card_description>Patients who took part in a video-based educational program had a better understanding of, and fewer concerns about, participating in clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-28</field_date_posted>
  <field_date_reviewed>2016-01-28</field_date_reviewed>
  <field_pretty_url>trial-participation-video</field_pretty_url>
  <para_id>1034898</para_id>
  <related_resource_id>6598468</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1035636</id>
  <title>Tackling the Global Cancer Burden: A Conversation with NCI’s Dr. Ted Trimble</title>
  <langcode>en</langcode>
  <field_short_title>Tackling the Global Cancer Burden: A Conversation with NCI’s Dr. Ted Trimble</field_short_title>
  <field_page_description>In honor of World Cancer Day, the director of NCI’s Center for Global Health discusses key opportunities in global cancer research.</field_page_description>
  <field_feature_card_description>Dr. Ted Trimble of NCI’s Center for Global Health discusses key opportunities in global cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-04</field_date_posted>
  <field_date_reviewed>2016-02-03</field_date_reviewed>
  <field_pretty_url>trimble-global-cancer</field_pretty_url>
  <para_id>1035636</para_id>
  <related_resource_ids>6611597</related_resource_ids>
  <related_resource_ids>6611599</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1043841</id>
  <title>Sunitinib and Sorafenib Ineffective as Adjuvant Therapies for Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Adjuvant Anti-Angiogenesis Drugs Are No Benefit in Kidney Cancer</field_short_title>
  <field_page_description>Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.</field_page_description>
  <field_feature_card_description>Anti-angiogenesis drugs don't improve survival and may cause serious side effects.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-08</field_date_posted>
  <field_date_reviewed>2016-04-08</field_date_reviewed>
  <field_pretty_url>adjuvant-angiogenesis-kidney</field_pretty_url>
  <para_id>1043841</para_id>
  <related_resource_id>6890248</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1047361</term_id>
  <id>1047364</id>
  <title>Care for Childhood Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Survivorship Care for Children</field_short_title>
  <field_page_description>Survivorship care for children who have been treated for cancer is important. Get your child's treatment summary, survivorship plan, and recommendations on follow-up care clinics. Learn about long-term and late effects.</field_page_description>
  <field_feature_card_description>Get your child's treatment summary, survivorship plan, and recommendations on follow-up care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-04</field_date_posted>
  <field_date_reviewed>2018-09-10</field_date_reviewed>
  <para_id>1047364</para_id>
  <related_resource_ids>7119476</related_resource_ids>
  <related_resource_ids>7119477</related_resource_ids>
  <related_resource_ids>7119480</related_resource_ids>
  <related_resource_ids>7119481</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894082</term_id>
  <id>1047453</id>
  <title>National Minority Health Month Spotlight: Career Development</title>
  <langcode>en</langcode>
  <field_short_title>National Minority Health Month: Career Development</field_short_title>
  <field_page_description>April is National Minority Health Month and in support of the 2016 theme, Accelerating Health Equity for the Nation, the NCI Center to Reduce Cancer Health Disparities (CRCHD) is highlighting how diversity training and career development opportunities are contributing to efforts to reduce the unequal burden of cancer i</field_page_description>
  <field_feature_card_description>CRCHD'S diversity training and career development opportunities are contributing to efforts to reduce the unequal burden of cancer in our society.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-04-28</field_date_posted>
  <field_date_reviewed>2016-04-28</field_date_reviewed>
  <field_pretty_url>nmhm-2016</field_pretty_url>
  <para_id>1047453</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047526</id>
  <title>New on NCI’s Websites for May 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for May 2016</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>An update on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-02</field_date_posted>
  <field_date_reviewed>2016-04-29</field_date_reviewed>
  <field_pretty_url>new-online-may-2016</field_pretty_url>
  <para_id>1047526</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1047564</term_id>
  <id>1047566</id>
  <title>Cancer Systems Biology Consortium</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Systems Biology Consortium</field_short_title>
  <field_page_description>The CSBC looks at the changing cancer ecosystem, allowing researchers to understand and predict how one alteration effects an entire tumor system.</field_page_description>
  <field_feature_card_description>The CSBC looks to understand changes in the overall cancer ecosystem.</field_feature_card_description>
  <field_list_description>The Cancer Systems Biology Consortium seeks to provide a bird’s eye view of the changing cancer ecosystem, allowing cancer biologists and oncologists to understand and predict how one alteration effects an entire tumor system.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-29</field_date_posted>
  <field_date_reviewed>2016-04-29</field_date_reviewed>
  <para_id>1047566</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1047850</id>
  <title>A Conversation with Arul Chinnaiyan</title>
  <langcode>en</langcode>
  <field_short_title>A Conversation with Arul Chinnaiyan</field_short_title>
  <field_page_description>In a new blog in RAS Dialogue, Dr. Chinnaiyan discusses the biology behind his lab's discovery of the interaction of RAS with the RNA processing enzyme AGO2.</field_page_description>
  <field_feature_card_description>In a new blog in RAS Dialogue, Dr. Chinnaiyan discusses the biology behind his lab's discovery of the interaction of RAS with the RNA processing enzyme AGO2.</field_feature_card_description>
  <field_list_description>Arul Chinnaiyan and colleagues discovered a strong interaction between the KRAS and AGO2 proteins that seems to inhibit KRAS signaling. They are also pioneers in using genomic data to guide therapy for cancer patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-10</field_date_posted>
  <field_date_reviewed>2016-05-05</field_date_reviewed>
  <field_pretty_url>arul-chinnaiyan-interview</field_pretty_url>
  <para_id>1047850</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>903959</term_id>
  <id>866520</id>
  <title>About The Center for Cancer Genomics (CCG)</title>
  <langcode>en</langcode>
  <field_short_title>About CCG</field_short_title>
  <field_page_description>The Center for Cancer Genomics applies next-generation sequencing and genomic analysis to identify genetic drivers of cancer and produce data for researchers.</field_page_description>
  <field_list_description>The Center for Cancer Genomics uses cancer genomic techniques such as next-generation sequencing to better diagnose and treat cancer patients. The Cancer Genome Atlas (TCGA) and the Office of Cancer Genomics (OCG) are both part of CCG.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2014-12-03</field_date_reviewed>
  <para_id>866520</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>783955</term_id>
  <id>867853</id>
  <title>Office of Budget and Finance (OBF)</title>
  <langcode>en</langcode>
  <field_short_title>Office of Budget and Finance (OBF)</field_short_title>
  <field_page_description>OBF advises the NCI Office of the Director and other senior staff on the management of financial and personnel resources to ensure fiscally responsible and efficient operation of the Institute.</field_page_description>
  <field_feature_card_description>OBF advises the NCI Office of the Director and other senior staff on the management of financial and personnel resources to ensure fiscally responsible and efficient operation of the Institute.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-05</field_date_posted>
  <field_date_reviewed>2014-12-05</field_date_reviewed>
  <para_id>867853</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>869606</term_id>
  <id>869607</id>
  <title>CRCHD Funding for Research and Training</title>
  <langcode>en</langcode>
  <field_short_title>Funding for Research &amp; Training </field_short_title>
  <field_page_description>CRCHD provides extramural research grants to researchers and institutions and training and career development funding opportunities to increase workforce diversity.</field_page_description>
  <field_feature_card_description>Find the latest CRCHD funding opportunities for cancer and cancer health disparities research and training.</field_feature_card_description>
  <field_list_description>CRCHD provides extramural grants to researchers and institutions conducting research on cancer and cancer health disparities. CRCHD is committed to the training and development of a strong workforce of cancer researchers from diverse populations.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-12-08</field_date_reviewed>
  <para_id>869607</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>870055</term_id>
  <id>870060</id>
  <title>What We Do &amp; Future Goals</title>
  <langcode>en</langcode>
  <field_short_title>What We Do &amp; Future Goals</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-12-10</field_date_reviewed>
  <para_id>870060</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>860262</term_id>
  <id>870062</id>
  <title>Debate, Research on E-Cigarettes Continue</title>
  <langcode>en</langcode>
  <field_short_title>Debate, Research on E-Cigarettes Continue</field_short_title>
  <field_page_description>Since they first began to be sold in North America in the mid-2000s, electronic cigarettes have been the subject of intense debate. NCI's Dr. Michele Bloch recently presented an update on some of the issues surrounding e-cigarettes.</field_page_description>
  <field_feature_card_description>A blog post about the intense debate over electronic cigarettes.</field_feature_card_description>
  <field_list_description>Since they first began to be sold in North America in the mid-2000s, electronic cigarettes have been the subject of intense debate. NCI's Dr. Michele Bloch recently presented an update on some of the issues surrounding e-cigarettes.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-11</field_date_posted>
  <field_date_reviewed>2014-12-10</field_date_reviewed>
  <field_pretty_url>e-cigarettes</field_pretty_url>
  <para_id>870062</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882364</term_id>
  <id>882350</id>
  <title>Thorium </title>
  <langcode>en</langcode>
  <field_short_title>Thorium </field_short_title>
  <field_page_description>Learn about thorium, which can raise the  risk of liver, lung, and pancreatic cancers. The primary ways people are exposed are inhalation, intravenous injection, ingestion, and absorption through the skin.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-20</field_date_reviewed>
  <para_id>882350</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916474</term_id>
  <id>882657</id>
  <title>Coke Oven Emissions</title>
  <langcode>en</langcode>
  <field_short_title>Coke Oven Emissions</field_short_title>
  <field_page_description>Learn about coke oven emissions, which can raise your risk of lung cancer. Workers at coking plants and coal-tar production plants may be exposed to coke oven emissions. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-01</field_date_reviewed>
  <para_id>882657</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>887320</id>
  <title>The United States - Latin America Cancer Research Network: A multidisciplinary and collaborative approach to conducting clinical cancer research in Latin America </title>
  <langcode>en</langcode>
  <field_short_title>US-LA CRN Clinical Cancer Research in Latin America</field_short_title>
  <field_page_description>The United States – Latin America Cancer Research Network (US-LA CRN) convened its Annual Meeting, in coordination with the Ministry of Health of Chile to discuss the Network’s first multilateral clinical research study: Molecular Profiling of Breast Cancer (MPBC).  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-29</field_date_posted>
  <field_date_reviewed>2014-12-29</field_date_reviewed>
  <field_pretty_url>uslacrn-clinical-cancer-research</field_pretty_url>
  <para_id>887320</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1060461</id>
  <title>Nanoparticle that Mimics Salmonella Counteracts Chemotherapy Resistance</title>
  <langcode>en</langcode>
  <field_short_title>Nanoparticle Counteracts Chemotherapy Resistance</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a nanoparticle that mimics Salmonella and may help counteract chemotherapy resistance.</field_page_description>
  <field_feature_card_description>Nanoparticle that mimics Salmonella may help counteract chemotherapy resistance.</field_feature_card_description>
  <field_list_description>A nanoparticle that mimics Salmonella may help to counteract chemotherapy resistance, according to a new study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-22</field_date_posted>
  <field_date_reviewed>2016-08-19</field_date_reviewed>
  <field_pretty_url>chemotherapy-resistance-salmonella</field_pretty_url>
  <para_id>1060461</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1060809</id>
  <title>FDA Approves Pembrolizumab for Head and Neck Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Pembrolizumab for Head and Neck Cancer</field_short_title>
  <field_page_description>FDA granted pembrolizumab accelerated approval for some patients with head and neck cancer.</field_page_description>
  <field_feature_card_description>First immunotherapy drug approved for patients with this cancer type.</field_feature_card_description>
  <field_list_description>FDA granted pembrolizumab an accelerated approval for patients with recurrent or metastatic head and neck cancer that has continued to progress despite standard treatment with chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-24</field_date_posted>
  <field_date_reviewed>2016-08-24</field_date_reviewed>
  <field_pretty_url>fda-pembrolizumab-hnscc</field_pretty_url>
  <para_id>1060809</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1061146</term_id>
  <id>1061148</id>
  <title>Cancer Clinical Trials API</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Clinical Trials API</field_short_title>
  <field_page_description>Access NCI-supported cancer clinical trials information through an application programming interface (API).</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-31</field_date_posted>
  <field_date_reviewed>2016-08-31</field_date_reviewed>
  <para_id>1061148</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1061720</term_id>
  <id>1061722</id>
  <title>Learn About the RAS Initiative</title>
  <langcode>en</langcode>
  <field_short_title>About the RAS Initiative </field_short_title>
  <field_page_description>The RAS Initiative, a "hub and spoke" model, connects researchers to better understand and target the more than 30% of cancers driven by mutations in RAS genes. Includes oversight and contact information.</field_page_description>
  <field_feature_card_description>Discover the problem with RAS genes and how the RAS Initiative is structured to oversee and evaluate its goals and progress.</field_feature_card_description>
  <field_list_description>The "hub and spoke" model of the RAS Initiative connects researcher collaborators to better understand and target the more than 30% of cancers driven by mutations in RAS genes. Find more on the problem with RAS genes, RAS Initiative origins and oversight, and contact information.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-14</field_date_posted>
  <field_date_reviewed>2016-09-14</field_date_reviewed>
  <para_id>1061722</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1061763</id>
  <title>CGH Roundtable on HPV Screening</title>
  <langcode>en</langcode>
  <field_short_title>CGH Roundtable on HPV Screening</field_short_title>
  <field_page_description>The NCI Center for Global Health extends its congratulations on Pink Ribbon Red Ribbon’s fifth anniversary and continues to build on its three-year partnership. We look forward to participating in PRRR fifth-anniversary-related activities. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-14</field_date_posted>
  <field_date_reviewed>2016-09-14</field_date_reviewed>
  <field_pretty_url>prrr-roundtable</field_pretty_url>
  <para_id>1061763</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1062269</id>
  <title>CGH Announces Recipients of Regional Centers of Research Excellence (RCREs) P20 Grant Awards </title>
  <langcode>en</langcode>
  <field_short_title>Recipients of Regional Centers of Research Excellence (RCREs) P20 Grant Awards Announced</field_short_title>
  <field_page_description>NCI, Center for Global Health (CGH) release of the applications represents novel global collaborations charged with planning and designing sustainable, Regional Centers of Research Excellence (RCREs) for non-communicable diseases, including cancer, in low- and middle-income countries (LMICs) or regions. </field_page_description>
  <field_feature_card_description>Recipients of Regional Centers of Research Excellence (RCREs) P20 Grant Awards Announced</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-21</field_date_posted>
  <field_date_reviewed>2016-09-26</field_date_reviewed>
  <field_pretty_url>RCREs</field_pretty_url>
  <para_id>1062269</para_id>
  <related_resource_ids>6395452</related_resource_ids>
  <related_resource_ids>6395453</related_resource_ids>
  <related_resource_ids>6395454</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1062779</id>
  <title>A Key Data Sharing Partnership: The Multiple Myeloma Research Foundation Donates Data to the GDC</title>
  <langcode>en</langcode>
  <field_short_title>The MMRF Contributes to GDC</field_short_title>
  <field_page_description>MMRF will share its genomic and clinical data on multiple myeloma patients through a first of its kind partnership with the NCI Genomic Data Commons (GDC).</field_page_description>
  <field_list_description>The Multiple Myeloma Research Foundation (MMRF), an advocacy and research organization, has emerged as a leader in data sharing by donating robust datasets on multiple myeloma to the GDC. By sharing their data, they hope to energize research on multiple myeloma and facilitate advances in cancer care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-28</field_date_posted>
  <field_date_reviewed>2016-09-27</field_date_reviewed>
  <field_pretty_url>mmrf-shares-genomic-data-commons</field_pretty_url>
  <para_id>1062779</para_id>
  <related_resource_id>6477896</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>16374</term_id>
  <id>1052944</id>
  <title>Find NCI-Supported Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Find NCI-Supported Clinical Trials</field_short_title>
  <field_page_description>Find an NCI-supported clinical trial—and learn how to locate other research studies—that may be right for you or a loved one.</field_page_description>
  <field_feature_card_description>Find an NCI-supported clinical trial—and learn how to locate other research studies—that may be right for you or a loved one.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-23</field_date_posted>
  <field_date_reviewed>2016-06-23</field_date_reviewed>
  <para_id>1052944</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1055469</id>
  <title>3-D View of Mutations May Identify Potential Targets for Cancer Drugs</title>
  <langcode>en</langcode>
  <field_short_title>3-D View of Mutations May Identify Potential Targets for Cancer Drugs</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a new 3-D modeling tool that may help identify effective treatments for some cancers.</field_page_description>
  <field_feature_card_description>A new tool models how mutations affect the structure of cancer-related proteins and how those proteins may interact with drugs.</field_feature_card_description>
  <field_list_description>A new 3-D modeling tool may help identify mutations in cancer cells that could be targeted with new or existing drugs, a new study suggests. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-14</field_date_posted>
  <field_date_reviewed>2016-07-14</field_date_reviewed>
  <field_pretty_url>protein-structure-drug-targets</field_pretty_url>
  <para_id>1055469</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1056297</id>
  <title>Anthrax Toxin-Based Cancer Therapy Targets Tumor Blood Vessels</title>
  <langcode>en</langcode>
  <field_short_title>Anthrax Toxin-Based Cancer Therapy Targets Tumor Blood Vessels</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study which shows that an anthrax toxin-based cancer therapy may attack tumors by selectively targeting blood vessels that feed them.</field_page_description>
  <field_feature_card_description>Therapy based on anthrax toxin has potential to treat different cancer types.</field_feature_card_description>
  <field_list_description>A therapy that uses the anthrax toxin selectively targets blood vessels that feed tumors and support their growth and spread, researchers have found.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-20</field_date_posted>
  <field_date_reviewed>2016-07-20</field_date_reviewed>
  <field_pretty_url>toxin-targets-tumor-vessels</field_pretty_url>
  <para_id>1056297</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1060186</id>
  <title>CA-125 Testing, CT Scans Still Used for Ovarian Cancer Surveillance Despite Lack of Proven Benefit</title>
  <langcode>en</langcode>
  <field_short_title>Tests without Proven Benefit Still Used for Ovarian Cancer Surveillance</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a study that shows clinicians continue to use routine CA-125 testing and CT scans to monitor for recurrences although the benefit of these tests has not been proven</field_page_description>
  <field_feature_card_description>Study shows clinicians continue to use CA-125 tests and CT scans to monitor for recurrences.</field_feature_card_description>
  <field_list_description>A new study shows clinicians continue to use CA-125 testing and CT scans to monitor for recurrences although the benefit of these tests has not been proven.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-16</field_date_posted>
  <field_date_reviewed>2016-08-15</field_date_reviewed>
  <field_pretty_url>surveillance-tests-ovarian</field_pretty_url>
  <para_id>1060186</para_id>
  <related_resource_id>6624975</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>1060214</id>
  <title>Clearing The Air: Quit Smoking Today</title>
  <langcode>en</langcode>
  <field_short_title>Clearing The Air: Quit Smoking Today</field_short_title>
  <field_page_description>This booklet outlines successful strategies that can help people quit smoking and stay smoke-free.</field_page_description>
  <field_feature_card_description>This booklet outlines successful strategies that can help people quit smoking and stay smoke-free.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-16</field_date_posted>
  <field_date_reviewed>2016-08-16</field_date_reviewed>
  <field_pretty_url>clearing-the-air</field_pretty_url>
  <para_id>1060214</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1061150</term_id>
  <id>1061151</id>
  <title>Research Directions for Childhood Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Research Directions for Childhood Cancer</field_short_title>
  <field_page_description>NCI has identified areas for which more research is needed on childhood cancers, including investments in basic research, immunotherapies, and moleculary targeted therapies.</field_page_description>
  <field_feature_card_description>NCI has identified areas for which more research is needed on childhood cancers, and identified opportunities to gain new insights.</field_feature_card_description>
  <field_list_description>Making rapid progress against childhood cancers is a high-priority goal for NCI. To that end, NCI has identified areas for which more research is needed on childhood cancers, and identified opportunities to gain new insights.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-31</field_date_posted>
  <field_date_reviewed>2016-08-31</field_date_reviewed>
  <para_id>1061151</para_id>
  <related_resource_ids>6890484</related_resource_ids>
  <related_resource_ids>6890485</related_resource_ids>
  <related_resource_ids>6890504</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1061647</term_id>
  <id>1061651</id>
  <title>RAS Collaborations</title>
  <langcode>en</langcode>
  <field_short_title>Collaborations</field_short_title>
  <field_page_description>RAS Initiative collaborations with both organizations and individual scientists have expanded research capabilities and maximized the impact of RAS Initiative discoveries. </field_page_description>
  <field_feature_card_description>RAS Initiative collaborations with both organizations and individual scientists have expanded research capabilities and maximized the impact of RAS Initiative discoveries. </field_feature_card_description>
  <field_list_description>The RAS Initiative has engaged in numerous formal collaborations with both organizations and individual scientists.  These arrangements bring outside expertise to the Initiative's project areas to apply the best ideas and newest technologies to the problem of RAS-driven cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-12</field_date_posted>
  <field_date_reviewed>2016-09-12</field_date_reviewed>
  <para_id>1061651</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1037158</id>
  <title>NCI-DOE Collaboration Paving Way for Large-Scale Computational Cancer Science</title>
  <langcode>en</langcode>
  <field_short_title>Paving the Way for Large-Scale Computational Cancer Science</field_short_title>
  <field_page_description>NCI and the Department of Energy have entered into a collaboration to develop a plan to use large-scale computing to influence cancer science and, ultimately, clinical treatment.</field_page_description>
  <field_feature_card_description>Effort looks to expand cancer research capabilities, advance strategic computing.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-17</field_date_posted>
  <field_date_reviewed>2016-02-12</field_date_reviewed>
  <field_pretty_url>nci-doe-computing</field_pretty_url>
  <para_id>1037158</para_id>
  <related_resource_ids>6611839</related_resource_ids>
  <related_resource_ids>6611840</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1037619</id>
  <title>What’s New on NCI’s Websites?</title>
  <langcode>en</langcode>
  <field_short_title>What’s New on NCI’s Websites?</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-19</field_date_posted>
  <field_date_reviewed>2016-02-19</field_date_reviewed>
  <field_pretty_url>new-online-february-2016</field_pretty_url>
  <para_id>1037619</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1038587</id>
  <title>Study of Cancer’s Origins Reveals Genetic Reprogramming of Single Cells</title>
  <langcode>en</langcode>
  <field_short_title>Zebrafish Model of Cancer Reveals Genetic Reprogramming of Single Cells</field_short_title>
  <field_page_description>Researchers have used a new zebrafish model of cancer to characterize the early genetic changes associated with the initiation of tumors.</field_page_description>
  <field_feature_card_description>A new zebrafish model of cancer lets researchers observe early genetic changes in cancer cells.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-24</field_date_posted>
  <field_date_reviewed>2016-02-24</field_date_reviewed>
  <field_pretty_url>zebrafish-model-cancer-origins</field_pretty_url>
  <para_id>1038587</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1041541</id>
  <title>High-Magnification Microscopy Visualizes Tumor Blood Vessels in Real Time</title>
  <langcode>en</langcode>
  <field_short_title>Researchers visualize tumor blood vessels during surgery</field_short_title>
  <field_page_description>High powered intravital microscopy reveals that 50 percent of blood vessels in melanoma tumors do not have any blood flow, according to a new study. </field_page_description>
  <field_feature_card_description>Intravital microscopy visualizes blood vessels in human tumors in real time.</field_feature_card_description>
  <field_list_description>High-powered intravital microscopy reveals that 50 percent of blood vessels in melanoma tumors do not have any blood flow, according to a new study. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-17</field_date_posted>
  <field_date_reviewed>2016-03-16</field_date_reviewed>
  <field_pretty_url>intravital-microscopy</field_pretty_url>
  <para_id>1041541</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1042455</id>
  <title>Blocking Calcium Transfer May Selectively Kill Cancer Cells</title>
  <langcode>en</langcode>
  <field_short_title>Blocking Calcium Transfer May Selectively Kill Cancer Cells</field_short_title>
  <field_page_description>A new study shows that blocking the transfer of calcium ions into mitochondria is toxic to cancer cells and impairs growth of tumors in mice, while sparing normal cells.</field_page_description>
  <field_feature_card_description>In this mouse study, the new approach created an “energy crisis” from which cancer cells can’t recover.</field_feature_card_description>
  <field_list_description>A new study shows that blocking the transfer of calcium ions (Ca2+) into mitochondria is toxic to cancer cells and impairs growth of tumors in mice, while sparing normal cells.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-31</field_date_posted>
  <field_date_reviewed>2016-03-31</field_date_reviewed>
  <field_pretty_url>blocking-calcium</field_pretty_url>
  <para_id>1042455</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047449</id>
  <title>The Cancer Community's Next Steps for the Moonshot Initiative</title>
  <langcode>en</langcode>
  <field_short_title>Next Steps for the Moonshot Initiative</field_short_title>
  <field_page_description>The National Cancer Moonshot Initiative’s Blue Ribbon Panel is moving quickly to develop recommendations on how to accelerate progress against cancer.</field_page_description>
  <field_feature_card_description>The blue ribbon panel for Vice President Biden’s moonshot initiative is moving quickly ahead with its work.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-29</field_date_posted>
  <field_date_reviewed>2016-04-28</field_date_reviewed>
  <field_pretty_url>moonshot-blue-ribbon-panel</field_pretty_url>
  <para_id>1047449</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1047603</term_id>
  <id>1047622</id>
  <title>Midcareer Investigator Award in Patient-Oriented Research (K24)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K24 Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-22</field_date_reviewed>
  <para_id>1047622</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>895218</id>
  <title>Grantee Spotlight: Beatriz M. Carreno, Ph.D. - Seeking a Vaccine to Cure Melanoma </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Beatriz M. Carreno, Ph.D. - Seeking a Vaccine to Cure Melanoma </field_short_title>
  <field_page_description>CRCHD grantee Dr. Beatriz Carreno is studying the use of vaccines as a potential cure for metastatic melanoma.</field_page_description>
  <field_feature_card_description>CRCHD grantee Dr. Beatriz Carreno is studying the use of vaccines as a potential cure for metastatic melanoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-05</field_date_posted>
  <field_date_reviewed>2014-06-05</field_date_reviewed>
  <field_pretty_url>carreno-spotlight</field_pretty_url>
  <para_id>895218</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>899198</id>
  <title>Grantee Spotlight: Dr. Meena Jaggi - Investigating Curcumin (Turmeric) as HPV Repressor for Native American Women</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Dr. Meena Jaggi - Investigating Curcumin (Turmeric) as HPV Repressor for Native A</field_short_title>
  <field_page_description>Dr. Meena Jaggi’s research, funded by an NCI/CRCHD U01 grant, involves the use of curcumin (commonly known as turmeric) to inhibit human papillomavirus (HPV) infection among Native American (NA) women.</field_page_description>
  <field_feature_card_description>Dr. Jaggi researches using curcumin to inhibit HPV infection in Native American women.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-20</field_date_posted>
  <field_date_reviewed>2015-01-20</field_date_reviewed>
  <field_pretty_url>jaggi-spotlight</field_pretty_url>
  <para_id>899198</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>899525</id>
  <title>A Good Year: FDA Approved Nine New Cancer Drugs in 2014</title>
  <langcode>en</langcode>
  <field_short_title>A Good Year: FDA Approved Nine New Cancer Drugs in 2014</field_short_title>
  <field_page_description>In 2014, the Food and Drug Administration (FDA) approved 41 drugs that had not been approved previously for any indication, the most in nearly 20 years. Of these 41 novel drugs, 9 were approved for the treatment of cancer or cancer-related conditions.</field_page_description>
  <field_feature_card_description>In 2014, the Food and Drug Administration (FDA) approved 41 drugs that had not been approved previously for any indication, the most in nearly 20 years. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-23</field_date_posted>
  <field_date_reviewed>2015-01-23</field_date_reviewed>
  <field_pretty_url>fda-nine-new-cancer-drugs</field_pretty_url>
  <para_id>899525</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919329</term_id>
  <id>903598</id>
  <title>Finding Health Care Services</title>
  <langcode>en</langcode>
  <field_short_title>Finding Health Care Services</field_short_title>
  <field_page_description>If you have been diagnosed with cancer, finding a doctor and treatment hospital for your cancer care is an important step to getting the best treatment possible. Learn tips for choosing a doctor and treatment facility to manage your cancer care.</field_page_description>
  <field_feature_card_description>Learn tips for choosing a doctor and a hospital or treatment facility to manage your cancer care. </field_feature_card_description>
  <field_list_description>If you have been diagnosed with cancer, finding a doctor and treatment facility for your cancer care is an important step to getting the best treatment possible. Learn tips for choosing a doctor and hospital or treatment facility to manage your cancer care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-10</field_date_posted>
  <field_date_reviewed>2015-02-02</field_date_reviewed>
  <para_id>903598</para_id>
  <related_resource_ids>7162139</related_resource_ids>
  <related_resource_ids>7162140</related_resource_ids>
  <related_resource_ids>7162141</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903592</term_id>
  <id>903604</id>
  <title>Using Trusted Resources</title>
  <langcode>en</langcode>
  <field_short_title>Using Trusted Resources</field_short_title>
  <field_page_description>Information to help people evaluate the source and credibility of health information that they find in print or online.</field_page_description>
  <field_feature_card_description>Information to help people evaluate the source and credibility of health information that they find in print or online.</field_feature_card_description>
  <field_list_description>Some online sources can provide misleading or incorrect information. Health information, whether in print or online, should come from a trusted, credible source</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-10</field_date_posted>
  <field_date_reviewed>2015-02-02</field_date_reviewed>
  <para_id>903604</para_id>
  <related_resource_ids>6995929</related_resource_ids>
  <related_resource_ids>6995930</related_resource_ids>
  <related_resource_ids>6995933</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899930</term_id>
  <id>903717</id>
  <title>Skin and Nail Changes during Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Skin and Nail Changes</field_short_title>
  <field_page_description>Cancer treatments can cause skin to become dry, itchy, red, or peel. Nails may become dark, yellow, or cracked. Learn about signs of skin problems that may need urgent medical care. Get a helpful list of questions to ask your doctor.</field_page_description>
  <field_list_description>Information about what causes skin and nail changes, a side effect of some cancer treatments, and ways to prevent or manage them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-02-04</field_date_reviewed>
  <para_id>903717</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903759</term_id>
  <id>903748</id>
  <title>Lymphedema and Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Lymphedema</field_short_title>
  <field_page_description>Lymphedema is a side effect of some cancer treatments. Symptoms of lymphedema are presented. Ways to treat or manage swelling in the arm or leg are covered for cancer patients and cancer survivors.</field_page_description>
  <field_list_description>Information about what causes lymphedema, a side effect of some cancer treatments, and ways to manage or treat it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-02-04</field_date_reviewed>
  <para_id>903748</para_id>
  <related_resource_id>7061826</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903865</term_id>
  <id>903866</id>
  <title>Symptoms of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Symptoms </field_short_title>
  <field_page_description>Cancer can cause different symptoms, such as abnormal bumps, night sweats, or unknown weight gain or loss. Only a doctor can tell if symptoms are caused by cancer or some other problem.</field_page_description>
  <field_feature_card_description>Cancer has many different symptoms. Only a doctor can tell if your symptoms are caused by cancer. </field_feature_card_description>
  <field_list_description>Cancer can cause many different symptoms. Only a doctor can tell if your symptoms are caused by cancer or some other problem. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-05</field_date_posted>
  <field_date_reviewed>2018-03-29</field_date_reviewed>
  <para_id>903866</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1048567</term_id>
  <id>1048568</id>
  <title>Intramural Investigators Submitting Data</title>
  <langcode>en</langcode>
  <field_short_title>Intramural Investigators Submitting Data</field_short_title>
  <field_page_description>Find general requirements for intramural investigators submitting genomic data. Different processes may exist based on operational differences in NCI intramural research programs. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-13</field_date_posted>
  <field_date_reviewed>2016-05-13</field_date_reviewed>
  <para_id>1048568</para_id>
  <related_resource_id>7083164</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>676217</id>
  <title>Drugs Approved for Endometrial Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Endometrial Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for endometrial cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-12-06</field_date_posted>
  <field_date_reviewed>2013-12-06</field_date_reviewed>
  <field_pretty_url>endometrial</field_pretty_url>
  <para_id>676217</para_id>
  <related_resource_ids>6423953</related_resource_ids>
  <related_resource_ids>6423954</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974559</term_id>
  <id>974560</id>
  <title>Extramural vs Intramural and RMS Funding</title>
  <langcode>en</langcode>
  <field_short_title>Extramural vs Intramural &amp; RMS Funding</field_short_title>
  <field_page_description>See a comparison of extramural funding and intramural and research management funding by mechanism since 2014.</field_page_description>
  <field_feature_card_description>See a comparison of extramural and intramural funding by mechanism since 2014.</field_feature_card_description>
  <field_list_description>See total dollar amounts and a comparison of extramural funding versus intramural and research management and support funding.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-08</field_date_reviewed>
  <para_id>974560</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>975113</id>
  <title>Test May Identify Poor Prognosis for Some Patients with Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Test May Identify Poor Prognosis for Some Patients with Lung Cancer</field_short_title>
  <field_page_description>A panel of three genetic markers may help to identify patients with early-stage lung cancer who have a very strong likelihood of their disease returning after surgery.</field_page_description>
  <field_feature_card_description>Markers could help guide decisions on post-surgical therapy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-13</field_date_posted>
  <field_date_reviewed>2015-07-10</field_date_reviewed>
  <field_pretty_url>lung-prognostic</field_pretty_url>
  <para_id>975113</para_id>
  <related_resource_id>6572905</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>987801</id>
  <title>Targeted Therapies, Tooth Extraction, and Metastasis</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Therapies, Tooth Extraction, and Metastasis</field_short_title>
  <field_page_description>Resistance often develops to targeted cancer drugs. Mouse studies indicate that dying cancer cells secrete signals that help other cancer cells survive.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-24</field_date_posted>
  <field_date_reviewed>2015-08-21</field_date_reviewed>
  <field_pretty_url>obenauf-rosen-massague</field_pretty_url>
  <para_id>987801</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>988237</id>
  <title>FDA Approves Expanded Indication for Carfilzomib in Patients with Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves New Indication for Carfilzomib</field_short_title>
  <field_page_description>The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.</field_page_description>
  <field_feature_card_description>Approval expands indication for carfilzomib in patients with multiple myeloma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-24</field_date_posted>
  <field_date_reviewed>2015-08-24</field_date_reviewed>
  <field_pretty_url>carfilzomib-myeloma</field_pretty_url>
  <para_id>988237</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>988479</id>
  <title>Risk of Breast Cancer Death is Low After a Diagnosis of Ductal Carcinoma in Situ</title>
  <langcode>en</langcode>
  <field_short_title>Risk of Breast Cancer Death is Low After DCIS Diagnosis  </field_short_title>
  <field_page_description>Women who are diagnosed with a condition called ductal carcinoma in situ generally have a low risk of dying from breast cancer, a new study has found.</field_page_description>
  <field_feature_card_description>Treatment to prevent recurrence doesn’t reduce breast cancer death risk.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-26</field_date_posted>
  <field_date_reviewed>2015-08-26</field_date_reviewed>
  <field_pretty_url>dcis-low-risk</field_pretty_url>
  <para_id>988479</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>989310</id>
  <title>Skillful News Reporting Drives Progress in Research</title>
  <langcode>en</langcode>
  <field_short_title>Skillful News Reporting Drives Progress in Research</field_short_title>
  <field_page_description>Call for Applications for Cancer Research in the Media Workshops in India: Deadline Extended to September 4, 2015.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-08-31</field_date_posted>
  <field_date_reviewed>2015-08-31</field_date_reviewed>
  <field_pretty_url>crim</field_pretty_url>
  <para_id>989310</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>1000675</id>
  <title>Researcher Interview: Tom Hudson</title>
  <langcode>en</langcode>
  <field_short_title>Researcher Interview: Tom Hudson</field_short_title>
  <field_page_description>Tom Hudson, M.D., President and Scientific Director of the Ontario Institute for Cancer Research, describes the International Cancer Genome Consortium (ICGC), which brings together cancer genomic data and research from across the world.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-09</field_date_posted>
  <field_date_reviewed>2015-09-08</field_date_reviewed>
  <field_pretty_url>tom-hudson-interview</field_pretty_url>
  <para_id>1000675</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>10960</term_id>
  <id>1004879</id>
  <title>Join the Conversation about the Annual Plan and Budget</title>
  <langcode>en</langcode>
  <field_short_title>Join the Conversation</field_short_title>
  <field_page_description>We invite you to comment on blog posts and discuss the Annual Plan and Budget Proposal with the cancer research community. </field_page_description>
  <field_feature_card_description>We invite your comments about the Annual Plan and Budget Proposal. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-25</field_date_posted>
  <field_date_reviewed>2015-09-25</field_date_reviewed>
  <field_pretty_url>plan-conversation</field_pretty_url>
  <para_id>1004879</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1007881</term_id>
  <id>1007882</id>
  <title>Information on DCB Funding Mechanisms</title>
  <langcode>en</langcode>
  <field_short_title>Information on DCB Funding Mechanisms</field_short_title>
  <field_page_description>The Division of Cancer Biology funds investigator-initiated cancer research using a variety of grant mechanisms such as FOA, PA, RFA &amp; NOT.  </field_page_description>
  <field_list_description>DCB uses different funding mechanisms to support investigator-initiated cancer research including Funding Opportunity Announcements (FOAs), Program Announcements (PA), Requests for Application (RFA), and Notices (NOT).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2015-10-01</field_date_reviewed>
  <para_id>1007882</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1012245</id>
  <title>TCGA Wins 2015 Sammies People’s Choice Award</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Wins 2015 Sammies People’s Choice Award</field_short_title>
  <field_page_description>The Partnership for Public Service presented the 2015 People’s Choice Award to the government staff and researchers who have worked on The Cancer Genome Atlas.</field_page_description>
  <field_feature_card_description>The Partnership for Public Service presented the 2015 People’s Choice Award to the government staff and researchers who have worked on The Cancer Genome Atlas.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-08</field_date_posted>
  <field_date_reviewed>2015-10-08</field_date_reviewed>
  <field_pretty_url>tcga-sammie</field_pretty_url>
  <para_id>1012245</para_id>
  <related_resource_id>5987271</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1022102</id>
  <title>A Holistic Approach to Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>A Holistic Approach to Cancer Health Disparities</field_short_title>
  <field_page_description>Recognizing that complex factors underlie health disparities, NCI is taking a holistic approach in our efforts to address this serious public health issue.</field_page_description>
  <field_feature_card_description>NCI leaders discuss efforts in biology, clinical trials, and training a more diverse workforce. Join our Twitter chat, 3 pm ET, Nov. 18.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-11-05</field_date_posted>
  <field_date_reviewed>2015-11-05</field_date_reviewed>
  <field_pretty_url>annual-plan-disparities</field_pretty_url>
  <para_id>1022102</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1026034</term_id>
  <id>1026786</id>
  <title>Hearings and Testimonies </title>
  <langcode>en</langcode>
  <field_short_title>Hearings &amp; Testimonies </field_short_title>
  <field_page_description>Written testimony from NCI experts from appropriations hearings and other hearings focused on cancer research and related topics.</field_page_description>
  <field_feature_card_description>Find written testimony from the NCI Director and other NCI experts. Includes relevant Appropriations hearings and hearings that focused on a particular cancer related topic.</field_feature_card_description>
  <field_list_description>Find written testimony from NCI experts from appropriations hearings and other hearings focused on a particular cancer related topic.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-11-16</field_date_reviewed>
  <para_id>1026786</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1028126</id>
  <title>Patient with Brain Tumor Responds Dramatically to Targeted Therapy</title>
  <langcode>en</langcode>
  <field_short_title>Patient with Brain Tumor Responds Dramatically to Targeted Therapy</field_short_title>
  <field_page_description>A patient with a papillary craniopharyngioma saw his tumor shrink more than 80 percent after treatment with a targeted drug that inhibits a mutant form of the BRAF protein.</field_page_description>
  <field_feature_card_description>Findings suggest a potential new therapeutic strategy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-03</field_date_posted>
  <field_date_reviewed>2015-12-01</field_date_reviewed>
  <field_pretty_url>brain-tumor-targeted-therapy</field_pretty_url>
  <para_id>1028126</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1026055</term_id>
  <id>1028164</id>
  <title>Legislative History</title>
  <langcode>en</langcode>
  <field_short_title>Legislative History</field_short_title>
  <field_page_description>Learn about the legislation that has created and influenced the NCI, including The National Cancer Institute Act of 1937 and The National Cancer Act of 1971.</field_page_description>
  <field_feature_card_description>Learn about the legislation that has created and influenced the NCI, including The National Cancer Institute Act of 1937 and The National Cancer Act of 1971.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-16</field_date_posted>
  <field_date_reviewed>2015-12-02</field_date_reviewed>
  <para_id>1028164</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>1030185</id>
  <title>Treating Cancer without Harming the Heart</title>
  <langcode>en</langcode>
  <field_short_title>Treating Cancer without Harming the Heart</field_short_title>
  <field_page_description>Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies.</field_page_description>
  <field_feature_card_description>Researchers study ways to prevent, manage, and possibly reverse heart damage caused by some cancer treatments.</field_feature_card_description>
  <field_list_description>Some cancer treatments may damage the heart, and researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse these side effects.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-07</field_date_posted>
  <field_date_reviewed>2015-12-07</field_date_reviewed>
  <field_pretty_url>cardiotoxicity</field_pretty_url>
  <para_id>1030185</para_id>
  <related_resource_id>6979113</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>65980</term_id>
  <id>65990</id>
  <title>Mentored Clinical Scientist Research Career Development Award (K08)</title>
  <langcode>en</langcode>
  <field_short_title>NCI K08 Award</field_short_title>
  <field_page_description>For postdoctoral candidates or mentored junior faculty are pursuing careers in basic science.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-18</field_date_posted>
  <field_date_reviewed>2017-12-11</field_date_reviewed>
  <para_id>65990</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420501</term_id>
  <id>420502</id>
  <title>Where Trials Take Place</title>
  <langcode>en</langcode>
  <field_short_title>Where Trials Take Place</field_short_title>
  <field_page_description>Information about the various settings in which cancer clinical trials take place.</field_page_description>
  <field_feature_card_description>Information about the various settings in which cancer clinical trials take place.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2012-09-11</field_date_reviewed>
  <para_id>420502</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420521</term_id>
  <id>420524</id>
  <title>Informed Consent</title>
  <langcode>en</langcode>
  <field_short_title>Informed Consent</field_short_title>
  <field_page_description>Information about the ways in which clinical trial participants are protected before and during the conduct of a study.</field_page_description>
  <field_feature_card_description>Information about the ways in which clinical trial participants are protected before and during the conduct of a study.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>420524</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420530</term_id>
  <id>420531</id>
  <title>Ending Trials Early</title>
  <langcode>en</langcode>
  <field_short_title>Ending Trials Early</field_short_title>
  <field_page_description>Information about why clinical trials may end early.</field_page_description>
  <field_feature_card_description>Information about why clinical trials may end early.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>420531</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938229</term_id>
  <id>476532</id>
  <title>Treating Patients with High-Risk Smoldering Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Treating Patients with High-Risk Smoldering Myeloma</field_short_title>
  <field_page_description>In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide. </field_page_description>
  <field_feature_card_description>In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-12-11</field_date_posted>
  <field_date_reviewed>2012-12-11</field_date_reviewed>
  <field_pretty_url>lenalidomide-high-risk-smoldering</field_pretty_url>
  <para_id>476532</para_id>
  <related_resource_ids>6235663</related_resource_ids>
  <related_resource_ids>6235664</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478619</id>
  <title>Contacts</title>
  <langcode>en</langcode>
  <field_short_title>Contacts</field_short_title>
  <field_page_description>BIQSFP contact list.</field_page_description>
  <field_feature_card_description>BIQSFP contact list.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>contacts</field_pretty_url>
  <para_id>478619</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>479707</id>
  <title>Breast Reconstruction After Mastectomy</title>
  <langcode>en</langcode>
  <field_short_title>Breast Reconstruction After Mastectomy</field_short_title>
  <field_page_description>A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction. </field_page_description>
  <field_feature_card_description>Information about surgical options, follow-up care, and breast cancer screening after reconstruction. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-17</field_date_posted>
  <field_date_reviewed>2017-02-24</field_date_reviewed>
  <field_pretty_url>reconstruction-fact-sheet</field_pretty_url>
  <para_id>479707</para_id>
  <related_resource_ids>6500330</related_resource_ids>
  <related_resource_ids>6500331</related_resource_ids>
  <related_resource_ids>6500332</related_resource_ids>
  <related_resource_ids>6500335</related_resource_ids>
  <related_resource_ids>6500336</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>819880</id>
  <title>Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Post-Treatment “Chemobrain”</field_short_title>
  <field_page_description>An NCI research update about research to investigate what factors play a role in “chemobrain” or cognitive impairment after cancer treatment.</field_page_description>
  <field_feature_card_description>Researchers are investigating factors that might predict who’s at risk and how to lessen its impact.</field_feature_card_description>
  <field_list_description>Researchers are investigating factors that might predict who’s more at risk for experiencing “chemobrain” after cancer treatment and what can be done to lessen its impact.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-03-24</field_date_posted>
  <field_date_reviewed>2014-08-27</field_date_reviewed>
  <field_pretty_url>understanding-chemobrain</field_pretty_url>
  <para_id>819880</para_id>
  <related_resource_id>6545022</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904176</term_id>
  <id>828658</id>
  <title>Cancer Health Disparities Definitions</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Health Disparities Definitions</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828658</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833183</term_id>
  <id>833186</id>
  <title>Patient Navigation Research Program (PNRP)</title>
  <langcode>en</langcode>
  <field_short_title>PNRP </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833186</para_id>
  <related_resource_ids>7250969</related_resource_ids>
  <related_resource_ids>7250972</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>837414</id>
  <title>Global Health Diplomacy on Display:  Dr. Varmus and Indian Prime Minister Modi</title>
  <langcode>en</langcode>
  <field_short_title>Global Health Diplomacy on Display:  Dr. Varmus and Indian Prime Minister Modi</field_short_title>
  <field_page_description>Global Health Diplomacy on Display:  Dr. Varmus and Indian Prime Minister Modi</field_page_description>
  <field_feature_card_description>Global Health Diplomacy on Display:  Dr. Varmus and Indian Prime Minister Modi</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-06</field_date_posted>
  <field_date_reviewed>2014-10-06</field_date_reviewed>
  <field_pretty_url>global-health-diplomacy</field_pretty_url>
  <para_id>837414</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>848639</term_id>
  <id>848368</id>
  <title>The Continuing Umbrella of Research Experiences (CURE)</title>
  <langcode>en</langcode>
  <field_short_title>Continuing Umbrella of Research Experiences</field_short_title>
  <field_page_description>The CURE program offers training and career development opportunities to increase diversity in the cancer and cancer health disparities research workforce.</field_page_description>
  <field_feature_card_description>The CURE program offers training and career development to increase diversity in the cancer and cancer health disparities research workforce.</field_feature_card_description>
  <field_list_description>The Center to Reduce Cancer Health Disparities (CRCHD) CURE program offers unique training and career development opportunities to enhance and increase diversity in the cancer and cancer health disparities research workforce.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <para_id>848368</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>848847</term_id>
  <id>848845</id>
  <title>Tips and Tools for Applying for Grants </title>
  <langcode>en</langcode>
  <field_short_title>Tips &amp; Tools </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <para_id>848845</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>855118</id>
  <title>Regional Cancer Registries – 20 Years and Growing</title>
  <langcode>en</langcode>
  <field_short_title>Regional Cancer Registries – 20 Years and Growing</field_short_title>
  <field_page_description>The NCI, Center for Global Health (CGH), the University of California at Irvine, the Middle East Cancer Consortium, and the International Agency for Research on Cancer partnered in support of the training course, held in Ankara, Turkey this past October, on The Uses of Cancer Registry Data in Cancer Control Research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-07</field_date_posted>
  <field_date_reviewed>2014-11-07</field_date_reviewed>
  <field_pretty_url>regional-cancer-registries</field_pretty_url>
  <para_id>855118</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>860822</term_id>
  <id>858227</id>
  <title>Adjusting to Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Adjusting to Cancer</field_short_title>
  <field_page_description>Information that helps you and your family face life’s changes from cancer. Includes talking with your doctors, talking to children, changes for the family, and information on cancer support groups.</field_page_description>
  <field_feature_card_description>Learn tips for talking about the changes cancer brings for you and your family.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-14</field_date_reviewed>
  <para_id>858227</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858162</term_id>
  <id>858316</id>
  <title>Changes for the Family</title>
  <langcode>en</langcode>
  <field_short_title>Changes for the Family</field_short_title>
  <field_page_description>Information that addresses family changes for people with cancer. </field_page_description>
  <field_feature_card_description>Information that addresses family changes for people with cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-14</field_date_reviewed>
  <para_id>858316</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066798</id>
  <title>NCI’s Office of Cancer Survivorship: Celebrating 20 Years, Planning for Continued Progress</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s Office of Cancer Survivorship: Celebrating 20 Years</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from Dr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on efforts to ensure continued progress in survivorship research</field_page_description>
  <field_feature_card_description>NCI-supported research helping improve lives of survivors, their families.</field_feature_card_description>
  <field_list_description>Dr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on the office’s 20th anniversary and efforts to ensure continued progress in survivorship research and improve survivors’ lives.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-17</field_date_posted>
  <field_date_reviewed>2016-11-16</field_date_reviewed>
  <field_pretty_url>ocs-20th-anniversary</field_pretty_url>
  <para_id>1066798</para_id>
  <related_resource_id>6611819</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1066996</id>
  <title>Developer Interview: Vincent Ferretti</title>
  <langcode>en</langcode>
  <field_short_title>Question &amp; Answer with Vincent Ferretti</field_short_title>
  <field_page_description>In this Q&amp;A, GDC web interface developer Vincent Ferretti, Ph.D., explains his team's design process and describes search and visualization expansions.</field_page_description>
  <field_list_description>In this Developer Interview, Vincent Ferretti, Ph.D., explains his team's process for developing and designing the GDC web interfaces and describes upcoming expansions to GDC's search and visualization capabilities. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-11-21</field_date_posted>
  <field_date_reviewed>2016-11-18</field_date_reviewed>
  <field_pretty_url>vincent-ferretti-interview</field_pretty_url>
  <para_id>1066996</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1067965</id>
  <title>Immune-Cell Traps May Aid Cancer Metastasis</title>
  <langcode>en</langcode>
  <field_short_title>Immune-Cell Traps May Aid Cancer Metastasis</field_short_title>
  <field_page_description>A Cancer Currents blog post on a new study that suggests cancer cells may exploit a normal function of neutrophils, a type of immune cell, to help form metastatic tumors.</field_page_description>
  <field_feature_card_description>Drug that disintegrates traps may hinder cancer from spreading. </field_feature_card_description>
  <field_list_description>Cancer cells may exploit a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors, a new study suggests.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-06</field_date_posted>
  <field_date_reviewed>2016-12-02</field_date_reviewed>
  <field_pretty_url>nets-metastasis</field_pretty_url>
  <para_id>1067965</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1071049</term_id>
  <id>1071047</id>
  <title>Screen to Save: NCI Colorectal Cancer Outreach and Screening Initiative</title>
  <langcode>en</langcode>
  <field_short_title>Screen to Save</field_short_title>
  <field_page_description>NCI Colorectal Cancer Outreach and Screening Initiative aims to increase colorectal cancer screening rates among ethnically and racially diverse and rural communities nationwide.
</field_page_description>
  <field_feature_card_description>Working through community health educators, this initiative aims to increase colorectal cancer screening rates in racially and ethnically diverse and rural communities nationwide.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-17</field_date_posted>
  <field_date_reviewed>2017-01-17</field_date_reviewed>
  <para_id>1071047</para_id>
  <related_resource_ids>6911062</related_resource_ids>
  <related_resource_ids>6911063</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>1071558</id>
  <title>Pembrolizumab Improves Survival for Some Patients with Advanced Non-Small Cell Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab for Non-Small Cell Lung Cancer Improves Survival</field_short_title>
  <field_page_description>A summary of clinical trial results showing that pembrolizumab improved progression-free and overall survival for patients with advanced non-small cell lung cancer.</field_page_description>
  <field_feature_card_description>Pembrolizumab improved survival for patients with advanced disease.</field_feature_card_description>
  <field_list_description>Results from a phase III trial showed that the immune checkpoint inhibitor pembrolizumab (Keytruda®) improved progression-free and overall survival among patients with advanced non-small cell lung cancer compared with chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-24</field_date_posted>
  <field_date_reviewed>2017-01-23</field_date_reviewed>
  <field_pretty_url>pembrolizumab-nsclc-keynote-024</field_pretty_url>
  <para_id>1071558</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1072644</id>
  <title>First Cohort of Affordable Technologies for Cancer Detection, Diagnosis, and Treatment in LMICs Enters their Second Phase </title>
  <langcode>en</langcode>
  <field_short_title>First Cohort of ACTs Enters Second Phase</field_short_title>
  <field_page_description>The Affordable Cancer Technologies Program promotes the development and validation of low-cost, portable technologies.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-06</field_date_posted>
  <field_date_reviewed>2017-02-06</field_date_reviewed>
  <field_pretty_url>acts-transition</field_pretty_url>
  <para_id>1072644</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1072646</id>
  <title>Third Cohort joins NCI’s Affordable Cancer Technologies Program: supporting the development of affordable technologies for cancer detection, diagnosis, and treatment in LMICs</title>
  <langcode>en</langcode>
  <field_short_title>Third Cohort joins NCI’s Affordable Cancer Technologies Program: supporting the development of affor</field_short_title>
  <field_page_description>CGH is pleased to welcome the third cohort of investigator teams to the Affordable Cancer Technologies Program.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-06</field_date_posted>
  <field_date_reviewed>2017-02-06</field_date_reviewed>
  <field_pretty_url>acts-cohort3</field_pretty_url>
  <para_id>1072646</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1073550</id>
  <title>A new focus for the International Cancer Screening Network</title>
  <langcode>en</langcode>
  <field_short_title>A new focus for the International Cancer Screening Network</field_short_title>
  <field_page_description>The ICSN is thinking about how to take advantage of the nearly three decades of work in cancer screening program research and implementation and reach out more actively to low- and middle-income countries considering screening. For that purpose, ICSN is migrating from its historical place under NCI Division of Cancer C</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-17</field_date_posted>
  <field_date_reviewed>2017-02-17</field_date_reviewed>
  <field_pretty_url>icsn</field_pretty_url>
  <para_id>1073550</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073557</id>
  <title>Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot Funding Opportunities</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from NCI Acting Director Dr. Doug Lowy describing a series of funding opportunity announcements related to the Beau Biden Cancer Moonshot&amp;#8480;.</field_page_description>
  <field_feature_card_description>Funding will support research aligned with the Cancer Moonshot’s goals.</field_feature_card_description>
  <field_list_description>NCI has issued a series of funding opportunity announcements aligned with goals of the recommendations in the Beau Biden Cancer Moonshot&amp;#8480; Blue Ribbon Panel report released last fall. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-17</field_date_posted>
  <field_date_reviewed>2017-02-17</field_date_reviewed>
  <field_pretty_url>moonshot-funding-opportunities</field_pretty_url>
  <para_id>1073557</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1073680</id>
  <title>Screen to Save: Message from the Branch Chief</title>
  <langcode>en</langcode>
  <field_short_title>Screen to Save: Message from the Branch Chief</field_short_title>
  <field_page_description>Screen to Save, S2S, colorectal cancer,  screening, education and outreach </field_page_description>
  <field_list_description>Dr. LeeAnn Bailey provides updates about Screen to Save efforts to encourage screening to save lives and increase outreach, awareness, and care provision in racially/ethnically diverse communities and rural areas. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-22</field_date_posted>
  <field_date_reviewed>2017-02-21</field_date_reviewed>
  <field_pretty_url>screen-to-save-bailey-message</field_pretty_url>
  <para_id>1073680</para_id>
  <related_resource_id>6501825</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1074760</id>
  <title>New on NCI Websites for March 2017</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI Websites for March 2017</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-06</field_date_posted>
  <field_date_reviewed>2017-03-06</field_date_reviewed>
  <field_pretty_url>new-online-march-2017</field_pretty_url>
  <para_id>1074760</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1075365</id>
  <title>Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen</title>
  <langcode>en</langcode>
  <field_short_title>Putting the Cancer Patient Front and Center</field_short_title>
  <field_page_description>A Cancer Currents blog featuring NCI’s Dr. Paul Jacobsen discussing NCI’s Healthcare Delivery Research Program and improving the delivery of cancer care.</field_page_description>
  <field_feature_card_description>NCI’s Healthcare Delivery Research Program supports innovative research to improve the delivery of cancer care.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Paul Jacobsen discusses NCI’s Healthcare Delivery Research Program and its role in advancing innovative research to improve the delivery of cancer care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-14</field_date_posted>
  <field_date_reviewed>2017-03-13</field_date_reviewed>
  <field_pretty_url>cancer-care-delivery-jacobsen</field_pretty_url>
  <para_id>1075365</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1075683</id>
  <title>New Report: Guiding Principles for Quality Cancer Treatment Services</title>
  <langcode>en</langcode>
  <field_short_title>New Report: Guiding Principles for Quality Cancer Treatment Services</field_short_title>
  <field_page_description>C/Can 2025 is a first-of-its-kind multi-sectorial initiative led by UICC which aims to increase the number of people with access to quality cancer care services in cities around the world. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-17</field_date_posted>
  <field_date_reviewed>2017-03-17</field_date_reviewed>
  <field_pretty_url>ccan-2025</field_pretty_url>
  <para_id>1075683</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1078443</term_id>
  <id>1078448</id>
  <title>2015 Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>2015 Social Media Events</field_short_title>
  <field_page_description>Find past social media events involving NCI and its partners from 2015.</field_page_description>
  <field_feature_card_description>Find past social media events involving NCI and its partners from 2015.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-28</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <para_id>1078448</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078428</term_id>
  <id>1078673</id>
  <title>NCI HIV and AIDS Research</title>
  <langcode>en</langcode>
  <field_short_title>NCI HIV and AIDS Research</field_short_title>
  <field_page_description>OHAM is driving important advances in prevention, diagnosis, and treatment of HIV-associated malignancies. Learn about major programs and initiatives. </field_page_description>
  <field_feature_card_description>Learn about research being conducted by OHAM and the NCI and how this research is  driving important advances in prevention, diagnosis, and treatment of HIV/AIDS and HIV-associated malignancies.</field_feature_card_description>
  <field_list_description>OHAM manages and facilitates major programs and initiatives in research, training, international studies, and clinical trials. Learn about research being conducted by OHAM and the NCI and how this research is  driving important advances in prevention, diagnosis, and treatment of HIV/AIDS and HIV-associated malignancies.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078673</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078432</term_id>
  <id>1078687</id>
  <title>HIV and AIDS Research News &amp; Events</title>
  <langcode>en</langcode>
  <field_short_title>News &amp; Events</field_short_title>
  <field_page_description>OHAM monitors HIV/AIDS research and events. Keep up-to-date with news about HIV/AIDS-related cancer research and learn about relevant meetings and conferences.</field_page_description>
  <field_feature_card_description>Keep up-to-date with news about HIV/AIDS-related cancer research and learn about relevant meetings and conferences.</field_feature_card_description>
  <field_list_description>OHAM monitors developments in HIV/AIDS research and curates a list of relevant events. Keep up-to-date with news about HIV/AIDS-related cancer research and learn about meetings and conferences in the field.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078687</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1078430</term_id>
  <id>1078698</id>
  <title>HIV and AIDS Research Resources</title>
  <langcode>en</langcode>
  <field_short_title>HIV and AIDS Research Resources</field_short_title>
  <field_page_description>NCI offers resources to investigators researching HIV/AIDS and HIV-malignancies. Find resources that are specific to this area and links to other selected resources.</field_page_description>
  <field_feature_card_description>Find information about NCI resources that are specific to HIV/AIDS-related research and links to other selected resources.</field_feature_card_description>
  <field_list_description>NCI makes a number of resources available to investigators researching HIV/AIDS and HIV-malignancies. Find information on resources provided by the NCI that are specific to research in HIV/AIDS and HIV-associated malignancies and links to selected resources provided by other components of the NIH.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>1078698</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1082603</term_id>
  <id>1080220</id>
  <title>Strengthening Capacity for Research for HIV-Associated Malignancies in Africa and Other Low- and Middle-Income Countries (LMICs)</title>
  <langcode>en</langcode>
  <field_short_title>OHAM: Strengthening Research in Africa and Other Low- and Middle-Income Countries (LMICs)</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080220</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1082596</term_id>
  <id>1080221</id>
  <title>International Conference on Malignancies in HIV/AIDS (ICMH)</title>
  <langcode>en</langcode>
  <field_short_title>International Conference on Malignancies in HIV/AIDS (ICMH)</field_short_title>
  <field_page_description>This biannual conference focuses on presentation of basic, epidemiologic, and clinical aspects of research on malignancies in HIV-infected and other immunosuppressed individuals. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080221</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080236</term_id>
  <id>1080252</id>
  <title>OHAM Staff and Contact Information</title>
  <langcode>en</langcode>
  <field_short_title>OHAM Staff and Contact Information</field_short_title>
  <field_page_description>Contact the NCI Office of HIV and AIDS Malignancy and learn more about leadership and staff. </field_page_description>
  <field_feature_card_description>Contact the Office of HIV and AIDS Malignancy and learn more about leadership and staff. </field_feature_card_description>
  <field_list_description>Contact the Office of HIV and AIDS Malignancy and learn more about leadership and staff. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-04-04</field_date_reviewed>
  <para_id>1080252</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1080376</id>
  <title>Researchers Design a Precise Library for CRISPR-Mediated Genetic Screens</title>
  <langcode>en</langcode>
  <field_short_title>Optimized CRISPR Library</field_short_title>
  <field_page_description>Researchers used machine learning method to optimize CRISPR libraries for genomic studies.</field_page_description>
  <field_list_description>Researchers in the Cancer Target Discovery and Development Network used machine learning to create improved CRISPR libraries for genomic studies. Their new libraries of single guide RNAs can be used to alter gene expression with greater sensitivity and specificity.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-06</field_date_posted>
  <field_date_reviewed>2017-04-06</field_date_reviewed>
  <field_pretty_url>crispr-genomics-library</field_pretty_url>
  <para_id>1080376</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1081663</id>
  <title>FDA Approves Pembrolizumab for Hodgkin Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Pembrolizumab for Hodgkin Lymphoma</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on the FDA’s approval of pembrolizumab for the treatment of some adult and pediatric patients with classical Hodgkin lymphoma.</field_page_description>
  <field_feature_card_description>The checkpoint inhibitor is approved for adults and children with refractory or relapsed disease.</field_feature_card_description>
  <field_list_description>The FDA approved pembrolizumab for the treatment of some adult and pediatric patients with classical Hodgkin lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-17</field_date_posted>
  <field_date_reviewed>2017-04-17</field_date_reviewed>
  <field_pretty_url>fda-pembrolizumab-hodgkin-lymphoma</field_pretty_url>
  <para_id>1081663</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1081704</term_id>
  <id>1081705</id>
  <title>NCI's Genome Characterization Pipeline</title>
  <langcode>en</langcode>
  <field_short_title>NCI's Genome Characterization Pipeline</field_short_title>
  <field_page_description>The Genome Characterization Pipeline, run by NCI’s Center for Cancer Genomics, transforms cancer tissue samples into rich genomic datasets that are shared with the research community. </field_page_description>
  <field_feature_card_description>This efficient workflow transforms cancer tissue samples into rich, publicly available genomic and clinical data. CCG partners with expert research teams to produce and share high quality, harmonized raw and processed data with researchers worldwide. </field_feature_card_description>
  <field_list_description>NCI’s Genome Characterization Pipeline is an efficient workflow that transforms cancer tissue samples into rich, publicly available genomic and clinical data. By partnering with foremost experts in tissue processing, bioinformatics, and data science, CCG produces and shares high quality, harmonized raw and processed data with researchers worldwide. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-04</field_date_posted>
  <field_date_reviewed>2017-04-17</field_date_reviewed>
  <para_id>1081705</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1082561</id>
  <title>Patients Who Choose No Intervention for Small Thyroid Cancers Report Lack of Support</title>
  <langcode>en</langcode>
  <field_short_title>Choosing No Intervention for Thyroid Cancer Can Be Difficult</field_short_title>
  <field_page_description>An NCI &lt;i&gt;Cancer Currents&lt;/i&gt; blog on a study showing that patients with early stage thyroid cancers who don’t pursue immediate intervention experience a lack of support from doctors, loved ones.</field_page_description>
  <field_feature_card_description>Patients with small thyroid cancers who choose not to pursue immediate intervention report lack of support.</field_feature_card_description>
  <field_list_description>Patients who choose not to pursue immediate biopsy or treatment for small, asymptomatic thyroid cancers, or suspected cancers, can experience a lack of support from doctors and loved ones, a new study shows.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-27</field_date_posted>
  <field_date_reviewed>2017-04-26</field_date_reviewed>
  <field_pretty_url>thyroid-cancer-surveillance-support</field_pretty_url>
  <para_id>1082561</para_id>
  <related_resource_id>6635913</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1080236</term_id>
  <id>1082574</id>
  <title>Robert Yarchoan, M.D.</title>
  <langcode>en</langcode>
  <field_short_title>Robert Yarchoan, M.D.</field_short_title>
  <field_page_description>Learn more about Robert Yarchoan, M.D., director of NCI Office of HIV and AIDS Malignancy. </field_page_description>
  <field_feature_card_description>Learn more about Robert Yarchoan, M.D., director of Office of HIV and AIDS Malignancy. </field_feature_card_description>
  <field_list_description>Learn more about Robert Yarchoan, M.D., director of Office of HIV and AIDS Malignancy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-04-27</field_date_posted>
  <field_date_reviewed>2017-04-27</field_date_reviewed>
  <field_pretty_url>yarchoan-bio</field_pretty_url>
  <para_id>1082574</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1083953</id>
  <title>The Mutational Spectra of Cancer Genes in TCGA Data</title>
  <langcode>en</langcode>
  <field_short_title>The Mutational Spectra of Cancer Genes in TCGA Data</field_short_title>
  <field_page_description>The Cancer Genome Atlas has catalogued mutations in more than 30 cancer types. Bar graphs show data for KRAS, HRAS, NRAS, BRAF, TP53, EGFR, PIK3CA, and PTEN.</field_page_description>
  <field_feature_card_description>KRAS, HRAS, NRAS, BRAF, TP53, EGFR, PIK3CA, and PTEN mutations in cancers.</field_feature_card_description>
  <field_list_description>The Cancer Genome Atlas has catalogued mutations in more than 30 cancer types. The NCI RAS Initiative uses TCGA data to prioritize and inform its research objectives. The bar graphs show data for KRAS, HRAS, NRAS, BRAF, TP53, EGFR, PIK3CA, and PTEN.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-10</field_date_posted>
  <field_date_reviewed>2017-05-10</field_date_reviewed>
  <field_pretty_url>cancer-mutation-spectra</field_pretty_url>
  <para_id>1083953</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084756</id>
  <title>Childhood Cancer - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancer</field_short_title>
  <field_page_description>Blog posts on childhood cancer research—including new treatments, the biology of pediatric cancers, and special research initiatives—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Read posts about research addressing childhood cancer from Cancer Currents, NCI's research news blog.</field_feature_card_description>
  <field_list_description>Blog posts on childhood cancer research—including new treatments, the biology of pediatric cancers, and special research initiatives—from NCI Cancer Currents.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>childhood-cancer</field_pretty_url>
  <para_id>1084756</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915376</term_id>
  <id>1085524</id>
  <title>Aiming to Prevent Hereditary Cancers, Researchers Focus on Lynch Syndrome</title>
  <langcode>en</langcode>
  <field_short_title>NCI Lynch Syndrome Workshop Focuses on Preventing Hereditary Cancers</field_short_title>
  <field_page_description>An NCI research update article about a workshop to discuss new strategies for preventing hereditary cancers by using Lynch syndrome as a model.</field_page_description>
  <field_feature_card_description>Experts discussed how to use Lynch syndrome as a model for preventing hereditary cancers. </field_feature_card_description>
  <field_list_description>Experts at a workshop hosted by NCI discussed issues related to using Lynch syndrome as a model for preventing hereditary cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-22</field_date_posted>
  <field_date_reviewed>2017-05-19</field_date_reviewed>
  <field_pretty_url>lynch-syndrome-hereditary-cancers</field_pretty_url>
  <para_id>1085524</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086024</id>
  <title>Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Regorafenib for Liver Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on FDA’s approval of regorafenib (Stivarga®), the first drug approved for liver cancer in nearly a decade.</field_page_description>
  <field_feature_card_description>Regorafenib is the first drug approved for liver cancer in nearly a decade.</field_feature_card_description>
  <field_list_description>FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-05-24</field_date_posted>
  <field_date_reviewed>2017-05-24</field_date_reviewed>
  <field_pretty_url>fda-regorafenib-liver</field_pretty_url>
  <para_id>1086024</para_id>
  <related_resource_id>6622455</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1086779</id>
  <title>HPV Vaccination Linked to Decreased Oral HPV Infections</title>
  <langcode>en</langcode>
  <field_short_title>HPV Vaccine May Prevent Oral HPV Infection</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study showing that the HPV vaccine Gardasil may sharply reduce oral HPV infections linked to oropharyngeal cancer.</field_page_description>
  <field_feature_card_description>More than half of oropharyngeal cancers in the US are linked to HPV 16, which is covered by vaccines.</field_feature_card_description>
  <field_list_description>A study of more than 2,600 young adults found that the prevalence of oral infection with four HPV types, including two cancer-causing types, was 88% lower in those who reported receiving at least one dose of an HPV vaccine than in those not vaccinated.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-05</field_date_posted>
  <field_date_reviewed>2017-06-04</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-oral-infection</field_pretty_url>
  <para_id>1086779</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080236</term_id>
  <id>1087222</id>
  <title>Geraldina Dominguez, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Geraldina Dominguez, Ph.D.</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-07-10</field_date_posted>
  <field_date_reviewed>2017-06-09</field_date_reviewed>
  <field_pretty_url>geraldina-dominguez</field_pretty_url>
  <para_id>1087222</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087279</id>
  <title>Genomic Study Seeks Clues to Help Explain Breast Cancer Disparities</title>
  <langcode>en</langcode>
  <field_short_title>Genome Study of Breast Cancer in African Americans</field_short_title>
  <field_page_description>A Cancer Currents blog on a genomic study that assessed the extent to which molecular characteristics of breast tumors may help to explain some breast cancer disparities.</field_page_description>
  <field_feature_card_description>At a molecular level, tumors in blacks and whites are more similar than different.</field_feature_card_description>
  <field_list_description>Using one of the largest collections of tumor samples from African Americans with breast cancer, researchers tried to assess the extent to which the molecular characteristics on these tumors might help to explain breast cancer disparities. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-13</field_date_posted>
  <field_date_reviewed>2017-06-12</field_date_reviewed>
  <field_pretty_url>genome-breast-cancer-disparities</field_pretty_url>
  <para_id>1087279</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1087896</id>
  <title>CRCHD Announces New CURE Distinguished Scholars Seminar Series</title>
  <langcode>en</langcode>
  <field_short_title>CURE Distinguished Scholars Seminar Series</field_short_title>
  <field_page_description>In celebration of 21 years of the CURE program, CRCHD is pleased to announce a new scientific seminar series the CURE Distinguished Scholars Seminar Series. </field_page_description>
  <field_feature_card_description>CRCHD is pleased to announce the CURE Distinguished Scholars Seminar Series. </field_feature_card_description>
  <field_list_description>In celebration of 21 years of the Continuing Umbrella of Research Experiences (CURE) program, CRCHD is pleased to announce a new scientific seminar series, the CURE Distinguished Scholars Seminar Series.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-21</field_date_posted>
  <field_date_reviewed>2017-06-19</field_date_reviewed>
  <field_pretty_url>inaugural-cure-seminar</field_pretty_url>
  <para_id>1087896</para_id>
  <related_resource_ids>6620149</related_resource_ids>
  <related_resource_ids>6620160</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1090873</id>
  <title>Survivors of Breast Cancer Differ on Who Should Manage Follow-Up Care</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer Survivors’ Preferences on Follow-Up Care</field_short_title>
  <field_page_description>Some survivors of early-stage breast cancer prefer that their oncologist handle aspects of their routine follow-up care, according to a new study discussed in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Breast cancer survivors have varied opinions about who should handle follow-up care.</field_feature_card_description>
  <field_list_description>Many survivors of early-stage breast cancer prefer that their oncologist handle aspects of routine medical care usually overseen by primary care practitioners, leading to concerns about gaps in care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-02</field_date_posted>
  <field_date_reviewed>2017-08-01</field_date_reviewed>
  <field_pretty_url>survivorship-care-preferences</field_pretty_url>
  <para_id>1090873</para_id>
  <related_resource_id>6649797</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1092165</id>
  <title>Study Uncovers Previously Unrecognized Effect of Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Unrecognized Effect of Chemotherapy Uncovered</field_short_title>
  <field_page_description>A study conducted primarily in mice suggests that pre-surgical chemotherapy in breast cancer can cause changes in cells in and around the tumor that aid metastasis.</field_page_description>
  <field_feature_card_description>Study in mice suggests chemotherapy could aid metastasis.</field_feature_card_description>
  <field_list_description>A new study conducted primarily in mice suggests that chemotherapy given before surgery for breast cancer can cause changes in cells in and around the tumor that are tied to an increased risk of the cancer spreading to other areas of the body.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-15</field_date_posted>
  <field_date_reviewed>2017-08-14</field_date_reviewed>
  <field_pretty_url>chemotherapy-effect-metastasis</field_pretty_url>
  <para_id>1092165</para_id>
  <related_resource_id>6664841</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>16374</term_id>
  <id>1092402</id>
  <title>We've Updated Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>We've Updated Clinical Trials</field_short_title>
  <field_search_engine_restrictions>ExcludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <field_pretty_url>options</field_pretty_url>
  <para_id>1092402</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1092428</term_id>
  <id>1092431</id>
  <title>Manage Your Award</title>
  <langcode>en</langcode>
  <field_short_title>Manage Your Award</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <para_id>1092431</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1093388</id>
  <title>Heart Attack, Stroke Risk May Be Elevated Following Cancer Diagnosis</title>
  <langcode>en</langcode>
  <field_short_title>Heart Attack, Stroke Risk Elevated Following Cancer Diagnosis</field_short_title>
  <field_page_description>A cancer diagnosis can come with an increased risk of a heart attack or stroke in the months after beginning treatment, a new study suggests.</field_page_description>
  <field_feature_card_description>Highest risk seen in lung cancer, advanced cancers.</field_feature_card_description>
  <field_list_description>A diagnosis of cancer can come with an increased risk of a heart attack or stroke in the months after beginning treatment, a new study suggests. Within 6 months of a diagnosis, the risk of either event was more than twice that seen in people without cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-25</field_date_posted>
  <field_date_reviewed>2017-08-25</field_date_reviewed>
  <field_pretty_url>heart-attack-stroke-risk-cancer</field_pretty_url>
  <para_id>1093388</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>14564</id>
  <title>Secondhand Smoke and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Secondhand Smoke and Cancer</field_short_title>
  <field_page_description>A fact sheet that summarizes the studies on the health effects of exposure to environmental (secondhand) tobacco smoke.</field_page_description>
  <field_feature_card_description> Harmful chemicals in the smoke inhaled by smokers are also found in environmental (secondhand) tobacco smoke.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-10</field_date_posted>
  <field_date_reviewed>2018-12-04</field_date_reviewed>
  <field_pretty_url>second-hand-smoke-fact-sheet</field_pretty_url>
  <para_id>14564</para_id>
  <related_resource_ids>7258444</related_resource_ids>
  <related_resource_ids>7258445</related_resource_ids>
  <related_resource_ids>7258446</related_resource_ids>
  <related_resource_ids>7258447</related_resource_ids>
  <related_resource_ids>7258448</related_resource_ids>
  <related_resource_ids>7258464</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11982</term_id>
  <id>14707</id>
  <title>Vaginal Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Vaginal Cancer</field_short_title>
  <field_page_description>Two-thirds of vaginal cancer cases are caused by human papillomavirus (HPV). Vaccines that protect against infection with HPV may reduce the risk of vaginal cancer. When found early, vaginal cancer can often be cured. Start here to find information on vaginal cancer treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about vaginal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14707</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11932</term_id>
  <id>14831</id>
  <title>Plasma Cell Neoplasms (Including Multiple Myeloma)—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Plasma Cell Neoplasms (Including Multiple Myeloma)</field_short_title>
  <field_page_description>Plasma cell neoplasms occur when abnormal plasma cells form cancerous tumors. When there is only one tumor, the disease is called a plasmacytoma. When there are multiple tumors, it is called multiple myeloma. Start here to find information on plasma cell neoplasms treatment, research, and statistics.</field_page_description>
  <field_list_description>Information about multiple myeloma and other plasma cell neoplasms. Learn about treatment, clinical trials, research, and statistics from the National Cancer Institute.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14831</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>14957</id>
  <title>Eliminating Hairy Cell Leukemia Minimal Residual Disease</title>
  <langcode>en</langcode>
  <field_short_title>Eliminating Hairy Cell Leukemia Minimal Residual Disease</field_short_title>
  <field_page_description>In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.</field_page_description>
  <field_list_description>&lt;span&gt;In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either&lt;/span&gt; &lt;span&gt;concurrent&lt;/span&gt; &lt;span&gt;rituximab or rituximab at least 6 months after completing cladribine therapy.&lt;/span&gt;</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2010-10-19</field_date_posted>
  <field_date_reviewed>2010-10-20</field_date_reviewed>
  <field_pretty_url>cladribine-hairy-cell</field_pretty_url>
  <para_id>14957</para_id>
  <related_resource_ids>5421811</related_resource_ids>
  <related_resource_ids>5421812</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>178191</id>
  <title>Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival</title>
  <langcode>en</langcode>
  <field_short_title>Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival</field_short_title>
  <field_page_description>Postmenopausal women with early-stage hormone receptor-positive breast cancer had delayed disease recurrence and longer survival after taking 2-3 years of tamoxifen followed by exemestane for a total of 5 years compared to taking tamoxifen for 5 years.</field_page_description>
  <field_feature_card_description>Postmenopausal women with early-stage hormone receptor-positive breast cancer had delayed disease recurrence and longer survival after taking 2-3 years of tamoxifen followed by exemestane for a total of 5 years compared to taking tamoxifen for 5 years.</field_feature_card_description>
  <field_list_description>Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-02-01</field_date_posted>
  <field_date_reviewed>2012-02-01</field_date_reviewed>
  <field_pretty_url>exemestane-prolongs-survival</field_pretty_url>
  <para_id>178191</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938161</term_id>
  <id>939859</id>
  <title>Bladder Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on bladder cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939859</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940225</term_id>
  <id>940232</id>
  <title>Stomach (Gastric) Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Stomach (Gastric) Cancer</field_short_title>
  <field_page_description>Almost all gastric cancers are adenocarcinomas. Other types of gastric cancer are gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, and lymphomas. Find evidence-based information on gastric cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about stomach (gastric) cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940232</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940313</term_id>
  <id>940322</id>
  <title>Head and Neck Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer </field_short_title>
  <field_page_description>Head and neck cancers include hypopharyngeal, laryngeal, lip and oral cavity, metastatic squamous neck, nasopharyngeal, oropharyngeal, paranasal sinus, and salivary gland cancers. Find evidence-based information on head and neck cancer treatment, causes and prevention, research, screening, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about head and neck cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940322</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>940446</id>
  <title>Leukemia Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on leukemia, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940446</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940644</term_id>
  <id>940649</id>
  <title>Myeloproliferative Neoplasms—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Myeloproliferative Neoplasms </field_short_title>
  <field_page_description>Myeloproliferative neoplasms and myelodysplastic syndromes are diseases of the blood cells. They include chronic myeloproliferative neoplasms, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms. Find evidence-based information on myeloproliferative neoplasms treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Myeloproliferative Neoplasms.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940649</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>940891</id>
  <title>Prostate Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on prostate cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940891</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938032</term_id>
  <id>15347</id>
  <title>Video Eases End-of-Life Care Discussions</title>
  <langcode>en</langcode>
  <field_short_title>End-of-Life Care Video</field_short_title>
  <field_page_description>Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative. </field_page_description>
  <field_feature_card_description>Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative.</field_feature_card_description>
  <field_list_description>Patients with advanced cancer who watched a video that depicts options for end-of-life care were more certain of their end-of-life decision making than patients who only listened to a verbal narrative and were likely to choose comfort care over aggressive medical care for their end-of-life care preferences, according to an article published online November 30, 2009, in the Journal of Clinical Oncology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-01-12</field_date_posted>
  <field_date_reviewed>2013-01-03</field_date_reviewed>
  <field_pretty_url>video-helps-end-of-life-discussions</field_pretty_url>
  <para_id>15347</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>336369</term_id>
  <id>336402</id>
  <title>NCI Dictionary of Genetics Terms</title>
  <langcode>en</langcode>
  <field_short_title>NCI Dictionary of Genetics Terms</field_short_title>
  <field_page_description>A dictionary of more than 150 genetics-related terms written for healthcare professionals. This resource was developed to support the comprehensive, evidence-based, peer-reviewed PDQ cancer genetics information summaries. </field_page_description>
  <field_feature_card_description>A dictionary of more than 150 genetics-related terms written for healthcare professionals, developed to support the comprehensive, evidence-based, peer-reviewed PDQ cancer genetics information summaries. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-07-20</field_date_posted>
  <field_date_reviewed>2012-07-20</field_date_reviewed>
  <para_id>336402</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>396051</term_id>
  <id>396064</id>
  <title>Phases of Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Phases of Clinical Trials</field_short_title>
  <field_page_description>Information about the phases of cancer clinical trials. If a new treatment is successful in one phase, it will proceed to further testing in the next phase.</field_page_description>
  <field_feature_card_description>Information about the phases of cancer clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-08-10</field_date_posted>
  <field_date_reviewed>2012-08-10</field_date_reviewed>
  <para_id>396064</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>922411</id>
  <title>National Lung Screening Trial: Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>National Lung Screening Trial: Questions and Answers</field_short_title>
  <field_page_description>Learn the results of the National Lung Screening Trial (NLST), which compared two ways of detecting lung cancer: low-dose helical (spiral) computed tomography  and standard chest X-ray, for their effects on lung cancer death rates in a high-risk population.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-09-18</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>nlst-qa</field_pretty_url>
  <para_id>922411</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>923820</id>
  <title>India Models New Institute on NCI</title>
  <langcode>en</langcode>
  <field_short_title>India Models New Institute on NCI</field_short_title>
  <field_page_description>Health officials in India recently announced that the country of 1.25 billion is establishing a national cancer institute, which will be modeled after the U.S. National Cancer Institute (NCI).</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-03</field_date_posted>
  <field_date_reviewed>2015-04-03</field_date_reviewed>
  <field_pretty_url>india-delegation</field_pretty_url>
  <para_id>923820</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>915878</term_id>
  <id>929550</id>
  <title>Risk Factors for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Risk Factors</field_short_title>
  <field_page_description>Information about behaviors, exposures, and other factors that may influence the risk of cancer.</field_page_description>
  <field_feature_card_description>Information about behaviors, exposures, and other factors that may influence your risk of cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-06</field_date_reviewed>
  <para_id>929550</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929876</term_id>
  <id>929880</id>
  <title>NCI Mobile Apps</title>
  <langcode>en</langcode>
  <field_short_title>Mobile Apps</field_short_title>
  <field_page_description>Download free mobile apps from the National Cancer Institute, including apps for smoking cessation support and the training of the next generation of cancer researchers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-07</field_date_posted>
  <field_date_reviewed>2015-04-07</field_date_reviewed>
  <para_id>929880</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>930340</id>
  <title>The RAS Problem: Turning Off a Broken Switch </title>
  <langcode>en</langcode>
  <field_short_title>The RAS Problem: Turning Off a Broken Switch </field_short_title>
  <field_page_description>The RAS gene is commonly mutated in cancer and researchers are working to better understand how to develop  drugs that can target the RAS protein, which for many years has been considered to be “undruggable.”</field_page_description>
  <field_feature_card_description>The RAS gene is commonly mutated in cancer and researchers are working to better understand how to develop  drugs that can target the RAS protein, which for many years has been considered to be “undruggable.”</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-09</field_date_posted>
  <field_date_reviewed>2015-04-09</field_date_reviewed>
  <field_pretty_url>turning-off-broken-switch</field_pretty_url>
  <para_id>930340</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>921717</id>
  <title>A Week of Excitement and Hope: Communicating the Story of Cancer </title>
  <langcode>en</langcode>
  <field_short_title>A Week of Excitement and Hope: Communicating the Story of Cancer </field_short_title>
  <field_page_description>Peter Garrett, acting director of NCI's communications office, discusses the Annual Report to the Nation on the Status of Cancer and activities surrounding the broadcast of the documentary film, Cancer: The Emperor of All Maladies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-30</field_date_posted>
  <field_date_reviewed>2015-03-30</field_date_reviewed>
  <field_pretty_url>garret-arn</field_pretty_url>
  <para_id>921717</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>921992</id>
  <title>Looking to the Future of Childhood Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Looking to the Future of Childhood Cancer Research</field_short_title>
  <field_page_description>NCI’s Dr. Malcolm Smith discusses future directions of childhood cancer research, including treatment directions and clinical trials.</field_page_description>
  <field_feature_card_description>NCI’s Dr. Malcolm Smith discusses future directions of childhood cancer research, including treatment directions and clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-31</field_date_posted>
  <field_date_reviewed>2015-03-31</field_date_reviewed>
  <field_pretty_url>future-childhood-cancer-research</field_pretty_url>
  <para_id>921992</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922511</term_id>
  <id>922514</id>
  <title>Reports, Research, and Literature</title>
  <langcode>en</langcode>
  <field_short_title>Reports, Research, and Literature</field_short_title>
  <field_page_description>Reports and research projects that address the special challenges facing adolescents and young adults with cancer and provide details about incidence, outcomes, and survival for this population. </field_page_description>
  <field_feature_card_description>Reports and research projects that address the special challenges facing adolescents and young adults with cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-01</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <para_id>922514</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>922522</id>
  <title>The Cancer Genome Atlas: Generating a "Parts List" for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>The Cancer Genome Atlas: Generating a "Parts List" for Cancer</field_short_title>
  <field_page_description>Jean-Claude Zenklusen, Ph.D., discusses the accomplishments and future of The Cancer Genome Atlas, inspired by topics covered in the documentary film, Cancer: The Emperor of All Maladies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-04-02</field_date_reviewed>
  <field_pretty_url>tcga-parts-list</field_pretty_url>
  <para_id>922522</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929888</term_id>
  <id>929890</id>
  <title>PDQ&amp;reg; Cancer Information Summaries</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Information Summaries</field_short_title>
  <field_page_description>Peer-reviewed, evidence-based summaries on topics including adult and pediatric cancer treatment, supportive and palliative care, screening, prevention, genetics, and complementary and alternative medicine. References to published literature are included.</field_page_description>
  <field_feature_card_description>PDQ cancer information summaries are peer-reviewed and evidence-based, for patients and professionals. </field_feature_card_description>
  <field_list_description>PDQ cancer information summaries are peer-reviewed, evidence-based summaries on topics including adult and pediatric cancer treatment, supportive and palliative care, screening, prevention, genetics, and complementary and alternative medicine, typically available in both a Patient and Health Professional format.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-07</field_date_posted>
  <field_date_reviewed>2015-04-07</field_date_reviewed>
  <para_id>929890</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>929892</term_id>
  <id>929896</id>
  <title>PDQ&amp;reg; Levels of Evidence</title>
  <langcode>en</langcode>
  <field_short_title>Levels of Evidence</field_short_title>
  <field_page_description>PDQ cancer information summaries include level-of-evidence designations to help readers understand the strength of the evidence supporting the use of specific interventions or approaches.</field_page_description>
  <field_feature_card_description>Levels of evidence are determined by each PDQ Editorial Board, and refer to the strength of evidence supporting the use of specific interventions or approaches.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-16</field_date_posted>
  <field_date_reviewed>2015-04-07</field_date_reviewed>
  <para_id>929896</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>930032</id>
  <title>Turning Evidence into Practice</title>
  <langcode>en</langcode>
  <field_short_title>Turning Evidence into Practice</field_short_title>
  <field_page_description>CGH CRTA, Hillary Topazian, attended the National Cancer Institute’s 3rd Symposium on Global Cancer Research; a satellite meeting to the 6th Annual Consortium of Universities for Global Health (CUGH) Conference in Boston. The Symposium centered on the theme of implementation science, a field which studies the integrati</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-08</field_date_posted>
  <field_date_reviewed>2015-04-08</field_date_reviewed>
  <field_pretty_url>symposium-global-research</field_pretty_url>
  <para_id>930032</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>936162</id>
  <title>Advancing Cancer Care Delivery Research in the Next Decade</title>
  <langcode>en</langcode>
  <field_short_title>Advancing Cancer Care Delivery Research in the Next Decade</field_short_title>
  <field_page_description>NCI’s new Healthcare Delivery Research Program (HDRP) will focus on advancing the science of cancer care delivery in ways that improve survival and enhance patient care experiences.</field_page_description>
  <field_feature_card_description>NCI’s new Healthcare Delivery Research Program (HDRP) will focus on advancing the science of cancer care delivery in ways that improve survival and enhance patient care experiences.</field_feature_card_description>
  <field_list_description>A more substantial and coordinated effort is needed to advance the science of cancer care delivery to help address the complex problems facing our health care systems. In response, NCI has created a new Healthcare Delivery Research Program (HDRP) to strengthen its support and coordination of research in ways that both improve survival and enhance patient care experiences.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-14</field_date_posted>
  <field_date_reviewed>2015-04-14</field_date_reviewed>
  <field_pretty_url>advancing-care-delivery</field_pretty_url>
  <para_id>936162</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>349495</term_id>
  <id>936262</id>
  <title>2014 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2014 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2014.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <para_id>936262</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>941398</id>
  <title>Treatment Research</title>
  <langcode>en</langcode>
  <field_short_title>Treatment Research</field_short_title>
  <field_page_description>Find research articles on cancer treatment, including news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_list_description>Find research articles on cancer treatment, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941398</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>914792</term_id>
  <id>941573</id>
  <title>Grants &amp; Training</title>
  <langcode>en</langcode>
  <field_short_title>Grants &amp; Training</field_short_title>
  <field_page_description>Information about grants and other funding opportunities, the NCI grants process, and funding for training.</field_page_description>
  <field_feature_card_description>Information about grants and other funding opportunities, the NCI grants process, and funding for training.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>941573</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>953136</id>
  <title>Collateral Damage: Missing Tumor Suppressor Gene Creates Opening for Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Missing Tumor Suppressor Gene Creates Treatment Opportunity</field_short_title>
  <field_page_description>Tumor cells that are missing one copy of the tumor suppressor gene TP53 often harbor another genetic alteration that may make them susceptible to a targeted attack, according to a new study.</field_page_description>
  <field_feature_card_description>Tumor cells missing one copy of the TP53 gene may be susceptible to a targeted attack.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2015-05-12</field_date_reviewed>
  <field_pretty_url>collateral-vulnerability</field_pretty_url>
  <para_id>953136</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>960046</id>
  <title>Ras: Do We Know Its Structure Well Enough?</title>
  <langcode>en</langcode>
  <field_short_title>Ras: Do We Know Its Structure Well Enough?</field_short_title>
  <field_page_description>Carla Mattos discusses how subtle changes in distant parts of RAS molecules may influence the conversion of GTP to GDP that is fundamental to RAS signaling.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-27</field_date_posted>
  <field_date_reviewed>2015-05-27</field_date_reviewed>
  <field_pretty_url>mattos-ras-structure</field_pretty_url>
  <para_id>960046</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>962854</id>
  <title>Dr. Stefan Ambs: Increasing Diversity in Cancer Research: One Lab at a Time</title>
  <langcode>en</langcode>
  <field_short_title>Dr. Stefan Ambs: Increasing Diversity in Cancer Research: One Lab at a Time</field_short_title>
  <field_page_description>As part of the series “Increasing Diversity in Cancer Research,” CRCHD interviewed Dr. Stefan Ambs, an investigator at NCI’s Center for Cancer Research, who is using novel approaches to discover gene differences in the tumors of African American patients.</field_page_description>
  <field_feature_card_description>Dr. Ambs investigates gene differences in the tumors of African American patients.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-06-02</field_date_posted>
  <field_date_reviewed>2015-06-02</field_date_reviewed>
  <field_pretty_url>ambs-spotlight</field_pretty_url>
  <para_id>962854</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>747173</id>
  <title>Research Programs and Initiatives</title>
  <langcode>en</langcode>
  <field_short_title>Research Programs and Initiatives</field_short_title>
  <field_page_description>CGH develops international initiatives and collaborates with other NCI divisions, NCI-designated Cancer Centers, and other countries to support cancer control planning, encourage capacity building, and support cancer research and research networks.</field_page_description>
  <field_feature_card_description>Learn about our international research programs and initiatives which promote knowledge sharing in cancer research and cancer control.</field_feature_card_description>
  <field_list_description>Learn about our international research programs and initiatives which promote knowledge sharing in cancer research and cancer control.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-08</field_date_reviewed>
  <para_id>747173</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>748346</id>
  <title>The "Accidental" Cure—Platinum-based Treatment for Cancer: The Discovery of Cisplatin</title>
  <langcode>en</langcode>
  <field_short_title>Use of Cisplatin for Cancer Treatment</field_short_title>
  <field_page_description>Prior to the discovery of cisplatin in 1965, men with testicular cancer had few medical options. Now, thanks to NCI research, cisplatin and similar chemotherapy drugs are known for curing testicular and other forms of cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-30</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <field_pretty_url>cisplatin</field_pretty_url>
  <para_id>748346</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748498</id>
  <title>Cancer Detection, Diagnosis, and Treatment Technologies for Global Health </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Detection, Diagnosis, and Treatment Technologies for Global Health</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <field_pretty_url>technologies</field_pretty_url>
  <para_id>748498</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762664</id>
  <title>United States-Latin America Cancer Research Network (US-LA CRN)</title>
  <langcode>en</langcode>
  <field_short_title>United States-Latin America Cancer Research Network (US-LA CRN)</field_short_title>
  <field_page_description>The US–LA CRN was established in 2009 to increase cancer research capacity in Latin America. NCI formalized bilateral agreements with the governments of Argentina, Brazil, Chile, Colombia, Mexico, Peru, Puerto Rico, and Uruguay, to facilitate interactions at the government, institution, and investigator levels.</field_page_description>
  <field_feature_card_description>The US–LA CRN was established in 2009 to increase cancer research capacity in Latin America. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>us-la-crn</field_pretty_url>
  <para_id>762664</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>792865</term_id>
  <id>768977</id>
  <title>The Global Cancer Research Story</title>
  <langcode>en</langcode>
  <field_short_title>Global Cancer Research Story</field_short_title>
  <field_page_description>In 2012 alone, nearly 8.2 million people worldwide died from cancer and its predicted that 13.2 people will die in 2030.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-05-16</field_date_reviewed>
  <para_id>768977</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770439</term_id>
  <id>770440</id>
  <title>Gynecologic Cancers Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Gynecologic Cancers Steering Committee</field_short_title>
  <field_page_description>The Gynecologic Cancers Steering Committee evaluates and prioritizes concepts for phase 2 and 3 clinical trials in adult gynecologic cancers. The GCSC is also intent on fostering collaboration with international groups and institutions conducting trials.</field_page_description>
  <field_feature_card_description>The Gynecologic Cancers Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials. </field_feature_card_description>
  <field_list_description>The Gynecologic Cancers Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770440</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>922405</id>
  <title>Prostate Cancer Prevention Trial (PCPT): Questions and Answers</title>
  <langcode>en</langcode>
  <field_short_title>Prostate Cancer Prevention Trial (PCPT): Questions and Answers</field_short_title>
  <field_page_description>Learn the results of the Prostate Cancer Prevention Trial, which was a study designed to see whether the drug finasteride (trade name Proscar) could prevent prostate cancer in men ages 55 and older.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-01</field_date_posted>
  <field_date_reviewed>2015-04-01</field_date_reviewed>
  <field_pretty_url>prostate-cancer-prevention-trial-qa</field_pretty_url>
  <para_id>922405</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922594</term_id>
  <id>922595</id>
  <title>Chronic Inflammation</title>
  <langcode>en</langcode>
  <field_short_title>Chronic Inflammation</field_short_title>
  <field_page_description>Information about how chronic inflammation can lead to cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-02</field_date_reviewed>
  <para_id>922595</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>930057</id>
  <title>Global Cancer Humanitarian Award Honors Pat Garcia-Gonzalez of the Max Foundation</title>
  <langcode>en</langcode>
  <field_short_title>Global Cancer Humanitarian Award </field_short_title>
  <field_page_description>Pat Garcia-Gonzalez of the Max Foundation accepted the first annual NCI Global Cancer Medicine Humanitarian Award for her work in  chronic myeloid leukemia at the NCI, Center for Global Health Symposium for Global Cancer Research, held in Boston on March 25, 2015.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-08</field_date_posted>
  <field_date_reviewed>2015-04-08</field_date_reviewed>
  <field_pretty_url>humanitarian-award</field_pretty_url>
  <para_id>930057</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>930167</term_id>
  <id>930168</id>
  <title>NCI Dictionaries</title>
  <langcode>en</langcode>
  <field_short_title>NCI Dictionaries</field_short_title>
  <field_page_description>Links to NCI's three main dictionaries; the NCI Dictionary of Cancer Terms, the NCI Dictionary of Genetics Terms, and the NCI Drug Dictionary.</field_page_description>
  <field_feature_card_description>Links to NCI's dictionaries of cancer terms, genetics terms and cancer drug terms.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-15</field_date_posted>
  <field_date_reviewed>2015-04-08</field_date_reviewed>
  <para_id>930168</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936428</id>
  <title>Grantee Spotlight: Kurt Richard Weiss, M.D. - From Osteosarcoma Survivor to Osteosarcoma Researcher</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Kurt Richard Weiss, M.D. - From Osteosarcoma Survivor to Osteosarcoma Researcher</field_short_title>
  <field_page_description>Dr. Kurt Richard Weiss, NCI/CRCHD K08 recipient and osteosarcoma survivor, research focuses on identifying the factors and mechanisms related to osteosarcoma cell metastasis.</field_page_description>
  <field_feature_card_description>Dr. Weiss researches factors and mechanisms related to osteosarcoma cell metastasis.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-27</field_date_posted>
  <field_date_reviewed>2014-06-27</field_date_reviewed>
  <field_pretty_url>weiss-spotlight-blog</field_pretty_url>
  <para_id>936428</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>953206</term_id>
  <id>937872</id>
  <title>Common Cancer Types</title>
  <langcode>en</langcode>
  <field_short_title>Common Cancer Types</field_short_title>
  <field_page_description>List of common cancer types, or cancers that are diagnosed with the greatest frequency in the United States; provides most recent incidence and mortality statistics for these cancers. </field_page_description>
  <field_list_description>This list of common cancer types includes cancers that are diagnosed with the greatest frequency in the United States; provides most recent incidence and mortality statistics for these cancers. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-21</field_date_posted>
  <field_date_reviewed>2015-04-21</field_date_reviewed>
  <para_id>937872</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>937959</id>
  <title>HPV Vaccine Effective Against Infection at Multiple Sites, Provides Partial Protection in Women with Previous Infections</title>
  <langcode>en</langcode>
  <field_short_title>HPV Vaccine Effective at Multiple Anatomic Sites</field_short_title>
  <field_page_description>A new study from NCI researchers finds that the HPV vaccine protects young women from infection with high-risk HPV types at the three primary anatomic sites where persistent HPV infections can cause cancer. The multi-site protection also was observed at l</field_page_description>
  <field_list_description>A new study from NCI researchers finds that the HPV vaccine protects young women from infection with high-risk HPV types at the three primary anatomic sites where persistent HPV infections can cause cancer. The multi-site protection also was observed at lower levels in previously HPV-exposed women.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-22</field_date_posted>
  <field_date_reviewed>2015-04-22</field_date_reviewed>
  <field_pretty_url>hpvvaccine-multisite</field_pretty_url>
  <para_id>937959</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>315053</term_id>
  <id>315056</id>
  <title>NCI Dictionary of Cancer Terms Widget </title>
  <langcode>en</langcode>
  <field_short_title>NCI Dictionary Widget</field_short_title>
  <field_page_description>Tool for websites to let users look up cancer-related terms</field_page_description>
  <field_feature_card_description>Tool for websites to let users look up cancer-related terms</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-06-05</field_date_posted>
  <field_date_reviewed>2012-06-05</field_date_reviewed>
  <para_id>315056</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>318034</id>
  <title>For Some Skin Cancers, Targeted Drug Hits the Mark</title>
  <langcode>en</langcode>
  <field_short_title>For Some Skin Cancers, Targeted Drug Hits the Mark</field_short_title>
  <field_page_description>Two studies reported June 7, 2012, in NEJM indicate that the drug vismodegib can elicit responses in people with advanced or metastatic basal cell carcinoma and help shrink or prevent tumors in those with basal cell nevus syndrome.</field_page_description>
  <field_feature_card_description>Two studies reported June 7, 2012, in NEJM indicate that the drug vismodegib can elicit responses in people with advanced or metastatic basal cell carcinoma and help shrink or prevent tumors in those with basal cell nevus syndrome.</field_feature_card_description>
  <field_list_description>Two studies reported June 7, 2012, in the New England Journal of Medicine indicate that the drug vismodegib (Erivedge™) can elicit responses in people with advanced or metastatic basal cell carcinoma and help shrink or prevent tumors in those with basal cell nevus syndrome.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-06-15</field_date_posted>
  <field_date_reviewed>2012-06-15</field_date_reviewed>
  <field_pretty_url>vismodegib-basal-cell</field_pretty_url>
  <para_id>318034</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>417536</term_id>
  <id>321607</id>
  <title>Coordinating Center for Clinical Trials (CCCT)</title>
  <langcode>en</langcode>
  <field_short_title>Coordinating Center for Clinical Trials (CCCT)</field_short_title>
  <field_page_description>The Coordinating Center for Clinical Trials (CCCT) plays a key role in supporting NCI’s clinical and translational research programs to advance science and patient care.</field_page_description>
  <field_feature_card_description>Coordinates the integration of NCI's clinical and associated translational research programs. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-06-21</field_date_posted>
  <field_date_reviewed>2012-06-21</field_date_reviewed>
  <para_id>321607</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>920598</id>
  <title>FDA Approves First Therapy for High-Risk Neuroblastoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves First Therapy for High-Risk Neuroblastoma</field_short_title>
  <field_page_description>The FDA has approved dinutuximab as part of first-line therapy for children with high-risk neuroblastoma.</field_page_description>
  <field_feature_card_description>The FDA has approved dinutuximab (Unituxin™) as part of first-line therapy for children with high-risk neuroblastoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-27</field_date_posted>
  <field_date_reviewed>2015-03-27</field_date_reviewed>
  <field_pretty_url>dinutuximab-neuroblastoma</field_pretty_url>
  <para_id>920598</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>921989</term_id>
  <id>921990</id>
  <title>Childhood Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Childhood Cancers</field_short_title>
  <field_page_description>Information about the common types of pediatric cancers, the latest treatments, where to go for treatment, and where to find information about coping and survivorship. </field_page_description>
  <field_feature_card_description>Information and resources for understanding the basics of pediatric cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-13</field_date_posted>
  <field_date_reviewed>2015-03-30</field_date_reviewed>
  <para_id>921990</para_id>
  <related_resource_ids>7240787</related_resource_ids>
  <related_resource_ids>7240788</related_resource_ids>
  <related_resource_ids>7240789</related_resource_ids>
  <related_resource_ids>7240790</related_resource_ids>
  <related_resource_ids>7240791</related_resource_ids>
  <related_resource_ids>7240806</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>941428</term_id>
  <id>922213</id>
  <title>NCI Director Dr. Norman E. Sharpless</title>
  <langcode>en</langcode>
  <field_short_title>Director's Page</field_short_title>
  <field_page_description>Information about NCI Director Dr. Norman E. Sharpless</field_page_description>
  <field_feature_card_description>Information about NCI Director Dr. Norman E. Sharpless</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-17</field_date_posted>
  <field_date_reviewed>2015-03-31</field_date_reviewed>
  <para_id>922213</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>899356</term_id>
  <id>936263</id>
  <title>2015 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2015 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2015.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <para_id>936263</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>936344</id>
  <title>Microscopy Advances Open Up New Avenues of Cancer Discovery</title>
  <langcode>en</langcode>
  <field_short_title>Microscopy Opening Up New Cancer Discovery Avenues</field_short_title>
  <field_page_description>Today’s high-powered microscopes are allowing researchers to study the fine details of individual cells and to peer into cells, opening up new avenues of discovery about the inner workings of cells, including the events that can cause healthy cells to tra</field_page_description>
  <field_list_description>Today’s high-powered microscopes are allowing researchers to study the fine details of individual cells and to peer into cells, opening up new avenues of discovery about the inner workings of cells, including the events that can cause healthy cells to transform into cancer cells.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <field_pretty_url>microscopy-advances</field_pretty_url>
  <para_id>936344</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936439</id>
  <title>Grantee Spotlight: Shawna Hudson, Ph.D. - Helping Cancer Survivors EXCEL </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Shawna Hudson, Ph.D. - Helping Cancer Survivors EXCEL </field_short_title>
  <field_page_description>Dr. Shawna Hudson, an NCI/CRCHD K01 awardee, works to ensure cancer survivors continue to stay in touch with their physicians and seek the follow-up care they need.</field_page_description>
  <field_feature_card_description>Dr. Hudson works to ensure cancer survivors receive necessary follow-up care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-05</field_date_posted>
  <field_date_reviewed>2014-06-05</field_date_reviewed>
  <field_pretty_url>hudson-spotlight-blog</field_pretty_url>
  <para_id>936439</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>937990</id>
  <title>Special Spotlight: In Memoriam Alessandra Margherita Bini, Ph.D. CRCHD Program Director </title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: In Memoriam Alessandra Margherita Bini, Ph.D. CRCHD Program Director </field_short_title>
  <field_page_description>CRCHD remembers our friend and colleague, Dr. Alessandra Margherita Bini. Dr. Bini, a Program Director in CRCHD’s Diversity Training Branch, passed away February 26, 2014. </field_page_description>
  <field_feature_card_description>CRCHD remembers our friend and colleague, Dr. Alessandra Margherita Bini.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-14</field_date_posted>
  <field_date_reviewed>2014-03-14</field_date_reviewed>
  <field_pretty_url>bini-spotlight</field_pretty_url>
  <para_id>937990</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>937992</id>
  <title>Special Spotlight: In Memoriam Patricia Susana Lorenzo, Ph.D. Cancer Researcher and Former CRCHD Grantee </title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: In Memoriam Patricia Susana Lorenzo, Ph.D. </field_short_title>
  <field_page_description>CRCHD celebrates the life and work of Dr. Patricia Susana Lorenzo, a compassionate woman, friend, colleague, wife, and dedicated researcher.</field_page_description>
  <field_feature_card_description>CRCHD celebrates the life and work of Dr. Patricia Susana Lorenzo.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-14</field_date_posted>
  <field_date_reviewed>2014-03-14</field_date_reviewed>
  <field_pretty_url>lorenzo-spotlight</field_pretty_url>
  <para_id>937992</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>939610</id>
  <title>Enzymology of GTP-competitive RAS inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Enzymology of GTP-competitive RAS inhibitors</field_short_title>
  <field_page_description>RAS molecules have affinities for GTP and GDP that are in the picomolar range.  Ken Westover argues that covalent inhibitors of RAS are logical drug candidates.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-04-29</field_date_reviewed>
  <field_pretty_url>Enzymology-of-GTP-competitive-RAS-inhibitors</field_pretty_url>
  <para_id>939610</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939791</term_id>
  <id>939796</id>
  <title>Adrenocortical Carcinoma—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Adrenocortical Carcinoma</field_short_title>
  <field_page_description>Adrenocortical carcinoma is also called cancer of the adrenal cortex. A tumor of the adrenal cortex may be functioning or nonfunctioning. Most adrenocortical tumors are functioning. Find evidence-based information on adrenocortical carcinoma including treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about adrenocortical carcinoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939796</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>938137</term_id>
  <id>939825</id>
  <title>Anal Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on anal cancer, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939825</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>940149</term_id>
  <id>940154</id>
  <title>Extracranial Germ Cell Tumors—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Extracranial Germ Cell Tumors</field_short_title>
  <field_page_description>Extracranial germ cell tumors (GCTs) arise from primordial germ cells, which migrate during embryogenesis from the yolk sac to the gonads. Childhood extracranial GCTs can be divided into the following two types: gonadal, and extragonadal. Find evidence-based information on extracranial germ cell tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about extracranial germ cell tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-01</field_date_posted>
  <field_date_reviewed>2015-05-01</field_date_reviewed>
  <para_id>940154</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>915875</term_id>
  <id>15422</id>
  <title>Cancer Clusters</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Clusters</field_short_title>
  <field_page_description>A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.</field_page_description>
  <field_list_description>A fact sheet that describes what constitutes a cancer cluster, the process for reporting and investigating suspected clusters, and the challenges in investigating suspected clusters.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-08-29</field_date_reviewed>
  <field_pretty_url>cancer-clusters-fact-sheet</field_pretty_url>
  <para_id>15422</para_id>
  <related_resource_id>7116878</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11954</term_id>
  <id>15458</id>
  <title>Prostate-Specific Antigen (PSA) Test</title>
  <langcode>en</langcode>
  <field_short_title>Prostate-Specific Antigen (PSA) Test</field_short_title>
  <field_page_description>A fact sheet that describes the PSA screening test for prostate cancer and explains the benefits and limitations of the test.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-09</field_date_posted>
  <field_date_reviewed>2017-10-04</field_date_reviewed>
  <field_pretty_url>psa-fact-sheet</field_pretty_url>
  <para_id>15458</para_id>
  <related_resource_ids>6934053</related_resource_ids>
  <related_resource_ids>6934054</related_resource_ids>
  <related_resource_ids>6934055</related_resource_ids>
  <related_resource_ids>6934057</related_resource_ids>
  <related_resource_ids>6934061</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>45782</term_id>
  <id>16358</id>
  <title>Contact the Center for Cancer Training</title>
  <langcode>en</langcode>
  <field_short_title>Program Contacts</field_short_title>
  <field_page_description>Contact staff at the Center for Cancer Training and read staff bios. </field_page_description>
  <field_list_description>Program contacts for NCI training programs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2016-01-15</field_date_reviewed>
  <para_id>16358</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>916844</term_id>
  <id>16360</id>
  <title>Training</title>
  <langcode>en</langcode>
  <field_short_title>Training</field_short_title>
  <field_page_description>NCI offers training at laboratories and clinics in Maryland and at universities and institutions nationwide. These cancer training and career development opportunities cover a broad spectrum of disciplines for individuals at career stages ranging from high school and graduate students to scientists, clinicians, and hea</field_page_description>
  <field_feature_card_description>CCT supports NCI's goal of training cancer researchers for the 21st century.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-31</field_date_posted>
  <field_date_reviewed>2008-11-14</field_date_reviewed>
  <para_id>16360</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>488281</id>
  <title>When Your Parent Has Cancer: A Guide for Teens</title>
  <langcode>en</langcode>
  <field_short_title>When Your Parent Has Cancer: A Guide for Teens</field_short_title>
  <field_page_description>Help for teens whose mom or dad has cancer. Learn how families cope and find support when a parent has cancer. Tips to help you talk with your friends, deal with stress, and take care of your mind and body are also shared.</field_page_description>
  <field_feature_card_description>Information for teens and children who have a parent with cancer. </field_feature_card_description>
  <field_list_description>Information to help teens cope and find support when a parent has cancer. Help for teens whose mom or dad has cancer. Knowing how the cancer will be treated can help you to manage. Get tips to take care of yourself, talk with your friends, and help your parent and siblings.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2013-01-10</field_date_reviewed>
  <field_pretty_url>when-your-parent-has-cancer</field_pretty_url>
  <para_id>488281</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12612</term_id>
  <id>505627</id>
  <title>Policies</title>
  <langcode>en</langcode>
  <field_short_title>Policies</field_short_title>
  <field_page_description>Learn about the policies governing the National Cancer Institute’s website, including accessibility, comments, privacy and security, reuse of graphics and text, and more.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2013-02-05</field_date_reviewed>
  <para_id>505627</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505619</term_id>
  <id>505754</id>
  <title>Reuse of NCI Information</title>
  <langcode>en</langcode>
  <field_short_title>Reuse of NCI Information</field_short_title>
  <field_page_description>Find information about use of NCI information, registered trademarks, and copyrighted material.</field_page_description>
  <field_list_description>Information about use of NCI information, registered trademarks, and copyrighted material.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2018-05-08</field_date_reviewed>
  <para_id>505754</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>505621</term_id>
  <id>505756</id>
  <title>Freedom of Information Act</title>
  <langcode>en</langcode>
  <field_short_title>Freedom of Information Act</field_short_title>
  <field_page_description>Learn about the Freedom of Information Act (FOIA) and how it provides  individuals with a right to access information in the possession of the U.S. federal government. </field_page_description>
  <field_feature_card_description>The Freedom of Information Act (FOIA) provides individuals with a right to access information in the possession of the U.S. federal government. </field_feature_card_description>
  <field_list_description>The Freedom of Information Act (FOIA) provides individuals with a right to access information in the possession of the U.S. federal government. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-02-05</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <para_id>505756</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>936441</id>
  <title>Grantee Spotlight: Julie Dang, M.P.H. - Personalizing Outreach to Address Asian Cancer Health Disparities </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Julie Dang, M.P.H.</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-15</field_date_posted>
  <field_date_reviewed>2014-05-15</field_date_reviewed>
  <field_pretty_url>dang-spotlight</field_pretty_url>
  <para_id>936441</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>937991</id>
  <title>Grantee Spotlight: Nathan Ellis, Ph.D. Seeks Molecular Basis of Colorectal Cancer Disparities in African Americans </title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Nathan Ellis, Ph.D.</field_short_title>
  <field_page_description>Dr. Nathan Ames Ellis, a CRCHD U01 grantee, uses comparative population-genetic analysis to shed new light on cancer susceptibility and the biological basis of colorectal cancer disparities in African Americans.</field_page_description>
  <field_feature_card_description>Dr. Ellis researches a biological basis of CRC disparities in African Americans.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-28</field_date_posted>
  <field_date_reviewed>2014-03-28</field_date_reviewed>
  <field_pretty_url>ellis-spotlight</field_pretty_url>
  <para_id>937991</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>939817</term_id>
  <id>939824</id>
  <title>Anal Cancer—Health Professional Version</title>
  <langcode>en</langcode>
  <field_short_title>Anal Cancer</field_short_title>
  <field_page_description>Anal cancer is a rare malignancy and accounts for a small percentage of cancers of the lower alimentary tract. The most common type of anal cancer is squamous cell carcinoma in the anal canal. Find evidence-based information on anal cancer treatment, causes and prevention, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about anal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-30</field_date_posted>
  <field_date_reviewed>2015-04-30</field_date_reviewed>
  <para_id>939824</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919356</term_id>
  <id>768980</id>
  <title>CGH Future Directions</title>
  <langcode>en</langcode>
  <field_short_title>CGH Future Directions</field_short_title>
  <field_page_description>Looking ahead, the Center for Global Health has three major future directions that will help to acheive NCI’s goal of advancing global cancer research, building expertise, and leveraging resources across nations to address the challenges of cancer and reduce cancer deaths worldwide.
</field_page_description>
  <field_feature_card_description>As cancer diseases and research continue to evolve, we too will move forward with stronger, more collaborative work. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-05-16</field_date_reviewed>
  <para_id>768980</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11914</term_id>
  <id>13813</id>
  <title>Head and Neck Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Cancer</field_short_title>
  <field_page_description>Head and neck cancers include cancers in the larynx (voice box), throat, lips, mouth, nose, and salivary glands. Start here to find information on head and neck cancer treatment in adults and children, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>Information about head and neck cancer treatment, prevention, causes, screening, clinical trials, research and statistics from the National Cancer Institute.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13813</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>13912</id>
  <title>Chemicals in Meat Cooked at High Temperatures and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Chemicals in Meat Cooked at High Temperatures and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that explains how certain chemicals form in meat cooked using high-temperature methods. Includes results of research on consumption of these chemicals and cancer risk.</field_page_description>
  <field_list_description>A fact sheet that explains how certain chemicals are formed in meat that is cooked using high-temperature methods, such as pan frying or grilling, and describes the results of research on the relationship between consumption of these chemicals and cancer risk.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-02</field_date_posted>
  <field_date_reviewed>2017-07-11</field_date_reviewed>
  <field_pretty_url>cooked-meats-fact-sheet</field_pretty_url>
  <para_id>13912</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciLandingPage</CONTENTTYPENAME>
  <term_id>12664</term_id>
  <id>13963</id>
  <title>News &amp; Events</title>
  <langcode>en</langcode>
  <field_short_title>News &amp; Events</field_short_title>
  <field_page_description>The latest cancer news from the U.S. government's principal agency for cancer research, plus resources designed for science writers and reporters.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13963</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>126781</id>
  <title>Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer</field_short_title>
  <field_page_description>A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the BCIRG-006 trial.</field_page_description>
  <field_feature_card_description>A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the BCIRG-006 trial.</field_feature_card_description>
  <field_list_description>A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial reported October 6, 2011, in the New England Journal of Medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-11-03</field_date_posted>
  <field_date_reviewed>2011-11-03</field_date_reviewed>
  <field_pretty_url>less-heart-toxic-regimen</field_pretty_url>
  <para_id>126781</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>759773</id>
  <title>Velcade®: A New Tool in the Fight against Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>Velcade® and the Fight against Multiple Myeloma</field_short_title>
  <field_page_description>Velcade® represents a new type of anticancer drug called proteasome inhibitors. It has shown promise in the treatment of multiple myeloma, a cancer of the white blood cells. Velcade® is being studied for use in a variety of blood cancers and solid tumors.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-30</field_date_posted>
  <field_date_reviewed>2014-04-21</field_date_reviewed>
  <field_pretty_url>velcade</field_pretty_url>
  <para_id>759773</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762657</id>
  <title>Cancer Control Leadership Forums</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Control Leadership Forums</field_short_title>
  <field_page_description>The Cancer Control Leadership Forums help increase the capacity of participating countries to initiate or enhance cancer control planning and implementation in their respective countries.</field_page_description>
  <field_feature_card_description>The Cancer Control Leadership Forums help increase the capacity of participating countries to initiate or enhance cancer control planning and implementation in their respective countries.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>cancer-control-leadership-forums</field_pretty_url>
  <para_id>762657</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>13377</id>
  <title>Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Trastuzumab Benefits Women with Locally Advanced or Inflammatory</field_short_title>
  <field_page_description>Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, accord</field_page_description>
  <field_list_description>Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published &lt;span&gt;in the January 30, 2010, &lt;em&gt;Lancet&lt;/em&gt;.&lt;/span&gt;</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2010-03-15</field_date_posted>
  <field_date_reviewed>2010-03-09</field_date_reviewed>
  <field_pretty_url>trastuzumab-locally-advanced-inflammatory</field_pretty_url>
  <para_id>13377</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12608</term_id>
  <id>13430</id>
  <title>Syndication Services</title>
  <langcode>en</langcode>
  <field_short_title>Syndication Services</field_short_title>
  <field_page_description>Information about Cancer.gov's content dissemination program, which makes cancer information available in XML format for use in Web sites and in other information products.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2010-05-14</field_date_reviewed>
  <para_id>13430</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952689</term_id>
  <id>13491</id>
  <title>PDQ&amp;reg; Cancer Integrative, Alternative, and Complementary Therapies Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Integrative Therapies Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of oncology, pharmacology, natural products, drug discovery and development, traditional Chinese medicine, acupuncture, and homeopathy.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-05-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13491</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>13803</id>
  <title>Breast Cancer Risk in American Women</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer Risk in American Women</field_short_title>
  <field_page_description>A fact sheet that provides statistics about a woman’s risk of developing breast cancer and information about breast cancer risk factors.</field_page_description>
  <field_feature_card_description>A fact sheet that provides statistics about a woman’s risk of developing breast cancer and information about breast cancer risk factors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-09-28</field_date_posted>
  <field_date_reviewed>2012-09-24</field_date_reviewed>
  <field_pretty_url>risk-fact-sheet</field_pretty_url>
  <para_id>13803</para_id>
  <related_resource_ids>7119336</related_resource_ids>
  <related_resource_ids>7119337</related_resource_ids>
  <related_resource_ids>7119338</related_resource_ids>
  <related_resource_ids>7119339</related_resource_ids>
  <related_resource_ids>7119341</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11984</term_id>
  <id>14016</id>
  <title>Vulvar Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Vulvar Cancer</field_short_title>
  <field_page_description>Vulvar cancer usually forms slowly, most often on the vaginal lips or the sides of the vaginal opening. Having vulvar intraepithelial neoplasia or human papillomavirus (HPV) infection can increase the risk of developing vulvar cancer. Start here to find information on vulvar cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about vulvar cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14016</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>136764</id>
  <title>Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit</title>
  <langcode>en</langcode>
  <field_short_title>Long-Term Data from 20 Trials Confirm Tamoxifen's Long-Lasting Benefit</field_short_title>
  <field_page_description>Women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant tamoxifen had a lower risk of recurrence in the 15 years after treatment than women who did not receive tamoxifen.</field_page_description>
  <field_feature_card_description>Women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant tamoxifen had a lower risk of recurrence in the 15 years after treatment than women who did not receive tamoxifen.</field_feature_card_description>
  <field_list_description>In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-11-23</field_date_posted>
  <field_date_reviewed>2011-11-23</field_date_reviewed>
  <field_pretty_url>tamoxifen-long-lasting-benefit</field_pretty_url>
  <para_id>136764</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>746640</term_id>
  <id>748305</id>
  <title>Resources</title>
  <langcode>en</langcode>
  <field_short_title>Resources</field_short_title>
  <field_page_description>Find helpful education materials, documents and essays, and online tools.</field_page_description>
  <field_feature_card_description>Find helpful education materials, documents and essays, and online tools.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-09</field_date_reviewed>
  <para_id>748305</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748891</id>
  <title>Cancer Clinical Trial Leadership and Management Program</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Clinical Trial Leadership and Management Program</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-10</field_date_reviewed>
  <field_pretty_url>clinical-trial-leadership-management</field_pretty_url>
  <para_id>748891</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133184</term_id>
  <id>1133238</id>
  <title>Angiosarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Angiosarcoma</field_short_title>
  <field_page_description>Angiosarcoma is a rare cancer that develops in the inner lining of blood vessels and lymph vessels. Angiosarcomais a fast-growing cancer, so your doctors will treat it aggressively. Learn more about the diagnosis, treatment, and prognosis for this rare tumor.</field_page_description>
  <field_feature_card_description>Angiosarcoma is a rare cancer that develops in the inner lining of blood vessels and lymph vessels.</field_feature_card_description>
  <field_list_description>Angiosarcoma is a rare cancer that develops in the inner lining of blood vessels and lymph vessels. This cancer can occur anywhere in the body, but most often is in the skin, breast, liver and spleen.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>angiosarcoma</field_pretty_url>
  <para_id>1133238</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133186</term_id>
  <id>1133241</id>
  <title>Clear cell renal carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Clear cell renal carcinoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>clear-cell-renal-carcinoma</field_pretty_url>
  <para_id>1133241</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133186</term_id>
  <id>1133242</id>
  <title>Papillary renal cell carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Papillary renal cell carcinoma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>papillary-renal-cell-carcinoma</field_pretty_url>
  <para_id>1133242</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133196</term_id>
  <id>1133255</id>
  <title>The Role of Families and Caregivers of People with Rare Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Family and Caregivers</field_short_title>
  <field_page_description>When your loved one has a rare cancer, it can affect your entire family.Caregivers often need to handle details of medical care and provide physical and emotional support. But there are many sources of support to help families cope and handle the stress of having a rare cancer.</field_page_description>
  <field_feature_card_description>When a loved one has a rare cancer, it can affect the entire family. Caregivers have a lot of responsibilities, but support is available.</field_feature_card_description>
  <field_list_description>When your loved one has a rare cancer, it can affect your entire family. Parents, spouses, adult children, or other loved ones often need to handle details of medical care and provide physical and emotional support. But there are many sources of support to help families cope and handle the stress of having a rare cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133255</para_id>
  <related_resource_id>7196876</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133470</term_id>
  <id>1134559</id>
  <title>Participating in a Clinical Trial for Rare Cancer</title>
  <langcode>en</langcode>
  <field_short_title> Participating in a Clinical Trial for Rare Cancer</field_short_title>
  <field_page_description>When you are diagnosed with a rare cancer, you and your family may think about joining a clinical trial or study.You may get access to a new drug, or a chance to see world-renowned doctors. You are also helping future rare cancer patients by helping researchers today.</field_page_description>
  <field_feature_card_description>By joining a clinical trial or study, you may get access to a new drug, or a chance to see world-renowned doctors.</field_feature_card_description>
  <field_list_description>By joining a clinical trial or study, you may get access to a new drug, or a chance to see world-renowned doctors. You are also helping future rare cancer patients by helping researchers today.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134559</para_id>
  <related_resource_id>7264857</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133188</term_id>
  <id>1134560</id>
  <title>What are rare nerve tumors?</title>
  <langcode>en</langcode>
  <field_short_title>Rare Nerve Tumors</field_short_title>
  <field_page_description>Rare nerve tumors can form in the nervous system anywhere in the body. They can form in nerve cells or in cells around the nerve cells, like Schwann or perineurial cells.</field_page_description>
  <field_list_description>Rare nerve tumors can form in the nervous system anywhere in the body. They can form in nerve cells or in cells around the nerve cells, like Schwann or perineurial cells.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-07</field_date_posted>
  <field_date_reviewed>2019-01-07</field_date_reviewed>
  <para_id>1134560</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1135271</term_id>
  <id>1135277</id>
  <title>Frederick National Laboratory for Cancer Research Acquisitions</title>
  <langcode>en</langcode>
  <field_short_title>FNLCR Acquisitions </field_short_title>
  <field_page_description>The NCI Office of Acquisition administers contracts for the Frederick National Laboratory for Cancer Research. Browse opportunities for subcontracting and learn more about the prime contract competition.</field_page_description>
  <field_list_description>The Frederick National Laboratory for Cancer Research has a primary contractor and subcontracts. Browse opportunities for subcontracting and learn more about the prime contract competition.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-15</field_date_posted>
  <field_date_reviewed>2019-01-15</field_date_reviewed>
  <para_id>1135277</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1135275</term_id>
  <id>1135290</id>
  <title>About the Office of Acquisitions</title>
  <langcode>en</langcode>
  <field_short_title>About OA</field_short_title>
  <field_page_description>NCI’s Office of Office of Acquisitions (OA) has several divisions that handle contracting and acquisitions for different parts of the National Cancer Institute.</field_page_description>
  <field_feature_card_description>Learn more about the Office of Acquisitions, its divisions, and how to contact the office. </field_feature_card_description>
  <field_list_description>Learn more about the Office of Acquisitions, its divisions, and how to contact the office. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-16</field_date_posted>
  <field_date_reviewed>2019-01-16</field_date_reviewed>
  <para_id>1135290</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11928</term_id>
  <id>13712</id>
  <title>Malignant Mesothelioma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Malignant Mesothelioma</field_short_title>
  <field_page_description>Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure. Start here to find information on malignant mesothelioma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Malignant Mesothelioma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13712</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>915878</term_id>
  <id>13762</id>
  <title>Statins and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Statins and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet about results from animal research and ongoing observational studies of people taking statins that suggest that these drugs may lower the risk of certain cancers.</field_page_description>
  <field_list_description>A fact sheet about results from animal research and ongoing observational studies of  people taking statins that suggest that these drugs may lower the risk of certain cancers, including colorectal and skin cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-06-02</field_date_posted>
  <field_date_reviewed>2005-06-02</field_date_reviewed>
  <field_pretty_url>statins-fact-sheet</field_pretty_url>
  <para_id>13762</para_id>
  <related_resource_id>7232859</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911286</term_id>
  <id>13779</id>
  <title>Hyperthermia in Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Hyperthermia in Cancer Treatment</field_short_title>
  <field_page_description>A fact sheet that defines hyperthermia (treating tumors with heat) and its side effects.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-09-09</field_date_posted>
  <field_date_reviewed>2011-08-31</field_date_reviewed>
  <field_pretty_url>hyperthermia-fact-sheet</field_pretty_url>
  <para_id>13779</para_id>
  <related_resource_ids>7232779</related_resource_ids>
  <related_resource_ids>7232780</related_resource_ids>
  <related_resource_ids>7232781</related_resource_ids>
  <related_resource_ids>7232783</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11898</term_id>
  <id>13890</id>
  <title>Uterine Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Uterine Cancer</field_short_title>
  <field_page_description>Uterine cancers can be of two types: endometrial cancer (common) and uterine sarcoma (rare). Endometrial cancer can often be cured. Uterine sarcoma is often more aggressive and harder to treat. Start here to find information on uterine cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about uterine cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13890</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11934</term_id>
  <id>13892</id>
  <title>Myeloproliferative Neoplasms—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Myeloproliferative Neoplasms</field_short_title>
  <field_page_description>Myeloproliferative neoplasms and myelodysplastic syndromes are diseases in which the bone marrow makes too many red blood cells, white blood cells, or platelets. Sometimes both conditions are present. Start here to find information on myeloproliferative neoplasms treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Myeloproliferative Neoplasms.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13892</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11944</term_id>
  <id>13896</id>
  <title>Pancreatic Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Pancreatic Cancer</field_short_title>
  <field_page_description>Pancreatic cancer can form in exocrine cells and neuroendocrine cells. The exocrine type is more common and is usually found at an advanced stage. Pancreatic neuroendocrine tumors are less common but have a better prognosis. Start here to find information on pancreatic cancer treatment, research, and statistics.</field_page_description>
  <field_feature_card_description>Treatment options depend on how far the cancer has spread.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about pancreatic cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>13896</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911184</term_id>
  <id>13960</id>
  <title>Antiperspirants/Deodorants and Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Antiperspirants/Deodorants and Breast Cancer</field_short_title>
  <field_page_description>A fact sheet describing studies on whether there is a link between underarm antiperspirants or deodorants and breast cancer. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2005-08-18</field_date_posted>
  <field_date_reviewed>2016-08-09</field_date_reviewed>
  <field_pretty_url>antiperspirants-fact-sheet</field_pretty_url>
  <para_id>13960</para_id>
  <related_resource_id>6530456</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>112306</id>
  <title>Moving Beyond Breast Cancer Videos</title>
  <langcode>en</langcode>
  <field_short_title>Moving Beyond Breast Cancer Videos</field_short_title>
  <field_page_description>Several breast cancer survivors discuss their journey and offer tips and advice to help cope with the challenges of recovery.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-11-14</field_date_posted>
  <field_date_reviewed>2011-10-05</field_date_reviewed>
  <field_pretty_url>beyond-cancer-video</field_pretty_url>
  <para_id>112306</para_id>
  <related_resource_id>6190488</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919159</term_id>
  <id>770089</id>
  <title>NCTN: NCI’s National Clinical Trials Network</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s National Clinical Trials Network</field_short_title>
  <field_page_description>Information about the National Clinical Trial Network's infrastructure and a synopsis of how NCTN improves the speed and efficiency of cancer clinical trials.</field_page_description>
  <field_feature_card_description>An overview of NCI's state-of-the-art clinical trials infrastructure.</field_feature_card_description>
  <field_list_description>Information about NCI's National Clinical Trial Network (NCTN), a collection of organizations and clinicians that coordinates and supports cancer clinical trials at more than 3,000 sites across the United States and Canada.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-29</field_date_posted>
  <field_date_reviewed>2014-05-19</field_date_reviewed>
  <para_id>770089</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>908136</id>
  <title>Exposure to Secondhand Smoke Plummets, but Disparities Persist</title>
  <langcode>en</langcode>
  <field_short_title>Exposure to Secondhand Smoke Plummets, but Disparities Persist</field_short_title>
  <field_page_description>Second-hand smoke exposure has fallen by 50 percent since 1999, a new study finds, but millions are still routinely exposed to secondhand smoke.</field_page_description>
  <field_feature_card_description>Second-hand smoke exposure has fallen by 50 percent since 1999, a new study finds, but millions are still routinely exposed to secondhand smoke.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-13</field_date_posted>
  <field_date_reviewed>2015-02-13</field_date_reviewed>
  <field_pretty_url>secondhand-smoke-exposure-plummets</field_pretty_url>
  <para_id>908136</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>909432</term_id>
  <id>909433</id>
  <title>Health Communications Publications</title>
  <langcode>en</langcode>
  <field_short_title>Health Communications Publications</field_short_title>
  <field_page_description>Publications about best practices in health communication program planning, developed by the National Cancer Institute for health professionals.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2015-02-17</field_date_reviewed>
  <para_id>909433</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>911481</id>
  <title>Genetic Studies Yield Clues to Treatment-Related Side Effects in Children with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Genetic Studies Yield Clues to Treatment-Related Side Effects in Children with Cancer</field_short_title>
  <field_page_description>Researchers have identified genetic variations in children with brain cancer that increased their risk of rapid hearing loss after treatment.</field_page_description>
  <field_feature_card_description>Researchers have identified genetic variations in children with brain cancer that increased their risk of rapid hearing loss after treatment.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-26</field_date_posted>
  <field_date_reviewed>2015-02-26</field_date_reviewed>
  <field_pretty_url>genetic-studies</field_pretty_url>
  <para_id>911481</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>912681</id>
  <title>Special Spotlight: Widely Acclaimed Cancer Disparities Researcher, Claudia R. Baquet, MD, MPH, Retires from University of Maryland Baltimore School of Medicine</title>
  <langcode>en</langcode>
  <field_short_title>Special Spotlight: Widely Acclaimed Cancer Disparities Researcher, Claudia R. Baquet, Retires</field_short_title>
  <field_page_description>Dr. Claudia R. Baquet, an internationally recognized expert in cancer health disparity research and a former NCI/CRCHD grantee, announces her retirement from the University of Maryland Baltimore School of Medicine.</field_page_description>
  <field_feature_card_description>Dr. Claudia R. Baquet, a former NCI/CRCHD grantee, announces her retirement.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-03</field_date_posted>
  <field_date_reviewed>2015-03-03</field_date_reviewed>
  <field_pretty_url>baquet-spotlight</field_pretty_url>
  <para_id>912681</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>915130</id>
  <title>Divide and Conquer: The Molecular Diagnosis of Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Divide and Conquer: The Molecular Diagnosis of Cancer</field_short_title>
  <field_page_description>CCG promotes the transformation of cancer diagnosis and treatment through genomics. Using a “team science” approach, CCG supports research in structural, functional, and computational genomics that provide data and resources to the cancer research community.</field_page_description>
  <field_feature_card_description>Learn more about the vision of CCG's Director, Louis M. Staudt, M.D., Ph.D., in this Director's Note. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <field_pretty_url>april-leadership-update</field_pretty_url>
  <para_id>915130</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>915144</id>
  <title>American Society of Clinical Oncology (ASCO) Recognizes TCGA’s Importance in the Past Decade and in Tumor Biology</title>
  <langcode>en</langcode>
  <field_short_title>ASCO Recognizes TCGA’s Importance in the Past Decade and in Tumor Biology</field_short_title>
  <field_page_description>The American Society of Clinical Oncology (ASCO) highlighted TCGA’s role in advancing knowledge about cancer genes, pathways, and subtypes, in its 2015 Annual Report on Progress Against Cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <field_pretty_url>asco-how-far-weve-come</field_pretty_url>
  <para_id>915144</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>915357</id>
  <title>Diet</title>
  <langcode>en</langcode>
  <field_short_title>Diet</field_short_title>
  <field_page_description>Information about certain foods, minerals, and other parts of a person's diet and their associations with reducing or increasing the risk of cancer.</field_page_description>
  <field_feature_card_description>Scientists have studied many dietary components to see if they raise or lower the risk of cancer. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915357</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915273</term_id>
  <id>915364</id>
  <title>Legal Requirements</title>
  <langcode>en</langcode>
  <field_short_title>Legal Requirements</field_short_title>
  <field_page_description>Research grants are subject to many requirements from a variety of legal authorities, with the broadest being the U.S. Constitution.</field_page_description>
  <field_feature_card_description>Learn about the legal requirements research grants are subject to.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915364</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917006</term_id>
  <id>917210</id>
  <title>CTRP System Access and Training</title>
  <langcode>en</langcode>
  <field_short_title>CTRP System Access and Training</field_short_title>
  <field_page_description>Find Clinical Trials Reporting Program (CTRP) user guides, resources, and contact information.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-17</field_date_posted>
  <field_date_reviewed>2015-03-17</field_date_reviewed>
  <para_id>917210</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1120621</id>
  <title>TCGA's Study of Adrenocortical Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Adrenocortical Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Adrenocortical Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Adrenocortical Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of adrenocortical carcinoma (adrenal cortex cancer), including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-26</field_date_posted>
  <field_date_reviewed>2018-07-26</field_date_reviewed>
  <field_pretty_url>adrenocortical</field_pretty_url>
  <para_id>1120621</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1121095</id>
  <title>Aggressive Prostate Cancer Subtype More Common Than Expected</title>
  <langcode>en</langcode>
  <field_short_title>Aggressive Prostate Cancer Subtype More Common Than Expected</field_short_title>
  <field_page_description>Some men with advanced prostate cancer may be more likely than previously thought to develop a more aggressive form of the disease, a new study shows. As this Cancer Currents post reports, the subtype, called t-SCNC, was linked with shorter survival.</field_page_description>
  <field_feature_card_description>Subtype linked with shorter survival than others.</field_feature_card_description>
  <field_list_description>Researchers have found that men with advanced prostate cancer may be more likely than previously thought to develop a more aggressive form of the disease. The subtype, called t-SCNC, was linked with shorter survival than other subtypes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-31</field_date_posted>
  <field_date_reviewed>2018-07-30</field_date_reviewed>
  <field_pretty_url>prostate-cancer-neuroendocrine-more-common</field_pretty_url>
  <para_id>1121095</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121637</id>
  <title>TCGA's Study of Papillary Renal Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Papillary Renal Cell Carcinoma</field_short_title>
  <field_page_description>A summary of TCGA's study of papillary renal cell (kidney) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Papillary Renal Cell Carcinoma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-08</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <field_pretty_url>renal-cell-papillary</field_pretty_url>
  <para_id>1121637</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1121643</id>
  <title>TCGA's Study of Hepatocellular Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Hepatocellular Carcinoma</field_short_title>
  <field_page_description>TCGA's Study of Hepatocellular Carcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Hepatocellular Carcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of hepatocellular (liver) carcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-08</field_date_posted>
  <field_date_reviewed>2018-08-08</field_date_reviewed>
  <field_pretty_url>liver</field_pretty_url>
  <para_id>1121643</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1123797</id>
  <title>TCGA's Study of Lung Adenocarcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Lung Adenocarcinoma</field_short_title>
  <field_page_description>TCGA's Study of Lung Adenocarcinoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Lung Adenocarcinoma</field_feature_card_description>
  <field_list_description>A summary of TCGA's study of lung adenocarcinoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-08-30</field_date_posted>
  <field_date_reviewed>2018-08-30</field_date_reviewed>
  <field_pretty_url>lung-adenocarcinoma</field_pretty_url>
  <para_id>1123797</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1123947</id>
  <title>TCGA's Study of Paraganglioma &amp; Pheochromocytoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Paraganglioma &amp; Pheochromocytoma</field_short_title>
  <field_page_description>TCGA's Study of Paraganglioma &amp; Pheochromocytoma</field_page_description>
  <field_feature_card_description>TCGA's Study of Paraganglioma &amp; Pheochromocytoma </field_feature_card_description>
  <field_list_description>A summary of TCGA's study of  paraganglioma &amp; pheochromocytoma, including what was known prior to the study and main findings from the characterization and analysis.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-09-05</field_date_posted>
  <field_date_reviewed>2018-09-05</field_date_reviewed>
  <field_pretty_url>paraganglioma</field_pretty_url>
  <para_id>1123947</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1124937</id>
  <title>Working with NCI Divisions, Offices and Centers to Advance Global Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Working with NCI Divisions, Offices and Centers to Advance Global Cancer Research</field_short_title>
  <field_page_description>According to recently released global cancer burden statistics, an estimated 18.1 new cancer cases and 9.6 million deaths from cancer were expected in 2018.  Read CGH's newest Spotlight Blog to see how we are Working with NCI Divisions, Offices, and Centers to Advance Global Cancer Research.</field_page_description>
  <field_feature_card_description>NCI's Center for Global Health supports efforts at NCI and elsewhere to further research that will lessen the burden of cancer worldwide.</field_feature_card_description>
  <field_list_description>The Center for Global Health is partnering with NCI divisions, offices, and centers, and partners around the world to recognize World Cancer Research Day (WCRD) on September 24. WCRD is a global initiative to increase awareness about the importance of cancer research and the dedication of cancer researchers worldwide.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-09-24</field_date_posted>
  <field_date_reviewed>2018-09-24</field_date_reviewed>
  <field_pretty_url>cancer-research-day</field_pretty_url>
  <para_id>1124937</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762663</id>
  <title>Women's Cancers Program (WCP)</title>
  <langcode>en</langcode>
  <field_short_title>Women's Cancers Program (WCP)</field_short_title>
  <field_page_description>CGH is committed to build capacity for prevention, screening, detection, diagnosis and treatment of women’s cancers in LMICs.</field_page_description>
  <field_feature_card_description>CGH is committed to build capacity for prevention, screening, detection, diagnosis and treatment of women’s cancers in LMICs.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>womens-cancers-program</field_pretty_url>
  <para_id>762663</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770427</term_id>
  <id>770429</id>
  <title>Breast Cancer Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770429</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>906093</term_id>
  <id>906094</id>
  <title>Cancer Staging</title>
  <langcode>en</langcode>
  <field_short_title>Staging</field_short_title>
  <field_page_description>Staging is the process of determining how much cancer is within the body (tumor size) and if it has spread. Learn about the TNM Staging system and other ways that stage is described.</field_page_description>
  <field_feature_card_description>Stage describes details about your cancer, such as tumor size and if it has spread. Staging guides decisions about treatment. </field_feature_card_description>
  <field_list_description>Staging is the process of determining details about your cancer, such as tumor size and if it has spread. The stage guides decisions about treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-09</field_date_posted>
  <field_date_reviewed>2015-03-09</field_date_reviewed>
  <para_id>906094</para_id>
  <related_resource_ids>7091925</related_resource_ids>
  <related_resource_ids>7091926</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>860150</term_id>
  <id>907517</id>
  <title>Spotlight on Scientists Videos</title>
  <langcode>en</langcode>
  <field_short_title>Video Stories</field_short_title>
  <field_page_description>Researchers, fellows, principal investigators, and medical doctors provide inspiration and advice to students interested in medical research.</field_page_description>
  <field_feature_card_description>NCI-supported scientists explain key aspects of basic and clinical cancer research; describe how and why they became cancer researchers, with advice for students; and offer their perspectives on a range of challenges and achievements in cancer research.</field_feature_card_description>
  <field_list_description>NCI scientists, from postdoctoral fellows to principal investigators, discuss various topics including their personal backgrounds, how they came to be in the field of cancer research, their current projects, and a look to the future of medical oncology. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-13</field_date_posted>
  <field_date_reviewed>2015-02-13</field_date_reviewed>
  <para_id>907517</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>903584</term_id>
  <id>911505</id>
  <title>Managing Cancer Care</title>
  <langcode>en</langcode>
  <field_short_title>Managing Cancer Care</field_short_title>
  <field_page_description>Information on choosing a doctor or treatment facility, home care, financial help, insurance coverage, end-of-life planning, and resources to help you avoid scams.</field_page_description>
  <field_feature_card_description>Information on choosing a doctor or treatment facility, home care, financial help, insurance coverage, end-of-life planning, and resources to help you avoid scams.</field_feature_card_description>
  <field_list_description>Helpful information about health care services, insurance and finance options, advanced planning, home care, and how to avoid scams with print and online sources of health information.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-26</field_date_posted>
  <field_date_reviewed>2015-02-26</field_date_reviewed>
  <para_id>911505</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>912900</term_id>
  <id>912902</id>
  <title>Hormone Therapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Hormone Therapy </field_short_title>
  <field_page_description>Hormone therapy is a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow. Learn about the types of hormone therapy and side effects that may happen.</field_page_description>
  <field_feature_card_description>Hormone therapy is a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow. Learn about the types of hormone therapy and side effects that may happen.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-17</field_date_reviewed>
  <para_id>912902</para_id>
  <related_resource_ids>7090661</related_resource_ids>
  <related_resource_ids>7090662</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914814</term_id>
  <id>915046</id>
  <title>Step 3: Peer Review and Funding Outcomes</title>
  <langcode>en</langcode>
  <field_short_title>Step 3: Peer Review and Funding Outcomes</field_short_title>
  <field_page_description>The NCI review process seeks to achieve a balanced grant portfolio, that addresses scientific priorities. Learn about NCI’s peer review for grant applications. </field_page_description>
  <field_feature_card_description>Each grant application is reviewed for scientific and technical merit.</field_feature_card_description>
  <field_list_description>The NIH Peer Review process provides fair, independent, expert, and timely review of each grant application. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915046</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919362</term_id>
  <id>768983</id>
  <title>Contact The Center for Global Health</title>
  <langcode>en</langcode>
  <field_short_title>Contact CGH</field_short_title>
  <field_page_description>The CGH U.S. offices is located at 9609 Medical Center Drive, Rockville, MD 20892.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-05-16</field_date_reviewed>
  <para_id>768983</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770435</term_id>
  <id>770437</id>
  <title>Genitourinary Cancers Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Genitourinary Cancers Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770437</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770469</term_id>
  <id>770497</id>
  <title>Head and Neck Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Head and Neck Steering Committee</field_short_title>
  <field_page_description>The Head and Neck Steering Committee addresses the design, prioritization and evaluation of concepts for phase II and phase III clinical trials in adult head and neck cancers. </field_page_description>
  <field_feature_card_description>The Head and Neck Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials. </field_feature_card_description>
  <field_list_description>The Head and Neck Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770497</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>909539</id>
  <title>"Flipping the Switch": An Interview with Dr. Mark Gilbert, Chief of NIH’s Neuro-Oncology Branch</title>
  <langcode>en</langcode>
  <field_short_title>"Flipping the Switch": Dr. Mark Gilbert Interview</field_short_title>
  <field_page_description>NCI's Dr. Mark Gilbert discusses new developments in neuro-oncology and the priorities of the Neuro-Oncology Branch.</field_page_description>
  <field_feature_card_description>NCI's Dr. Mark Gilbert discusses new developments in neuro-oncology and the priorities of the Neuro-Oncology Branch.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-02-18</field_date_posted>
  <field_date_reviewed>2015-02-18</field_date_reviewed>
  <field_pretty_url>gilbert-interview</field_pretty_url>
  <para_id>909539</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911286</term_id>
  <id>912891</id>
  <title>Surgery to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Surgery</field_short_title>
  <field_page_description>Surgery, when used to treat cancer, is a procedure in which a surgeon removes cancer from your body. Learn how surgery is performed and different types of surgery.</field_page_description>
  <field_feature_card_description>Surgery, when used to treat cancer, is a procedure in which a surgeon removes cancer from your body. Learn the different ways that surgery is used against cancer and what you can expect before, during, and after surgery.</field_feature_card_description>
  <field_list_description>When used to treat cancer, surgery is a procedure in which a surgeon removes cancer from your body. Learn the different ways that surgery is used against cancer and what you can expect before, during, and after surgery.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-17</field_date_reviewed>
  <para_id>912891</para_id>
  <related_resource_ids>7192091</related_resource_ids>
  <related_resource_ids>7192092</related_resource_ids>
  <related_resource_ids>7192093</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>913173</term_id>
  <id>913176</id>
  <title>NCI CCT K Awards Evaluation</title>
  <langcode>en</langcode>
  <field_short_title>Evaluation of the Career Development (K) Awards Program</field_short_title>
  <field_page_description>A recent evaluation of CCT's K Awards Program tracked participants' subsequent outcomes and demonstrated the program had a positive influence on their research careers.</field_page_description>
  <field_feature_card_description>A recent evaluation of CCT's K Awards Program tracked participants' subsequent outcomes and demonstrated the program had a positive influence on their research careers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-05</field_date_posted>
  <field_date_reviewed>2015-03-05</field_date_reviewed>
  <para_id>913176</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914506</term_id>
  <id>914512</id>
  <title>Cancer Prevention Research </title>
  <langcode>en</langcode>
  <field_short_title>Cancer Prevention Research </field_short_title>
  <field_page_description>NCI’s prevention research has a broad focus, from identifying environmental and lifestyle factors that influence cancer risk to studying the biology of how cancer develops and studying ways to disseminate prevention interventions.</field_page_description>
  <field_feature_card_description>NCI-supported scientists are studying cancer risk, cancer biology, prevention interventions, and more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-05-10</field_date_posted>
  <field_date_reviewed>2015-03-10</field_date_reviewed>
  <para_id>914512</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>915112</term_id>
  <id>915129</id>
  <title>Researcher Interview: Elaine Mardis</title>
  <langcode>en</langcode>
  <field_short_title>Researcher Interview: Elaine Mardis</field_short_title>
  <field_page_description>Elaine Mardis Ph.D., Professor of Medicine at Washington University School of Medicine, discusses her translational research applying genomics techniques to clinical trials, and forecasts the future of team science and cancer genomics. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <field_pretty_url>elaine-mardis-interview</field_pretty_url>
  <para_id>915129</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>914830</term_id>
  <id>915263</id>
  <title>Research Performance Progress Report (RPPR)</title>
  <langcode>en</langcode>
  <field_short_title>Research Performance Progress Report (RPPR)</field_short_title>
  <field_page_description>Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award.</field_page_description>
  <field_feature_card_description>Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-02</field_date_posted>
  <field_date_reviewed>2015-03-12</field_date_reviewed>
  <para_id>915263</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911142</term_id>
  <id>915358</id>
  <title>Hormones </title>
  <langcode>en</langcode>
  <field_short_title>Hormones</field_short_title>
  <field_page_description>information about the female hormones that are associated with an increased risk of certain cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-04-29</field_date_posted>
  <field_date_reviewed>2015-03-13</field_date_reviewed>
  <para_id>915358</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>898585</term_id>
  <id>916661</id>
  <title>Progress in Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Progress</field_short_title>
  <field_page_description>Through its Annual Report to the Nation and other reports and publications, the National Cancer Institute – leader of the National Cancer Program – marks the progress that’s been made by the cancer research community. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-16</field_date_posted>
  <field_date_reviewed>2015-03-16</field_date_reviewed>
  <para_id>916661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>761484</id>
  <title>Refining Preoperative Therapy for Locally Advanced Rectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Refining Preoperative Therapy for Locally Advanced Rectal Cancer</field_short_title>
  <field_page_description>In the PROSPECT trial, patients with locally advanced, resectable rectal cancer will be randomly assigned to receive either standard neoadjuvant chemoradiation therapy or neoadjuvant FOLFOX chemotherapy, with chemoradiation reserved for nonresponders.</field_page_description>
  <field_feature_card_description>In the PROSPECT trial, patients with locally advanced, resectable rectal cancer will be randomly assigned to receive either standard neoadjuvant chemoradiation therapy or neoadjuvant FOLFOX chemotherapy, with chemoradiation reserved for nonresponders.</field_feature_card_description>
  <field_list_description>In the current clinical trial, dubbed PROSPECT, patients with locally advanced, resectable rectal cancer will be randomly assigned to receive either standard neoadjuvant chemoradiation therapy or neoadjuvant FOLFOX chemotherapy, with chemoradiation reserved for those patients who cannot tolerate or do not respond to FOLFOX chemotherapy. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-04-25</field_date_posted>
  <field_date_reviewed>2014-04-25</field_date_reviewed>
  <field_pretty_url>preop-treatment</field_pretty_url>
  <para_id>761484</para_id>
  <related_resource_id>6494620</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762665</id>
  <title>International Bilateral Programs for Collaborative Scientific Research</title>
  <langcode>en</langcode>
  <field_short_title>International Bilateral Programs for Collaborative Scientific Research</field_short_title>
  <field_page_description>The International Bilateral Programs for Collaborative Scientific Research seeks to enhance the global activities of NCI’s intramural researchers and grantees through co-funded support for collaborative research between NIH and international scientific research agencies.</field_page_description>
  <field_feature_card_description>The United States–China Program for Biomedical Research Cooperation co-funds U.S. and Chinese scientists to conduct collaborative basic and translational biomedical research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>international-bilateral-programs</field_pretty_url>
  <para_id>762665</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>765087</term_id>
  <id>762709</id>
  <title>Center for Global Health Staff</title>
  <langcode>en</langcode>
  <field_short_title>CGH Staff</field_short_title>
  <field_page_description>Contact information for NCI's Center for Global Health leadership and staff. CGH is a collaborative team of over 40 cancer researchers, scientists, and communication experts. </field_page_description>
  <field_feature_card_description>Find CGH's leadership, US-based, and offsite staff names and emails.</field_feature_card_description>
  <field_list_description>The Center for Global Health is a collaborative team of over 40 cancer researchers, scientists, and communication experts. Find contact information for CGH leadership and staff.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <para_id>762709</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770425</term_id>
  <id>770423</id>
  <title>Brain Malignancies Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Brain Malignancies Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770423</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770431</term_id>
  <id>770433</id>
  <title>Gastrointestinal Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Gastrointestinal Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>770433</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>907072</id>
  <title>Twitter Chat on Non-Communicable Diseases and Global Health</title>
  <langcode>en</langcode>
  <field_short_title>Twitter Chat on Non-Communicable Diseases and Global Health</field_short_title>
  <field_page_description>Twitter Chat on Non-Communicable Diseases and Global Health</field_page_description>
  <field_feature_card_description>Twitter Chat on Non-Communicable Diseases and Global Health</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-12</field_date_posted>
  <field_date_reviewed>2015-02-12</field_date_reviewed>
  <field_pretty_url>twitter-chat</field_pretty_url>
  <para_id>907072</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>903750</term_id>
  <id>911134</id>
  <title>Diagnosis and Staging</title>
  <langcode>en</langcode>
  <field_short_title>Diagnosis and Staging</field_short_title>
  <field_page_description>Cancer can cause many different symptoms. The doctor will order tests to determine if symptoms are caused by cancer or some other problem. If cancer is diagnosed, the doctor will run tests to determine the stage. Knowing the stage helps the doctor plan treatment and discuss prognosis.</field_page_description>
  <field_feature_card_description>Cancer can cause many different symptoms. The doctor will order tests to determine if symptoms are caused by cancer or some other problem.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-24</field_date_posted>
  <field_date_reviewed>2015-02-24</field_date_reviewed>
  <para_id>911134</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938026</term_id>
  <id>911742</id>
  <title>Gardasil 9 Vaccine Protects against Additional HPV Types</title>
  <langcode>en</langcode>
  <field_short_title>Gardasil 9 Protects against Additional HPV Types</field_short_title>
  <field_page_description>A summary of results from a large randomized clinical trial that shows a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by seven HPV types that cause cancer and two HPV types that cause genital warts.</field_page_description>
  <field_feature_card_description>In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by seven HPV types that cause cancer and two HPV types that cause genital warts.</field_feature_card_description>
  <field_list_description>In a large randomized clinical trial, a new human papillomavirus (HPV) vaccine effectively prevented infection and disease caused by nine HPV types, including seven types that cause cervical and other cancers—five of which were not covered by the previously available HPV vaccines—and two types that cause genital warts.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-02</field_date_posted>
  <field_date_reviewed>2015-03-02</field_date_reviewed>
  <field_pretty_url>gardasil9-prevents-more-HPV-types</field_pretty_url>
  <para_id>911742</para_id>
  <related_resource_id>6668445</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>748892</id>
  <title>Health Economics Fellowships in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Health Economics Fellowships in Cancer</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-10</field_date_reviewed>
  <field_pretty_url>health-economics-fellowships</field_pretty_url>
  <para_id>748892</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>762633</id>
  <title>The International Cancer Control Partnership (ICCP)</title>
  <langcode>en</langcode>
  <field_short_title>The International Cancer Control Partnership (ICCP)</field_short_title>
  <field_page_description>The ICCP is a collaboration of governments, United Nations agencies, and Non-government organizations (NGOs) that work together to reduce the global burden of cancer.</field_page_description>
  <field_feature_card_description>The ICCP works together to reduce the global burden of cancer by ensuring countries have national cancer control plans. </field_feature_card_description>
  <field_list_description>The ICCP is a collaboration of governments, United Nations agencies, and Non-government organizations (NGOs) that work together to reduce the global burden of cancer by ensuring countries have national cancer control plans. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-23</field_date_posted>
  <field_date_reviewed>2014-04-30</field_date_reviewed>
  <field_pretty_url>ICCP</field_pretty_url>
  <para_id>762633</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>763025</id>
  <title>Drugs Approved for Multicentric Castleman Disease</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Multicentric Castleman Disease</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for mutlicentric Castleman disease.</field_page_description>
  <field_feature_card_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for mutlicentric Castleman disease.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-01</field_date_posted>
  <field_date_reviewed>2014-05-01</field_date_reviewed>
  <field_pretty_url>multicentric-castleman-disease</field_pretty_url>
  <para_id>763025</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>695683</term_id>
  <id>768882</id>
  <title>Office of Advocacy Relations</title>
  <langcode>en</langcode>
  <field_short_title>Office of Advocacy Relations</field_short_title>
  <field_page_description>OAR brings the cancer advocacy and NCI communities together to help identify research opportunities that speed advances and improve patient outcomes.</field_page_description>
  <field_feature_card_description>OAR brings the cancer advocacy and NCI communities together to help identify research opportunities that speed advances and improve patient outcomes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-15</field_date_posted>
  <field_date_reviewed>2014-05-15</field_date_reviewed>
  <para_id>768882</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770425</term_id>
  <id>770404</id>
  <title>Brain Malignancies Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Brain Malignancies Steering Committee</field_short_title>
  <field_page_description>The Brain Malignancies Steering Committee addresses the design, prioritization, and evaluation of concepts for large phase 2 and phase 3 clinical trials in both adult and pediatric brain cancers.</field_page_description>
  <field_feature_card_description>The BMSC evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_feature_card_description>
  <field_list_description>The Brain Malignancy Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770404</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>770427</term_id>
  <id>770428</id>
  <title>Breast Cancer Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Breast Cancer Steering Committee</field_short_title>
  <field_page_description>The Breast Cancer Steering Committee addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 treatment trials in adult breast cancer.</field_page_description>
  <field_feature_card_description>The Breast Cancer Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.</field_feature_card_description>
  <field_list_description>The Breast Cancer Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-21</field_date_posted>
  <field_date_reviewed>2014-05-21</field_date_reviewed>
  <para_id>770428</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>608324</id>
  <title>Stories of Discovery</title>
  <langcode>en</langcode>
  <field_short_title>Stories of Discovery</field_short_title>
  <field_page_description>Read these stories describing landmark developments in cancer prevention and treatment supported by NCI funding.</field_page_description>
  <field_feature_card_description>Collection of stories that describe landmark developments in cancer prevention and treatment supported by NCI funding.</field_feature_card_description>
  <field_list_description>Collection of stories that describe landmark developments in cancer prevention and treatment supported by NCI funding.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-07-31</field_date_posted>
  <field_date_reviewed>2013-07-31</field_date_reviewed>
  <para_id>608324</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>609331</id>
  <title>Radium-223 Improves Survival in Patients with Advanced Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Radium-223 for Advanced Prostate Cancer</field_short_title>
  <field_page_description>A summary of results from a phase III trial that compared radium-223 dichloride plus the best standard of care versus a placebo plus the best standard of care in men with metastatic, castration-resistant prostate cancer.</field_page_description>
  <field_feature_card_description>Results from a phase III trial show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with placebo.</field_feature_card_description>
  <field_list_description>Results from a phase III trial show that radium-223 dichloride (Xofigo®) improves overall survival in men with advanced prostate cancer that has spread to their bones compared with placebo.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-08-02</field_date_posted>
  <field_date_reviewed>2013-08-01</field_date_reviewed>
  <field_pretty_url>radium-223-improves-survival</field_pretty_url>
  <para_id>609331</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>678040</id>
  <title>Preventing Stomach Cancer: The Link to H. pylori Bacteria</title>
  <langcode>en</langcode>
  <field_short_title>The Link to H. pylori Bacteria</field_short_title>
  <field_page_description>NCI supported research to solidify the link between H. pylori infections and stomach cancer. As a result, new cancer treatment and prevention strategies are being developed, encouraging scientists to carefully examine other cancers for viral and bacterial connections.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-07</field_date_posted>
  <field_date_reviewed>2013-12-10</field_date_reviewed>
  <field_pretty_url>stomach-cancer</field_pretty_url>
  <para_id>678040</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919481</term_id>
  <id>698662</id>
  <title>About the Office of Advocacy Relations</title>
  <langcode>en</langcode>
  <field_short_title>About OAR</field_short_title>
  <field_page_description>OAR works with cancer research advocates and organizations to ensure the advocacy community's perspectives and ideas are integrated into NCI activities to advance research.</field_page_description>
  <field_list_description>OAR links NCI and the advocacy community to communicate NCI priorities and ensure appropriate involvement of research advocates in Institute activities to advance research. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-30</field_date_posted>
  <field_date_reviewed>2014-01-30</field_date_reviewed>
  <para_id>698662</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>12738</term_id>
  <id>65884</id>
  <title>Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Postdoctoral Fellows (F32)</title>
  <langcode>en</langcode>
  <field_short_title>NCI F32 Award</field_short_title>
  <field_page_description>For postdoctoral candidates or mentored junior faculty who have Ph.D.s and are pursuing careers in basic science.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-17</field_date_posted>
  <field_date_reviewed>2011-03-17</field_date_reviewed>
  <para_id>65884</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938223</term_id>
  <id>68632</id>
  <title>Novel Combination Chemotherapy for Localized Ewing Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Novel Combination Chemotherapy for Localized Ewing Sarcoma</field_short_title>
  <field_page_description>In this clinical trial, researchers will test whether the addition of the drug combination vincristine, topotecan, and cyclophosphamide to a standard chemotherapy regimen improves overall survival in patients with extracranial Ewing</field_page_description>
  <field_feature_card_description>In this clinical trial, researchers will test whether the addition of the drug combination vincristine, topotecan, and cyclophosphamide to a standard chemotherapy regimen improves overall survival in patients with extracranial Ewing</field_feature_card_description>
  <field_list_description>In this clinical trial, researchers will test whether the addition of the drug combination vincristine, topotecan, and cyclophosphamide to a standard chemotherapy regimen improves overall survival and event-free survival in newly diagnosed patients with non-metastatic Ewing sarcoma of the bone or soft tissue (excluding the soft tissue of the skull).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-03-22</field_date_posted>
  <field_date_reviewed>2011-03-24</field_date_reviewed>
  <field_pretty_url>novel-chemo-combo</field_pretty_url>
  <para_id>68632</para_id>
  <related_resource_ids>6494106</related_resource_ids>
  <related_resource_ids>6494107</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420504</term_id>
  <id>420505</id>
  <title>Questions to Ask Your Doctor about Treatment Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>Questions to Ask about Treatment Clinical Trials</field_short_title>
  <field_page_description>Suggested questions to ask your doctor, if you are thinking about taking part in a clinical trial.</field_page_description>
  <field_feature_card_description>Suggested questions to ask your doctor, if you are thinking about taking part in a clinical trial.</field_feature_card_description>
  <field_list_description>If you are thinking about taking part in a clinical trial, be sure to ask your doctor if there is a trial you can join. If your doctor offers you a trial, here are some questions you may want to ask.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>420505</para_id>
  <related_resource_ids>7090857</related_resource_ids>
  <related_resource_ids>7090858</related_resource_ids>
  <related_resource_ids>7090859</related_resource_ids>
  <related_resource_ids>7090860</related_resource_ids>
  <related_resource_ids>7090861</related_resource_ids>
  <related_resource_ids>7090863</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>420527</term_id>
  <id>420528</id>
  <title>Scientific Review</title>
  <langcode>en</langcode>
  <field_short_title>Scientific Review</field_short_title>
  <field_page_description>Scientific review ensures that studies are based on sound science, which contributes to the safety of clinical trial participants. Learn about the role of Institutional Review Boards (IRBs), Data and Safety Monitoring Boards (DSMBs), and government agenci</field_page_description>
  <field_feature_card_description>Information about the role of scientific review in protecting the safety of participants in cancer clinical trials.</field_feature_card_description>
  <field_list_description>Scientific review ensures that research studies are based on sound science, which contributes to the safety of clinical trial participants. Learn about the role of Institutional Review Boards (IRBs), Data and Safety Monitoring Boards (DSMBs), and government agencies in this review process.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-11</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <para_id>420528</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>425264</term_id>
  <id>425591</id>
  <title>Special Funding</title>
  <langcode>en</langcode>
  <field_short_title>Special Funding</field_short_title>
  <field_page_description>Funding opportunities for biomarker, imaging, quality of life and cost effectiveness studies (BIQSFP) and mid-career clinical investigators (CCITLA)</field_page_description>
  <field_feature_card_description>Explore funding opportunities for biomarker, imaging, quality of life and cost effectiveness studies (BIQSFP) and mid-career clinical investigators (CCITLA).</field_feature_card_description>
  <field_list_description>Explore funding opportunities for biomarker, imaging, quality of life and cost effectiveness studies (BIQSFP) and mid-career clinical investigators (CCITLA).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-09-14</field_date_posted>
  <field_date_reviewed>2012-09-14</field_date_reviewed>
  <para_id>425591</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133416</id>
  <title>The HPV Vaccine: Increasing the Use of an Important Cancer Prevention Tool</title>
  <langcode>en</langcode>
  <field_short_title>President’s Cancer Panel Report: Increasing HPV Vaccine Use</field_short_title>
  <field_page_description>A new report on the HPV vaccine from the President’s Cancer Panel identifies priorities and strategies for improving uptake of this cancer prevention tool.</field_page_description>
  <field_feature_card_description>President’s Cancer Panel identifies priorities, strategies for increasing vaccine uptake.</field_feature_card_description>
  <field_list_description>Dr. Barbara Rimer, chair of the President’s Cancer Panel, summarizes the panel’s recent report on the HPV vaccine, which includes priorities and strategies to ensure that more people receive this critical cancer vaccine.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-12-19</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-presidents-cancer-panel-improving-uptake</field_pretty_url>
  <para_id>1133416</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134343</term_id>
  <id>1134347</id>
  <title>2019 Speakers for the Preparing for Science-Based Non-Traditional Careers Course</title>
  <langcode>en</langcode>
  <field_short_title>2019 Preparing for Science-Based Non-Traditional Careers Course Speakers</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-02</field_date_posted>
  <field_date_reviewed>2019-01-02</field_date_reviewed>
  <field_pretty_url>2019-speakers</field_pretty_url>
  <para_id>1134347</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134378</term_id>
  <id>1134379</id>
  <title>Johns Hopkins/NCI Molecular Target and Drug Discovery Fellowship</title>
  <langcode>en</langcode>
  <field_short_title>JHU and NCI Molecular Target and Drug Discovery Fellowship</field_short_title>
  <field_page_description>Training fellows in bioassay development, chemical libraries, molecular targets and cancer, and high-throughput screening laboratory automation.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-03</field_date_posted>
  <field_date_reviewed>2019-01-03</field_date_reviewed>
  <para_id>1134379</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114848</term_id>
  <id>1134483</id>
  <title>Director’s Innovation Award Program</title>
  <langcode>en</langcode>
  <field_short_title>NCI Director’s Innovation Award Program</field_short_title>
  <field_page_description>The NCI Director’s Intramural Innovation Award Program is designed to support development of highly innovative approaches and technology aimed at significant problems from across the CCR portfolio.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-04</field_date_posted>
  <field_date_reviewed>2019-01-04</field_date_reviewed>
  <field_pretty_url>directors-innovation-awards</field_pretty_url>
  <para_id>1134483</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1135220</id>
  <title>Managing Cancer Pain: Are Better Approaches on the Horizon?</title>
  <langcode>en</langcode>
  <field_short_title>Developing Better Approaches for Managing Cancer Pain</field_short_title>
  <field_page_description>Pain is common in cancer patients and long-term survivors, so researchers are studying potential new pain medications and nondrug approaches for cancer pain.</field_page_description>
  <field_feature_card_description>Researchers are studying potentially nonaddictive medications and non-drug treatments.</field_feature_card_description>
  <field_list_description>Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-23</field_date_posted>
  <field_date_reviewed>2019-01-15</field_date_reviewed>
  <field_pretty_url>cancer-pain-new-approaches</field_pretty_url>
  <para_id>1135220</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1135269</term_id>
  <id>1135276</id>
  <title>Contracting Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Contracting Opportunities</field_short_title>
  <field_page_description>Contracting opportunities with the National Cancer Institute can be found in several different ways. The NCI Office of Acquisitions also works to connect small and disadvantaged buisnesses with subcontracting opportunities. </field_page_description>
  <field_list_description>Explore the different ways to find NCI contracting and subcontracting opportunities, as well as upcoming small business events.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-15</field_date_posted>
  <field_date_reviewed>2019-01-15</field_date_reviewed>
  <para_id>1135276</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1135988</id>
  <title>Glioblastoma Study Highlights Sex Differences in Brain Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Study Reveals Sex Differences in Glioblastoma</field_short_title>
  <field_page_description>Men and women with glioblastoma appear to respond differently to treatment. A new study identifies biological factors that might contribute to this sex difference.</field_page_description>
  <field_feature_card_description>Biological factors may explain differences in treatment response by men and women. </field_feature_card_description>
  <field_list_description>Men and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-30</field_date_posted>
  <field_date_reviewed>2019-01-28</field_date_reviewed>
  <field_pretty_url>glioblastoma-treatment-response-differs-by-sex</field_pretty_url>
  <para_id>1135988</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127122</term_id>
  <id>1137841</id>
  <title>TCGA's Study of Gastric Adenocarcinoma</title>
  <langcode>en</langcode>
  <field_short_title>TCGA's Study of Gastric Adenocarcinoma</field_short_title>
  <field_page_description>A summary of TCGA's study of gastric adenocarcinoma (stomach cancer), including what was known prior to the study and main findings from the characterization and analysis.</field_page_description>
  <field_feature_card_description>TCGA's Study of Gastric Adenocarcinoma</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>stomach</field_pretty_url>
  <para_id>1137841</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1134650</id>
  <title>Immunotherapy Effective in Alveolar Soft Part Sarcoma</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Effective in Alveolar Soft Part Sarcoma</field_short_title>
  <field_page_description>In some people with alveolar soft part sarcoma (ASPS), atezolizumab (Tecentriq) shrank tumors or stopped them from growing, a small clinical trial has shown.</field_page_description>
  <field_feature_card_description>Checkpoint inhibitor may be new option for rare, hard-to-treat cancer.</field_feature_card_description>
  <field_list_description>People with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-01-09</field_date_posted>
  <field_date_reviewed>2019-01-08</field_date_reviewed>
  <field_pretty_url>atezolizumab-alveolar-soft-part-sarcoma-trial</field_pretty_url>
  <para_id>1134650</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1134388</term_id>
  <id>1134661</id>
  <title>2019 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2019 Press Releases</field_short_title>
  <field_page_description>Press releases from NCI for the year 2019.</field_page_description>
  <field_list_description>Press releases from the National Cancer Institute for the year 2019.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-09</field_date_posted>
  <field_date_reviewed>2018-02-09</field_date_reviewed>
  <para_id>1134661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1137807</term_id>
  <id>1137813</id>
  <title>MyPART Upcoming Events</title>
  <langcode>en</langcode>
  <field_short_title>Upcoming Events</field_short_title>
  <field_page_description>MyPART team members are participating in meetings to talk about our programs and to answer questions. Find us at events across the country!</field_page_description>
  <field_list_description>MyPART team members are participating in meetings to talk about our programs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <para_id>1137813</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894088</term_id>
  <id>1138083</id>
  <title>CRCHD Supplements Café celebrates Black History Month</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Supplements Café celebrates Black History Month</field_short_title>
  <field_page_description>In observance of Black History month, CRCHD staff will be blogging about influential black doctors, scientists, and medical innovators, as well as rising stars from our portfolio.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-15</field_date_posted>
  <field_date_reviewed>2019-02-15</field_date_reviewed>
  <field_pretty_url>BlackHistoryMonth2019</field_pretty_url>
  <para_id>1138083</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1138892</id>
  <title>Partnering with Small Business to Advance Innovation in Cancer Research and Care</title>
  <langcode>en</langcode>
  <field_short_title>Partnering with Small Business to Advance Progress against Cancer</field_short_title>
  <field_page_description>The NCI director describes how NCI’s SBIR/STTR programs act as “engines of innovation” and shares new recommendations for strengthening the programs.</field_page_description>
  <field_feature_card_description>NCI’s SBIR/STTR programs are “engines of innovation,” NCI Director says.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless describes how NCI’s Small Business Innovation Research and Small Business Technology Transfer Programs act as “engines of innovation” and shares recommendations from a federal working group for strengthening the programs.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-21</field_date_posted>
  <field_date_reviewed>2019-02-20</field_date_reviewed>
  <field_pretty_url>nci-sbir-working-with-small-business</field_pretty_url>
  <para_id>1138892</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114848</term_id>
  <id>1139660</id>
  <title>NCI Director’s Intramural Innovation Award Program</title>
  <langcode>en</langcode>
  <field_short_title>NCI Director’s Intramural Innovation Award Program</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-01</field_date_posted>
  <field_date_reviewed>2019-03-01</field_date_reviewed>
  <field_pretty_url>past-recipients</field_pretty_url>
  <para_id>1139660</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>94636</id>
  <title>New Therapies Offer Valuable Options for Patients with Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>New Therapies Offer Valuable Options for Patients with Melanoma</field_short_title>
  <field_page_description>Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that vemurafenib and ipilimumab (Yervoy™) offer valuable new options for the disease. </field_page_description>
  <field_feature_card_description>Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that vemurafenib and ipilimumab (Yervoy™) offer valuable new options for the disease. </field_feature_card_description>
  <field_list_description>Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that the molecularly targeted agent vemurafenib and the immunotherapy agent ipilimumab (Yervoy™) offer valuable new options for a disease in which effective treatments have been lacking.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-07-19</field_date_posted>
  <field_date_reviewed>2011-07-19</field_date_reviewed>
  <field_pretty_url>vemurafenib-ipilimumab</field_pretty_url>
  <para_id>94636</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>987523</id>
  <title>U.S. and Peru Formalize Alliance in Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>U.S. and Peru Formalize Alliance in Cancer Research</field_short_title>
  <field_page_description>The National Cancer Institute (NCI) Center for Global Health (CGH) had the pleasure of welcoming a delegation of health officials from the Government of Peru for the signing of a memorandum of understanding (MOU) between the U.S. and Peru. </field_page_description>
  <field_feature_card_description>The NCI Center for Global Health and Peru agree to expand knowledge exchange and cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-08-20</field_date_posted>
  <field_date_reviewed>2015-08-20</field_date_reviewed>
  <field_pretty_url>peru-signing</field_pretty_url>
  <para_id>987523</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>988292</id>
  <title>Taking Food Away: Targeting Nutrient Scavenging by RAS-driven Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Taking Food Away: Targeting Nutrient Scavenging by RAS-driven Cancers</field_short_title>
  <field_page_description>Cancers driven by mutant KRAS genes are more dependent on scavenging nutrients from the tumor microenvironment, via macropinocytosis, and from internal recycling of cellular components, via autophagy. These differences may be cancer vulnerabilities.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-08-25</field_date_posted>
  <field_date_reviewed>2015-08-25</field_date_reviewed>
  <field_pretty_url>targeting-nutrient-scavenging</field_pretty_url>
  <para_id>988292</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>989416</id>
  <title>Anyone Can Get Skin Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Anyone Can Get Skin Cancer</field_short_title>
  <field_page_description> Covers skin cancer risk information for minority audiences. The goal of the brochure is to dispel the belief that only people with light skin are at risk for skin cancer.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-09-01</field_date_posted>
  <field_date_reviewed>2015-09-01</field_date_reviewed>
  <field_pretty_url>anyone-can-get-skin-cancer</field_pretty_url>
  <para_id>989416</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>994198</id>
  <title>Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Improves Survival, But Is Underused</title>
  <langcode>en</langcode>
  <field_short_title>IP Chemo for Ovarian Cancer is Underused</field_short_title>
  <field_page_description>Use of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use in clinical practice has been limited, according to a new study.</field_page_description>
  <field_feature_card_description>Intraperitoneal chemotherapy improves survival in advanced ovarian cancer. Its underuse may be due to side effects, technical challenges.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-04</field_date_posted>
  <field_date_reviewed>2015-09-03</field_date_reviewed>
  <field_pretty_url>IP-Chemo</field_pretty_url>
  <para_id>994198</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>1001477</id>
  <title>The Biology of Cancer Health Disparities</title>
  <langcode>en</langcode>
  <field_short_title>The Biology of Cancer Health Disparities</field_short_title>
  <field_page_description>These examples show how biology contributes to health disparities (differences in disease incidence and outcomes among distinct racial and ethnic groups, ), and how biological factors interact with other relevant factors, such as diet and the environment.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-11</field_date_posted>
  <field_date_reviewed>2015-09-11</field_date_reviewed>
  <field_pretty_url>biology-cancer-health-disparities</field_pretty_url>
  <para_id>1001477</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1052661</term_id>
  <id>1002084</id>
  <title>About the Genomic Data Sharing (GDS) Policy</title>
  <langcode>en</langcode>
  <field_short_title>About the GDS Policy</field_short_title>
  <field_page_description>Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.</field_page_description>
  <field_feature_card_description>Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.</field_feature_card_description>
  <field_list_description>The NIH Genomic Data Sharing (GDS) Policy was issued to promote broad and robust sharing of genomic research data and ensure proper oversight and appropriate protections for research involving human data. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-22</field_date_posted>
  <field_date_reviewed>2015-09-15</field_date_reviewed>
  <para_id>1002084</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1004619</id>
  <title>"Fine Tuning" Engineered T Cells May Extend Immunotherapy Approach to More Cancer Types</title>
  <langcode>en</langcode>
  <field_short_title>Expanding Immunotherapy to More Cancer Types</field_short_title>
  <field_page_description>Engineering immune cells to have a decreased affinity for their targets on cancer cells may not weaken their efficacy but may reduce the risk of side effects.</field_page_description>
  <field_feature_card_description>Early studies explore ways to ‘fine tune’ immune cells to treat cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-09-28</field_date_posted>
  <field_date_reviewed>2015-09-23</field_date_reviewed>
  <field_pretty_url>finetuned-tcells</field_pretty_url>
  <para_id>1004619</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1126285</term_id>
  <id>1004649</id>
  <title>NCI at APHA 2018</title>
  <langcode>en</langcode>
  <field_short_title>APHA 2018</field_short_title>
  <field_page_description>Check out this year’s APHA Annual Meeting schedule to see which NCI experts will be presenting, which poster sessions feature NCI research, and interactive sessions to attend with NCI experts.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-10-11</field_date_posted>
  <field_date_reviewed>2018-10-11</field_date_reviewed>
  <para_id>1004649</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1002053</term_id>
  <id>1011470</id>
  <title>NCI Grant Policies</title>
  <langcode>en</langcode>
  <field_short_title>NCI Grant Policies</field_short_title>
  <field_page_description>Research grants are subject to a variety of policy requirements. Find highlights of policy announcements or changes specific to NCI.</field_page_description>
  <field_feature_card_description>Research grants are subject to a variety of policy requirements. Find highlights of policy announcements or changes specific to NCI.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-10-06</field_date_posted>
  <field_date_reviewed>2015-10-06</field_date_reviewed>
  <para_id>1011470</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1015773</id>
  <title>In Triple-Negative Breast Cancer, Targeting an Addiction</title>
  <langcode>en</langcode>
  <field_short_title>In Triple-Negative Breast Cancer, Targeting an Addiction</field_short_title>
  <field_page_description>A new approach to disrupting genes that promote the development and spread of tumors may hold promise for treating an aggressive and difficult-to-treat type of breast cancer.</field_page_description>
  <field_feature_card_description>The new therapy targets and disrupts genes driving this difficult-to-treat type of cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-26</field_date_posted>
  <field_date_reviewed>2015-10-22</field_date_reviewed>
  <field_pretty_url>targeting-transcription</field_pretty_url>
  <para_id>1015773</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1130979</id>
  <title>NCI-MATCH Update: More Labs, New Arms, and Initial Findings</title>
  <langcode>en</langcode>
  <field_short_title>NCI-MATCH: More Labs, New Arms, and Initial Findings</field_short_title>
  <field_page_description>The NCI-MATCH cancer precision medicine trial is adding new treatment arms and testing labs, and reporting initial findings, NCI’s Dr. Lyndsay Harris explains.</field_page_description>
  <field_feature_card_description>An update on the largest precision medicine trial of its kind.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Lyndsay Harris provides an update on the NCI-MATCH trial, including the opening of new trial treatment arms and the addition of new laboratories to perform testing on tumor samples of prospective trial participants.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-11-15</field_date_posted>
  <field_date_reviewed>2018-11-14</field_date_reviewed>
  <field_pretty_url>nci-match-update-new-arms-more-labs</field_pretty_url>
  <para_id>1130979</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133176</term_id>
  <id>1133219</id>
  <title>Chondromyxoid fibroma</title>
  <langcode>en</langcode>
  <field_short_title>Chondromyxoid fibroma</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>chondromyxoid-fibroma</field_pretty_url>
  <para_id>1133219</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133178</term_id>
  <id>1133226</id>
  <title>Rhabdoid Tumor</title>
  <langcode>en</langcode>
  <field_short_title>Rhabdoid Tumor</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-17</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <field_pretty_url>rhabdoid-tumor</field_pretty_url>
  <para_id>1133226</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133472</term_id>
  <id>1133253</id>
  <title>The Role of Advocacy in MyPART</title>
  <langcode>en</langcode>
  <field_short_title>The Role of Advocacy in MyPART</field_short_title>
  <field_page_description>Our mission is to engage patients as partners in rare tumor research. Non-profit organizations dedicated to improving the experiences and outcomes of people with rare solid tumors are important members of the MyPART network.</field_page_description>
  <field_feature_card_description>Non-profit organizations are important members of the MyPART network.</field_feature_card_description>
  <field_list_description>In the MyPART network, our mission is to engage patients as partners in rare tumor research. Advocacy groups like yours are a critical bridge between patients and researchers as you help share experience and expertise between these groups. Non-profit organizations dedicated to improving the experiences and outcomes of people with rare solid tumors are important members of the MyPART network.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133253</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1133463</term_id>
  <id>1133260</id>
  <title>What Is MyPART?</title>
  <langcode>en</langcode>
  <field_short_title>What Is MyPART?</field_short_title>
  <field_page_description>MyPART is a group of scientists, patients, family members, advocates, and healthcare providers who want to help find treatments for rare cancers. We are working on childhood, teen, and young adult solid rare tumors that have no cures. </field_page_description>
  <field_feature_card_description>MyPART is a group of scientists, patients, family members, advocates, and healthcare providers working on rare tumors.</field_feature_card_description>
  <field_list_description>MyPART is the My Pediatric and Adult Rare Tumor network. It is a group of scientists, patients, family members, advocates, and healthcare providers who want to help find treatments for rare cancers. We are working on childhood, teen, and young adult solid rare tumors that have no cures. We think that working as a team will help us find treatments for rare cancers faster. Everyone can play a part.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-27</field_date_posted>
  <field_date_reviewed>2018-12-17</field_date_reviewed>
  <para_id>1133260</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1133377</id>
  <title>Statistical Analysis of Research Data</title>
  <langcode>en</langcode>
  <field_short_title>Statistical Analysis of Research Data</field_short_title>
  <field_page_description>The Statistical Analysis of Research Data (SARD) course is designed to provide NIH postdoctoral and clinical fellows an overview on the general principles of statistical analysis of research data. </field_page_description>
  <field_feature_card_description>The Statistical Analysis of Research Data (SARD) course is designed to provide NIH postdoctoral and clinical fellows an overview on the general principles of statistical analysis of research data. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-19</field_date_posted>
  <field_date_reviewed>2018-12-19</field_date_reviewed>
  <field_pretty_url>statistical-analysis-research-data</field_pretty_url>
  <para_id>1133377</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1133421</id>
  <title>New on NCI Websites for December 2018</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI Websites for December 2018</field_short_title>
  <field_page_description>See selected content that has been added to NCI’s websites as of December 2018, in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of December 2018.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-12-28</field_date_posted>
  <field_date_reviewed>2018-12-19</field_date_reviewed>
  <field_pretty_url>new-online-december-2018</field_pretty_url>
  <para_id>1133421</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1133198</term_id>
  <id>1133528</id>
  <title>News</title>
  <langcode>en</langcode>
  <field_short_title>News</field_short_title>
  <field_page_description>The latest news and clinics from MyPART.</field_page_description>
  <field_feature_card_description>MyPART hosts events and participates in scientific conferences that help promote rare tumor research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2018-12-20</field_date_reviewed>
  <para_id>1133528</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114844</term_id>
  <id>1134421</id>
  <title>CCR Fellows and Young Investigators Association</title>
  <langcode>en</langcode>
  <field_short_title>CCR Fellows &amp; Young Investigators Association</field_short_title>
  <field_page_description>The Fellows and Young Investigators Association enhances the intramural training program by organizing, promoting and informing the NCI fellows of career development and training opportunities at the NIH. This association fosters communcation among fellows, NCI research community and senior management. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-04</field_date_posted>
  <field_date_reviewed>2019-01-04</field_date_reviewed>
  <field_pretty_url>fellows-young-investigators-association</field_pretty_url>
  <para_id>1134421</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>449472</id>
  <title>Comparing Relaxation Programs for Breast Cancer Patients Receiving Radiotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Comparing Relaxation Programs for Breast Cancer Patients Receiving Radiotherapy</field_short_title>
  <field_page_description>In this study, women with breast cancer who have had surgery and are scheduled to undergo radiation therapy will be randomly assigned to one of two different stretching and relaxation programs or to a control group that will receive usual care. </field_page_description>
  <field_feature_card_description>In this study, women with breast cancer who have had surgery and are scheduled to undergo radiation therapy will be randomly assigned to one of two different stretching and relaxation programs or to a control group that will receive usual care. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-10-16</field_date_posted>
  <field_date_reviewed>2012-10-16</field_date_reviewed>
  <field_pretty_url>relaxation-radiotherapy</field_pretty_url>
  <para_id>449472</para_id>
  <related_resource_ids>6494197</related_resource_ids>
  <related_resource_ids>6494198</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>463785</id>
  <title>Chemotherapy and You: Support for People With Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Chemotherapy and You: Support for People With Cancer</field_short_title>
  <field_page_description>Covers side effects that patients may have during chemotherapy and ways to manage them.</field_page_description>
  <field_feature_card_description>Covers side effects that patients may have during chemotherapy and ways to manage them.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-20</field_date_reviewed>
  <field_pretty_url>chemo-and-you</field_pretty_url>
  <para_id>463785</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>464419</id>
  <title>Cancer Pain Control: Support for People With Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Pain Control: Support for People With Cancer</field_short_title>
  <field_page_description>Covers pain control medicines for cancer patients, pain control plans, talking with your health care team about pain, and coping with the physical and emotional effects of pain.</field_page_description>
  <field_feature_card_description>Covers pain control medicines for cancer patients, pain control plans, talking with your health care team about pain, and coping with the physical and emotional effects of pain.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2012-11-23</field_date_reviewed>
  <field_pretty_url>pain-control</field_pretty_url>
  <para_id>464419</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>476945</id>
  <title>New Drug Shows Promise against Drug-Resistant Leukemias</title>
  <langcode>en</langcode>
  <field_short_title>New Drug Shows Promise against Drug-Resistant Leukemias</field_short_title>
  <field_page_description>A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.</field_page_description>
  <field_feature_card_description>A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-12</field_date_reviewed>
  <field_pretty_url>ponatinib-cml</field_pretty_url>
  <para_id>476945</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478618</id>
  <title>Funded Studies</title>
  <langcode>en</langcode>
  <field_short_title>Funded Studies</field_short_title>
  <field_page_description>BIQSFP funded studies associated with NCI network trials. </field_page_description>
  <field_feature_card_description>BIQSFP funded studies associated with NCI network trials. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>funded-studies</field_pretty_url>
  <para_id>478618</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>917237</term_id>
  <id>478620</id>
  <title>Glossary</title>
  <langcode>en</langcode>
  <field_short_title>Glossary</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-12-17</field_date_posted>
  <field_date_reviewed>2012-12-17</field_date_reviewed>
  <field_pretty_url>glossary</field_pretty_url>
  <para_id>478620</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>822283</id>
  <title>Preserving Fertility while Battling Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Preserving Fertility while Battling Cancer</field_short_title>
  <field_page_description>Some oncologists neglect to discuss the possibility of treatment-related infertility with patients of reproductive age. Researchers are developing decision aids to help patients make an informed, carefully considered decision about fertility.</field_page_description>
  <field_feature_card_description>An article about cancer treatment-related infertility and research on decision aids to help patients make an informed, carefully considered decision about fertility.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-01-11</field_date_posted>
  <field_date_reviewed>2014-09-04</field_date_reviewed>
  <field_pretty_url>fertility-preservation</field_pretty_url>
  <para_id>822283</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>828581</term_id>
  <id>828647</id>
  <title>Meetings &amp; Events</title>
  <langcode>en</langcode>
  <field_short_title>Meetings &amp; Events</field_short_title>
  <field_page_description>Upcoming meetings and events NCI CRCHD may attend as well as select resources from recent past meetings and events.</field_page_description>
  <field_feature_card_description>A list of CRCHD upcoming and past meetings and events.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-17</field_date_reviewed>
  <para_id>828647</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>699643</id>
  <title>Blocking DNA Repair in Advanced BRCA-Mutated Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Blocking DNA Repair in Advanced BRCA-Mutated Cancer</field_short_title>
  <field_page_description>In this trial, patients with relapsed or refractory advanced cancer and confirmed BRCA mutations who have not previously been treated with a PARP inhibitor will be given BMN 673 by mouth once a day in 28-day cycles.</field_page_description>
  <field_feature_card_description>In this trial, patients with relapsed or refractory advanced cancer and confirmed BRCA mutations who have not previously been treated with a PARP inhibitor will be given BMN 673 by mouth once a day in 28-day cycles.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-01-31</field_date_posted>
  <field_date_reviewed>2018-02-28</field_date_reviewed>
  <field_pretty_url>advanced-brca-mutated-cancer</field_pretty_url>
  <para_id>699643</para_id>
  <related_resource_ids>7250726</related_resource_ids>
  <related_resource_ids>7250727</related_resource_ids>
  <related_resource_ids>7250728</related_resource_ids>
  <related_resource_ids>7250729</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11502</term_id>
  <id>707545</id>
  <title>NCI and Medical Decision Making</title>
  <langcode>en</langcode>
  <field_short_title>NCI and Medical Decision Making</field_short_title>
  <field_page_description>NCI conducts and facilitates basic and translational research that can inform standard clinical practice and medical decision making.</field_page_description>
  <field_feature_card_description>Information on NCI's role in support of medical decision making.</field_feature_card_description>
  <field_list_description>Information on NCI's role in support of medical decision making.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-02-18</field_date_posted>
  <field_date_reviewed>2014-03-25</field_date_reviewed>
  <field_pretty_url>medical-decision-making</field_pretty_url>
  <para_id>707545</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069530</term_id>
  <id>974490</id>
  <title>Mutations in Human Cancers Through the Lens of KRAS</title>
  <langcode>en</langcode>
  <field_short_title>Mutations in Human Cancers Related to KRAS</field_short_title>
  <field_page_description>Exome sequences from The Cancer Genome Atlas were analyzed for the types of missense mutations in KRAS that were associated with missense mutations in other commonly mutated genes.</field_page_description>
  <field_feature_card_description>Cancers with high rates of KRAS mutations were analyzed for mutation rates in other genes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-07-07</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <field_pretty_url>kras-cancer-co-mutation</field_pretty_url>
  <para_id>974490</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974535</term_id>
  <id>974536</id>
  <title>Grant and Contract Awards</title>
  <langcode>en</langcode>
  <field_short_title>Grant and Contract Awards</field_short_title>
  <field_page_description>Find information about grant and contract awards by state, by country, and by institutions that received more than $15 million in support from NCI.</field_page_description>
  <field_feature_card_description>See grant and contract awards by state, by country, and by institutions that received more than $15 million in support.</field_feature_card_description>
  <field_list_description>See the number and dollar amount of grant and contract awards by state, by country, and by institutions that received more than $15 million in support from NCI.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974536</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974634</term_id>
  <id>974635</id>
  <title>NCI Personnel</title>
  <langcode>en</langcode>
  <field_short_title>Personnel and Staffing Levels</field_short_title>
  <field_page_description>See NCI-staffing levels by type of appointment since 2009, including full-time, permanent appointments; appointments other than full-time, permanent; and training fellows.</field_page_description>
  <field_feature_card_description>See NCI-staffing levels by type of appointment since 2009. </field_feature_card_description>
  <field_list_description>Find  the number of NCI employees by full-time, permanent appointments; appointments other than full-time, permanent; and training fellows.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-08</field_date_reviewed>
  <para_id>974635</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>975112</term_id>
  <id>975114</id>
  <title>NCI Budget Fact Book Archive</title>
  <langcode>en</langcode>
  <field_short_title>NCI Budget Fact Book Archive</field_short_title>
  <field_page_description>History of NCI Budget Fact Books from 2017 to 1971. View and download NCI’s archived Budget Fact Books.</field_page_description>
  <field_feature_card_description>All of the NCI Budget Fact Books, dating back to 1971, available as PDFs.</field_feature_card_description>
  <field_list_description>Collection of NCI Budget Fact Books from 1971 to 2017. For summary data on yearly expenditures, view and download NCI’s archived Budget Fact Books.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-12-16</field_date_posted>
  <field_date_reviewed>2015-07-10</field_date_reviewed>
  <para_id>975114</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>975213</id>
  <title>Healthy Border 2020 Embassy Launch</title>
  <langcode>en</langcode>
  <field_short_title>Healthy Border 2020 Embassy Launch</field_short_title>
  <field_page_description>The U.S.-Mexico Border Health Commission launched the Healthy Border 2020 at the Mexican Embassy in the United States on June 24, 2015. This new initiative aims to strengthening what was accomplished on the previous plan of action entitled Healthy Border 2010.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-10</field_date_posted>
  <field_date_reviewed>2015-07-10</field_date_reviewed>
  <field_pretty_url>healthyborder</field_pretty_url>
  <para_id>975213</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>918917</term_id>
  <id>975284</id>
  <title>Fostering Cooperation in Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Fostering Cooperation in Cancer Research</field_short_title>
  <field_page_description>Thursday, June 25, 2015 Memorandum of Understanding (MoU) was signed between US National Cancer Institute and three agencies of the Indian government - the Department of Biotechnology, the Indian Council of Medical Research, and the Indian National Cancer Institute, a part of the All India Institute of Medical Sciences</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-10</field_date_posted>
  <field_date_reviewed>2015-07-10</field_date_reviewed>
  <field_pretty_url>indiamou</field_pretty_url>
  <para_id>975284</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974492</term_id>
  <id>976613</id>
  <title>Dr. Ruth L. Kirschstein National Research Service Awards (NRSA)</title>
  <langcode>en</langcode>
  <field_short_title>Dr. Ruth L. Kirschstein National Research Service Awards</field_short_title>
  <field_page_description>The NCI Ruth L. Kirschstein National Research Service Award (NRSA) program helps ensure that a diverse pool of highly trained scientists is available to meet the Nation’s research needs. Learn more about the NRSA program and the types of predoc and postdoc trainees awarded.</field_page_description>
  <field_feature_card_description>Learn about the program and the types of predoc and postdoc trainees awarded.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-14</field_date_reviewed>
  <para_id>976613</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1137972</term_id>
  <id>1137909</id>
  <title>NCI at AACR 2019</title>
  <langcode>en</langcode>
  <field_short_title>NCI at AACR 2019</field_short_title>
  <field_page_description>NCI is participating at the American Association for Cancer Research (AACR) Annual Meeting, March 29-April 3, 2019 at the Georgia World Congress Center in Atlanta, GA. See the schedule of NCI-sponsored sessions and NCI expert booth presentations</field_page_description>
  <field_feature_card_description>Information about NCI-related sessions and activities at the American Association for Cancer Research (AACR) Annual Meeting.</field_feature_card_description>
  <field_list_description>Information about NCI's presence at the American Association for Cancer Research (AACR) Annual Meeting, to be held March 29 - April 3, 2019 at the Georgia World Congress Center in Atlanta, GA.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-22</field_date_posted>
  <field_date_reviewed>2018-02-26</field_date_reviewed>
  <para_id>1137909</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1138001</term_id>
  <id>1137916</id>
  <title>Sessions Featuring NCI Staff</title>
  <langcode>en</langcode>
  <field_short_title>Sessions Featuring NCI Staff</field_short_title>
  <field_page_description>The NCI-sponsored sessions at AACR are dedicated to discussing programs held throughout NCI, while the poster sessions and presentations offer a platform for NCI scientists to relay study findings. Find the sessions led by NCI staff at AACR 2019.</field_page_description>
  <field_feature_card_description>Each year, NCI sponsors sessions to present and showcase programs and resources.</field_feature_card_description>
  <field_list_description>Each year, NCI sponsors sessions to present and showcase programs and resources.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-03-26</field_date_reviewed>
  <para_id>1137916</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1139109</id>
  <title>Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults </title>
  <langcode>en</langcode>
  <field_short_title>Childhood Leukemia Treatment Also Effective for Young Adults</field_short_title>
  <field_page_description>A treatment regimen designed for children with acute lymphoblastic leukemia is also effective for older adolescents and young adults with the disease.</field_page_description>
  <field_feature_card_description>Treatment will likely become standard for AYAs with this cancer.</field_feature_card_description>
  <field_list_description>A clinical trial found that an intensive treatment regimen developed specifically for children with acute lymphoblastic leukemia is also effective for older adolescents and young adults with the disease. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-25</field_date_posted>
  <field_date_reviewed>2019-02-22</field_date_reviewed>
  <field_pretty_url>aya-leukemia-pediatric-regimen-effective</field_pretty_url>
  <para_id>1139109</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1139477</id>
  <title>UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation</title>
  <langcode>en</langcode>
  <field_short_title>Trial Tests E-cigarettes against Nicotine Replacement</field_short_title>
  <field_page_description>E-cigarettes plus counseling may help smokers trying to quit tobacco more than nicotine-replacement products like patches and gums, a UK clinical trial has found.</field_page_description>
  <field_feature_card_description>UK study shows e-cigarettes plus counseling improved the ability to quit smoking.</field_feature_card_description>
  <field_list_description>Researchers in the United Kingdom have found that e-cigarettes combined with counseling may be more helpful to smokers trying to quit tobacco than nicotine-replacement products, such as patches, gums, and lozenges. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-08</field_date_posted>
  <field_date_reviewed>2019-02-28</field_date_reviewed>
  <field_pretty_url>e-cigarettes-nrt-smoking-cessation-clinical-trial</field_pretty_url>
  <para_id>1139477</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894088</term_id>
  <id>1139752</id>
  <title>Now Accepting iCURE Applications for 2019</title>
  <langcode>en</langcode>
  <field_short_title>Now Accepting iCURE Applications for 2019</field_short_title>
  <field_page_description>Apply for a Fall 2019 iCURE research experience by March 31, 2019!</field_page_description>
  <field_feature_card_description>The Intramural Continuing Umbrella of Research Experiences  (iCURE) program is now accepting applications for Fall 2019 research experiences!</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-03-01</field_date_posted>
  <field_date_reviewed>2019-03-01</field_date_reviewed>
  <field_pretty_url>2019-applications</field_pretty_url>
  <para_id>1139752</para_id>
  <related_resource_ids>7268456</related_resource_ids>
  <related_resource_ids>7268457</related_resource_ids>
  <related_resource_ids>7268458</related_resource_ids>
  <related_resource_ids>7268606</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>99821</id>
  <title>Drugs Approved for Wilms Tumor and Other Childhood Kidney Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Wilms Tumor </field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for Wilms tumor and other childhood kidney cancers. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-04</field_date_posted>
  <field_date_reviewed>2011-07-26</field_date_reviewed>
  <field_pretty_url>wilms-tumor</field_pretty_url>
  <para_id>99821</para_id>
  <related_resource_ids>6994878</related_resource_ids>
  <related_resource_ids>6994879</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>99866</id>
  <title>Abiraterone Improves Survival in Metastatic Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Abiraterone Improves Survival in Metastatic Prostate Cancer</field_short_title>
  <field_page_description>A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo. </field_page_description>
  <field_feature_card_description>A multinational phase III trial found that the drug abiraterone acetate prolonged the median survival of patients with metastatic castration-resistant prostate cancer by 4 months compared with patients who received a placebo. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-07-27</field_date_posted>
  <field_date_reviewed>2012-12-31</field_date_reviewed>
  <field_pretty_url>abiraterone</field_pretty_url>
  <para_id>99866</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>94637</id>
  <title>Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women</title>
  <langcode>en</langcode>
  <field_short_title>Exemestane Reduces Breast Cancer Risk in High-Risk Postmenopausal Women</field_short_title>
  <field_page_description>Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane—used to treat early and advanced breast cancer—substantially reduced the risk of invasive breast cancer in high-risk postmenopausal women.</field_page_description>
  <field_feature_card_description>Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane—used to treat early and advanced breast cancer—substantially reduced the risk of invasive breast cancer in high-risk postmenopausal women.</field_feature_card_description>
  <field_list_description>Clinical trial results presented at the 2011 ASCO annual meeting showed that the aromatase inhibitor exemestane (Aromasin®)—commonly used to treat early and advanced-stage breast cancer—substantially reduced the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-07-19</field_date_posted>
  <field_date_reviewed>2011-07-19</field_date_reviewed>
  <field_pretty_url>exemestane-reduces-risk</field_pretty_url>
  <para_id>94637</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>102660</id>
  <title>Drugs Approved for Liver Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Liver Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for liver cancer. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-04</field_date_posted>
  <field_date_reviewed>2011-08-05</field_date_reviewed>
  <field_pretty_url>liver</field_pretty_url>
  <para_id>102660</para_id>
  <related_resource_ids>7234190</related_resource_ids>
  <related_resource_ids>7234192</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>608323</term_id>
  <id>679249</id>
  <title>Targeted Treatments for a Type of Pancreatic Cancer: Rapamycin and Other mTOR Inhibitors</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Treatments for a Type of Pancreatic Cancer</field_short_title>
  <field_page_description>Thanks to discovering the anticancer effects of mTOR inhibitors, cancer treatment for pNet, a rare type of pancreatic cancer, were revolutionized. Through clinical trials, NCI continues to investigate the life-saving potential of mTOR inhibitors.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-03-07</field_date_posted>
  <field_date_reviewed>2013-12-12</field_date_reviewed>
  <field_pretty_url>mtor-inhibitors</field_pretty_url>
  <para_id>679249</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974639</term_id>
  <id>974641</id>
  <title>NCI and NIH AIDS Funding History</title>
  <langcode>en</langcode>
  <field_short_title>AIDS Funding History</field_short_title>
  <field_page_description>NCI scientists have made a number of key discoveries in HIV/AIDS research. Find information about the history of funding levels for HIV/AIDS research year over year. </field_page_description>
  <field_feature_card_description>Information about the history of NCI funding levels for HIV/AIDS research year over year. </field_feature_card_description>
  <field_list_description>See the total dollar amount and a comparison of NIH and NCI funding levels for HIV/AIDS research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-08</field_date_reviewed>
  <para_id>974641</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894080</term_id>
  <id>979458</id>
  <title>Director's Corner: Professional Development Workshop Helps Early Stage Investigators Build Independent Careers in Scientific Research</title>
  <langcode>en</langcode>
  <field_short_title>Director's Corner: Professional Development Workshop Helps Early Stage Investigators</field_short_title>
  <field_page_description>The Professional Development and Mock Review Workshop is a seminal event organized each year for CURE scholars and trainees. The event includes informative presentations, interactive discussions, a mock review, and poster session.</field_page_description>
  <field_feature_card_description>The Professional Development and Mock Review Workshop is an important annual event.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-07-23</field_date_posted>
  <field_date_reviewed>2015-07-23</field_date_reviewed>
  <field_pretty_url>PDW-2015</field_pretty_url>
  <para_id>979458</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>821432</id>
  <title>National Lung Screening Trial</title>
  <langcode>en</langcode>
  <field_short_title>National Lung Screening Trial</field_short_title>
  <field_page_description>The National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. </field_page_description>
  <field_feature_card_description>The National Lung Screening Trial (NLST) used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. </field_feature_card_description>
  <field_list_description>Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-08</field_date_posted>
  <field_date_reviewed>2014-09-08</field_date_reviewed>
  <field_pretty_url>nlst</field_pretty_url>
  <para_id>821432</para_id>
  <related_resource_ids>6485036</related_resource_ids>
  <related_resource_ids>6485037</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836725</id>
  <title>Understanding Cervical Changes: A Health Guide for Women</title>
  <langcode>en</langcode>
  <field_short_title>Understanding Cervical Changes: A Health Guide for Women</field_short_title>
  <field_page_description>Explains next steps after an abnormal Pap or HPV test result, including how cervical conditions are diagnosed and treated – as well as information about screening guidelines and HPV vaccines.</field_page_description>
  <field_feature_card_description>Explains next steps after an abnormal Pap or HPV test result, including how cervical conditions are diagnosed and treated – as well as information about screening guidelines and HPV vaccines.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>understanding-cervical-changes</field_pretty_url>
  <para_id>836725</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836829</id>
  <title>Facing Forward: Making a Difference in Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Facing Forward: Making a Difference in Cancer</field_short_title>
  <field_page_description>Covers the different ways of volunteering or becoming involved in cancer-related activities.</field_page_description>
  <field_feature_card_description>Covers the different ways of volunteering or becoming involved in cancer-related activities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>make-a-difference</field_pretty_url>
  <para_id>836829</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836921</id>
  <title>Thinking About Complementary and Alternative Medicine</title>
  <langcode>en</langcode>
  <field_short_title>Thinking About Complementary and Alternative Medicine</field_short_title>
  <field_page_description>Covers how to make informed choices when looking for complementary and alternative medicine (CAM).</field_page_description>
  <field_feature_card_description>Covers how to make informed choices when looking for complementary and alternative medicine (CAM).</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>thinking-about-cam</field_pretty_url>
  <para_id>836921</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>847971</term_id>
  <id>847972</id>
  <title>CRCHD Diversity Training</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Diversity Training</field_short_title>
  <field_page_description>The Center to Reduce Cancer Health Disparities (CRCHD) funds cancer research training for those from backgrounds underrepresented in cancer biomedical and behavioral sciences.</field_page_description>
  <field_feature_card_description>The Center to Reduce Cancer Health Disparities (CRCHD) funds cancer research training for those from backgrounds underrepresented in cancer biomedical and behavioral sciences.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-10-29</field_date_reviewed>
  <para_id>847972</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>849741</id>
  <title>CURE Scholar Spotlight - Dr. Donita Colette Brady</title>
  <langcode>en</langcode>
  <field_short_title>CURE Scholar Spotlight - Dr. Brady</field_short_title>
  <field_page_description>Donita C. Brady, a Research Associate Senior at the Department of Pharmacology and Cancer Biology at Duke University, is investigating the role that copper plays in cell growth and tumor biology. Inspired by her mentor Christopher Counter, a cancer biologist, and Dennis Thiele, a copper biologist, at Duke University, B</field_page_description>
  <field_feature_card_description>Donita C. Brady, a Research Associate Senior at the Department of Pharmacology and Cancer Biology at Duke University, is investigating the role that copper plays in cell growth and tumor biology. Inspired by her mentor Christopher Counter, a cancer biolog</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-08-21</field_date_posted>
  <field_date_reviewed>2014-10-30</field_date_reviewed>
  <field_pretty_url>brady-spotlight</field_pretty_url>
  <para_id>849741</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915609</term_id>
  <id>850495</id>
  <title>Tackling Cancer Health Disparities: Small Steps, Big Hopes</title>
  <langcode>en</langcode>
  <field_short_title>Tackling Cancer Health Disparities</field_short_title>
  <field_page_description>An article about steps for developing and testing ways to reduce—or eliminate—cancer-related health disparities.</field_page_description>
  <field_feature_card_description>An article about steps for developing and testing ways to reduce—or eliminate—cancer-related health disparities.</field_feature_card_description>
  <field_list_description>Numerous studies have documented disparities in cancer incidence and mortality among certain populations. But, by and large, cancer-related health disparities in the United States have been an intractable problem. Researchers believe the time is now ripe for actively developing and testing ways to reduce—or better yet, eliminate—these disparities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-11-03</field_date_posted>
  <field_date_reviewed>2014-10-31</field_date_reviewed>
  <field_pretty_url>health-disparity-studies</field_pretty_url>
  <para_id>850495</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>857168</id>
  <title>National Cancer Institute’s New NCD Coordinator</title>
  <langcode>en</langcode>
  <field_short_title>National Cancer Institute’s New NCD Coordinator</field_short_title>
  <field_page_description>National Cancer Institute’s New NCD Coordinator</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-12</field_date_posted>
  <field_date_reviewed>2014-11-12</field_date_reviewed>
  <field_pretty_url>ncd-new-coordinator</field_pretty_url>
  <para_id>857168</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858166</term_id>
  <id>859567</id>
  <title>Talking to Children about Your Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Talking to Children</field_short_title>
  <field_page_description>Information to help you talk to your kids, teens, and adult children about cancer.</field_page_description>
  <field_feature_card_description>Information to help you talk to your kids, teens, and adult children about cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859567</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858181</term_id>
  <id>859665</id>
  <title>Follow-Up Medical Care</title>
  <langcode>en</langcode>
  <field_short_title>Follow-Up Medical Care</field_short_title>
  <field_page_description>Information about follow-up medical care for patients who have completed cancer treatment. Discusses your follow-up care plan, getting a wellness plan, and guidelines for a healthy lifestyle.  </field_page_description>
  <field_feature_card_description>Once you're done with cancer treatment, you should receive a follow-up cancer plan from your doctor. Learn more.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859665</para_id>
  <related_resource_ids>6634194</related_resource_ids>
  <related_resource_ids>6634195</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066544</id>
  <title>Symposium Brings Rising Global Cancer Burden into Focus</title>
  <langcode>en</langcode>
  <field_short_title>Symposium Focuses on Global Cancer Burden </field_short_title>
  <field_page_description>The NCI Global Cancer Research Symposium examined ways of increasing research collaboration, particularly in cancer prevention and screening, to reduce the global cancer burden.</field_page_description>
  <field_feature_card_description>The NCI-sponsored event examined ways of increasing research collaboration, particularly in cancer prevention and screening, to reduce the cancer burden.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post about the NCI Global Cancer Research Symposium, which examined ways of increasing research collaboration, particularly in cancer prevention and screening, to reduce the cancer burden.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-09</field_date_posted>
  <field_date_reviewed>2016-11-09</field_date_reviewed>
  <field_pretty_url>global-cancer-symposium</field_pretty_url>
  <para_id>1066544</para_id>
  <related_resource_id>6624805</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894082</term_id>
  <id>1066826</id>
  <title>NCI’s CRCHD Launches National Colorectal Cancer Outreach and Screening Initiative</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Launches National Colorectal Cancer Outreach and Screening Initiative</field_short_title>
  <field_page_description>The NCI CRCHD launches National Screen to Save Colorectal Cancer Outreach and Screening Initiative which aims to increase colorectal cancer screening rates among racially and ethnically diverse and rural communities.</field_page_description>
  <field_feature_card_description>A new initiative aims to increase colorectal cancer screening among racially and ethnically diverse communities and in rural areas.</field_feature_card_description>
  <field_list_description>The NCI Center to Reduce Cancer Health Disparities (CRCHD) is pleased to announce the launch of the National “Screen to Save” (S2S) Colorectal Cancer Outreach and Screening Initiative. This innovative initiative aims to increase colorectal cancer screening rates among racially and ethnically diverse and rural communities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-11-22</field_date_posted>
  <field_date_reviewed>2016-11-16</field_date_reviewed>
  <field_pretty_url>screentosave-launch</field_pretty_url>
  <para_id>1066826</para_id>
  <related_resource_ids>6443974</related_resource_ids>
  <related_resource_ids>6443975</related_resource_ids>
  <related_resource_ids>6443976</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1068117</id>
  <title>CGH Continues Building Partnership with the Commonwealth of Independent States at World Cancer Congress</title>
  <langcode>en</langcode>
  <field_short_title>Recent Activities with partners in the Commonwealth of Independent States</field_short_title>
  <field_page_description>NCI's Center for Global Health and Commonwealth of Independent States partners collaborate on cancer control in Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan.</field_page_description>
  <field_feature_card_description>CGH Continues Building Partnership with the Commonwealth of Independent States at World Cancer Congress</field_feature_card_description>
  <field_list_description>During the recent World Cancer Congress, the National Cancer Institute Center for Global Health (NCI CGH) staff had the opportunity to follow up with several partners in the Commonwealth of Independent States (CIS). The long-term relationships with CIS countries have recently been reinvigorated following the Central Asia Leadership Forum (CALF) that was co-sponsored by NCI CGH and the Uzbekistan National Cancer Center in Tashkent, Uzbekistan, in October 2015.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-07</field_date_posted>
  <field_date_reviewed>2016-12-06</field_date_reviewed>
  <field_pretty_url>partnership-commonwealth-independent-states</field_pretty_url>
  <para_id>1068117</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1092473</term_id>
  <id>1092474</id>
  <title>Monitoring Research Grant Awards</title>
  <langcode>en</langcode>
  <field_short_title>Monitoring Research Grant Awards</field_short_title>
  <field_page_description>NCI grants management staff regularly monitor individual grants within each budget period and within the overall project period.</field_page_description>
  <field_feature_card_description>Monitoring grant awards requires ongoing analysis.</field_feature_card_description>
  <field_list_description>NCI grants management and program staff monitor individual grants within each budget period and within the overall project period. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-17</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <para_id>1092474</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1093241</id>
  <title>Neratinib Approved by FDA for HER2-Positive Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Neratinib for HER2-Positive Breast Cancer</field_short_title>
  <field_page_description>Neratinib (Nerlynx) has been approved by FDA for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab (Herceptin).</field_page_description>
  <field_feature_card_description>The drug reduces the risk of recurrence, but has side effects in the gut.</field_feature_card_description>
  <field_list_description>FDA has approved neratinib for patients with early-stage HER2-positive breast cancer who have finished at least 1 year of adjuvant therapy with trastuzumab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-23</field_date_posted>
  <field_date_reviewed>2017-08-23</field_date_reviewed>
  <field_pretty_url>neratinib-breast-cancer-fda</field_pretty_url>
  <para_id>1093241</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>14626</id>
  <title>The TAILORx Breast Cancer Trial</title>
  <langcode>en</langcode>
  <field_short_title>The TAILORx Breast Cancer Trial</field_short_title>
  <field_page_description>A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx.</field_page_description>
  <field_feature_card_description>A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx.</field_feature_card_description>
  <field_list_description>A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2006-05-23</field_date_posted>
  <field_date_reviewed>2018-06-04</field_date_reviewed>
  <field_pretty_url>tailorx</field_pretty_url>
  <para_id>14626</para_id>
  <related_resource_ids>6990017</related_resource_ids>
  <related_resource_ids>6990019</related_resource_ids>
  <related_resource_ids>6990020</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11906</term_id>
  <id>14885</id>
  <title>Extragonadal Germ Cell Tumors—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Extragonadal Germ Cell Tumors</field_short_title>
  <field_page_description>Extragonadal germ cell tumors form in parts of the body outside the gonads. They may begin to grow anywhere in the body, but usually form in the pineal gland in the brain, the chest, the lower part of the spine, or the abdomen. Start here to find information on extragonadal germ cell tumors treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Extragonadal Germ Cell Tumor .</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14885</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>10960</term_id>
  <id>14930</id>
  <title>NCI Budget and Appropriations</title>
  <langcode>en</langcode>
  <field_short_title>Budget and Appropriations</field_short_title>
  <field_page_description>Information about NCI's current and previous annual budgets, strategic plans for the institute, and Congressional Justification documents.</field_page_description>
  <field_feature_card_description>Find information about NCI’s budget activities in relation to grant funding.</field_feature_card_description>
  <field_list_description>Information about how NCI allocates its budget to achieve research goals. Learn more about the current fiscal year 2018 budget, the NCI budget process, and recent trends in NCI budgets. 
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-24</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14930</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>929549</term_id>
  <id>14987</id>
  <title>Ataxia Telangiectasia</title>
  <langcode>en</langcode>
  <field_short_title>Ataxia Telangiectasia</field_short_title>
  <field_page_description>A fact sheet about ataxia telangiectasia (A-T), a rare, recessive genetic disorder of childhood that occurs in between one out of 40,000 and one out of 100,000 persons worldwide.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2002-02-26</field_date_posted>
  <field_date_reviewed>2006-01-26</field_date_reviewed>
  <field_pretty_url>ataxia-fact-sheet</field_pretty_url>
  <para_id>14987</para_id>
  <related_resource_ids>6188441</related_resource_ids>
  <related_resource_ids>6188442</related_resource_ids>
  <related_resource_ids>6188443</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>915528</term_id>
  <id>14999</id>
  <title>Biological Therapies for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Biological Therapies for Cancer</field_short_title>
  <field_page_description>A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies.</field_page_description>
  <field_feature_card_description>An overview of the immune system and certain biological therapies such as adoptive T-cell transfer, gene therapy, and more.</field_feature_card_description>
  <field_list_description>A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies, such as monoclonal antibodies, cytokines, therapeutic vaccines, the bacterium bacillus Calmet-Guérin, cancer-killing viruses, gene therapy, and adoptive T-cell transfer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-21</field_date_posted>
  <field_date_reviewed>2018-04-26</field_date_reviewed>
  <field_pretty_url>bio-therapies-fact-sheet</field_pretty_url>
  <para_id>14999</para_id>
  <related_resource_ids>7229132</related_resource_ids>
  <related_resource_ids>7229133</related_resource_ids>
  <related_resource_ids>7229134</related_resource_ids>
  <related_resource_ids>7229136</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11978</term_id>
  <id>15048</id>
  <title>Urethral Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Urethral Cancer</field_short_title>
  <field_page_description>Urethral cancer is rare and is more common in men than in women. Urethral cancer can metastasize (spread) quickly to tissues around the urethra and has often spread to nearby lymph nodes by the time it is diagnosed. Start here to find information on urethral cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about urethral cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15048</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1065961</id>
  <title>DINO RNA Molecule Triggers Anticancer Response in Damaged Cells</title>
  <langcode>en</langcode>
  <field_short_title>DINO RNA Molecule Triggers Anticancer Response in Damaged Cells</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a noncoding RNA called DINO, which helps accelerate the cellular self-destruct process that prevents tumor development.</field_page_description>
  <field_feature_card_description>A type of RNA may play a critical role in preventing tumor development.</field_feature_card_description>
  <field_list_description>Studies in cells and mice found that, in cells with damaged DNA, a noncoding RNA called DINO stabilizes the p53 protein and guides the cells into cell death, preventing tumor development.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-24</field_date_posted>
  <field_date_reviewed>2016-10-24</field_date_reviewed>
  <field_pretty_url>dino-p53</field_pretty_url>
  <para_id>1065961</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1066212</id>
  <title>Structure of KRAS4b-PDE&amp;delta; Complex</title>
  <langcode>en</langcode>
  <field_short_title>Structure of the KRAS4b-PDEδ complex</field_short_title>
  <field_page_description>The structure of farnesylated, carboxymethylated KRAS4b protein complexed with its chaperone PDEδ has been solved.</field_page_description>
  <field_feature_card_description>In a new RAS Dialogue, Dhirendra Simanshu describes how the structure of KRAS4b complexed with a chaperone illuminates a long-standing puzzle of cancer therapy.</field_feature_card_description>
  <field_list_description>The structure of fully modified KRAS4b protein complexed to its chaperone PDEδ has been solved.  All the amino acids of KRAS4b are seen, including the entire HVR.  The structure shows how PDEδ can bind both farnesylated and geranylgeranylated KRAS4b protein.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-02</field_date_posted>
  <field_date_reviewed>2016-11-01</field_date_reviewed>
  <field_pretty_url>kras4b-pded-complex</field_pretty_url>
  <para_id>1066212</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066609</id>
  <title>CDC Updates Recommendations on HPV Vaccine</title>
  <langcode>en</langcode>
  <field_short_title>CDC Updates Recommendations on HPV Vaccine</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about an updated CDC recommendation that those younger than age 15 need only two doses of the HPV vaccine instead of three.</field_page_description>
  <field_feature_card_description>Two doses of the vaccine, instead of three, are recommended for those younger than age 15.</field_feature_card_description>
  <field_list_description>Updated CDC recommendations advise those younger than age 15 need only two doses of the HPV vaccine instead of three.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-14</field_date_posted>
  <field_date_reviewed>2016-11-10</field_date_reviewed>
  <field_pretty_url>hpv-vaccine-doses</field_pretty_url>
  <para_id>1066609</para_id>
  <related_resource_ids>6816190</related_resource_ids>
  <related_resource_ids>6816191</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1067183</id>
  <title>Device Uses Cancer Cells' Mass to Predict Response to Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Device May Predict Cancer Treatment Response</field_short_title>
  <field_page_description>A blog post on a study demonstrating the ability of a device, called a suspended microchannel resonator, to predict cancer cell death or growth following cancer treatment.</field_page_description>
  <field_feature_card_description>Measuring change in mass of cancer cells predicted whether the cells were sensitive or resistant to a particular drug.</field_feature_card_description>
  <field_list_description>Scientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology could potentially help clinicians determine whether a drug effectively kills cancer cells.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-22</field_date_posted>
  <field_date_reviewed>2016-11-22</field_date_reviewed>
  <field_pretty_url>cell-mass-treatment-response</field_pretty_url>
  <para_id>1067183</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1069132</id>
  <title>Targeting the KRAS G12D Neoantigen to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeting the KRAS G12D Neoantigen to Treat Cancer</field_short_title>
  <field_page_description>Steven A. Rosenberg and colleagues at the National Cancer Institute have treated a patient with metastatic colon cancer by using the patient's own cells to target the G12D mutation in KRAS.</field_page_description>
  <field_feature_card_description>In a new RAS Dialogue, Jim Hartley of the NCI RAS Initiative describes an innovative treatment for cancers caused by the G12D mutation of KRAS.</field_feature_card_description>
  <field_list_description>The G12D mutation of the oncogene KRAS causes thousands of cancers every year. Steven Rosenberg and colleagues at the National Cancer Institute have treated a patient with metastatic colon cancer by using the patient's own cells to target KRAS G12D.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-15</field_date_posted>
  <field_date_reviewed>2016-12-15</field_date_reviewed>
  <field_pretty_url>immunotherapy-kras-g12d-rosenberg</field_pretty_url>
  <para_id>1069132</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>937976</term_id>
  <id>1069449</id>
  <title>Identifying Novel Drug Combinations to Overcome Treatment Resistance</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combinations to Overcome Treatment Resistance</field_short_title>
  <field_page_description>A review of current research identifying and testing drug combination approaches that have the potential to overcome or delay resistance to cancer treatment.</field_page_description>
  <field_feature_card_description>Scientists are exploring drug combinations to overcome treatment resistance.</field_feature_card_description>
  <field_list_description>Drug resistance is a common occurrence that can lead to tumor relapse and patient death. Scientists are exploring combinations of different cancer drugs that have the potential to kill more cancer cells and overcome or delay drug resistance.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-21</field_date_posted>
  <field_date_reviewed>2016-12-20</field_date_reviewed>
  <field_pretty_url>drug-combo-resistance</field_pretty_url>
  <para_id>1069449</para_id>
  <related_resource_id>6470008</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1069570</id>
  <title>CGH Director strengthens research and control partnerships in Kenya</title>
  <langcode>en</langcode>
  <field_short_title>CGH Director strengthens research and control partnerships in Kenya</field_short_title>
  <field_page_description>NCI’s Center for Global Health director Edward Trimble met with Kenyan partners in December 2016 to increase engagement in cancer control strategy.</field_page_description>
  <field_feature_card_description>Partners aim to increase coordination of Kenya cancer control strategy with MOU </field_feature_card_description>
  <field_list_description>Center for Global Health director Edward Trimble met with Kenyan partners and stakeholders in December 2016 to reiterate longer-term engagement to support national cancer control planning and expanded research capacity.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-12-21</field_date_posted>
  <field_date_reviewed>2016-12-21</field_date_reviewed>
  <field_pretty_url>trimble-partnerships-kenya</field_pretty_url>
  <para_id>1069570</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1071062</id>
  <title>The Global Economic Burden of Tobacco: An Interview with Dr. Mark Parascandola</title>
  <langcode>en</langcode>
  <field_short_title>Economic Study of Global Tobacco Burden</field_short_title>
  <field_page_description>In an interview on Cancer Currents, Dr. Mark Parascandola discusses findings from an economics study showing that, globally, tobacco use burdens economies with more than US $1 trillion annually in health care costs and lost productivity.</field_page_description>
  <field_feature_card_description>Global cost of tobacco tops $1 trillion, but control strategies can be "highly cost effective," says NCI’s Dr. Mark Parascandola.</field_feature_card_description>
  <field_list_description>NCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-18</field_date_posted>
  <field_date_reviewed>2017-01-17</field_date_reviewed>
  <field_pretty_url>tobacco-global-economic-burden</field_pretty_url>
  <para_id>1071062</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1074765</id>
  <title>Democratizing Access to CCG Data: Cancer Genomics Cloud Pilots</title>
  <langcode>en</langcode>
  <field_short_title>Clouds Democratize CCG Data</field_short_title>
  <field_page_description>The cloud pilots provide access to NCI data and computational resources in the cloud, enabling diverse researchers to advance precision oncology.</field_page_description>
  <field_list_description>Big data is essential to cancer research. Yet as we collect more cancer data, we limit the number of researchers who can participate. By enabling access to NCI data and computational resources in the cloud, the cloud pilots contribute to a cancer data ecosystem that enables diverse researchers to advance precision oncology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-07</field_date_posted>
  <field_date_reviewed>2017-03-06</field_date_reviewed>
  <field_pretty_url>cloud-pilots-democratize-data</field_pretty_url>
  <para_id>1074765</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1080186</id>
  <title>Avelumab Becomes First Approved Treatment for Patients with Merkel Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>Avelumab First Approved Drug for Rare Skin Cancer </field_short_title>
  <field_page_description>A Cancer Currents blog on the FDA’s first-ever approval of a drug for the rare skin cancer Merkel cell carcinoma and updated data on patients’ tumor responses.</field_page_description>
  <field_feature_card_description>Updated data show sustained tumor reductions in responding patients.</field_feature_card_description>
  <field_list_description>The FDA has approved the first drug ever for the rare skin cancer, Merkel cell carcinoma, and updated data show an improved tumor response rate and that patients’ tumors continued to respond for at least a year.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-03</field_date_posted>
  <field_date_reviewed>2017-04-02</field_date_reviewed>
  <field_pretty_url>avelumab-fda-merkel-cell</field_pretty_url>
  <para_id>1080186</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1080368</term_id>
  <id>1080369</id>
  <title>Cancer Moonshot&amp;#8480; Blue Ribbon Panel Members</title>
  <langcode>en</langcode>
  <field_short_title>Blue Ribbon Panel Members</field_short_title>
  <field_page_description>Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.</field_page_description>
  <field_feature_card_description>Blue Ribbon Panel Members</field_feature_card_description>
  <field_list_description>To ensure that the Cancer Moonshot's goals and approaches are grounded in the best science, the Moonshot Task Force consulted with external experts, including the presidentially appointed National Cancer Advisory Board (NCAB). A Blue Ribbon Panel of experts was established as a working group of the NCAB to assist the board in providing this advice.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-07</field_date_posted>
  <field_date_reviewed>2016-08-18</field_date_reviewed>
  <para_id>1080369</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1082116</id>
  <title>PARP Inhibitors May Be Effective in Brain, Other Cancers with IDH Mutations</title>
  <langcode>en</langcode>
  <field_short_title>PARP Inhibitors May Treat Cancers with IDH Mutations</field_short_title>
  <field_page_description>A Cancer Currents blog on studies that suggest brain and other cancers with an IDH mutation are susceptible to treatment with PARP inhibitors, such as olaparib.</field_page_description>
  <field_feature_card_description>These drugs exploit a weakness caused by the mutation—the inability to repair DNA.</field_feature_card_description>
  <field_list_description>Studies presented at the 2017 AACR annual meeting suggest that therapies which take advantage of the mutations in the IDH gene may be more effective than drugs that block it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-24</field_date_posted>
  <field_date_reviewed>2017-04-21</field_date_reviewed>
  <field_pretty_url>idh-mutation-parp</field_pretty_url>
  <para_id>1082116</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1082165</id>
  <title>Making Greater Progress Against Cancer—Not Just a Hope but a Reality</title>
  <langcode>en</langcode>
  <field_short_title>Making Greater Progress Against Cancer a Reality</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from Acting NCI Director Dr. Doug Lowy on the recent Annual Report to the Nation and how NCI is promoting further progress against cancer.</field_page_description>
  <field_feature_card_description>Cancer trends are encouraging, says Acting NCI Director Dr. Doug Lowy.</field_feature_card_description>
  <field_list_description>Acting NCI Director Dr. Doug Lowy discusses what he calls encouraging news in the most recent Annual Report to the Nation and how NCI is helping to achieve further progress against cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-04-21</field_date_posted>
  <field_date_reviewed>2017-04-21</field_date_reviewed>
  <field_pretty_url>lowy-report-to-nation</field_pretty_url>
  <para_id>1082165</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>836659</id>
  <title>When Someone You Love Has Advanced Cancer: Support for Caregivers</title>
  <langcode>en</langcode>
  <field_short_title>When Someone You Love Has Advanced Cancer</field_short_title>
  <field_page_description>Covers coping strategies and communication tips to address the concerns that cancer caregivers face when their loved one has been told that he or she has advanced cancer.</field_page_description>
  <field_feature_card_description>Covers coping strategies and communication tips to address the concerns that cancer caregivers face when their loved one has been told that he or she has advanced cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-03</field_date_reviewed>
  <field_pretty_url>when-someone-you-love-has-advanced-cancer</field_pretty_url>
  <para_id>836659</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>837258</id>
  <title>Treatment Choices for Men With Early-Stage Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Treatment Choices for Men With Early-Stage Prostate Cancer</field_short_title>
  <field_page_description>Covers the treatment options for early-stage prostate cancer, such as active surveillance, surgery, and radiation therapy, and helps men decide which treatment is the best for them.</field_page_description>
  <field_feature_card_description>Covers the treatment options for early-stage prostate cancer, such as active surveillance, surgery, and radiation therapy, and helps men decide which treatment is the best for them.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2014-10-04</field_date_reviewed>
  <field_pretty_url>understanding-prostate-cancer-treatment</field_pretty_url>
  <para_id>837258</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858160</term_id>
  <id>858277</id>
  <title>Talking with Your Health Care Team</title>
  <langcode>en</langcode>
  <field_short_title>Talking with Your Health Care Team</field_short_title>
  <field_page_description>talking to your doctor, ask questions, take notes, ask about costs</field_page_description>
  <field_feature_card_description>Tips to make it easier to talk with your doctors and learn about cancer and your treatment.</field_feature_card_description>
  <field_list_description>Tips to make it easier to talk with your doctors and learn about cancer and your treatment. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-14</field_date_reviewed>
  <para_id>858277</para_id>
  <related_resource_id>7127613</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>857991</term_id>
  <id>859577</id>
  <title>Self-Image and Sexuality</title>
  <langcode>en</langcode>
  <field_short_title>Self-Image &amp; Sexuality</field_short_title>
  <field_page_description>Cancer and its treatment can change how you look and feel about yourself. Learn to cope with body changes and issues related to sexuality and intimacy.</field_page_description>
  <field_feature_card_description>Cancer can affect your looks and also how you feel about your body and physical intimacy. Here are steps to help you cope. </field_feature_card_description>
  <field_list_description>Cancer and its treatment can affect how you look and feel about yourself and your body. There are steps you can take to cope with body changes and issues related to sexuality and intimacy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859577</para_id>
  <related_resource_ids>7234147</related_resource_ids>
  <related_resource_ids>7234148</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858174</term_id>
  <id>859630</id>
  <title>Going Back to Work</title>
  <langcode>en</langcode>
  <field_short_title>Going Back to Work</field_short_title>
  <field_page_description>Information and guidance on going back to work, including talking with and relating to others at work, your legal rights, and handling problems at work.</field_page_description>
  <field_feature_card_description>Information and guidance on going back to work, including talking with and relating to others at work, your legal rights, and handling problems at work. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859630</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858179</term_id>
  <id>859637</id>
  <title>A New Normal</title>
  <langcode>en</langcode>
  <field_short_title>A New Normal</field_short_title>
  <field_page_description>Adjusting to physical and emotional changes after cancer treatment and tips on coping with fear of recurrence.</field_page_description>
  <field_feature_card_description>Adjusting to physical and emotional changes after cancer treatment and tips on coping with fear of recurrence.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859637</para_id>
  <related_resource_id>7120030</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066679</id>
  <title>More Immunotherapy Options Approved for Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>More Immunotherapy Options Approved for Lung Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about the FDA approval of the checkpoint inhibitors atezolizumab and pembrolizumab for patients with the most common form of lung cancer.</field_page_description>
  <field_feature_card_description>Approvals include a new checkpoint inhibitor and expanded approval of another.</field_feature_card_description>
  <field_list_description>The FDA has approved atezolizumab and expanded the approval of pembrolizumab for some patients with non-small cell lung cancer.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-17</field_date_posted>
  <field_date_reviewed>2016-11-14</field_date_reviewed>
  <field_pretty_url>fda-atezolizumab-pembrolizumab-lung</field_pretty_url>
  <para_id>1066679</para_id>
  <related_resource_ids>6890281</related_resource_ids>
  <related_resource_ids>6890284</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11826</term_id>
  <id>849987</id>
  <title>Breast Changes and Conditions</title>
  <langcode>en</langcode>
  <field_short_title>Breast Changes and Conditions</field_short_title>
  <field_page_description>Breast changes include benign conditions and those that increase the risk of breast cancer. Symptoms and treatment of breast conditions such as ADH, ALH, cysts, DCIS, and LCIS are explained to women who may have received an abnormal mammogram finding.</field_page_description>
  <field_feature_card_description>Including changes that are benign (not cancer) and those that may increase a woman’s risk of cancer.</field_feature_card_description>
  <field_list_description>Breast changes and conditions such as adenosis, ADH, ALH, cysts, DCIS, duct ectasia, fat necrosis, fibrocystic breast changes, fibroadenomas, and LCIS are explained, together with information about how these conditions are found, diagnosed, and treated.

</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-30</field_date_posted>
  <field_date_reviewed>2014-10-30</field_date_reviewed>
  <para_id>849987</para_id>
  <related_resource_ids>7166918</related_resource_ids>
  <related_resource_ids>7166919</related_resource_ids>
  <related_resource_ids>7166920</related_resource_ids>
  <related_resource_ids>7166921</related_resource_ids>
  <related_resource_ids>7166925</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>857987</term_id>
  <id>858130</id>
  <title>Feelings and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Feelings and Cancer</field_short_title>
  <field_page_description>Ways to cope with your emotions and manage the emotional effects of cancer, including anger, fear, stress, and depression.</field_page_description>
  <field_feature_card_description>Ways to cope with your emotions and manage the emotional effects of cancer, including anger, fear, stress, and depression.</field_feature_card_description>
  <field_list_description>Cancer can bring up a wide range of feelings, whether you're in treatment now, done with treatment, or a friend or family member. Learn tips for coping with the many emotions that arise with cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-14</field_date_reviewed>
  <para_id>858130</para_id>
  <related_resource_ids>7103280</related_resource_ids>
  <related_resource_ids>7103281</related_resource_ids>
  <related_resource_ids>7103282</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1065432</id>
  <title>Metabolomics Study Reveals another Energy Source for Cancer Cells </title>
  <langcode>en</langcode>
  <field_short_title>Study Reveals another Cancer Cell Energy Source</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post on a study showing that, instead of discarding lactate, cancer cells can use it to fuel biochemical reactions, support their growth.</field_page_description>
  <field_feature_card_description>Offers new insights into how cancer cells get energy to survive and grow.</field_feature_card_description>
  <field_list_description>Researchers have found that cancer cells can use the compound lactate to fuel biochemical reactions and to generate other compounds they need for growth and survival.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-20</field_date_posted>
  <field_date_reviewed>2016-10-20</field_date_reviewed>
  <field_pretty_url>cancer-metabolism-lactate</field_pretty_url>
  <para_id>1065432</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1066057</id>
  <title>‘Unexpected’ Vulnerability Creates Treatment Opportunity in Aggressive Type of Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>New Treatment Opportunity in Aggressive Lung Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a study that identified a way to target a key vulnerability in lung cancers that have mutations in the KRAS gene.</field_page_description>
  <field_feature_card_description>Suggests potential treatment opportunity in cancers with KRAS mutations.</field_feature_card_description>
  <field_list_description>A new study has identified a potentially critical vulnerability in lung cancers that have mutations in the KRAS gene, and showed that a drug already under study may be able to exploit it.

</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-27</field_date_posted>
  <field_date_reviewed>2016-10-27</field_date_reviewed>
  <field_pretty_url>nsclc-kras-xpo1</field_pretty_url>
  <para_id>1066057</para_id>
  <related_resource_id>6598414</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1067305</id>
  <title>Partnership in Cancer Control Planning Saves Lives</title>
  <langcode>en</langcode>
  <field_short_title>Partnership in Cancer Control Planning Saves Lives</field_short_title>
  <field_page_description>NCI’s Center for Global Health and partner Pink Ribbon Red Ribbon collaborate to reduce cervical and breast cancer in Zambia, Botswana, Ethiopia, and Tanzania.</field_page_description>
  <field_feature_card_description>CGH helps control cervical and breast cancer in Sub-Saharan Africa.</field_feature_card_description>
  <field_list_description>NCI’s Center for Global Health and partner Pink Ribbon Red Ribbon see success in large-scale training and collaboration efforts to address the growing burden of cervical and breast cancer in Zambia, Botswana, Ethiopia, and Tanzania.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-28</field_date_posted>
  <field_date_reviewed>2016-11-28</field_date_reviewed>
  <field_pretty_url>partnership-cancer-control-africa</field_pretty_url>
  <para_id>1067305</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1067780</term_id>
  <id>1067782</id>
  <title>Cancer Moonshot&amp;#8480; – Funding Opportunities</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Moonshot – Funding Opportunities</field_short_title>
  <field_page_description>NCI is accepting applications for research grants that support the Cancer Moonshot Blue Ribbon Panel recommendations to accelerate cancer research.</field_page_description>
  <field_feature_card_description>New opportunities announced for research grants that align with the goals of the Cancer Moonshot.</field_feature_card_description>
  <field_list_description>New Cancer Moonshot funding opportunities from NCI support goals articulated in the recommendations made by the Blue Ribbon Panel.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-12</field_date_posted>
  <field_date_reviewed>2017-09-27</field_date_reviewed>
  <para_id>1067782</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1068124</term_id>
  <id>1068129</id>
  <title>Interagency Oncology Task Force Fellowship</title>
  <langcode>en</langcode>
  <field_short_title>Interagency Oncology Task Force Fellowship</field_short_title>
  <field_page_description>In collaboration with FDA, these fellowships train scientists in research and research-related regulatory review, policies, and regulations to develop a skill set that bridges the two disparate processes.</field_page_description>
  <field_feature_card_description>NCI and FDA train scientists in research and regulatory review.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-12-06</field_date_posted>
  <field_date_reviewed>2016-12-06</field_date_reviewed>
  <para_id>1068129</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952662</term_id>
  <id>15076</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Genetics</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genetics</field_short_title>
  <field_page_description>Genetics of specific cancers and inherited cancer syndromes, and ethical, legal, and social concerns.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15076</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911286</term_id>
  <id>15170</id>
  <title>Photodynamic Therapy for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Photodynamic Therapy for Cancer</field_short_title>
  <field_page_description>A fact sheet that explains photodynamic therapy, how it is administered, and indications and side effects of treatment.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-09-06</field_date_posted>
  <field_date_reviewed>2011-09-06</field_date_reviewed>
  <field_pretty_url>photodynamic-fact-sheet</field_pretty_url>
  <para_id>15170</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911184</term_id>
  <id>15241</id>
  <title>Fluoridated Water</title>
  <langcode>en</langcode>
  <field_short_title>Fluoridated Water</field_short_title>
  <field_page_description>A fact sheet that reviews research about the possibility of a connection between fluoridated water and cancer.</field_page_description>
  <field_feature_card_description>A fact sheet about the possibility of a connection between fluoridated water and cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-02-21</field_date_posted>
  <field_date_reviewed>2017-05-15</field_date_reviewed>
  <field_pretty_url>fluoridated-water-fact-sheet</field_pretty_url>
  <para_id>15241</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858183</term_id>
  <id>859781</id>
  <title>Family Issues after Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Family Issues</field_short_title>
  <field_page_description>Discusses common family problems and issues that often occur after treatment and ways to cope.</field_page_description>
  <field_feature_card_description>Discusses common family problems and issues that often occur after treatment and ways to cope.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859781</para_id>
  <related_resource_ids>5781671</related_resource_ids>
  <related_resource_ids>5781672</related_resource_ids>
  <related_resource_ids>5781673</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858193</term_id>
  <id>859988</id>
  <title>Caregiving after Treatment Ends</title>
  <langcode>en</langcode>
  <field_short_title>Caregiving After Treatment Ends</field_short_title>
  <field_page_description>Even when treatment ends, both cancer survivors and caregivers are still dealing with a lot. Find information to help you understand and cope with the transition after cancer treatment. </field_page_description>
  <field_feature_card_description>Discusses the transition for cancer patients and caregivers after treatment and ways to cope.</field_feature_card_description>
  <field_list_description>Discusses the transition for cancer patients and caregivers after treatment and ways to cope.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-18</field_date_reviewed>
  <para_id>859988</para_id>
  <related_resource_ids>6780064</related_resource_ids>
  <related_resource_ids>6780066</related_resource_ids>
  <related_resource_ids>6780067</related_resource_ids>
  <related_resource_ids>6780068</related_resource_ids>
  <related_resource_ids>6780069</related_resource_ids>
  <related_resource_ids>6780070</related_resource_ids>
  <related_resource_ids>6780071</related_resource_ids>
  <related_resource_ids>6780072</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>860631</term_id>
  <id>860657</id>
  <title>Support for Teens When a Family Member has Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Support for Teens When a Family Member has Cancer</field_short_title>
  <field_page_description>When a parent, brother, or sister has been diagnosed with cancer, family members need extra support. Information to help teens learn how to cope, talk with family members, manage stress, and get support from counselors when a loved one has been diagnosed with, or is being treated for, cancer.</field_page_description>
  <field_feature_card_description>When a family member has cancer, everyone in the family needs support.</field_feature_card_description>
  <field_list_description>When a family member has cancer, whether it’s a parent or sibling, everyone in the family needs extra support.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2017-10-20</field_date_reviewed>
  <para_id>860657</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1070648</id>
  <title>For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint Pain</title>
  <langcode>en</langcode>
  <field_short_title>Drug Reduces Cancer Treatment-Related Joint Pain </field_short_title>
  <field_page_description>A Cancer Currents blog post about a clinical trial demonstrating that duloxetine (Cymbalta®) may reduce joint pain caused by aromatase inhibitors in women being treated for early-stage breast cancer. </field_page_description>
  <field_feature_card_description>Drug helps with common side effect of standard breast cancer therapy.</field_feature_card_description>
  <field_list_description>Researchers have found that duloxetine (Cymbalta®), a drug most commonly used to treat depression, may also reduce joint pain caused by aromatase inhibitors in some women being treated for early-stage breast cancer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-04</field_date_posted>
  <field_date_reviewed>2017-01-03</field_date_reviewed>
  <field_pretty_url>duloxetine-breast-joint-pain</field_pretty_url>
  <para_id>1070648</para_id>
  <related_resource_id>6617665</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1071546</id>
  <title>Shifts Seen in Tobacco Product Types Purchased in US</title>
  <langcode>en</langcode>
  <field_short_title>Shifts Seen in Tobacco Product Types Purchased in US</field_short_title>
  <field_page_description>A Cancer Currents blog post on a new study showing shifts in the types of tobacco products purchased in the United States, including increased purchases of snuff and large cigars.</field_page_description>
  <field_feature_card_description>U.S. consumers are purchasing fewer cigarettes and small cigars but more snuff and other tobacco products. </field_feature_card_description>
  <field_list_description>The consumption of cigarettes, small cigars, and chewing tobacco has declined over the past 15 years, according to a new study. These declines were partially offset by a rise in consumption of large cigars, pipe tobacco, and snuff.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-23</field_date_posted>
  <field_date_reviewed>2017-01-23</field_date_reviewed>
  <field_pretty_url>tobacco-consumption-shifting</field_pretty_url>
  <para_id>1071546</para_id>
  <related_resource_ids>6612105</related_resource_ids>
  <related_resource_ids>6612106</related_resource_ids>
  <related_resource_ids>6612110</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1099301</term_id>
  <id>1073391</id>
  <title>Selected Publications by Dr. Doug Lowy</title>
  <langcode>en</langcode>
  <field_short_title>Selected Publications by Doug Lowy</field_short_title>
  <field_page_description>In these selected published articles, Douglas R. Lowy, M.D., Deputy Director of the National Cancer Institute (NCI), presents some of his work in cancer research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-28</field_date_posted>
  <field_date_reviewed>2017-02-15</field_date_reviewed>
  <para_id>1073391</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1073661</id>
  <title>Conditional Reprogramming: An Interview with Dr. Richard Schlegel on Growing Cancer Cells</title>
  <langcode>en</langcode>
  <field_short_title>Conditional Reprogramming to Grow Cancer Cells</field_short_title>
  <field_page_description>An NCI Cancer Currents blog featuring Dr. Richard Schlegel discussing conditional reprogramming, a new cell culture technique for rapidly growing normal and tumor cells.</field_page_description>
  <field_feature_card_description>Conditional reprogramming can rapidly grow cultures of cancer cells from patients.</field_feature_card_description>
  <field_list_description>Dr. Richard Schlegel describes an innovative cell culture technique he helped to develop. Called conditional reprogramming, the technique can be used to rapidly establish cell cultures of normal and tumor cells from patient samples.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-22</field_date_posted>
  <field_date_reviewed>2017-02-21</field_date_reviewed>
  <field_pretty_url>schlegel-conditional-reprogramming</field_pretty_url>
  <para_id>1073661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1074403</id>
  <title>FDA Approves Nivolumab for Bladder Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Nivolumab for Bladder Cancer</field_short_title>
  <field_page_description>A Cancer Currents blog on the clinical trial that led the FDA to approve nivolumab for bladder cancer and what the approval means for patients.</field_page_description>
  <field_feature_card_description>FDA approval adds a new treatment option for patients whose cancer has progressed during or after initial treatment. </field_feature_card_description>
  <field_list_description>The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-01</field_date_posted>
  <field_date_reviewed>2017-02-28</field_date_reviewed>
  <field_pretty_url>fda-nivolumab-bladder</field_pretty_url>
  <para_id>1074403</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1074833</term_id>
  <id>1074842</id>
  <title>Center for Cancer Genomics Research</title>
  <langcode>en</langcode>
  <field_short_title>CCG Research</field_short_title>
  <field_page_description>NCI’s Center for Cancer Genomics aims to transform the diagnosis and treatment of cancer through structural, functional, and computational genomics research, and the promotion of data sharing. </field_page_description>
  <field_feature_card_description>Learn about CCG’s programs and collaborations, which study the molecular basis of cancer through structural, functional, and computational genomics research.</field_feature_card_description>
  <field_list_description>CCG studies cancer through structural, functional, and computational genomics, and promotes data sharing. The Genome Characterization Pipeline transforms tissue samples into rich, publicly available data that fuel innovation by the research community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-03-06</field_date_posted>
  <field_date_reviewed>2017-03-06</field_date_reviewed>
  <para_id>1074842</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1075757</id>
  <title>Researchers Use CRISPR Gene-Editing Tool to Help Turn Immune Cells against Tumors</title>
  <langcode>en</langcode>
  <field_short_title>CRISPR Gene-Editing Tool May Help Improve Cancer Immunotherapy</field_short_title>
  <field_page_description>A Cancer Currents blog about using the CRISPR gene-editing technology to genetically engineered immune cells and improve the ability of these cells to kill cancer cells in mice.</field_page_description>
  <field_feature_card_description>The gene-editing tool improved the ability of immune cells to kill cancer cells in mice.</field_feature_card_description>
  <field_list_description>Using a new tool for editing genomes, known as CRISPR, researchers have genetically engineered immune cells and improved the ability of these cells to kill cancer cells in mice. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-03-20</field_date_posted>
  <field_date_reviewed>2017-03-17</field_date_reviewed>
  <field_pretty_url>crispr-immunotherapy</field_pretty_url>
  <para_id>1075757</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>860258</term_id>
  <id>1084758</id>
  <title>Clinical Trial Results - Cancer Currents Blog</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trial Results</field_short_title>
  <field_page_description>Blog posts on practice-changing cancer clinical trials—including trials of targeted therapies, immunotherapies, and prevention drugs—from NCI Cancer Currents.</field_page_description>
  <field_feature_card_description>Blog posts from NCI Cancer Currents on practice-changing cancer clinical trials.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-12</field_date_posted>
  <field_date_reviewed>2017-05-12</field_date_reviewed>
  <field_pretty_url>clinical-trial-results</field_pretty_url>
  <para_id>1084758</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1085441</id>
  <title>ROS1+ Cancer Patients Partner to Increase Research</title>
  <langcode>en</langcode>
  <field_short_title>ROS1 Patient-Driven Research</field_short_title>
  <field_page_description>ROS1ders, a group of lung cancer patients who share a rare genetic abnormality, united to promote research by foundations, academics, and industry.</field_page_description>
  <field_feature_card_description>Meet the ROS1ders, a group of lung cancer patients with a rare gene fusion who have united to promote lifesaving research.</field_feature_card_description>
  <field_list_description>ROS1ders, a group of lung cancer patients who share a rare genetic abnormality involving the &lt;em&gt;ROS1&lt;/em&gt; gene, united to support each other and promote research. They formed the Global ROS1 Initiative, a collaboration between foundations, academic researchers, and industry that aims to improve outcomes for future patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-05-23</field_date_posted>
  <field_date_reviewed>2017-05-18</field_date_reviewed>
  <field_pretty_url>ros1-patient-driven-research</field_pretty_url>
  <para_id>1085441</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087084</id>
  <title>Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Test Could Reduce Unnecessary Prostate Biopsies</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study showing that two biomarkers in urine may help identify who does and doesn’t need a biopsy to detect a suspected prostate cancer.</field_page_description>
  <field_feature_card_description>Biomarkers in urine could help identify men with suspected prostate cancer.</field_feature_card_description>
  <field_list_description>Findings from a new study show testing for two biomarkers in urine may help some men avoid an unnecessary biopsy to detect a suspected prostate cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-09</field_date_posted>
  <field_date_reviewed>2017-06-08</field_date_reviewed>
  <field_pretty_url>biomarkers-urine-prostate-biopsy</field_pretty_url>
  <para_id>1087084</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087294</id>
  <title>Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Trastuzumab Emtansine for HER2-Positive Breast Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on results from the TH3RESA and EMILIA clinical trials showing trastuzumab emtansine (T-DM1) improved overall survival in patients with previously treated metastatic HER2-positive breast cancer.</field_page_description>
  <field_feature_card_description>Benefit seen even in patients previously treated with other HER2-targeted drugs.</field_feature_card_description>
  <field_list_description>Two clinical trials show that trastuzumab emtansine (T-DM1) improves survival compared with other standard treatments for patients with HER2-positive metastatic breast cancer that has progressed after treatment with other HER2-targeted drugs.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-14</field_date_posted>
  <field_date_reviewed>2017-06-13</field_date_reviewed>
  <field_pretty_url>trastuzumab-emtansine-breast-cancer</field_pretty_url>
  <para_id>1087294</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1087306</id>
  <title>Disease Dynamic Trial Listing Page</title>
  <langcode>en</langcode>
  <field_short_title>Disease Dynamic Trial Listing Page</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-06-13</field_date_posted>
  <field_date_reviewed>2017-06-13</field_date_reviewed>
  <field_pretty_url>disease</field_pretty_url>
  <para_id>1087306</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1087879</id>
  <title>FDA Approves Pembrolizumab for Tumors with Specific Genetic Features</title>
  <langcode>en</langcode>
  <field_short_title>Pembrolizumab Approved for Tumors with Specific Genetic Features</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on FDA’s approval of pembrolizumab for patients with mismatch repair deficient and microsatellite instability high tumors.</field_page_description>
  <field_feature_card_description>Pembrolizumab is approved for mismatch repair deficient and microsatellite instability high tumors.</field_feature_card_description>
  <field_list_description>FDA approved pembrolizumab for patients with solid tumors that have specific genetic features, called mismatch repair deficiency and high microsatellite instability. This is the first approval based on a genetic feature, rather than cancer type.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-20</field_date_posted>
  <field_date_reviewed>2017-06-19</field_date_reviewed>
  <field_pretty_url>fda-pembrolizumab-genetic-features</field_pretty_url>
  <para_id>1087879</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1088669</id>
  <title>Introducing DAVE: Online Analysis Tools for the Genomic Data Commons</title>
  <langcode>en</langcode>
  <field_short_title>DAVE Provides New Tools for Genomic Data Commons</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post from NCI’s Dr. Louis Staudt about the release of an online, open-access cancer research resource for the Genomic Data Commons called DAVE.</field_page_description>
  <field_feature_card_description>Online, open-access resource provides broad access to genomic analysis tools. </field_feature_card_description>
  <field_list_description>NCI has released an online, open-access cancer research resource for the Genomic Data Commons called the Data Analysis, Visualization, and Exploration Tools, or DAVE.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-29</field_date_posted>
  <field_date_reviewed>2017-06-29</field_date_reviewed>
  <field_pretty_url>gdc-dave-tools</field_pretty_url>
  <para_id>1088669</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>881600</id>
  <title>Promoting Cancer Control in Indonesia</title>
  <langcode>en</langcode>
  <field_short_title>Promoting Cancer Control in Indonesia</field_short_title>
  <field_page_description>CGH's Kalina Duncan travels to Indonesia on detail with the Ministry of Health this past spring to address important global issues of cancer control and cancer research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-15</field_date_posted>
  <field_date_reviewed>2014-12-15</field_date_reviewed>
  <field_pretty_url>promoting-cancer-control-in-indonesia</field_pretty_url>
  <para_id>881600</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>916478</term_id>
  <id>882397</id>
  <title>Strong Inorganic Acid Mists Containing Sulfuric Acid</title>
  <langcode>en</langcode>
  <field_short_title>Strong Inorganic Acid Mists Containing Sulfuric Acid</field_short_title>
  <field_page_description>Copper smelting and other manufacturing processes generate strong inorganic acid mists that can increase your risk of laryngeal and lung cancers. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-20</field_date_reviewed>
  <para_id>882397</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1092594</id>
  <title>NCI Program Supports Small Businesses to Advance Cancer Research Innovation – A Q&amp;A with Michael Weingarten</title>
  <langcode>en</langcode>
  <field_short_title>Supporting Small Business to Drive Cancer Research Innovation</field_short_title>
  <field_page_description>NCI’s SBIR program is offering funding to help small businesses develop innovative cancer-related therapies and technologies, including those prioritized by the Cancer Moonshot.</field_page_description>
  <field_feature_card_description>NCI is offering funds to spur the development of new cancer therapies and technologies.</field_feature_card_description>
  <field_list_description>NCI’s Small Business Innovation Research Program recently issued contract solicitations to spur the development of new cancer-related therapies and technologies, including seven opportunities specific to the Cancer Moonshot.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-21</field_date_posted>
  <field_date_reviewed>2017-08-17</field_date_reviewed>
  <field_pretty_url>sbir-contract-solicitations-cancer-moonshot</field_pretty_url>
  <para_id>1092594</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11908</term_id>
  <id>14581</id>
  <title>Gallbladder Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Gallbladder Cancer </field_short_title>
  <field_page_description>Gallbladder cancer is a rare cancer that is usually diagnosed late due a to lack of early signs and symptoms. It is sometimes found when the gallbladder is checked for gallstones or removed. Start here to find information on gallbladder cancer treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about gallbladder cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11888</term_id>
  <id>14587</id>
  <title>Cancers by Body Location/System</title>
  <langcode>en</langcode>
  <field_short_title>Cancers by Body Location/System</field_short_title>
  <field_page_description>A list of all cancers, organized by location and/or function in the body. Cancers on the list are linked to information about treatment, supportive care, screening, prevention, clinical trials, and other topics.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2010-07-09</field_date_reviewed>
  <para_id>14587</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11958</term_id>
  <id>14938</id>
  <title>Skin Cancer (Including Melanoma)—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Skin Cancer </field_short_title>
  <field_page_description>Skin cancer is the most common type of cancer. The main types of skin cancer are squamous cell carcinoma, basal cell carcinoma, and melanoma. Most deaths from skin cancer are caused by melanoma. Start here to find information on skin cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_list_description>Information about skin cancer treatment, prevention, causes, screening, clinical trials, research, and other topics from the National Cancer Institute.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14938</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1108288</id>
  <title>Cabozantinib Approval Expands Initial Treatment Options for Advanced Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Cabozantinib for Initial Treatment of Kidney Cancer</field_short_title>
  <field_page_description>FDA has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma. The approval adds another tyrosine kinase inhibitor to the available options for patients with advanced kidney cancer.</field_page_description>
  <field_feature_card_description>Cabozantinib (Cabometyx®) is approved for the initial treatment of advanced renal cell carcinoma.</field_feature_card_description>
  <field_list_description>The Food and Drug Administration has approved cabozantinib (Cabometyx®) as an initial treatment for patients with advanced renal cell carcinoma, the most common type of kidney cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-27</field_date_posted>
  <field_date_reviewed>2018-02-26</field_date_reviewed>
  <field_pretty_url>cabozantinib-fda-first-line-kidney</field_pretty_url>
  <para_id>1108288</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1111028</id>
  <title>Forging Military Partnerships to Empower the Cancer Research Enterprise</title>
  <langcode>en</langcode>
  <field_short_title>NCI Partners with VA, DoD for Cancer Research</field_short_title>
  <field_page_description>Partnerships and collaborations are an important component of NCI’s success. In this Cancer Currents blog post, NCI Director Dr. Norman Sharpless describes three efforts made possible by a memorandum of agreement with three US military institutions: the APOLLO network, NAVIGATE, and BD-STEP.</field_page_description>
  <field_feature_card_description>NCI Director describes three collaborative efforts: APOLLO, NAVIGATE, and BD-STEP.</field_feature_card_description>
  <field_list_description>Partnerships and collaborations are an important component of NCI’s success. NCI Director Dr. Norman Sharpless describes three efforts made possible by a memorandum of agreement with three US military institutions: the APOLLO network, NAVIGATE, and BD-STEP.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-27</field_date_posted>
  <field_date_reviewed>2018-03-26</field_date_reviewed>
  <field_pretty_url>sharpless-va-dod-collaborations</field_pretty_url>
  <para_id>1111028</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1112035</id>
  <title>Office of Cancer Genomics: Integration of Structural, Functional, and Computational Genomic Data Advances Precision Oncology</title>
  <langcode>en</langcode>
  <field_short_title>Collaborative Genomics Study Advances Precision Oncology</field_short_title>
  <field_page_description>A collaborative study conducted by two Office of Cancer Genomics (OCG) initiatives highlights the importance of integrating structural and functional genomics programs to improve cancer therapies, and more specifically, contribute to precision oncology treatments for children.</field_page_description>
  <field_feature_card_description>A collaborative study conducted by two OCG initiatives highlights the importance of integrating structural and functional genomics programs to improve cancer therapies, and more specifically, contribute to precision oncology treatments for children.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-04-05</field_date_posted>
  <field_date_reviewed>2018-04-02</field_date_reviewed>
  <field_pretty_url>ocg-collaborative-study</field_pretty_url>
  <para_id>1112035</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1112214</id>
  <title>Interactive App Improves Colorectal Cancer Screening Rates</title>
  <langcode>en</langcode>
  <field_short_title>App Improves Colorectal Cancer Screening Rates</field_short_title>
  <field_page_description>Colorectal cancer screening reduces deaths from the disease, yet about one-third of Americans aren’t up to date with screening. In this Cancer Currents blog post, learn what happened when people waiting for routine checkups could order their own screening test using a computer app.</field_page_description>
  <field_feature_card_description>Learn what happened when an app allowed people to order their own screening test.</field_feature_card_description>
  <field_list_description>Colorectal cancer screening reduces deaths from the disease, yet about one-third of Americans aren’t up to date with screening. Learn what happened when people waiting for routine checkups used an app that allowed them to order their own screening test.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-09</field_date_posted>
  <field_date_reviewed>2018-04-05</field_date_reviewed>
  <field_pretty_url>colorectal-cancer-screening-app-improves-rates</field_pretty_url>
  <para_id>1112214</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134584</term_id>
  <id>1134603</id>
  <title>Brain Tumors Through the Single-Cell RNA Sequencing Lens: Researcher Interview with Mario Suvà</title>
  <langcode>en</langcode>
  <field_short_title>Mario Suvà on Single-cell RNA Sequencing</field_short_title>
  <field_page_description>A neuropathologist talks about single-cell RNA sequencing technology and the brain cancer research it enables.</field_page_description>
  <field_feature_card_description>Researcher Interview on Single-Cell RNA Sequencing </field_feature_card_description>
  <field_list_description>Brain cancers are notoriously hard to study, model, and treat. Dr. Mario Suvà speaks about how single-cell RNA sequencing is helping researchers gain clarity on the origins, development, and response to treatment for these cancers.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-01-15</field_date_posted>
  <field_date_reviewed>2019-01-08</field_date_reviewed>
  <field_pretty_url>interview-scRNA-seq</field_pretty_url>
  <para_id>1134603</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1134352</term_id>
  <id>1136288</id>
  <title>Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Pembrolizumab to Treat Merkel Cell Carcinoma</field_short_title>
  <field_page_description>FDA has approved pembrolizumab (Keytruda) to treat people with locally advanced or metastatic Merkel cell carcinoma, a rare and deadly form of skin cancer.</field_page_description>
  <field_feature_card_description>The approval is for locally advanced or metastatic forms of the skin cancer.</field_feature_card_description>
  <field_list_description>FDA has approved pembrolizumab (Keytruda) to treat people with Merkel cell carcinoma, a rare and deadly form of skin cancer. The approval covers use of the drug to treat locally advanced or metastatic forms of the disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-02-04</field_date_posted>
  <field_date_reviewed>2019-01-30</field_date_reviewed>
  <field_pretty_url>pembrolizumab-merkel-cell-carcinoma-fda-approval</field_pretty_url>
  <para_id>1136288</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>911172</term_id>
  <id>1139566</id>
  <title>HPV and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>HPV and Cancer</field_short_title>
  <field_page_description>Human papillomaviruses (HPVs) are a group of more than 200 related viruses that can cause several cancers including cervical cancer, anal cancer, and oropharyngeal cancer. Learn more about how HPV is transmitted, the different types of HPV, and vaccines to prevent HPV.</field_page_description>
  <field_feature_card_description>Learn about the link between human papillomavirus (HPV) infection and cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-01</field_date_posted>
  <field_date_reviewed>2019-02-28</field_date_reviewed>
  <field_pretty_url>hpv-and-cancer</field_pretty_url>
  <para_id>1139566</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>105036</id>
  <title>Drugs Approved for Retinoblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Retinoblastoma</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for retinoblastoma. The list includes generic names and brand names. The drug names link to NCI’s Cancer Drug Information summaries. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-10-04</field_date_posted>
  <field_date_reviewed>2011-08-16</field_date_reviewed>
  <field_pretty_url>retinoblastoma</field_pretty_url>
  <para_id>105036</para_id>
  <related_resource_ids>6994929</related_resource_ids>
  <related_resource_ids>6994931</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>107272</id>
  <title>Cetuximab Combined with Oxaliplatin-Based Chemotherapy May Not Be Effective First-Line Treatment for Metastatic Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Cetuximab Plus Oxaliplatin May Not Be Effective Primary Treatment for Metastatic Colorectal Cancer</field_short_title>
  <field_page_description>In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer.</field_page_description>
  <field_feature_card_description>In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer.</field_feature_card_description>
  <field_list_description>In a randomized phase III trial, the addition of the targeted therapy cetuximab to oxaliplatin and fluoropyrimidine chemotherapy did not prolong survival or time to disease progression of patients with advanced colorectal cancer. The results were published on June 5, 2011 in The Lancet.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-08-30</field_date_posted>
  <field_date_reviewed>2011-08-30</field_date_reviewed>
  <field_pretty_url>cetuximab-chemo-no-benefit</field_pretty_url>
  <para_id>107272</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>11740</term_id>
  <id>109064</id>
  <title>Inclusion Criteria for NCI Cancer Genetics Services Directory</title>
  <langcode>en</langcode>
  <field_short_title>Inclusion Criteria for NCI Cancer Genetics Services Directory</field_short_title>
  <field_page_description>Professionals who provide services related to cancer genetics (cancer risk assessment, genetic counseling, genetic susceptibility testing, and others) must meet these criteria before applying to be listed in the National Cancer Institute's Cancer Genetics Services Directory. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2011-09-12</field_date_posted>
  <field_date_reviewed>2011-09-12</field_date_reviewed>
  <para_id>109064</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1127298</term_id>
  <id>633818</id>
  <title>Pediatric Terminology</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Terminology</field_short_title>
  <field_page_description>The National Institute of Child Health and Human Development (NICHD) works with NCI Enterprise Vocabulary Services (EVS) to provide standardized terminology for coding pediatric clinical trials and other research activities.
</field_page_description>
  <field_feature_card_description>National Institute of Child Health and Human Development (NICHD) and NCI EVS joint standardized terminology for coding pediatric clinical trials and other research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2013-09-05</field_date_posted>
  <field_date_reviewed>2017-03-31</field_date_reviewed>
  <para_id>633818</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1093697</id>
  <title>U.S. - China Program for Biomedical Research Cooperation</title>
  <langcode>en</langcode>
  <field_short_title>U.Sl - China Program for Biomedical Research Cooperation</field_short_title>
  <field_page_description>U.S. - China Program for Biomedical Research Cooperation Preliminary Program Review.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-08-28</field_date_posted>
  <field_date_reviewed>2017-08-28</field_date_reviewed>
  <field_pretty_url>international-bilateral-programs-china</field_pretty_url>
  <para_id>1093697</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1096125</id>
  <title>Working with India to Advance Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Working with India to Advance Cancer Research </field_short_title>
  <field_page_description>CGH visits India to further develop our collaboration in cancer research.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-15</field_date_posted>
  <field_date_reviewed>2017-09-15</field_date_reviewed>
  <field_pretty_url>India-collaboration</field_pretty_url>
  <para_id>1096125</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1099118</term_id>
  <id>1099174</id>
  <title>Supporting Cancer Research Through Priority initiatives at NCI</title>
  <langcode>en</langcode>
  <field_short_title>Supporting Cancer Research Priority Initiatives</field_short_title>
  <field_page_description>CRS leads priority initiatives to support cancer research to advance scientific knowledge and help people live longer, healthier lives. Learn more about the Resources for Cancer Researchers portal, Team Science, and Idea Generation with NCI staff.</field_page_description>
  <field_feature_card_description>Learn about CRS priority initaitives focused on supporting cancer research and advancing scientific knowledge.</field_feature_card_description>
  <field_list_description>CRS leads and supports priority initiatives in support of NCI's mission to advance scientific knowledge and help people live longer, healthier lives. Learn more about the Resources for Cancer Researchers portal, Team Science, and Idea Generation.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-13</field_date_posted>
  <field_date_reviewed>2017-10-26</field_date_reviewed>
  <para_id>1099174</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099213</id>
  <title>TMIST Trial Aims to Provide Clarity on Breast Cancer Screening Approaches</title>
  <langcode>en</langcode>
  <field_short_title>TMIST Trial Comparing Breast Cancer Screening Approaches</field_short_title>
  <field_page_description>TMIST, a breast cancer screening clinical trial, is comparing tomosynthesis, or 3D mammography, and 2D digital mammography, as this Cancer Currents article explains.</field_page_description>
  <field_feature_card_description>This large nationwide trial is comparing 2D vs 3D mammography.</field_feature_card_description>
  <field_list_description>A large nationwide clinical trial called TMIST has been launched to compare two techniques used for mammograms: tomosynthesis, often called 3D mammography, and standard 2D digital mammography.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-30</field_date_posted>
  <field_date_reviewed>2017-10-26</field_date_reviewed>
  <field_pretty_url>tmist-breast-cancer-screening</field_pretty_url>
  <para_id>1099213</para_id>
  <related_resource_id>6765625</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1099372</id>
  <title>Glutamine, Cystine, and Cancer Susceptibilities</title>
  <langcode>en</langcode>
  <field_short_title>Glutamine, Cystine, and Cancer Susceptibilities</field_short_title>
  <field_page_description>Cancer cells generate increased amounts of toxic ROS. Recent papers show how understanding how cancers deal with ROS can lead to therapeutic opportunities.</field_page_description>
  <field_feature_card_description>Understanding how cancers deal with ROS can lead to new therapies.</field_feature_card_description>
  <field_list_description>The rapid growth of cancer cells generates increased amounts of toxic reactive oxygen species (ROS). Four recent papers show how understanding how cancers deal with ROS can lead to therapeutic opportunities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-30</field_date_posted>
  <field_date_reviewed>2017-10-30</field_date_reviewed>
  <field_pretty_url>glutamine-cystine-ros</field_pretty_url>
  <para_id>1099372</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1099540</id>
  <title>HIV and Cancer Interaction Highlights Need to Address Disease Stigma</title>
  <langcode>en</langcode>
  <field_short_title>HIV and Cancer Interaction Highlights Need to Address Disease Stigma</field_short_title>
  <field_page_description>The global landscape of disease highlights disparities that exist between nations.  An estimated 36 million people worldwide live with HIV and AIDS, of which only 1 million are located within the United States.  While the diagnosis of a life-threatening disease can be devastating, individuals with HIV and AIDS frequent</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-11-02</field_date_posted>
  <field_date_reviewed>2017-11-02</field_date_reviewed>
  <field_pretty_url>stigma</field_pretty_url>
  <para_id>1099540</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1099823</id>
  <title>Study Tracks the Evolution of Treatment Resistance in Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Tracking Treatment Resistance in Metastatic Breast Cancer</field_short_title>
  <field_page_description>In women with metastatic breast cancer that is resistant to available treatments, a new study suggests that their tumors may have common vulnerabilities.</field_page_description>
  <field_feature_card_description>Cells in treatment-resistant tumors may have common vulnerabilities.</field_feature_card_description>
  <field_list_description>A new study suggests that the cells in treatment-resistant tumors in women with metastatic breast cancer share important characteristics that could potentially make tumors vulnerable to therapies that otherwise might not have been considered.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-07</field_date_posted>
  <field_date_reviewed>2017-11-06</field_date_reviewed>
  <field_pretty_url>metastatic-breast-cancer-treatment-resistance-evolution</field_pretty_url>
  <para_id>1099823</para_id>
  <related_resource_id>6780201</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100184</id>
  <title>Alternate Driver of Treatment-Resistant Prostate Cancer Identified</title>
  <langcode>en</langcode>
  <field_short_title>New Subtype of Treatment-Resistant Prostate Cancer Identified</field_short_title>
  <field_page_description>An emerging subtype of treatment-resistant metastatic prostate cancer can grow without help from androgen hormones, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Tumors use alternate communication route to fuel their survival and growth.</field_feature_card_description>
  <field_list_description>Researchers have identified an emerging subtype of metastatic prostate cancer that is resistant to therapies that block hormones that fuel the disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-14</field_date_posted>
  <field_date_reviewed>2017-11-14</field_date_reviewed>
  <field_pretty_url>prostate-cancer-resistant-new-subtype</field_pretty_url>
  <para_id>1100184</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>14625</id>
  <title>Paget Disease of the Breast</title>
  <langcode>en</langcode>
  <field_short_title>Paget Disease of the Breast</field_short_title>
  <field_page_description>A fact sheet about Paget disease of the breast, a rare type of cancer that is sometimes called Paget disease of the nipple or mammary Paget disease.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-05-21</field_date_posted>
  <field_date_reviewed>2012-04-10</field_date_reviewed>
  <field_pretty_url>paget-breast-fact-sheet</field_pretty_url>
  <para_id>14625</para_id>
  <related_resource_ids>6983587</related_resource_ids>
  <related_resource_ids>6983588</related_resource_ids>
  <related_resource_ids>6983593</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952687</term_id>
  <id>14637</id>
  <title>PDQ&amp;reg; Cancer Genetics Editorial Board</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genetics Editorial Board</field_short_title>
  <field_page_description>Experts in the fields of epidemiology, primary care, ethics, law, psychology, social sciences, and medical genetics.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2002-05-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14637</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11920</term_id>
  <id>14653</id>
  <title>Kidney (Renal Cell) Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Kidney Cancer</field_short_title>
  <field_page_description>Kidney cancer can develop in adults and children. The main types of kidney cancer are renal cell cancer, transitional cell cancer, and Wilms tumor. Certain inherited conditions increase the risk of kidney cancer. Start here to find information on kidney cancer treatment, research, and statistics.</field_page_description>
  <field_list_description>NCI's gateway for information about Kidney Cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14653</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11890</term_id>
  <id>14756</id>
  <title>Cervical Cancer—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Cervical Cancer </field_short_title>
  <field_page_description>Cervical cancer is the fourth most common cancer in women worldwide. The primary risk factor for cervical cancer is human papillomavirus (HPV) infection. Start here to find evidence-based information on cervical cancer treatment, causes and prevention, screening, research, and statistics.</field_page_description>
  <field_feature_card_description>When caught early, cervical cancer is very treatable. Learn about risk factors and treatment.</field_feature_card_description>
  <field_list_description>NCI's gateway for information about cervical cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14756</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911291</term_id>
  <id>14875</id>
  <title>Harms of Cigarette Smoking and Health Benefits of Quitting</title>
  <langcode>en</langcode>
  <field_short_title>Harms of Cigarette Smoking and Health Benefits of Quitting</field_short_title>
  <field_page_description>A fact sheet that lists some of the cancer-causing chemicals in tobacco smoke and describes the health problems caused by cigarette smoking and the benefits of quitting.</field_page_description>
  <field_feature_card_description>Get the facts about the health problems caused by cigarette smoking and the benefits of quitting.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-21</field_date_posted>
  <field_date_reviewed>2017-12-19</field_date_reviewed>
  <field_pretty_url>cessation-fact-sheet</field_pretty_url>
  <para_id>14875</para_id>
  <related_resource_ids>6810673</related_resource_ids>
  <related_resource_ids>6810674</related_resource_ids>
  <related_resource_ids>6810675</related_resource_ids>
  <related_resource_ids>6810676</related_resource_ids>
  <related_resource_ids>6810681</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911172</term_id>
  <id>15074</id>
  <title>HIV Infection and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>HIV Infection and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that describes the increased risk of certain types of cancer by people infected with HIV. </field_page_description>
  <field_feature_card_description>Persons with HIV are at increased risk of certain types of cancer. Learn more from this fact sheet, including ways to lower the risk or find cancer early.</field_feature_card_description>
  <field_list_description>A fact sheet that describes the increased risk of certain types of cancer by people infected with HIV. These cancers include Kaposi sarcoma, Hodgkin and non-Hodgkin lymphoma, and cancers of the anus, cervix, liver, and lung.  Also describes what people with HIV infection can do to lower their risk of cancer or find cancer early.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-05</field_date_posted>
  <field_date_reviewed>2017-09-14</field_date_reviewed>
  <field_pretty_url>hiv-fact-sheet</field_pretty_url>
  <para_id>15074</para_id>
  <related_resource_ids>7267699</related_resource_ids>
  <related_resource_ids>7267700</related_resource_ids>
  <related_resource_ids>7267701</related_resource_ids>
  <related_resource_ids>7267702</related_resource_ids>
  <related_resource_ids>7267703</related_resource_ids>
  <related_resource_ids>7267706</related_resource_ids>
  <related_resource_ids>7267733</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938026</term_id>
  <id>15160</id>
  <title>Treatment Regimen Extends Survival for Women with Cervical Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Treatment Extends Survival for Women with Cervical Cancer</field_short_title>
  <field_page_description>Patients with locally advanced cervical cancer who received gemcitabine (Gemzar&amp;reg;) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-06-29</field_date_posted>
  <field_date_reviewed>2011-10-20</field_date_reviewed>
  <field_pretty_url>gemcitabine-improves-survival</field_pretty_url>
  <para_id>15160</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>916821</term_id>
  <id>15247</id>
  <title>Research Program Contacts</title>
  <langcode>en</langcode>
  <field_short_title>Research Program Contacts</field_short_title>
  <field_page_description>Contact NCI staff about funding announcements, grants, and investigator-initiated awards.</field_page_description>
  <field_feature_card_description>Contact NCI staff about funding announcements, grants, and investigator-initiated awards.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15247</para_id>
  <related_resource_id>7146435</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938410</term_id>
  <id>15059</id>
  <title>PDQ&amp;reg; Editorial Boards</title>
  <langcode>en</langcode>
  <field_short_title>Editorial Boards</field_short_title>
  <field_page_description>Description About the PDQ Editorial Boards</field_page_description>
  <field_list_description>Description of the PDQ editorial boards.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>15059</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>15185</id>
  <title>Calcium and Cancer Prevention</title>
  <langcode>en</langcode>
  <field_short_title>Calcium and Cancer Prevention</field_short_title>
  <field_page_description>A fact sheet that summarizes the results of studies on calcium and cancer prevention.  It includes information about dietary recommendations for calcium.</field_page_description>
  <field_list_description>A fact sheet that summarizes the results of studies on calcium and cancer prevention.  It includes information about dietary recommendations for calcium, and the amount of calcium in foods and supplements.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2009-05-04</field_date_posted>
  <field_date_reviewed>2009-05-04</field_date_reviewed>
  <field_pretty_url>calcium-fact-sheet</field_pretty_url>
  <para_id>15185</para_id>
  <related_resource_ids>6246257</related_resource_ids>
  <related_resource_ids>6246258</related_resource_ids>
  <related_resource_ids>6246260</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>903966</term_id>
  <id>867900</id>
  <title>CCG Contact and Staff</title>
  <langcode>en</langcode>
  <field_short_title>CCG Contact &amp; Staff</field_short_title>
  <field_page_description>Contact information and staff listing for the Center for Cancer Genomics Office of the Director, Office of Cancer Genomics, and the Cancer Genome Atlas Program Office.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2014-12-05</field_date_reviewed>
  <para_id>867900</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>869765</term_id>
  <id>869871</id>
  <title>Aflatoxins</title>
  <langcode>en</langcode>
  <field_short_title>Aflatoxins</field_short_title>
  <field_page_description>Learn about aflatoxins, a family of toxins associated with an increased risk of liver cancer. Aflatoxins are produced by certain fungi found on agricultural crops such as maize (corn), peanuts, cottonseed, and tree nuts. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2018-12-28</field_date_reviewed>
  <para_id>869871</para_id>
  <related_resource_ids>7268112</related_resource_ids>
  <related_resource_ids>7268113</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>860262</term_id>
  <id>873808</id>
  <title>Method for Identifying Combination Therapies to Combat Treatment Resistance Shows Promise</title>
  <langcode>en</langcode>
  <field_short_title>Method for Studying Treatment Resistance Shows Promise</field_short_title>
  <field_page_description>A blog post about a method for studying treatment resistance</field_page_description>
  <field_feature_card_description>Researchers have reported on a method for studying treatment resistance that may identify combinations of targeted therapies that can help to combat resistance in some patients. </field_feature_card_description>
  <field_list_description>Researchers from the Massachusetts General Hospital Cancer Center in Boston have reported on a method for studying treatment resistance that may identify combinations of targeted therapies that can help to combat resistance in some patients. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-12</field_date_posted>
  <field_date_reviewed>2014-12-12</field_date_reviewed>
  <field_pretty_url>treatment-resistance</field_pretty_url>
  <para_id>873808</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>881839</term_id>
  <id>881840</id>
  <title>CRCHD Mission</title>
  <langcode>en</langcode>
  <field_short_title>Mission</field_short_title>
  <field_page_description>The National Cancer Institute (NCI) established the Center to Reduce Cancer Health Disparities (CRCHD) in 2001 to help reduce the unequal burden of cancer in our society.</field_page_description>
  <field_feature_card_description>NCI established CRCHD in 2001 to help reduce the unequal burden of cancer </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-12-15</field_date_reviewed>
  <para_id>881840</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882332</term_id>
  <id>882333</id>
  <title>Vinyl Chloride</title>
  <langcode>en</langcode>
  <field_short_title>Vinyl Chloride</field_short_title>
  <field_page_description>Learn about vinyl chloride, which can raise the  risk of a rare form of liver cancer, as well as brain and lung cancers, and leukemia and lymphoma. Vinyl chloride is used primarily to make PVC, a substance used in products such as pipes.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2018-12-28</field_date_reviewed>
  <para_id>882333</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>917510</term_id>
  <id>882379</id>
  <title>Soot</title>
  <langcode>en</langcode>
  <field_short_title>Soot</field_short_title>
  <field_page_description>Learn about soot, which can raise the risk of scrotal and other skin cancers, as well as lung, esophageal, and bladder cancers. Soot is a byproduct of the burning of carbon-containing materials, such as wood, fuel oil, plastics, and household refuse. Chimney sweeps face the highest risk.</field_page_description>
  <field_list_description>Learn about soot, which can raise the risk of scrotal and other skin cancers, as well as lung, esophageal, and bladder cancers</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-20</field_date_reviewed>
  <para_id>882379</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938142</term_id>
  <id>225392</id>
  <title>Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer</field_short_title>
  <field_page_description>In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks.</field_page_description>
  <field_feature_card_description>In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks.</field_feature_card_description>
  <field_list_description>In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2012-03-07</field_date_posted>
  <field_date_reviewed>2012-03-07</field_date_reviewed>
  <field_pretty_url>valproic-acid</field_pretty_url>
  <para_id>225392</para_id>
  <related_resource_ids>6496433</related_resource_ids>
  <related_resource_ids>6496434</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922399</term_id>
  <id>253797</id>
  <title>Colonoscopy Reduces Risk of Death from Colorectal Cancer in High-Risk Patients</title>
  <langcode>en</langcode>
  <field_short_title>Colonoscopy Reduces Risk of Death from Colorectal Cancer in High-Risk Patients</field_short_title>
  <field_page_description>Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half.</field_page_description>
  <field_feature_card_description>Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half. </field_feature_card_description>
  <field_list_description>Long-term results from the National Polyp Study confirm that removing precancerous adenomas not only reduces the risk of colorectal cancer but also reduces the number of deaths from the disease by more than half. The findings appeared February 23, 2012, in the New England Journal of Medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2012-03-19</field_date_posted>
  <field_date_reviewed>2012-03-19</field_date_reviewed>
  <field_pretty_url>colonoscopy-reduces-deaths</field_pretty_url>
  <para_id>253797</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858185</term_id>
  <id>859757</id>
  <title>Late Side Effects of Cancer Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Late Side Effects</field_short_title>
  <field_page_description>Cancer treatment can cause late side effects that may not show up for months or years after treatment. These late effects may include heart and lung problems, bone loss, eye and hearing changes,  lymphedema, and other problems</field_page_description>
  <field_feature_card_description>Cancer survivors may have late side effects. Ways to manage include regular checkups, healthy eating, and exercise.</field_feature_card_description>
  <field_list_description>Cancer treatment can cause late side effects that may not show up for months or years after treatment. These late effects may include heart and lung problems, bone loss, eye and hearing changes,  lymphedema, and other problems.  </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859757</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>10962</term_id>
  <id>860046</id>
  <title>The Cancer Information Service (CIS)</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Information Service (CIS)</field_short_title>
  <field_page_description>The Cancer Information Service (CIS), NCI's contact center, provides accurate, up-to-date, and reliable information on cancer that is easy to understand. Trained information specialists provide personalized responses to a range of cancer questions.</field_page_description>
  <field_feature_card_description>The NCI offers free, scientifically accurate, and easy-to-understand information on a range of cancer topics in English and Spanish. Get live help from compassionate information specialists at 1-800-4-CANCER.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-11-18</field_date_posted>
  <field_date_reviewed>2014-11-18</field_date_reviewed>
  <para_id>860046</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903754</term_id>
  <id>860491</id>
  <title>Understanding Cancer Prognosis</title>
  <langcode>en</langcode>
  <field_short_title>Prognosis</field_short_title>
  <field_page_description>Prognosis describes how serious your cancer is and your chances of survival. Learn about survival statistics and how they are used to estimate prognosis.</field_page_description>
  <field_feature_card_description>Prognosis describes how serious your cancer is and your chances of survival. Learn about survival statistics and how they are used to estimate prognosis.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-11-24</field_date_posted>
  <field_date_reviewed>2018-08-29</field_date_reviewed>
  <para_id>860491</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>861460</term_id>
  <id>867268</id>
  <title>State and County Exposure Levels to I-131</title>
  <langcode>en</langcode>
  <field_short_title>State and County Exposure Levels to I-131</field_short_title>
  <field_page_description>Estimated average exposures to I-131 (iodine-131) for individuals living in the contiguous United States at the time of the Cold War, listed by state and county.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2003-08-01</field_date_posted>
  <field_date_reviewed>2014-12-04</field_date_reviewed>
  <field_pretty_url>stateandcountyexposure</field_pretty_url>
  <para_id>867268</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882283</term_id>
  <id>882315</id>
  <title>Wood Dust </title>
  <langcode>en</langcode>
  <field_short_title>Wood Dust </field_short_title>
  <field_page_description>Learn about wood dust, which can raise the risk of cancers of the paranasal sinuses and nasal cavity. High amounts of wood dust are produced in sawmills, and in the furniture-making, cabinet-making, and carpentry industries.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2018-12-28</field_date_reviewed>
  <para_id>882315</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>840891</term_id>
  <id>685623</id>
  <title>When Your Brother or Sister Has Cancer: A Guide for Teens</title>
  <langcode>en</langcode>
  <field_short_title>When Your Brother or Sister Has Cancer</field_short_title>
  <field_page_description>Help when a brother or sister has cancer. Learn how families cope and find support when a sibling has cancer. Tips to help you talk with your friends, deal with stress, and take care of your mind and body are also shared.</field_page_description>
  <field_feature_card_description>Information for teens and children who have a sibling with cancer. </field_feature_card_description>
  <field_list_description>Information to help teens cope and find support when a brother or sister has cancer. Help for teens whose sibling has cancer. Knowing how the cancer will be treated can help you to manage. Get tips to take care of yourself, talk with your friends, and help your sibling.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-17</field_date_posted>
  <field_date_reviewed>2013-12-26</field_date_reviewed>
  <field_pretty_url>sibling-has-cancer</field_pretty_url>
  <para_id>685623</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>708410</id>
  <title>Combination of Obinutuzumab Plus Chlorambucil Improves Survival in Patients with Chronic Lymphocytic Leukemia and Other Health Conditions</title>
  <langcode>en</langcode>
  <field_short_title>Obinutuzumab Plus Chlorambucil for Chronic Lymphocytic Leukemia</field_short_title>
  <field_page_description>A summary of results from an international phase III trial that compared the combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) versus chlorambucil alone, as well as obinutuzumab plus chlorambucil versus  rituximab (Rituxan®) plus chloramb</field_page_description>
  <field_feature_card_description>In an international randomized phase III  trial, previously untreated patients with chronic lymphocytic leukemia (CLL) and other health conditions who received a combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) lived longer without their</field_feature_card_description>
  <field_list_description>In an international randomized phase III trial, previously untreated patients with chronic lymphocytic leukemia and other health conditions who received a combination of obinutuzumab (Gazyva™) and chlorambucil (Leukeran®) lived longer without their disease getting worse (progression-free survival) and had better overall survival than patients who received chlorambucil alone. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-02-21</field_date_posted>
  <field_date_reviewed>2014-02-21</field_date_reviewed>
  <field_pretty_url>obinutuzumab-chlorambucil-cll</field_pretty_url>
  <para_id>708410</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>974322</term_id>
  <id>974323</id>
  <title>Bypass Budget Requests and NCI Appropriations</title>
  <langcode>en</langcode>
  <field_short_title>Bypass Requests and Appropriations</field_short_title>
  <field_page_description>NCI receives its budget from the United States Congress as part of the federal budget process. Find information about appropriations for each fiscal year since 1938 and budget requests since 1974.</field_page_description>
  <field_feature_card_description>Information about appropriations for each fiscal year since 1938 and budget requests since 1974.</field_feature_card_description>
  <field_list_description>Find information on NCI Appropriations for each fiscal year since 1938 and Bypass Budget requests since 1974. Also graphically displays the Bypass Budget compared to NCI Appropriations, since 1974.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-12-20</field_date_posted>
  <field_date_reviewed>2015-07-07</field_date_reviewed>
  <para_id>974323</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1094068</id>
  <title>New on NCI’s Websites for September 2017</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for September 2017</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-01</field_date_posted>
  <field_date_reviewed>2017-09-01</field_date_reviewed>
  <field_pretty_url>new-online-september-2017</field_pretty_url>
  <para_id>1094068</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1096310</id>
  <title>Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Nerve Damage after Chemotherapy for Breast Cancer</field_short_title>
  <field_page_description>Peripheral neuropathy can persist for 2 years or more in women with breast cancer treated with taxane chemotherapy drugs, as this Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>Many women report issues 2 years after treatment.</field_feature_card_description>
  <field_list_description>Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-19</field_date_posted>
  <field_date_reviewed>2017-09-18</field_date_reviewed>
  <field_pretty_url>peripheral-neuropathy-chemotherapy-breast-cancer</field_pretty_url>
  <para_id>1096310</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1096610</term_id>
  <id>1096590</id>
  <title>NCI Deputy Director</title>
  <langcode>en</langcode>
  <field_short_title>NCI Deputy Director</field_short_title>
  <field_page_description>Learn about Douglas R. Lowy, M.D., Deputy Director of the National Cancer Institute. His research interests include the biology of papillomaviruses and the regulation of normal and neoplastic cell growth.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-17</field_date_posted>
  <field_date_reviewed>2017-09-22</field_date_reviewed>
  <para_id>1096590</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1097513</id>
  <title>Timing and Sequence Critical for Immunotherapy Combination</title>
  <langcode>en</langcode>
  <field_short_title>Timing and Sequence Critical for Immunotherapy Combination</field_short_title>
  <field_page_description>Combining two immune checkpoint inhibitors, an OX40 agonist and a PD-1 inhibitor, may require a specific sequence, as this Cancer Currents post on a new study in mice explains.</field_page_description>
  <field_feature_card_description>Mouse study suggests timing, sequence of therapies are critical.</field_feature_card_description>
  <field_list_description>When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific sequence.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-03</field_date_posted>
  <field_date_reviewed>2017-10-03</field_date_reviewed>
  <field_pretty_url>combining-checkpoint-inhibitors</field_pretty_url>
  <para_id>1097513</para_id>
  <related_resource_id>6730424</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938032</term_id>
  <id>1097676</id>
  <title>Adding Immune-based Treatments to Standard Glioblastoma Therapy</title>
  <langcode>en</langcode>
  <field_short_title>Adding Immunotherapy and Vaccine to Standard Glioblastoma Therapy</field_short_title>
  <field_page_description>This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.</field_page_description>
  <field_feature_card_description>This clinical trial is testing immunotherapy and vaccine therapy for glioblastoma patients.</field_feature_card_description>
  <field_list_description>This phase 2 trial is testing standard therapy (surgery, radiation, and temozolomide)  plus the checkpoint inhibitor pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-11</field_date_posted>
  <field_date_reviewed>2017-10-05</field_date_reviewed>
  <field_pretty_url>immunotherapy-with-standard-glioblastoma-treatment</field_pretty_url>
  <para_id>1097676</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1097874</term_id>
  <id>1097875</id>
  <title>Access to the National Cryo-Electron Microscopy Facility</title>
  <langcode>en</langcode>
  <field_short_title>NCEF Access</field_short_title>
  <field_page_description>The National Cryo-EM Facility (NCEF) at NCI provides researchers access to the latest technology for high resolution imaging. Find information on how to request access to NCEF.</field_page_description>
  <field_feature_card_description>Information on how to submit projects to NCEF and get access to the latest technology for high resolution imaging.</field_feature_card_description>
  <field_list_description>Information on how to submit projects to the National Cryo-EM Facility (NCEF) and get access to the latest technology for high resolution imaging.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-13</field_date_posted>
  <field_date_reviewed>2017-10-09</field_date_reviewed>
  <para_id>1097875</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1098692</id>
  <title>Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Nivolumab Approved by FDA for Advanced Liver Cancer</field_short_title>
  <field_page_description>The immunotherapy nivolumab (Opdivo®) has been approved by FDA for patients with advanced liver cancer who have previously been treated with sorafenib (Nexavar®).</field_page_description>
  <field_feature_card_description>Accelerated approval for patients whose cancer progressed on targeted therapy.</field_feature_card_description>
  <field_list_description>The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-20</field_date_posted>
  <field_date_reviewed>2017-10-20</field_date_reviewed>
  <field_pretty_url>opdivo-fda-liver</field_pretty_url>
  <para_id>1098692</para_id>
  <related_resource_id>6783532</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1113671</id>
  <title>PACHE Trainee Spotlight: Roslyn Curry Featured on Thesis Thursday Radio Show</title>
  <langcode>en</langcode>
  <field_short_title>PACHE Trainee Spotlight: Roslyn Curry Featured on Thesis Thursday Radio Show</field_short_title>
  <field_page_description>Roslyn Curry, a student at the University of Arizona (UA), was featured on a local radio program, Thesis Thursday, where she discussed her participation in the U54 PACHE Partnership for Native American Cancer Prevention (NACP) as a research trainee in Dr. William Montfort’s Lab at the University of Arizona Cancer Cente</field_page_description>
  <field_list_description>Roslyn Curry, a student at the University of Arizona (UA), was featured on a local radio program, Thesis Thursday, where she discussed her participation in the U54 PACHE Partnership for Native American Cancer Prevention (NACP) as a research trainee in Dr. William Montfort’s Lab at the University of Arizona Cancer Center.   </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-04-24</field_date_posted>
  <field_date_reviewed>2018-04-24</field_date_reviewed>
  <field_pretty_url>pache-spotlight-curry</field_pretty_url>
  <para_id>1113671</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1115690</id>
  <title>Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests</title>
  <langcode>en</langcode>
  <field_short_title>Less Therapy Okay for Some Children with Wilms Tumor?</field_short_title>
  <field_page_description>Some children with advanced Wilms tumor, a form of kidney cancer, may be able to skip radiation therapy, findings from an NCI-funded clinical trial show. It’s unclear if the finding will change clinical practice, as this Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>Trial results suggest some children may safely skip radiation.</field_feature_card_description>
  <field_list_description>Results from an NCI-sponsored clinical trial may point to an important change in how some children with advanced Wilms tumor, a form of kidney cancer, are treated. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-23</field_date_posted>
  <field_date_reviewed>2018-05-16</field_date_reviewed>
  <field_pretty_url>wilms-tumor-skip-radiation-therapy</field_pretty_url>
  <para_id>1115690</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922517</term_id>
  <id>1117061</id>
  <title>Patrick McGarey</title>
  <langcode>en</langcode>
  <field_short_title>Patrick McGarey</field_short_title>
  <field_page_description>Patrick McGarey, Associate Director for Finance and Legislation, oversees NCI budget, legislation, grants financing and administration, and technology transfer. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-05</field_date_posted>
  <field_date_reviewed>2018-06-05</field_date_reviewed>
  <field_pretty_url>patrick-mcgarey-bio</field_pretty_url>
  <para_id>1117061</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1118165</id>
  <title>New on NCI Websites for June 2018</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI Websites for June 2018</field_short_title>
  <field_page_description>NCI’s online collection of cancer information products is constantly growing. See selected content of interest to the cancer community that has been added as of June 2018 in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of June 2018.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-25</field_date_posted>
  <field_date_reviewed>2018-06-21</field_date_reviewed>
  <field_pretty_url>new-online-june-2018</field_pretty_url>
  <para_id>1118165</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919516</term_id>
  <id>807051</id>
  <title>OGA Staff</title>
  <langcode>en</langcode>
  <field_short_title>OGA Staff</field_short_title>
  <field_page_description>We are a team of over 60 grants specialists, team leaders, and branch chiefs who work together to help financially support cancer research activities throughout the United States and around the world.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2019-02-07</field_date_posted>
  <field_date_reviewed>2019-02-07</field_date_reviewed>
  <para_id>807051</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>814411</term_id>
  <id>814412</id>
  <title>About the NCI Council of Research Advocates</title>
  <langcode>en</langcode>
  <field_short_title>About the NCI Council of Research Advocates</field_short_title>
  <field_page_description>The NCRA focuses on matters that facilitate research and often identifies and responds to challenges facing the Institute at the request of NCI leadership.</field_page_description>
  <field_feature_card_description>The NCRA advises NCI on matters that facilitate better research outcomes for patients.</field_feature_card_description>
  <field_list_description>The NCI Council of Research Advocates advises NCI on matters that facilitate better research outcomes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-01-30</field_date_posted>
  <field_date_reviewed>2014-01-30</field_date_reviewed>
  <para_id>814412</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>816949</term_id>
  <id>816965</id>
  <title>RAS Drug Discovery</title>
  <langcode>en</langcode>
  <field_short_title>RAS Drug Discovery</field_short_title>
  <field_page_description>The RAS Drug Discovery group aims to develop assays that will reveal aspects of RAS biology upon which cancer cells depend. Successful assay formats are made available for high-throughput screening programs to yield potentially effective drug compounds.</field_page_description>
  <field_feature_card_description>This group has developed and validated in vitro and in vivo assays suitable for screening large libraries of candidate drug compounds.</field_feature_card_description>
  <field_list_description>This group has developed and validated in vitro and in vivo assays suitable for screening large libraries of candidate drug compounds.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-20</field_date_posted>
  <field_date_reviewed>2014-08-19</field_date_reviewed>
  <para_id>816965</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1031690</id>
  <title>Two Small RNAs, Often Missing from Cancer Cells, May Suppress Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Two Small RNAs, Often Missing from Cancer Cells, May Suppress Tumors</field_short_title>
  <field_page_description>Two small RNAs that are frequently deleted from cancer cells may help suppress tumors by interacting with RAS proteins, a new study suggests.</field_page_description>
  <field_feature_card_description>These RNA molecues may inhibit the cancer-promoting activities of certain RAS proteins, which are found in many cancers.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-14</field_date_posted>
  <field_date_reviewed>2015-12-14</field_date_reviewed>
  <field_pretty_url>rna-tumor-suppressors</field_pretty_url>
  <para_id>1031690</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1033153</id>
  <title>What's New on NCI’s Websites?</title>
  <langcode>en</langcode>
  <field_short_title>What's New on NCI’s Websites?</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_list_description>NCI is constantly publishing new information on its websites, so periodically we provide updates on new content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-22</field_date_posted>
  <field_date_reviewed>2015-12-21</field_date_reviewed>
  <field_pretty_url>new-online-december-2015</field_pretty_url>
  <para_id>1033153</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1011702</term_id>
  <id>1033574</id>
  <title>DNA and Chromosome Aberrations Research</title>
  <langcode>en</langcode>
  <field_short_title>DNA and Chromosome Aberrations Research</field_short_title>
  <field_page_description>Part of NCI's Division of Cancer Biology's research portfolio, this research area is focused on making clear the genetic and epigenetic mechanisms of tumorigenesis and mechanisms of chemical and physical carcinogenesis.</field_page_description>
  <field_feature_card_description>Examines cancer genetics and epigenetics, including regulation of gene expression, mechanisms of DNA damage/repair, genomic instability, and related molecular, cytogenetic, and chromosomal effects during induction and progression to malignancy.</field_feature_card_description>
  <field_list_description>Examines cancer genetics and epigenetics, including regulation of gene expression, mechanisms of DNA damage/repair, genomic instability, and related molecular, cytogenetic, and chromosomal effects during induction and progression to malignancy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <para_id>1033574</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1033862</id>
  <title>Genome Study Links Misfolded DNA to Brain Tumors </title>
  <langcode>en</langcode>
  <field_short_title>Genome Study Links Misfolded DNA to Brain Tumors </field_short_title>
  <field_page_description>Changes in the packaging of DNA in the cell nucleus may activate growth-promoting genes that cause cancer. </field_page_description>
  <field_feature_card_description>Changes in the packaging of DNA may activate growth-promoting genes.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-12</field_date_posted>
  <field_date_reviewed>2016-01-12</field_date_reviewed>
  <field_pretty_url>misfolded-dna</field_pretty_url>
  <para_id>1033862</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1034142</term_id>
  <id>1034143</id>
  <title>Support for Families When a Child Has Cancer                                                                                   </title>
  <langcode>en</langcode>
  <field_short_title>Support for Families When a Child Has Cancer</field_short_title>
  <field_page_description>When a child has been diagnosed with cancer, parents need practical advice and information. Learn how to talk with your child and their siblings about cancer. Get answers to commonly asked questions from parents and children. Tips to help you talk with your child’s doctor, during treatment, are included.</field_page_description>
  <field_feature_card_description>Advice to help families cope, after a child has been diagnosed with cancer.</field_feature_card_description>
  <field_list_description>Practical information for parents, when a child has cancer. Tips to help children, siblings, and parents cope. Answers to commonly asked questions from parents and children.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-20</field_date_posted>
  <field_date_reviewed>2018-03-22</field_date_reviewed>
  <para_id>1034143</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>941579</term_id>
  <id>829631</id>
  <title>NCI-MATCH Trial (Molecular Analysis for Therapy Choice)</title>
  <langcode>en</langcode>
  <field_short_title>NCI-MATCH Trial (Molecular Analysis for Therapy Choice)</field_short_title>
  <field_page_description>Information about the NCI-MATCH precision medicine trial, in which patients with advanced solid tumors and lymphomas are assigned to treatment arms based on the molecular profiles of their disease.</field_page_description>
  <field_feature_card_description>A precision medicine trial in which patients will receive drugs that target specific abnormalities in their tumors.</field_feature_card_description>
  <field_list_description>Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-06-01</field_date_posted>
  <field_date_reviewed>2014-09-19</field_date_reviewed>
  <field_pretty_url>nci-match</field_pretty_url>
  <para_id>829631</para_id>
  <related_resource_ids>7235809</related_resource_ids>
  <related_resource_ids>7235810</related_resource_ids>
  <related_resource_ids>7235813</related_resource_ids>
  <related_resource_ids>7235817</related_resource_ids>
  <related_resource_ids>7235818</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833181</term_id>
  <id>833187</id>
  <title>Special Populations Networks (SPN) </title>
  <langcode>en</langcode>
  <field_short_title>SPN </field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833187</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833194</term_id>
  <id>833197</id>
  <title>Geographic Management of Cancer Health Disparities Program (GMaP)</title>
  <langcode>en</langcode>
  <field_short_title>GMaP</field_short_title>
  <field_page_description>GMaP is a regional strategy to build critical “hubs” for the support and efficient management of cancer health disparities research, diversity training, and education and outreach programs.</field_page_description>
  <field_feature_card_description>GMaP supports the efficient management of cancer health disparities research, diversity training, and education and outreach programs.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833197</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>833196</term_id>
  <id>833198</id>
  <title>National Outreach Network (NON)</title>
  <langcode>en</langcode>
  <field_short_title>NON</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-24</field_date_posted>
  <field_date_reviewed>2014-09-24</field_date_reviewed>
  <para_id>833198</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>858168</term_id>
  <id>859575</id>
  <title>Cancer Support Groups</title>
  <langcode>en</langcode>
  <field_short_title>Support Groups</field_short_title>
  <field_page_description>Information explaining the types of support groups, the benefits of joining a support group, and where to find one.</field_page_description>
  <field_feature_card_description>Information explaining the types of support groups, the benefits of joining a support group, and where to find one.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859575</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>857993</term_id>
  <id>859583</id>
  <title>Day-to-Day Life</title>
  <langcode>en</langcode>
  <field_short_title>Day-to-Day Life</field_short_title>
  <field_page_description>Enjoy life and stay active during and after cancer treatment. Get tips for keeping up with your daily routine, going back to work, and finding spiritual well-being.</field_page_description>
  <field_feature_card_description>Dealing with cancer is a life-changing event for most people. While it can be hard, there are actions you can take to adjust to your new way of life.</field_feature_card_description>
  <field_list_description>While dealing with cancer can be hard, there are actions you can take to adjust to your new way of life. Find tips for keeping up with your daily routine, going back to work, and finding comfort and meaning.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-11-17</field_date_reviewed>
  <para_id>859583</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>930502</term_id>
  <id>1066022</id>
  <title>New Therapies Are Changing the Outlook for Advanced Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>New Therapies Available for Advanced Melanoma</field_short_title>
  <field_page_description>An article about a host of new treatment options that have been produced in the last several years for patients with the skin cancer melanoma.</field_page_description>
  <field_feature_card_description>n the last several years, after decades of little progress, a host of new treatment options have been produced for patients with the skin cancer melanoma. And the progress is showing no signs of slowing.</field_feature_card_description>
  <field_list_description>In the last several years, after decades of little progress, a host of new treatment options have been produced for patients with the skin cancer melanoma. Since 2011, the FDA has approved seven new treatments for advanced melanoma that has spread to other parts of the body. And the progress is showing no signs of slowing.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-19</field_date_posted>
  <field_date_reviewed>2016-10-26</field_date_reviewed>
  <field_pretty_url>advanced-melanoma-therapies</field_pretty_url>
  <para_id>1066022</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>1066661</id>
  <title>Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Ribociclib Improves Progression-Free Survival in Breast Cancer</field_short_title>
  <field_page_description>A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.</field_page_description>
  <field_feature_card_description>Combination therapy that includes ribociclib improves progression-free survival for some women with metastatic breast cancer.</field_feature_card_description>
  <field_list_description>First-line therapy consisting of ribociclib plus letrozole (Femara®) improves progression-free survival for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to the interim results of a phase III clinical trial.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-14</field_date_posted>
  <field_date_reviewed>2016-11-14</field_date_reviewed>
  <field_pretty_url>ribociclib-metastatic-breast</field_pretty_url>
  <para_id>1066661</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1108310</id>
  <title>Lung Cancer Screening Most Beneficial for Those at Highest Risk, Analysis Suggests</title>
  <langcode>en</langcode>
  <field_short_title>Lung Cancer Screening May Benefit Those at Highest Risk</field_short_title>
  <field_page_description>People at the highest risk for lung cancer, based on a risk model, may be more likely to benefit from screening with low-dose CT, a new analysis suggests. The study authors believe the findings may better define who should undergo lung cancer screening, as this Cancer Currents blog post explains.</field_page_description>
  <field_feature_card_description>Can risk models help define who should be screened for lung cancer?</field_feature_card_description>
  <field_list_description>An analysis of data from a demonstration project led by the Veterans Health Administration may help to better define who is most likely to benefit from lung cancer screening.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-28</field_date_posted>
  <field_date_reviewed>2018-02-27</field_date_reviewed>
  <field_pretty_url>lung-cancer-screening-identifying-who-benefits</field_pretty_url>
  <para_id>1108310</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>1110239</id>
  <title>TEST - What's New in Breast Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>TEST - What's New in Breast Cancer Research</field_short_title>
  <field_feature_card_description>Clinical advances, research findings, and NCI programs that are leading to progress in preventing and treating breast cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-21</field_date_posted>
  <field_date_reviewed>2018-03-15</field_date_reviewed>
  <field_pretty_url>draft</field_pretty_url>
  <para_id>1110239</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1112845</id>
  <title>Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Expands Approval of Brentuximab for Hodgkin Lymphoma</field_short_title>
  <field_page_description>The FDA has expanded the approved uses of brentuximab (Adcetris) in people with Hodgkin lymphoma. As this Cancer Currents post explains, it can now be used in combination with three chemotherapy drugs as an initial treatment in patients with advanced disease.</field_page_description>
  <field_feature_card_description>Drug can now be used as part of an initial treatment in people with advanced disease.</field_feature_card_description>
  <field_list_description>The FDA has expanded the approved uses of brentuximab (Adcetris) in people with Hodgkin lymphoma. Under the new approval, brentuximab can be used in combination with three other chemotherapy drugs as an initial treatment in patients with advanced disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-17</field_date_posted>
  <field_date_reviewed>2018-04-10</field_date_reviewed>
  <field_pretty_url>brentuximab-fda-expanded-indication-hodgkin-lymphoma</field_pretty_url>
  <para_id>1112845</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113481</id>
  <title>NCI Expands Repository of Cancer Research Models: A Conversation with Drs. Doroshow and Evrard</title>
  <langcode>en</langcode>
  <field_short_title>NCI Expands Repository of Cancer Research Models</field_short_title>
  <field_page_description>NCI is expanding its Patient-Derived Models Repository (PDMR), which generates and distributes models like patient-derived xenografts and organoids. In this Cancer Currents Q&amp;A with Drs. Yvonne Evrard and James Doroshow,  learn how the expansion can help cancer researchers make more rapid progress.</field_page_description>
  <field_feature_card_description>Expansion addresses need for models that closely resemble human tumors.</field_feature_card_description>
  <field_list_description>NCI is expanding its Patient-Derived Models Repository (PDMR), which provides cancer research models made directly from human tumor tissue. In this Q&amp;A, Drs. Yvonne Evrard and James Doroshow explain how the new models can help cancer researchers make more rapid progress. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-20</field_date_posted>
  <field_date_reviewed>2018-04-20</field_date_reviewed>
  <field_pretty_url>nci-pdmr-cancer-research-models</field_pretty_url>
  <para_id>1113481</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>919353</term_id>
  <id>1114552</id>
  <title> International Cancer Screening Network</title>
  <langcode>en</langcode>
  <field_short_title> International Cancer Screening Network</field_short_title>
  <field_page_description>The International Cancer Screening Network promotes evidence-based cancer screening implementation and evaluation with cooperation from multilateral organizations around the globe. Learn more about how ICSN aims to reduce the global burden of cancer by supporting research and international collaboration.</field_page_description>
  <field_list_description>The International Cancer Screening Network (ICSN) is a consortium of countries, organizations, and experts working towards reducing the global cancer burden through context-specific, evidence-based cancer screening programs. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-01</field_date_posted>
  <field_date_reviewed>2018-05-01</field_date_reviewed>
  <field_pretty_url>icsn</field_pretty_url>
  <para_id>1114552</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114548</term_id>
  <id>1114561</id>
  <title>Radiation Therapy Side Effects</title>
  <langcode>en</langcode>
  <field_short_title>Radiation Therapy Side Effects</field_short_title>
  <field_page_description>Radiation therapy has side effects because it not only kills or slows the growth of cancer cells, it can also affect nearby healthy cells. Many people who get radiation therapy experience fatigue. Other side effects depend on the part of the body that is being treated. Learn more about possible side effects.</field_page_description>
  <field_list_description>Radiation not only kills or slows the growth of cancer cells, it can also affect nearby healthy cells. Damage to healthy cells can cause side effects. Many people who get radiation therapy experience fatigue. Other side effects depend on the part of the body that is being treated. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-01</field_date_posted>
  <field_date_reviewed>2018-05-01</field_date_reviewed>
  <para_id>1114561</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109389</id>
  <title>Targeted Therapy Larotrectinib Shows Promise in Early Trials, Regardless of Cancer Type</title>
  <langcode>en</langcode>
  <field_short_title>Larotrectinib Shows Promise, Regardless of Cancer Type</field_short_title>
  <field_page_description>Larotrectinib shrank tumors in patients with 13 different cancer types, clinical trials show. The drug, which targets tumors with TRK fusions, was effective in children and adults. Update reflects FDA approval.</field_page_description>
  <field_feature_card_description>In small trials, drug shrinks tumors in adults and children.</field_feature_card_description>
  <field_list_description>Initial results from a series of three small clinical trials of a targeted cancer therapy called larotrectinib suggest that it may be effective in patients—children and adults—with a wide variety of cancer types.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-09</field_date_posted>
  <field_date_reviewed>2018-03-08</field_date_reviewed>
  <field_pretty_url>larotrectinib-effective-across-cancer-types</field_pretty_url>
  <para_id>1109389</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1102947</term_id>
  <id>1111025</id>
  <title>Scientists in the Community Staff and Contact Information</title>
  <langcode>en</langcode>
  <field_short_title>Contact Scientists in the Community</field_short_title>
  <field_page_description>Find staff and contact information for NCI Scientists in the Community. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-03-23</field_date_posted>
  <field_date_reviewed>2018-03-23</field_date_reviewed>
  <para_id>1111025</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1111088</id>
  <title>Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Immunotherapy Drug Targets Two Proteins</field_short_title>
  <field_page_description>Two groups of researchers, working independently, have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein. The result, this Cancer Currents blog describes, is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system.</field_page_description>
  <field_feature_card_description>NCI investigators have tested the drug in clinical trials.</field_feature_card_description>
  <field_list_description>Two independent groups of researchers have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein. The result is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-04</field_date_posted>
  <field_date_reviewed>2018-03-27</field_date_reviewed>
  <field_pretty_url>y-trap-immunotherapy-drug</field_pretty_url>
  <para_id>1111088</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1114603</id>
  <title>Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Rucaparib Approved as Maintenance Therapy for Ovarian Cancer</field_short_title>
  <field_page_description>FDA has expanded its approval of rucaparib for women with ovarian, fallopian tube, or primary peritoneal cancer. As this Cancer Currents blog post explains, it can now be used to treat women with recurrent disease whose tumors shrank after subsequent treatment with a platinum-based chemotherapy.</field_page_description>
  <field_feature_card_description>Rucaparib approval also includes fallopian tube or primary peritoneal cancer.</field_feature_card_description>
  <field_list_description>FDA has expanded its approval of rucaparib (Rubraca) as a maintenance therapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer whose tumors shrank after subsequent treatment with a platinum-based chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-04</field_date_posted>
  <field_date_reviewed>2018-05-03</field_date_reviewed>
  <field_pretty_url>rucaparib-fda-ovarian-cancer-maintenance-therapy</field_pretty_url>
  <para_id>1114603</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1114840</term_id>
  <id>1114852</id>
  <title>Resources for Trainees</title>
  <langcode>en</langcode>
  <field_short_title>Resources for Trainees</field_short_title>
  <field_page_description>Fellows and cancer research trainees can find orientation, community involvement, and career development information. Learn more about resources for trainees. </field_page_description>
  <field_feature_card_description>Trainees will find materials to support their onboarding and enhance their time at NCI.</field_feature_card_description>
  <field_list_description>Find orientation, community involvement, and career development information for fellows and trainees at NCI. Learn more about resources for trainees.
Feature Description (75) Trainees will find materials to support their onboarding and enhance their time at NCI.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-04</field_date_reviewed>
  <para_id>1114852</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1115383</id>
  <title>After TCGA: Building Clinical Genomic Resources</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Genomic Resources</field_short_title>
  <field_page_description>Clinical focus on upcoming cancer characterization projects after TCGA</field_page_description>
  <field_feature_card_description>Upcoming Clinical Genomic Resources</field_feature_card_description>
  <field_list_description>The Center for Cancer Genomics (CCG) continues to build genomic resources with a special focus on clinical features and patient outcome. A new wave of cancer characterization projects will generate data relevant for precision medicine and build on the legacy left by The Cancer Genome Atlas, which officially concluded in April 2018. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-16</field_date_posted>
  <field_date_reviewed>2018-05-15</field_date_reviewed>
  <field_pretty_url>After-TCGA</field_pretty_url>
  <para_id>1115383</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1110912</id>
  <title>Higher Risk of Heart Failure Seen in Some Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Higher Risk of Heart Failure Seen in Some Cancers</field_short_title>
  <field_page_description>Some people treated for breast cancer or lymphoma have a higher risk of developing congestive heart failure than people who haven’t had cancer, a new study shows. As this Cancer Currents blog post reports, the risk persisted for at least 20 years.</field_page_description>
  <field_feature_card_description>Increased risk found in people treated for lymphoma, breast cancer.</field_feature_card_description>
  <field_list_description>Some people who have been treated for breast cancer or lymphoma have a higher risk of developing congestive heart failure than people who haven’t had cancer, results from a new study show.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-26</field_date_posted>
  <field_date_reviewed>2018-03-23</field_date_reviewed>
  <field_pretty_url>increased-heart-failure-risk</field_pretty_url>
  <para_id>1110912</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113696</id>
  <title>Cancer Control in American Indian and Alaska Native Populations: A Conversation with Dr. Shobha Srinivasan</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Control in American Indian and Alaska Native Populations</field_short_title>
  <field_page_description>American Indian and Alaska Native (AI/AN) populations are disproportionately affected by certain cancers. In this interview, Dr. Shobha Srinivasan discusses some of these disparities and programs funded by NCI that are helping to address them.</field_page_description>
  <field_feature_card_description>NCI-funded research is helping to address cancer disparities in these groups.</field_feature_card_description>
  <field_list_description>American Indian and Alaska Native populations are disproportionately affected by certain cancers. In this interview, Dr. Shobha Srinivasan discusses some of these disparities and programs funded by NCI that are helping to address them.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-25</field_date_posted>
  <field_date_reviewed>2018-04-25</field_date_reviewed>
  <field_pretty_url>american-indian-alaska-native-cancer-control</field_pretty_url>
  <para_id>1113696</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114556</term_id>
  <id>1114559</id>
  <title>External Beam Radiation Therapy for Cancer</title>
  <langcode>en</langcode>
  <field_short_title>External Beam Radiation</field_short_title>
  <field_page_description>External beam radiation therapy is used to treat many types of cancer. it is a local treatment, where a machine aims radiation at your cancer. Learn more about different types of external beam radiation therapy, and what to expect if you're receiving treatment.</field_page_description>
  <field_feature_card_description>This type of cancer treatment comes from a machine that aims radiation at a specifc part of your body.</field_feature_card_description>
  <field_list_description>External beam radiation therapy comes from a machine that aims radiation at your cancer. It is a local treatment, which means it treats a specific part of your body. External beam radiation therapy is used to treat many types of cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-01</field_date_posted>
  <field_date_reviewed>2018-05-01</field_date_reviewed>
  <para_id>1114559</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1115077</term_id>
  <id>1115078</id>
  <title>Mentoring for Trainees and Fellows</title>
  <langcode>en</langcode>
  <field_short_title>Mentoring</field_short_title>
  <field_page_description>Mentorship is an important part of the trainee experience at NCI and NIH. Learn how to choose and find mentors and how to get involved in mentoring others.</field_page_description>
  <field_feature_card_description>Trainees will learn how to choose and find mentors and mentees. </field_feature_card_description>
  <field_list_description>Learn how to choose a good mentor and how to get involved in mentoring others.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-09</field_date_reviewed>
  <para_id>1115078</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1115090</id>
  <title>FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Immunotherapy Combination Approved for Advanced Kidney Cancer</field_short_title>
  <field_page_description>FDA has approved the combination of the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) as an initial treatment for some patients with advanced kidney cancer. The approval is expected to immediately affect patient care, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>First immunotherapy treatment approved as initial treatment of kidney cancer.</field_feature_card_description>
  <field_list_description>FDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-10</field_date_posted>
  <field_date_reviewed>2018-05-09</field_date_reviewed>
  <field_pretty_url>kidney-cancer-fda-nivolumab-ipilimumab-first-line</field_pretty_url>
  <para_id>1115090</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116639</id>
  <title>Easing Concerns about Giving Research Study Participants Their Genetic Test Results </title>
  <langcode>en</langcode>
  <field_short_title>Easing Concerns About Returning Genetic Test Results </field_short_title>
  <field_page_description>Women with breast cancer participating in a research study were given the opportunity to learn their genetic research results. This Cancer Currents blog details the impact these results had on women who opted to review their results with a genetic counselor. </field_page_description>
  <field_feature_card_description>Overall, participants who received their results had positive experiences.</field_feature_card_description>
  <field_list_description>Do cancer study participants want to receive their genetic test results? A recent study involving women with a history of breast cancer tested an approach for returning genetic research results and evaluated the impact those results had on the women.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-01</field_date_posted>
  <field_date_reviewed>2018-05-31</field_date_reviewed>
  <field_pretty_url>breast-cancer-returning-genetic-testing-results</field_pretty_url>
  <para_id>1116639</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>919351</term_id>
  <id>771896</id>
  <title>NCI Summer Curriculum in Cancer Prevention Program</title>
  <langcode>en</langcode>
  <field_short_title>NCI Summer Curriculum in Cancer Prevention Program</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-02-03</field_date_posted>
  <field_date_reviewed>2016-02-03</field_date_reviewed>
  <field_pretty_url>summer-curriculum-prevention</field_pretty_url>
  <para_id>771896</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938142</term_id>
  <id>772122</id>
  <title>Sorafenib Improves Progression-Free Survival in Some Patients with Metastatic Thyroid Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Sorafenib Improves Progression-Free Survival in Some Patients with Metastatic Thyroid Cancer</field_short_title>
  <field_page_description>A summary of results from an international phase III trial that compared sorafenib (Nexavar®) and a placebo for the treatment of locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine</field_page_description>
  <field_feature_card_description>Results from an international phase III trial show that sorafenib (Nexavar®) may benefit  patients with locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine. Patients who were treat</field_feature_card_description>
  <field_list_description>Results from an international phase III trial show that sorafenib (Nexavar®) may benefit  patients with locally advanced or metastatic differentiated thyroid cancer that is no longer responding to treatment with radioactive iodine. Patients who were treated with sorafenib lived longer without their cancers getting worse than patients who received a placebo.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-05-27</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>sorafenib</field_pretty_url>
  <para_id>772122</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>487755</term_id>
  <id>777775</id>
  <title>Steps to Find a Clinical Trial</title>
  <langcode>en</langcode>
  <field_short_title>Steps to Find a Clinical Trial</field_short_title>
  <field_page_description>Learn how to gather details about your cancer, places to search for clinical trials, how to narrow your search, and questions to ask to help you find a trial that is appropriate for you. </field_page_description>
  <field_feature_card_description>Learn about the steps you need to take to find a cancer clinical trial that might be right for you.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-30</field_date_posted>
  <field_date_reviewed>2014-05-30</field_date_reviewed>
  <para_id>777775</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922410</term_id>
  <id>789639</id>
  <title>Lung-MAP: Master Protocol for Lung Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Lung-MAP: Master Protocol for Lung Cancer</field_short_title>
  <field_page_description>The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.</field_page_description>
  <field_feature_card_description>Lung-MAP is a precision medicine research study for people with advanced non-small cell lung cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-06-16</field_date_posted>
  <field_date_reviewed>2014-06-10</field_date_reviewed>
  <field_pretty_url>lung-map</field_pretty_url>
  <para_id>789639</para_id>
  <related_resource_ids>7251250</related_resource_ids>
  <related_resource_ids>7251251</related_resource_ids>
  <related_resource_ids>7251252</related_resource_ids>
  <related_resource_ids>7251254</related_resource_ids>
  <related_resource_ids>7251255</related_resource_ids>
  <related_resource_ids>7251257</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1054637</id>
  <title>Study Forecasts ‘Silver Tsunami’ of Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Study Forecasts ‘Silver Tsunami’ of Cancer Survivors</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on an NCI study that is forecasting a substantial increase in older cancer survivors over the next 25 years.</field_page_description>
  <field_feature_card_description>Survivors aged 65 and older will increase the demand for cancer and survivorship care.</field_feature_card_description>
  <field_list_description>According to an NCI study, the number of older cancer survivors will grow substantially over the next quarter century, increasing the demand for cancer and survivorship care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-08</field_date_posted>
  <field_date_reviewed>2016-07-07</field_date_reviewed>
  <field_pretty_url>cancer-silver-tsunami</field_pretty_url>
  <para_id>1054637</para_id>
  <related_resource_id>6611774</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1047564</term_id>
  <id>1061084</id>
  <title>New Awards in NCI’s Cancer Systems Biology Consortium </title>
  <langcode>en</langcode>
  <field_short_title>New Awards in NCI’s Cancer Systems Biology Consortium </field_short_title>
  <field_page_description>Announcement that NCI awarded four new grants in the Cancer Systems Biology Consortium (CSBC).</field_page_description>
  <field_feature_card_description>Research in cancer systems biology will focus on the analysis of cancer as a complex biological system.</field_feature_card_description>
  <field_list_description>The National Cancer Institute awarded four new grants in NCI’s Cancer Systems Biology Consortium (CSBC).  The institutions receiving Center grants are: Arizona State University, Harvard Medical School, University of California-Irvine, and Vanderbilt University.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-06-08</field_date_posted>
  <field_date_reviewed>2016-08-29</field_date_reviewed>
  <field_pretty_url>announcement</field_pretty_url>
  <para_id>1061084</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061186</id>
  <title>Engineered Stem Cells Help Identify Potential New Treatment for Medulloblastoma</title>
  <langcode>en</langcode>
  <field_short_title>Improved Lab Model Developed for Studying Medulloblastoma</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about neural stem cells engineered to provide a new laboratory model for studying medulloblastoma.</field_page_description>
  <field_feature_card_description>Stem cells engineered to mimic medulloblastoma development point to potential new treatments.</field_feature_card_description>
  <field_list_description>Stem cells engineered to mimic medulloblastoma development may help researchers identify potential new treatments, according to a new study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-01</field_date_posted>
  <field_date_reviewed>2016-09-01</field_date_reviewed>
  <field_pretty_url>medulloblastoma-model</field_pretty_url>
  <para_id>1061186</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1061650</term_id>
  <id>1061652</id>
  <title>RAS Initiative Events</title>
  <langcode>en</langcode>
  <field_short_title>RAS Events</field_short_title>
  <field_page_description>The NCI RAS Initiative has organized multiple events with outside experts to discuss how the latest scientific and technological breakthroughs can be applied to discover vulnerabilities in RAS-driven cancers.</field_page_description>
  <field_feature_card_description>The RAS Initiative has organized multiple events with outside experts to discuss how the latest scientific and technological breakthroughs can be applied to discover vulnerabilities in RAS-driven cancers.</field_feature_card_description>
  <field_list_description>A fundamental aspect of scientific research is to enable and encourage the exchange of information and ideas through in-person workshops and meetings. The NCI RAS Initiative has organized multiple events with invited outside experts to discuss how the latest scientific and technological breakthroughs can be applied to discover vulnerabilities in cancers caused by mutant RAS genes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-12</field_date_posted>
  <field_date_reviewed>2016-09-28</field_date_reviewed>
  <para_id>1061652</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894082</term_id>
  <id>1062763</id>
  <title>Program Spotlight: Twenty Years of Professional Development and Mock Review Workshops </title>
  <langcode>en</langcode>
  <field_short_title>Twenty Years of Professional Development and Mock Review Workshops </field_short_title>
  <field_page_description>Twenty Years of Professional Development and Mock Review Workshops, 2016 </field_page_description>
  <field_list_description>CRCHD brought together CURE scholars to learn about NCI career development and funding opportunities and to enhance skills needed to build a successful career in cancer and cancer disparities research.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-26</field_date_posted>
  <field_date_reviewed>2016-09-26</field_date_reviewed>
  <field_pretty_url>PDW-2016</field_pretty_url>
  <para_id>1062763</para_id>
  <related_resource_ids>6459560</related_resource_ids>
  <related_resource_ids>6459561</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1035119</id>
  <title>NCI-MATCH: A Status Report and Future Directions</title>
  <langcode>en</langcode>
  <field_short_title>NCI-MATCH: A Status Report and Future Directions</field_short_title>
  <field_page_description>Leaders of the NCI-MATCH trial provide an update to the cancer community on the trial’s status and plans for it moving forward.</field_page_description>
  <field_feature_card_description>An update on the status and progress of the NCI-MATCH trial.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-02-01</field_date_posted>
  <field_date_reviewed>2016-02-01</field_date_reviewed>
  <field_pretty_url>nci-match-update</field_pretty_url>
  <para_id>1035119</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1038560</id>
  <title>The CTD&lt;sup&gt;2&lt;/sup&gt; Dashboard: A Platform to Explore Evidence-based Observations</title>
  <langcode>en</langcode>
  <field_short_title>The CTD2 Dashboard</field_short_title>
  <field_page_description>Findings from CTD2 centers are displayed on the Dashboard for the community to explore. </field_page_description>
  <field_feature_card_description>Learn more about the CTD2 Dashboard</field_feature_card_description>
  <field_list_description>The CTD&lt;sup&gt;2&lt;/sup&gt; dashboard provides the research community with an interactive portal for discovering connections between genes, proteins, perturbagens, and diseases. The portal also ranks CTD&lt;sup&gt;2&lt;/sup&gt; findings by the level of biological evidence.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-03-02</field_date_posted>
  <field_date_reviewed>2016-03-02</field_date_reviewed>
  <field_pretty_url>dashboard</field_pretty_url>
  <para_id>1038560</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1041012</id>
  <title>Novel Strategy Isolates Immune Cells in the Blood that Recognize Melanoma</title>
  <langcode>en</langcode>
  <field_short_title>Identifying Immune Cells in Blood that Recognize Tumors</field_short_title>
  <field_page_description>NCI scientists have developed a novel strategy for identifying immune cells circulating in the blood that recognize specific proteins on tumor cells, a finding they believe may have potential implications for immune-based therapies.</field_page_description>
  <field_feature_card_description>Researchers used a novel approach to identify immune cells circulating in the blood of patients with melanoma.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-11</field_date_posted>
  <field_date_reviewed>2016-03-10</field_date_reviewed>
  <field_pretty_url>reactive-immune-cells-blood</field_pretty_url>
  <para_id>1041012</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1044319</id>
  <title>Toward Precision Therapy for Children with Cancer: An Interview with Dr. Javed Khan</title>
  <langcode>en</langcode>
  <field_short_title>Toward Precision Therapy for Children with Cancer: An Interview with Dr. Javed Khan</field_short_title>
  <field_page_description>NCI’s Dr. Javed Khan discusses a new NCI clinical program and the promise and challenges of genome-guided therapy for children with cancer.</field_page_description>
  <field_feature_card_description>NCI’s ClinOmics program will use genomic data to guide cancer treatment decisions.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-04-13</field_date_posted>
  <field_date_reviewed>2016-04-12</field_date_reviewed>
  <field_pretty_url>nci-clinomics-pediatric</field_pretty_url>
  <para_id>1044319</para_id>
  <related_resource_ids>6617679</related_resource_ids>
  <related_resource_ids>6617680</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116069</id>
  <title>FDA Approves Second CAR T-Cell Therapy for Lymphoma</title>
  <langcode>en</langcode>
  <field_short_title>Tisagenlecleucel Approved to Treat Some Lymphomas</field_short_title>
  <field_page_description>FDA has approved the CAR T-cell therapy tisagenlecleucel for adults with diffuse large B-cell lymphoma that is relapsed or refractory. Learn more about this new approval and how it may affect patients in this NCI Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Tisagenlecleucel is a new option for some patients with common lymphoma.</field_feature_card_description>
  <field_list_description>FDA has approved tisagenlecleucel (Kymriah) for certain kinds of non-Hodgkin lymphoma. Read about the trial that led to the approval and what the approval means for people with lymphoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-22</field_date_posted>
  <field_date_reviewed>2018-05-22</field_date_reviewed>
  <field_pretty_url>tisagenlecleucel-fda-lymphoma</field_pretty_url>
  <para_id>1116069</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1116081</id>
  <title>Can Immunotherapy Succeed in Glioblastoma?</title>
  <langcode>en</langcode>
  <field_short_title>Can Immunotherapy Succeed in Glioblastoma?</field_short_title>
  <field_page_description>Researchers are hopeful that, for the deadly brain cancer glioblastoma, immunotherapy might succeed where other therapies have not. As this Cancer Currents post reports, different immunotherapy approaches are being tested in clinical trials.</field_page_description>
  <field_feature_card_description>Researchers hope to overcome unique challenges of this deadly cancer.</field_feature_card_description>
  <field_list_description>Despite continued efforts to develop new therapies for glioblastoma, none have been able to improve how long patients live appreciably. Despite some setbacks, researchers are hopeful that immunotherapy might be able to succeed where other therapies have not.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-24</field_date_posted>
  <field_date_reviewed>2018-05-22</field_date_reviewed>
  <field_pretty_url>immunotherapy-glioblastoma</field_pretty_url>
  <para_id>1116081</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1116105</term_id>
  <id>1116106</id>
  <title>Meet the Expert Sessions</title>
  <langcode>en</langcode>
  <field_short_title>Meet the Expert Sessions</field_short_title>
  <field_page_description>Meet the Expert Sessions at American Public Health Association (APHA) Annual Meeting and Expo from Saturday, November 10 to Wednesday, November 14 in San Diego, CA.</field_page_description>
  <field_feature_card_description>Meet the Expert Sessions at American Public Health Association (APHA) Annual Meeting and Expo from Saturday, November 10 to Wednesday, November 14 in San Diego, CA.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-22</field_date_posted>
  <field_date_reviewed>2018-05-22</field_date_reviewed>
  <para_id>1116106</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1116535</id>
  <title>The Genomic Data Commons Turns 2: Progress in Clinical Tool Development</title>
  <langcode>en</langcode>
  <field_short_title>Genomic Data Commons Turns 2</field_short_title>
  <field_page_description>Milestones and challenges ahead in building an interactive, open-access precision medicine tool</field_page_description>
  <field_feature_card_description>The Genomic Data Commons Turns 2</field_feature_card_description>
  <field_list_description>The Genomic Data Commons (GDC) launched two years ago with the goal to build a collaborative, interactive knowledge system that anyone can use. Dr. Lou Staudt reflects on milestones reached at the GDC’s two year anniversary and challenges ahead in building clinically relevant tools and advancing precision medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-31</field_date_posted>
  <field_date_reviewed>2018-05-30</field_date_reviewed>
  <field_pretty_url>GDC-2-years</field_pretty_url>
  <para_id>1116535</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1117603</id>
  <title>Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Nelarabine Improves Survival in Young Patients with T-Cell ALL</field_short_title>
  <field_page_description>For some children and young adults with T-cell ALL, adding nelarabine (Arranon) to chemotherapy should be the standard of care, new clinical trial results suggest.</field_page_description>
  <field_feature_card_description>Findings from clinical trial expected to change practice.</field_feature_card_description>
  <field_list_description>This NCI-funded Children’s Oncology Group trial tested the addition of nelarabine (Arranon) to standard treatment for children and young adults with T-cell acute lymphoblastic leukemia (T-ALL).
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-14</field_date_posted>
  <field_date_reviewed>2018-06-14</field_date_reviewed>
  <field_pretty_url>leukemia-nelarabine-improves-survival</field_pretty_url>
  <para_id>1117603</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1068421</id>
  <title>FDA Approves New Use for Daratumumab in Multiple Myeloma</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves New Use for Daratumumab in Multiple Myeloma</field_short_title>
  <field_page_description>A Cancer Currents blog post on the FDA’s approval of daratumumab in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.</field_page_description>
  <field_feature_card_description>Drug can now be used earlier as part of three-drug combination.</field_feature_card_description>
  <field_list_description>The FDA has approved daratumumab, in combination with either of two other standard therapies, in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-09</field_date_posted>
  <field_date_reviewed>2016-12-09</field_date_reviewed>
  <field_pretty_url>daratumumab-fda-myeloma-new</field_pretty_url>
  <para_id>1068421</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1069645</id>
  <title>New on NCI’s Websites for December 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for December 2016</field_short_title>
  <field_page_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-12-28</field_date_posted>
  <field_date_reviewed>2016-12-22</field_date_reviewed>
  <field_pretty_url>new-online-december-2016</field_pretty_url>
  <para_id>1069645</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1070753</id>
  <title>FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about the FDA approval of rucaparib for women with BRCA-positive ovarian cancer who have received at least two chemotherapy regimens.</field_page_description>
  <field_feature_card_description>In two small clinical trials, the drug shrank tumors in women with advanced disease.</field_feature_card_description>
  <field_list_description>The FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-09</field_date_posted>
  <field_date_reviewed>2017-01-09</field_date_reviewed>
  <field_pretty_url>fda-rucaparib-ovarian</field_pretty_url>
  <para_id>1070753</para_id>
  <related_resource_id>6612086</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1072118</id>
  <title>Together, WE CAN Make a Difference</title>
  <langcode>en</langcode>
  <field_short_title>Together, WE CAN Make a Difference</field_short_title>
  <field_page_description>This Saturday, February 4th is World Cancer Day 2017.  It is a day to reflect on the progress that’s been made in research, treatment, and policy, all aimed at reducing the global burden of cancer. The Center for Global Health has worked determinedly this past year to bring us closer to this goal. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-01-30</field_date_posted>
  <field_date_reviewed>2017-01-30</field_date_reviewed>
  <field_pretty_url>wcd-2017</field_pretty_url>
  <para_id>1072118</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070072</term_id>
  <id>1072628</id>
  <title>The K-Ras Anchor: Another Twist to the Tale</title>
  <langcode>en</langcode>
  <field_short_title>The K-Ras Anchor: Another Twist to the Tale</field_short_title>
  <field_page_description>The amino acid sequence of the C-terminus of K-Ras4B combines with its lipid modifications to strongly influence its interactions with the plasma membrane.</field_page_description>
  <field_feature_card_description>John Hancock summarizes his group's recent work on how KRas4b interacts with the plasma membrane.</field_feature_card_description>
  <field_list_description>The specific amino acid sequence of the polybasic domain of K-Ras4B combines with its C-terminal lipid modifications to strongly influence its interactions with the plasma membrane.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-02-06</field_date_posted>
  <field_date_reviewed>2017-02-06</field_date_reviewed>
  <field_pretty_url>kras4b-hvr-sequence-lipids-hancock</field_pretty_url>
  <para_id>1072628</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1116317</id>
  <title>Tobacco Breaks Hearts: World No Tobacco Day 2018</title>
  <langcode>en</langcode>
  <field_short_title>Tobacco Breaks Hearts: World No Tobacco Day 2018</field_short_title>
  <field_page_description>This year World No Tobacco Day highlights the impact of tobacco use on heart disease under the banner “Tobacco Breaks Hearts.” Read more about the effects of tobacco use on your health.</field_page_description>
  <field_feature_card_description>Learn how NCI works internationally to reduce the global burden of tobacco-associated cancers.</field_feature_card_description>
  <field_list_description>This year World No Tobacco Day highlights the impact of tobacco use on heart disease under the banner “Tobacco Breaks Hearts.” There are many reasons to focus on heart health. More people die from cardiovascular diseases (CVDs) worldwide than from any other cause, and tobacco use is responsible for about 10% of these deaths.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-24</field_date_posted>
  <field_date_reviewed>2018-05-24</field_date_reviewed>
  <field_pretty_url>wntd</field_pretty_url>
  <para_id>1116317</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1117036</id>
  <title>Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Toxin-Based Drug May Be New Option for Rare Leukemia</field_short_title>
  <field_page_description>In patients with hairy cell leukemia, the toxin-based treatment moxetumomab pasudotox may be an effective new treatment option. As this Cancer Currents post explains, the drug looked to be highly effective in a large clinical trial.</field_page_description>
  <field_feature_card_description>Moxetumomab Pasudotox shows efficacy against hairy cell leukemia.</field_feature_card_description>
  <field_list_description>People diagnosed with hairy cell leukemia (HCL) may have an effective new treatment option, a type of drug called an immunotoxin. Read more about how this treatment, moxetumomab pasudotox, fared in a phase 3 clinical trial in patients with advanced HCL.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-05</field_date_posted>
  <field_date_reviewed>2018-06-04</field_date_reviewed>
  <field_pretty_url>hairy-cell-leukemia-moxetumomab</field_pretty_url>
  <para_id>1117036</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922517</term_id>
  <id>1117067</id>
  <title>Donna Siegle</title>
  <langcode>en</langcode>
  <field_short_title>Donna Siegle</field_short_title>
  <field_page_description>Donna Siegle serves as the NCI Acting Executive Officer, responsible for leading the NCI Office of Management (OM). </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-05</field_date_posted>
  <field_date_reviewed>2018-06-05</field_date_reviewed>
  <field_pretty_url>donna-siegle-bio</field_pretty_url>
  <para_id>1117067</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>14381</id>
  <title>Surgery to Reduce the Risk of Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Surgery to Reduce the Risk of Breast Cancer</field_short_title>
  <field_page_description>A fact sheet that describes mastectomy and salpingo-oophorectomy, two surgeries that may be used to reduce breast cancer risk in women at very high risk, and nonsurgical options.</field_page_description>
  <field_list_description>A fact sheet that describes mastectomy and salpingo-oophorectomy, two prophylactic surgeries that may be performed to reduce the risk of breast cancer in women at very high risk; the situations in which they may be considered; and nonsurgical options.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2013-10-18</field_date_posted>
  <field_date_reviewed>2013-08-12</field_date_reviewed>
  <field_pretty_url>risk-reducing-surgery-fact-sheet</field_pretty_url>
  <para_id>14381</para_id>
  <related_resource_ids>7119357</related_resource_ids>
  <related_resource_ids>7119358</related_resource_ids>
  <related_resource_ids>7119359</related_resource_ids>
  <related_resource_ids>7119390</related_resource_ids>
  <related_resource_ids>7119391</related_resource_ids>
  <related_resource_ids>7119394</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1050046</id>
  <title>A short narrative - Challenges and opportunities in expanding research in the Middle East, North Africa Region</title>
  <langcode>en</langcode>
  <field_short_title>A short narrative - Challenges and opportunities in expanding research in the Middle East, North Afr</field_short_title>
  <field_page_description>CGH CRTA, Hedieh Mehrtash interviews CGH's Dr. Marie Ricciardone who works with a network of partners in the Middle East and North Africa region, on experiences, challenges, and opportunities in the region.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-05-18</field_date_posted>
  <field_date_reviewed>2016-05-18</field_date_reviewed>
  <field_pretty_url>mena</field_pretty_url>
  <para_id>1050046</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052074</id>
  <title>Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack</title>
  <langcode>en</langcode>
  <field_short_title>Antibody Targets Tumor Cells, Spurs Immune Attack</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on an antibody derived from patients that killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer without evidence of side effects.</field_page_description>
  <field_feature_card_description>The CFH antibodies have the potential to selectively target tumors in people without harming healthy cells.</field_feature_card_description>
  <field_list_description>The CFH antibodies killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer, without evidence of side effects. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-06</field_date_posted>
  <field_date_reviewed>2016-06-06</field_date_reviewed>
  <field_pretty_url>cfh-antibody</field_pretty_url>
  <para_id>1052074</para_id>
  <related_resource_id>6625015</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052543</id>
  <title>Blood Test for Genetic Changes in Tumors Shows Promise as Alternative to Tumor Biopsy</title>
  <langcode>en</langcode>
  <field_short_title>Blood Test Shows Promise as Alternative to Tumor Biopsy</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about a study which showed that a so-called liquid biopsy produced results highly similar to those of traditional tumor biopsies.</field_page_description>
  <field_feature_card_description>Liquid biopsy assesses mutations, other changes in genetic material shed by tumors.</field_feature_card_description>
  <field_list_description>The largest study of its kind to date has shown that a test that assesses DNA mutations and other changes in genetic material shed from tumors into the blood—a liquid biopsy—produced results highly similar to those of traditional tumor biopsies.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-14</field_date_posted>
  <field_date_reviewed>2016-06-14</field_date_reviewed>
  <field_pretty_url>asco-liquid-biopsy</field_pretty_url>
  <para_id>1052543</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1044202</term_id>
  <id>1052784</id>
  <title>Addressing a silent killer - The International Conference on Betel Quid and Areca Nut</title>
  <langcode>en</langcode>
  <field_short_title>Addressing a silent killer - The International Conference on Betel Quid and Areca Nut</field_short_title>
  <field_page_description>The Center for Global Health, National Cancer Institute, in coordination with the National Institute of Dental and Craniofacial Research , The University of Texas at MD Anderson Cancer Center, Oral Cancer Research Coordinating Center, University of Malaya, Taiwan Health Promotion Administration, Ministry of Health and </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-20</field_date_posted>
  <field_date_reviewed>2016-06-20</field_date_reviewed>
  <field_pretty_url>betel_quid</field_pretty_url>
  <para_id>1052784</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>915373</term_id>
  <id>1055261</id>
  <title>Seeking Cancer Clues in Blood, Researchers Explore Exosomes </title>
  <langcode>en</langcode>
  <field_short_title>Seeking Cancer Clues in Blood, Researchers Explore Exosomes</field_short_title>
  <field_page_description>A feature-length Research Update article about exploring ways to use vesicles known as exosomes to develop new clinical tests and tools for patients with cancer. </field_page_description>
  <field_feature_card_description>Researchers are using vesicles called exosomes to gain insights into cancer and to develop clinical tools for patients. </field_feature_card_description>
  <field_list_description>Researchers are exploring ways to use vesicles called exosomes to gain insights into cancer and to develop clinical tools for patients. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-12</field_date_posted>
  <field_date_reviewed>2016-07-12</field_date_reviewed>
  <field_pretty_url>exosomes</field_pretty_url>
  <para_id>1055261</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1047990</id>
  <title>After Rising for Decades, Thyroid Cancer Incidence Stabilizes</title>
  <langcode>en</langcode>
  <field_short_title>U.S. Thyroid Cancer Incidence Stabilizes</field_short_title>
  <field_page_description>After rising steadily since the 1990s, the incidence of thyroid cancer in the United States may be leveling off, according to an analysis of data from NCI’s SEER program. </field_page_description>
  <field_feature_card_description>The trend occurred amid growing awareness about the potential for detection of small indolent thyroid nodules.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-06</field_date_posted>
  <field_date_reviewed>2016-05-06</field_date_reviewed>
  <field_pretty_url>thyroid-incidence-trend</field_pretty_url>
  <para_id>1047990</para_id>
  <related_resource_id>6612969</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1048214</id>
  <title>Calling on Data Enthusiasts to Help Advance Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Data Sharing and the Cancer Moonshot </field_short_title>
  <field_page_description>Health data enthusiasts of all stripes were in Washington, D.C., today for Health Datapalooza. NCI's Dr. Warren Kibbe explains that this annual event explores a topic that is central to NCI’s efforts against cancer: creating knowledge from data.</field_page_description>
  <field_feature_card_description>NCI's Dr. Warren Kibbe encourages the data innovation community to share their ideas for the National Cancer Moonshot initiative. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-09</field_date_posted>
  <field_date_reviewed>2016-05-09</field_date_reviewed>
  <field_pretty_url>datapalooza-moonshot</field_pretty_url>
  <para_id>1048214</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1051289</id>
  <title>Survival Disparities Identified in Young African Americans with Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Survival Disparities Identified in Young African Americans with Colorectal Cancer</field_short_title>
  <field_page_description>A blog post on a new study that found African Americans younger than age 50 who are diagnosed with colorectal cancer have significantly worse survival rates than whites of the same age.</field_page_description>
  <field_feature_card_description>African Americans had worse 5-year survival rates than whites and Hispanics.</field_feature_card_description>
  <field_list_description>African Americans younger than age 50 had significantly worse 5-year survival rates at every stage of disease compared with young white and Hispanic patients, a new study shows.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-05-25</field_date_posted>
  <field_date_reviewed>2016-05-25</field_date_reviewed>
  <field_pretty_url>colorectal-survival-disparities</field_pretty_url>
  <para_id>1051289</para_id>
  <related_resource_ids>6598472</related_resource_ids>
  <related_resource_ids>6598473</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1052108</term_id>
  <id>1052115</id>
  <title>Budget and Appropriations Status</title>
  <langcode>en</langcode>
  <field_short_title>Budget and Appropriations Status</field_short_title>
  <field_page_description>Information on the status of budget and appropriations legislation in the current Congress, including a recap of the previous year’s appropriations request.</field_page_description>
  <field_feature_card_description>Information on the status of current budget and appropriations legislation.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-06-08</field_date_posted>
  <field_date_reviewed>2016-06-08</field_date_reviewed>
  <para_id>1052115</para_id>
  <related_resource_id>7196112</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1052849</id>
  <title>Extended Adjuvant Therapy Beneficial for Some Women with Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Extended Adjuvant Therapy Beneficial for Some Women with Breast Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on findings from a recent clinical trial which showed that extending adjuvant therapy with an aromatase inhibitor can have important benefits for some women with early-stage cancer.</field_page_description>
  <field_feature_card_description>Extending therapy with aromatase inhibitors can benefit some postmenopausal women with breast cancer.</field_feature_card_description>
  <field_list_description>Results from a recent clinical trial showed that extending adjuvant therapy with an aromatase inhibitor to 10 years after initial treatment can have important benefits for postmenopausal women with early-stage hormone receptor–positive breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-06-22</field_date_posted>
  <field_date_reviewed>2016-06-22</field_date_reviewed>
  <field_pretty_url>adjuvant-aromatase-breast</field_pretty_url>
  <para_id>1052849</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1055682</id>
  <title>New on NCI's Websites for July 2016</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for July 2016</field_short_title>
  <field_page_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_page_description>
  <field_feature_card_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_feature_card_description>
  <field_list_description>An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-15</field_date_posted>
  <field_date_reviewed>2016-07-15</field_date_reviewed>
  <field_pretty_url>new-online-july-2016</field_pretty_url>
  <para_id>1055682</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>417547</term_id>
  <id>1057088</id>
  <title>Scientific Steering Committees</title>
  <langcode>en</langcode>
  <field_short_title>Scientific Steering Committees</field_short_title>
  <field_page_description>A functional overview of NCI's Scientific Steering Committees (SSCs). SSCs are tasked with evaluating and prioritizing clinical trials based on scientific merit in a transparent process.</field_page_description>
  <field_feature_card_description>NCI's Scientific Steering Committees are tasked with evaluating and prioritizing clinical trials based on scientific merit. Learn more about the different committees and their work.</field_feature_card_description>
  <field_list_description>NCI's Scientific Steering Committees are tasked with evaluating and prioritizing clinical trials based on scientific merit. Learn more about the different committees and their work.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-07-27</field_date_posted>
  <field_date_reviewed>2016-07-27</field_date_reviewed>
  <para_id>1057088</para_id>
  <related_resource_id>7239708</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1057845</id>
  <title>Mutations Linked to Immunotherapy Resistance</title>
  <langcode>en</langcode>
  <field_short_title>Mutations Linked to Immunotherapy Resistance</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a study that identified acquired mutations in relapsed melanoma tumors that led to resistance to the checkpoint inhibitor pembrolizumab.</field_page_description>
  <field_feature_card_description>Mutations in relapsed melanoma tumors block the immunotherapy drug pembrolizumab.</field_feature_card_description>
  <field_list_description>Researchers identified mutations in relapsed melanoma tumors that block the anticancer effects of the checkpoint inhibitor pembrolizumab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-05</field_date_posted>
  <field_date_reviewed>2016-08-02</field_date_reviewed>
  <field_pretty_url>immunotherapy-resistance-melanoma</field_pretty_url>
  <para_id>1057845</para_id>
  <related_resource_ids>6890263</related_resource_ids>
  <related_resource_ids>6890267</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1061101</id>
  <title>Tumor DNA in Blood May Signal Response to T-Cell Transfer Immunotherapy </title>
  <langcode>en</langcode>
  <field_short_title>Tumor DNA in Blood May Signal Immunotherapy Response</field_short_title>
  <field_page_description>An NCI Cancer Currents blog about using tumor DNA in blood as a marker of response for a form of immunotherapy.</field_page_description>
  <field_feature_card_description>Tumor DNA in blood may identify patients who are responding to T-cell transfer immunotherapy.</field_feature_card_description>
  <field_list_description>A study suggests that doctors could use circulating tumor DNA to quickly identify patients who are responding to T-cell transfer immunotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-31</field_date_posted>
  <field_date_reviewed>2016-08-30</field_date_reviewed>
  <field_pretty_url>ctdna-immunotherapy-response</field_pretty_url>
  <para_id>1061101</para_id>
  <related_resource_ids>6890295</related_resource_ids>
  <related_resource_ids>6890297</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1061644</term_id>
  <id>1061645</id>
  <title>RAS Community Outreach</title>
  <langcode>en</langcode>
  <field_short_title>RAS Community Outreach</field_short_title>
  <field_page_description>Through community and technical collaborations, workshops and symposia, and the distribution of reference reagents, the RAS Initiative seeks to increase the sharing of knowledge and resources essential to defeating cancers caused by mutant RAS genes.</field_page_description>
  <field_feature_card_description>Through community and technical collaborations, workshops and symposia, and the distribution of reference reagents, the RAS Initiative seeks to increase the sharing of knowledge and resources essential to defeating cancers caused by mutant RAS genes.</field_feature_card_description>
  <field_list_description>Through community and technical collaborations, workshops, and symposia, the RAS Initiative seeks to increase the sharing of knowledge and resources that are essential to defeat cancers caused by mutant RAS genes.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-12</field_date_posted>
  <field_date_reviewed>2016-09-28</field_date_reviewed>
  <para_id>1061645</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1063148</id>
  <title>Study Confirms Benefits of Early Palliative Care for Advanced Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Study Confirms Early Palliative Care Benefits</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about a clinical trial showing that patients with advanced cancer who receive early palliative care had improved quality of life and mood. </field_page_description>
  <field_feature_card_description>Trial shows early palliative care in advanced cancer improves quality of life.</field_feature_card_description>
  <field_list_description>A randomized clinical trial has found that patients who received palliative care along with standard treatment for advanced cancer reported having a better quality of life and mood than patients who did not receive early palliative care. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-10-05</field_date_posted>
  <field_date_reviewed>2016-10-03</field_date_reviewed>
  <field_pretty_url>palliative-care-quality</field_pretty_url>
  <para_id>1063148</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1093741</term_id>
  <id>1093742</id>
  <title>Sexual Health Issues in Women with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Sexual Health Issues in Women</field_short_title>
  <field_page_description>Cancer treatments such as chemotherapy, hormone therapy, and radiation may cause sexual problems in women. Conditions may include vaginal dryness, vaginal stenosis, and vaginal atrophy. Learn how to manage and treat these sexual problems.</field_page_description>
  <field_feature_card_description>Sexual health issues are common in women being treated for cancer.</field_feature_card_description>
  <field_list_description>Sexual health issues and changes in a woman’s sex life are common during treatment for cancer. Learn about factors that determine whether a woman’s sexual health is affected and ways to manage changes during treatment for cancer.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-22</field_date_posted>
  <field_date_reviewed>2017-08-28</field_date_reviewed>
  <para_id>1093742</para_id>
  <related_resource_ids>7107069</related_resource_ids>
  <related_resource_ids>7107070</related_resource_ids>
  <related_resource_ids>7107087</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894084</term_id>
  <id>1093825</id>
  <title>CRCHD Hosts Career Development and Scientific Workshop</title>
  <langcode>en</langcode>
  <field_short_title>CRCHD Hosts Career Development and Scientific Workshop</field_short_title>
  <field_page_description>CRCHD recently hosted a Career Development and Scientific Workshop to support investigators interested in applying for NIH funding opportunities.</field_page_description>
  <field_feature_card_description>CRCHD recently hosted a Career Development and Scientific Workshop to support investigators interested in applying for NIH grants.</field_feature_card_description>
  <field_list_description>CRCHD recently hosted a Career Development and Scientific Workshop to support investigators interested in applying for Continuing Umbrella of Research Experiences (CURE) and cancer health disparities translational research funding opportunities.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-08-30</field_date_posted>
  <field_date_reviewed>2017-08-29</field_date_reviewed>
  <field_pretty_url>crchd-workshop-philadelphia</field_pretty_url>
  <para_id>1093825</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1093957</id>
  <title>NCI supports 10 New Bilateral Collaborative Research Partnerships on Cancer</title>
  <langcode>en</langcode>
  <field_short_title>NCI supports 10 New Bilateral Collaborative Research Partnerships on Cancer</field_short_title>
  <field_page_description>The Center for Global Health works with foreign scientific funding agencies to incentivize cooperation on work that is of importance to the American cancer research enterprise.
</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-08-30</field_date_posted>
  <field_date_reviewed>2017-08-30</field_date_reviewed>
  <field_pretty_url>bilateral-partnerships</field_pretty_url>
  <para_id>1093957</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1095446</id>
  <title>CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia </title>
  <langcode>en</langcode>
  <field_short_title>FDA Approves CAR T-Cell Therapy for Children with Leukemia</field_short_title>
  <field_page_description>Tisagenlecleucel (Kymriah™), a form of CAR T-cell therapy, has been approved by FDA for some children and young adults with advanced acute lymphoblastic leukemia (ALL).</field_page_description>
  <field_feature_card_description>Approval hailed as a milestone for cancer immunotherapy and childhood cancer.</field_feature_card_description>
  <field_list_description>FDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-11</field_date_posted>
  <field_date_reviewed>2017-09-08</field_date_reviewed>
  <field_pretty_url>tisagenlecleucel-fda-childhood-leukemia</field_pretty_url>
  <para_id>1095446</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1095763</id>
  <title>FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer</title>
  <langcode>en</langcode>
  <field_short_title>FDA Expands Approval of Olaparib for Ovarian Cancer</field_short_title>
  <field_page_description>Olaparib tablets (Lynparza®) have been approved by FDA for some women with ovarian cancer to use as a maintenance treatment, this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Approval covers use of olaparib tablets for longer-term treatment.</field_feature_card_description>
  <field_list_description>FDA has granted regular approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-14</field_date_posted>
  <field_date_reviewed>2017-09-12</field_date_reviewed>
  <field_pretty_url>fda-olaparib-ovarian-cancer-maintenance</field_pretty_url>
  <para_id>1095763</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1096315</id>
  <title>Why I Do Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Why I Do Cancer Research</field_short_title>
  <field_page_description>World Cancer Research Day is recognized on September 24, 2017. This day presents an opportunity for all of us to remind the world of the critically important roles research and cancer researchers play in reducing the global burden of cancer. Together with ten other global partners, NCI participated in the planning and </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-09-18</field_date_posted>
  <field_date_reviewed>2017-09-18</field_date_reviewed>
  <field_pretty_url>cancer-research-day</field_pretty_url>
  <para_id>1096315</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1097879</term_id>
  <id>1097880</id>
  <title>National Cryo-Electron Microscopy Facility Team Members</title>
  <langcode>en</langcode>
  <field_short_title>NCEF Team Members</field_short_title>
  <field_page_description>The National Cryo-Electron Microscopy Facility team is responsible for the operational activities of NCEF. Find team member bios and a list of NCEF working group members.</field_page_description>
  <field_list_description>The National Cryo-Electron Microscopy Facility team is responsible for the operational activities of NCEF. View team member bios and a list of NCEF working group members.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-10-13</field_date_posted>
  <field_date_reviewed>2017-10-09</field_date_reviewed>
  <para_id>1097880</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1098487</term_id>
  <id>1098488</id>
  <title>Supporting Informed Decision Making</title>
  <langcode>en</langcode>
  <field_short_title>Supporting Informed Decision Making</field_short_title>
  <field_page_description>CRS conducts portfolio analyses and collects data on scientific topics, funding mechanisms, and investigator characteristics to help NCI leadership make data-driven decisions about the scientific research enterprise.</field_page_description>
  <field_feature_card_description>CRS conducts portfolio analyses and collects data on scientific topics, funding mechanisms, and investigator characteristics to help NCI leadership make data-driven decisions about the scientific research enterprise.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-13</field_date_posted>
  <field_date_reviewed>2017-10-17</field_date_reviewed>
  <para_id>1098488</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1056370</id>
  <title>Olanzapine Helps Prevent Nausea and Vomiting Caused by Chemotherapy</title>
  <langcode>en</langcode>
  <field_short_title>Olanzapine Helps Prevent Nausea and Vomiting Caused by Chemotherapy</field_short_title>
  <field_page_description>An NCI Cancer Currents blog on a large clinical trial that showed an anti-psychotic drug can help prevent nausea and vomiting in patients receiving chemotherapy.</field_page_description>
  <field_feature_card_description>Researchers confirm the drug can help prevent these common chemotherapy-induced side effects.</field_feature_card_description>
  <field_list_description>A drug currently used to treat several psychiatric conditions can help prevent nausea and vomiting in patients receiving chemotherapy, a large clinical trial showed.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-07-21</field_date_posted>
  <field_date_reviewed>2016-07-21</field_date_reviewed>
  <field_pretty_url>olanzapine-chemotherapy-nausea</field_pretty_url>
  <para_id>1056370</para_id>
  <related_resource_ids>6611795</related_resource_ids>
  <related_resource_ids>6611796</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1032046</term_id>
  <id>1060839</id>
  <title>Pancreatic Organoids - A Conversation with Senthil Muthuswamy</title>
  <langcode>en</langcode>
  <field_short_title>Pancreatic Organoids Mimic Patient Tumors</field_short_title>
  <field_page_description>Pancreatic organoids can be established quickly, cheaply, and reliably. They mimic patient histopathology and can be frozen and revived for large studies.</field_page_description>
  <field_feature_card_description>In a new RAS Dialogue, Dr. Senthil Muthuswamy describes how 3-dimensional cultures of pancreatic tumor cells called organoids may improve treatment of pancreatic cancers.</field_feature_card_description>
  <field_list_description>Pancreatic cancer organoids can be established from tumor biopsies more quickly and cheaply and with more success than patient-derived xenografts. The organoids mimic patient histopathology and may allow drugs to be optimized for precision medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-08-25</field_date_posted>
  <field_date_reviewed>2016-08-25</field_date_reviewed>
  <field_pretty_url>senthil-uthuswamy-interview</field_pretty_url>
  <para_id>1060839</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1062133</id>
  <title>Forging Collaborations to Spur Global Progress against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Spurring Global Progress against Cancer </field_short_title>
  <field_page_description>An NCI Cancer Currents blog about international collaborations announced by NCI and NIH to accelerate progress in reducing the global cancer burden.</field_page_description>
  <field_feature_card_description>New collaborations will accelerate progress in reducing the global cancer burden.</field_feature_card_description>
  <field_list_description>NCI and NIH announce efforts to establish international collaborations that can accelerate progress in reducing the global cancer burden.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-22</field_date_posted>
  <field_date_reviewed>2016-09-19</field_date_reviewed>
  <field_pretty_url>global-cancer-collaboration</field_pretty_url>
  <para_id>1062133</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1035160</term_id>
  <id>1062708</id>
  <title>Using Genomics to Better Treat Children with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Genomics and Childhood Cancer</field_short_title>
  <field_page_description>NCI's Center for Cancer Genomics seeks to use genomics to find better treatments for childhood cancer</field_page_description>
  <field_list_description>Every year approximately 13,000 American children and their families receive a cancer diagnosis. By encouraging a collaborative model for pediatric cancer research and interrogating the genomic underpinnings of these diseases, NCI’s Center for Cancer Genomics aims to improve the effectiveness of childhood cancer treatments and preserve the quality of life of young cancer survivors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-09-26</field_date_posted>
  <field_date_reviewed>2016-09-26</field_date_reviewed>
  <field_pretty_url>childhood-cancer-month</field_pretty_url>
  <para_id>1062708</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1062940</id>
  <title>Studies Highlight Potential of Targeting HIF-2 in Kidney Cancer</title>
  <langcode>en</langcode>
  <field_short_title>New Drugs Show Potential Against Kidney Cancer</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post about two studies that suggest a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.</field_page_description>
  <field_feature_card_description>Drugs target molecular driver of most common kidney cancer type.</field_feature_card_description>
  <field_list_description>Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-09-29</field_date_posted>
  <field_date_reviewed>2016-09-29</field_date_reviewed>
  <field_pretty_url>hif2-kidney-cancer</field_pretty_url>
  <para_id>1062940</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1100186</term_id>
  <id>1100187</id>
  <title>Contact the Office of Communications and Public Liaison</title>
  <langcode>en</langcode>
  <field_short_title>Contact &amp; Staff</field_short_title>
  <field_page_description>Find contact and staff information for NCI's Office of Communications and Public Liaison (OCPL). OCPL is staffed by experts in science writing, digital communications, and media and public affairs.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-11-17</field_date_posted>
  <field_date_reviewed>2017-11-14</field_date_reviewed>
  <para_id>1100187</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1100186</term_id>
  <id>1100355</id>
  <title>Peter Garrett</title>
  <langcode>en</langcode>
  <field_short_title>Peter Garrett, Director, OCPL</field_short_title>
  <field_page_description>Bio for Peter Garrett, director of NCI's Office of Communications and Public Liaison (OCPL). As OCPL Director, Peter oversees digital communications and social media, science writing, clearance, stakeholder outreach, media relations, and internal communications.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-11-21</field_date_posted>
  <field_date_reviewed>2017-11-16</field_date_reviewed>
  <field_pretty_url>peter-garrett-bio</field_pretty_url>
  <para_id>1100355</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100545</id>
  <title>Endometrial Cancer Incidence Rising in the US and Worldwide</title>
  <langcode>en</langcode>
  <field_short_title>Endometrial Cancer Incidence Rising Worldwide</field_short_title>
  <field_page_description>Endometrial cancer diagnoses have increased worldwide in recent years, with the highest incidence rates in North America and Europe, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Diagnoses of endometrial cancer have increased worldwide.</field_feature_card_description>
  <field_list_description>Diagnoses of endometrial cancer have increased worldwide in recent years, with rates rising in more than half of the 43 countries studied during the decade ending around 2010, a team of international researchers has shown. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-11-20</field_date_posted>
  <field_date_reviewed>2017-11-20</field_date_reviewed>
  <field_pretty_url>endometrial-cancer-incidence-rising</field_pretty_url>
  <para_id>1100545</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1101896</id>
  <title>Addressing a silent killer – WHO Western Pacific Region Sub-Regional Workshop on Betel (Areca) Nut and Tobacco Use</title>
  <langcode>en</langcode>
  <field_short_title>Addressing a silent killer – WHO Western Pacific Region Sub-Regional Workshop on Betel (Areca) Nut a</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-12-11</field_date_posted>
  <field_date_reviewed>2017-12-11</field_date_reviewed>
  <field_pretty_url>betel-quid-workshop</field_pretty_url>
  <para_id>1101896</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102179</id>
  <title>NCI: Taking Risks to Advance Science </title>
  <langcode>en</langcode>
  <field_short_title>NCI: Taking Risks to Advance Science</field_short_title>
  <field_page_description>Dr. Norman Sharpless discusses his experience thus far as NCI director and areas, like big data, where NCI can help advance cancer research.</field_page_description>
  <field_feature_card_description>Dr. Norman Sharpless discusses areas where NCI can help to advance cancer research.</field_feature_card_description>
  <field_list_description>Norman Sharpless, M.D., offers his thoughts on his experience thus far as NCI director and areas, like big data, where NCI can play an important role in advancing science.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-15</field_date_posted>
  <field_date_reviewed>2017-12-15</field_date_reviewed>
  <field_pretty_url>norman-sharpless-nci-advancing-science</field_pretty_url>
  <para_id>1102179</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102620</id>
  <title>New on NCI’s Websites for December 2017</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI’s Websites for December 2017</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-27</field_date_posted>
  <field_date_reviewed>2017-12-27</field_date_reviewed>
  <field_pretty_url>new-online-December-2017</field_pretty_url>
  <para_id>1102620</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1102818</term_id>
  <id>1102830</id>
  <title>2017 Social Media Events</title>
  <langcode>en</langcode>
  <field_short_title>2017 Social Media Events</field_short_title>
  <field_page_description>Find past social media events involving NCI and its partners from 2017.</field_page_description>
  <field_feature_card_description>Find past social media events involving NCI and its partners from 2017.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-03</field_date_posted>
  <field_date_reviewed>2017-03-28</field_date_reviewed>
  <para_id>1102830</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1102951</term_id>
  <id>1102952</id>
  <title>Volunteer Opportunities and Events</title>
  <langcode>en</langcode>
  <field_short_title>Volunteer Opportunities</field_short_title>
  <field_page_description>Volunteer with Scientists in the Community. NCI Trainees can participate upcoming events or an ongoing opportunity with flexible days and times.</field_page_description>
  <field_feature_card_description>Participate in an upcoming event or an ongoing opportunity with flexible days and times.</field_feature_card_description>
  <field_list_description>Volunteer with Scientists in the Community. Participate in an upcoming event or an ongoing opportunity with flexible days and times.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-05</field_date_reviewed>
  <para_id>1102952</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1104028</term_id>
  <id>1104029</id>
  <title>Intramural Continuing Umbrella of Research Experiences (iCURE)</title>
  <langcode>en</langcode>
  <field_short_title>iCURE</field_short_title>
  <field_page_description>iCURE supports mentored research experiences for students and scientists in the NCI research community. iCURE encourages the participation of underrepresented individuals.</field_page_description>
  <field_feature_card_description>iCURE encourages research experiences for underrepresented students and scientists in the NCI intramural research community.</field_feature_card_description>
  <field_list_description>iCURE supports mentored research experiences of undergraduate students, post-baccalaureate and post-master’s individuals, graduate students, and postdoctoral fellows in the NCI research community. iCURE encourages the participation of individuals from underrepresented populations. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-06</field_date_posted>
  <field_date_reviewed>2018-01-16</field_date_reviewed>
  <para_id>1104029</para_id>
  <related_resource_ids>7268424</related_resource_ids>
  <related_resource_ids>7268427</related_resource_ids>
  <related_resource_ids>7268428</related_resource_ids>
  <related_resource_ids>7268436</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1104185</id>
  <title>Nilotinib Can Be Discontinued in Some Patients with Chronic Myelogenous Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Nilotinib Can Be Stopped in Some Patients with CML</field_short_title>
  <field_page_description>FDA now says nilotinib (Tasignia) can be safely stopped in some patients with CML whose cancer has been in remission for an extended period.</field_page_description>
  <field_feature_card_description>Patients in remission for extended period can safely stop taking the drug, FDA says.</field_feature_card_description>
  <field_list_description>On December 22, FDA approved an update to the label of nilotinib (Tasignia) that states that some patients with CML who are taking nilotinib and whose cancer has been in remission for an extended period can safely stop taking it.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-19</field_date_posted>
  <field_date_reviewed>2018-01-19</field_date_reviewed>
  <field_pretty_url>nilotinib-cml-fda-discontinue</field_pretty_url>
  <para_id>1104185</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102630</term_id>
  <id>1105752</id>
  <title>Recommended Reads in Cancer Genomics</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genomics Reading List</field_short_title>
  <field_page_description>CCG leadership recommends some leisure reading and academic resources in cancer genomics.</field_page_description>
  <field_feature_card_description>Cancer Genomics Reading List</field_feature_card_description>
  <field_list_description>CCG Director, Dr. Louis M. Staudt and The Cancer Genome Atlas Director, Dr. Jean Claude Zenklusen pick their favorite books and review articles related to cancer genomics. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-20</field_date_posted>
  <field_date_reviewed>2018-02-12</field_date_reviewed>
  <field_pretty_url>winter-reading-list</field_pretty_url>
  <para_id>1105752</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerResearch</CONTENTTYPENAME>
  <term_id>1107038</term_id>
  <id>1107039</id>
  <title>Gastrointestinal Carcinoid Tumors Research</title>
  <langcode>en</langcode>
  <field_short_title>Research</field_short_title>
  <field_page_description>Find research articles on gastrointestinal carcinoid tumors, which may include news stories, clinical trials, blog posts, and descriptions of active studies.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-12</field_date_posted>
  <field_date_reviewed>2018-02-12</field_date_reviewed>
  <para_id>1107039</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107042</id>
  <title>New Cancer Treatment Approach Targets Circadian Clock</title>
  <langcode>en</langcode>
  <field_short_title>Targeting the Circadian Clock to Treat Cancer</field_short_title>
  <field_page_description>Two compounds that target components of the circadian clock killed several types of cancer cells in the lab and slowed the growth of brain cancer in mice without harming healthy cells, as this Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>Blocking components of circadian clock kills cancer cells in lab study.</field_feature_card_description>
  <field_list_description>Two compounds that target components of the circadian clock killed several types of cancer cells in the lab and slowed the growth of brain tumors in mice without harming healthy cells, a new study showed.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-13</field_date_posted>
  <field_date_reviewed>2018-02-12</field_date_reviewed>
  <field_pretty_url>targeting-circadian-clock-cancer</field_pretty_url>
  <para_id>1107042</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>1107074</term_id>
  <id>1107075</id>
  <title>NCI’s Role in Immunotherapy Research</title>
  <langcode>en</langcode>
  <field_short_title>NCI’s Role in Immunotherapy Research</field_short_title>
  <field_page_description>Advances in cancer immunotherapy are the result of several decades of basic research, much of it supported by NCI, on how the immune system responds to cancer. Learn how NCI continues to support a wide range of research, from basic research to clinical trials, to advance the field of cancer immunotherapy.</field_page_description>
  <field_feature_card_description>NCI supports a wide range of immunotherapy research, from basic science to clinical trials.</field_feature_card_description>
  <field_list_description>Advances in cancer immunotherapy are the result of several decades of basic research, much of it supported by NCI, on how the immune system responds to cancer. NCI continues to support a wide range of research, from basic research to clinical trials, to advance the field of cancer immunotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-13</field_date_reviewed>
  <para_id>1107075</para_id>
  <related_resource_ids>7190498</related_resource_ids>
  <related_resource_ids>7190499</related_resource_ids>
  <related_resource_ids>7190500</related_resource_ids>
  <related_resource_ids>7190501</related_resource_ids>
  <related_resource_ids>7190502</related_resource_ids>
  <related_resource_ids>7190503</related_resource_ids>
  <related_resource_ids>7190504</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107110</id>
  <title>Clinical Trials to Treat Pituitary Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Pituitary Tumors</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>pituitary-tumors</field_pretty_url>
  <para_id>1107110</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1107678</id>
  <title>Can Oxygen “Microbubbles” Make Radiation Therapy More Effective?</title>
  <langcode>en</langcode>
  <field_short_title>Using Oxygen “Microbubbles” to Improve Radiation Therapy</field_short_title>
  <field_page_description>Oxygen-carrying “microbubbles” could potentially improve the effectiveness of radiation therapy in the treatment of breast cancer, findings from a study in mice suggest. Using the bubbles along with radiation slowed tumor growth more than radiation alone, as this NCI Cancer Currents post reports.</field_page_description>
  <field_feature_card_description>In mouse study, bubbles helped slow tumor growth.</field_feature_card_description>
  <field_list_description>A new study in mice raises the possibility that using microscopic, oxygen-carrying bubbles may improve the effectiveness of radiation therapy in the treatment of breast cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-20</field_date_posted>
  <field_date_reviewed>2018-02-20</field_date_reviewed>
  <field_pretty_url>microbubbles-radiation-breast-cancer</field_pretty_url>
  <para_id>1107678</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109911</id>
  <title>Drug Combination Reduces Number of Colorectal Polyps in Patients with Hereditary Cancer Syndrome</title>
  <langcode>en</langcode>
  <field_short_title>Drug Combo Decreases Colorectal Polyps in People with FAP</field_short_title>
  <field_page_description>In people with familial adenomatous polyposis, or FAP, a combination treatment of erlotinib (Tarceva) and sulindac (Aflodac) decreased the number of precancerous colorectal polyps, according to recently published clinical trial results.</field_page_description>
  <field_feature_card_description>Erlotinib and sulindac reduced colorectal polyps by more than two-thirds.</field_feature_card_description>
  <field_list_description>People with FAP, an inherited condition that greatly increases their risk of gastrointestinal cancer, who took the drugs erlotinib (Tarceva) and sulindac (Aflodac) saw a substantial decrease in the number of precancerous lesions in the colon and rectum.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-14</field_date_posted>
  <field_date_reviewed>2018-03-13</field_date_reviewed>
  <field_pretty_url>fap-erlotinib-sulindac-colorectal-polyps</field_pretty_url>
  <para_id>1109911</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1110615</id>
  <title>Abemaciclib Approval Expands Initial Treatment Options for Advanced Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Abemaciclib Gets New Approval for Breast Cancer</field_short_title>
  <field_page_description>DA has approved the CDK4/6 inhibitor abemaciclib (Verzenio) as a first-line treatment in some women with advanced or metastatic breast cancer. Under the approval, it must be used in combination with an aromatase inhibitor, as this Cancer Currents blog post explains.</field_page_description>
  <field_feature_card_description>Drug now also approved for initial treatment of metastatic disease.</field_feature_card_description>
  <field_list_description>FDA has approved the CDK4/6 inhibitor abemaciclib (Verzenio) as a first-line treatment in some women with advanced or metastatic breast cancer. Under the approval, the drug must be used in combination with an aromatase inhibitor.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-20</field_date_posted>
  <field_date_reviewed>2018-03-20</field_date_reviewed>
  <field_pretty_url>abemaciclib-fda-breast-cancer-first-line</field_pretty_url>
  <para_id>1110615</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1111690</id>
  <title>NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>NCTN Navigator Opens to Cancer Researchers </field_short_title>
  <field_page_description>NCI has launched Navigator, a new resource for blood and tissue specimens and clinical data from phase 3 cancer clinical trials. As this Cancer Currents post explains, the resource can help researchers answer important questions about patient care.</field_page_description>
  <field_feature_card_description>New resource houses patient specimens from large NCI-funded clinical trials. </field_feature_card_description>
  <field_list_description>NCI has launched Navigator, a new resource for researchers interested in using specimens and clinical data collected from large cancer clinical trials. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-02</field_date_posted>
  <field_date_reviewed>2018-03-30</field_date_reviewed>
  <field_pretty_url>nctn-navigator-cancer-clinical-trial-specimens</field_pretty_url>
  <para_id>1111690</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1114581</id>
  <title>Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers</title>
  <langcode>en</langcode>
  <field_short_title>Experimental Test Detects Endometrial and Ovarian Cancers</field_short_title>
  <field_page_description>Finding a way to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment, has been a challenge for cancer researchers. An experimental liquid biopsy test called PapSEEK may help to change that, this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Experimental liquid biopsy test detects cancer DNA in Pap test samples.</field_feature_card_description>
  <field_list_description>Scientists have struggled to come up with a simple test to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment. Can a liquid biopsy test called PapSEEK change that? </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-02</field_date_posted>
  <field_date_reviewed>2018-05-02</field_date_reviewed>
  <field_pretty_url>liquid-biopsy-screening-test-endometrial-ovarian</field_pretty_url>
  <para_id>1114581</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114846</term_id>
  <id>1114851</id>
  <title>Courses and Fellowships for Trainees and Fellows</title>
  <langcode>en</langcode>
  <field_short_title>Courses and Fellowships</field_short_title>
  <field_page_description>Cancer research fellows and trainees at NCI can take advantage of scientific and professional development courses. Current and prospective trainees will also find a listing of fellowships opportunities. Learn more about courses and fellowships. </field_page_description>
  <field_feature_card_description>Trainees will find listing of scientific and professional development opportunities. </field_feature_card_description>
  <field_list_description>Take advantage of scientific and professional development courses during your time at NCI and learn about additional fellowships. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-04</field_date_reviewed>
  <para_id>1114851</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1115758</term_id>
  <id>1115765</id>
  <title>Collaboration and Team Science: A Field Guide</title>
  <langcode>en</langcode>
  <field_short_title>Collaboration and Team Science</field_short_title>
  <field_page_description>Collaboration and Team Science: A Field Guide provides insight into the practices of conducting collaborative work. Since its 2010 publication, the authors have worked and learned from teams and organizations all over the world. Learn from these experiences in the second edition of the Team Science Field Guide.</field_page_description>
  <field_feature_card_description>This newly updated field guide from NCI provides insight into the practices of conducting collaborative work.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-18</field_date_posted>
  <field_date_reviewed>2018-05-17</field_date_reviewed>
  <para_id>1115765</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>922517</term_id>
  <id>1117070</id>
  <title>Paulette Gray, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Paulette Gray, Ph.D.</field_short_title>
  <field_page_description>Paulette S. Gray, Ph.D. is the Director for the Division of Extramural Activities (DEA). As the director of the division, she is responsible for the overall scientific, fiscal, and administrative management of the division, including broad strategic planning, development, implementation, and evaluation.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-06-05</field_date_posted>
  <field_date_reviewed>2018-06-05</field_date_reviewed>
  <field_pretty_url>paulette-gray-bio</field_pretty_url>
  <para_id>1117070</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1134297</term_id>
  <id>1117589</id>
  <title>TCGA Timeline &amp; Milestones</title>
  <langcode>en</langcode>
  <field_short_title>Timeline &amp; Milestones</field_short_title>
  <field_page_description>The events leading up to TCGA's inception in 2006 and major milestones in the program's history.</field_page_description>
  <field_feature_card_description>The events leading up to the TCGA's inception in 2006 and major milestones in the program's history.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-13</field_date_posted>
  <field_date_reviewed>2018-06-13</field_date_reviewed>
  <para_id>1117589</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1118607</id>
  <title>Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer </title>
  <langcode>en</langcode>
  <field_short_title>Chemotherapy Change Improves Pancreatic Cancer Outcomes</field_short_title>
  <field_page_description>For people with early-stage pancreatic cancer, results from two clinical trials suggest that altering the type and timing of chemotherapy improves survival. The findings will likely change the standard of care, as this Cancer Currents post explains.</field_page_description>
  <field_feature_card_description>Results suggest new standard of care for early-stage disease.</field_feature_card_description>
  <field_list_description>Results from two clinical trials are expected to improve the outlook for some people with early-stage pancreatic cancer. Altering the chemotherapy drugs used and the timing of treatment substantially improved survival. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-28</field_date_posted>
  <field_date_reviewed>2018-06-27</field_date_reviewed>
  <field_pretty_url>pancreatic-cancer-chemotherapy-regimen-change</field_pretty_url>
  <para_id>1118607</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1118652</id>
  <title>NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>NExT: Advancing Promising Cancer Therapies</field_short_title>
  <field_page_description>The NCI Experimental Therapeutics (NExT) program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to clinical trials. Learn about recent successes from NExT in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Recent successes highlight the program’s growth.</field_feature_card_description>
  <field_list_description>The NCI Experimental Therapeutics (NExT) program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-29</field_date_posted>
  <field_date_reviewed>2018-06-28</field_date_reviewed>
  <field_pretty_url>next-developing-cancer-therapies</field_pretty_url>
  <para_id>1118652</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1119325</id>
  <title>Can Age Affect Response to Immune Checkpoint Inhibitors?</title>
  <langcode>en</langcode>
  <field_short_title>Patient Age and Response to Immune Checkpoint Inhibitors</field_short_title>
  <field_page_description>The age of patients with melanoma may influence how well their cancer responds to immune checkpoint inhibitors. As this Cancer Currents post explains, researchers who led the study believe the findings may point to a strategy to improve responses to these immunotherapy drugs.</field_page_description>
  <field_feature_card_description>Older people respond better to the immunotherapy, study finds.</field_feature_card_description>
  <field_list_description>A new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors. Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-06</field_date_posted>
  <field_date_reviewed>2018-07-03</field_date_reviewed>
  <field_pretty_url>age-checkpoint-inhibitor-response</field_pretty_url>
  <para_id>1119325</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129036</term_id>
  <id>1119356</id>
  <title>Outcomes &amp; Impact of The Cancer Genome Atlas</title>
  <langcode>en</langcode>
  <field_short_title>TCGA Outcomes &amp; Impact</field_short_title>
  <field_page_description>TCGA has changed our understanding of cancer, how research is conducted, how the disease is treated in the clinic, and more. Learn about the impact of the TCGA program.</field_page_description>
  <field_feature_card_description>TCGA has changed our understanding of cancer, how research is conducted, how the disease is treated in the clinic, and more.</field_feature_card_description>
  <field_list_description>The outcomes and impact of TCGA are far-reaching. Learn how the program has changed our understanding of cancer, how research is conducted, how the disease is treated in the clinic, and more.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-07-05</field_date_reviewed>
  <para_id>1119356</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1119642</term_id>
  <id>1119646</id>
  <title>Cancer Research Training Award (CRTA)</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Research Training Award (CRTA)</field_short_title>
  <field_page_description>The Cancer Research Training Award (CRTA) is an NCI fellowship award with an “umbrella” appointment mechanism for fellowship programs within NCI divisions, offices, and centers. Learn more about CRTA at NCI. </field_page_description>
  <field_feature_card_description>CRTA is a ellowship award with an “umbrella” appointment mechanism for fellowships throughout NCI. </field_feature_card_description>
  <field_list_description>The Cancer Research Training Award (CRTA) is an NCI fellowship award with an “umbrella” appointment mechanism for fellowship programs within NCI divisions, offices, and centers.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-07-11</field_date_posted>
  <field_date_reviewed>2018-07-11</field_date_reviewed>
  <para_id>1119646</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11912</term_id>
  <id>14091</id>
  <title>Gestational Trophoblastic Disease—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Gestational Trophoblastic Disease</field_short_title>
  <field_page_description>Gestational trophoblastic disease (GTD) is a general term for rare tumors that form from the tissues surrounding fertilized egg. GTD is often found early and usually cured. Start here to find information on gestational trophoblastic disease treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about gestational trophoblastic disease.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14091</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>11886</term_id>
  <id>14237</id>
  <title>Mammograms</title>
  <langcode>en</langcode>
  <field_short_title>Mammograms</field_short_title>
  <field_page_description>A fact sheet that defines screening and diagnostic mammograms; discusses the benefits and potential harms of screening mammography; and summarizes how findings, including breast density, are reported.</field_page_description>
  <field_feature_card_description>Learn about mammograms, their benefits and potential harms, and new mammogram technologies.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-01-06</field_date_posted>
  <field_date_reviewed>2016-12-07</field_date_reviewed>
  <field_pretty_url>mammograms-fact-sheet</field_pretty_url>
  <para_id>14237</para_id>
  <related_resource_ids>7260926</related_resource_ids>
  <related_resource_ids>7260927</related_resource_ids>
  <related_resource_ids>7260929</related_resource_ids>
  <related_resource_ids>7260933</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>952652</term_id>
  <id>14308</id>
  <title>PDQ&amp;reg; Cancer Information Summaries: Adult Treatment</title>
  <langcode>en</langcode>
  <field_short_title>Adult Treatment</field_short_title>
  <field_page_description>Treatment options for adult cancers.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14308</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911145</term_id>
  <id>14469</id>
  <title>Physical Activity and Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Physical Activity and Cancer</field_short_title>
  <field_page_description>A fact sheet that summarizes evidence linking exercise and other physical activity, including work and household chores, to reduced cancer risks.</field_page_description>
  <field_feature_card_description>This fact sheet summarizes how physical activity, or the lack of it, is linked to cancer.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-02-03</field_date_posted>
  <field_date_reviewed>2017-01-27</field_date_reviewed>
  <field_pretty_url>physical-activity-fact-sheet</field_pretty_url>
  <para_id>14469</para_id>
  <related_resource_ids>6893079</related_resource_ids>
  <related_resource_ids>6893080</related_resource_ids>
  <related_resource_ids>6893081</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>139068</id>
  <title>Radiation Therapy after Breast-Conserving Surgery Improves Survival</title>
  <langcode>en</langcode>
  <field_short_title>Radiation Therapy after Breast-Conserving Surgery Improves Survival</field_short_title>
  <field_page_description>Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease.</field_page_description>
  <field_feature_card_description>Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease.</field_feature_card_description>
  <field_list_description>Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease, according to updated results from a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-02</field_date_posted>
  <field_date_reviewed>2011-12-02</field_date_reviewed>
  <field_pretty_url>radiation-improves-survival</field_pretty_url>
  <para_id>139068</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>150014</id>
  <title>Two Drugs that Hit One Target Improve Survival in Women with Metastatic Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Drug Combination Improves Survival in Women with Metastatic Breast Cancer</field_short_title>
  <field_page_description>Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy may be a new treatment option for women with HER2-positive metastatic breast cancer.</field_page_description>
  <field_feature_card_description>Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and the investigational agent pertuzumab, with chemotherapy may be a new treatment option for women with HER2-positive metastatic breast cancer.</field_feature_card_description>
  <field_list_description>Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and pertuzumab, with chemotherapy is a new treatment option for women with HER2-positive metastatic breast cancer, according to final results from a large clinical trial.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-21</field_date_posted>
  <field_date_reviewed>2011-12-21</field_date_reviewed>
  <field_pretty_url>two-drugs-one-target</field_pretty_url>
  <para_id>150014</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771999</term_id>
  <id>772117</id>
  <title>Pediatric Leukemia and Lymphoma Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric Leukemia and Lymphoma Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772117</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogSeries</CONTENTTYPENAME>
  <term_id>919769</term_id>
  <id>792905</id>
  <title>CGH Spotlight Blog</title>
  <langcode>en</langcode>
  <field_short_title>CGH Spotlight Blog</field_short_title>
  <field_page_description>Stay up-to-date with the latest information and news from CGH and the global health communities.</field_page_description>
  <field_feature_card_description>Stay up-to-date with the latest information and news from CGH and the global health communities.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-06-17</field_date_posted>
  <field_date_reviewed>2014-06-17</field_date_reviewed>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>919529</term_id>
  <id>799546</id>
  <title>RAS Central</title>
  <langcode>en</langcode>
  <field_short_title>RAS Central</field_short_title>
  <field_page_description>RAS Central is NCI's online forum for RAS researchers, featuring blog posts, an online discussion forum, events and videos, and other useful tools and resources.</field_page_description>
  <field_feature_card_description>To help solve the 30-year challenge of how to treat RAS-driven cancers, we need an open model of collaboration. RAS Central is the hub for the RAS blog, online discussion forum, and other useful resources. Help advance the research and join our community.</field_feature_card_description>
  <field_list_description>To help solve the 30-year challenge of how to treat RAS-driven cancers, we need an open model of collaboration. Whether you are a dedicated RAS expert or curious researcher, we encourage you to help advance the research by joining our RAS community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <para_id>799546</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069528</term_id>
  <id>866187</id>
  <title>Quantitative Assays for RAS Pathway Proteins and Phosphorylation States</title>
  <langcode>en</langcode>
  <field_short_title>Quantitative Assays for RAS Pathway Proteins and Phosphorylation States</field_short_title>
  <field_page_description>The NCI CPTAC program is applying its expertise in quantitative proteomics to develop assays for RAS pathway proteins.  Targets include key phosphopeptides that should increase our understanding of how the RAS pathway is regulated.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-01</field_date_posted>
  <field_date_reviewed>2014-12-01</field_date_reviewed>
  <field_pretty_url>ras-quantitative-assays</field_pretty_url>
  <para_id>866187</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>860262</term_id>
  <id>866206</id>
  <title>Building on Opportunities in Cancer Research: NCI’s Annual Plan and Budget Proposal for FY 2016</title>
  <langcode>en</langcode>
  <field_short_title>Building on Opportunities in Cancer Research: NCI’s Annual Plan and Budget Proposal for FY 2016</field_short_title>
  <field_page_description>NCI’s Director, Dr. Harold Varmus, introduces the NCI Annual Plan and Budget Proposal for Fiscal Year 2016.</field_page_description>
  <field_feature_card_description>NCI’s Director introduces the NCI Annual Plan and Budget Proposal for Fiscal Year 2016.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-12-02</field_date_posted>
  <field_date_reviewed>2014-12-02</field_date_reviewed>
  <field_pretty_url>NCIresearchfuture</field_pretty_url>
  <para_id>866206</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>912567</term_id>
  <id>867905</id>
  <title>Cancer Genomics Overview</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Genomics Overview</field_short_title>
  <field_page_description>Cancer genomics uses technologies such as sequencing to identify DNA and RNA alterations, define molecular subtypes, and develop precision medicine in oncology.</field_page_description>
  <field_list_description>Cancer is caused by changes to the cell’s DNA. Cancer genomics uses technologies such as sequencing to identify genetic alterations, define molecular subtypes, and develop precision medicine approaches for cancer treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-13</field_date_posted>
  <field_date_reviewed>2014-12-05</field_date_reviewed>
  <para_id>867905</para_id>
  <related_resource_ids>6567827</related_resource_ids>
  <related_resource_ids>6567828</related_resource_ids>
  <related_resource_ids>6567829</related_resource_ids>
  <related_resource_ids>6567830</related_resource_ids>
  <related_resource_ids>6567831</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>904107</term_id>
  <id>870061</id>
  <title>Message from the Director</title>
  <langcode>en</langcode>
  <field_short_title>Message from the Director</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-02-17</field_date_posted>
  <field_date_reviewed>2014-12-10</field_date_reviewed>
  <para_id>870061</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882493</term_id>
  <id>882505</id>
  <title>Formaldehyde</title>
  <langcode>en</langcode>
  <field_short_title>Formaldehyde</field_short_title>
  <field_page_description>Learn about formaldehyde, which can raise your risk of myeloid leukemia and rare cancers of or near the nasal cavity. Formaldehyde is used in pressed-wood building materials, fungicides, germicides, disinfectants, and certain preservatives. Other sources include tobacco smoke and car emissions.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-02-14</field_date_reviewed>
  <para_id>882505</para_id>
  <related_resource_id>7252884</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>882522</term_id>
  <id>882531</id>
  <title>Aristolochic Acids </title>
  <langcode>en</langcode>
  <field_short_title>Aristolochic Acids </field_short_title>
  <field_page_description>Learn about aristolochic acids, which may increase your risk of bladder cancer and cancers of the upper urinary tract (renal pelvis and ureter).  Aristolochic acids are found naturally in many types of plants, some of which are used in herbal products marketed as dietary supplements.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-20</field_date_posted>
  <field_date_reviewed>2019-01-14</field_date_reviewed>
  <para_id>882531</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>915875</term_id>
  <id>883453</id>
  <title>Cancer-Causing Substances in the Environment</title>
  <langcode>en</langcode>
  <field_short_title>Cancer-Causing Substances</field_short_title>
  <field_page_description>This page lists substances that may cause or contribute to the development of cancer, depending on amount of exposure, an individual's genetic background, and other factors.</field_page_description>
  <field_feature_card_description>Learn about some of the most likely carcinogens to affect human health.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-18</field_date_posted>
  <field_date_reviewed>2014-12-16</field_date_reviewed>
  <para_id>883453</para_id>
  <related_resource_ids>7194198</related_resource_ids>
  <related_resource_ids>7194226</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>11502</term_id>
  <id>889734</id>
  <title>Journal of the National Cancer Institute, Published by Oxford University Press, Is Not Affiliated With NCI</title>
  <langcode>en</langcode>
  <field_short_title>JNCI, Published by Oxford University Press, Is Not Affiliated With NCI</field_short_title>
  <field_page_description>The Journal of the National Cancer Institute was created by the NCI in the 1940s, but is no longer published by or affiliated with the Institute.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-08</field_date_posted>
  <field_date_reviewed>2015-01-05</field_date_reviewed>
  <field_pretty_url>jnci</field_pretty_url>
  <para_id>889734</para_id>
  <related_resource_id>5093564</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>894075</id>
  <title>Analyzing the Gut Microbiome to Help Detect Colorectal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Analyzing the Gut Microbiome to Help Detect Colorectal Cancer</field_short_title>
  <field_page_description>Two studies suggest that changes in the gut microbiome could help distinguish people with healthy colons from those with colorectal polyps or colorectal cancer.</field_page_description>
  <field_feature_card_description>Two studies suggest that changes in the gut microbiome could help distinguish people with healthy colons from those with colorectal polyps or colorectal cancer.</field_feature_card_description>
  <field_list_description>New research suggests that identifying specific changes in the gut microbiome could potentially help screen patients for colorectal cancer.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-01-13</field_date_posted>
  <field_date_reviewed>2015-01-12</field_date_reviewed>
  <field_pretty_url>gut-microbiome</field_pretty_url>
  <para_id>894075</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>918919</term_id>
  <id>896515</id>
  <title>Drugs Approved for Esophageal Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Drugs Approved for Esophageal Cancer</field_short_title>
  <field_page_description>This page lists cancer drugs approved by the Food and Drug Administration (FDA) for esophageal cancer. The list includes generic names and brand names. The drug names link to NCI's Cancer Drug Information summaries.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-15</field_date_posted>
  <field_date_reviewed>2015-01-15</field_date_reviewed>
  <field_pretty_url>esophageal</field_pretty_url>
  <para_id>896515</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>828705</term_id>
  <id>899250</id>
  <title>Grantee Spotlight: Veena Rao, Ph.D. - Unraveling the Mysteries of BRCA1 in African American Women</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Veena Rao, Ph.D. - Unraveling the Mysteries of BRCA1 in African American Women</field_short_title>
  <field_page_description>Dr. Veena N. Rao, a CRCHD PACHE U54 grantee, researches the BRCA1 gene and its role in breast and ovarian cancer in diverse populations and trains diverse scholars in cancer health disparities research.</field_page_description>
  <field_feature_card_description>Dr. Rao researches the BRCA1 gene and trains diverse scholars in her lab.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-10-20</field_date_posted>
  <field_date_reviewed>2014-10-20</field_date_reviewed>
  <field_pretty_url>rao-spotlight</field_pretty_url>
  <para_id>899250</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>792907</term_id>
  <id>902306</id>
  <title>CGH Celebrates World Cancer Day 2015</title>
  <langcode>en</langcode>
  <field_short_title>CGH Celebrates World Cancer Day 2015</field_short_title>
  <field_page_description>List of activities CGH is participating in for World Cancer Day 2015.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-01-30</field_date_posted>
  <field_date_reviewed>2015-01-30</field_date_reviewed>
  <field_pretty_url>World-Cancer-Day-2015</field_pretty_url>
  <para_id>902306</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903594</term_id>
  <id>903599</id>
  <title>People in Health Care</title>
  <langcode>en</langcode>
  <field_short_title>People in Health Care</field_short_title>
  <field_page_description>Information about the treatment team of health care providers who work together to help cancer patients.</field_page_description>
  <field_feature_card_description>Information about the treatment team of health care providers who work together to help cancer patients.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-10</field_date_posted>
  <field_date_reviewed>2015-02-02</field_date_reviewed>
  <para_id>903599</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>903752</term_id>
  <id>903689</id>
  <title>How Cancer Is Diagnosed</title>
  <langcode>en</langcode>
  <field_short_title>Diagnosis</field_short_title>
  <field_page_description>Learn about tests and procedures that diagnose cancer. Your doctor may ask about personal and family medical history or order lab tests, imaging scans, or a biopsy.</field_page_description>
  <field_feature_card_description>Learn about tests and procedures that doctors might order to diagnose cancer. </field_feature_card_description>
  <field_list_description>If you have a symptom that does not go away or a screening test result that suggests cancer, the doctor must find out whether it is due to cancer or some other cause. Learn about tests and procedures that help figure out the reason for your problems.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-03-09</field_date_posted>
  <field_date_reviewed>2015-03-09</field_date_reviewed>
  <para_id>903689</para_id>
  <related_resource_ids>7158675</related_resource_ids>
  <related_resource_ids>7158677</related_resource_ids>
  <related_resource_ids>7158678</related_resource_ids>
  <related_resource_ids>7158679</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1093791</term_id>
  <id>1093801</id>
  <title>Engineering Personalized Micro-Tumor Ecosystems</title>
  <langcode>en</langcode>
  <field_short_title>Engineering Micro-Tumor Ecosystems</field_short_title>
  <field_page_description>This study seeks to develop a micronized tumor ecosystem which can be used to choose the most effective cancer therapy for a patient before initiation of treatment.</field_page_description>
  <field_feature_card_description>NCI-Funded grant that investigates Engineering Micro-Tumor Ecosystems.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-27</field_date_posted>
  <field_date_reviewed>2017-09-27</field_date_reviewed>
  <para_id>1093801</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1096918</term_id>
  <id>1096919</id>
  <title>TMIST (Tomosynthesis Mammographic Imaging Screening Trial)</title>
  <langcode>en</langcode>
  <field_short_title>TMIST (Tomosynthesis Mammographic Imaging Screening Trial)</field_short_title>
  <field_page_description>TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).</field_page_description>
  <field_feature_card_description>TMIST is a randomized breast screening trial that compares standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-09-26</field_date_posted>
  <field_date_reviewed>2017-09-25</field_date_reviewed>
  <para_id>1096919</para_id>
  <related_resource_ids>6713441</related_resource_ids>
  <related_resource_ids>6713443</related_resource_ids>
  <related_resource_ids>6713444</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1097711</id>
  <title>Addressing the Global Burden of Breast Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Addressing the Global Burden of Breast Cancer</field_short_title>
  <field_page_description>The US National Cancer Institute’s Center for Global Health (CGH) has been a key partner in a multi-institutional expert team that has developed a set of publications to address foundational concerns in breast cancer care across the cancer care continuum and within limited resource settings.  </field_page_description>
  <field_feature_card_description>NCI's Center for Global Health has helped develop publications offering resource-appropriate guidelines about breast cancer care.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-06</field_date_posted>
  <field_date_reviewed>2017-10-06</field_date_reviewed>
  <field_pretty_url>breast-cancer</field_pretty_url>
  <para_id>1097711</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>45782</term_id>
  <id>1097899</id>
  <title>Ofelia Olivero, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>Ofelia Olivero, Ph.D.</field_short_title>
  <field_page_description>Read more about Intramural Diversity Workforce Branch Chief Ofelia Olivero, Ph.D.</field_page_description>
  <field_list_description>Biography of Ofelia Olivero, Ph.D.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-10-10</field_date_posted>
  <field_date_reviewed>2017-10-10</field_date_reviewed>
  <field_pretty_url>ofelia-olivero</field_pretty_url>
  <para_id>1097899</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1098454</term_id>
  <id>1098455</id>
  <title>2016 Outstanding Investigator Award Recipients</title>
  <langcode>en</langcode>
  <field_short_title>NCI Outstanding Investigator Award Recipients</field_short_title>
  <field_page_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_page_description>
  <field_feature_card_description>Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-10-14</field_date_posted>
  <field_date_reviewed>2015-10-14</field_date_reviewed>
  <para_id>1098455</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1099364</term_id>
  <id>1099383</id>
  <title>Create an Adult Immunotherapy Network</title>
  <langcode>en</langcode>
  <field_short_title>Adult Immunotherapy Network</field_short_title>
  <field_page_description>This Cancer Moonshot initiative aims to establish an adult cancer immunotherapy network to develop immune-based approaches for the treatment and prevention of cancer in adult patients and discover why immunotherapy is effective in some patients but not in others. </field_page_description>
  <field_list_description>Establish a cancer immunotherapy research network to develop immune-based approaches for the treatment and prevention of cancer in adult patients.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2017-10-30</field_date_reviewed>
  <para_id>1099383</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1099367</term_id>
  <id>1099385</id>
  <title>Minimize Cancer Treatment’s Debilitating Side Effects</title>
  <langcode>en</langcode>
  <field_short_title>Symptom Management</field_short_title>
  <field_page_description>Cancer Moonshot initiative to develop a better system for monitoring and managing patient-reported side effects, in an effort to minimize debilitating side effects and reduce cancer costs related to poorly controlled symptoms.</field_page_description>
  <field_feature_card_description>Patients may abandon their effective cancer treatments due to debilitating side effects. Guidelines for routine monitoring can minimize harmful symptoms.</field_feature_card_description>
  <field_list_description>Accelerate the development of guidelines for routine monitoring and management of patient reported symptoms to minimize debilitating side effects of cancer and its treatment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-10-22</field_date_posted>
  <field_date_reviewed>2017-10-30</field_date_reviewed>
  <para_id>1099385</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1066360</term_id>
  <id>1100197</id>
  <title>Engaging Brazilian Partners in Collaborative Cancer Research</title>
  <langcode>en</langcode>
  <field_short_title>Engaging Brazilian Partners in Collaborative Cancer Research</field_short_title>
  <field_page_description>CGH engages with Brazilian partners to further collaborative cancer research projects. </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-11-14</field_date_posted>
  <field_date_reviewed>2017-11-14</field_date_reviewed>
  <field_pretty_url>brazil-visit</field_pretty_url>
  <para_id>1100197</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070074</term_id>
  <id>1100551</id>
  <title>Hope for a Rare Disease Through TCGA: My Perspective as a Caregiver, Patient Advocate, and Physician </title>
  <langcode>en</langcode>
  <field_short_title>Hope for a Rare Disease Through TCGA</field_short_title>
  <field_page_description>Faced with a rare disease, a caregiver founds a patient advocacy group and joins a collaborative genomic research effort.</field_page_description>
  <field_feature_card_description>The CURE OM patient advocacy group teams up with TCGA</field_feature_card_description>
  <field_list_description>The founder of the Melanoma Research Foundation's Community United for Research and Education of Ocular Melanoma (CURE OM) initiative describes her journey from having a loved one diagnosed with a rare disease, to forming a patient advocacy group, to teaming up with The Cancer Genome Atlas in a collaborative research effort.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2017-11-20</field_date_posted>
  <field_date_reviewed>2017-11-20</field_date_reviewed>
  <field_pretty_url>cure-om</field_pretty_url>
  <para_id>1100551</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1100977</id>
  <title>Expanding Cancer Clinical Trial Access for Patients with HIV</title>
  <langcode>en</langcode>
  <field_short_title>Expanding Clinical Trial Access for Patients with HIV</field_short_title>
  <field_page_description>The immunotherapy drug pembrolizumab (Keytruda) is being tested in people with cancer who are HIV positive, as this Cancer Currents blog post explains.</field_page_description>
  <field_feature_card_description>NCI study shows people with HIV can safely participate in cancer trials.</field_feature_card_description>
  <field_list_description>People with HIV are often excluded from clinical trials to protect their safety. Preliminary results from an NCI-sponsored study of an immunotherapy drug show that people with HIV can safely participate in clinical trials.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-01</field_date_posted>
  <field_date_reviewed>2017-11-30</field_date_reviewed>
  <field_pretty_url>immunotherapy-cancer-HIV</field_pretty_url>
  <para_id>1100977</para_id>
  <related_resource_id>6805430</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1101156</id>
  <title>Fat Cells May Hinder Effectiveness of Chemotherapy </title>
  <langcode>en</langcode>
  <field_short_title>Fat Cells May Hinder Effectiveness of Chemotherapy</field_short_title>
  <field_page_description>Study shows fat cells can absorb and break down two chemotherapy drugs commonly used to treat leukemia, potentially reducing their effectiveness.</field_page_description>
  <field_feature_card_description>Finding may help explain link between obesity, poorer outcomes in some cancers.</field_feature_card_description>
  <field_list_description>Researchers have shown that fat cells can absorb two commonly used chemotherapy drugs and break them down chemically into a less toxic form, potentially reducing the drugs’ effectiveness. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-04</field_date_posted>
  <field_date_reviewed>2017-12-01</field_date_reviewed>
  <field_pretty_url>fat-cells-absorb-chemotherapy</field_pretty_url>
  <para_id>1101156</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1070066</term_id>
  <id>1102037</id>
  <title>Prior Cancers Common in Patients Newly Diagnosed with Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Prior Cancers Common in Patients Newly Diagnosed with Cancer</field_short_title>
  <field_page_description>Many patients diagnosed with a new cancer have had one or more cancers in the past, which has potential implications for clinical trial enrollment.</field_page_description>
  <field_feature_card_description>Finding has implications for screening, clinical trial enrollment.</field_feature_card_description>
  <field_list_description>A new study shows that many patients diagnosed with a new cancer have had one or more cancers in the past, which has potential implications for long-term surveillance and clinical trial enrollment.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2017-12-14</field_date_posted>
  <field_date_reviewed>2017-12-14</field_date_reviewed>
  <field_pretty_url>prior-cancer-common-newly-diagnosed</field_pretty_url>
  <para_id>1102037</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1102945</term_id>
  <id>1102954</id>
  <title>What We Do</title>
  <langcode>en</langcode>
  <field_short_title>What We Do</field_short_title>
  <field_page_description>NCI fellows and trainees volunteer for science outreach and teaching activities in the greater Washington, D.C. area. Learn more about our seminars, teaching opportunities, and other ways we assist in the classroom.</field_page_description>
  <field_feature_card_description>NCI fellows and trainees participate in science outreach and teaching activities in the greater Washington, D.C. area. Learn more about the types of actives and why you should volunteer. </field_feature_card_description>
  <field_list_description>NCI fellows and trainees participate in science outreach and teaching activities in the greater Washington, D.C. area. Learn more about the types of actives and why you should volunteer. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-05</field_date_posted>
  <field_date_reviewed>2018-01-05</field_date_reviewed>
  <para_id>1102954</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1103372</id>
  <title>CGH at APEC: HPV Workshop</title>
  <langcode>en</langcode>
  <field_short_title>APEC 2017</field_short_title>
  <field_page_description>CGH at APEC 2017: HPV Workshop</field_page_description>
  <field_list_description>APEC is the premier forum for facilitating economic growth, cooperation, trade and investment in the Asia-Pacific region.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-10</field_date_posted>
  <field_date_reviewed>2018-01-10</field_date_reviewed>
  <field_pretty_url>apec-2017</field_pretty_url>
  <para_id>1103372</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1103386</id>
  <title>Grantee Spotlight: Luis G. Carvajal-Carmona, PhD</title>
  <langcode>en</langcode>
  <field_short_title>Grantee Spotlight: Luis G. Carvajal-Carmona, PhD</field_short_title>
  <field_page_description>CRCHD R21 grantee, Dr. Luis G. Carvajal-Carmona, is an Associate Professor specializing in cancer genetics, epidemiology, and cancer disparities.</field_page_description>
  <field_feature_card_description>CRCHD grantee, Dr. Carvajal-Carmona, specializes in cancer genetics, epidemiology, &amp; cancer disparities.</field_feature_card_description>
  <field_list_description>Dr. Carvajal-Carmona is an Associate Professor and CRCHD R21 awardee researching cancer genetics, epidemiology, and cancer health disparities.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-01-19</field_date_posted>
  <field_date_reviewed>2018-01-10</field_date_reviewed>
  <field_pretty_url>carvajal-carmona-spotlight</field_pretty_url>
  <para_id>1103386</para_id>
  <related_resource_ids>6816933</related_resource_ids>
  <related_resource_ids>6816934</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1105355</id>
  <title>TARGET Study Finds Major Differences between Childhood and Adult AML</title>
  <langcode>en</langcode>
  <field_short_title>Study Finds Differences between Childhood and Adult Leukemia</field_short_title>
  <field_page_description>Researchers with TARGET, an NCI-funded program, completed a comprehensive genomic analysis of pediatric acute myeloid leukemia. Learn what they found in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Findings have influenced clinical trials testing therapies for kids with AML.</field_feature_card_description>
  <field_list_description>An NCI-funded study has found significant differences in the genetics of acute myeloid leukemia in younger and older patients. The findings could help guide the development of treatments tailored specifically for childhood AML.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-01-30</field_date_posted>
  <field_date_reviewed>2018-01-30</field_date_reviewed>
  <field_pretty_url>genetic-differences-childhood-adult-aml</field_pretty_url>
  <para_id>1105355</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1102622</term_id>
  <id>1106668</id>
  <title>2018 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2018 Press Releases</field_short_title>
  <field_page_description>Press releases from NCI for the year 2018.</field_page_description>
  <field_list_description>Press releases from the National Cancer Institute for the year 2018.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-09</field_date_posted>
  <field_date_reviewed>2018-02-09</field_date_reviewed>
  <para_id>1106668</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1106698</id>
  <title>Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Using Oncolytic Viruses to Treat Cancer</field_short_title>
  <field_page_description>Cancer treatments known as oncolytic viruses are being tested in clinical trials, and one, T-VEC or Imlygic®, has been approved by the FDA. Research now suggests that these treatments work not only by infecting and killing tumor cells, but that they may also be a form of cancer immunotherapy.</field_page_description>
  <field_feature_card_description>Treatments may also stimulate an immune response against tumors.</field_feature_card_description>
  <field_list_description>A small but growing number of patients with cancer are being treated with oncolytic viruses, which infect and kill tumor cells. But research now suggests that these treatments also work against cancer by spurring an immune response.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-02-09</field_date_posted>
  <field_date_reviewed>2018-02-09</field_date_reviewed>
  <field_pretty_url>oncolytic-viruses-to-treat-cancer</field_pretty_url>
  <para_id>1106698</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciAppModulePage</CONTENTTYPENAME>
  <term_id>941577</term_id>
  <id>1107098</id>
  <title>Clinical Trials to Treat Adult Brain Tumors</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Trials to Treat Adult Brain Tumors</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-02-14</field_date_posted>
  <field_date_reviewed>2018-02-14</field_date_reviewed>
  <field_pretty_url>adult-brain-tumors</field_pretty_url>
  <para_id>1107098</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1108384</id>
  <title>New on NCI Websites, March 2018</title>
  <langcode>en</langcode>
  <field_short_title>New on NCI Websites, March 2018</field_short_title>
  <field_page_description>An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.</field_page_description>
  <field_feature_card_description>An update on new content of interest to the cancer community recently added to NCI’s websites.</field_feature_card_description>
  <field_list_description>NCI periodically provides updates on new websites and other online content of interest to the cancer community.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-02</field_date_posted>
  <field_date_reviewed>2018-02-27</field_date_reviewed>
  <field_pretty_url>new-online-march-2018</field_pretty_url>
  <para_id>1108384</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1109183</id>
  <title>Testing an Interactive Approach to Promote Exercise in Young Cancer Survivors</title>
  <langcode>en</langcode>
  <field_short_title>Promoting Exercise in Young Cancer Survivors</field_short_title>
  <field_page_description>In children and adolescent cancer survivors, an online game helped them get regular exercise, as this NCI Cancer Currents post explains. A NCI-funded trial is testing the approach for acute lymphoblastic leukemia (ALL) survivors.</field_page_description>
  <field_feature_card_description>Clinical trials hope to improve the long-term health of young cancer survivors.</field_feature_card_description>
  <field_list_description>An interactive website designed to promote physical activity among children and adolescents who have completed treatment for cancer may indeed help encourage them to get regular exercise, according to preliminary results from a pilot study.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-06</field_date_posted>
  <field_date_reviewed>2018-03-05</field_date_reviewed>
  <field_pretty_url>childhood-cancer-survivors-increasing-activity</field_pretty_url>
  <para_id>1109183</para_id>
  <related_resource_id>6928283</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1110774</id>
  <title>Many Men with Penile Cancer Do Not Get Recommended Treatments, Study Finds</title>
  <langcode>en</langcode>
  <field_short_title>Are Men with Penile Cancer Getting Recommended Treatments?</field_short_title>
  <field_page_description>Professional guidelines recommend that men with penile cancer that has not spread beyond nearby lymph nodes undergo lymph node dissection and receive chemotherapy. As this Cancer Currents blog post reports, that’s not happening for many men. 	</field_page_description>
  <field_feature_card_description>Analysis suggests treatment of some men conflicts with guidelines.</field_feature_card_description>
  <field_list_description>An analysis of records from a national cancer treatment database has found that many men with penile cancer that has not spread beyond nearby lymph nodes did not undergo lymph node biopsy or receive chemotherapy, as recommended by widely used professional guidelines.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-03-22</field_date_posted>
  <field_date_reviewed>2018-03-22</field_date_reviewed>
  <field_pretty_url>penile-cancer-recommended-treatment</field_pretty_url>
  <para_id>1110774</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1111556</term_id>
  <id>1111557</id>
  <title>The Finding Cancer Trials Collaborative</title>
  <langcode>en</langcode>
  <field_short_title>Finding Cancer Trials Collaborative </field_short_title>
  <field_feature_card_description>Let's collaborate! NCI wants to hear from data experts, patient advocates, and others about how our clinical trial data might serve you better.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-13</field_date_posted>
  <field_date_reviewed>2018-03-29</field_date_reviewed>
  <para_id>1111557</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113120</id>
  <title>Advancing Patient Care Through Focused Innovation</title>
  <langcode>en</langcode>
  <field_short_title>Advancing Patient Care Through Focused Innovation</field_short_title>
  <field_page_description>In this Cancer Currents post, NCI Director Dr. Norman Sharpless describes the key areas of opportunity he has identified that, with enhanced attention from NCI, he believes can accelerate progress in cancer research and care.</field_page_description>
  <field_feature_card_description>NCI Director Dr. Sharpless describes key areas of focus for the institute.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless describes the focus areas of opportunity he has identified that, with enhanced attention from NCI, he believes can accelerate progress in cancer research and care.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-16</field_date_posted>
  <field_date_reviewed>2018-04-13</field_date_reviewed>
  <field_pretty_url>sharpless-nci-focus-areas</field_pretty_url>
  <para_id>1113120</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>894086</term_id>
  <id>1113383</id>
  <title>PACHE Spotlight: Yamilé Molina, Ph.D.</title>
  <langcode>en</langcode>
  <field_short_title>PACHE Spotlight: Yamilé Molina, Ph.D.</field_short_title>
  <field_page_description>Dr. Yamilé Molina, an Assistant Professor at the University of Illinois-Chicago, discusses her work comparing intervention approaches’ effects on cancer disparities.  Dr. Molina also describes what CRCHD diversity training programs, including PACHE, have meant to her career.</field_page_description>
  <field_feature_card_description>Dr. Yamilé Molina, a K01 awardee, shares information on her work, partnerships, and mentors.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-23</field_date_posted>
  <field_date_reviewed>2018-04-23</field_date_reviewed>
  <field_pretty_url>pache-spotlight-molina</field_pretty_url>
  <para_id>1113383</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1113389</id>
  <title>Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug</title>
  <langcode>en</langcode>
  <field_short_title>Study Tests Way to Lower Dose of Prostate Cancer Drug</field_short_title>
  <field_page_description>In a small clinical trial, researchers compared the efficacy of a low dose of the cancer drug abiraterone (Zytiga) taken with a low-fat breakfast with a full dose taken on an empty stomach, as directed on the drug’s label. Learn what they found in this Cancer Currents blog post.</field_page_description>
  <field_feature_card_description>Study shows effectiveness is the same when a lower dose is taken with food.</field_feature_card_description>
  <field_list_description>In a small clinical trial, researchers compared the efficacy of a much lower dose of the cancer drug abiraterone (Zytiga) taken with a low-fat breakfast with a full dose taken on an empty stomach, as directed on the drug’s label.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-04-23</field_date_posted>
  <field_date_reviewed>2018-04-18</field_date_reviewed>
  <field_pretty_url>prostate-cancer-abiraterone-food-low-dose</field_pretty_url>
  <para_id>1113389</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114558</term_id>
  <id>1114560</id>
  <title>Brachytherapy to Treat Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Brachytherapy</field_short_title>
  <field_page_description>When getting brachytherapy, a solid source of radiation is put inside your body. It can be used treat different kinds of cancer, head and neck, breast, cervix, prostate, and eye. Learn more about how what to expect when getting internal radiation therapy. </field_page_description>
  <field_list_description>In brachytherapy, a solid source of radiation is placed inside your body, in or near a tumor. It is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-01</field_date_posted>
  <field_date_reviewed>2018-05-01</field_date_reviewed>
  <para_id>1114560</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1114848</term_id>
  <id>1114853</id>
  <title>Career Planning for Trainees and Fellows</title>
  <langcode>en</langcode>
  <field_short_title>Career Planning</field_short_title>
  <field_page_description>Cancer research fellows and trainees at NCI can gain technical experience and professional skills while planning for academic, government, or industry careers. Learn more about career development at NCI. </field_page_description>
  <field_feature_card_description>Find help in planning for academic, government, or industry careers. </field_feature_card_description>
  <field_list_description>Learn about opportunities to gain technical experience and professional skills while planning for academic, government, or industry careers.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-25</field_date_posted>
  <field_date_reviewed>2018-05-04</field_date_reviewed>
  <para_id>1114853</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102626</term_id>
  <id>1116072</id>
  <title>Building Partnerships to Promote Global Health Equity: Takeaways from the 6th Annual Symposium on Global Cancer Research </title>
  <langcode>en</langcode>
  <field_short_title>Building Partnerships to Promote Global Health Equity: Takeaways from the 6th Annual Symposium</field_short_title>
  <field_page_description>CGH celebrated yet another successful and inspiring Annual Symposium on Global Cancer Research (ASGCR) held in conjunction with the 9th Annual CUGH (Consortium of University on Global Health) Conference on March 15, 2018 in New York, NY. Read more about ASGCR and new global collaborations in cancer research.  </field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2018-05-21</field_date_posted>
  <field_date_reviewed>2018-05-21</field_date_reviewed>
  <field_pretty_url>asgcr</field_pretty_url>
  <para_id>1116072</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1102624</term_id>
  <id>1117512</id>
  <title>Maximizing the Prospects for Progress Against Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Maximizing the Prospects for Progress Against Cancer</field_short_title>
  <field_page_description>The 2018 American Society of Clinical Oncology annual meeting featured numerous, potentially practice changing research findings, according to NCI Director Dr. Norman Sharpless. In this Cancer Currents post, Dr. Sharpless discusses the rapid pace of progress in cancer research. </field_page_description>
  <field_feature_card_description>The NCI director highlights research findings from the 2018 ASCO annual meeting.</field_feature_card_description>
  <field_list_description>NCI Director Dr. Norman Sharpless highlights some of the important research findings from the 2018 American Society of Clinical Oncology annual meeting and discusses the rapid pace of progress in cancer research.
</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-06-11</field_date_posted>
  <field_date_reviewed>2018-06-11</field_date_reviewed>
  <field_pretty_url>asco-sharpless-maximizing-progress</field_pretty_url>
  <para_id>1117512</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1129038</term_id>
  <id>1119635</id>
  <title>TCGA Ethics &amp; Policies</title>
  <langcode>en</langcode>
  <field_short_title>Ethics &amp; Policies</field_short_title>
  <field_page_description>Ethics and research policies addresed by TCGA for conducting human genomics research.</field_page_description>
  <field_feature_card_description>Ethics and research policies addresed by TCGA for conducting human genomics research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2019-03-06</field_date_posted>
  <field_date_reviewed>2018-07-10</field_date_reviewed>
  <para_id>1119635</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911288</term_id>
  <id>14059</id>
  <title>Targeted Cancer Therapies</title>
  <langcode>en</langcode>
  <field_short_title>Targeted Cancer Therapies</field_short_title>
  <field_page_description>A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.</field_page_description>
  <field_feature_card_description>Describes targeted cancer therapies, drugs that  interfere with specific molecules involved in cancer cell growth and survival.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2018-05-14</field_date_posted>
  <field_date_reviewed>2018-07-26</field_date_reviewed>
  <field_pretty_url>targeted-therapies-fact-sheet</field_pretty_url>
  <para_id>14059</para_id>
  <related_resource_ids>7242791</related_resource_ids>
  <related_resource_ids>7242792</related_resource_ids>
  <related_resource_ids>7242793</related_resource_ids>
  <related_resource_ids>7242794</related_resource_ids>
  <related_resource_ids>7242799</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911116</term_id>
  <id>14115</id>
  <title>Acrylamide and Cancer Risk</title>
  <langcode>en</langcode>
  <field_short_title>Acrylamide and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet about acrylamide and cancer risk. </field_page_description>
  <field_feature_card_description>A fact sheet about acrylamide and cancer risk.</field_feature_card_description>
  <field_list_description>A fact sheet that reviews research about a possible connection between acrylamide and cancer risk. Acrylamide is a chemical that has been found in certain foods, with especially high levels in potato chips, French fries, and other foods produced by high-temperature cooking.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2017-12-05</field_date_reviewed>
  <field_pretty_url>acrylamide-fact-sheet</field_pretty_url>
  <para_id>14115</para_id>
  <related_resource_ids>6806046</related_resource_ids>
  <related_resource_ids>6806047</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11956</term_id>
  <id>14208</id>
  <title>Retinoblastoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Retinoblastoma</field_short_title>
  <field_page_description>Retinoblastoma is a very rare childhood cancer that forms in the tissues of the retina. Most cases of retinoblastoma are not inherited, but some are, and children with a family history of the disease should have their eyes checked beginning at an early age. Start here to find information on retinoblastoma treatment.</field_page_description>
  <field_list_description>NCI's gateway for information about Retinoblastoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14208</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvTopicPage</CONTENTTYPENAME>
  <term_id>12774</term_id>
  <id>14257</id>
  <title>Key Initiatives</title>
  <langcode>en</langcode>
  <field_short_title>Key Initiatives</field_short_title>
  <field_page_description>Learn about major research initiatives NCI has developed to address specific issues of high priority for the cancer research community.</field_page_description>
  <field_feature_card_description>Read about major research initiatives NCI has developed to address high-priority issues for the cancer research community.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-03-09</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14257</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>12758</term_id>
  <id>14365</id>
  <title>The NCI Intramural Research Program</title>
  <langcode>en</langcode>
  <field_short_title>Intramural Research</field_short_title>
  <field_page_description>The intramural research program supports projects conducted by scientists located at NCI.</field_page_description>
  <field_feature_card_description>NCI provides sustained support to scientists working in many urgent areas of cancer research.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-05-07</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14365</para_id>
  <related_resource_id>7238012</related_resource_id>
</row>
<row>
  <CONTENTTYPENAME>cgvFactSheet</CONTENTTYPENAME>
  <term_id>911142</term_id>
  <id>14370</id>
  <title>Reproductive History and Cancer Risk </title>
  <langcode>en</langcode>
  <field_short_title>Reproductive History and Cancer Risk</field_short_title>
  <field_page_description>A fact sheet that describes what is known about the relationship between pregnancy, miscarriage, abortion, fertility treatment and the risk of cancer. </field_page_description>
  <field_feature_card_description>A fact sheet that describes what is known about the relationship between pregnancy, miscarriage, abortion, fertility treatment and the risk of cancer. </field_feature_card_description>
  <field_list_description>A fact sheet that describes what is known about the relationship between pregnancy, miscarriage, abortion, fertility treatment, and the risks of breast, ovarian, and endometrial cancers. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-11-30</field_date_posted>
  <field_date_reviewed>2016-11-09</field_date_reviewed>
  <field_pretty_url>reproductive-history-fact-sheet</field_pretty_url>
  <para_id>14370</para_id>
  <related_resource_ids>6442056</related_resource_ids>
  <related_resource_ids>6442057</related_resource_ids>
  <related_resource_ids>6442058</related_resource_ids>
</row>
<row>
  <CONTENTTYPENAME>cgvCancerTypeHome</CONTENTTYPENAME>
  <term_id>11870</term_id>
  <id>14506</id>
  <title>Adrenocortical Carcinoma—Patient Version</title>
  <langcode>en</langcode>
  <field_short_title>Adrenocortical Carcinoma</field_short_title>
  <field_page_description>Adrenocortical carcinoma is a rare cancer which forms in the cortex (outer layer) of an adrenal gland. There are two adrenal glands. One sits on top of each kidney. Start here to find information on adrenocortical carcinoma treatment and research.</field_page_description>
  <field_list_description>NCI's gateway for information about adrenocortical carcinoma.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>1980-01-01</field_date_posted>
  <field_date_reviewed>2004-12-29</field_date_reviewed>
  <para_id>14506</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922407</term_id>
  <id>138990</id>
  <title>Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen</title>
  <langcode>en</langcode>
  <field_short_title>Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen</field_short_title>
  <field_page_description>After a median of 8 years of follow-up, women with estrogen-receptor positive breast cancer who received 5 years of letrozole were less likely to have their cancer recur or to die during follow-up than women who received 5 years of tamoxifen.</field_page_description>
  <field_feature_card_description>After a median of 8 years of follow-up, women with estrogen-receptor positive breast cancer who received 5 years of letrozole were less likely to have their cancer recur or to die during follow-up than women who received 5 years of tamoxifen.</field_feature_card_description>
  <field_list_description>After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2011-12-02</field_date_posted>
  <field_date_reviewed>2011-12-02</field_date_reviewed>
  <field_pretty_url>letrozole-prevents-recurrence</field_pretty_url>
  <para_id>138990</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771993</term_id>
  <id>772093</id>
  <title>Lymphoma Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Lymphoma Steering Committee</field_short_title>
  <field_page_description>The Lymphoma Steering Committee addresses the design, prioritization and evaluation of concepts for phase II and phase III clinical trials in adult lymphoma.  </field_page_description>
  <field_feature_card_description>The Lymphoma Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials.  </field_feature_card_description>
  <field_list_description>The Lymphoma Steering Committee evaluates and prioritizes concepts for phase 3 and large phase 2 therapeutic clinical trials to be conducted in the NCI National Clinical Trials Network (NCTN). </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772093</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771993</term_id>
  <id>772094</id>
  <title>Lymphoma Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Lymphoma Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772094</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>771997</term_id>
  <id>772113</id>
  <title>Pediatric and Adolescent Solid Tumor Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Pediatric and Adolescent Solid Tumor Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772113</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772006</term_id>
  <id>772123</id>
  <title>Symptom Management and Health-Related Quality of Life Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Symptom Management and Health-Related QoL SC</field_short_title>
  <field_page_description>The Symptom Management and Health-Related Quality of Life Steering Committee (SxQoLSC) evaluates and prioritizes clinical trial concepts to manage cancer symptoms and cancer treatment side effects.</field_page_description>
  <field_feature_card_description>The SxQOL Steering Committee evaluates and prioritizes  concepts for symptom management intervention clinical trials conducted through NCORP.</field_feature_card_description>
  <field_list_description>The Symptom Management and Health-Related Quality of Life Steering Committee evaluates and prioritizes concepts for symptom management intervention clinical trials conducted through NCORP. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772123</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772006</term_id>
  <id>772124</id>
  <title>Symptom Management and Health-Related Quality of Life Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Symptom Management and Health-Related Quality of Life Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772124</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772008</term_id>
  <id>772125</id>
  <title>Clinical Imaging Steering Committee</title>
  <langcode>en</langcode>
  <field_short_title>Clinical Imaging Steering Committee</field_short_title>
  <field_page_description>The Clinical Imaging Steering Committee serves as a forum for the extramural imaging and oncology communities to provide strategic input to the NCI regarding its significant investment in imaging activities in clinical trials.</field_page_description>
  <field_feature_card_description>The CISC serves as an expert voice in clinical imaging.</field_feature_card_description>
  <field_list_description>The Clinical Imaging Steering Committee serves as a forum for the imaging and oncology communities. The committee is an expert voice in clinical imaging. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <para_id>772125</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>772128</term_id>
  <id>772130</id>
  <title>Patient Advocate Steering Committee Roster</title>
  <langcode>en</langcode>
  <field_short_title>Patient Advocate Steering Committee Roster</field_short_title>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-05-23</field_date_posted>
  <field_date_reviewed>2014-05-23</field_date_reviewed>
  <field_pretty_url>roster</field_pretty_url>
  <para_id>772130</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938030</term_id>
  <id>797387</id>
  <title>Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia</title>
  <langcode>en</langcode>
  <field_short_title>Ibrutinib Improves Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia</field_short_title>
  <field_page_description>A summary of results from an international phase III trial that compared ibrutinib (Imbruvica®) and ofatumumab (Arzerra®) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).</field_page_description>
  <field_feature_card_description>In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting wo</field_feature_card_description>
  <field_list_description>In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated with ibrutinib (Imbruvica®) lived longer without their disease getting worse than patients who received ofatumumab (Arzerra®). Patients who received ibrutinib also lived longer and were more likely to show a clinical response to treatment than those who received ofatumumab.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-06-27</field_date_posted>
  <field_date_reviewed>2014-06-27</field_date_reviewed>
  <field_pretty_url>ibrutinib-cll</field_pretty_url>
  <para_id>797387</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>922403</term_id>
  <id>797388</id>
  <title>Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer</title>
  <langcode>en</langcode>
  <field_short_title>Enzalutamide Improves Survival in Patients with Metastatic Prostate Cancer</field_short_title>
  <field_page_description>A summary of results from an international phase III trial that compared enzalutamide (Xtandi®) and placebo for the treatment of metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. </field_page_description>
  <field_feature_card_description>In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial </field_feature_card_description>
  <field_list_description>In an international randomized phase III clinical trial, the hormone therapy enzalutamide (Xtandi®) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-06-27</field_date_posted>
  <field_date_reviewed>2014-06-27</field_date_reviewed>
  <field_pretty_url>enzalutamide-metastatic</field_pretty_url>
  <para_id>797388</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1069528</term_id>
  <id>799465</id>
  <title>Are All RAS Proteins Created Equal in Cancer?</title>
  <langcode>en</langcode>
  <field_short_title>Are All RAS Proteins Created Equal in Cancer?</field_short_title>
  <field_page_description>Different cancers seem to be preferentially driven by differnt mutations in RAS genes.  Channing Der discusses what mechanisms could explain these variations.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-06-30</field_date_reviewed>
  <field_pretty_url>ras-proteins-created-equal</field_pretty_url>
  <para_id>799465</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>801795</term_id>
  <id>801797</id>
  <title>RAS Tools and Resources</title>
  <langcode>en</langcode>
  <field_short_title>Tools and Resources</field_short_title>
  <field_page_description>Find RAS datasets, tools, and resources. You can also share your own tools with the community for further collaboration. </field_page_description>
  <field_feature_card_description>Find databases that contain information on RAS and the RAS pathway, and news about the renewed attack on cancers caused by mutant RAS.</field_feature_card_description>
  <field_list_description>Find up-to-date RAS datasets, tools, and resources. You can also share your own tools with the community for further collaboration. </field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2014-09-22</field_date_posted>
  <field_date_reviewed>2014-07-07</field_date_reviewed>
  <para_id>801797</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>890156</term_id>
  <id>1030601</id>
  <title>Precision Medicine Trials for Cancer: A New Era</title>
  <langcode>en</langcode>
  <field_short_title>Trials offer flexibility, efficiency, and potential for rapid advances.</field_short_title>
  <field_page_description>Advances in genomics, imaging, bioinformatics, and related disciplines, allow us to design smaller, quicker, and smarter trials that incorporate the principal tenets of precision medicine.</field_page_description>
  <field_feature_card_description>NCI is designing smaller, quicker, and smarter clinical trials that incorporate the principal tenets of precision medicine.</field_feature_card_description>
  <field_list_description>NCI is designing smaller, quicker, and smarter clinical trials that incorporate the principal tenets of precision medicine.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2015-12-10</field_date_posted>
  <field_date_reviewed>2015-12-10</field_date_reviewed>
  <field_pretty_url>precision-medicine-trials</field_pretty_url>
  <para_id>1030601</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1011700</term_id>
  <id>1033572</id>
  <title>Cancer Cell Biology Research</title>
  <langcode>en</langcode>
  <field_short_title>Cancer Cell Biology Research</field_short_title>
  <field_page_description>Part of NCI's Division of Cancer Biology research portfolio, this research defines the biological basis for the differences between normal cells and cancer cells.</field_page_description>
  <field_feature_card_description>NCI supports research into the biology of cancer, with an emphasis on processes and molecular targets that might lead to better therapies. </field_feature_card_description>
  <field_list_description>A research area that defines the biological basis for the differences between normal cells and cancer cells, with a major emphasis on studies that reveal processes and molecular targets where there is potential for therapeutic or preventive intervention.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-01-06</field_date_reviewed>
  <para_id>1033572</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1034233</id>
  <title>Supporting Vice President Biden's Cancer Initiative</title>
  <langcode>en</langcode>
  <field_short_title>Supporting Vice President Biden’s Cancer Initiative</field_short_title>
  <field_page_description>A message from NCI Acting Director Doug Lowy on the Institute's readiness to work with partners on Vice President Biden's cancer research initiative.</field_page_description>
  <field_feature_card_description>A message from NCI Acting Director Doug Lowy on the Institute's readiness to work with Vice President Biden on his cancer research initiative.</field_feature_card_description>
  <field_list_description>During his 2016 State of the Union address to Congress, President Obama tasked Vice President Biden with leading a new initiative to accelerate cancer research. This message from NCI Acting Director Doug Lowy states that the Institute stands ready to work with partners across the cancer research community on the initiative.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-01-21</field_date_posted>
  <field_date_reviewed>2016-01-21</field_date_reviewed>
  <field_pretty_url>biden-cancer-initiative</field_pretty_url>
  <para_id>1034233</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1034468</term_id>
  <id>1034471</id>
  <title>2016 Press Releases</title>
  <langcode>en</langcode>
  <field_short_title>2016 Press Releases</field_short_title>
  <field_page_description>Press releases from the National Cancer Institute for the year 2016.</field_page_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2015-04-15</field_date_posted>
  <field_date_reviewed>2015-04-15</field_date_reviewed>
  <para_id>1034471</para_id>
</row>
<row>
  <CONTENTTYPENAME>nciGeneral</CONTENTTYPENAME>
  <term_id>1038935</term_id>
  <id>1038936</id>
  <title>Center for Research Strategy Contact and Staff</title>
  <langcode>en</langcode>
  <field_short_title>CRS Contact and Staff</field_short_title>
  <field_page_description>Staff and contact information for the Center for Research Strategy.</field_page_description>
  <field_feature_card_description>Staff and contact information for the Center for Research Strategy.</field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>0</field_public_use>
  <field_date_posted>2016-03-29</field_date_posted>
  <field_date_reviewed>2016-03-02</field_date_reviewed>
  <para_id>1038936</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvBlogPost</CONTENTTYPENAME>
  <term_id>1033569</term_id>
  <id>1041318</id>
  <title>Keeping Pace: How New Data Can Affect Ongoing Clinical Trials</title>
  <langcode>en</langcode>
  <field_short_title>How New Data Can Affect Ongoing Clinical Trials</field_short_title>
  <field_page_description>Research results sometimes outrace the design of an ongoing clinical trial and the trial has to be recalibrated to include newer treatments, according to NCI’s Dr. Jo Anne Zujewski.</field_page_description>
  <field_feature_card_description>Sometimes ongoing clinical trials must be recalibrated to include newer treatments. </field_feature_card_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-16</field_date_posted>
  <field_date_reviewed>2016-03-14</field_date_reviewed>
  <field_pretty_url>recalibrating-clinical-trials</field_pretty_url>
  <para_id>1041318</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>938223</term_id>
  <id>1041767</id>
  <title>Vaccine Therapy for Unresectable Chordoma</title>
  <langcode>en</langcode>
  <field_short_title>Vaccine Therapy for Unresectable Chordoma</field_short_title>
  <field_page_description>In this phase II clinical trial, adult patients with inoperable chordoma who are scheduled to undergo radiation therapy will be randomly assigned to receive a yeast-based vaccine that targets a protein called brachyury or a placebo injection.</field_page_description>
  <field_feature_card_description>In this phase II clinical trial, adult patients with unresectable localized chordoma who are scheduled to undergo radiation therapy will be randomly assigned to receive the yeast-brachyury vaccine or a placebo injection. </field_feature_card_description>
  <field_list_description>In this phase II clinical trial, adult patients with inoperable chordoma, a type of bone cancer, who are scheduled to undergo radiation therapy will be randomly assigned to receive a yeast-based vaccine that targets a protein called brachyury or a placebo injection.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-03-23</field_date_posted>
  <field_date_reviewed>2016-03-17</field_date_reviewed>
  <field_pretty_url>chordoma-vaccine-trial</field_pretty_url>
  <para_id>1041767</para_id>
</row>
<row>
  <CONTENTTYPENAME>cgvArticle</CONTENTTYPENAME>
  <term_id>1042135</term_id>
  <id>1042136</id>
  <title>Special Research Programs</title>
  <langcode>en</langcode>
  <field_short_title>DCB's Special Research Programs</field_short_title>
  <field_page_description>Research Programs from NCI's Division of Cancer Biology - PS-ON, CSBC, TMEN, OMF, BETRNet, KRAS, MCL, TEC</field_page_description>
  <field_feature_card_description>Special research programs from NCI's Division of Cancer Biology.</field_feature_card_description>
  <field_list_description>Special research programs from NCI's Division of Cancer Biology.</field_list_description>
  <field_search_engine_restrictions>IncludeSearch</field_search_engine_restrictions>
  <field_public_use>1</field_public_use>
  <field_date_posted>2016-08-08</field_date_posted>
  <field_date_reviewed>2016-03-25</field_date_reviewed>
  <para_id>1042136</para_id>
</row>
</rows>
